Clustering O 0 0.00014286684745457023
of O 0 3.770926923607476e-06
missense O 0 0.12674261629581451
mutations O 0 0.0007894498412497342
in O 0 1.0693413514673011e-06
the O 0 1.9920411432394758e-05
ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999901056289673
telangiectasia I-Disease 1 0.9999880790710449
gene O 0 6.853500508441357e-06
in O 0 7.301186144559324e-08
a O 0 1.0314439577996382e-06
sporadic B-Disease 0 0.00037567090475931764
T I-Disease 1 0.6356795430183411
- I-Disease 0 0.4440426826477051
cell I-Disease 1 0.6309755444526672
leukaemia I-Disease 1 0.7930236458778381
. O 0 3.8552234400413e-06

Ataxia B-Disease 1 0.9999979734420776
- I-Disease 1 0.9999855756759644
telangiectasia I-Disease 1 0.9999957084655762
( O 0 0.001642413786612451
A B-Disease 1 0.9999445676803589
- I-Disease 1 0.9999676942825317
T I-Disease 1 0.9999954700469971
) O 0 1.5408969034069742e-07
is O 0 3.791925706764232e-08
a O 0 6.3858681187412e-07
recessive B-Disease 0 0.00015433011867571622
multi I-Disease 0 0.001085453201085329
- I-Disease 1 0.9660310745239258
system I-Disease 0 0.051643967628479004
disorder I-Disease 1 0.7790031433105469
caused O 0 1.4877800822432619e-05
by O 0 3.7304329225662514e-07
mutations O 0 2.040810613834765e-06
in O 0 1.3739628990094843e-08
the O 0 8.4104732067658e-09
ATM O 0 4.069726458055811e-07
gene O 0 1.1997815363429254e-07
at O 0 2.3002483473533175e-08
11q22 O 0 4.1929774852178525e-06
- O 0 3.374073276063427e-05
q23 O 0 3.486010973574594e-05
( O 0 9.182591753642555e-08
ref O 0 2.2805281332693994e-05
. O 0 7.516774758187239e-08
3 O 0 2.0836903047438682e-07
) O 0 2.2082451778260292e-07
. O 0 8.593073630436265e-07

The O 0 5.20090952704777e-06
risk O 0 2.9574105155916186e-06
of O 0 2.4921530439314665e-07
cancer B-Disease 0 0.002434687688946724
, O 0 3.559037509148766e-07
especially O 0 1.8485029329440295e-07
lymphoid B-Disease 0 1.4492416084976867e-05
neoplasias I-Disease 0 0.000972509675193578
, O 0 1.7201540458700038e-07
is O 0 7.382151068213716e-08
substantially O 0 2.22816493078426e-06
elevated O 0 3.3447307941969484e-05
in O 0 7.260232450789772e-07
A B-Disease 1 0.9999840259552002
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
patients O 1 0.9766386151313782
and O 0 6.02469981458853e-07
has O 0 1.272696522391925e-06
long O 0 4.497697148053703e-07
been O 0 1.2885290061603882e-06
associated O 0 2.5096065314755833e-07
with O 0 1.001501118480519e-06
chromosomal O 1 0.9999277591705322
instability O 1 0.9987356066703796
. O 0 2.2106265532784164e-05

By O 0 1.6801779565867037e-05
analysing O 0 0.00020169455092400312
tumour B-Disease 1 0.9999191761016846
DNA O 0 9.105027857003734e-05
from O 0 6.556178391292633e-07
patients O 0 5.486976533575216e-06
with O 0 3.355695241680223e-07
sporadic B-Disease 0 0.002091109286993742
T I-Disease 1 0.526652991771698
- I-Disease 0 0.01981602981686592
cell I-Disease 0 0.020936261862516403
prolymphocytic I-Disease 1 0.6994425654411316
leukaemia I-Disease 1 0.9533849358558655
( O 0 4.45912263558057e-07
T B-Disease 0 0.0009535163408145308
- I-Disease 0 0.0004432507266756147
PLL I-Disease 0 0.016840703785419464
) O 0 6.229854676575997e-08
, O 0 1.3273542265324068e-08
a O 0 7.255471246025991e-08
rare O 0 1.3245604577605263e-06
clonal B-Disease 0 3.917224603355862e-05
malignancy I-Disease 0 0.00042299629421904683
with O 0 7.700873538851738e-08
similarities O 0 5.513637120202475e-07
to O 0 7.580499783443884e-08
a O 0 7.17038619768573e-06
mature B-Disease 0 1.762588908604812e-05
T I-Disease 0 0.012117731384932995
- I-Disease 0 0.01054626889526844
cell I-Disease 0 0.10827065259218216
leukaemia I-Disease 0 0.323901891708374
seen O 0 2.3085656266630394e-06
in O 0 7.962878356693182e-08
A B-Disease 1 0.9918511509895325
- I-Disease 1 0.999396800994873
T I-Disease 1 0.9999933242797852
, O 0 9.109898968517882e-08
we O 0 5.174134898311422e-09
demonstrate O 0 3.184521446542021e-08
a O 0 2.1902911484517062e-08
high O 0 5.103703415443306e-08
frequency O 0 6.66442332430961e-08
of O 0 4.322920688082377e-09
ATM O 0 5.6578423937025946e-06
mutations O 0 2.8847946396126645e-06
in O 0 2.352631582880349e-07
T B-Disease 0 0.0069058556109666824
- I-Disease 0 0.006831540260463953
PLL I-Disease 0 0.13155297935009003
. O 0 6.497248250525445e-06

In O 0 6.779161140002543e-06
marked O 0 4.928991529595805e-06
contrast O 0 1.1726151569746435e-06
to O 0 6.410861885797203e-08
the O 0 1.375326252883724e-08
ATM O 0 1.788112285794341e-06
mutation O 0 1.1173401617270429e-06
pattern O 0 4.6007883724996645e-07
in O 0 3.350182282702008e-07
A B-Disease 1 0.9999610185623169
- I-Disease 1 0.9999920129776001
T I-Disease 1 0.9999982118606567
, O 0 8.499446124687893e-08
the O 0 6.922093565009391e-09
most O 0 8.901716697096163e-09
frequent O 0 1.3513906083062466e-07
nucleotide O 0 8.830544118154648e-08
changes O 0 2.4057614567141172e-08
in O 0 2.7881091213544096e-08
this O 0 4.014196122170688e-07
leukaemia B-Disease 0 0.15696512162685394
were O 0 4.923692358715925e-06
missense O 0 0.0007648260216228664
mutations O 0 4.5903903810540214e-05
. O 0 2.3953348318173084e-06

These O 0 5.5458499446103815e-06
clustered O 0 1.0204300451732706e-05
in O 0 9.918395704744398e-08
the O 0 1.2976600238800984e-08
region O 0 4.3157061924148366e-08
corresponding O 0 2.491021255934811e-08
to O 0 7.784530353660557e-09
the O 0 2.8645337213362154e-09
kinase O 0 2.5587453933439974e-07
domain O 0 3.56446818727818e-08
, O 0 7.664866075174359e-09
which O 0 4.8802788477075865e-09
is O 0 1.1838789504281522e-08
highly O 0 1.4666431624732468e-08
conserved O 0 2.394623166424026e-08
in O 0 7.956832526190283e-09
ATM O 0 4.694520612247288e-07
- O 0 3.294367843409418e-06
related O 0 3.601027387389877e-08
proteins O 0 8.73432171033528e-09
in O 0 8.679634788677504e-09
mouse O 0 6.184339440551412e-07
, O 0 1.7851453648631832e-08
yeast O 0 4.337980499258265e-07
and O 0 1.0786583715116649e-07
Drosophila O 0 2.528783397792722e-06
. O 0 1.4474504723693826e-06

The O 0 5.135795163369039e-06
resulting O 0 6.9186248765618075e-06
amino O 0 4.466336349651101e-07
- O 0 3.5989721709484e-06
acid O 0 1.4453179346674006e-06
substitutions O 0 2.440966397898592e-07
are O 0 6.491057469304451e-09
predicted O 0 1.4414290205877478e-07
to O 0 2.246735952837753e-08
interfere O 0 3.555580576630746e-07
with O 0 2.6843463274417445e-07
ATP O 0 5.2955867431592196e-05
binding O 0 4.419787728693336e-06
or O 0 8.60166835536802e-08
substrate O 0 6.534258773172041e-06
recognition O 0 2.2749366053176345e-06
. O 0 1.3652842199007864e-06

Two O 0 2.050690454780124e-06
of O 0 1.9731294287339551e-07
seventeen O 0 5.381049504649127e-06
mutated O 0 7.619273674208671e-05
T B-Disease 0 0.0007176992949098349
- I-Disease 0 9.493907418800518e-05
PLL I-Disease 0 0.0014856233028694987
samples O 0 1.2644612752410467e-06
had O 0 5.117033197166165e-07
a O 0 4.513754845447693e-07
previously O 0 4.501521743804915e-06
reported O 0 1.0517279406485613e-05
A B-Disease 1 0.9639854431152344
- I-Disease 1 0.9998196959495544
T I-Disease 1 0.9999912977218628
allele O 0 0.00020846624101977795
. O 0 2.2064693894208176e-06

In O 0 1.2868729754700325e-05
contrast O 0 2.9732824259554036e-05
, O 0 1.2541853777747747e-07
no O 0 1.64748925612912e-07
mutations O 0 3.728100068656204e-07
were O 0 5.8001884184477603e-08
detected O 0 2.387518520663434e-07
in O 0 7.051514927525204e-09
the O 0 1.3623115080463322e-08
p53 O 0 4.609475183769973e-07
gene O 0 1.236494568956914e-07
, O 0 1.2650877678765937e-08
suggesting O 0 1.0118457538510484e-07
that O 0 4.400573772045391e-08
this O 0 1.7019858944422595e-07
tumour B-Disease 1 0.9999270439147949
suppressor O 0 0.001052740029990673
is O 0 1.8714914062911703e-07
not O 0 3.7704481314904115e-08
frequently O 0 2.5198613684551674e-07
altered O 0 1.8351830703977612e-06
in O 0 1.8214140595773642e-07
this O 0 8.68150664246059e-07
leukaemia B-Disease 0 0.345665842294693
. O 0 5.378581590775866e-06

Occasional O 0 0.0015368227614089847
missense O 0 0.25807663798332214
mutations O 0 0.001166978501714766
in O 0 6.231589395611081e-07
ATM O 0 4.075745437148726e-06
were O 0 1.0064867410619627e-06
also O 0 5.168299139768351e-07
found O 0 3.105698453964578e-07
in O 0 6.478369414253393e-07
tumour B-Disease 1 0.9999946355819702
DNA O 0 4.384306521387771e-05
from O 0 2.0216050700128108e-07
patients O 0 2.9810803425789345e-06
with O 0 9.677886936287905e-08
B B-Disease 0 4.286151579435682e-06
- I-Disease 0 0.00011126112076453865
cell I-Disease 0 0.00023289791715797037
non I-Disease 0 3.925333203369519e-06
- I-Disease 1 0.5866115689277649
Hodgkins I-Disease 1 0.9963498115539551
lymphomas I-Disease 1 0.8807033896446228
( O 0 1.2355266676422616e-07
B B-Disease 0 4.7600610741938e-07
- I-Disease 0 2.7056394173996523e-06
NHL I-Disease 0 8.888213756108598e-07
) O 0 1.344179434425996e-08
and O 0 2.1710006237185553e-08
a O 0 9.420576816410176e-07
B B-Disease 0 7.195197667897446e-06
- I-Disease 0 3.2424646633444354e-05
NHL I-Disease 0 1.5199734662019182e-05
cell O 0 6.192240107338876e-05
line O 0 9.29520683712326e-06
. O 0 1.5002520967755117e-06

The O 0 8.365589110326255e-07
evidence O 0 2.607955877920176e-07
of O 0 6.265099106173011e-09
a O 0 1.0347982737357597e-07
significant O 0 5.43031539734784e-08
proportion O 0 3.583869911949478e-08
of O 0 4.563424305104036e-09
loss O 0 2.095736135743209e-06
- O 0 2.205262035204214e-06
of O 0 3.028612027833333e-08
- O 0 0.0003293752670288086
function O 0 4.184832960163476e-07
mutations O 0 2.1058023946807225e-07
and O 0 4.3824628370714436e-09
a O 0 7.462761431042964e-08
complete O 0 3.620531856540765e-07
absence O 0 1.0955235296705723e-07
of O 0 2.3046167196838496e-09
the O 0 6.320889145428055e-09
normal O 0 1.4866115449763129e-08
copy O 0 3.8159775783697114e-08
of O 0 1.6479843045758003e-09
ATM O 0 7.538326229905579e-08
in O 0 4.7386619073108704e-09
the O 0 6.540170627289399e-09
majority O 0 2.2754284145776182e-07
of O 0 1.5222516580593037e-08
mutated O 0 0.006152160465717316
tumours B-Disease 1 0.9997642636299133
establishes O 0 1.7419530422557727e-06
somatic O 0 3.1746956210554345e-06
inactivation O 0 4.417372474563308e-05
of O 0 1.3119375807946199e-08
this O 0 1.7648023487026876e-08
gene O 0 1.1601199645383531e-07
in O 0 2.2919010689292918e-08
the O 0 2.693014877763744e-08
pathogenesis O 0 1.8899992255683173e-06
of O 0 5.563249416695726e-08
sporadic B-Disease 0 0.002058806363493204
T I-Disease 0 0.12300345301628113
- I-Disease 0 0.000837006198707968
PLL I-Disease 0 0.0027660143095999956
and O 0 2.5588306584722886e-07
suggests O 0 3.807202730854442e-08
that O 0 5.351857179647368e-09
ATM O 0 1.1536216959484591e-07
acts O 0 4.867573366595934e-08
as O 0 4.176746770667705e-08
a O 0 1.0849164027604274e-05
tumour B-Disease 1 0.9999735355377197
suppressor O 0 0.0736129954457283
. O 0 1.0121762898052111e-05

As O 0 3.7590564261336112e-06
constitutional O 0 2.056685616480536e-06
DNA O 0 2.4020077944442164e-06
was O 0 1.8761284081847407e-06
not O 0 3.590684372056785e-08
available O 0 1.2565291029886794e-08
, O 0 1.6556978010839885e-08
a O 0 6.575633619831933e-07
putative O 0 0.0021386092994362116
hereditary O 1 0.9601755142211914
predisposition O 0 0.05136467516422272
to O 0 2.6028696083812974e-05
T B-Disease 0 0.10439497232437134
- I-Disease 0 0.0011687317164614797
PLL I-Disease 0 0.001893953769467771
will O 0 2.870070261451474e-07
require O 0 5.606198882901481e-08
further O 0 6.047932288311131e-08
investigation O 0 5.217444822847028e-07
. O 0 3.046221479507949e-07
. O 0 8.519081688973529e-07

Myotonic B-Disease 1 0.9999958276748657
dystrophy I-Disease 1 0.9999992847442627
protein O 0 0.002859013620764017
kinase O 0 0.00039852334884926677
is O 0 3.5323347447047126e-07
involved O 0 3.644142410053064e-08
in O 0 7.216410136123841e-09
the O 0 4.328068570202959e-09
modulation O 0 4.415160788084904e-07
of O 0 3.447597984873596e-09
the O 0 3.7356876703142916e-08
Ca2 O 0 8.127249020617455e-05
+ O 0 5.422689810075099e-06
homeostasis O 0 1.1742943570425268e-05
in O 0 2.9082809760438977e-07
skeletal O 0 0.007633105386048555
muscle O 0 0.007921122014522552
cells O 0 4.366310895420611e-05
. O 0 2.4380658487643814e-06

Myotonic B-Disease 1 0.9999983310699463
dystrophy I-Disease 1 0.9999998807907104
( O 1 0.9223124384880066
DM B-Disease 1 0.9999997615814209
) O 0 9.713552572065964e-06
, O 0 6.783758976780518e-08
the O 0 1.5729474611703154e-08
most O 0 1.5681251852583955e-07
prevalent O 0 1.9042550775338896e-05
muscular B-Disease 1 0.9999607801437378
disorder I-Disease 1 0.9998183846473694
in O 0 1.5991428881534375e-05
adults O 0 0.00026993508799932897
, O 0 3.0054476951590914e-07
is O 0 4.702909279785672e-07
caused O 0 2.7244868761044927e-06
by O 0 1.2881318411928078e-07
( O 0 5.4753492406689475e-08
CTG O 0 9.885257895803079e-06
) O 0 2.1777523784294317e-08
n O 0 2.8735101409438357e-07
- O 0 8.490735012856021e-07
repeat O 0 3.802544199515978e-07
expansion O 0 7.651431133126607e-08
in O 0 1.532175808449665e-08
a O 0 7.535263790714453e-08
gene O 0 9.387218113943163e-08
encoding O 0 4.471672099271018e-08
a O 0 1.346078448705157e-07
protein O 0 6.483771244347736e-07
kinase O 0 6.827933702879818e-06
( O 0 1.7715886713176587e-07
DM B-Disease 1 0.9999698400497437
protein O 0 5.844715360581176e-06
kinase O 0 4.230693775753025e-06
; O 0 8.735275969229406e-08
DMPK O 0 4.9050390771299135e-06
) O 0 8.839116993897278e-09
and O 0 5.9637934590739405e-09
involves O 0 1.7083856107547035e-08
changes O 0 6.412867747940254e-08
in O 0 4.4062343107498236e-08
cytoarchitecture O 0 1.8195465600001626e-05
and O 0 3.404738606604951e-07
ion O 0 0.00017675964045338333
homeostasis O 0 0.0004872401768807322
. O 0 2.3667398636462167e-06

To O 0 6.760869837307837e-06
obtain O 0 2.23011443267751e-06
clues O 0 1.2843578360843821e-06
to O 0 2.8382231676005176e-08
the O 0 9.229788489051316e-09
normal O 0 6.025756249528058e-08
biological O 0 2.283266375968651e-08
role O 0 1.0820414786394394e-08
of O 0 4.171196277269473e-09
DMPK O 0 4.3209376599406824e-05
in O 0 6.662491358611078e-08
cellular O 0 8.213976911974896e-07
ion O 0 9.372979548061267e-06
homeostasis O 0 9.708375728223473e-06
, O 0 1.3853465041790969e-08
we O 0 3.948870119785397e-09
have O 0 1.1895807006112591e-08
compared O 0 5.278352688264931e-08
the O 0 1.8395299505868934e-08
resting O 0 3.92870424548164e-06
[ O 0 2.470170841206709e-07
Ca2 O 0 1.955491825356148e-06
+ O 0 2.4476824478369963e-07
] O 0 3.447849650228818e-08
i O 0 1.6568225902346967e-08
, O 0 1.4419310190305623e-09
the O 0 1.4640990642078577e-09
amplitude O 0 1.0374820647029992e-07
and O 0 9.031057679464993e-09
shape O 0 6.136686181434925e-08
of O 0 1.163161567063753e-08
depolarization O 0 6.5975582401733845e-06
- O 0 0.002344338921830058
induced O 0 0.005865700077265501
Ca2 O 0 4.226917008054443e-05
+ O 0 1.1165242312927148e-06
transients O 0 1.6426115507783834e-06
, O 0 9.147713697643667e-09
and O 0 3.2640641300929474e-09
the O 0 3.515166824286098e-09
content O 0 1.45014809049826e-08
of O 0 3.578963569950133e-09
ATP O 0 9.64948071668914e-07
- O 0 3.3320948205073364e-06
driven O 0 1.2907428299513413e-06
ion O 0 1.0939154435618548e-06
pumps O 0 2.56914950114151e-06
in O 0 2.6906121775027714e-08
cultured O 0 2.1254306830087444e-06
skeletal O 0 0.00036141255986876786
muscle O 0 1.8429071133141406e-05
cells O 0 1.486850180754118e-07
of O 0 3.619183397418624e-09
wild O 0 5.664941227223608e-08
- O 0 1.179306400445057e-05
type O 0 1.7986889133680961e-06
and O 0 2.3097143753147975e-07
DMPK O 0 0.0003260432567913085
[ O 0 4.280251175714511e-07
- O 0 8.027199328353163e-06
/ O 0 3.9590149754076265e-06
- O 0 6.581284833373502e-05
] O 0 4.98413010063814e-06
knockout O 0 0.00021386878506746143
mice O 0 0.0006833434454165399
. O 0 1.5853375998631236e-06

In O 0 1.529448309156578e-05
vitro O 0 5.7066918088821694e-05
- O 0 0.00011902425467269495
differentiated O 0 2.6246825655107386e-05
DMPK O 0 0.00012141226034145802
[ O 0 1.0330052191420691e-06
- O 0 5.9402896113169845e-06
/ O 0 3.0118139875412453e-06
- O 0 1.952394813997671e-05
] O 0 6.604077498195693e-07
myotubes O 0 1.3483645489031915e-06
exhibit O 0 1.0518480308974176e-07
a O 0 8.953468011441146e-08
higher O 0 9.244926246765317e-08
resting O 0 2.7761675482906867e-06
[ O 0 3.4859050401792047e-07
Ca2 O 0 1.9598494418460177e-06
+ O 0 3.0898371505827527e-07
] O 0 2.1576667563749652e-08
i O 0 9.601104800083249e-09
than O 0 3.3089775364203433e-09
do O 0 6.326147605761889e-09
wild O 0 1.9832670616892756e-08
- O 0 7.456808816641569e-06
type O 0 1.6088509937617346e-06
myotubes O 0 1.1609290595515631e-05
because O 0 2.545530897180015e-08
of O 0 1.144996764068651e-09
an O 0 2.716715918893442e-08
altered O 0 9.84388293545635e-07
open O 0 7.142031677176419e-08
probability O 0 2.407491983547061e-08
of O 0 7.895951448233518e-09
voltage O 0 1.435993272025371e-05
- O 0 3.349327380419709e-05
dependent O 0 1.3735129869019147e-06
l O 0 6.7433998083288316e-06
- O 0 3.004344080181909e-06
type O 0 1.0143901363335317e-06
Ca2 O 0 3.5886901059711818e-06
+ O 0 6.058127723918005e-07
and O 0 4.374322060129998e-08
Na O 0 4.20548803958809e-06
+ O 0 1.3881247014069231e-06
channels O 0 9.10348717297893e-07
. O 0 5.961236979601381e-07

The O 0 2.783863692457089e-06
mutant O 0 1.904827331600245e-05
myotubes O 0 1.9217706721974537e-05
exhibit O 0 1.0319861303287325e-06
smaller O 0 9.992793792434895e-08
and O 0 3.6789426616223864e-08
slower O 0 2.7416688226367114e-06
Ca2 O 0 4.45510886493139e-05
+ O 0 1.318889417234459e-06
responses O 0 1.1773355623745374e-07
upon O 0 3.686381333523059e-08
triggering O 0 5.171651764612761e-07
by O 0 5.517409107369531e-08
acetylcholine O 0 3.6660196656157495e-06
or O 0 9.553649249482987e-08
high O 0 2.6503542471800756e-07
external O 0 8.751985660637729e-06
K O 0 1.625030199647881e-05
+ O 0 2.5777737846510718e-06
. O 0 4.2851524995057844e-07

In O 0 7.743757123535033e-06
addition O 0 5.207999720369116e-07
, O 0 4.9741544216885814e-08
we O 0 1.327602294765029e-08
observed O 0 3.479540566786454e-08
that O 0 1.1557927948047109e-08
these O 0 1.485041511983809e-08
Ca2 O 0 1.0426798326079734e-05
+ O 0 4.0947111301647965e-06
transients O 0 1.9369981600902975e-05
partially O 0 6.604357167816488e-06
result O 0 8.49842436423387e-08
from O 0 4.909791684326592e-09
an O 0 9.179909277179377e-09
influx O 0 7.43663051139265e-08
of O 0 8.84405793044607e-09
extracellular O 0 3.9928684714141127e-07
Ca2 O 0 3.273217089372338e-06
+ O 0 9.31983450414009e-08
through O 0 6.47530340458502e-09
the O 0 9.060578065600566e-09
l O 0 3.511032218739274e-06
- O 0 1.0238496543024667e-05
type O 0 6.033247700543143e-06
Ca2 O 0 2.2430582248489372e-05
+ O 0 2.6077270831592614e-06
channel O 0 2.870715889002895e-06
. O 0 4.7581323769918527e-07

Neither O 0 1.9002425688086078e-05
the O 0 2.416122413251287e-07
content O 0 1.322994620522877e-07
nor O 0 2.7284517756243076e-08
the O 0 2.028060830383538e-09
activity O 0 4.1916767834493385e-09
of O 0 3.63601748709641e-09
Na O 0 2.086335598505684e-06
+ O 0 1.2623033853742527e-06
/ O 0 4.193950360331655e-07
K O 0 4.6332922920555575e-07
+ O 0 4.933525588057819e-07
ATPase O 0 2.2060737592255464e-06
and O 0 3.1774325748301635e-07
sarcoplasmic O 0 0.00011662783072097227
reticulum O 0 0.0003869685751851648
Ca2 O 0 4.459674164536409e-05
+ O 0 3.067779516641167e-06
- O 0 1.3680590882358956e-06
ATPase O 0 4.396091753733344e-06
are O 0 3.537903481287685e-08
affected O 0 1.182117159714835e-07
by O 0 3.0391092309400847e-07
DMPK O 0 0.0023402338847517967
absence O 0 3.079259840887971e-05
. O 0 3.7795355183334323e-06

In O 0 1.2289169717405457e-05
conclusion O 0 1.7490843902123743e-06
, O 0 6.542930464092933e-08
our O 0 1.4366691836187329e-08
data O 0 3.639571843905287e-08
suggest O 0 5.329998842285022e-08
that O 0 2.715824543031431e-08
DMPK O 0 3.696893327287398e-05
is O 0 5.0127468398386554e-08
involved O 0 1.6321752838166503e-08
in O 0 1.1407945699204447e-08
modulating O 0 7.474826588804717e-07
the O 0 1.6989071482953477e-08
initial O 0 7.220529596452252e-08
events O 0 4.279440801724377e-09
of O 0 2.5804280934238477e-09
excitation O 0 5.651515380122873e-07
- O 0 1.038448499457445e-05
contraction O 0 9.94017409539083e-06
coupling O 0 4.437145435076673e-06
in O 0 3.3912965591298416e-07
skeletal O 0 0.04358037933707237
muscle O 0 0.005239860154688358
. O 0 1.5007271940703504e-06
. O 0 1.6395127886426053e-06

Constitutional O 0 0.0022350770886987448
RB1 O 1 0.8519852161407471
- O 0 0.0024887744802981615
gene O 0 9.125829092226923e-05
mutations O 0 0.0001099958608392626
in O 0 1.4349774346555932e-06
patients O 0 4.130056549911387e-05
with O 0 6.243367351999041e-07
isolated O 0 1.960634472197853e-05
unilateral B-Disease 0 0.0003588971740100533
retinoblastoma I-Disease 1 0.6367058157920837
. O 0 1.5098821677383967e-05

In O 0 2.859454252757132e-05
most O 0 7.43878263165243e-06
patients O 0 1.598627568455413e-05
with O 0 2.074925475881173e-07
isolated O 0 5.785013399872696e-06
unilateral B-Disease 0 8.827151032164693e-05
retinoblastoma I-Disease 0 0.16024604439735413
, O 0 2.1170817490201443e-06
tumor B-Disease 0 1.1291801456536632e-05
development O 0 1.6885499221075406e-08
is O 0 1.830032303473672e-08
initiated O 0 8.044750643421139e-08
by O 0 2.504589602381202e-08
somatic O 0 7.911163493190543e-07
inactivation O 0 2.212541403423529e-05
of O 0 1.4178394458497223e-08
both O 0 4.8446953115899305e-08
alleles O 0 1.7433077914574824e-07
of O 0 1.3277795751776011e-08
the O 0 5.048324851486541e-07
RB1 O 0 0.0023742010816931725
gene O 0 1.0149407899007201e-05
. O 0 2.3993129616428632e-06

However O 0 1.5549563613603823e-05
, O 0 9.960045588286448e-08
some O 0 5.390027091323191e-09
of O 0 4.76967398910233e-09
these O 0 1.1422277168549044e-07
patients O 0 1.2934960977872834e-05
can O 0 5.612992026726715e-07
transmit O 0 0.0007056738249957561
retinoblastoma B-Disease 0 0.011945567093789577
predisposition O 0 0.00020012010645586997
to O 0 4.283452881281846e-07
their O 0 7.136802082641225e-07
offspring O 0 2.8015698262606747e-05
. O 0 1.9689891814778093e-06

To O 0 3.420005214138655e-06
determine O 0 9.37179379434383e-07
the O 0 5.599978791792637e-08
frequency O 0 8.147257517521211e-07
and O 0 5.5022336908905345e-08
nature O 0 6.782206440902883e-08
of O 0 1.334192223367836e-08
constitutional O 0 4.7718447603983805e-05
RB1 O 0 0.1061907410621643
- O 0 0.0002760925854090601
gene O 0 3.2085210932564223e-06
mutations O 0 2.4791370378807187e-06
in O 0 2.631695963373204e-07
patients O 0 2.3639613573323004e-05
with O 0 1.5539319520030404e-07
isolated O 0 7.4534668783599045e-06
unilateral B-Disease 0 5.7357177865924314e-05
retinoblastoma I-Disease 0 0.006460168398916721
, O 0 1.3401786702615937e-07
we O 0 1.5325266389254466e-08
analyzed O 0 1.4300290729352128e-07
DNA O 0 6.99197286735398e-08
from O 0 8.949930574431164e-09
peripheral O 0 1.5419287819895544e-06
blood O 0 9.108437097893329e-07
and O 0 9.180298121691521e-08
from O 0 1.7566523524692457e-07
tumor B-Disease 0 0.015394634567201138
tissue O 0 0.0005794998724013567
. O 0 5.686229542334331e-06

The O 0 1.6583389879087918e-06
analysis O 0 6.959228926461947e-07
of O 0 9.690928237660046e-08
tumors B-Disease 1 0.998640239238739
from O 0 1.9674509132983076e-07
54 O 0 3.6168603401165456e-06
( O 0 3.796557379587284e-08
71 O 0 1.2603811683220556e-06
% O 0 1.8338933926997925e-08
) O 0 2.9101927534469496e-09
of O 0 3.902961065449517e-09
76 O 0 1.611008519830648e-05
informative O 0 5.1496594096533954e-05
patients O 0 0.2916512191295624
showed O 0 0.0004393580893520266
loss O 0 1.3830939451509039e-06
of O 0 1.3274351395864414e-08
constitutional O 0 0.00011035158968297765
heterozygosity O 0 0.19754493236541748
( O 0 2.0721859073091764e-06
LOH O 1 0.9992684721946716
) O 0 1.3988633895678504e-07
at O 0 1.6513871514689527e-07
intragenic O 0 3.800156991928816e-05
loci O 0 7.976656888786238e-06
. O 0 2.3587315354234306e-06

Three O 0 2.203180883952882e-06
of O 0 1.90614059647487e-07
13 O 0 2.2101885406300426e-06
uninformative O 0 0.020510897040367126
patients O 0 0.00831206701695919
had O 0 2.916512585215969e-06
constitutional O 0 6.883230526000261e-06
deletions O 0 0.00020440007210709155
. O 0 1.1722008821379859e-05

For O 0 6.503987606265582e-06
39 O 0 5.5839964261394925e-06
randomly O 0 9.233328341906599e-07
selected O 0 7.062756708364759e-07
tumors B-Disease 1 0.9847864508628845
, O 0 2.1479479528352385e-07
SSCP O 0 0.00012759520905092359
, O 0 4.191946914033906e-07
hetero O 0 4.438172618392855e-05
- O 0 2.8835331249865703e-05
duplex O 0 0.00024653872242197394
analysis O 0 1.756473153591287e-07
, O 0 1.452052345030097e-08
sequencing O 0 4.7586631524154654e-08
, O 0 1.1457008675108682e-08
and O 0 7.771475907247805e-09
Southern O 0 2.273726984469704e-08
blot O 0 2.032725024037063e-05
analysis O 0 5.0054282496603264e-08
were O 0 1.6128584690022763e-08
used O 0 6.043551081802434e-08
to O 0 2.3841350582642917e-07
identify O 0 1.0756053598015569e-05
mutations O 0 1.815758878365159e-05
. O 0 2.358736310270615e-06

Mutations O 0 0.028126947581768036
were O 0 9.169033546641003e-06
detected O 0 8.373416676477063e-06
in O 0 2.659469089394406e-07
21 O 0 1.1117282383565907e-06
( O 0 4.5351391975145816e-08
91 O 0 2.4910152660595486e-06
% O 0 2.3644735946959372e-08
) O 0 7.1788908151404485e-09
of O 0 1.9263149297898963e-08
23 O 0 0.004353631753474474
tumors B-Disease 1 0.9999802112579346
with O 0 0.0009304684936068952
LOH O 1 0.999985933303833
. O 0 2.761068390100263e-05

In O 0 6.433574526454322e-06
6 O 0 1.997745130211115e-06
( O 0 8.958438968420523e-08
38 O 0 4.7357099219880183e-07
% O 0 2.9640684573450926e-08
) O 0 3.977678186828371e-09
of O 0 1.4727710606621258e-08
16 O 0 0.0003215232864022255
tumors B-Disease 1 0.9999951124191284
without O 0 3.455230762483552e-05
LOH O 1 0.999936580657959
, O 0 9.527736466452552e-08
one O 0 4.754253879468706e-08
mutation O 0 2.761194082268048e-07
was O 0 2.56777781260098e-07
detected O 0 3.6735542607857496e-07
, O 0 1.2387483927511767e-08
and O 0 2.503825236033208e-08
in O 0 6.221233661563019e-08
9 O 0 5.053300924373616e-07
( O 0 1.561334883604104e-08
56 O 0 4.4631087803281844e-07
% O 0 1.1897508755964736e-08
) O 0 3.413696658682852e-09
of O 0 7.50747286559772e-09
the O 0 9.540513019601349e-06
tumors B-Disease 1 0.999998927116394
without O 0 0.0001249894849024713
LOH O 1 0.9999549388885498
, O 0 1.8155766667860007e-07
both O 0 8.56687591976879e-08
mutations O 0 1.0855287655431312e-06
were O 0 1.747722535583307e-07
found O 0 9.928083954946487e-07
. O 0 1.8178166101279203e-06

Thus O 0 1.246477768290788e-05
, O 0 1.507001741174463e-07
a O 0 3.704417750327593e-08
total O 0 1.4210367993428008e-08
of O 0 8.599680079157679e-09
45 O 0 5.375173941501998e-07
mutations O 0 9.360520607515355e-07
were O 0 1.4234298362225672e-07
identified O 0 6.334287263598526e-07
in O 0 4.0152298197426717e-07
tumors B-Disease 1 0.9997792840003967
of O 0 2.3672221516335412e-07
36 O 0 0.00020194413082208484
patients O 0 0.0003227870911359787
. O 0 3.5414318517723586e-06

Thirty O 0 7.524605462094769e-05
- O 0 1.607173908269033e-05
nine O 0 3.165328337217943e-07
of O 0 1.394261328613311e-08
the O 0 3.24047491062629e-08
mutations O 0 1.0572450719337212e-06
- O 0 5.226366738497745e-06
including O 0 1.6386860579586937e-07
34 O 0 5.617516762868036e-07
small O 0 1.2802351534446643e-07
mutations O 0 1.265335868083639e-06
, O 0 1.929742410311519e-08
2 O 0 5.3564349400403444e-08
large O 0 4.48406467512541e-08
structural O 0 1.0932021723419894e-05
alterations O 0 2.9315619030967355e-05
, O 0 9.213451335199352e-08
and O 0 1.6904552069263445e-07
hypermethylation O 0 0.00031816537375561893
in O 0 7.133971280381957e-07
3 O 0 2.9942360924906097e-05
tumors O 1 0.9999710321426392
- O 0 0.011108972132205963
were O 0 1.5738409047116875e-06
not O 0 4.294471978028014e-08
detected O 0 8.58021920180363e-08
in O 0 4.737505499008421e-09
the O 0 1.3101596252340642e-08
corresponding O 0 2.387994300079299e-07
peripheral O 0 2.4352228138013743e-05
blood O 0 1.9886871086782776e-05
DNA O 0 1.6459469406981952e-05
. O 0 1.6212031823670259e-06

In O 0 7.304462542379042e-06
6 O 0 3.7065638025524095e-06
( O 0 7.787994604768755e-08
17 O 0 1.7010869157729758e-07
% O 0 8.597941025811906e-09
) O 0 1.1296774626856632e-09
of O 0 8.944414098266407e-10
the O 0 2.246924601934097e-08
36 O 0 0.0001999985979637131
patients O 0 0.00010880670743063092
, O 0 4.149075394366264e-08
a O 0 6.308576416813594e-07
mutation O 0 1.0794029776661773e-06
was O 0 6.523939077851537e-07
detected O 0 1.8616118779846147e-07
in O 0 1.3759559713832914e-08
constitutional O 0 1.031987153510272e-06
DNA O 0 5.824266736453865e-06
, O 0 2.6650237572312108e-08
and O 0 9.532040934345787e-09
1 O 0 8.23522405823951e-09
of O 0 1.2569432161768646e-09
these O 0 7.252631828436051e-09
mutations O 0 3.220563939976273e-07
is O 0 1.704987084849563e-08
known O 0 4.7071090136796556e-08
to O 0 4.618610560669367e-08
be O 0 5.488293197686289e-08
associated O 0 7.428039339174575e-08
with O 0 1.6884236231362593e-07
reduced O 0 3.535543874022551e-05
expressivity O 0 0.07013300061225891
. O 0 1.2031760888930876e-05

The O 0 1.26530687794002e-06
presence O 0 4.2321195792283106e-07
of O 0 9.857738625385082e-09
a O 0 4.638305881599081e-07
constitutional O 0 2.3308170057134703e-05
mutation O 0 3.8790618418715894e-05
was O 0 2.4845760435709963e-06
not O 0 4.639155193331135e-08
associated O 0 1.7083824133123926e-08
with O 0 4.992801283520976e-09
an O 0 8.437952203621535e-08
early O 0 1.7732954802340828e-06
age O 0 6.542063601955306e-07
at O 0 2.2148002187805105e-07
treatment O 0 0.00010254353401251137
. O 0 3.710807959578233e-06

In O 0 1.1463758710306138e-05
1 O 0 2.3414941097144037e-06
patient O 0 8.347200491698459e-06
, O 0 9.368919506869133e-08
somatic O 0 6.19720822214731e-06
mosaicism O 0 0.009710084646940231
was O 0 2.17218494071858e-05
demonstrated O 0 6.110861932029366e-07
by O 0 2.176498270500815e-08
molecular O 0 2.195612154309856e-07
analysis O 0 2.264560272635663e-08
of O 0 3.751709165555894e-09
DNA O 0 3.4317827157792635e-07
and O 0 6.690762432981501e-08
RNA O 0 4.1575131604076887e-07
from O 0 9.455106209088626e-08
peripheral O 0 1.2824146324419416e-05
blood O 0 1.562416582601145e-05
. O 0 1.9228407381888246e-06

In O 0 2.202871473855339e-05
2 O 0 5.492838317877613e-05
patients O 0 2.68145067821024e-05
without O 0 5.127276381244883e-08
a O 0 5.896980610486935e-07
detectable O 0 1.1503962014103308e-05
mutation O 0 1.2382521390463808e-06
in O 0 6.678458674969079e-08
peripheral O 0 3.236194243072532e-05
blood O 0 2.0296782167861238e-05
, O 0 2.1545541528666945e-07
mosaicism O 0 0.0002741740318015218
was O 0 1.2682820852205623e-05
suggested O 0 2.995024317442585e-07
because O 0 9.84195747122385e-09
1 O 0 4.8006234543152004e-09
of O 0 2.688466338440776e-09
the O 0 3.5546210597203753e-07
patients O 0 0.002064779633656144
showed O 0 0.27042555809020996
multifocal O 1 0.9999856948852539
tumors B-Disease 1 0.9999996423721313
and O 0 3.3826401590886235e-07
the O 0 2.64873634137075e-08
other O 0 1.095092816427723e-08
later O 0 6.308774800345418e-07
developed O 0 7.293265298358165e-07
bilateral B-Disease 0 3.7708116451540263e-06
retinoblastoma I-Disease 0 0.07225237041711807
. O 0 1.2287071513128467e-05

In O 0 3.4902434435934993e-06
conclusion O 0 9.108158565140911e-07
, O 0 2.140459187671695e-08
our O 0 9.828188929361659e-09
results O 0 3.852521857083957e-08
emphasize O 0 1.1667661681258323e-07
that O 0 1.5372428663340543e-08
the O 0 4.738083703159646e-09
manifestation O 0 2.4216888050432317e-07
and O 0 4.669471209695075e-08
transmissibility O 0 1.3516810213332064e-06
of O 0 2.5515925372587844e-08
retinoblastoma B-Disease 0 2.4398834284511395e-05
depend O 0 1.5898783090051438e-07
on O 0 6.260574281213849e-08
the O 0 7.988066208497457e-09
nature O 0 9.130056710660028e-09
of O 0 1.303125829466012e-09
the O 0 5.720083517957164e-09
first O 0 1.6786121648237895e-07
mutation O 0 2.2025663781732874e-07
, O 0 3.6790601676273127e-09
its O 0 4.1082981461215695e-09
time O 0 9.52415390997885e-09
in O 0 5.633819188943789e-09
development O 0 6.471697844290247e-09
, O 0 7.202645591064538e-09
and O 0 4.658580188277028e-09
the O 0 2.9652036381833113e-09
number O 0 7.255136047490396e-09
and O 0 9.61220880668634e-09
types O 0 1.627422285821467e-08
of O 0 5.445684347904489e-09
cells O 0 1.8440869098412804e-07
that O 0 7.036107518842982e-08
are O 0 2.6895397908788254e-08
affected O 0 8.983163723996768e-08
. O 0 1.4271189741066337e-07
. O 0 1.1429592632339336e-06

Hereditary B-Disease 1 0.9999927282333374
deficiency I-Disease 1 0.9983739852905273
of I-Disease 0 1.3744089244482893e-07
the I-Disease 0 3.5735901349198684e-08
fifth I-Disease 0 6.595052468583162e-07
component I-Disease 0 6.656279794015063e-08
of I-Disease 0 5.418828052938807e-09
complement I-Disease 0 1.3737931681134796e-07
in O 0 1.733397567704742e-07
man O 0 6.594075966859236e-05
. O 0 2.2504386834043544e-06

I O 0 0.001105891540646553
. O 0 9.014876559376717e-05

Clinical O 0 0.0029901876114308834
, O 0 5.736306320613949e-06
immunochemical O 0 0.00017193116946145892
, O 0 8.298786724481033e-07
and O 0 3.6333091202322976e-07
family O 0 1.9410733784752665e-06
studies O 0 8.161060804923181e-07
. O 0 1.9186752524547046e-06

The O 0 1.6949071550698136e-06
first O 0 7.358645461863489e-07
recognized O 0 4.908183655061293e-07
human O 0 2.406204941962642e-07
kindred O 0 0.00023688242072239518
with O 0 0.003366206306964159
hereditary B-Disease 1 0.9999939203262329
deficiency I-Disease 0 0.4479241371154785
of I-Disease 0 9.90326931571417e-09
the I-Disease 0 2.8091887926962045e-08
fifth I-Disease 0 6.075426881579915e-07
component I-Disease 0 5.374877076746998e-08
of I-Disease 0 1.3013729649458128e-08
complement I-Disease 0 5.933031843596837e-07
( O 0 1.4961828753712325e-07
C5 O 0 1.2581602277350612e-05
) O 0 4.894488014883791e-08
is O 0 1.8838076698557416e-07
described O 0 7.453744274243945e-06
. O 0 2.2365786662703613e-06

The O 0 2.820455620167195e-06
proband O 0 2.8507063689175993e-05
, O 0 8.4921381926506e-08
a O 0 1.9741307255571883e-07
20 O 0 7.995279815986578e-08
- O 0 1.6491318319822312e-06
year O 0 2.1681086082026013e-07
- O 0 8.301181878778152e-06
old O 0 5.058452734374441e-05
black O 0 8.735966730455402e-06
female O 0 2.5665105567895807e-05
with O 0 0.0007932530716061592
systemic B-Disease 1 0.9999998807907104
lupus I-Disease 1 0.9999998807907104
erythematosus I-Disease 1 0.9999997615814209
since O 0 0.014663041569292545
age O 0 6.9678426370956e-06
11 O 0 2.489345263256837e-07
, O 0 8.791034389332708e-08
lacked O 0 8.184917533071712e-06
serum O 0 3.339141039759852e-05
hemolytic O 0 4.1848717955872416e-05
complement O 0 9.516149646060512e-08
activity O 0 4.907584738589321e-08
, O 0 3.418774241481515e-08
even O 0 1.9678488172303332e-07
during O 0 3.866947281494504e-06
remission O 0 0.00018019354320131242
. O 0 3.5617949833977036e-06

C5 O 0 0.10914763808250427
was O 0 0.0001429224357707426
undetectable O 0 3.237841883674264e-05
in O 0 1.8357137321345363e-07
her O 0 1.1019558314728783e-06
serum O 0 2.231801545349299e-06
by O 0 6.738134317174627e-08
both O 0 8.080781555008798e-08
immunodiffusion O 0 3.591780841816217e-05
and O 0 2.1512414605240338e-06
hemolytic O 0 0.017907757312059402
assays O 0 0.00012251173029653728
. O 0 4.348511538410094e-06

Other O 0 5.229669568507234e-07
complement O 0 3.5794775499198295e-07
components O 0 1.2070404409314506e-07
were O 0 2.5232321121393397e-08
normal O 0 2.916289787435744e-08
during O 0 1.2848009589561116e-07
remission O 0 7.729701792413834e-06
of O 0 1.369729858424762e-07
lupus O 1 0.5551100969314575
, O 0 2.6624533688845986e-07
but O 0 3.770801129121537e-07
C1 O 0 3.596424721763469e-05
, O 0 6.787252715412251e-08
C4 O 0 7.762138920952566e-06
, O 0 1.887306950720813e-07
C2 O 0 1.6939722627284937e-05
, O 0 5.0098119430685983e-08
and O 0 5.017280457764173e-08
C3 O 0 3.527246371959336e-05
levels O 0 1.7908293159507593e-07
fell O 0 4.6761833800701424e-06
during O 0 1.7641395970713347e-06
exacerbations O 0 0.31298789381980896
. O 0 1.6640784451738e-05

A O 0 5.481933112605475e-05
younger O 0 3.604307858040556e-05
half O 0 7.940391810734582e-07
- O 0 6.606637271033833e-06
sister O 0 7.372922937065596e-06
, O 0 6.70660611490348e-08
who O 0 1.1383935998310335e-06
had O 0 3.3328510653518606e-06
no O 0 1.4056678310225834e-06
underlying O 0 0.0032422137446701527
disease O 0 0.00020456171478144825
, O 0 1.1616411654813419e-07
was O 0 8.030421668081544e-06
also O 0 1.5889084181708313e-07
found O 0 2.5151742022444523e-08
to O 0 3.533964942903367e-08
lack O 0 8.584898978369893e-07
immunochemically O 0 0.014789950102567673
detectable O 0 0.00017484182899352163
C5 O 0 0.00010142545943381265
. O 0 1.730811845845892e-06

By O 0 1.639996116864495e-05
hemolytic O 0 0.015922963619232178
assay O 0 4.902169166598469e-05
, O 0 7.45128204471257e-07
she O 0 2.7250978291704087e-06
exhibited O 0 1.2030623111058958e-06
1 O 0 5.4919794933994126e-08
- O 0 5.021592642151518e-06
2 O 0 1.4939058701202157e-07
% O 0 5.343738340712889e-09
of O 0 5.109542233761033e-10
the O 0 1.479807743010042e-08
normal O 0 2.311402198529322e-07
serum O 0 3.569653699742048e-06
C5 O 0 4.1583634811104275e-06
level O 0 2.733207260519066e-08
and O 0 2.7143952863184495e-08
normal O 0 4.717400159393037e-08
concentrations O 0 6.379099914965991e-08
of O 0 1.9677797169492806e-09
other O 0 6.209849967575565e-09
complement O 0 2.631153677157272e-07
components O 0 1.135599291046674e-06
. O 0 7.791067559992371e-07

C5 O 0 0.014539910480380058
levels O 0 4.6723944251425564e-06
of O 0 3.887383215328555e-08
other O 0 2.0101158071383907e-08
family O 0 1.1338901373392218e-07
members O 0 1.341807465138345e-08
were O 0 6.168912136672589e-08
either O 0 4.409580611763886e-08
normal O 0 4.980704915169554e-08
or O 0 1.2599921994649321e-08
approximately O 0 7.832547055386385e-09
half O 0 4.6530413300160944e-08
- O 0 4.677922788687283e-06
normal O 0 2.1867144539555738e-07
, O 0 2.8050713751781586e-08
consistent O 0 2.726683874243463e-07
with O 0 1.300066287512891e-06
autosomal O 0 0.11804387718439102
codominant O 0 0.00375200598500669
inheritance O 0 1.104964553633181e-06
of O 0 9.410591417235992e-09
the O 0 9.816015023034197e-08
gene O 0 4.959242232871475e-06
determining O 0 4.9100381147582084e-05
C5 B-Disease 1 0.9999959468841553
deficiency I-Disease 1 0.9999958276748657
. O 0 3.3179752790601924e-05

Normal O 0 0.0010010154219344258
hemolytic O 1 0.9525400996208191
titers O 0 0.0173041895031929
were O 0 4.718840500572696e-06
restored O 0 2.5817691948759602e-06
to O 0 2.703220616240287e-07
both O 0 1.0025732990470715e-06
homozygous O 0 0.017632152885198593
C5 B-Disease 1 0.9999449253082275
- I-Disease 1 0.99994957447052
deficient I-Disease 1 0.9999971389770508
( O 0 2.0786280856555095e-06
C5D B-Disease 1 0.9999550580978394
) O 0 3.361396352374868e-07
sera O 0 7.257993729581358e-06
by O 0 2.110085794981842e-08
addition O 0 1.0633253388903086e-08
of O 0 3.686126071045237e-09
highly O 0 2.1829428931141592e-07
purified O 0 4.183877990726614e-06
human O 0 1.157841325039044e-06
C5 O 0 0.00012591011181939393
. O 0 5.595180937234545e-06

In O 0 6.893149929965148e-06
specific O 0 1.204003524435393e-06
C5 O 0 0.00015688421262893826
titrations O 0 0.005265240091830492
, O 0 6.544335064972984e-07
however O 0 1.8195841278156877e-07
, O 0 2.4859044600589186e-08
it O 0 2.3311613972509804e-08
was O 0 1.3719682101509534e-06
noted O 0 2.297048382615685e-07
that O 0 1.0803504757461724e-08
when O 0 2.2335928662187143e-08
limited O 0 1.2557121564782392e-08
amounts O 0 7.431749438069346e-09
of O 0 5.529395163961226e-09
C5 O 0 2.117513986377162e-06
were O 0 7.280799252384895e-08
assayed O 0 6.220989803296106e-07
in O 0 1.3017229960610166e-08
the O 0 3.255366198828824e-09
presence O 0 1.0821570306518424e-08
of O 0 4.010558551925669e-09
low O 0 3.512414536999131e-07
dilutions O 0 8.708724635653198e-06
of O 0 2.72412012947143e-08
either O 0 9.477528237766819e-07
C5D B-Disease 1 0.9999727010726929
serum O 0 2.433103509247303e-05
, O 0 1.3329153780716751e-08
curving O 0 1.7298006582677772e-07
rather O 0 3.4621365330167464e-08
than O 0 2.321258385507008e-08
linear O 0 5.462184731186426e-07
dose O 0 9.078249604499433e-06
- O 0 1.1721540431608446e-05
response O 0 5.446465252134658e-07
plots O 0 2.835889176822093e-07
were O 0 1.3412039834292955e-07
consistently O 0 1.5349099840022973e-06
obtained O 0 1.517217356195033e-07
, O 0 1.5376739881389767e-08
suggesting O 0 9.290585722965261e-08
some O 0 2.3467487508810336e-08
inhibitory O 0 1.698241817393864e-06
effect O 0 2.2023741621524096e-06
. O 0 1.1060429869758082e-06

Further O 0 1.7803375158109702e-05
studies O 0 2.5634569738031132e-06
suggested O 0 1.2081222848792095e-06
that O 0 9.710596771128621e-08
low O 0 9.319920764028211e-07
dilutions O 0 2.373335519223474e-05
of O 0 2.3104456658984418e-07
C5D B-Disease 1 0.9999914169311523
serum O 0 7.572011963929981e-05
contain O 0 1.250590315748923e-07
a O 0 2.1369922365011007e-07
factor O 0 7.250587685803112e-08
( O 0 1.0603360856009658e-08
or O 0 6.869011581756013e-09
factors O 0 9.191051475454515e-09
) O 0 5.615377496326346e-09
interfering O 0 2.9536279200215176e-08
at O 0 9.886396590275126e-09
some O 0 3.921735824974348e-09
step O 0 5.3232120933444094e-08
in O 0 1.0890438773003552e-08
the O 0 3.256423397601793e-08
hemolytic O 0 8.268499368568882e-05
assay O 0 1.3465783013089094e-06
of O 0 2.6851777690239942e-08
C5 O 0 3.840831413981505e-05
, O 0 4.378554763206921e-08
rather O 0 2.706144996977855e-08
than O 0 1.8554610292653706e-08
a O 0 2.831921790402703e-07
true O 0 1.731843894958729e-06
C5 O 0 3.518434095894918e-05
inhibitor O 0 1.352582148683723e-05
or O 0 6.051141667740012e-07
inactivator O 0 0.000245285511482507
. O 0 4.631376214092597e-06

Of O 0 2.992088866449194e-06
clinical O 0 5.755409074481577e-05
interest O 0 4.4798588305638987e-07
are O 0 4.477774240285726e-08
( O 0 1.944128236175402e-08
a O 0 2.568654622336908e-07
) O 0 1.014868278303993e-08
the O 0 5.867895946920498e-09
documentation O 0 7.979283367376411e-08
of O 0 1.0845150910654411e-07
membranous O 1 0.9978189468383789
glomerulonephritis B-Disease 1 0.9999997615814209
, O 0 0.18481233716011047
vasculitis B-Disease 1 0.999997615814209
, O 0 3.3238720789086074e-05
and O 0 0.002162280725315213
arthritis B-Disease 1 1.0
in O 0 1.5195196283457335e-06
an O 0 4.245014508796885e-07
individual O 0 1.0924082971541793e-07
lacking O 0 6.053200195310637e-06
C5 O 0 0.00011632638779701665
( O 0 2.328019910180501e-08
and O 0 7.951553193663585e-09
its O 0 2.5974506101533734e-08
biologic O 0 2.277035491715651e-06
functions O 0 2.772877749634972e-08
) O 0 1.356725931600522e-08
, O 0 2.0009350620853184e-08
and O 0 5.905310018761156e-08
( O 0 1.7425890064259875e-08
b O 0 5.4111364278242036e-08
) O 0 2.7162792015644754e-09
a O 0 4.045995538604075e-08
remarkable O 0 3.3844628433143953e-07
propensity O 0 2.7328762371325865e-05
to O 0 0.00013471579586621374
bacterial B-Disease 1 0.999997615814209
infections I-Disease 1 0.9999992847442627
in O 0 2.39801977386378e-07
the O 0 3.4200134280126804e-08
proband O 0 2.8938909963471815e-05
, O 0 1.6050391238309203e-08
even O 0 9.652628030210053e-09
during O 0 1.2819645789363676e-08
periods O 0 2.0816118606603595e-08
of O 0 2.273288002285767e-09
low O 0 1.551101007635225e-07
- O 0 1.2610336852958426e-05
dose O 0 6.964680778764887e-06
or O 0 1.1976765357246677e-08
alternate O 0 6.439243804834405e-08
- O 0 4.484865712583996e-06
day O 0 2.244561756015173e-06
corticosteroid O 1 0.6224963665008545
therapy O 0 0.0010852008126676083
. O 0 2.3141403744375566e-06

Other O 0 1.5163507214310812e-06
observations O 0 3.210385102647706e-06
indicate O 0 8.023493478503951e-07
that O 0 6.892427961702197e-08
the O 0 1.1438999081292422e-07
C5D B-Disease 1 0.999962568283081
state O 0 1.21968113830917e-07
is O 0 9.602881156922649e-09
compatible O 0 3.440649365415993e-08
with O 0 2.3266794713094896e-08
normal O 0 9.441968273904422e-08
coagulation O 0 2.803053291700053e-07
function O 0 1.749372557924289e-08
and O 0 7.387499945110676e-09
the O 0 1.0151430807070483e-08
capacity O 0 6.205613800602805e-08
to O 0 3.380272062258882e-08
mount O 0 1.7447562186134746e-06
a O 0 2.180958654207643e-05
neutrophilic O 0 0.29880398511886597
leukocytosis O 0 0.08439204096794128
during O 0 8.851477468851954e-05
pyogenic B-Disease 1 0.9616684317588806
infection I-Disease 0 0.03753289580345154
. O 0 7.674347557440342e-07
. O 0 1.330908048657875e-06

Susceptibility O 1 0.9947803616523743
to O 0 0.44232356548309326
ankylosing B-Disease 1 0.9999998807907104
spondylitis I-Disease 1 1.0
in O 0 0.014366654679179192
twins O 0 0.004203751217573881
: O 0 2.7234500876716083e-08
the O 0 3.6087541843699e-09
role O 0 1.9267339723683108e-08
of O 0 4.638064599049585e-09
genes O 0 1.5179206513948884e-07
, O 0 1.7029793752953992e-07
HLA O 0 0.00022725255985278636
, O 0 1.6272848313292343e-07
and O 0 3.700512607451856e-08
the O 0 9.309423631975733e-08
environment O 0 3.814522415268584e-06
. O 0 2.2877488845551852e-06

OBJECTIVE O 0 2.819038309098687e-05
To O 0 6.237844445422525e-07
determine O 0 2.869090565127408e-07
the O 0 1.4310435503261942e-08
relative O 0 1.9004140483502852e-07
effects O 0 2.194255586118743e-07
of O 0 1.243826819319338e-08
genetic O 0 1.3238216070021736e-06
and O 0 2.3600495069331373e-07
environmental O 0 4.458811986296496e-07
factors O 0 5.8915283318583533e-08
in O 0 4.949704361933982e-07
susceptibility O 1 0.9755679368972778
to O 1 0.9850448966026306
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.0001520760852145031
AS B-Disease 1 0.7003050446510315
) O 0 7.69084692819888e-07
. O 0 1.0281617051077774e-06

METHODS O 0 0.00022749863273929805
Twins O 0 0.001697068684734404
with O 0 9.85577457868203e-07
AS B-Disease 0 0.0800042375922203
were O 0 2.701808057281596e-07
identified O 0 8.967089115685667e-08
from O 0 2.309558544411061e-09
the O 0 6.598019020032098e-09
Royal O 0 2.729394282141584e-06
National O 0 1.51278456428372e-07
Hospital O 0 5.623314791591838e-05
for O 0 5.6730186770437285e-06
Rheumatic B-Disease 1 0.9999716281890869
Diseases I-Disease 0 0.05148595571517944
database O 0 9.504187801212538e-06
. O 0 1.943956021932536e-06

Clinical O 0 0.0011352309957146645
and O 0 2.5423685201531043e-06
radiographic O 0 0.0029581065755337477
examinations O 0 1.1433329746068921e-05
were O 0 3.4344412824793835e-07
performed O 0 5.633628461509943e-07
to O 0 6.696661358773781e-08
establish O 0 9.324908205599058e-07
diagnoses O 1 0.729995608329773
, O 0 1.9507422166498145e-06
and O 0 0.0002541684953030199
disease O 0 0.018188243731856346
severity O 0 0.025810401886701584
was O 0 0.00010287907934980467
assessed O 0 2.8902670123898133e-07
using O 0 3.201140685860082e-08
a O 0 1.0047050835737537e-07
combination O 0 1.315930262535403e-07
of O 0 1.0583498522009904e-08
validated O 0 1.3692221045857877e-06
scoring O 0 8.578597316954983e-07
systems O 0 3.83002543458133e-06
. O 0 2.104918166878633e-06

HLA O 0 0.013499202206730843
typing O 0 0.00010122931416844949
for O 0 3.4466841043467866e-06
HLA O 0 0.00029810250271111727
- O 0 0.00011990562779828906
B27 O 0 2.106779174937401e-05
, O 0 1.6550039561025187e-07
HLA O 0 2.2403131879400462e-05
- O 0 1.768800757417921e-05
B60 O 0 8.951947165769525e-06
, O 0 2.974477908423978e-08
and O 0 6.432247090515375e-08
HLA O 0 0.0008755991002544761
- O 0 0.09214792400598526
DR1 O 1 0.9998579025268555
was O 0 5.39787697562133e-06
performed O 0 1.0588166787783848e-07
by O 0 7.80451170356855e-09
polymerase O 0 3.662050005459605e-07
chain O 0 5.015601232116751e-07
reaction O 0 8.147920027568034e-08
with O 0 9.544939949535092e-09
sequence O 0 2.5230493250205654e-08
- O 0 3.8220238707253884e-07
specific O 0 1.0121116389427698e-08
primers O 0 1.0497631137695862e-06
, O 0 1.9314436272566127e-08
and O 0 1.808094296507079e-08
zygosity O 0 9.515742931398563e-06
was O 0 6.672270842500438e-07
assessed O 0 1.327876191226096e-07
using O 0 1.9029349118682148e-07
microsatellite O 0 6.606386159546673e-05
markers O 0 2.9475493647623807e-05
. O 0 4.277184871170903e-06

Genetic O 0 0.0020159378182142973
and O 0 3.60277340405446e-06
environmental O 0 8.661692731948278e-07
variance O 0 1.5586680035539757e-07
components O 0 3.2661151294632873e-07
were O 0 3.90544329320619e-07
assessed O 0 3.6375979561853455e-07
with O 0 1.9430199671433e-08
the O 0 1.753809364402059e-08
program O 0 4.770713957213957e-08
Mx O 0 7.900615059952543e-07
, O 0 4.26557100752234e-09
using O 0 4.596794944689009e-09
data O 0 5.496042732033857e-09
from O 0 1.7808833296939497e-09
this O 0 3.9093608350526665e-09
and O 0 1.7242824057461803e-08
previous O 0 1.379672482926253e-07
studies O 0 1.4128236358601498e-08
of O 0 6.682915998368344e-09
twins O 0 4.20055293943733e-05
with O 0 3.4446259178366745e-07
AS B-Disease 1 0.6631755232810974
. O 0 9.797599886951502e-06

RESULTS O 0 0.00012621519272215664
Six O 0 6.242462404770777e-07
of O 0 4.8102222649504256e-08
8 O 0 1.7659929198998725e-06
monozygotic O 0 0.0003508802328724414
( O 0 5.363280024539563e-07
MZ O 1 0.9721741676330566
) O 0 7.007793669799867e-07
twin O 0 0.03765355795621872
pairs O 0 3.5313782973389607e-06
were O 0 1.5921246813377365e-05
disease O 0 1.345540840702597e-05
concordant O 0 0.00025477385497651994
, O 0 6.677706778646098e-07
compared O 0 5.038618269281869e-07
with O 0 1.5766147498652572e-08
4 O 0 3.7453617096616654e-08
of O 0 5.364284572095812e-09
15 O 0 1.4460800912274863e-07
B27 O 0 2.7412897907197475e-06
- O 0 1.4321147318696603e-05
positive O 0 7.78211187935085e-07
dizygotic O 0 4.870842531090602e-06
( O 0 4.0081822305637616e-08
DZ O 0 2.798726018227171e-05
) O 0 9.264060452096601e-08
twin O 0 7.803740300005302e-05
pairs O 0 3.228220748496824e-07
( O 0 2.38772717153779e-08
27 O 0 4.767389327753335e-07
% O 0 1.1571516189690101e-08
) O 0 2.696848078187486e-09
and O 0 6.778271721685769e-09
4 O 0 2.0131162514758216e-08
of O 0 4.766472994077731e-09
32 O 0 6.235655973796383e-07
DZ O 0 0.0007196272490546107
twin O 0 0.002941498998552561
pairs O 0 2.430847132472991e-07
overall O 0 4.1144019746752747e-07
( O 0 2.3693447204209406e-08
12 O 0 1.1244826225720317e-07
. O 0 4.0167154935488725e-08
5 O 0 1.4778282775296248e-07
% O 0 8.187396360881394e-08
) O 0 1.1260279109137628e-07
. O 0 7.602405958095915e-07

Nonsignificant O 0 0.004501109477132559
increases O 0 5.011766916140914e-05
in O 0 2.7559482873584784e-07
similarity O 0 5.587164650933119e-07
with O 0 9.041246329388741e-08
regard O 0 2.2130730314984248e-07
to O 0 6.62968432152411e-07
age O 0 5.885479822609341e-06
at O 0 1.0932061513813096e-06
disease O 0 0.00010168596054427326
onset O 0 1.212385996041121e-05
and O 0 9.46338758467391e-08
all O 0 2.9908264753686353e-09
of O 0 2.9841595861057613e-09
the O 0 4.08729960099663e-07
disease O 0 0.00024551598471589386
severity O 0 0.005700386129319668
scores O 0 1.3575547200161964e-05
assessed O 0 1.9671049358294113e-06
were O 0 2.1823122153818986e-07
noted O 0 7.136815725061751e-07
in O 0 7.617022106387594e-07
disease O 0 0.00010072389704873785
- O 0 0.2975037395954132
concordant O 1 0.9966601133346558
MZ O 1 0.9999638795852661
twins O 0 0.14786216616630554
compared O 0 3.415836090425728e-06
with O 0 7.048431029943458e-07
concordant O 0 0.022800089791417122
DZ O 1 0.881243109703064
twins O 0 0.007581595331430435
. O 0 7.361267307715025e-06

HLA O 0 0.2919199764728546
- O 0 0.0006990053807385266
B27 O 0 6.615236634388566e-05
and O 0 4.757619649353728e-07
B60 O 0 6.3079896790441126e-06
were O 0 2.1994345900111512e-07
associated O 0 4.760860150554436e-08
with O 0 2.9848727933767805e-08
the O 0 1.8784771782520693e-06
disease O 0 6.55517796985805e-05
in O 0 1.779155240910768e-07
probands O 0 0.0049764011055231094
, O 0 4.1804689487889846e-08
and O 0 5.6037476880987924e-09
the O 0 6.542791197716724e-09
rate O 0 8.100302295588335e-08
of O 0 1.3689064992661315e-08
disease O 0 2.0175114059384214e-06
concordance O 0 1.1239760169701185e-05
was O 0 4.4242529838811606e-05
significantly O 0 2.24294171857764e-06
increased O 0 3.059903406210651e-07
among O 0 8.57933599718308e-08
DZ O 0 0.006901053246110678
twin O 0 0.0425628162920475
pairs O 0 1.7826590692493482e-07
in O 0 1.2110202618487165e-08
which O 0 2.4796252162673227e-08
the O 0 2.378155272708682e-08
co O 0 6.336091701086843e-06
- O 0 6.054888217477128e-05
twin O 0 0.013475056737661362
was O 0 7.8018490512477e-07
positive O 0 2.0461211391875622e-08
for O 0 1.0741207034925537e-08
both O 0 6.298675003790777e-08
B27 O 0 2.7288810088066384e-05
and O 0 4.261492904333863e-06
DR1 O 1 0.9960871934890747
. O 0 7.972838830028195e-06

Additive O 0 0.00022814357362221926
genetic O 0 9.118104935623705e-05
effects O 0 1.4148444279271644e-05
were O 0 3.895422082678124e-07
estimated O 0 1.5343523784849822e-07
to O 0 7.40316039582467e-08
contribute O 0 8.856181921146344e-08
97 O 0 3.628398985711101e-07
% O 0 1.5699590960593923e-08
of O 0 2.4734645442947567e-09
the O 0 4.507371187401077e-08
population O 0 2.2880537642322452e-07
variance O 0 7.049257533253694e-07
. O 0 1.5305511169572128e-06

CONCLUSION O 0 0.0005837439675815403
Susceptibility O 0 0.11578567326068878
to O 0 8.311368219438009e-06
AS B-Disease 0 0.2285776138305664
is O 0 4.2538491129562317e-07
largely O 0 3.004109601079108e-07
genetically O 0 4.162333482327085e-07
determined O 0 1.0478127023816342e-06
, O 0 1.6723127771456348e-08
and O 0 5.200839758856546e-09
the O 0 6.115278061713525e-09
environmental O 0 1.0906657621490012e-07
trigger O 0 1.0671765267034061e-06
for O 0 7.151614767053616e-08
the O 0 1.8210317875855253e-06
disease O 0 3.953401756007224e-05
is O 0 1.7195898749378102e-07
probably O 0 1.1718663017745712e-06
ubiquitous O 0 1.0734186616900843e-05
. O 0 2.6548493679001695e-06

HLA O 1 0.8630338311195374
- O 0 0.003119461005553603
B27 O 0 7.05272686900571e-05
accounts O 0 3.941731279155647e-07
for O 0 2.1342545508673538e-08
a O 0 1.6313916262333805e-07
minority O 0 2.981265652124421e-07
of O 0 4.366559114288293e-09
the O 0 4.993851376866587e-08
overall O 0 6.950772331038024e-06
genetic O 0 2.1050920622656122e-05
susceptibility O 0 0.0011328102555125952
to O 0 2.2780541257816367e-06
AS B-Disease 1 0.941009521484375
. O 0 1.4060061403142754e-05

Cell O 0 0.0002910730254370719
cycle O 0 3.3706670365063474e-05
- O 0 4.844149589189328e-05
dependent O 0 2.0167210550425807e-06
colocalization O 0 3.2617747365293326e-06
of O 0 3.134038095709002e-08
BARD1 O 0 0.00010625628056004643
and O 0 2.2623569861934811e-07
BRCA1 O 0 6.470456355600618e-06
proteins O 0 4.6701838840590426e-08
in O 0 1.5251490737000495e-08
discrete O 0 6.055857397768705e-07
nuclear O 0 2.017384531427524e-06
domains O 0 1.9266751678514993e-06
. O 0 1.436224692952237e-06

Germ O 0 0.0010394392302259803
- O 0 0.0019609062001109123
line O 0 2.339259117434267e-05
mutations O 0 2.492025032552192e-06
of O 0 1.200329258210786e-08
the O 0 1.3902585749292484e-07
BRCA1 O 0 0.00014202119200490415
gene O 0 2.172019321733387e-06
predispose O 0 1.2372662240522914e-05
women O 0 3.3697443768687663e-07
to O 0 8.934175355079788e-08
early O 0 2.696124738577055e-06
- O 0 0.4866582751274109
onset O 1 0.725236177444458
breast B-Disease 1 0.9999217987060547
and I-Disease 1 0.9948822259902954
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999979734420776
by O 0 1.8250271693887044e-07
compromising O 0 2.4178013973141788e-06
the O 0 7.052284445308032e-08
genes O 0 4.073310435614985e-07
presumptive O 0 0.003430466167628765
function O 0 1.2245050129422452e-07
as O 0 5.374938893965009e-08
a O 0 2.0533243514364585e-06
tumor B-Disease 0 0.0004484419187065214
suppressor O 0 0.0011357854818925261
. O 0 8.661017091071699e-06

Although O 0 1.714211430225987e-05
the O 0 1.5890476845470403e-07
biochemical O 0 3.2421062314824667e-06
properties O 0 2.5410906800971134e-07
of O 0 2.8587658462697618e-08
BRCA1 O 0 4.029812407679856e-05
polypeptides O 0 4.229999831295572e-06
are O 0 3.232684164800048e-08
not O 0 4.849243850912899e-08
understood O 0 1.3921135177952237e-07
, O 0 4.237553419272899e-09
their O 0 3.956280636430165e-09
expression O 0 5.656271184761863e-08
pattern O 0 9.6628554047129e-08
and O 0 2.7354445819582907e-08
subcellular O 0 9.800736506804242e-07
localization O 0 3.991201253938925e-07
suggest O 0 7.98636392573826e-08
a O 0 4.888227778110377e-08
role O 0 9.239214904255277e-08
in O 0 5.758422005897046e-08
cell O 0 4.690413334174082e-06
- O 0 3.350387851241976e-05
cycle O 0 3.5202385788579704e-06
regulation O 0 3.2623127026454313e-06
. O 0 2.421719727863092e-06

When O 0 2.521656824683305e-05
resting O 0 9.27975052036345e-05
cells O 0 1.2689575896729366e-06
are O 0 3.007313864600292e-08
induced O 0 2.4127384676830843e-06
to O 0 1.0476113487811745e-07
proliferate O 0 7.954876650728693e-07
, O 0 7.460225326383352e-09
the O 0 3.336686260624333e-09
steady O 0 4.216802267364983e-07
- O 0 1.7644945273787016e-06
state O 0 2.9121267175469256e-08
levels O 0 7.586035799533875e-09
of O 0 1.9018429053829777e-09
BRCA1 O 0 1.6458463960589143e-06
increase O 0 1.0330786892609467e-07
in O 0 2.265566934056551e-08
late O 0 1.1741303751477972e-06
G1 O 0 0.000386469007935375
and O 0 3.4426715700419663e-08
reach O 0 2.3377779712063784e-08
a O 0 8.237410753508811e-08
maximum O 0 3.5666587905325287e-07
during O 0 3.840676754407468e-07
S O 0 0.00012349510507192463
phase O 0 7.321710199903464e-06
. O 0 3.017031531271641e-06

Moreover O 0 6.720756937284023e-05
, O 0 8.801283684078953e-07
in O 0 1.5398362052110315e-07
S O 0 0.0001524297404102981
phase O 0 4.01736951971543e-06
cells O 0 1.4370343706104904e-06
, O 0 1.206439748102639e-07
BRCA1 O 0 4.204885954095516e-06
polypeptides O 0 9.27229564240406e-07
are O 0 2.2472502081427592e-08
hyperphosphorylated O 0 2.2787342004448874e-06
and O 0 3.744861842847058e-08
accumulate O 0 2.0911093656650337e-07
into O 0 1.8079528985026627e-08
discrete O 0 3.8181332229214604e-07
subnuclear O 0 1.6193680494325235e-05
foci O 0 8.22859783511376e-06
termed O 0 5.116753072798019e-06
" O 0 9.343539204564877e-07
BRCA1 O 0 2.6505604182602838e-05
nuclear O 0 3.609486384448246e-06
dots O 0 6.196570029715076e-05
. O 0 5.048111688665813e-06

" O 0 0.00013166152348276228
BRCA1 O 0 0.23574618995189667
associates O 0 0.00015919095312710851
in O 0 4.0890930108616885e-07
vivo O 0 3.281404133304022e-05
with O 0 2.0197821015699446e-07
a O 0 8.76573449204443e-06
structurally O 0 0.004155146423727274
related O 0 9.8403825177229e-07
protein O 0 2.5205106339853955e-06
termed O 0 3.09419228869956e-05
BARD1 O 0 0.004611754324287176
. O 0 8.220848940254655e-06

Here O 0 2.4205053250625497e-06
we O 0 9.992031380079425e-08
show O 0 8.316963118204512e-08
that O 0 7.735465601399483e-09
the O 0 6.733956059434831e-09
steady O 0 5.427783094091865e-07
- O 0 1.692096930128173e-06
state O 0 4.111780782523056e-08
levels O 0 8.160077946683941e-09
of O 0 3.9914036520372065e-09
BARD1 O 0 4.632051059161313e-05
, O 0 3.397115833081443e-08
unlike O 0 2.3614582289610553e-08
those O 0 2.638765872475801e-09
of O 0 5.030732275201899e-09
BRCA1 O 0 2.35718962358078e-05
, O 0 2.1747082712408883e-07
remain O 0 1.6335587815774488e-07
relatively O 0 8.218579239382962e-08
constant O 0 1.7769185944871424e-07
during O 0 1.5819138354800089e-07
cell O 0 5.252138635114534e-06
cycle O 0 3.7391309888334945e-06
progression O 0 1.815937321225647e-05
. O 0 2.967586851809756e-06

However O 0 1.0678803846531082e-05
, O 0 2.817351116846112e-07
immunostaining O 0 2.9696551791857928e-05
revealed O 0 4.985347004549112e-06
that O 0 1.2550852090953413e-07
BARD1 O 0 0.00016482606588397175
resides O 0 1.9378144315851387e-06
within O 0 2.332513382441448e-08
BRCA1 O 0 2.157555400117417e-06
nuclear O 0 6.021953709023364e-07
dots O 0 2.640268348841346e-06
during O 0 6.322681542769715e-07
S O 0 2.7493313609738834e-05
phase O 0 1.3600998727270053e-07
of O 0 3.4802092319097255e-09
the O 0 1.4072485399196921e-08
cell O 0 7.434474582623807e-07
cycle O 0 1.5448357260083867e-07
, O 0 8.912725668608346e-09
but O 0 7.444262983824501e-09
not O 0 6.908455585374895e-09
during O 0 2.397676190923903e-08
the O 0 5.8650790890624194e-08
G1 O 0 0.00041950427112169564
phase O 0 1.1783609807025641e-05
. O 0 2.8058263978891773e-06

Nevertheless O 0 0.0002633583208080381
, O 0 1.8392744323136867e-06
BARD1 O 0 3.713928163051605e-05
polypeptides O 0 3.075237373195705e-06
are O 0 1.5129483443843128e-08
found O 0 1.566782081852125e-08
exclusively O 0 2.009264932212318e-08
in O 0 7.565055248903718e-09
the O 0 3.5658263008997437e-09
nuclear O 0 3.050107721946915e-08
fractions O 0 4.158900424044987e-08
of O 0 3.089829281321954e-09
both O 0 4.5080419397436344e-08
G1 O 0 3.771736010094173e-05
- O 0 6.115092674008338e-06
and O 0 2.7833812055177987e-07
S O 0 3.850263237836771e-05
- O 0 1.789466114132665e-05
phase O 0 7.118169378372841e-06
cells O 0 6.966507498873398e-06
. O 0 1.6737603800720535e-06

Therefore O 0 2.545171264500823e-05
, O 0 7.006550504229381e-07
progression O 0 1.6420633528468898e-06
to O 0 1.597506553707717e-07
S O 0 0.00014725769869983196
phase O 0 8.749931339480099e-07
is O 0 4.0753651120439827e-08
accompanied O 0 1.2900338219878904e-07
by O 0 5.58536150663258e-09
the O 0 3.012685878545085e-09
aggregation O 0 6.056914259033874e-08
of O 0 7.106196964201672e-09
nuclear O 0 4.582074097925215e-07
BARD1 O 0 2.0334286091383547e-05
polypeptides O 0 1.657028406043537e-06
into O 0 3.925970588625205e-07
BRCA1 O 0 2.1201376512181014e-05
nuclear O 0 3.1982135624275543e-06
dots O 0 3.1225783459376544e-05
. O 0 4.490434093895601e-06

This O 0 2.807191322062863e-06
cell O 0 1.1018939403584227e-05
cycle O 0 1.4222075606085127e-06
- O 0 4.0486779653292615e-06
dependent O 0 4.42685660573261e-07
colocalization O 0 1.886048721644329e-06
of O 0 1.5551409049407994e-08
BARD1 O 0 0.00010462186037329957
and O 0 5.038133394918987e-07
BRCA1 O 0 2.2272715796134435e-05
indicates O 0 1.7648029881911498e-07
a O 0 1.3072670412839216e-07
role O 0 8.057741496259041e-08
for O 0 5.2211081680297866e-08
BARD1 O 0 0.0010451459093019366
in O 0 5.796898108201276e-07
BRCA1 O 0 0.0001583092234795913
- O 0 0.0012438180856406689
mediated O 0 0.014957688748836517
tumor B-Disease 0 0.021625544875860214
suppression O 0 2.6370464183855802e-05
. O 0 5.718914508179296e-06

Ethnic O 0 4.3205171095905825e-05
differences O 0 9.1236324806232e-06
in O 0 3.0230836500777514e-07
the O 0 1.8832598414064705e-07
HFE O 0 0.00016851451073307544
codon O 0 5.382384188123979e-06
282 O 0 1.1366371836629696e-05
( O 0 1.620751845621271e-06
Cys O 0 0.012815223075449467
/ O 0 0.00010514363384572789
Tyr O 0 0.00028338038828223944
) O 0 7.317678409890505e-07
polymorphism O 0 3.1738803954795e-05
. O 0 2.732009079409181e-06

Recent O 0 3.2814325095387176e-05
studies O 0 2.9811742479068926e-06
have O 0 4.782193059327255e-07
shown O 0 4.417613581608748e-06
that O 0 0.0013036178424954414
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.00013877038145437837
HH B-Disease 1 0.9874240756034851
) O 0 9.207320061932478e-08
is O 0 5.2300684671990894e-08
likely O 0 2.339569675768871e-07
to O 0 4.5104499690751254e-08
be O 0 4.2822435375455825e-07
caused O 0 1.8203702438768232e-06
by O 0 7.591481931967792e-08
homozygosity O 0 2.203487019869499e-05
for O 0 4.637270833995899e-08
a O 0 1.7008724171319045e-06
Cys282Tyr O 0 0.00025400161393918097
mutation O 0 9.336868060927372e-07
in O 0 1.5275713138862557e-08
the O 0 3.190022823673644e-08
HFE O 0 0.00015791978512424976
gene O 0 6.767080549252569e-07
located O 0 2.110388095388771e-07
4 O 0 6.064000217520515e-07
. O 0 6.501380767076625e-07

5 O 0 8.556766260880977e-05
Mb O 0 0.0007463560323230922
telomeric O 0 0.0016364010516554117
to O 0 1.2795183465641458e-05
HLA O 0 0.001843712874688208
- O 0 0.00023643385793548077
A O 0 4.393078779685311e-05
. O 0 5.496943686011946e-06

Population O 0 2.400344965280965e-05
studies O 0 4.781353482030681e-07
of O 0 1.2377990188383592e-08
this O 0 2.327380599354001e-08
polymorphism O 0 4.459452975424938e-05
are O 0 2.3261113923922494e-08
facilitated O 0 1.005005998422348e-07
by O 0 2.6134623354323594e-08
the O 0 1.1218814321978243e-08
fact O 0 1.575610752979628e-08
that O 0 1.4246924529004446e-08
the O 0 2.3296234274994276e-08
Cys282Tyr O 0 2.2546777472598478e-05
mutation O 0 4.838166773879493e-07
creates O 0 1.4281509663760517e-07
a O 0 3.162344341944845e-07
Rsal O 0 1.285176767851226e-05
restriction O 0 2.0922054773109267e-06
site O 0 2.0212264644214883e-06
. O 0 7.46780131066771e-07

We O 0 2.1039927560195792e-06
have O 0 1.2140364447077445e-07
studied O 0 7.177319361062473e-08
the O 0 3.004034709874759e-08
codon O 0 7.934169730106078e-07
282 O 0 2.0087952634639805e-06
( O 0 1.9449078081379412e-07
Cys O 0 0.001269161351956427
/ O 0 1.4601792827306781e-05
Tyr O 0 5.0089765863958746e-05
) O 0 6.073121028293826e-08
polymorphism O 0 1.8870636040446698e-06
in O 0 2.989544611864403e-08
different O 0 7.615930108784141e-09
ethnic O 0 8.849613664096978e-08
groups O 0 1.4446438001414208e-07
. O 0 1.1224495892747655e-06

In O 0 2.44754255618318e-06
agreement O 0 2.986501783652784e-07
with O 0 4.0552667002202725e-08
previous O 0 1.383696712764504e-07
observations O 0 4.006019764801749e-07
the O 0 7.40643670837926e-08
Tyr O 0 7.471443677786738e-05
allele O 0 6.092001967772376e-06
appeared O 0 1.6261520840998855e-06
to O 0 5.360135091336815e-08
be O 0 1.0687036677836659e-07
rare O 0 6.422292813113017e-07
or O 0 1.0645229764350006e-07
absent O 0 2.132140480171074e-06
in O 0 1.2949259087235987e-07
Asiatic O 0 1.8867414155465667e-06
( O 0 9.311390769539685e-09
Indian O 0 1.1709033742590691e-08
, O 0 1.329373500169595e-08
Chinese O 0 2.2425401979830895e-08
) O 0 9.825924252027107e-08
populations O 0 2.5796035174607823e-07
. O 0 7.813420097591006e-07

The O 0 2.566157263572677e-06
highest O 0 3.3356047879351536e-06
allele O 0 5.460317424876848e-06
frequency O 0 8.545478067389922e-07
( O 0 2.3856241426756242e-08
7 O 0 1.546290491205582e-07
. O 0 2.3934177306728088e-08
5 O 0 9.990888116817587e-08
% O 0 1.6001575176005645e-08
) O 0 7.900696985529976e-09
was O 0 4.5738482867818675e-07
found O 0 8.190676226149662e-08
in O 0 6.72396112122442e-08
Swedes O 0 0.0027073705568909645
. O 0 2.448661007292685e-06

Saamis O 0 0.0021154629066586494
( O 0 4.441286364453845e-06
2 O 0 1.8574246496427804e-06
% O 0 8.447292287883101e-08
) O 0 1.1277577094404023e-08
and O 0 3.619026145429416e-08
Mordvinians O 0 1.4133475815469865e-05
( O 0 1.3538023146963951e-08
1 O 0 2.340187066351973e-08
. O 0 8.371453752431535e-09
8 O 0 6.403309527058809e-08
% O 0 1.6945866931905584e-08
) O 0 7.92665932891623e-09
had O 0 9.501075624029909e-07
significantly O 0 4.246018647791061e-07
lower O 0 7.84962992383953e-08
frequencies O 0 5.547736847688611e-08
of O 0 6.031929178362816e-09
the O 0 1.814245678133375e-07
Tyr O 0 0.0005224840133450925
allele O 0 2.6602312573231757e-05
. O 0 1.03425611541752e-06

Comparisons O 0 3.2254010875476524e-05
with O 0 1.2026940794385155e-06
allele O 0 1.3440159818856046e-05
frequencies O 0 1.249354681931436e-06
based O 0 1.6659494406212616e-07
on O 0 7.052384489725227e-07
prevalence O 0 1.5713014363427646e-05
estimates O 0 1.4120200830802787e-07
of O 0 2.7539032387835505e-08
HH B-Disease 1 0.9979009628295898
showed O 0 0.007106790319085121
some O 0 3.483744137611211e-08
disagreements O 0 5.879880973225227e-07
with O 0 4.009030973861627e-08
the O 0 6.01133862687675e-08
RFLP O 0 0.00014657432620879263
data O 0 1.344379967349596e-07
, O 0 2.1063462085635365e-08
particularly O 0 4.834652500562697e-08
in O 0 1.1643496833357858e-07
Finns O 0 0.0005854054470546544
. O 0 2.5408994588360656e-06

The O 0 4.146879291511141e-06
newly O 0 5.661490831698757e-06
described O 0 6.989491794229252e-06
HFE O 0 0.00013293161464389414
marker O 0 6.571510766661959e-06
provides O 0 1.2677853078457701e-07
a O 0 7.861211770432419e-08
new O 0 2.7062997176585668e-08
approach O 0 5.633811639427222e-08
to O 0 1.8446387528570085e-08
the O 0 7.211828023656608e-09
screening O 0 1.0835123731567364e-07
of O 0 2.4864025505166865e-08
HH B-Disease 1 0.7573271989822388
as O 0 5.465634558277088e-07
well O 0 4.6723577895591006e-08
as O 0 4.147580412450225e-08
studies O 0 4.881619108942914e-09
of O 0 1.3002606769063618e-09
the O 0 8.519307925780595e-09
relationship O 0 4.906321038333772e-08
between O 0 2.1973542985165295e-08
the O 0 7.924742106979465e-08
HFE O 0 0.004839540459215641
Tyr O 0 0.0002789153659250587
allele O 0 4.624711436918005e-06
and O 0 1.537026719233836e-07
different O 0 2.798451248509082e-07
disorders O 0 0.006811324041336775
including O 0 6.11884897807613e-05
cancer B-Disease 1 0.9760892987251282

Autosomal B-Disease 1 0.9992973804473877
dominant I-Disease 1 0.9964593052864075
neurohypophyseal I-Disease 1 0.9999226331710815
diabetes I-Disease 1 0.9999959468841553
insipidus I-Disease 1 0.9995136260986328
associated O 0 3.379496047273278e-05
with O 0 2.0621992291580682e-07
a O 0 9.542897714709397e-06
missense O 0 0.001355658983811736
mutation O 0 6.574456620001001e-06
encoding O 0 7.939316901683924e-07
Gly23 O 0 1.0484211998118553e-05
- O 0 4.188952152617276e-05
- O 0 0.00034238319494761527
> O 0 7.797083526384085e-06
Val O 0 6.594440492335707e-05
in O 0 6.39845040950604e-07
neurophysin O 0 0.00023559427063446492
II O 0 0.0012376575032249093
. O 0 2.323866965525667e-06

Autosomal B-Disease 1 0.9994305968284607
dominant I-Disease 1 0.9945817589759827
neurohypophyseal I-Disease 1 0.9998905658721924
diabetes I-Disease 1 0.9999951124191284
insipidus I-Disease 1 0.9995149374008179
( O 0 1.0927425137197133e-05
ADNDI B-Disease 0 0.020963316783308983
) O 0 2.2523916243244457e-07
is O 0 2.6164059363509296e-07
an O 0 0.0002262791822431609
inherited B-Disease 1 0.9999997615814209
disease I-Disease 1 0.9999916553497314
caused O 0 0.0063240802846848965
by O 0 4.341351086623035e-06
progressive O 1 0.8094831705093384
degeneration O 0 0.3942118287086487
of O 0 4.317253754493322e-08
the O 0 1.4994152763847524e-07
magnocellular O 0 1.9521323338267393e-05
neurons O 0 5.264316769171273e-07
of O 0 4.9072075292144746e-09
the O 0 9.592337590902389e-09
hypothalamus O 0 1.9584556412155507e-06
leading O 0 4.3611930777842645e-07
to O 0 1.0784465587221348e-07
decreased O 0 1.1054271453758702e-06
ability O 0 4.4396326615014914e-08
to O 0 3.4646003399529945e-08
produce O 0 1.4767800848858315e-07
the O 0 1.0624824398064447e-07
hormone O 0 4.64592585558421e-06
arginine O 0 2.72099464382336e-06
vasopressin O 0 2.181973832193762e-05
( O 0 1.8662549905457126e-07
AVP O 0 1.3840381143381819e-05
) O 0 5.148203285898489e-07
. O 0 1.023967797664227e-06

Affected O 0 0.00016770629736129194
individuals O 0 9.725737299959292e-07
are O 0 6.733766610977909e-08
not O 0 3.7334513081077603e-07
symptomatic O 0 0.00023421263904310763
at O 0 1.1281459819656448e-06
birth O 0 7.441649358952418e-06
, O 0 7.118178046994217e-08
but O 0 1.4912581036696793e-07
usually O 0 1.8435645188219496e-06
develop O 0 9.26380162127316e-05
diabetes B-Disease 1 0.9905974268913269
insipidus I-Disease 0 0.018457040190696716
at O 0 6.94011532687e-08
1 O 0 1.0078508694277843e-07
- O 0 2.27850214287173e-05
6 O 0 3.5125226531818043e-06
yr O 0 0.00016515674360562116
of O 0 1.0020755070172527e-07
age O 0 1.6529563708900241e-06
. O 0 1.3526816928788321e-06

The O 0 5.158360181667376e-06
genetic O 0 5.96913787376252e-06
locus O 0 2.342738298466429e-06
of O 0 4.4939199028704024e-08
the O 0 1.337683897872921e-06
disease O 0 2.5506749807391316e-05
is O 0 7.9927488627618e-08
the O 0 1.0997673172141731e-07
AVP O 0 0.00033574903500266373
- O 0 0.018749207258224487
neurophysin O 0 0.09321699291467667
II O 0 0.010897848755121231
( O 0 1.2594593101766804e-07
NPII O 0 1.1123527656309307e-05
) O 0 2.9595604189580627e-08
gene O 0 6.953630560246893e-08
, O 0 2.4518962860042848e-08
and O 0 6.08399659540737e-08
mutations O 0 9.616472880225047e-07
that O 0 1.0980779308056299e-07
cause O 0 1.3644017826663912e-06
ADNDI B-Disease 0 0.006800187285989523
have O 0 6.031264661032765e-07
been O 0 2.817428992329951e-07
found O 0 3.611358678767829e-08
in O 0 4.376932150051971e-09
both O 0 3.6337155506771524e-09
the O 0 4.728225366790184e-09
signal O 0 1.5501220218538947e-07
peptide O 0 3.4116869329636756e-08
of O 0 1.7760054538129566e-09
the O 0 5.924146950775366e-09
prepro O 0 3.723388545040507e-06
- O 0 9.432152182853315e-06
AVP O 0 2.416168717900291e-05
- O 0 2.2930544218979776e-05
NPII O 0 3.9781920349923894e-05
precursor O 0 3.74984381323884e-07
and O 0 6.017808118485846e-08
within O 0 6.331534052606003e-08
NPII O 0 0.00010319969442207366
itself O 0 7.1172803473018575e-06
. O 0 2.0377340206323424e-06

An O 0 9.561163096805103e-06
affected O 0 2.663138957359479e-06
girl O 0 2.0738048988278024e-05
who O 0 1.0321721219952451e-06
presented O 0 2.853103922006994e-07
at O 0 2.402510190790963e-08
9 O 0 9.299715486577043e-08
months O 0 7.300767634887961e-08
of O 0 6.778271721685769e-09
age O 0 3.6283921645008377e-07
and O 0 6.422378362458403e-08
her O 0 1.038550544762984e-05
similarly O 0 2.0900773961329833e-05
affected O 0 3.682572753405111e-07
younger O 0 1.7651982489041984e-06
brother O 0 2.5682627438072814e-06
and O 0 7.993526907057458e-08
father O 0 1.2646216873690719e-06
were O 0 2.212650507260605e-08
all O 0 4.589908453311864e-09
found O 0 1.3396490139427897e-08
to O 0 2.3195234177819657e-08
have O 0 3.5917256724360414e-08
a O 0 7.795073315719492e-07
novel O 0 1.849162254075054e-05
missense O 0 0.00011692068073898554
mutation O 0 2.911438059527427e-06
( O 0 4.275127096775577e-08
G1758 O 0 4.620708295988152e-06
- O 0 8.126195461954921e-05
- O 0 0.0033579773735255003
> O 0 1.090601108444389e-05
T O 0 1.057459394360194e-05
) O 0 6.10080830298898e-09
encoding O 0 1.373365510204394e-08
the O 0 4.2391135046671025e-09
amino O 0 1.4792857605527843e-08
acid O 0 3.8473519481385665e-08
substitution O 0 3.349300214949835e-08
Gly23 O 0 2.3834832063585054e-06
- O 0 6.668875357718207e-06
- O 0 0.00012253955355845392
> O 0 1.2018710549455136e-05
Val O 0 0.00011690238898154348
within O 0 3.9267760598704626e-07
NPII O 0 9.115618013311177e-05
. O 0 2.649777798069408e-06

The O 0 1.1470364370325115e-05
mutation O 0 6.775797373848036e-05
was O 0 6.438614036596846e-06
confirmed O 0 1.308096670982195e-06
by O 0 1.1548831935215276e-07
restriction O 0 2.968908802358783e-06
endonuclease O 0 0.00037497287848964334
analysis O 0 9.028982276504394e-06
. O 0 4.386936325317947e-06

A O 0 5.168344432604499e-05
T1 O 0 0.0003723695408552885
- O 0 8.597356099926401e-06
weighted O 0 4.4547573452291545e-07
magnetic O 0 2.3421373498422327e-06
resonance O 0 5.083838459540857e-06
imaging O 0 5.204214176046662e-06
of O 0 2.7888431120004498e-08
the O 0 2.1677448103218921e-07
fathers O 0 7.10981748852646e-06
pituitary O 0 5.046297155786306e-05
gland O 0 1.7204070900334045e-05
demonstrates O 0 5.77595619688509e-06
an O 0 1.0960415011140867e-06
attenuated O 0 0.0008148809429258108
posterior O 0 0.0003171783755533397
pituitary O 0 0.00034539986518211663
bright O 0 0.00017531074990984052
spot O 0 4.306884511606768e-05
. O 0 8.506623998982832e-06

This O 0 7.633545465068892e-06
mutation O 0 0.00016795929695945233
may O 0 1.92457991943229e-06
be O 0 1.972831320529167e-08
valuable O 0 1.4966259342941157e-08
for O 0 8.575455012760358e-09
developing O 0 5.752175979978347e-08
models O 0 3.4679200666687393e-07
of O 0 5.06647879205957e-08
dominantly B-Disease 1 0.9277788400650024
inherited I-Disease 1 0.9981064796447754
neurodegeneration I-Disease 1 0.9999991655349731
, O 0 4.933219770464348e-07
as O 0 2.100957452455532e-08
the O 0 5.061685293128448e-09
early O 0 9.84355708055773e-08
age O 0 4.426011912528338e-08
of O 0 4.0934446943197145e-09
onset O 0 3.1761946956976317e-06
of O 0 3.530755066094571e-07
symptoms O 1 0.5699767470359802
suggests O 0 7.470201239812013e-07
that O 0 4.043148749133252e-08
this O 0 4.681814047557964e-08
mutation O 0 1.8027194528258406e-06
may O 0 2.4200105031013663e-07
be O 0 3.341400756085022e-08
particularly O 0 8.8486345362071e-08
deleterious O 0 2.749264467638568e-06
to O 0 2.1573998765234137e-07
the O 0 1.6909775979456754e-07
magnocellular O 0 0.00010738242417573929
neuron O 0 0.00015576342411804944
. O 0 1.3061578840734e-07
. O 0 4.998444751436182e-07

Frequent O 0 0.0005087698809802532
inactivation O 0 0.0009563741041347384
of O 0 1.618746750864375e-06
PTEN O 0 0.023481125012040138
/ O 0 5.069279359304346e-05
MMAC1 O 0 0.0005884756101295352
in O 0 5.392556431615958e-06
primary O 0 0.3718104660511017
prostate B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999983310699463
. O 0 3.379390182089992e-05

Sporadic B-Disease 1 0.9994984865188599
prostate I-Disease 1 0.9999986886978149
carcinoma I-Disease 1 1.0
is O 0 1.6736115867388435e-05
the O 0 9.543286694224662e-08
most O 0 2.1279952022723592e-07
common O 0 1.4460459851761698e-06
male B-Disease 0 0.17017440497875214
cancer I-Disease 0 0.0020540780387818813
in O 0 4.146623311385156e-08
the O 0 1.7988273981472958e-08
Western O 0 6.730876833671573e-08
world O 0 4.3784709191641014e-08
, O 0 8.767370829332322e-09
yet O 0 2.4013649735366016e-08
many O 0 8.631358405786216e-10
of O 0 5.5616522498525e-10
the O 0 4.7927093405064625e-09
major O 0 3.752304778004145e-08
genetic O 0 1.0548617268568705e-07
events O 0 1.0479626944004394e-08
involved O 0 1.5929918717461078e-08
in O 0 1.4326193564784262e-08
the O 0 1.3579685820275245e-08
progression O 0 2.9526603384510963e-07
of O 0 6.1089830971639e-09
this O 0 1.435905403468496e-07
often O 0 3.756902879104018e-05
fatal O 1 0.9995457530021667
cancer B-Disease 1 0.9137924313545227
remain O 0 1.6668568605382461e-06
to O 0 3.9209007240970095e-07
be O 0 8.219830647249182e-07
elucidated O 0 0.00018589702085591853
. O 0 2.014602614508476e-06

Numerous O 0 7.382941112155095e-05
cytogenetic O 0 0.008701976388692856
and O 0 5.053843779023737e-06
allelotype O 0 0.00034069488174282014
studies O 0 7.436416922246281e-07
have O 0 1.6378204747979908e-07
reported O 0 9.240983445124584e-07
frequent O 0 3.4972706544067478e-06
loss O 0 1.55882826220477e-05
of O 0 7.226054776765523e-08
heterozygosity O 0 0.00012252341548446566
on O 0 1.1582334309423459e-06
chromosomal O 0 5.0593793275766075e-05
arm O 0 2.076416785712354e-05
10q O 0 1.3565284461947158e-05
in O 0 9.76177375378029e-07
sporadic B-Disease 1 0.9834334850311279
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999977350234985
. O 0 1.90113623830257e-05

Deletion O 0 0.004468354396522045
mapping O 0 9.481566667091101e-05
studies O 0 7.31891759642167e-06
have O 0 1.0251814046569052e-06
unambiguously O 0 7.690224447287619e-05
identified O 0 9.123659765464254e-07
a O 0 2.275610597735067e-07
region O 0 3.342459109489937e-08
of O 0 6.3030949348785725e-09
chromosome O 0 2.85159921986633e-06
10q23 O 0 2.142407311112038e-06
to O 0 3.033572326671674e-08
be O 0 9.54035339617576e-09
the O 0 8.940444828908767e-09
minimal O 0 2.3665630521918501e-07
area O 0 6.96118078735708e-08
of O 0 5.931725155505774e-08
loss O 0 8.531573257641867e-05
. O 0 4.054319106217008e-06

A O 0 2.6338671887060627e-05
new O 0 4.1891403270710725e-06
tumor B-Disease 0 5.185787085792981e-05
suppressor O 0 4.82270224893e-05
gene O 0 2.847224095603451e-06
, O 0 2.4934391262831923e-07
PTEN O 0 0.00029601636924780905
/ O 0 1.1510854164953344e-05
MMAC1 O 0 0.0009659398347139359
, O 0 2.8058295242772147e-07
was O 0 1.7901768387673656e-06
isolated O 0 4.1490568492008606e-07
recently O 0 5.030619831813965e-07
at O 0 1.266410798450579e-08
this O 0 9.037002257628046e-09
region O 0 2.1278486528331086e-08
of O 0 1.261485582659816e-08
chromosome O 0 6.843540177214891e-06
10q23 O 0 6.076063073123805e-06
and O 0 5.4315378861247154e-08
found O 0 2.6705189171138954e-08
to O 0 1.2963834450374634e-08
be O 0 2.357875672487353e-08
inactivated O 0 9.17103761821636e-07
by O 0 3.4610934562806506e-08
mutation O 0 3.289748349288857e-07
in O 0 2.26019196247762e-07
three O 0 0.00866326130926609
prostate B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999986886978149
cell O 0 0.06114678084850311
lines O 0 8.901842375053093e-05
. O 0 5.066714038548525e-06

We O 0 1.95882712432649e-05
screened O 0 0.0005680537433363497
80 O 0 0.00021032479708082974
prostate B-Disease 1 0.9994310736656189
tumors I-Disease 1 0.9999784231185913
by O 0 1.399580241923104e-06
microsatellite O 0 0.00015852053184062243
analysis O 0 1.1198973197679152e-06
and O 0 1.4921744195817155e-07
found O 0 2.909354464009084e-07
chromosome O 0 2.456644097037497e-06
10q23 O 0 1.9062874798692064e-06
to O 0 5.635079958210554e-08
be O 0 3.455262387319635e-08
deleted O 0 9.371051987727697e-07
in O 0 1.7790668493944395e-07
23 O 0 4.27824534199317e-06
cases O 0 1.1114345852547558e-06
. O 0 4.006809376733145e-06

We O 0 2.5564213501638733e-06
then O 0 1.7423603537736199e-07
proceeded O 0 3.34033728677241e-07
with O 0 1.3344645388713161e-08
sequence O 0 2.0406920597793032e-08
analysis O 0 8.890213010204207e-09
of O 0 1.1334718719169246e-09
the O 0 1.1883402706303059e-08
entire O 0 2.0108103626625962e-07
PTEN O 0 0.0006144522340036929
/ O 0 6.41499809717061e-06
MMAC1 O 0 0.00023899064399302006
coding O 0 2.789274503811612e-06
region O 0 8.159677378216657e-08
and O 0 4.955196786227134e-08
tested O 0 1.6642471223349276e-07
for O 0 1.3162009260270224e-08
homozygous O 0 1.2337399084572098e-06
deletion O 0 8.742707677811268e-07
with O 0 1.932342641453033e-08
new O 0 1.5453132107268175e-07
intragenic O 0 7.542946696048602e-05
markers O 0 8.398067166126566e-07
in O 0 1.695168627691146e-08
these O 0 8.689672981176955e-09
23 O 0 2.677338670764584e-07
cases O 0 4.4452505676417786e-08
with O 0 1.1554802625823868e-07
10q23 O 0 0.00018627122335601598
loss O 0 6.081349965825211e-06
of O 0 1.7371010585520708e-07
heterozygosity O 0 0.0002613409887999296
. O 0 5.069217877462506e-06

The O 0 1.1589339692363865e-06
identification O 0 4.136686300171277e-07
of O 0 1.5472117809167685e-08
the O 0 2.2662323573285903e-08
second O 0 5.148159516465967e-07
mutational O 0 0.00020698770822491497
event O 0 5.072067779110512e-07
in O 0 1.0611699963192223e-07
10 O 0 6.816846109813923e-08
( O 0 2.7426333204516595e-08
43 O 0 2.1609982923109783e-06
% O 0 3.868980229526642e-07
) O 0 7.37926427518687e-07
tumors B-Disease 1 0.9999253749847412
establishes O 0 0.0005821260856464505
PTEN O 0 0.36369016766548157
/ O 0 6.6197358137287665e-06
MMAC1 O 0 4.1679410060169175e-05
as O 0 6.597656465601176e-08
a O 0 1.2170157503987866e-07
main O 0 1.3063397830137546e-07
inactivation O 0 7.951683073770255e-06
target O 0 5.176319106681149e-08
of O 0 1.0609995548804818e-08
10q O 0 5.036772563471459e-06
loss O 0 2.7497208066051826e-06
in O 0 7.935297503536276e-07
sporadic B-Disease 1 0.9986478686332703
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
. O 0 6.115460109867854e-06
. O 0 6.633620614593383e-06

Risk O 0 0.000287542468868196
reversals O 0 0.00011285299842711538
in O 0 1.9003447278009844e-06
predictive O 0 1.638364301470574e-05
testing O 0 1.0431512237119023e-05
for O 0 4.8411569878226146e-05
Huntington B-Disease 1 0.9999862909317017
disease I-Disease 1 0.9998745918273926
. O 0 1.4549429579346906e-05

The O 0 2.0062298062839545e-06
first O 0 6.143596351648739e-07
predictive O 0 2.960342044389108e-06
testing O 0 2.5281758553319378e-06
for O 0 1.4503159036394209e-05
Huntington B-Disease 1 0.9999953508377075
disease I-Disease 1 0.9998987913131714
( O 0 2.6145249876208254e-07
HD B-Disease 0 0.0003166750248055905
) O 0 2.1193345745018632e-08
was O 0 2.1050414034107234e-07
based O 0 3.071468768212071e-08
on O 0 4.869523451134228e-08
analysis O 0 2.827870027033441e-08
of O 0 8.722818023443324e-09
linked O 0 1.4160740420265938e-06
polymorphic O 0 1.676013744145166e-05
DNA O 0 5.467451501317555e-06
markers O 0 7.146023222048825e-07
to O 0 5.7989495871879626e-08
estimate O 0 5.593723173547005e-08
the O 0 4.05631706001941e-09
likelihood O 0 2.6410633680029605e-08
of O 0 4.212707960249418e-09
inheriting O 0 3.807246855558333e-07
the O 0 5.113447443250152e-08
mutation O 0 1.2929382364745834e-06
for O 0 2.262469109837184e-07
HD B-Disease 0 0.0010027813259512186
. O 0 2.9069628908473533e-06

Limits O 0 9.310590940003749e-06
to O 0 4.210581892039045e-07
accuracy O 0 3.648378310572298e-07
included O 0 3.7763719262784434e-08
recombination O 0 1.392348423223666e-07
between O 0 1.911980618274356e-08
the O 0 2.5445553220038164e-08
DNA O 0 9.855756388787995e-07
markers O 0 4.1932744920814e-07
and O 0 1.2791460335392912e-08
the O 0 2.1399122474008436e-08
mutation O 0 6.988406084929011e-07
, O 0 4.7029448779767336e-08
pedigree O 0 1.7482572047811118e-06
structure O 0 1.437644101542901e-07
, O 0 9.606544892903912e-09
and O 0 1.0060086985674843e-08
whether O 0 3.166399764609196e-08
DNA O 0 1.708200869643406e-07
samples O 0 6.63688410895702e-08
were O 0 5.5294087530910474e-08
available O 0 1.352395795350958e-08
from O 0 1.3873878934589357e-08
family O 0 1.3338897986159282e-07
members O 0 1.2489158507378306e-07
. O 0 5.025133873459708e-07

With O 0 1.1148250678161276e-06
direct O 0 5.803131557513552e-07
tests O 0 1.7332833124328317e-07
for O 0 1.1051941584128144e-08
the O 0 6.957782971994675e-08
HD B-Disease 0 0.0005373142194002867
mutation O 0 2.6989908974428545e-07
, O 0 3.6300995542859482e-09
we O 0 3.747839816270471e-09
have O 0 1.147144068625039e-08
assessed O 0 6.36366550565981e-08
the O 0 6.262566909498446e-09
accuracy O 0 1.4526236213896482e-07
of O 0 8.0041724359603e-09
results O 0 1.2194524288133834e-06
obtained O 0 7.809339308550989e-08
by O 0 8.884788016416678e-09
linkage O 0 2.730456856170349e-07
approaches O 0 1.270269791575629e-07
when O 0 5.9608268543343e-08
requested O 0 5.810386483062757e-08
to O 0 1.4609810250476585e-08
do O 0 1.6080972997656318e-08
so O 0 7.18569914681666e-09
by O 0 6.253948470202886e-09
the O 0 2.593079706514345e-08
test O 0 6.510594516839774e-07
individuals O 0 1.607671578085501e-07
. O 0 8.245709182119754e-07

For O 0 2.376091288169846e-06
six O 0 6.415626216949022e-07
such O 0 3.172777951476746e-08
individuals O 0 1.4223302535754101e-08
, O 0 2.5219618393634846e-08
there O 0 3.135281545496582e-08
was O 0 1.7633776678849244e-06
significant O 0 9.22845373452219e-08
disparity O 0 4.901316970062908e-07
between O 0 1.9323978861507385e-08
the O 0 7.423422232477606e-08
tests O 0 2.258475433336571e-06
. O 0 2.2433246158470865e-06

Three O 0 7.068038485158468e-06
went O 0 1.2788918866135646e-06
from O 0 4.231263872611635e-08
a O 0 5.054327516518242e-07
decreased O 0 9.664016943133902e-06
risk O 0 1.502687752008569e-07
to O 0 4.1805165551522805e-08
an O 0 1.9378427396077313e-07
increased O 0 6.440616289182799e-06
risk O 0 3.5315196100782487e-07
, O 0 3.298399064988189e-08
while O 0 2.0303453140968486e-08
in O 0 7.561737902506138e-09
another O 0 2.151133138283967e-08
three O 0 1.2917112712784729e-08
the O 0 3.821090643896241e-08
risk O 0 7.252648401845363e-07
was O 0 1.2482502825150732e-05
decreased O 0 1.0028114047599956e-05
. O 0 1.532514147584152e-06

Knowledge O 0 2.666607997525716e-06
of O 0 6.201590707632931e-08
the O 0 3.829809713806753e-08
potential O 0 7.425037296115988e-08
reasons O 0 5.9237432736836126e-08
for O 0 8.575422150158829e-09
these O 0 8.106187721068636e-09
changes O 0 6.494254023436952e-08
in O 0 4.407882414625419e-08
results O 0 5.263171942715417e-07
and O 0 2.6295777999507663e-08
impact O 0 4.6994120594945343e-08
of O 0 1.7928665219102413e-09
these O 0 1.079732481201745e-08
risk O 0 6.921198547615859e-08
reversals O 0 7.936924703244586e-06
on O 0 9.419711204827763e-06
both O 0 4.6548707359761465e-06
patients O 0 5.2702813263749704e-05
and O 0 3.00553608667542e-08
the O 0 1.4699226724701475e-08
counseling O 0 8.220381175760849e-08
team O 0 1.4309807561119214e-08
can O 0 2.1333581567972715e-09
assist O 0 7.440018379156754e-09
in O 0 2.255769127046392e-09
the O 0 1.7226708948214764e-09
development O 0 9.864580263752032e-10
of O 0 1.3433328893697194e-09
strategies O 0 1.632987967070676e-08
for O 0 8.351135782902475e-09
the O 0 3.1434371550176365e-08
prevention O 0 2.54892285056485e-07
and O 0 7.982328042999143e-08
, O 0 2.7104324118454315e-08
where O 0 3.289471450784731e-08
necessary O 0 2.783454533528129e-08
, O 0 1.4783998913969754e-08
management O 0 9.111633225700189e-09
of O 0 1.5020301669110836e-09
a O 0 6.790606335016491e-07
risk O 0 2.4580825197517697e-07
reversal O 0 9.398626730217075e-07
in O 0 1.0221999247050917e-08
any O 0 7.601911100607595e-09
predictive O 0 2.4940123921624036e-07
testing O 0 2.1979123232540587e-07
program O 0 9.444904236488583e-08
. O 0 8.26829520406136e-08
. O 0 4.5325450059863215e-07

A O 0 0.00013962716911919415
novel O 0 3.7096033338457346e-05
common O 0 2.138355284841964e-06
missense O 0 6.444183964049444e-05
mutation O 0 6.661984571110224e-06
G301C O 0 4.4387115849531256e-06
in O 0 4.126881947286165e-08
the O 0 3.648391810884277e-08
N O 0 7.762227141938638e-06
- O 0 4.397718657855876e-05
acetylgalactosamine O 0 0.0001067230841726996
- O 0 6.520278111565858e-05
6 O 0 2.7719477202481357e-06
- O 0 0.00015655036258976907
sulfate O 0 0.0014043929986655712
sulfatase O 0 5.97429861954879e-05
gene O 0 1.5858911410759902e-06
in O 0 2.979282385240367e-07
mucopolysaccharidosis B-Disease 0 0.0002922943385783583
IVA I-Disease 0 0.0033142445608973503
. O 0 1.8199491023551673e-05

Mucopolysaccharidosis B-Disease 1 0.6142599582672119
IVA I-Disease 1 0.9921154379844666
( O 0 0.0021416139788925648
MPS B-Disease 1 0.9999899864196777
IVA I-Disease 1 0.9999710321426392
) O 0 2.817248514475068e-06
is O 0 6.070417271075712e-07
an O 0 9.213500561600085e-06
autosomal B-Disease 1 0.9955341815948486
recessive I-Disease 1 0.9967531561851501
lysosomal I-Disease 1 0.9959040284156799
storage I-Disease 1 0.9890846610069275
disorder I-Disease 1 0.994335949420929
caused O 0 1.9834576960420236e-05
by O 0 2.2023270673798834e-07
a O 0 0.005495736841112375
genetic B-Disease 1 0.9998089671134949
defect I-Disease 1 0.9998533725738525
in O 0 1.8510233985580271e-06
N O 0 2.699549622775521e-05
- O 0 0.00011002187966369092
acetylgalactosamine O 0 0.00035350886173546314
- O 0 0.0002349072601646185
6 O 0 5.347999831428751e-06
- O 0 0.005608889739960432
sulfate O 0 0.07673467695713043
sulfatase O 0 0.00020661937014665455
( O 0 1.8254068834266945e-07
GALNS O 0 1.9743310986086726e-05
) O 0 3.6314833096184884e-07
. O 0 6.382811648109055e-07

In O 0 6.085074801376322e-06
previous O 0 2.1293644749675877e-06
studies O 0 8.65073204181499e-08
, O 0 2.093860729246444e-08
we O 0 1.2286442974129841e-08
have O 0 1.690293238709728e-08
found O 0 2.4514474006309683e-08
two O 0 1.8135894563897637e-08
common O 0 6.540260244491947e-08
mutations O 0 3.8804463997621497e-07
in O 0 3.703308593117072e-08
Caucasians O 0 9.219303365171072e-07
and O 0 6.449126033203356e-08
Japanese O 0 4.929368060402339e-07
, O 0 2.1197233479597344e-07
respectively O 0 9.257539659301983e-07
. O 0 6.39443612726609e-07

To O 0 3.3414789868402295e-06
characterize O 0 7.464243481081212e-06
the O 0 1.1091012908082121e-07
mutational O 0 0.00023210959625430405
spectrum O 0 6.773493623768445e-06
in O 0 3.032843309824784e-08
various O 0 5.79822767576843e-09
ethnic O 0 1.2510365365869802e-07
groups O 0 4.3464446264351864e-08
, O 0 8.077299185060838e-08
mutations O 0 3.9464029555347224e-07
in O 0 2.208392047009511e-08
the O 0 3.786288615970079e-08
GALNS O 0 0.00016577079077251256
gene O 0 3.691172878461657e-07
in O 0 7.425461490129237e-08
Colombian O 0 3.7366229662438855e-05
MPS B-Disease 1 0.9999948740005493
IVA I-Disease 1 0.9999984502792358
patients O 1 0.9968991279602051
were O 0 3.8027360460546333e-06
investigated O 0 1.7052041130227735e-06
, O 0 4.090449223781434e-08
and O 0 1.231457815720205e-07
genetic O 0 4.573189755774365e-07
backgrounds O 0 7.308751293066962e-08
were O 0 1.5370441985851357e-07
extensively O 0 4.814348244508437e-07
analyzed O 0 5.338759478945576e-07
to O 0 2.9363722120478997e-08
identify O 0 9.429675884575772e-08
racial O 0 9.523212440853968e-08
origin O 0 7.28224307522396e-08
, O 0 2.923212072403203e-08
based O 0 3.928370873040876e-08
on O 0 1.8953586788938992e-07
mitochondrial O 0 3.3633979910518974e-05
DNA O 0 7.971729246492032e-06
( O 0 6.370174787662108e-08
mtDNA O 0 8.998698035611596e-07
) O 0 7.654949030211355e-08
lineages O 0 7.416176117658324e-07
. O 0 8.314218007399177e-07

Three O 0 1.5539480955339968e-05
novel O 0 2.9743485356448218e-05
missense O 0 0.0007885555387474597
mutations O 0 8.464201528113335e-05
never O 0 3.793672931351466e-06
identified O 0 5.817594228574308e-07
previously O 0 2.1949085748929065e-07
in O 0 1.3274402910212757e-08
other O 0 8.419043240337487e-09
populations O 0 1.7545520591966124e-08
and O 0 2.4485503402615905e-08
found O 0 1.1623504292401776e-07
in O 0 1.557919837580357e-08
16 O 0 5.397087221581387e-08
out O 0 1.0005110517852245e-08
of O 0 8.280174768060533e-09
19 O 0 9.363189974465058e-07
Colombian O 0 1.080586571333697e-05
MPS B-Disease 1 0.9998955726623535
IVA I-Disease 1 0.9994205236434937
unrelated O 0 2.7034886443288997e-05
alleles O 0 3.765647761611035e-06
account O 0 5.461085947899846e-07
for O 0 2.286149509700408e-07
84 O 0 2.5070565243368037e-05
. O 0 5.031669388699811e-06

2 O 0 8.802107004157733e-06
% O 0 2.033213633012565e-07
of O 0 5.141846504130854e-09
the O 0 2.9821126901197204e-08
alleles O 0 6.981591127441789e-07
in O 0 7.978628957516776e-08
this O 0 8.454658484424726e-08
study O 0 1.4602534292862401e-06
. O 0 1.7403158381057438e-06

The O 0 7.77090826886706e-06
G301C O 0 4.5219247112981975e-05
and O 0 9.8843327123177e-07
S162F O 0 7.768826617393643e-05
mutations O 0 9.52123536990257e-06
account O 0 3.884274804022425e-07
for O 0 1.8056789485854097e-07
68 O 0 1.934646388690453e-05
. O 0 2.9667069156857906e-06

4 O 0 3.971259866375476e-05
% O 0 1.8082326960211503e-06
and O 0 3.358067317549285e-07
10 O 0 8.912132898331038e-07
. O 0 1.462949171582295e-06

5 O 0 3.313845445518382e-05
% O 0 8.078591804405733e-07
of O 0 3.0182434329617536e-08
mutations O 0 3.7269376207405003e-06
, O 0 1.103435920413176e-07
respectively O 0 3.558070318376849e-07
, O 0 2.8422537212691168e-08
whereas O 0 2.158926371009784e-08
the O 0 4.555684274265559e-09
remaining O 0 9.356472219224088e-08
F69V O 0 0.00010365711204940453
is O 0 5.688816528959251e-08
limited O 0 2.4300979006852685e-08
to O 0 1.3620932826086118e-08
a O 0 2.6468609348739847e-07
single O 0 2.224373019998893e-06
allele O 0 1.4197157724993303e-05
. O 0 1.348387627331249e-06

The O 0 1.1781878129113466e-05
skewed O 0 0.00015302478277590126
prevalence O 0 2.8866861612186767e-05
of O 0 3.5743536130894427e-08
G301C O 0 7.727600859652739e-06
in O 0 1.2659161541250796e-07
only O 0 1.0091088853414476e-07
Colombian O 0 9.800262887438294e-06
patients O 0 0.0002506561577320099
and O 0 1.6279986994049978e-06
haplotype O 0 0.0016082734800875187
analysis O 0 6.601785429438678e-08
by O 0 1.703781116191294e-08
restriction O 0 3.6083741861148155e-07
fragment O 0 7.369253125943942e-06
length O 0 2.4903145003918326e-06
polymorphisms O 0 1.302512487200147e-06
in O 0 2.255271347451071e-08
the O 0 3.432148432125359e-08
GALNS O 0 0.00023231464729178697
gene O 0 3.9841046373112476e-07
suggest O 0 9.294715397345499e-08
that O 0 2.0213537510471724e-08
G301C O 0 1.5506587942581973e-06
originated O 0 8.591322853135352e-08
from O 0 5.1921271726484974e-09
a O 0 2.1875779054880695e-07
common O 0 2.893171142659412e-07
ancestor O 0 2.9363723115238827e-06
. O 0 2.2741880911780754e-06

Investigation O 0 2.1555790226557292e-05
of O 0 2.473711901984643e-07
the O 0 1.1455615123168172e-07
genetic O 0 5.113530505695962e-07
background O 0 3.097587750744424e-07
by O 0 5.1598672001773593e-08
means O 0 1.966489904248192e-08
of O 0 9.000053147190101e-09
mtDNA O 0 9.099198905460071e-07
lineages O 0 8.268357731822107e-08
indicate O 0 6.297341315075755e-08
that O 0 5.354246823685571e-09
all O 0 2.9725253369861093e-09
our O 0 3.112360502655065e-08
patients O 0 7.381080422419473e-07
are O 0 3.3734819382402748e-09
probably O 0 5.562093008393276e-08
of O 0 8.21291834540716e-09
native O 0 1.6441899219898914e-07
American O 0 1.4499885310215177e-06
descent O 0 0.00012479953875299543

Low O 0 7.905982056399807e-05
frequency O 0 1.3349706023291219e-05
of O 0 2.563383532105945e-07
BRCA1 O 0 0.00032773081329651177
germline O 0 0.00032184741576202214
mutations O 0 3.7331177736632526e-05
in O 0 3.819189373643894e-07
45 O 0 9.683298230811488e-06
German O 1 0.988681435585022
breast B-Disease 1 0.9999847412109375
/ I-Disease 1 0.9999967813491821
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
families O 0 5.0362399633741006e-05
. O 0 5.221738774707774e-06

In O 0 3.953487976104952e-06
this O 0 7.701858351083501e-08
study O 0 6.80122269614003e-08
we O 0 9.619856911058378e-09
investigated O 0 3.1817654644328286e-07
45 O 0 1.494482830821653e-06
German O 1 0.858528733253479
breast B-Disease 1 0.9999852180480957
/ I-Disease 1 0.9999971389770508
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
families O 0 1.4572650570698897e-06
for O 0 1.0421507568025845e-07
germline O 0 0.00020508960005827248
mutations O 0 4.895631263934774e-06
in O 0 5.321384932699402e-08
the O 0 3.776761161589093e-07
BRCA1 O 0 0.0004130104498472065
gene O 0 1.1058014024456497e-05
. O 0 2.673121343832463e-06

We O 0 6.0086326811870094e-06
identified O 0 2.725199010455981e-06
four O 0 4.0348064089812397e-07
germline O 0 1.497145331086358e-05
mutations O 0 6.7500268414733e-06
in O 0 2.8078156333322113e-07
three O 0 7.89645200711675e-05
breast B-Disease 1 0.9999407529830933
cancer I-Disease 1 0.9840136170387268
families O 0 2.654014110703429e-07
and O 0 6.450935075008601e-08
in O 0 1.9917098370569875e-07
one O 0 0.00031756446696817875
breast B-Disease 1 0.9998918771743774
- I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
family O 0 2.3833719751564786e-05
. O 0 1.942697380741265e-08
among O 0 4.815213561215614e-09
these O 0 2.5120230340291982e-09
were O 0 4.140766662885653e-08
one O 0 4.0296768588632403e-07
frameshift O 0 0.09742829948663712
mutation O 0 2.5531685423629824e-06
, O 0 1.951052475135384e-08
one O 0 5.842882089268642e-08
nonsense O 0 1.5138024537009187e-05
mutation O 0 1.0133729801964364e-06
, O 0 1.204096822249312e-08
one O 0 1.0637675629254773e-08
novel O 0 1.1619934525697317e-07
splice O 0 3.7192367017269135e-06
site O 0 1.5346200825661072e-06
mutation O 0 6.460705321842397e-07
, O 0 1.764098911394285e-08
and O 0 3.9858676359472156e-08
one O 0 5.054775442658865e-07
missense O 0 0.0005950904451310635
mutation O 0 3.836182440863922e-05
. O 0 2.7207454422750743e-06

The O 0 7.537867531937081e-06
missense O 0 0.0015546047361567616
mutation O 0 0.00013092538574710488
was O 0 3.417951120354701e-06
also O 0 3.16483948381574e-07
found O 0 1.7166537702451024e-07
in O 0 8.464872536251278e-08
2 O 0 1.7495115116616944e-06
. O 0 2.1745331650890876e-06

8 O 0 1.4456941244134214e-05
% O 0 2.567241494944028e-07
of O 0 6.095016047424906e-09
the O 0 1.0931520577628362e-08
general O 0 9.798394273730082e-08
population O 0 3.714124474640812e-08
, O 0 1.3871471971071969e-08
suggesting O 0 8.647943872119868e-08
that O 0 1.36579512144408e-08
it O 0 4.054029645317314e-08
is O 0 2.2656367093532026e-07
not O 0 8.462202458758838e-06
disease O 0 6.437169940909371e-05
associated O 0 3.7499121390283108e-06
. O 0 1.6528414334970876e-06

The O 0 4.132741196372081e-06
average O 0 6.703281997033628e-06
age O 0 4.980648782293429e-07
of O 0 1.6770201227700454e-07
disease O 0 0.00016350146324839443
onset O 0 0.00023822371440473944
in O 0 1.716776182547619e-06
those O 0 2.0057733252087928e-07
families O 0 2.038513997604241e-07
harbouring O 0 0.00011297229502815753
causative O 0 0.0009947625221684575
mutations O 0 2.55045360972872e-05
was O 0 1.4194325785865658e-06
between O 0 1.041645916188827e-07
32 O 0 3.7678712487831945e-06
. O 0 2.271076027682284e-06

3 O 0 3.079579983022995e-05
and O 0 1.8466580513631925e-06
37 O 0 1.113298367272364e-05
. O 0 2.3005347884463845e-06

4 O 0 3.385722084203735e-05
years O 0 2.5358424409205327e-06
, O 0 8.477572777110254e-08
whereas O 0 9.58202761580651e-08
the O 0 2.703070300924537e-08
family O 0 2.735599196057592e-07
harbouring O 0 3.0302064715215238e-06
the O 0 1.1483879802653973e-07
missense O 0 5.2596220484701917e-05
mutation O 0 1.3011144801566843e-06
had O 0 1.8058081252547709e-07
an O 0 1.8737232210241928e-08
average O 0 1.8729377870840835e-07
age O 0 4.096101946515773e-08
of O 0 6.431803090123367e-09
onset O 0 1.8887001260736724e-06
of O 0 1.2812280658636155e-07
51 O 0 4.7787711082492024e-05
. O 0 3.0500866614602273e-06

2 O 0 9.021223377203569e-05
years O 0 1.88448975677602e-05
. O 0 9.512058568361681e-06

These O 0 4.416067440615734e-06
findings O 0 4.481329597183503e-06
show O 0 7.252150453496142e-07
that O 0 2.2631100193848397e-07
BRCA1 O 0 6.059064617147669e-05
is O 0 2.8345399982754316e-07
implicated O 0 1.374050270896987e-06
in O 0 1.79073484929404e-08
a O 0 3.707421925014387e-08
small O 0 1.358891044134225e-08
fraction O 0 6.43730402316578e-08
of O 0 1.8832633941201493e-07
breast B-Disease 1 0.9998981952667236
/ I-Disease 1 0.999996542930603
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
families O 0 1.480157152400352e-06
suggesting O 0 3.401032699912321e-07
the O 0 1.2716437680637682e-08
involvement O 0 1.6370147193356388e-07
of O 0 4.3042053476938236e-08
another O 0 1.4134527191345114e-05
susceptibility O 0 0.08053008466959
gene O 0 8.606511073594447e-06
( O 0 6.749981480425049e-07
s O 0 0.00020132199279032648
) O 0 4.062942934979219e-06

Paternal O 0 0.31997501850128174
transmission O 0 0.09118946641683578
of O 0 0.00028594236937351525
congenital B-Disease 1 0.9999971389770508
myotonic I-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999998807907104
. O 0 0.11275115609169006

We O 0 1.0320036381017417e-05
report O 0 2.044472921625129e-06
a O 0 4.938505639984214e-07
rare O 0 8.76153706030891e-07
case O 0 1.1944231346205925e-06
of O 0 6.469028335231997e-07
paternally O 1 0.9840447902679443
transmitted O 1 0.9998754262924194
congenital B-Disease 1 0.9999992847442627
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.31246691942214966
DM B-Disease 1 0.9999992847442627
) O 0 5.0101039960281923e-05
. O 0 1.1085488949902356e-05

The O 0 3.382679551577894e-06
proband O 0 5.4340489441528916e-05
is O 0 1.8893022968313744e-07
a O 0 2.399584673185018e-07
23 O 0 2.8836234378104564e-07
year O 0 6.893821336007022e-08
old O 0 4.056778834637953e-06
, O 0 2.3461411728931125e-06
mentally B-Disease 1 0.999976396560669
retarded I-Disease 1 0.9999865293502808
male O 0 0.011731491424143314
who O 0 0.002341344952583313
suffers O 1 0.9997914433479309
severe O 1 0.9990720748901367
muscular B-Disease 1 0.999822199344635
weakness I-Disease 1 0.9937566518783569
. O 0 2.8924976504640654e-05

He O 0 3.968616874772124e-05
presented O 0 1.1059248208766803e-05
with O 0 8.959496881288942e-06
respiratory O 1 0.9383708834648132
and O 0 2.3515710836363724e-06
feeding O 0 2.6068564693559892e-05
difficulties O 0 2.7715392207028344e-05
at O 0 8.192096174752805e-07
birth O 0 5.655205313814804e-05
. O 0 5.002983471058542e-06

His O 0 3.9809361624065787e-05
two O 0 1.651899037824478e-05
sibs O 0 0.3183537423610687
suffer O 0 0.023846331983804703
from O 0 1.2841080661019078e-06
childhood O 0 0.0008668168447911739
onset O 1 0.817043662071228
DM B-Disease 1 0.9999991655349731
. O 0 0.0008401432423852384

Their O 0 5.816767497890396e-06
late O 0 5.006434548704419e-06
father O 0 4.751353117171675e-06
had O 0 2.8288499720474647e-07
the O 0 2.567336387926389e-08
adult O 0 6.720556484651752e-07
type O 0 7.989294772414723e-07
of O 0 1.6817271841773618e-07
DM B-Disease 1 0.9999997615814209
, O 0 2.842199819497182e-06
with O 0 1.9505303328060108e-07
onset O 0 7.478871793864528e-06
around O 0 2.002566077408119e-07
30 O 0 4.120134349250293e-07
years O 0 4.800608053301403e-07
. O 0 7.955483170007938e-07

Only O 0 4.006213202956133e-06
six O 0 4.1099229974861373e-07
other O 0 1.8573590665482698e-08
cases O 0 2.9182709582187272e-08
of O 0 2.2200101312819243e-08
paternal O 0 0.012606547214090824
transmission O 0 0.002590712858363986
of O 0 8.65967922436539e-06
congenital B-Disease 1 0.9999994039535522
DM I-Disease 1 1.0
have O 0 0.04740243777632713
been O 0 4.4382621126715094e-05
reported O 0 2.699822471186053e-05
recently O 0 6.995333023951389e-06
. O 0 1.1787437870225403e-06

We O 0 3.785274202527944e-06
review O 0 8.890722824617114e-07
the O 0 9.642768361572962e-08
sex O 0 5.156871907274763e-07
related O 0 1.5476611281428632e-07
effects O 0 1.1842130334116518e-06
on O 0 5.917508588026976e-06
transmission O 0 0.003919732291251421
of O 0 2.7796280846814625e-05
congenital B-Disease 1 0.9999971389770508
DM I-Disease 1 0.9999998807907104
. O 0 0.009136617183685303

Decreased O 0 0.0012977077858522534
fertility O 0 2.349496389797423e-05
of O 0 1.2417793016084033e-07
males O 0 1.1492396652101888e-06
with O 0 3.9233918869285844e-07
adult O 0 0.00010339965956518427
onset O 0 0.008612444624304771
DM B-Disease 1 0.9999996423721313
and O 0 5.528434485313483e-06
contraction O 0 3.9141750676208176e-06
of O 0 4.669130415635436e-09
the O 0 1.7502870264252124e-08
repeat O 0 1.2943262390763266e-06
upon O 0 1.772227449237107e-07
male O 0 3.1066660994838458e-06
transmission O 0 1.3794634696751018e-06
contribute O 0 3.321942543266232e-08
to O 0 1.9784385685284178e-08
the O 0 1.381863157234875e-08
almost O 0 1.5959000165821635e-07
absent O 0 3.7307032130229345e-07
occurrence O 0 1.5448077306245978e-07
of O 0 3.862100683704739e-08
paternal O 0 0.00037040692404843867
transmission O 0 0.0013451799750328064
of O 0 1.8334376363782212e-05
congenital B-Disease 1 0.9999986886978149
DM I-Disease 1 0.9999998807907104
. O 0 0.022772150114178658

Also O 0 5.460843567561824e-06
the O 0 1.427854101621051e-07
fathers O 0 1.5019513455172273e-07
of O 0 9.03219365966379e-09
the O 0 8.702481579803134e-08
reported O 0 6.594835576834157e-05
congenitally O 0 0.25790101289749146
affected O 0 2.7053711164626293e-06
children O 0 7.437608360305603e-07
showed O 0 4.25011285187793e-06
, O 0 2.0799213018563023e-08
on O 0 8.777145410476805e-08
average O 0 2.448560110224207e-07
, O 0 2.5651189616837655e-08
shorter O 0 1.5607176919729682e-06
CTG O 0 1.1965405974478927e-05
repeat O 0 1.2304370784477214e-06
lengths O 0 3.1511503948422614e-06
and O 0 6.495964299801926e-08
hence O 0 1.4037667028787837e-07
less O 0 7.56689075842587e-07
severe O 1 0.9498104453086853
clinical O 1 0.983644962310791
symptoms O 1 0.9898931384086609
than O 0 3.8726864204363665e-07
the O 0 6.562715526570173e-08
mothers O 0 7.8997788932611e-07
of O 0 2.236031093616475e-08
children O 0 1.125910239352379e-05
with O 0 0.009842757135629654
congenital B-Disease 1 0.9999990463256836
DM I-Disease 1 1.0
. O 0 0.024980152025818825

We O 0 5.352540938474704e-06
conclude O 0 2.823676823027199e-06
that O 0 2.8134982699157263e-07
paternal O 0 5.290589251671918e-05
transmission O 0 0.0001456600584788248
of O 0 6.22395555183175e-06
congenital B-Disease 1 0.9999994039535522
DM I-Disease 1 1.0
is O 0 0.008137168362736702
rare O 0 2.121114630426746e-05
and O 0 6.532854968099855e-07
preferentially O 0 1.8760101738735102e-05
occurs O 0 3.968238360130272e-08
with O 0 3.3826587753083004e-08
onset O 0 3.3976518807321554e-06
of O 0 1.0563596930524e-07
DM B-Disease 1 0.9999986886978149
past O 0 8.922354936657939e-06
30 O 0 3.5548109167393704e-07
years O 0 6.908023664209395e-08
in O 0 1.3847494706453745e-08
the O 0 4.817255216948979e-08
father O 0 1.3847561604052316e-05
. O 0 2.9969729098411335e-07
. O 0 9.492471235716948e-07

The O 0 3.173523145960644e-05
RB1 O 0 0.016440270468592644
gene O 0 1.7994532754528336e-05
mutation O 0 1.1658072253339924e-05
in O 0 7.478335106725353e-08
a O 0 1.0223607205261942e-06
child O 0 2.0840745492023416e-05
with O 0 1.1886498214153107e-05
ectopic B-Disease 1 0.9998921155929565
intracranial I-Disease 1 0.9999517202377319
retinoblastoma I-Disease 1 0.9091852903366089
. O 0 2.1277905034366995e-05

The O 0 2.2647629521088675e-05
RB1 O 0 0.005857174750417471
gene O 0 1.8762410036288202e-05
mutation O 0 2.9448181521729566e-05
was O 0 1.4766633285034914e-06
investigated O 0 1.3529087254937622e-06
in O 0 3.807987170034721e-08
a O 0 1.2920347671752097e-06
child O 0 1.8730854208115488e-05
with O 0 1.2437692930689082e-05
ectopic B-Disease 1 0.9999262094497681
intracranial I-Disease 1 0.9999349117279053
retinoblastoma I-Disease 0 0.006199402268975973
using O 0 1.3108227676639217e-06
DNA O 0 9.624794756746269e-07
obtained O 0 8.693423581007664e-08
from O 0 4.0711833904083505e-09
both O 0 6.009639008652812e-09
the O 0 3.1830758473461174e-08
pineal B-Disease 0 3.59058212779928e-05
and I-Disease 0 1.1613964488788042e-05
retinal I-Disease 1 0.9976571798324585
tumours I-Disease 1 0.9999790191650391
of O 0 2.1560916252383322e-07
the O 0 1.924745220094337e-06
patient O 0 0.0017995609669014812
. O 0 7.773124707455281e-06

A O 0 3.3958785934373736e-05
nonsense O 0 0.00020037309150211513
mutation O 0 2.5143399398075417e-05
in O 0 3.136597968023125e-07
exon O 0 6.094082436902681e-06
17 O 0 4.88541786580754e-07
( O 0 9.230826769623945e-09
codon O 0 6.676496866475645e-08
556 O 0 2.7121706125399214e-07
) O 0 5.813687309341731e-09
of O 0 2.6278768050502777e-09
the O 0 8.102296078504878e-08
RB1 O 0 0.00034895239514298737
gene O 0 2.7379329026189225e-07
was O 0 4.2488701978982135e-07
found O 0 1.8989405603520026e-08
to O 0 1.1743903627348118e-08
be O 0 2.3668649262731378e-08
present O 0 2.673097476701969e-08
homozygously O 0 4.993450602341909e-06
in O 0 2.5223563682175154e-08
both O 0 1.3601487047765204e-08
the O 0 6.018014886421952e-08
retinal B-Disease 0 0.00035812341957353055
and I-Disease 0 1.0396823881819728e-06
the I-Disease 0 1.9503347630234202e-06
pineal I-Disease 0 0.35170334577560425
tumours I-Disease 1 0.9999761581420898
. O 0 1.9833705664495938e-05

The O 0 1.8885272083934979e-06
same O 0 5.309315724844055e-07
mutation O 0 1.7231865285793901e-06
was O 0 3.259226275531546e-07
present O 0 4.7032408190261776e-08
heterozygously O 0 1.1215668564545922e-05
in O 0 2.861979275792237e-08
the O 0 1.82736048515153e-08
DNA O 0 1.4243397572499816e-07
from O 0 3.6185687779521913e-09
the O 0 4.683865739707471e-09
constitutional O 0 3.0662772587675136e-07
cells O 0 3.318637098459476e-08
of O 0 2.4105235585381024e-09
the O 0 2.9401943990592372e-08
patient O 0 2.6469153453945182e-05
, O 0 8.788084215893832e-08
proving O 0 3.593161750359286e-07
it O 0 1.8097123799520887e-08
to O 0 2.242613028613505e-08
be O 0 2.1087178225798198e-08
of O 0 2.3025352291483614e-08
germline O 0 1.3591105926025193e-05
origin O 0 8.357710612472147e-07
. O 0 1.073876887858205e-06

The O 0 6.011894129187567e-06
initial O 0 2.230211248388514e-05
mutation O 0 2.5153185561066493e-05
was O 0 2.775378789010574e-06
shown O 0 3.301931030819105e-07
to O 0 4.554365773401514e-08
have O 0 8.108062132805571e-08
occurred O 0 1.0621156576462454e-07
in O 0 2.8275248808995457e-08
the O 0 1.4819522675679764e-07
paternally O 0 0.00014970859047025442
derived O 0 8.289425750263035e-06
RB1 O 0 0.0006271408637985587
allele O 0 5.378144123824313e-05
. O 0 3.1492966172663728e-06

The O 0 2.118859129041084e-06
mutation O 0 1.3622521692013834e-05
is O 0 5.419141047013909e-08
in O 0 1.1689798462555245e-08
an O 0 2.815223254515331e-08
area O 0 3.344129595461709e-08
of O 0 1.4156904537543369e-09
the O 0 1.1830302071302867e-08
gene O 0 5.4833545704013886e-08
that O 0 3.2857450094070373e-09
encodes O 0 2.855027680936928e-08
the O 0 3.736954301558626e-09
protein O 0 2.239321794661464e-08
- O 0 1.071998326551693e-06
binding O 0 5.15615852236806e-07
region O 0 6.355866588592107e-08
known O 0 5.3851284320671766e-08
as O 0 1.6925515211596576e-08
the O 0 1.6379821943246498e-08
pocket O 0 0.0005112903309054673
region O 0 7.74834489902787e-08
and O 0 4.9788813072382254e-08
has O 0 2.678493160601647e-07
been O 0 2.476884333191265e-07
detected O 0 2.642066760927264e-07
in O 0 8.43328251676212e-09
other O 0 9.60634327640264e-09
cases O 0 4.553045584998472e-08
of O 0 4.985457380257685e-08
retinoblastoma B-Disease 0 0.017270127311348915
. O 0 1.269679046345118e-06
. O 0 1.3436600738714333e-06

Low O 0 6.160094199003652e-05
levels O 0 3.2203951150222565e-07
of O 0 9.856686133957737e-09
beta O 0 9.110836884929085e-08
hexosaminidase O 0 1.7670492979959818e-06
A O 0 5.790659542981302e-07
in O 0 1.1219803042195053e-07
healthy O 0 1.0766774494186393e-06
individuals O 0 2.668589260679255e-08
with O 0 1.619335193936422e-06
apparent O 1 0.9995958209037781
deficiency O 1 0.7151811122894287
of O 0 1.7637489690969232e-08
this O 0 1.6453068951705063e-07
enzyme O 0 2.6028224056062754e-06
. O 0 9.296387588619837e-07

Appreciable O 0 0.0007436791202053428
beta O 0 2.7382135158404708e-05
hexosaminidase O 0 9.96933231363073e-05
A O 0 3.6124756661592983e-06
( O 0 7.22398709740446e-08
hex O 0 2.709073669393547e-06
A O 0 3.9197828982651117e-07
) O 0 1.2213008382389035e-08
activity O 0 1.4084622357302123e-08
has O 0 8.750050284334066e-08
been O 0 2.1620463996896433e-07
detected O 0 4.530799060376012e-07
in O 0 5.32457278268339e-08
cultured O 0 5.193407923798077e-05
skin O 1 0.7759389877319336
fibroblasts O 0 0.0003681269590742886
and O 0 0.0011558897094801068
melanoma B-Disease 1 0.9998859167098999
tissue O 0 0.000392178597394377
from O 0 1.40384173619168e-07
healthy O 0 1.6614798141745268e-06
individuals O 0 2.7128011836907717e-08
previously O 0 9.405809464624326e-07
reported O 0 4.265648385626264e-06
as O 0 6.804582994845987e-07
having O 0 6.158502219477668e-05
deficiency B-Disease 0 9.408738696947694e-05
of I-Disease 0 7.478175412245491e-09
hex I-Disease 0 2.73197770184197e-06
A I-Disease 0 3.450876704391703e-07
activity O 0 2.326240000627422e-08
indistinguishable O 0 1.0275761042066733e-07
from O 0 3.766694067763865e-09
that O 0 9.912226595076845e-09
of O 0 5.231535027405698e-08
patients O 0 0.002292841672897339
with O 0 0.12881387770175934
Tay B-Disease 1 1.0
- I-Disease 1 0.9999988079071045
Sachs I-Disease 1 0.9999994039535522
disease I-Disease 1 0.5646750926971436
( O 0 1.4949049500501133e-06
TSD B-Disease 0 0.0012369273463264108
) O 0 1.6581366253376473e-06
. O 0 2.7840073926199693e-06

Identification O 0 2.9777427698718384e-05
and O 0 1.2829108300138614e-06
quantitation O 0 2.1398533135652542e-05
of O 0 4.500722283751202e-08
hex O 0 6.874387509014923e-06
A O 0 6.91217394432897e-07
, O 0 7.38077119422087e-08
amounting O 0 5.506768729901523e-07
to O 0 2.355354666860876e-07
3 O 0 2.0659012989199255e-06
. O 0 2.590806388980127e-06

5 O 0 0.0001166034780908376
% O 0 7.830375579942483e-06
- O 0 6.178090552566573e-05
6 O 0 2.1867634131922387e-05
. O 0 3.6218482364347437e-06

9 O 0 3.143549838569015e-05
% O 0 3.6000253089696344e-07
of O 0 8.563016962170877e-09
total O 0 2.1329766397570893e-08
beta O 0 7.23510140687722e-08
hexosaminidase O 0 2.0310637864895398e-06
activity O 0 4.320219204601017e-08
, O 0 2.0419651747261014e-08
has O 0 1.0507190495445684e-07
been O 0 7.431823689785233e-08
obtained O 0 5.260161017872633e-08
by O 0 3.530454506517344e-08
cellulose O 0 1.2817238712159451e-05
acetate O 0 0.00011342002107994631
gel O 0 0.005473182071000338
electrophoresis O 0 1.4956356608308852e-05
, O 0 8.471575796420439e-08
DEAE O 0 7.054133220663061e-06
- O 0 2.984792672577896e-06
cellulose O 0 5.202616193855647e-06
ion O 0 5.215005330683198e-06
- O 0 2.308583361809724e-06
exchange O 0 1.026304872198125e-07
chromatography O 0 1.0902347185037797e-06
, O 0 1.0608037115389379e-07
radial O 0 5.2958062042307574e-06
immunodiffusion O 0 2.1008245312259533e-05
, O 0 1.3044076752066758e-07
and O 0 2.8294192588873557e-07
radioimmunoassay O 0 0.0002002283144975081
. O 0 3.0120152132440126e-06

Previous O 0 4.4021082430845127e-05
family O 0 7.641959200554993e-06
studies O 0 2.870656317099929e-07
suggested O 0 5.175805881663109e-07
that O 0 6.276344777234044e-08
these O 0 1.3738579163202758e-08
individuals O 0 7.598692342014601e-09
may O 0 2.4229871087300126e-07
be O 0 3.727829422928153e-08
compound O 0 8.785132195043843e-07
heterozygotes O 0 1.492516048529069e-06
for O 0 7.097311183201782e-09
the O 0 1.839575602957666e-08
common O 0 8.869114509479914e-08
mutant O 0 9.628305633668788e-06
TSD B-Disease 0 4.681771679315716e-05
gene O 0 2.9450305305545044e-07
and O 0 1.4990343188969746e-08
a O 0 4.241890394496295e-07
rare O 0 4.198558599455282e-06
( O 0 1.127992632632413e-07
allelic O 0 5.141426299815066e-06
) O 0 1.1478164196887519e-07
mutant O 0 9.350882464786991e-06
gene O 0 3.2217881198448595e-06
. O 0 1.152694949269062e-06

Thus O 0 1.3544162356993183e-05
, O 0 1.468897465883856e-07
the O 0 3.0453293220489286e-08
postulated O 0 2.816705773511785e-06
rate O 0 1.4396211156508798e-07
mutant O 0 3.284751244336803e-07
gene O 0 7.609457952639787e-08
appears O 0 1.7397702833932271e-07
to O 0 1.0702678743257366e-08
code O 0 1.6173682837461456e-08
for O 0 1.0214359136284656e-08
the O 0 8.747075952442174e-09
expression O 0 4.2145750001054694e-08
of O 0 3.921474256429747e-09
low O 0 1.1630766039161244e-07
amounts O 0 2.5430415107052795e-08
of O 0 5.1245558907453415e-09
hex O 0 4.271535090083489e-06
A O 0 3.7637519199051894e-06
. O 0 1.4578822629118804e-06

Heterozygotes O 0 0.011007709428668022
for O 0 1.920176373459981e-06
the O 0 2.506554324099852e-07
rare O 0 1.0348155683459481e-06
mutant O 0 1.4046002434042748e-05
may O 0 5.093881441098347e-07
be O 0 1.9620390645513908e-08
indistinguishable O 0 1.9655810490348813e-07
from O 0 1.9413306517890305e-08
heterozygotes O 0 1.4346503576234682e-06
for O 0 2.1696676455462693e-08
the O 0 7.220474884661598e-08
common O 0 9.11946699488908e-07
TSD B-Disease 0 0.0009474086691625416
mutant O 0 0.00016007470549084246
. O 0 3.523389068504912e-06

However O 0 2.1391291738837026e-05
, O 0 4.602175067702774e-07
direct O 0 2.9366896114879637e-07
visualization O 0 1.171505346064805e-06
and O 0 7.518166000863857e-08
quantitation O 0 8.248144695244264e-06
of O 0 2.363242579406233e-08
hex O 0 7.412736067635706e-06
A O 0 4.398811768169253e-07
by O 0 9.826389479883346e-09
the O 0 7.04598912548704e-09
methods O 0 1.4430740691295796e-07
described O 0 1.4155543794913683e-05
may O 0 5.893337515772146e-07
prevent O 0 6.877772307234409e-08
false O 0 4.4140702470940596e-07
- O 0 3.830622517853044e-05
positive O 0 1.0468125765328296e-05
prenatal O 0 0.061461493372917175
diagnosis O 0 0.006984292063862085
of O 0 8.012958829795025e-08
TSD B-Disease 0 0.1409396231174469
in O 0 1.0480982382432558e-05
fetuses O 0 0.0012115025892853737
having O 0 2.1532662231038557e-07
the O 0 1.3856901404096789e-08
incomplete O 0 8.114039360407332e-07
hex B-Disease 0 0.000980462646111846
A I-Disease 0 0.00995570793747902
deficiency I-Disease 0 0.0005853056209161878
of O 0 4.099093509069007e-09
the O 0 2.696427792159284e-08
type O 0 5.4099054977996275e-06
described O 0 5.443689587991685e-06
in O 0 4.2210107409346165e-08
the O 0 3.349255450757482e-08
four O 0 7.926304874672496e-07
healthy O 0 6.508442766062217e-06
individuals O 0 1.4119233355813776e-06

The O 0 8.247413461504038e-06
tumor B-Disease 0 9.363385470351204e-05
suppressor O 0 6.673612369922921e-05
gene O 0 2.4049047624430386e-06
Smad4 O 0 1.38262639666209e-05
/ O 0 2.806347993100644e-06
Dpc4 O 0 6.906547696416965e-06
is O 0 4.696266842074692e-08
required O 0 3.208592147529998e-08
for O 0 1.1652444342757917e-08
gastrulation O 0 1.0659264262358192e-06
and O 0 8.342574631114985e-08
later O 0 1.3943522958470567e-07
for O 0 1.2054479192613599e-08
anterior O 0 1.320306523666659e-06
development O 0 1.1842989700028284e-08
of O 0 6.078182845925539e-09
the O 0 8.509145743573754e-08
mouse O 0 2.2450334654422477e-05
embryo O 0 1.3213092643127311e-05
. O 0 2.139383241228643e-06

Mutations O 0 0.008042019791901112
in O 0 2.2533592982654227e-06
the O 0 9.924316373144393e-07
SMAD4 O 0 0.03879981115460396
/ O 0 0.0002538444532547146
DPC4 O 0 0.03026438131928444
tumor B-Disease 0 0.0004099420621059835
suppressor O 0 0.00011271254334133118
gene O 0 7.379932753792673e-07
, O 0 1.3258865116938523e-08
a O 0 3.2225390356188655e-08
key O 0 2.8980027266811703e-08
signal O 0 2.7806456159851223e-07
transducer O 0 6.405657586583402e-06
in O 0 9.684406165888504e-08
most O 0 7.956668923725374e-08
TGFbeta O 0 6.0415190091589466e-05
- O 0 0.00019028301176149398
related O 0 4.973708769284713e-07
pathways O 0 1.9234738601880963e-07
, O 0 1.7535082719177808e-08
are O 0 2.6431785649094763e-09
involved O 0 8.789756478222444e-09
in O 0 2.3684229688569758e-08
50 O 0 1.527300952375299e-07
% O 0 3.841119777803215e-08
of O 0 1.0138973749462821e-07
pancreatic B-Disease 1 0.9997798800468445
cancers I-Disease 1 0.9909321069717407
. O 0 1.4581058167095762e-05

Homozygous O 0 0.005028554704040289
Smad4 O 0 0.002561194822192192
mutant O 0 0.002159076277166605
mice O 0 0.05428600683808327
die O 0 0.00034711090847849846
before O 0 4.3329526988600264e-07
day O 0 5.748161129304208e-07
7 O 0 2.1122216367075453e-06
. O 0 1.686273435552721e-06

5 O 0 2.775874236249365e-05
of O 0 9.590161198502756e-07
embryogenesis O 0 0.0001008812541840598
. O 0 1.0914500307990238e-05

Mutant O 0 0.00010856305743800476
embryos O 0 3.462157474132255e-05
have O 0 1.197023038912448e-06
reduced O 0 8.157006732290029e-07
size O 0 3.946862250359118e-07
, O 0 1.1910046282537223e-07
fail O 0 2.81951179204043e-06
to O 0 1.454580882409573e-07
gastrulate O 0 5.204707485972904e-05
or O 0 5.3113261344606144e-08
express O 0 1.6660176527238946e-07
a O 0 9.872701411950402e-08
mesodermal O 0 4.0419649849354755e-06
marker O 0 7.931325853860471e-06
, O 0 5.2597901145645665e-08
and O 0 4.05215843102269e-08
show O 0 1.5722416719654575e-06
abnormal O 0 6.115739779488649e-06
visceral O 0 0.00045392283936962485
endoderm O 0 0.00014553983055520803
development O 0 1.4138906863081502e-06
. O 0 3.2036930406320607e-06

Growth B-Disease 1 0.9949988126754761
retardation I-Disease 1 0.9996387958526611
of O 0 2.855091167930368e-07
the O 0 3.4979601082341105e-07
Smad4 O 0 0.0005590196815319359
- O 0 0.041989609599113464
deficient O 0 0.0007400258909910917
embryos O 0 1.1087190614489373e-06
results O 0 3.116177254014474e-07
from O 0 2.8715152922131892e-08
reduced O 0 5.274759473650192e-07
cell O 0 9.496908432993223e-07
proliferation O 0 1.188857581269076e-07
rather O 0 7.194135775989707e-08
than O 0 8.648422067381034e-08
increased O 0 1.0055896382255014e-06
apoptosis O 0 2.510858394089155e-05
. O 0 1.7115678474510787e-06

Aggregation O 0 5.8489102229941636e-05
of O 0 4.2753717366394994e-07
mutant O 0 2.1797071894980036e-05
Smad4 O 0 0.00012358109233900905
ES O 0 9.150470759777818e-06
cells O 0 4.660200261241698e-07
with O 0 2.217910832769121e-08
wild O 0 1.755630876232317e-07
- O 0 3.640694558271207e-05
type O 0 3.7164604691497516e-06
tetraploid O 0 1.9921266357414424e-05
morulae O 0 7.323123281821609e-05
rescues O 0 7.068362265272299e-06
the O 0 2.802911467369995e-07
gastrulation B-Disease 0 0.00010653802019078285
defect I-Disease 0 0.0007980341324582696
. O 0 6.686337201244896e-06

These O 0 4.265762527211336e-06
results O 0 2.0502484403550625e-06
indicate O 0 2.7090737830803846e-07
that O 0 9.613569318389636e-08
Smad4 O 0 1.338782658422133e-05
is O 0 1.2362704637780553e-07
initially O 0 3.078404802181467e-07
required O 0 8.931138495427149e-09
for O 0 1.777171187988813e-09
the O 0 3.072621490574079e-09
differentiation O 0 8.828838993224508e-09
of O 0 2.000506871269181e-09
the O 0 2.3060602316604673e-08
visceral O 0 5.0968748837476596e-05
endoderm O 0 2.30402347369818e-05
and O 0 4.921795948575891e-08
that O 0 1.5576315348653225e-08
the O 0 1.582275466205374e-08
gastrulation B-Disease 0 4.346625246398617e-06
defect I-Disease 0 1.1138368790852837e-05
in O 0 2.964775447367174e-08
the O 0 4.38965912508138e-08
epiblast O 0 6.833783845650032e-05
is O 0 1.0874585143483273e-07
secondary O 0 1.7529933060700387e-08
and O 0 1.6926968271491205e-08
non O 0 1.6437384431355895e-07
- O 0 9.488059731665999e-05
cell O 0 0.00017101148841902614
autonomous O 0 4.1428747863392346e-06
. O 0 1.2587535138663952e-06

Rescued O 0 0.0010789858642965555
embryos O 0 0.00010425625077914447
show O 0 9.362074342789128e-05
severe O 0 0.04983038827776909
anterior O 0 0.0004458019102457911
truncations O 0 0.0013128643622621894
, O 0 2.083349500026088e-06
indicating O 0 5.817960300191771e-07
a O 0 1.1147171363745656e-07
second O 0 6.266584051672908e-08
important O 0 1.1367069063794588e-08
role O 0 9.518237220618175e-08
for O 0 1.0136846384511955e-07
Smad4 O 0 2.5021958208526485e-05
in O 0 2.935381928637071e-07
anterior O 0 1.2582082490553148e-05
patterning O 0 9.841458813752979e-05
during O 0 5.973169663775479e-06
embryogenesis O 0 9.262828825740144e-05
. O 0 8.712138878763653e-06

Prevalence O 0 0.0006687141139991581
of O 0 3.6969998973290785e-07
p16 O 0 2.2978047127253376e-05
and O 0 6.602049893444928e-07
CDK4 O 0 0.003777492558583617
germline O 0 0.0001612973865121603
mutations O 0 9.760593457031064e-06
in O 0 2.802777885335672e-07
48 O 0 0.00024324885453097522
melanoma B-Disease 1 0.9949488639831543
- O 0 0.35183951258659363
prone O 0 0.06570593267679214
families O 0 1.8335213098907843e-06
in O 0 8.648073048789229e-07
France O 0 4.883961446466856e-05
. O 0 3.0888345463608857e-06

The O 0 6.9583334152412135e-06
French O 0 0.0003183556837029755
Familial B-Disease 1 0.6993308067321777
Melanoma I-Disease 1 0.9998842477798462
Study O 0 2.2010655811754987e-05
Group O 0 5.375510227167979e-06
. O 0 2.5459107746428344e-06

Germline O 0 0.1394302397966385
mutations O 0 0.020325230434536934
in O 0 1.7388027799825068e-06
the O 0 4.0149697611013835e-07
p16 O 0 1.709446223685518e-05
and O 0 3.3383884101567673e-07
CDK4 O 0 0.00020685215713456273
genes O 0 5.285747306515987e-07
have O 0 1.6146196912814048e-07
been O 0 3.970919522089389e-07
reported O 0 5.406874379332294e-07
in O 0 2.205356119944213e-09
a O 0 3.9901120629792786e-08
subset O 0 6.436272315113456e-08
of O 0 4.3412910599727184e-08
melanoma B-Disease 1 0.9546601176261902
pedigrees O 0 9.826476343732793e-06
, O 0 4.182606261338151e-08
but O 0 7.021026249276474e-08
their O 0 4.4613635452606104e-08
prevalence O 0 7.334498604905093e-06
is O 0 1.0409944906086821e-07
not O 0 4.661711372477839e-08
well O 0 7.230176635175667e-08
known O 0 8.678080121171661e-07
. O 0 1.5862253803788917e-06

We O 0 3.0911921840015566e-06
searched O 0 3.380315774847986e-06
for O 0 3.879183907429251e-08
such O 0 2.7187374129766795e-08
germline O 0 2.1262407244648784e-05
mutations O 0 4.294637619750574e-06
in O 0 1.5495780303353968e-07
48 O 0 6.73066642775666e-06
French O 0 0.0023809487465769053
melanoma B-Disease 1 0.9993096590042114
- O 1 0.5532249212265015
prone O 0 0.34070757031440735
families O 0 6.201341875566868e-07
selected O 0 6.890233095191434e-08
according O 0 1.301529461983364e-08
to O 0 7.965700987710989e-09
two O 0 8.366951576022075e-09
major O 0 3.9262285866925595e-08
criteria O 0 1.8996439621332684e-07
families O 0 1.480290467981149e-08
with O 0 9.26069976259214e-09
at O 0 3.041764884414988e-08
least O 0 6.076724190506866e-08
three O 0 3.272212723004486e-08
affected O 0 2.799694343025294e-08
members O 0 1.0878231648803194e-08
( O 0 9.405817458230104e-09
n O 0 6.107179615355562e-07
= O 0 4.4107420649197593e-07
20 O 0 3.401518355872213e-08
) O 0 6.497225868429268e-09
or O 0 5.620649723425686e-09
families O 0 9.05772612469491e-09
with O 0 1.511313030277961e-08
two O 0 1.658881672028656e-07
affected O 0 5.528048063752067e-08
members O 0 6.229400106860794e-09
, O 0 3.5156091371391085e-09
one O 0 3.0699092157249197e-09
of O 0 8.229739112408652e-10
them O 0 8.22636980757352e-09
affected O 0 8.561579889487803e-09
before O 0 4.398817754491802e-09
the O 0 4.531116370998234e-09
age O 0 1.8349744834722514e-08
of O 0 2.078734295807294e-09
50 O 0 3.9380786631681985e-08
( O 0 1.7909739469246233e-08
n O 0 5.336825097401743e-07
= O 0 6.213975893842871e-07
28 O 0 1.5122537888601073e-07
) O 0 4.0032448467286486e-09
, O 0 3.4574625384919955e-09
and O 0 9.107568033073221e-09
one O 0 3.158919881229849e-08
additional O 0 1.506349320834488e-07
minor O 0 1.4409112054636353e-06
criterion O 0 1.1765821909648366e-05
. O 0 2.2911485757504124e-06

Sixteen O 0 7.727872434770688e-05
different O 0 1.7519022321721422e-06
p16 O 0 5.436879291664809e-05
germline O 0 0.00026743157650344074
mutations O 0 5.11419348185882e-05
were O 0 5.114920327287109e-07
found O 0 2.5278089310631913e-07
in O 0 1.3645939134221408e-07
21 O 0 3.841621946776286e-06
families O 0 7.3567512970385e-08
, O 0 2.993670378259594e-08
while O 0 3.1387401122628944e-08
one O 0 8.494794201396871e-08
germline O 0 7.352062311838381e-06
mutation O 0 1.1882017361131147e-06
, O 0 5.4788383607728974e-08
Arg24His O 0 3.2443269901705207e-06
, O 0 5.610905517983156e-08
was O 0 4.932278443448013e-07
detected O 0 3.1353479812423757e-07
in O 0 2.5628596134197323e-08
the O 0 5.587239826354562e-08
CDK4 O 0 0.001153889810666442
gene O 0 7.282379101525294e-06
. O 0 2.725479589571478e-06

The O 0 1.9513599909259938e-06
frequency O 0 3.5616353670775425e-06
of O 0 1.2801447724086756e-07
p16 O 0 8.77088496054057e-06
gene O 0 1.1876036296598613e-06
mutation O 0 1.3726919405598892e-06
in O 0 2.5358149358112314e-08
our O 0 1.2787996439556082e-08
sample O 0 7.286661940497652e-08
( O 0 9.76853353762408e-09
44 O 0 1.6509652311924583e-07
% O 0 1.3658889130852003e-08
) O 0 2.3445105856723103e-09
is O 0 8.805126405775354e-09
among O 0 3.178378893409217e-09
the O 0 4.875952530625227e-09
highest O 0 2.2396257293166855e-07
rates O 0 1.0351259760454923e-07
yet O 0 1.2000229787645367e-07
reported O 0 2.6726192459136655e-07
and O 0 1.1419920120658844e-08
the O 0 4.259329244860055e-08
CDK4 O 0 0.0703386664390564
mutation O 0 1.68593567195785e-06
is O 0 7.391953715796262e-09
the O 0 3.1359737029390544e-09
second O 0 4.1102370573753433e-07
mutation O 0 1.1383100400053081e-06
detected O 0 2.118070341339262e-07
in O 0 1.1685384215809336e-08
this O 0 2.7008233871583798e-08
gene O 0 4.4859041281597456e-07
worldwide O 0 4.801120780939527e-07
. O 0 1.6826685396154062e-06

In O 0 8.677494406583719e-06
summary O 0 6.174537247716216e-06
, O 0 8.65923368564836e-08
our O 0 1.9412899732174083e-08
results O 0 1.127431232816889e-07
show O 0 2.1877406197745586e-07
frequent O 0 2.416468021237961e-07
involvement O 0 9.326644345719615e-08
of O 0 6.5038716634546745e-09
the O 0 2.4868816339562727e-08
p16 O 0 1.8574246496427804e-06
gene O 0 4.5432082629304205e-07
in O 0 2.476041345289559e-07
familial B-Disease 0 0.48648303747177124
melanoma I-Disease 1 0.9999812841415405
and O 0 5.611998403765028e-06
confirm O 0 5.50558979739435e-06
the O 0 6.292056653478539e-09
role O 0 2.189134207242205e-08
of O 0 1.9055901301356926e-09
the O 0 2.4162417844308948e-08
CDK4 O 0 0.00013413795386441052
gene O 0 2.187771883654932e-07
as O 0 9.309316340022633e-08
a O 0 1.3830115676682908e-05
melanoma B-Disease 1 0.9948534369468689
- O 0 0.030853401869535446
predisposing O 0 0.0004270099743735045
gene O 0 4.493458163778996e-06
. O 0 5.000952683076321e-07
. O 0 1.1899571745743742e-06

Progression O 0 0.0002126895124092698
of O 0 1.1975779443673673e-06
somatic O 0 4.211134000797756e-05
CTG O 0 0.0004661596904043108
repeat O 0 4.1205519664799795e-05
length O 0 1.374617113469867e-05
heterogeneity O 0 6.441218374675373e-06
in O 0 6.747522718342225e-08
the O 0 7.508435118097623e-08
blood O 0 1.6248219480985426e-06
cells O 0 1.6171143215615302e-06
of O 0 1.6720182429708075e-06
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
patients O 1 0.9998644590377808
. O 0 3.665666008600965e-05

The O 0 3.84723125534947e-06
genetic O 0 1.004586010822095e-05
basis O 0 8.839860470288841e-07
of O 0 4.418136086314917e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.06324940919876099
DM B-Disease 1 0.9999997615814209
) O 0 8.450223276668112e-07
is O 0 3.1887029905419695e-08
the O 0 6.083425319047819e-09
expansion O 0 4.1187508514894944e-08
of O 0 9.786846888459877e-09
an O 0 3.9871267176749825e-07
unstable O 0 0.00010222417768090963
CTG O 0 7.295541581697762e-05
repeat O 0 2.231043936262722e-06
in O 0 3.521167357689592e-08
the O 0 2.6897705396322635e-08
34 O 0 2.5376348844474705e-07
UTR O 0 2.243825520054088e-06
of O 0 1.1340302918938505e-08
the O 0 3.203908249815868e-07
DM B-Disease 1 0.999998927116394
protein O 0 1.0044528607977554e-05
kinase O 0 1.8681797655517585e-06
gene O 0 1.0417830509368287e-07
on O 0 1.7930970841462113e-07
chromosome O 0 2.5889963580993935e-05
19 O 0 2.779947863018606e-06
. O 0 1.8005614492722088e-06

One O 0 2.364989086345304e-06
of O 0 5.023514049184996e-08
the O 0 1.9084101410271614e-08
principal O 0 5.371085620708982e-08
features O 0 5.846471395898334e-08
of O 0 4.649064688777571e-09
the O 0 1.672602024882508e-06
DM B-Disease 1 1.0
mutation O 0 0.003516286611557007
is O 0 1.3384976682573324e-07
an O 0 4.14773033696747e-08
extraordinarily O 0 5.895321464777226e-06
high O 0 1.8210599250778614e-07
level O 0 9.189158767242134e-09
of O 0 3.4924978464800915e-09
somatic O 0 3.1965057587513e-06
mosaicism O 0 0.0035449466668069363
, O 0 1.2469676846649236e-07
due O 0 1.138571263936683e-07
to O 0 7.967026505184549e-08
an O 0 2.0114357823786122e-07
extremely O 0 6.647691861871863e-06
high O 0 4.850955406254798e-07
degree O 0 1.0639323022587632e-07
of O 0 1.0406287387354496e-08
somatic O 0 2.963146926049376e-06
instability O 0 1.545080408504873e-06
both O 0 2.9750625074598247e-08
within O 0 8.959495367832915e-09
and O 0 2.2777769004278525e-08
between O 0 3.3588960945962754e-08
different O 0 1.0171863351615684e-07
tissues O 0 6.22565357843996e-06
. O 0 1.805883812266984e-06

This O 0 7.910380190878641e-06
instability O 0 2.2469441319117323e-05
appears O 0 3.5249149732408114e-06
to O 0 8.243383575745611e-08
be O 0 1.8334876727976734e-08
biased O 0 2.496632305337698e-07
towards O 0 1.7911004235315886e-08
further O 0 2.0456724314499297e-08
expansion O 0 2.9353810049315143e-08
and O 0 9.64449409224244e-09
continuous O 0 6.048982470474584e-08
throughout O 0 6.054879264638657e-09
the O 0 3.796989833659836e-09
life O 0 9.644456788748812e-09
of O 0 8.611657498214242e-10
an O 0 2.25183267588136e-08
individual O 0 7.504180388195891e-09
, O 0 9.460171312980492e-09
features O 0 1.1864156590490893e-07
that O 0 3.031108519735426e-08
could O 0 1.4406566606339766e-07
be O 0 1.6974009753312203e-08
associated O 0 1.3618723038177905e-08
with O 0 6.897106441527967e-09
the O 0 3.156227634804054e-08
progressive O 0 1.5211248864943627e-05
nature O 0 7.33602760760732e-08
of O 0 2.4382599050909448e-08
the O 0 1.7976359458771185e-06
disease O 0 0.0003219303034711629
. O 0 4.2195565583824646e-06

Although O 0 1.85780918400269e-05
increasing O 0 1.2696330031758407e-06
measured O 0 2.920275392170879e-06
allele O 0 2.632911218825029e-06
size O 0 3.9266299722839904e-07
between O 0 5.43408646080934e-07
patients O 0 0.00017130491323769093
clearly O 0 1.3339042652660282e-06
correlates O 0 2.093231159960851e-06
with O 0 3.4354560085603225e-08
an O 0 1.1979076930401789e-07
increased O 0 3.4877582493209047e-06
severity O 0 0.00012410424824338406
of O 0 1.163714671292837e-07
symptoms O 0 0.09417127072811127
and O 0 1.3325065140179504e-07
an O 0 2.1493475799161388e-07
earlier O 0 6.190438853082014e-06
age O 0 9.332410400020308e-08
of O 0 5.768972854980348e-09
onset O 0 6.585752544197021e-06
, O 0 6.275183750403812e-08
this O 0 6.867360902163e-09
correlation O 0 4.36093507971691e-08
is O 0 1.8079390429193154e-08
not O 0 1.3038476076587813e-08
precise O 0 1.371767837099469e-07
and O 0 6.560387788567823e-08
measured O 0 4.330921910877805e-06
allele O 0 1.1669969808281166e-06
length O 0 6.657905373685935e-07
cannot O 0 1.1181136017057725e-07
be O 0 4.259627761626916e-09
used O 0 1.3797140319127266e-08
as O 0 9.124816457983798e-09
an O 0 1.3555180977675718e-08
accurate O 0 2.567332160197111e-07
predictor O 0 1.1126159051855211e-06
of O 0 7.287117131937748e-09
age O 0 9.105504261697206e-08
of O 0 3.612791488194489e-08
onset O 0 9.918563591782004e-05
. O 0 9.443889211979695e-06

In O 0 6.381694220181089e-06
order O 0 5.615272584691411e-07
to O 0 9.107500886784692e-08
further O 0 8.61769606785856e-08
characterize O 0 1.4433413753067725e-06
the O 0 1.0426080621073197e-07
dynamics O 0 3.2724992706789635e-06
of O 0 1.829642002348919e-07
DM B-Disease 1 0.9999977350234985
CTG O 0 0.004685088060796261
repeat O 0 1.017738031805493e-05
somatic O 0 3.976997959398432e-06
instability O 0 2.174711426050635e-06
, O 0 6.33003622851902e-08
we O 0 1.4838012596385397e-08
have O 0 2.5004656123428504e-08
studied O 0 1.1480398143248749e-07
repeat O 0 7.660900109840441e-07
length O 0 9.930413398251403e-07
changes O 0 2.53561154295312e-08
over O 0 1.8460923456586897e-08
time O 0 7.532504753271496e-08
in O 0 3.789229765516211e-07
111 O 0 0.09815008193254471
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
patients O 1 0.9996129870414734
with O 0 7.541174909420079e-06
varying O 0 3.969074896303937e-05
clinical O 0 0.0005675714928656816
severity O 0 0.017590904608368874
and O 0 8.971475153884967e-07
CTG O 0 2.191947351093404e-05
repeat O 0 5.836204763909336e-07
size O 0 2.9788836286570586e-08
over O 0 2.579031921357e-08
time O 0 2.21610108042114e-08
intervals O 0 4.2259244992237655e-08
of O 0 3.867435705018352e-09
1 O 0 6.410714803450901e-08
- O 0 1.156877442554105e-05
7 O 0 2.0672098344221013e-06
years O 0 7.407566613437666e-07
. O 0 9.143650459009223e-07

We O 0 4.173850811639568e-06
have O 0 3.1957208079802513e-07
found O 0 4.284040855395688e-08
a O 0 3.377578394747616e-08
direct O 0 7.569389026684803e-08
progression O 0 3.551754446107225e-07
of O 0 3.5855503011106293e-09
the O 0 1.1065652394393055e-08
size O 0 1.2423241457781842e-07
heterogeneity O 0 5.014774160372326e-07
over O 0 1.2876751043222612e-07
time O 0 7.512833377631978e-08
related O 0 3.818780669462285e-08
to O 0 7.103543708808502e-08
initial O 0 9.071264912563493e-07
CTG O 0 9.535391654935665e-06
repeat O 0 5.832482088408142e-07
size O 0 4.5368693690761575e-08
and O 0 5.696055627169017e-09
the O 0 4.792874097603317e-09
time O 0 1.1646800857079143e-08
interval O 0 4.3179042563679104e-08
and O 0 1.860983189772014e-08
always O 0 6.224604476301465e-08
biased O 0 2.125338340874805e-07
towards O 0 5.4546898553553547e-08
further O 0 1.213060869531546e-07
expansion O 0 1.6869215642145718e-06
. O 0 2.038334514509188e-06

Attempts O 0 8.194878319045529e-05
to O 0 3.0961782613303512e-06
mathematically O 0 8.805584002402611e-06
model O 0 1.1935463817280834e-06
the O 0 6.078370518025622e-08
dynamics O 0 9.245855835615657e-06
have O 0 3.3764067097763473e-07
proved O 0 2.306274836882949e-06
only O 0 7.06138294503944e-08
partially O 0 2.9485870527423685e-06
successful O 0 2.1319075926840014e-07
suggesting O 0 4.3974989694106625e-07
that O 0 2.5523128499571612e-08
individual O 0 6.276282604744665e-09
specific O 0 7.388655465234706e-09
genetic O 0 2.0473008532917447e-07
and O 0 2.2671193278256396e-07
/ O 0 1.3437660527415574e-05
or O 0 1.4172830731240538e-07
environmental O 0 6.188711267895997e-07
factors O 0 3.304791107439087e-08
also O 0 4.215539561869264e-08
play O 0 2.833755274878058e-08
a O 0 1.6782408351900813e-07
role O 0 4.088122125267546e-07
in O 0 5.584442419603874e-07
somatic O 0 3.789018956013024e-05
mosaicism O 0 0.0010716235265135765
. O 0 7.566998760921706e-07
. O 0 1.7830581100497511e-06

Aspartylglucosaminuria B-Disease 1 0.992395281791687
among O 0 1.6933618098846637e-05
Palestinian O 0 4.569007796817459e-05
Arabs O 0 2.81647480733227e-05
. O 0 3.008110979862977e-06

Aspartylglucosaminuria B-Disease 1 0.9999397993087769
( O 0 0.00927163939923048
AGU B-Disease 1 0.9999831914901733
) O 0 2.2593821995542385e-06
is O 0 2.1526768989588163e-07
a O 0 5.212449650571216e-06
rare O 0 0.00373648339882493
disorder B-Disease 0 0.191359743475914
of I-Disease 0 1.3602503656784393e-07
glycoprotein I-Disease 0 0.0013511503348127007
metabolism I-Disease 0 8.926791633712128e-05
caused O 0 7.763745088595897e-06
by O 0 1.913670359954267e-07
the O 0 1.3712892723560799e-06
deficiency B-Disease 0 0.00047235641977749765
of I-Disease 0 1.0244406212223112e-08
the I-Disease 0 4.2373298470010923e-07
lysosomal I-Disease 0 0.0011084070429205894
enzyme I-Disease 0 1.1125310265924782e-05
aspartylglucosaminidase I-Disease 0 9.36492215259932e-05
( O 0 3.8959498738222464e-07
AGA O 0 5.1318977057235315e-05
) O 0 5.164554295333801e-07
. O 0 9.748981710799853e-07

AGU B-Disease 1 0.9999872446060181
is O 0 0.0006458855350501835
inherited O 0 0.0037603387609124184
as O 0 1.564611693538609e-06
an O 0 5.5102909755078144e-06
autosomal O 1 0.9917668700218201
recessive O 1 0.9970585107803345
trait O 0 0.031824465841054916
and O 0 2.580198724899674e-06
occurs O 0 6.687585596409917e-08
with O 0 1.0984755327569928e-08
a O 0 8.501081083522877e-07
high O 0 7.205656515907322e-07
frequency O 0 1.9415067527006613e-06
in O 0 5.05545507678562e-08
Finland O 0 2.231136750197038e-05
because O 0 1.2928968118330886e-08
of O 0 3.3027163226506673e-09
a O 0 9.303980164077075e-07
founder O 0 1.8079299479722977e-05
effect O 0 2.125744913428207e-06
. O 0 1.1578468956940924e-06

While O 0 4.421069661475485e-06
very O 0 8.555516046726552e-07
few O 0 1.5317164070438594e-06
patients O 0 0.00014818029012531042
with O 0 1.653470280871261e-05
AGU B-Disease 1 0.9999986886978149
have O 0 2.74520516541088e-05
been O 0 1.5223566833810764e-06
reported O 0 3.9118884842537227e-07
from O 0 7.93382870512005e-09
non O 0 2.9189887840175288e-08
- O 0 3.7966408399370266e-06
Finnish O 0 0.000981203163973987
origin O 0 7.83664546588625e-08
, O 0 3.509942558821422e-08
we O 0 3.398419039513101e-07
diagnosed O 0 0.04205452278256416
the O 0 1.4337709899336915e-06
disorder O 0 0.11821217089891434
in O 0 4.882641633230378e-07
8 O 0 2.8855411073891446e-05
patients O 0 1.753885044308845e-05
originating O 0 3.522524139043526e-08
from O 0 1.4702786543807633e-08
3 O 0 8.04329260972736e-08
unrelated O 0 7.962891572788067e-07
families O 0 6.329807433758106e-08
, O 0 1.4565570971569741e-08
all O 0 3.9550887009909275e-09
Palestinian O 0 7.584150125694578e-07
Arabs O 0 2.2197778548616043e-07
from O 0 5.054112239832875e-09
the O 0 7.077358699092429e-09
region O 0 3.1411655498914115e-08
of O 0 2.4118904207171e-08
Jerusalem O 0 2.811971353366971e-05
. O 0 2.181953277613502e-06

The O 0 2.000451786443591e-05
clinical O 0 0.0016935162711888552
diagnosis O 1 0.6750980615615845
of O 0 5.168868938199012e-06
AGU B-Disease 1 0.9999988079071045
is O 0 2.029904499067925e-05
often O 0 8.516223033439019e-07
difficult O 0 5.665167464030674e-07
, O 0 3.906970036382518e-08
in O 0 1.6034663374853153e-08
particular O 0 7.1707071391813315e-09
early O 0 2.2077644601381508e-08
in O 0 3.7325160739953844e-09
the O 0 4.947865228643877e-09
course O 0 3.550828964193897e-08
of O 0 3.9330023682282444e-09
the O 0 9.01781277207192e-07
disease O 0 0.00016300490824505687
, O 0 3.419504679413876e-08
and O 0 1.2135174642935453e-08
most O 0 5.244760625799927e-09
of O 0 1.2944753047250401e-09
the O 0 4.6309290269164194e-07
patients O 0 0.008538410998880863
are O 0 1.7763979940355057e-06
diagnosed O 0 0.10371819138526917
after O 0 1.7130214757798967e-07
the O 0 9.251590604719695e-09
age O 0 3.0501190906306874e-08
of O 0 3.895731737202368e-09
5 O 0 1.675528693567685e-07
years O 0 7.025774380053917e-07
. O 0 1.1489371445350116e-06

However O 0 1.6740999853936955e-05
, O 0 4.237244581872801e-07
since O 0 1.9644473070457025e-07
these O 0 5.075570541634988e-08
patients O 0 1.4820358273937018e-06
excrete O 0 1.4682506161989295e-06
early O 0 1.1092451757122035e-07
large O 0 2.379085373149792e-08
amounts O 0 2.4211594507050904e-08
of O 0 5.177491324559469e-09
aspartylglucosamine O 0 6.138575827208115e-06
in O 0 1.068251336278081e-07
urine O 0 1.89754666735098e-06
, O 0 4.1978875486847755e-08
biochemical O 0 3.7717006762250094e-07
screening O 0 3.0733650646652677e-07
is O 0 7.022097747722e-08
easy O 0 4.0766562392491323e-07
by O 0 4.209080088912742e-07
urine O 0 1.6482686987728812e-05
chromatography O 0 1.2318762856011745e-05
. O 0 2.05154790933193e-07
. O 0 6.987579581618775e-07

Detection O 0 3.7497586163226515e-05
of O 0 8.242186595452949e-07
heterozygous O 0 1.963929935300257e-05
carriers O 0 5.282618076307699e-07
of O 0 5.159454019576515e-08
the O 0 9.292974027630407e-06
ataxia B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999905824661255
telangiectasia I-Disease 1 0.9999904632568359
( O 0 4.233730521718826e-07
ATM O 0 1.323618448623165e-06
) O 0 3.247206592504881e-08
gene O 0 6.100042782009041e-08
by O 0 2.6290361887504332e-08
G2 O 0 4.2083476728294045e-05
phase O 0 4.3667964746418875e-06
chromosomal O 0 6.064249828341417e-05
radiosensitivity O 0 2.4624736397527158e-05
of O 0 3.6763125876859704e-07
peripheral O 0 0.00037852098466828465
blood O 0 0.00039809729787521064
lymphocytes O 0 0.00019766711920965463
. O 0 4.5246861191117205e-06

In O 0 0.0058167544193565845
ataxia B-Disease 1 0.9999982118606567
- I-Disease 1 0.9999831914901733
telangiectasia I-Disease 1 0.9999951124191284
( O 0 4.5917826355434954e-05
A B-Disease 1 0.9999618530273438
- I-Disease 1 0.9999948740005493
T I-Disease 1 0.9999997615814209
) O 0 2.938357829407323e-05
patients O 0 0.00136371364351362
, O 0 7.773969201707587e-08
mutations O 0 2.1051758380963292e-07
in O 0 5.3260937882271264e-09
a O 0 8.057495648472468e-08
single O 0 4.1606705281083123e-07
gene O 0 1.0022761642858313e-07
, O 0 1.4054459818169107e-08
ATM O 0 2.1222233215212327e-07
, O 0 2.9703564052852016e-08
result O 0 4.8725894430390326e-08
in O 0 1.49195813037295e-07
an O 0 0.39943140745162964
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 2.8527035738079576e-06
embraces O 0 1.7847747812993475e-06
a O 0 4.2984709125448717e-07
variety O 0 2.6475444059315123e-08
of O 0 1.155475448655352e-08
clinical O 0 2.964144641737221e-06
features O 0 7.70361384638818e-06
and O 0 8.946022944655851e-07
manifests O 0 4.423987411428243e-05
extreme O 0 0.00018549758533481508
radiosensitivity O 0 8.071101183304563e-05
and O 0 2.5941483627889284e-08
a O 0 6.541882413557687e-08
strong O 0 3.5745586046687094e-07
pre O 0 6.1932614698889665e-06
- O 0 0.00019417483417782933
disposition O 0 4.159725358476862e-05
to O 0 6.606832812394714e-06
malignancy B-Disease 0 0.0011455357307568192
. O 0 3.826068223133916e-06

Heterozygotes O 0 0.0035490202717483044
for O 0 1.179184550892387e-06
the O 0 1.228423371912868e-07
ATM O 0 2.207945044574444e-06
gene O 0 3.2838428865034075e-07
have O 0 7.400139168112219e-08
no O 0 1.8263297363318998e-07
clinical O 0 9.453660254621354e-07
expression O 0 3.2325615961781295e-07
of O 0 3.8061497065200456e-08
A B-Disease 1 0.9999337196350098
- I-Disease 1 0.9999903440475464
T I-Disease 1 0.9999992847442627
but O 0 2.0430681615835056e-05
may O 0 4.6617878979304805e-06
be O 0 2.3856619009166025e-06
cancer B-Disease 0 0.00034073652932420373
prone O 0 5.415965915744891e-06
with O 0 5.4497913737350245e-08
a O 0 3.3279220588156022e-06
moderate O 0 0.003004192840307951
increase O 0 6.833521979388024e-07
in O 0 4.7346894405109197e-08
in O 0 2.0664890598709462e-07
vitro O 0 9.650777064962313e-05
radiosensitivity O 0 0.0008087241440080106
. O 0 2.3404070361721097e-06

We O 0 5.3368726184999105e-06
performed O 0 2.3471752683690283e-06
a O 0 7.912763066997286e-07
blind O 0 1.2042460184602533e-05
chromosomal O 0 2.445938480377663e-05
analysis O 0 4.402286606364214e-07
on O 0 6.840459718659986e-07
G2 O 0 0.0007579318480566144
- O 0 0.00022035703295841813
phase O 0 4.490027095016558e-06
lymphocytes O 0 3.2572143027209677e-06
from O 0 1.7834505428027114e-08
7 O 0 3.109776685050747e-07
unrelated O 0 2.7228661565459333e-06
A B-Disease 1 0.99992835521698
- I-Disease 1 0.9999983310699463
T I-Disease 1 1.0
patients O 1 0.8440579771995544
, O 0 1.5443791312463873e-07
13 O 0 1.6426258753199363e-07
obligate O 0 1.1656734386633616e-06
A B-Disease 1 0.998884379863739
- I-Disease 1 0.9999183416366577
T I-Disease 1 0.9999978542327881
heterozygotes O 0 0.01906426064670086
( O 0 9.890776908605403e-08
parents O 0 5.165637873005835e-08
of O 0 3.4983980157221595e-09
the O 0 7.752127544335963e-07
patients O 0 0.0017000361112877727
) O 0 5.351605025794015e-08
, O 0 2.656178565985101e-08
and O 0 2.7639856625683024e-08
14 O 0 5.291315119393403e-08
normal O 0 1.4134840853330388e-08
controls O 0 3.6582943607754714e-07
following O 0 6.311326217200985e-08
X O 0 1.0550509614404291e-05
- O 0 6.178636795084458e-06
irradiation O 0 1.6599656191829126e-06
with O 0 4.593186275769767e-08
1 O 0 7.334922713653214e-08
Gy O 0 1.7188589481520467e-05
in O 0 1.3382903674141744e-08
order O 0 4.885783333463678e-09
to O 0 7.987518202412502e-09
evaluate O 0 1.1048005887914769e-07
this O 0 9.576761605956108e-09
cytogenetic O 0 1.1259296115895268e-05
method O 0 1.161621199230467e-07
as O 0 1.3182408942213897e-08
a O 0 2.7192612606086186e-08
tool O 0 1.1509535369214063e-07
for O 0 3.0543809259597765e-08
detection O 0 1.7547002073570184e-07
of O 0 5.0134925544398357e-08
ATM O 0 1.0377089893154334e-05
carriers O 0 4.580218046612572e-06
. O 0 1.332970782641496e-06

Both O 0 5.822426828672178e-05
A B-Disease 1 0.8740503191947937
- I-Disease 1 0.9974464178085327
T I-Disease 1 0.9999443292617798
homozygotes O 0 0.0021755362395197153
and O 0 1.3381012422541971e-06
heterozygotes O 0 4.8644251364748925e-05
showed O 0 3.494841803330928e-05
significantly O 0 9.326757890448789e-07
increased O 0 8.443039689609577e-08
levels O 0 1.0350287737992403e-08
of O 0 1.2267710403079946e-08
radiation O 0 0.05214801803231239
- O 0 0.03096921741962433
induced O 1 0.5871037840843201
chromatid O 1 0.6377325654029846
damage O 0 0.00027780813979916275
relative O 0 6.555959544130019e-07
to O 0 5.3514110476271526e-08
that O 0 1.257581683233866e-08
of O 0 1.2209514288485934e-08
normal O 0 7.886409889579227e-07
controls O 0 3.6648489185608923e-05
. O 0 3.5819473396259127e-06

These O 0 3.395679641471361e-06
results O 0 1.242906364495866e-06
show O 0 2.2081019324105e-07
that O 0 1.4334228914947289e-08
the O 0 1.8752320585235793e-08
G2 O 0 9.009152563521639e-05
- O 0 2.8132777515565977e-05
phase O 0 1.0136184300790774e-06
chromosomal O 0 7.2597736107127275e-06
radiosensitivity O 0 1.8619579350342974e-05
assay O 0 2.6741056444734568e-06
can O 0 3.908773749117245e-08
be O 0 7.026033976842427e-09
used O 0 2.1924311255361317e-08
for O 0 5.583455475743904e-09
the O 0 5.747161413438562e-09
detection O 0 7.876491281422204e-08
of O 0 3.412637283872755e-08
A B-Disease 1 0.9998239874839783
- I-Disease 1 0.9999692440032959
T I-Disease 1 0.9999953508377075
heterozygotes O 0 0.005566436797380447
. O 0 5.218139449425507e-06

In O 0 6.458539701270638e-06
combination O 0 7.379556336672977e-06
with O 0 4.111616647151095e-07
molecular O 0 4.4019188862876035e-06
genetic O 0 1.465718469262356e-06
analyses O 0 7.240760737659002e-07
, O 0 3.6715469775572274e-08
this O 0 2.6272015674067006e-08
test O 0 4.592914990553254e-07
may O 0 3.1820690082895453e-07
be O 0 4.808880404993943e-09
of O 0 1.5315498869128419e-09
value O 0 5.095200261706623e-09
in O 0 5.380423218070973e-09
studies O 0 7.055039219494574e-09
of O 0 3.4165301698863004e-09
familial B-Disease 0 3.0088253879512195e-06
and I-Disease 0 8.025850775084109e-07
sporadic I-Disease 0 0.011943409219384193
cancers I-Disease 0 0.004880232270807028
aimed O 0 3.544868150129332e-07
at O 0 3.739658183121719e-08
determination O 0 2.410258446161606e-07
of O 0 5.103350186885791e-09
the O 0 1.1809222932868124e-08
potential O 0 3.9917409822010086e-08
involvement O 0 6.286888520889988e-08
of O 0 1.892417778037725e-08
ATM O 0 3.0525567126460373e-05
mutations O 0 1.3666058293893002e-05
in O 0 4.398509929615102e-07
tumor B-Disease 0 0.026659997180104256
risk O 0 1.3748904166277498e-06
or O 0 5.614181475266378e-08
development O 0 8.737275436487835e-08
. O 0 2.711322508730518e-07
. O 0 1.4912184269633144e-06

Ataxia B-Disease 1 0.9999954700469971
- I-Disease 1 0.9999244213104248
telangiectasia I-Disease 1 0.9999731779098511
: O 0 4.840751444135094e-06
identification O 0 5.24022368608712e-07
and O 0 4.5469185749880126e-08
detection O 0 8.842425813782029e-08
of O 0 6.93089274861336e-09
founder O 0 4.801619525096612e-06
- O 0 0.00014412541349884123
effect O 0 5.200180567044299e-06
mutations O 0 6.032501573827176e-07
in O 0 9.670189093924364e-09
the O 0 1.038340791126302e-08
ATM O 0 9.312164479524654e-07
gene O 0 3.0498986802740546e-07
in O 0 4.973129819063615e-08
ethnic O 0 5.939196512372291e-07
populations O 0 1.7999759620579425e-06
. O 0 2.2964181880524848e-06

To O 0 1.907444129756186e-06
facilitate O 0 3.7413104791994556e-07
the O 0 2.461690051802634e-08
evaluation O 0 4.562956235076854e-08
of O 0 1.0855598198133976e-08
ATM O 0 2.9785226161038736e-06
heterozygotes O 0 1.285421967622824e-05
for O 0 2.050278453680221e-07
susceptibility O 0 0.00025669444585219026
to O 0 1.2112209333281498e-06
other O 0 4.076784705375758e-07
diseases O 0 1.5545439964625984e-05
, O 0 2.9340544216438502e-08
such O 0 4.110981066673958e-08
as O 0 0.002101028338074684
breast B-Disease 1 0.9999618530273438
cancer I-Disease 1 0.9372501373291016
, O 0 6.82372771620976e-08
we O 0 7.788124811725083e-09
have O 0 5.549829484863267e-09
attempted O 0 2.797746674332302e-07
to O 0 2.3887386291221446e-08
define O 0 9.497924935431001e-08
the O 0 1.2507068269940191e-08
most O 0 5.014353376964209e-08
common O 0 1.0254712634605312e-07
mutations O 0 3.537934389896691e-07
and O 0 1.4591486241499751e-08
their O 0 1.8400950096975066e-08
frequencies O 0 4.412885118654231e-06
in O 0 1.2807306120521389e-05
ataxia B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999977350234985
telangiectasia I-Disease 1 0.9999986886978149
( O 0 1.466825506213354e-05
A B-Disease 1 0.9999315738677979
- I-Disease 1 0.999948263168335
T I-Disease 1 0.9999918937683105
) O 0 6.97959364970302e-07
homozygotes O 0 9.128984856943134e-06
from O 0 4.772688910748002e-08
10 O 0 7.824756664831511e-08
ethnic O 0 4.887277214038477e-07
populations O 0 1.2838507927881437e-06
. O 0 1.4865923958495841e-06

Both O 0 5.750876880483702e-06
genomic O 0 1.2211190551170148e-05
mutations O 0 3.1358700653072447e-05
and O 0 6.851507095007037e-08
their O 0 3.322671560113122e-08
effects O 0 5.305448667058954e-07
on O 0 2.9325809691727045e-07
cDNA O 0 2.296678985658218e-06
were O 0 9.163177878690476e-07
characterized O 0 5.401002454163972e-06
. O 0 2.1236819520709105e-06

Protein O 0 4.677434480981901e-05
- O 0 2.848227995855268e-05
truncation O 0 1.194807373394724e-05
testing O 0 5.337954576134507e-07
of O 0 1.7119999640158312e-08
the O 0 1.8566966630828574e-08
entire O 0 8.971314713335232e-08
ATM O 0 4.380484313060151e-07
cDNA O 0 1.5291680028894916e-06
detected O 0 1.5340056052082218e-06
92 O 0 7.295505497495469e-07
( O 0 2.7788184198129784e-08
66 O 0 1.2685353567576385e-06
% O 0 5.1382215815465315e-08
) O 0 1.6509046574242348e-08
truncating O 0 3.0708706617588177e-06
mutations O 0 1.5056815527714207e-06
in O 0 3.3488081641053213e-08
140 O 0 4.622091296369035e-07
mutant O 0 4.1366984078194946e-05
alleles O 0 1.7424450561520644e-05
screened O 0 0.00012688008428085595
. O 0 5.376555691327667e-06

The O 0 2.6968755264533684e-06
haplotyping O 0 6.129752728156745e-05
of O 0 6.340633831314335e-07
patients O 0 0.00011915279901586473
with O 0 4.817420631297864e-07
identical O 0 0.0012523845070973039
mutations O 0 2.3035225240164436e-05
indicates O 0 2.5605737619116553e-07
that O 0 1.844986918797531e-08
almost O 0 6.806462948816261e-09
all O 0 7.226475529087395e-10
of O 0 1.610681032993e-09
these O 0 7.64801288966055e-09
represent O 0 3.150844207766568e-08
common O 0 6.204950864230341e-08
ancestry O 0 5.171266934667074e-07
and O 0 3.653433111594495e-08
that O 0 4.44009877753615e-08
very O 0 6.466554935968816e-08
few O 0 2.302514019447699e-07
spontaneously O 0 2.0790246253454825e-06
recurring O 0 8.078151950030588e-06
ATM O 0 2.8114351152908057e-05
mutations O 0 1.4500184988719411e-05
exist O 0 6.185300662764348e-07
. O 0 1.976768999156775e-06

Assays O 0 0.0006900681182742119
requiring O 0 3.1011139071779326e-05
minimal O 0 6.956276592973154e-06
amounts O 0 3.064234022076562e-07
of O 0 2.679452926201975e-08
genomic O 0 5.083912810732727e-07
DNA O 0 1.04022990399244e-06
were O 0 3.980336771292059e-08
designed O 0 2.8008432195747446e-07
to O 0 3.198870146547961e-08
allow O 0 5.7118011653756184e-08
rapid O 0 3.4881463761848863e-07
screening O 0 5.779685920970223e-07
for O 0 6.867049506809053e-08
common O 0 4.4353927819429373e-07
ethnic O 0 5.541472546610748e-06
mutations O 0 5.697644155588932e-05
. O 0 3.4164193039032398e-06

These O 0 1.873712676569994e-06
rapid O 0 2.970228706544731e-06
assays O 0 1.3030867194174789e-05
detected O 0 8.000380148587283e-06
mutations O 0 3.039004468519124e-06
in O 0 7.781208921642246e-08
76 O 0 5.978441095066955e-06
% O 0 2.3669416648886e-08
of O 0 7.18424653101124e-09
Costa O 0 2.1339751583582256e-06
Rican O 0 0.008769706822931767
patients O 0 0.005579655058681965
( O 0 1.9117836203008665e-08
3 O 0 3.606471210559903e-08
) O 0 6.786085915422291e-09
, O 0 1.0756502355491193e-08
50 O 0 1.6761990906388746e-08
% O 0 4.764291183789737e-09
of O 0 3.930842318311534e-09
Norwegian O 1 0.6932625770568848
patients O 0 0.003536736126989126
( O 0 1.579938313511775e-08
1 O 0 2.161843681847131e-08
) O 0 6.077000236359709e-09
, O 0 1.0270113648402912e-08
25 O 0 2.2058703308402983e-08
% O 0 4.221459626307933e-09
of O 0 1.0161349983661694e-08
Polish O 1 0.9129136204719543
patients O 0 0.0916866883635521
( O 0 4.578701151558562e-08
4 O 0 8.551921126809248e-08
) O 0 7.789076050812582e-09
, O 0 9.428125835597712e-09
and O 0 9.393088973297381e-09
14 O 0 6.314926537243082e-08
% O 0 5.949091885781854e-09
of O 0 4.7626378396614655e-09
Italian O 0 0.2377319484949112
patients O 0 0.30463337898254395
( O 0 3.1652042764562793e-08
1 O 0 2.6936055164128447e-08
) O 0 4.240553241885436e-09
, O 0 2.525724962509912e-09
as O 0 3.355052680120707e-09
well O 0 4.171482270720617e-09
as O 0 1.958487061415326e-08
in O 0 1.3646264562794386e-07
patients O 0 6.934319571882952e-07
of O 0 9.907009435039527e-09
Amish O 0 1.4679868399980478e-05
/ O 0 1.5702667042205576e-06
Mennonite O 0 1.177087938231125e-06
and O 0 1.41569699962929e-07
Irish O 0 1.493166564614512e-06
English O 0 5.731399710384721e-07
backgrounds O 0 8.533555160283868e-07
. O 0 7.297697379726742e-07

Additional O 0 4.869767144555226e-05
mutations O 0 0.00018419194384478033
were O 0 8.806321147858398e-07
observed O 0 4.819019636670419e-07
in O 0 2.8759494341557e-08
Japanese O 0 2.123523046293485e-07
, O 0 3.501050116483384e-08
Utah O 0 1.939613980539434e-07
Mormon O 0 1.4419680383070954e-07
, O 0 1.824174056253014e-08
and O 0 1.41448186496973e-08
African O 0 7.344176111701017e-08
American O 0 9.61903197094216e-07
patients O 0 4.654216900235042e-05
. O 0 2.4587818643340142e-06

These O 0 8.951997756412311e-07
assays O 0 3.989932793047046e-06
should O 0 8.780092741744738e-08
facilitate O 0 6.615562853085066e-08
screening O 0 6.472169502558245e-07
for O 0 2.427568972507288e-07
A B-Disease 1 0.9996578693389893
- I-Disease 1 0.9999383687973022
T I-Disease 1 0.9999966621398926
heterozygotes O 0 0.00020923490228597075
in O 0 8.849529109511423e-08
the O 0 4.9350877162623874e-08
populations O 0 9.017961843937883e-08
studied O 0 2.48237085997971e-07
. O 0 1.724207550068968e-07
. O 0 8.079184681264451e-07

The O 0 2.8520822525024414e-05
von B-Disease 0 0.28576427698135376
Hippel I-Disease 1 0.9312687516212463
- I-Disease 1 0.6298635005950928
Lindau I-Disease 1 0.9329338073730469
tumor I-Disease 0 0.0013465386582538486
suppressor O 0 6.30417198408395e-05
gene O 0 4.86220130824222e-07
is O 0 3.179350471782527e-08
required O 0 1.8041740545982066e-08
for O 0 1.5696894450911714e-08
cell O 0 1.0146707154490286e-06
cycle O 0 4.424252608714596e-07
exit O 0 1.4813094821874984e-06
upon O 0 6.957589562262001e-07
serum O 0 1.4083491805649828e-05
withdrawal O 0 1.889746454253327e-05
. O 0 4.2776418922585435e-06

The O 0 2.9853622436348815e-06
inactivation O 0 4.0249418816529214e-05
of O 0 2.0086446284039994e-07
the O 0 7.935690859994793e-07
von B-Disease 1 0.8109540939331055
Hippel I-Disease 1 0.9966064691543579
- I-Disease 1 0.9852216839790344
Lindau I-Disease 1 0.9935474991798401
( I-Disease 0 2.8589131488843122e-06
VHL I-Disease 0 0.00031647004652768373
) I-Disease 0 5.464133323584974e-07
tumor I-Disease 0 3.472583193797618e-05
suppressor O 0 0.00010323768947273493
gene O 0 7.820524842827581e-06
predisposes O 0 0.0003209015994798392
affected O 0 9.044813964464993e-07
individuals O 0 4.458020796960227e-08
to O 0 6.728643597853079e-08
the O 0 8.852312589624489e-07
human O 0 0.0014525819569826126
VHL B-Disease 1 0.9999988079071045
cancer I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999990463256836
and O 0 1.775427563188714e-06
is O 0 4.843254259867535e-07
associated O 0 2.2868582050250552e-07
with O 0 1.997705112444237e-06
sporadic B-Disease 1 0.9985296726226807
renal I-Disease 1 0.9999995231628418
cell I-Disease 1 0.9999951124191284
carcinomas I-Disease 1 0.9999998807907104
( O 0 2.9605813324451447e-05
RCC B-Disease 0 0.3909154236316681
) O 0 3.8335193153216096e-07
and O 0 1.6664197346472065e-06
brain B-Disease 0 0.0007163176778703928
hemangioblastomas I-Disease 0 0.0003277601790614426
. O 0 2.4346177269762848e-06

VHL O 0 0.021179165691137314
- O 0 0.0018672735895961523
negative O 0 8.736467862036079e-05
786 O 0 0.0002825613191816956
- O 0 0.036441415548324585
0 O 0 3.34970754920505e-05
RCC B-Disease 0 0.0038559718523174524
cells O 0 5.937271225775476e-07
are O 0 1.2000294091762953e-08
tumorigenic O 0 8.886214345693588e-06
in O 0 1.7351339920423925e-07
nude O 0 0.2559986710548401
mice O 0 0.00358177931047976
which O 0 1.7790618755952892e-07
is O 0 7.098086030055129e-08
suppressed O 0 4.807067170986556e-07
by O 0 2.0425689584158135e-08
the O 0 1.3426164180430078e-08
reintroduction O 0 1.2366200508040492e-06
of O 0 2.444733695483592e-07
VHL B-Disease 0 0.0008488382445648313
. O 0 9.016428521135822e-06

Remarkably O 0 0.032401613891124725
, O 0 1.191326532534731e-06
this O 0 1.2698096440999507e-07
occurs O 0 7.039772498274033e-08
without O 0 1.1076231487550103e-08
affecting O 0 2.3907258395183817e-08
the O 0 9.941499179433322e-09
growth O 0 5.907517675041163e-08
rate O 0 4.437888634356568e-08
and O 0 9.188982907915033e-09
cell O 0 6.068240736567532e-07
cycle O 0 1.1834639224161947e-07
profile O 0 3.2042689213085396e-07
of O 0 3.912203005995707e-09
these O 0 8.266478168650337e-09
cells O 0 6.054141721278938e-08
in O 0 2.3494719059158342e-08
culture O 0 3.9067694501682126e-07
. O 0 1.2160891174062272e-06

The O 0 6.401504833775107e-06
786 O 0 8.028995216591284e-05
- O 0 0.0002726548118516803
0 O 0 2.7919943477172637e-06
cell O 0 1.944764562722412e-06
line O 0 4.957806254424213e-07
, O 0 2.243960750547558e-08
like O 0 4.5161574036001184e-08
many O 0 1.3761507489107316e-07
cancer B-Disease 0 0.00016322422015946358
cells O 0 5.745256430600421e-07
, O 0 5.110093681537364e-08
fails O 0 1.119830017159984e-06
to O 0 3.679118165678119e-08
exit O 0 3.74753454934762e-07
the O 0 1.5740999614877182e-08
cell O 0 8.061743983489578e-07
cycle O 0 4.0704560433368897e-07
upon O 0 2.2535391508426983e-07
serum O 0 2.847259338523145e-06
withdrawal O 0 5.835781394125661e-06
. O 0 1.7797997315938119e-06

Here O 0 7.680757335037924e-06
, O 0 1.743114950158997e-07
it O 0 2.5638129841354385e-08
is O 0 1.783001657429395e-08
shown O 0 5.33951300951685e-08
that O 0 8.531519490873052e-09
reintroduction O 0 1.3599287740362342e-07
of O 0 3.744359933222086e-09
the O 0 1.0335591049681625e-08
wild O 0 9.185937699385249e-08
- O 0 5.499390317709185e-05
type O 0 8.403648280363996e-06
VHL B-Disease 0 4.4605079892789945e-05
gene O 0 3.3790934139688034e-07
restores O 0 7.253381113514479e-07
the O 0 1.678176175801127e-08
ability O 0 7.968165505189972e-08
of O 0 2.342571825408868e-08
VHL O 0 0.00046322838170453906
- O 0 0.1371917575597763
negative O 0 0.003631644882261753
RCC B-Disease 1 0.9987725615501404
cancer I-Disease 0 0.14430174231529236
cells O 0 2.77471485787828e-07
to O 0 4.617729487677025e-08
exit O 0 6.77624427680712e-07
the O 0 3.5636794848414866e-08
cell O 0 9.88256033451762e-07
cycle O 0 1.5629116489890293e-07
and O 0 3.9382886285466157e-08
enter O 0 1.288906048557692e-07
G0 O 0 1.9222363334847614e-05
/ O 0 3.509057250994374e-06
quiescence O 0 1.367565528198611e-05
in O 0 5.231844397712848e-07
low O 0 1.13747864816105e-05
serum O 0 6.948279769858345e-05
. O 0 2.2666790755465627e-06

Both O 0 1.5245144822984003e-05
VHL O 0 0.0010775693226605654
- O 0 0.00020930953905917704
positive O 0 1.078476884686097e-06
and O 0 2.517257655654248e-07
VHL O 0 0.00020100532856304199
- O 0 0.0035756968427449465
negative O 0 1.5996736692613922e-05
RCC B-Disease 0 0.0012148363748565316
cells O 0 8.476939683532692e-07
exit O 0 5.917125918131205e-07
the O 0 2.5961183425238232e-08
cell O 0 1.2123673513997346e-06
cycle O 0 2.932401912403293e-07
by O 0 9.629737007799122e-08
contact O 0 5.844085535500199e-07
inhibition O 0 4.733885816676775e-06
. O 0 3.348621703480603e-06

The O 0 1.6753567251726054e-05
cyclin O 0 0.0004262478614691645
- O 0 4.5130156649975106e-05
dependent O 0 3.961964921472827e-06
kinase O 0 7.824523891031276e-06
inhibitor O 0 2.633531266837963e-06
, O 0 6.65793109533297e-08
p27 O 0 2.545044026192045e-06
, O 0 4.059956637547657e-08
accumulates O 0 3.1958853696778533e-07
upon O 0 4.08309119848127e-08
serum O 0 4.388939487398602e-07
withdrawal O 0 3.139602711144107e-07
, O 0 1.1207522021550176e-08
only O 0 4.151986754408199e-09
in O 0 2.6551589815682064e-09
the O 0 3.4319700414897625e-09
presence O 0 1.6411782155500987e-08
of O 0 6.470698199478875e-09
VHL B-Disease 0 0.00011415916378609836
, O 0 4.300356692965579e-08
as O 0 1.2774685309580036e-08
a O 0 7.961299530734323e-08
result O 0 1.9889871083478283e-08
of O 0 1.0134189043498054e-09
the O 0 3.2952724993151605e-09
stabilization O 0 3.427641104281065e-08
of O 0 3.98022814707133e-09
the O 0 2.802910792354396e-08
protein O 0 7.038455578367575e-07
. O 0 5.553739015340398e-07

We O 0 1.7023654663717025e-06
propose O 0 2.3710319965175586e-06
that O 0 4.236076733832306e-08
the O 0 1.5108374995520535e-08
loss O 0 1.844048114207908e-07
of O 0 5.607136532859158e-09
wild O 0 4.3956833906122483e-07
- O 0 0.007905754260718822
type O 0 5.362493538996205e-05
VHL B-Disease 0 0.00013714209489990026
gene O 0 6.939744139344839e-07
results O 0 2.3714046903933195e-07
in O 0 8.767386816543876e-09
a O 0 1.5267346498148981e-07
specific O 0 4.332613556812248e-08
cellular O 0 1.2320501809881534e-05
defect O 0 3.228213245165534e-05
in O 0 8.402507489790878e-08
serum O 0 4.345617981016403e-06
- O 0 1.0605356692394707e-05
dependent O 0 3.935075767458329e-07
growth O 0 6.258891716015569e-08
control O 0 2.9354657726798905e-07
, O 0 3.720995422895612e-08
which O 0 1.1022368084923073e-07
may O 0 5.472258521876938e-07
initiate O 0 2.065658918581903e-06
tumor B-Disease 0 0.002527740318328142
formation O 0 2.1029597974120406e-06
. O 0 1.2396983493090374e-06

This O 0 3.3709929994074628e-06
is O 0 4.0887965724323294e-07
corrected O 0 1.9255492134107044e-06
by O 0 1.7658427609035243e-08
the O 0 1.1002724953357301e-08
reintroduction O 0 3.5226594263804145e-07
of O 0 1.1219819739949344e-08
wild O 0 3.058409561162989e-07
- O 0 0.001792008290067315
type O 0 9.390810737386346e-05
VHL B-Disease 0 0.0009843740845099092
, O 0 6.513768653348961e-07
implicating O 0 2.9275612178025767e-05
VHL B-Disease 0 3.195394674548879e-05
as O 0 4.8475332192765563e-08
the O 0 6.390422857549538e-09
first O 0 1.3570318913025403e-07
tumor B-Disease 0 2.2863312096887967e-06
suppressor O 0 4.296710358175915e-06
involved O 0 3.1725782889679977e-08
in O 0 4.486680360571427e-09
the O 0 4.182125756813093e-09
regulation O 0 3.2720755882564845e-08
of O 0 5.13255749012842e-09
cell O 0 1.2853871567131137e-06
cycle O 0 6.008913828736695e-07
exit O 0 4.078840447618859e-06
, O 0 6.442437694431646e-08
which O 0 3.528912984052113e-08
is O 0 2.0500277031487713e-08
consistent O 0 9.380380561196944e-08
with O 0 1.1993703807888778e-08
its O 0 3.599296860556933e-08
gatekeeper O 0 4.243936018610839e-06
function O 0 3.906790979613106e-08
in O 0 2.686478950408855e-08
the O 0 1.771455231391883e-07
kidney O 0 0.009720852598547935
. O 0 1.2932971458212705e-06
. O 0 1.328805296907376e-06

Piebaldism B-Disease 1 0.9998542070388794
with O 1 0.6967899799346924
deafness B-Disease 1 0.9999997615814209
: O 0 1.6307010810123757e-05
molecular O 0 8.112012437777594e-06
evidence O 0 3.4081267585861497e-07
for O 0 6.127890372908951e-08
an O 0 5.1703673307201825e-06
expanded O 0 0.12878286838531494
syndrome O 1 0.9999096393585205
. O 0 6.676256816717796e-06

In O 0 5.157179657544475e-06
a O 0 1.2006815950371674e-06
South O 0 3.6353262089505733e-07
African O 0 1.0611699963192223e-07
girl O 0 1.184289772027114e-06
of O 0 2.25811209730864e-08
Xhosa O 0 7.216676021926105e-05
stock O 0 6.237850129764411e-07
with O 0 1.1531673749232141e-07
severe O 0 0.003374183550477028
piebaldism B-Disease 0 0.07414454966783524
and O 0 3.9676706364843994e-05
profound O 1 0.8893824219703674
congenital O 1 0.9999997615814209
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 0.0004168311133980751
identified O 0 3.7146603517612675e-06
a O 0 3.701233310948737e-07
novel O 0 6.166324055811856e-07
missense O 0 1.4043494047655258e-06
substitution O 0 4.6563794597886954e-08
at O 0 7.901300058676952e-09
a O 0 4.791048624497307e-08
highly O 0 5.8594213925289296e-08
conserved O 0 6.757169046522904e-08
residue O 0 1.3369846385558048e-07
in O 0 3.3508575913998584e-09
the O 0 3.88669230133587e-09
intracellular O 0 1.8631483555964223e-07
kinase O 0 2.2209468397704768e-07
domain O 0 7.515495781262871e-09
of O 0 1.7998355028581159e-09
the O 0 1.8637717147385047e-08
KIT O 0 3.0880197300575674e-05
proto O 0 0.004656661301851273
- O 0 0.00023377180332317948
oncogene O 0 0.00019019938190467656
, O 0 7.822009138180874e-07
R796G O 0 2.1176543668843806e-05
. O 0 1.703667976471479e-06

Though O 0 0.00010214759095106274
auditory B-Disease 0 0.0003659362264443189
anomalies I-Disease 0 0.023749785497784615
have O 0 2.153394689230481e-06
been O 0 7.781518434057944e-07
observed O 0 3.817382889792498e-07
in O 0 7.240016230980473e-08
mice O 0 3.0303797757369466e-05
with O 0 9.020283897598347e-08
dominant O 0 1.4214714610716328e-05
white O 0 1.4633406863140408e-05
spotting O 0 0.00010182180267293006
( O 0 5.395501716520812e-07
W O 0 0.04440014064311981
) O 0 3.204738874273971e-08
due O 0 2.3751006494876492e-07
to O 0 8.512747626809869e-07
KIT O 1 0.835816502571106
mutations O 0 0.004286646377295256
, O 0 5.067669917480089e-05
deafness B-Disease 1 0.9999997615814209
is O 0 4.1717817111930344e-06
not O 0 2.224537638539914e-07
typical O 0 4.361363892257941e-07
in O 0 1.762604568966708e-07
human O 0 8.828890827317082e-07
piebaldism B-Disease 0 0.0013626061845570803
. O 0 5.734402748203138e-06

Thus O 0 2.6155024897889234e-05
, O 0 3.964539700973546e-07
the O 0 2.948843302874593e-08
occurrence O 0 3.761441575989011e-07
of O 0 3.496506053579651e-07
sensorineural B-Disease 1 0.9999974966049194
deafness I-Disease 1 1.0
in O 0 0.00024002989812288433
this O 0 4.043164153699763e-06
patient O 0 0.00021854191436432302
extends O 0 3.711579665832687e-06
considerably O 0 1.976233988898457e-06
the O 0 1.7447474576215427e-08
phenotypic O 0 1.2246351843714365e-06
range O 0 3.5097151851459785e-08
of O 0 7.63512897350438e-09
piebaldism B-Disease 0 4.229074329487048e-05
due O 0 5.444388193609484e-07
to O 0 1.1846925218605975e-07
KIT O 0 0.00011536379315657541
gene O 0 6.542655910379835e-07
mutation O 0 5.109518497192767e-07
in O 0 1.664963988901036e-08
humans O 0 3.971024753468555e-08
and O 0 4.9128292545219665e-08
tightens O 0 0.3367667496204376
the O 0 5.270787255540199e-07
clinical O 0 3.845602805085946e-06
similarity O 0 8.872021908246097e-07
between O 0 3.6878368803172634e-08
piebaldism B-Disease 0 1.682652327872347e-05
and O 0 1.1887256512466138e-08
the O 0 3.2559372975526912e-09
various O 0 5.700533378671935e-09
forms O 0 1.8108212884726527e-07
of O 0 1.5878822523518465e-05
Waardenburg B-Disease 1 0.9999991655349731
syndrome I-Disease 1 0.999996542930603
. O 0 1.3779698520011152e-06
. O 0 1.9263372905697906e-06

Cycloheximide O 0 0.000259384949458763
facilitates O 0 6.477445367636392e-06
the O 0 1.6871311458999116e-07
identification O 0 8.960729047657878e-08
of O 0 1.466855881204765e-08
aberrant O 0 5.094326752441702e-06
transcripts O 0 8.604319191363174e-06
resulting O 0 6.117065822763834e-07
from O 0 1.4395546976686546e-08
a O 0 1.4379828883193113e-07
novel O 0 5.332103683031164e-07
splice O 0 4.338023700256599e-06
- O 0 4.348413858679123e-05
site O 0 1.1667566468531732e-06
mutation O 0 4.5958947225699376e-07
in O 0 2.4152740252247895e-08
COL17A1 O 0 4.344712942838669e-05
in O 0 7.5511763952818e-08
a O 0 3.1007523375592427e-06
patient O 0 0.00018333265325054526
with O 0 1.0943412235064898e-05
generalized O 0 0.07601205259561539
atrophic B-Disease 1 0.9997649788856506
benign I-Disease 1 0.996536135673523
epidermolysis I-Disease 1 0.998019814491272
bullosa I-Disease 1 0.9938958287239075
. O 0 6.419208511942998e-05

Patients O 1 0.9798689484596252
with O 0 1.3941576071374584e-05
generalized O 0 0.0048365518450737
atrophic B-Disease 1 0.9993162155151367
benign I-Disease 1 0.9938830137252808
epidermolysis I-Disease 1 0.9974216222763062
bullosa I-Disease 1 0.9940324425697327
often O 0 3.582182034733705e-05
show O 0 6.874347945995396e-06
decreased O 0 1.3989490526000736e-06
expression O 0 1.2950172845194174e-07
of O 0 3.2504662073051804e-08
type O 0 1.4899412235536147e-05
XVII O 0 0.37420654296875
collagen O 0 0.0005933260545134544
, O 0 2.598769412998081e-07
a O 0 8.69494670041604e-07
transmembrane O 0 1.2907335076306481e-05
hemidesmosomal O 0 9.319119271822274e-06
protein O 0 1.540904293051426e-07
encoded O 0 1.5542697440196207e-07
by O 0 1.8147491687159345e-07
COL17A1 O 0 0.00010484346421435475
. O 0 3.062722498725634e-06

This O 0 1.566822720633354e-05
report O 0 2.10330063055153e-06
documents O 0 3.0751886015423224e-07
a O 0 1.8843861937511974e-07
novel O 0 8.758505032346875e-07
splice O 0 6.3845677686913405e-06
- O 0 3.250743611715734e-05
site O 0 7.988265906533343e-07
mutation O 0 5.045542934567493e-07
in O 0 4.1251979610024136e-08
COL17A1 O 0 0.00019418445299379528
in O 0 2.2703086699493724e-07
a O 0 6.081912943045609e-06
patient O 0 0.0005715668085031211
with O 0 4.375317530502798e-06
generalized O 0 0.01854333095252514
atrophic B-Disease 1 0.9998478889465332
benign I-Disease 1 0.9933130145072937
epidermolysis I-Disease 1 0.9977995753288269
bullosa I-Disease 1 0.9941178560256958
, O 0 1.250983359568636e-06
and O 0 7.014200065214027e-08
applies O 0 1.4523881475270173e-07
a O 0 9.533680866979921e-08
new O 0 5.9241045846647467e-08
methodology O 0 1.4759015698473377e-07
to O 0 5.254435819779246e-08
define O 0 2.168046648876043e-07
and O 0 5.758619892048955e-08
characterize O 0 4.024280997327878e-07
the O 0 3.5774228024365584e-08
resulting O 0 3.896863915997528e-07
mRNA O 0 3.949614608700358e-07
splice O 0 1.0279098205501214e-05
variants O 0 3.3921096473932266e-06
. O 0 1.4095527376412065e-06

Mutational O 0 0.02177615277469158
analysis O 0 2.4176413717214018e-05
of O 0 8.17648583506525e-07
COL17A1 O 0 0.0036198445595800877
identified O 0 8.08968525234377e-06
a O 0 2.158814822905697e-06
maternally O 0 0.00027710184804163873
inherited O 0 0.0001095509942388162
G O 0 8.527304453309625e-05
- O 0 1.2155453987361398e-05
to O 0 3.390811684766959e-07
- O 0 0.0005238109151832759
T O 0 0.0002444772107992321
transversion O 0 1.7557927094458137e-06
at O 0 1.1046757286692355e-08
the O 0 1.2590168019244175e-08
- O 0 9.577839819030487e-07
1 O 0 8.298360398839577e-08
position O 0 1.173486197103557e-07
of O 0 4.1067725220500506e-08
exon O 0 1.1885511412401684e-05
32 O 0 4.800062924914528e-06
. O 0 1.562089096296404e-06

This O 0 3.131229277641978e-06
acceptor O 0 2.520253246984794e-06
splice O 0 9.48396154853981e-06
- O 0 4.01360412070062e-05
site O 0 1.4828501662123017e-06
mutation O 0 4.880658934780513e-07
led O 0 4.443979051416136e-08
to O 0 1.5790103446988724e-08
the O 0 5.306503236823801e-09
formation O 0 1.0104720615800034e-08
of O 0 2.653883113268307e-09
aberrant O 0 8.562299171899213e-07
transcripts O 0 1.440482492398587e-06
present O 0 6.648895123362308e-08
at O 0 4.13636982443677e-08
extremely O 0 1.0362217608417268e-06
low O 0 7.379760063486174e-06
levels O 0 7.040872560537537e-07
. O 0 9.073783076019026e-07

Based O 0 6.28804309599218e-06
on O 0 2.046687939127878e-07
our O 0 2.4362238448816242e-08
recent O 0 6.314709821708675e-08
finding O 0 6.166840904597848e-08
that O 0 8.499105064174728e-08
cycloheximide O 0 3.852132795145735e-05
stabilized O 0 5.826347478432581e-05
mutant O 0 4.400726538733579e-06
COL17A1 O 0 1.2473517926991917e-05
transcripts O 0 1.1170769766977173e-06
in O 0 2.4356152650284457e-08
keratinocytes O 0 5.177250841370551e-06
homozygous O 0 1.4682996152259875e-06
for O 0 1.900038348878752e-08
a O 0 1.873092742243898e-06
frameshift O 1 0.6710375547409058
mutation O 0 3.2643263239151565e-06
, O 0 1.2436085938816177e-08
the O 0 4.386133678480064e-09
effects O 0 1.0981950993027567e-07
of O 0 2.0957136026567014e-09
the O 0 1.367379898198351e-08
splice O 0 4.274208095012e-06
- O 0 3.5703444154933095e-05
site O 0 5.176388526706432e-07
mutation O 0 9.690300117881634e-08
on O 0 1.6097359889499785e-08
splicing O 0 1.3788569219741476e-07
of O 0 1.0595738508811792e-08
COL17A1 O 0 4.791228275280446e-05
transcripts O 0 1.415072233612591e-06
were O 0 3.499087242175847e-08
determined O 0 5.0384933558689227e-08
using O 0 3.021434125116684e-08
reverse O 0 8.669559861118614e-07
transcriptase O 0 3.214318212485523e-06
polymerase O 0 1.7237452993867919e-06
chain O 0 9.132818377111107e-07
reaction O 0 1.338590891464264e-07
of O 0 3.745488363904315e-09
total O 0 5.457582830104002e-08
RNA O 0 2.705299380068027e-07
from O 0 4.478184223444259e-08
keratinocytes O 0 4.684677605837351e-06
incubated O 0 5.4420079322881065e-06
for O 0 1.6012694459277554e-07
2 O 0 2.1639598344336264e-06
. O 0 2.3088232410373166e-06

5 O 0 1.6523541489732452e-05
h O 0 9.802412932913285e-06
in O 0 3.555755867523658e-08
the O 0 8.573884713314328e-09
presence O 0 2.436544477291136e-08
or O 0 9.42596845021626e-09
absence O 0 2.786025454781793e-08
of O 0 7.367518595202682e-09
10 O 0 2.1228569835329836e-07
microg O 0 1.4058143278816715e-05
cycloheximide O 0 2.6147094104089774e-05
per O 0 1.2857034334956552e-06
ml O 0 2.5302420908701606e-05
. O 0 2.125686023646267e-06

Using O 0 1.0563860087131616e-05
this O 0 3.539004183039651e-07
approach O 0 6.074164389247017e-07
, O 0 9.199369088719322e-08
an O 0 1.6359518895114888e-07
abnormally O 0 2.4143764676409774e-05
spliced O 0 0.004393431358039379
transcript O 0 0.00036457026726566255
was O 0 2.5014539914991474e-06
identified O 0 7.270779178725206e-08
that O 0 2.8813835761809514e-09
contains O 0 6.13303319241254e-09
an O 0 1.2025176410190852e-08
extra O 0 8.588963851252629e-08
264 O 0 2.2412623934542353e-07
bases O 0 2.917196795237942e-08
upstream O 0 5.1465981698584073e-08
from O 0 9.787034294106434e-09
exon O 0 6.10645770393603e-07
32 O 0 1.4890696320435381e-07
, O 0 8.087562619607525e-09
resulting O 0 4.933845332288911e-08
in O 0 1.1595289173271794e-08
a O 0 1.242008352164703e-06
premature O 0 0.00021061638835817575
termination O 0 2.9766060833935626e-06
codon O 0 8.694598250258423e-07
27 O 0 8.340138606399705e-07
bp O 0 2.587181597846211e-06
downstream O 0 1.8200215379238216e-07
from O 0 9.827664015915616e-09
the O 0 6.57692567074264e-08
cryptic O 0 2.4546663553337567e-05
splice O 0 6.853329250589013e-05
site O 0 1.5449490092578344e-05
. O 0 3.7491183775273385e-06

Three O 0 2.318538463441655e-06
other O 0 1.0125329907850755e-07
splice O 0 3.666785232780967e-06
variants O 0 1.3122599966663984e-06
, O 0 4.868892133913505e-08
including O 0 1.791158332764553e-08
one O 0 3.707224038862478e-08
derived O 0 1.1892154816450784e-08
from O 0 1.768885704578338e-09
the O 0 2.034798773919988e-09
skipping O 0 6.832544841017807e-08
of O 0 5.059156205078352e-09
exon O 0 1.219129217133741e-06
32 O 0 2.9845398330508033e-07
, O 0 2.0832919389590643e-08
were O 0 5.394308644213197e-08
also O 0 6.034860575709899e-07
identified O 0 1.5674658015996101e-06
. O 0 9.39993526571925e-07

These O 0 2.3559753117297078e-06
results O 0 1.1019316161764436e-06
indicate O 0 7.580181460298263e-08
the O 0 4.347312732022601e-09
usefulness O 0 7.857779138475962e-08
of O 0 1.7832125109862318e-08
cycloheximide O 0 0.0024459916166961193
treatment O 0 7.201632979558781e-05
in O 0 4.3850484132690326e-08
evaluating O 0 1.5123980290354666e-07
the O 0 2.0297411751357686e-08
abnormal O 0 1.741905180097092e-07
processing O 0 1.6061200369676953e-08
of O 0 2.915353958243827e-09
mRNA O 0 4.8862052182130356e-08
due O 0 2.2532590904233984e-08
to O 0 1.2170128904642752e-08
splice O 0 1.5070218069013208e-06
- O 0 9.368450992042199e-05
site O 0 2.3046852675179252e-06
mutations O 0 6.563466286024777e-07
, O 0 1.5968433686452954e-08
because O 0 1.6661774182580302e-08
( O 0 2.850297997625262e-09
i O 0 6.147276820911429e-08
) O 0 3.776650547848703e-09
aberrant O 0 1.5032553335458942e-07
splicing O 0 5.968074106021959e-07
often O 0 7.584910832747482e-08
generates O 0 1.5893417071310978e-07
a O 0 3.642232115907973e-07
premature O 0 1.557903851789888e-05
termination O 0 2.7569810754357604e-06
codon O 0 4.4864901838082005e-07
, O 0 5.7157134136787136e-08
( O 0 2.2416850598006022e-08
ii O 0 3.711604222189635e-06
) O 0 2.7515719480675216e-08
transcripts O 0 4.5417789351631654e-07
with O 0 1.3743381543918076e-07
premature O 0 5.451083052321337e-05
termination O 0 3.183202807122143e-06
codons O 0 6.217502459548996e-07
can O 0 5.609118503002719e-08
occur O 0 1.3857482272783272e-08
at O 0 1.375578140283551e-08
low O 0 4.3630899426716496e-07
or O 0 4.375214857077481e-08
undetectable O 0 1.7196700810018228e-06
levels O 0 3.755877742150915e-08
due O 0 2.3249095093547112e-08
to O 0 2.758397954494285e-08
nonsense O 0 2.4063226646831026e-06
- O 0 1.6805420273158234e-06
mediated O 0 1.251947537639353e-06
mRNA O 0 9.390351607407865e-08
decay O 0 1.2841626073623047e-07
, O 0 1.671591931540206e-08
and O 0 1.9208043156027088e-08
( O 0 1.2080811906400868e-08
iii O 0 2.0448082977964077e-06
) O 0 2.423699463349749e-09
the O 0 2.157821921144887e-09
levels O 0 4.350797055963085e-09
of O 0 1.0287675156206433e-09
these O 0 2.843754343118121e-09
transcripts O 0 2.655809225871053e-07
can O 0 3.0264867945106744e-08
be O 0 1.75306684724319e-08
increased O 0 6.817067088604745e-08
by O 0 1.2836680696182157e-07
cycloheximide O 0 0.00019081552454736084
. O 0 2.1039506918896222e-06

A O 0 6.23175801592879e-05
deletion O 0 0.000901194172911346
mutation O 0 5.3241397836245596e-05
in O 0 2.496334730039962e-07
COL17A1 O 0 0.00036889492184855044
in O 0 8.557126562891426e-08
five O 0 1.5567887601264374e-07
Austrian O 0 0.0018708823481574655
families O 0 2.2909489416633733e-07
with O 0 2.6291922949894797e-07
generalized O 0 0.00634324736893177
atrophic B-Disease 1 0.9999047517776489
benign I-Disease 1 0.995915949344635
epidermolysis I-Disease 1 0.9994494318962097
bullosa I-Disease 1 0.9923675656318665
represents O 0 5.912820597586688e-06
propagation O 0 4.238178519244684e-07
of O 0 1.5551469445540533e-08
an O 0 2.091306896545575e-07
ancestral O 0 1.2103515473427251e-05
allele O 0 3.81510253646411e-05
. O 0 2.7296259759168606e-06

Patients O 1 0.9161708950996399
with O 0 1.1512434866745025e-05
generalized O 0 0.004960630554705858
atrophic B-Disease 1 0.9996563196182251
benign I-Disease 1 0.9986070990562439
epidermolysis I-Disease 1 0.9994438290596008
bullosa I-Disease 1 0.9988716244697571
, O 0 4.230887498124503e-06
a O 0 8.409263045905391e-07
usually O 0 1.1017849743666375e-07
nonlethal O 0 6.984108722463134e-07
form O 0 9.301756165314146e-08
of O 0 6.581706912811569e-08
junctional B-Disease 1 0.6145162582397461
epidermolysis I-Disease 1 0.994985818862915
bullosa I-Disease 1 0.8963006734848022
, O 0 4.996028337700409e-07
have O 0 5.967447691546113e-08
generalized O 0 2.0959239463991253e-06
blistering B-Disease 0 0.12836375832557678
, O 0 1.2249061001057271e-05
nail B-Disease 1 0.9999244213104248
dystrophy I-Disease 1 0.9999572038650513
, O 0 5.912904452998191e-05
patchy B-Disease 1 0.9833720326423645
alopecia I-Disease 1 0.9999915361404419
, O 0 1.2697149031737354e-05
and O 0 3.3848533348646015e-05
dental B-Disease 1 0.9962548017501831
abnormalities I-Disease 1 0.9990752935409546
. O 0 1.3404090168478433e-05

Skin B-Disease 1 0.9993278980255127
fragility I-Disease 1 0.6459125280380249
in O 0 7.197029390226817e-06
most O 0 6.767584181943676e-07
cases O 0 4.171071736891463e-07
is O 0 2.1489029222721e-07
due O 0 5.967004312878998e-07
to O 0 3.3649212127784267e-07
mutations O 0 1.2159129028077587e-06
in O 0 8.659130301680307e-09
the O 0 1.5295304578444302e-08
gene O 0 1.4413863880236022e-07
encoding O 0 6.651862918261031e-07
type O 0 7.577124961244408e-06
XVII O 0 0.03245590999722481
collagen O 0 0.0009139410685747862
( O 0 8.189369964384241e-07
COL17A1 O 0 0.00026588657055981457
) O 0 1.024067387334071e-06
. O 0 9.877294360194355e-07

Recently O 0 8.58564380905591e-05
, O 0 4.773945079250552e-07
we O 0 6.616206604803665e-08
reported O 0 3.0937351880311326e-07
five O 0 7.726665529617094e-08
Austrian O 0 0.000658373930491507
families O 0 2.0942545120306022e-07
with O 0 2.4288752342727093e-07
generalized O 0 0.000998900504782796
atrophic B-Disease 1 0.9996789693832397
benign I-Disease 1 0.9626453518867493
epidermolysis I-Disease 1 0.9961054921150208
bullosa I-Disease 1 0.9792495369911194
who O 0 2.791521001199726e-05
share O 0 1.3837336609867634e-07
the O 0 3.8829593762557124e-08
same O 0 8.328041758431937e-07
COL17A1 O 0 0.01405025739222765
mutation O 0 4.8727961257100105e-05
. O 0 3.2599957648926647e-06

Affected O 0 0.00017331891285721213
individuals O 0 6.490020041383104e-07
in O 0 4.3359204227044756e-08
three O 0 5.696786331554904e-08
families O 0 1.9916218008120268e-08
are O 0 3.700129980188649e-09
homozygous O 0 2.8924759476467443e-07
for O 0 3.025747830065484e-08
4003delTC O 0 9.208642040903214e-06
, O 0 5.698438343415546e-08
whereas O 0 3.45282487046461e-08
those O 0 4.329365310695721e-09
in O 0 5.956074300428327e-09
two O 0 5.11480351406135e-08
others O 0 1.2035944507715612e-07
are O 0 2.6732198676882035e-08
compound O 0 6.08762320553069e-06
heterozygotes O 0 7.907339750090614e-05
. O 0 2.501325070625171e-06

To O 0 5.826805590913864e-06
determine O 0 1.1257847063461668e-06
if O 0 5.7035165923480236e-08
the O 0 1.555701700794998e-08
occurrence O 0 5.7778294149102294e-08
of O 0 7.186453210294985e-09
4003delTC O 0 4.629856903193286e-06
in O 0 4.383685237030477e-08
these O 0 1.1052869730576731e-08
unrelated O 0 4.589565492096881e-07
families O 0 7.021106540605615e-08
signifies O 0 2.1814841488776437e-07
propagation O 0 1.1808980104888178e-07
of O 0 7.130200874172488e-09
an O 0 9.923807908762683e-08
ancestral O 0 1.0727192147896858e-06
allele O 0 8.616756872470432e-07
or O 0 6.3890088775053755e-09
a O 0 7.72174431062922e-08
mutational O 0 3.966800795751624e-05
hot O 0 3.6297122278483585e-05
spot O 0 5.337310085451463e-06
, O 0 1.5436192768447654e-07
haplotypes O 0 5.635338766296627e-06
were O 0 1.4722100161179696e-07
determined O 0 4.443847956281388e-07
for O 0 4.847477441671799e-08
polymorphisms O 0 1.319834382229601e-06
both O 0 4.268682118890865e-08
within O 0 2.1163977237392828e-08
and O 0 1.0131163463711346e-07
flanking O 0 0.0002926937013398856
COL17A1 O 0 0.07790884375572205
. O 0 4.988157797924941e-06

Five O 0 2.5200462914654054e-05
intragenic O 0 0.00023180684365797788
polymorphisms O 0 7.380309398286045e-05
were O 0 8.940463089857076e-07
chosen O 0 2.2770956320528057e-07
based O 0 5.097574629076007e-08
on O 0 8.723870337234985e-08
their O 0 1.492333723263073e-07
informativeness O 0 0.00023422468802891672
. O 0 3.0145954497129424e-06

One O 0 2.709693490032805e-06
of O 0 7.217431630124338e-08
these O 0 3.2750286038663035e-08
, O 0 4.704389411358534e-08
not O 0 1.2740976274017157e-07
previously O 0 2.5342612843815004e-06
reported O 0 8.354929263987287e-07
, O 0 1.8140287494361473e-08
was O 0 4.5116635760678037e-07
2988 O 0 1.342185896646697e-06
A O 0 8.636822599328298e-07
or O 0 7.183632533269702e-08
C O 0 4.659369210457953e-07
that O 0 1.4878199117163149e-08
introduces O 0 3.246649669108592e-07
a O 0 1.2916808600493823e-07
new O 0 2.3060424680920732e-08
restriction O 0 4.8520377049499075e-08
site O 0 3.095836120792228e-08
for O 0 1.3941202858802626e-08
Eco0109 O 0 9.286098247685004e-06
I O 0 3.262334530518274e-06
. O 0 1.0070589269162156e-06

All O 0 6.692549163744843e-07
the O 0 2.1318852816420986e-07
4003delTC O 0 6.152464720798889e-06
alleles O 0 2.4980877242342103e-06
showed O 0 1.1992821100648143e-06
the O 0 9.704205439220459e-09
same O 0 1.1083400153211187e-07
haplotype O 0 2.036244586633984e-05
for O 0 1.4059767572405235e-08
these O 0 1.2865967846664716e-08
five O 0 8.753656288718048e-08
polymorphic O 0 2.7280380891170353e-05
markers O 0 2.533496626710985e-05
. O 0 3.5547773222788237e-06

Fourteen O 0 0.00029897456988692284
microsatellite O 0 0.0018701580120250583
polymorphisms O 0 0.0010455497540533543
were O 0 2.246463282062905e-06
selected O 0 1.1777443376104202e-07
based O 0 3.846376017691e-08
on O 0 9.205775342024936e-08
their O 0 2.808058674474978e-08
high O 0 3.8565733007089875e-07
heterozygosity O 0 1.1042006917705294e-05
and O 0 4.681019305508016e-08
their O 0 2.248467723120484e-08
location O 0 9.692795543969623e-08
within O 0 4.884658011405918e-08
10q23 O 0 7.017717962298775e-06
- O 0 2.5432838810957037e-05
q25 O 0 4.688178523792885e-05
near O 0 4.168671694060322e-06
COL17A1 O 0 0.00024453780497424304
. O 0 5.9342419262975454e-06

Three O 0 1.3372259672905784e-05
families O 0 2.800827132887207e-06
shared O 0 1.2949311667398433e-06
microsatellite O 0 8.21925641503185e-05
polymorphisms O 0 2.9901782909291796e-05
covering O 0 1.3914340115661616e-06
at O 0 1.2816985872632358e-07
most O 0 8.432643028299935e-08
19 O 0 1.1428285233705537e-06
cM O 0 2.5726661988301203e-05
, O 0 8.577945465049197e-08
whereas O 0 5.481451736955023e-08
the O 0 1.4274314175111158e-08
others O 0 1.2828762407934846e-07
shared O 0 3.3278531930136523e-08
smaller O 0 3.8215279829501014e-08
regions O 0 2.000568954940718e-08
consistent O 0 1.4162804973238963e-07
with O 0 3.238145751538468e-08
cross O 0 1.2249570602307358e-07
- O 0 9.994897482101806e-06
over O 0 2.0368058528674737e-07
events O 0 2.734140558402487e-08
during O 0 4.308566659005919e-08
passage O 0 5.197688679459134e-08
of O 0 3.8897178811225785e-09
this O 0 1.665666005123967e-08
mutation O 0 1.0590044752234462e-07
through O 0 1.28848531844028e-08
several O 0 1.1432346269657501e-07
generations O 0 6.497339768429811e-07
. O 0 8.806228493085655e-07

These O 0 2.0474269604164874e-06
results O 0 2.344097083550878e-06
indicate O 0 4.3592058318608906e-07
that O 0 5.241473033379407e-08
4003delTC O 0 1.6791591406217776e-05
occurs O 0 2.7453024742385423e-08
on O 0 2.0836854019989914e-08
a O 0 1.541109924119155e-07
single O 0 1.6168413594641606e-06
ancestral O 0 2.136944658559514e-06
allele O 0 7.975751941557974e-06
. O 0 2.519409463275224e-07
. O 0 6.115980681897781e-07

The O 0 7.1636541179032065e-06
haptoglobin O 0 0.00029347045347094536
- O 0 4.3489737436175346e-05
gene O 0 3.1983017834136263e-06
deletion O 0 9.029043212649412e-06
responsible O 0 8.203964512176753e-07
for O 0 3.539615249792405e-07
anhaptoglobinemia B-Disease 0 0.0008656711434014142
. O 0 5.211644293012796e-06

We O 0 1.9230699308536714e-06
have O 0 1.7947634489701159e-07
found O 0 3.3487509654150927e-08
an O 0 1.196194876484924e-08
allelic O 0 1.201449094878626e-06
deletion O 0 1.723176751511346e-06
of O 0 9.52767909012664e-09
the O 0 5.923132917473595e-08
haptoglobin O 0 6.884186586830765e-05
( O 0 6.342581571061601e-08
Hp O 0 4.5346203592089296e-07
) O 0 1.857642395464154e-08
gene O 0 3.660352376755327e-08
from O 0 3.508321189116259e-09
an O 0 1.668435345436592e-08
individual O 0 3.125596848008172e-08
with O 0 6.520244255625585e-07
anhaptoglobinemia B-Disease 0 0.0031909386161714792
. O 0 5.351056188374059e-06

The O 0 3.0841779334878083e-06
Hp O 0 1.4761742022528779e-05
gene O 0 2.1237590317468857e-06
cluster O 0 4.7228377297869883e-07
consists O 0 4.205693571179836e-08
of O 0 1.2980956753949613e-08
coding O 0 9.817173349802033e-07
regions O 0 1.961395490468476e-08
of O 0 2.1260218030505484e-09
the O 0 1.395019388894525e-08
alpha O 0 1.659122119690437e-07
chain O 0 1.363065678106068e-07
and O 0 4.5912220691946e-09
beta O 0 1.2813486272023056e-08
chain O 0 3.182026020454032e-08
of O 0 1.4766463607429614e-09
the O 0 1.2837949370236856e-08
haptoglobin O 0 6.140337518445449e-06
gene O 0 2.711061313220853e-07
( O 0 9.532877598417144e-09
Hp O 0 1.5546790166354185e-07
) O 0 7.311578453794709e-09
and O 0 2.714580338292194e-09
of O 0 5.901115152084913e-10
the O 0 5.390233148716561e-09
alpha O 0 5.7861551994164984e-08
chain O 0 1.2032327845190594e-07
and O 0 1.0479068279778403e-08
beta O 0 2.167773160977049e-08
chain O 0 6.028802346236262e-08
of O 0 1.9705814757742246e-09
the O 0 2.099899809593353e-08
haptoglobin O 0 2.8034646675223485e-05
- O 0 7.179362728493288e-05
related O 0 5.280890604808519e-07
gene O 0 3.6274994386076287e-07
( O 0 4.0388787425627015e-08
Hpr O 0 3.856311650451971e-06
) O 0 1.60704853868765e-08
, O 0 6.652292938724713e-09
in O 0 8.849289301338104e-09
tandem O 0 1.933017529154313e-06
from O 0 2.1818102879933576e-08
the O 0 3.7922585960359356e-08
5 O 0 7.060770030875574e-07
side O 0 5.706252977688564e-06
. O 0 1.95443089978653e-06

Southern O 0 2.720296470215544e-05
blot O 0 0.00021871532953809947
and O 0 7.918394544503826e-07
PCR O 0 2.8412778192432597e-05
analyses O 0 2.158961024179007e-06
have O 0 1.5940793218760518e-07
indicated O 0 1.0576071645118645e-06
that O 0 1.0824996898861627e-08
the O 0 6.796577967094208e-09
individual O 0 3.9562881859467325e-09
with O 0 2.3739948673551226e-08
anhaptoglobinemia B-Disease 0 8.292282291222364e-05
was O 0 3.014687536051497e-06
homozygous O 0 1.7442789612687193e-07
for O 0 2.8399058660255605e-09
the O 0 4.911290485409836e-09
gene O 0 7.954924541309083e-08
deletion O 0 1.0224105153611163e-06
and O 0 1.9753541025124832e-08
that O 0 1.730417054091049e-08
the O 0 9.55637968758083e-09
gene O 0 1.369253084249067e-07
deletion O 0 1.2735948757836013e-06
was O 0 4.943571525473089e-07
included O 0 2.6612953618609936e-08
at O 0 1.0602955846650275e-08
least O 0 2.3311169883299954e-08
from O 0 3.5217433413947674e-09
the O 0 7.289368664231688e-09
promoter O 0 1.2757003560182056e-06
region O 0 2.326249060047303e-08
of O 0 5.290555549208875e-09
Hp O 0 9.399048508385022e-07
to O 0 2.479916929587489e-07
Hpr O 0 5.451009201351553e-06
alpha O 0 1.3881826532724517e-07
but O 0 2.4782258023492432e-08
not O 0 9.797306965708685e-09
to O 0 7.546684344106325e-08
Hpr O 0 2.732605025812518e-05
beta O 0 4.4898331452714046e-07
( O 0 6.626650872476603e-08
Hpdel O 0 4.865104074269766e-06
) O 0 2.189520955653279e-07
. O 0 5.917204362049233e-07

In O 0 8.357484148291405e-06
addition O 0 9.283833719564427e-07
, O 0 6.930657292514297e-08
we O 0 1.0755599078038358e-08
found O 0 2.0111819765133987e-08
seven O 0 3.130835324327563e-08
individuals O 0 2.8956916864331106e-09
with O 0 1.5086344617998293e-08
hypohaptoglobinemia B-Disease 0 5.2953542763134465e-05
in O 0 7.101755272742594e-08
three O 0 6.160011167821722e-08
families O 0 3.369547840748055e-08
, O 0 8.269032569785395e-09
and O 0 8.013092411829348e-09
the O 0 1.71750116351177e-08
genotypes O 0 8.096964165815734e-07
of O 0 3.538340065389889e-09
six O 0 1.3056942194111798e-08
of O 0 9.439113934917032e-10
the O 0 8.283302932454717e-09
seven O 0 6.091857329693084e-08
individuals O 0 3.6462055597041854e-09
were O 0 1.3728731040885123e-08
found O 0 2.4189992231526958e-08
to O 0 3.566018591527609e-08
be O 0 3.9183439071166504e-07
Hp2 O 0 0.00026002872618846595
/ O 0 1.4148969967209268e-05
Hpdel O 0 5.9760881413239986e-05
. O 0 1.869815946520248e-06

The O 0 8.083730790531263e-06
phenotypes O 0 0.00031636812491342425
and O 0 8.631429295746784e-07
genotypes O 0 1.2246805454196874e-05
in O 0 3.9716159250247074e-08
one O 0 9.139081491582601e-09
of O 0 2.3461479425890275e-09
these O 0 6.414798026099788e-09
three O 0 4.768530459386966e-08
families O 0 3.464448283807542e-08
showed O 0 4.2920765963572194e-07
the O 0 6.295645338383338e-09
father O 0 5.062518653176085e-07
to O 0 3.348648647261143e-08
be O 0 6.344070158093018e-08
hypohaptoglobinemic B-Disease 0 1.684217386355158e-05
( O 0 3.1923789833854244e-08
Hp2 O 0 1.000650399873848e-06
) O 0 1.0182224841059906e-08
and O 0 3.157690642296984e-08
Hp2 O 0 4.837723736272892e-06
/ O 0 9.473389468439564e-07
Hpdel O 0 5.136671916261548e-06
, O 0 3.022990924250735e-08
the O 0 5.358282262335479e-09
mother O 0 3.704849689256662e-07
to O 0 2.0591583549389725e-08
be O 0 1.905224067400013e-08
Hp2 O 0 1.011216454571695e-06
- O 0 2.4147136628016597e-06
1 O 0 6.99106621482315e-08
and O 0 5.4234842394862426e-08
Hp1 O 0 4.474620709515875e-06
/ O 0 6.499868163700739e-07
Hp2 O 0 2.388926759522292e-06
, O 0 9.639602005506731e-09
one O 0 2.2905757290914153e-09
of O 0 7.598051077195578e-10
the O 0 5.877327513559294e-09
two O 0 3.7270186936666505e-08
children O 0 4.5212424026885856e-08
to O 0 2.466728510341909e-08
be O 0 1.0762887825421785e-07
hypohaptoglobinemic B-Disease 0 2.64966074610129e-05
( O 0 1.3194785708492418e-08
Hp2 O 0 5.950126933385036e-07
) O 0 6.039539091062807e-09
and O 0 2.07276080743668e-08
Hp2 O 0 6.046760972822085e-06
/ O 0 7.534127917097067e-07
Hpdel O 0 4.084060492459685e-06
, O 0 1.4878426490838592e-08
and O 0 4.632839001317279e-09
the O 0 3.5304394963020513e-09
other O 0 3.476135823632376e-09
child O 0 2.128831653180896e-07
to O 0 5.155872884188284e-08
be O 0 1.0702294872544371e-07
Hp1 O 0 2.6794969016918913e-06
and O 0 6.092648163757985e-08
Hp1 O 0 9.084329576580785e-06
/ O 0 9.282168775825994e-07
Hpdel O 0 4.0254230952996295e-06
, O 0 2.011504207644066e-08
showing O 0 1.6594513851941883e-07
an O 0 3.8926291523466716e-08
anomalous O 0 4.355151304480387e-06
inheritance O 0 7.993973554221157e-07
of O 0 2.6346784309794202e-08
Hp O 0 0.00010403738269815221
phenotypes O 0 0.0003141005872748792
in O 0 4.137687881211605e-08
the O 0 3.720697350217961e-08
child O 0 1.9741617052204674e-06
with O 0 3.1384112730847846e-07
Hp1 O 0 0.00036197391455061734
. O 0 1.9544197584764333e-06

The O 0 7.002161964919651e-06
Hp2 O 0 0.00016673145000822842
/ O 0 1.7327876776107587e-05
Hpdel O 0 3.6387162253959104e-05
individuals O 0 6.027434551469923e-08
had O 0 1.3123160158556857e-07
an O 0 1.8889451780523814e-08
extremely O 0 7.400640242849477e-07
low O 0 3.0746608103982e-07
level O 0 1.1255830045797666e-08
of O 0 6.716113887250685e-09
Hp O 0 1.233085981766635e-06
( O 0 2.377334418213195e-08
mean O 0 7.962378134607206e-08
+ O 0 2.230717512929914e-07
/ O 0 1.7937982477178593e-07
- O 0 4.046758931508521e-06
SD O 0 6.67421700200066e-05
= O 0 1.6117825225592242e-06
0 O 0 1.6657175194723095e-07
. O 0 1.6225097709821057e-08
049 O 0 2.9573031952168094e-06
+ O 0 4.0183022065320984e-07
/ O 0 1.318772007152802e-07
- O 0 1.0404639851913089e-06
0 O 0 1.9919775695598219e-07
. O 0 1.7703717603012592e-08
043 O 0 1.8888316617449163e-06
mg O 0 2.3773269276716746e-05
/ O 0 9.874204351945082e-07
ml O 0 5.344375040294835e-06
; O 0 1.4372396606177062e-07
n O 0 4.6023944832995767e-07
= O 0 3.5566523592933663e-07
6 O 0 3.8890224374199533e-08
) O 0 4.219833371621462e-09
, O 0 1.0572744457704175e-08
compared O 0 5.490115384532146e-08
with O 0 7.3254540211564745e-09
the O 0 1.3617217575756513e-08
level O 0 1.4069425624541054e-08
( O 0 3.6861191876624844e-09
1 O 0 6.532839602613194e-09
. O 0 6.776979422085105e-09
64 O 0 8.122689365563929e-08
+ O 0 5.0519464167564365e-08
/ O 0 3.082531563336488e-08
- O 0 3.3978261626543826e-07
1 O 0 3.170811879726898e-08
. O 0 1.1764551999249306e-08
07 O 0 3.135455699521117e-07
mg O 0 1.5451420040335506e-05
/ O 0 8.623350140624098e-07
ml O 0 2.849264092219528e-06
) O 0 1.504554170139727e-08
obtained O 0 2.8970962517860244e-08
from O 0 7.226230724910465e-09
52 O 0 8.142775982378225e-07
healthy O 0 2.4197751713472826e-07
volunteers O 0 2.0293470015531057e-07
having O 0 3.66421232911307e-07
phenotype O 0 5.271402551443316e-05
Hp2 O 0 5.360050181479892e-06
, O 0 3.72915209823077e-08
whereas O 0 2.806388010867522e-08
the O 0 6.13113826375411e-09
serum O 0 5.430900387182191e-07
Hp O 0 2.8759609449480195e-07
level O 0 7.878305119390916e-09
of O 0 1.41012801435636e-09
an O 0 1.1039091418751923e-08
individual O 0 5.409998227179358e-09
with O 0 7.519857803117702e-08
Hp1 O 0 0.00011146361794089898
/ O 0 6.425113042496378e-06
Hpdel O 0 3.129560354864225e-05
was O 0 7.125035608623875e-06
0 O 0 1.717850636850926e-06
. O 0 1.0354058304073988e-06

50 O 0 3.754402860067785e-05
mg O 0 0.000445076497271657
/ O 0 2.498871435818728e-05
ml O 0 4.4116979552200064e-05
, O 0 1.2418952621828794e-07
which O 0 2.5450114904401744e-08
was O 0 1.506311946286587e-07
approximately O 0 4.730011493592201e-09
half O 0 5.8193005969542355e-09
the O 0 1.4711475371242955e-09
level O 0 1.7651918815531076e-09
of O 0 1.0906688885370386e-09
Hp O 0 2.9258458766889817e-07
in O 0 2.0310658044309093e-08
control O 0 6.401440941772307e-07
sera O 0 3.4747570225590607e-06
from O 0 6.9484573650413495e-09
the O 0 1.124939075225484e-08
Hp1 O 0 0.00012900750152766705
phenotype O 0 0.000157916932948865
( O 0 1.4463057418367953e-08
1 O 0 2.0991510751855458e-08
. O 0 1.5138402531533757e-08
26 O 0 1.468554273742484e-07
+ O 0 1.9364681236311299e-07
/ O 0 1.9000823670012323e-07
- O 0 2.9928878575447015e-06
0 O 0 3.6787676549465687e-07
. O 0 2.9522423616867854e-08
33 O 0 3.006849453868199e-07
mg O 0 9.755131031852216e-06
/ O 0 1.5578119700876414e-06
ml O 0 1.760183477017563e-05
; O 0 1.9691609054461878e-07
n O 0 7.357662639151386e-07
= O 0 4.6763875616306905e-07
9 O 0 7.577261129654289e-08
) O 0 8.106079363301433e-09
, O 0 1.3051613123593597e-08
showing O 0 1.8244321609017788e-07
a O 0 2.6228988758703053e-07
gene O 0 6.99714178153954e-07
- O 0 9.957874135579914e-05
dosage O 0 0.00012751661415677518
effect O 0 3.691402071126504e-06
. O 0 1.1742938568204409e-06

The O 0 1.9566932678571902e-06
other O 0 1.771831961150383e-07
allele O 0 2.496346951375017e-06
( O 0 3.353391164750974e-08
Hp2 O 0 1.1142308267153567e-06
) O 0 5.143847570110438e-09
of O 0 1.3477780003157136e-09
individuals O 0 4.040148215977979e-09
with O 0 2.4112143393040242e-08
Hp2 O 0 6.044924884918146e-05
/ O 0 3.1320744255936006e-06
Hpdel O 0 1.1217154678888619e-05
was O 0 1.0709028401834075e-06
found O 0 2.1015548412606222e-08
to O 0 9.769427933292718e-09
have O 0 4.2470958305784734e-08
, O 0 2.4627702543966734e-08
in O 0 9.556981872549386e-09
all O 0 5.6143920623696886e-09
exons O 0 4.487547187181917e-07
, O 0 3.704580464614082e-08
no O 0 6.225851478802724e-08
mutation O 0 2.2725981807525386e-07
, O 0 2.3237832991185314e-08
by O 0 2.9322192673930658e-08
DNA O 0 9.690241995485849e-07
sequencing O 0 2.382751517870929e-06
. O 0 7.95743403614324e-07

On O 0 1.110317953134654e-06
the O 0 3.0954169005781296e-08
basis O 0 7.481443020651568e-09
of O 0 2.1952335504948906e-09
the O 0 1.1582910630636434e-08
present O 0 8.877102430915329e-08
study O 0 4.612272164195019e-08
, O 0 4.456641278238749e-09
the O 0 2.3666830717417042e-09
mechanism O 0 8.905877812992458e-09
of O 0 2.872549087484799e-09
anhaptoglobinemia B-Disease 0 1.6830692402436398e-05
and O 0 9.958199598258943e-09
the O 0 2.2448587433387956e-09
mechanism O 0 8.386844108088098e-09
of O 0 4.72829730924218e-09
anomalous O 0 5.999018867441919e-06
inheritance O 0 1.6482937326145475e-06
of O 0 4.3793061621499874e-08
Hp O 0 0.00010970496805384755
phenotypes O 0 0.00017656254931353033
were O 0 1.7497505666597135e-07
well O 0 1.5565750288715208e-07
explained O 0 2.7331659566698363e-06
. O 0 8.836859706207179e-07

However O 0 1.6215130017371848e-05
, O 0 1.2749191569128016e-07
the O 0 1.3252646091643783e-08
mechanism O 0 7.536284130083004e-08
of O 0 5.341101783074009e-08
hypohaptoglobinemia B-Disease 0 0.00042685188236646354
remains O 0 3.595704401959665e-05
unknown O 0 3.078837107750587e-05

ATM O 0 0.00111326202750206
mutations O 0 0.014638376422226429
and O 0 1.6582598618697375e-05
phenotypes O 0 0.04591051861643791
in O 0 0.0002532674407120794
ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999964237213135
telangiectasia I-Disease 1 0.9999978542327881
families O 0 8.88845170265995e-06
in O 0 5.9305147459554064e-08
the O 0 4.837595213302848e-08
British O 0 1.7442040189052932e-05
Isles O 0 7.839528848307964e-07
: O 0 1.1731791538238667e-08
expression O 0 9.85191128677343e-09
of O 0 1.7405485941424104e-09
mutant O 0 1.9366547121535405e-07
ATM O 0 1.4965966954605392e-07
and O 0 1.0821900708890553e-08
the O 0 8.764912351466592e-09
risk O 0 1.1024766166656264e-07
of O 0 1.8824894709723594e-07
leukemia B-Disease 1 0.9998123049736023
, O 0 0.07413763552904129
lymphoma B-Disease 1 0.9999997615814209
, O 0 9.253883035853505e-06
and O 0 0.00011879883822984993
breast B-Disease 1 0.9998526573181152
cancer I-Disease 1 0.9771471619606018
. O 0 6.411072263290407e-06

We O 0 3.2875918805075344e-06
report O 0 3.7764766602776945e-07
the O 0 1.3560041089988317e-08
spectrum O 0 1.0123901006409142e-07
of O 0 5.316543205680091e-09
59 O 0 1.8162968444812577e-06
ATM O 0 3.137485691695474e-05
mutations O 0 1.5280676961992867e-05
observed O 0 1.1831518804683583e-06
in O 0 6.059345651010517e-06
ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999988079071045
telangiectasia I-Disease 1 0.9999991655349731
( O 0 1.848400461312849e-05
A B-Disease 1 0.9999771118164062
- I-Disease 1 0.9999935626983643
T I-Disease 1 0.9999996423721313
) O 0 9.600468729331624e-06
patients O 0 1.5114193047338631e-05
in O 0 3.651099689250259e-08
the O 0 1.580032176207169e-07
British O 0 3.823195584118366e-05
Isles O 0 1.2239976058481261e-05
. O 0 1.8869051245928858e-06

Of O 0 3.439879947109148e-06
51 O 0 1.0491252396604978e-05
ATM O 0 2.0752171622007154e-05
mutations O 0 2.8789661882910877e-05
identified O 0 7.667741215300339e-07
in O 0 4.9052264472493334e-08
families O 0 6.74622313567852e-08
native O 0 1.835713092646074e-08
to O 0 1.6961420712391373e-08
the O 0 2.8027665521790368e-08
British O 0 1.1169448953296524e-05
Isles O 0 5.663773663400207e-07
, O 0 2.4880201010546443e-08
11 O 0 1.7932299201106616e-08
were O 0 2.5300270323214136e-08
founder O 0 2.988227606692817e-06
mutations O 0 6.210202059264702e-07
, O 0 8.293167041983907e-09
and O 0 9.174903503605947e-09
2 O 0 1.996223630840177e-08
of O 0 2.527131837126717e-09
these O 0 8.772136794732432e-09
11 O 0 1.467598025328698e-07
conferred O 0 1.2930763659824152e-06
a O 0 1.3325410691322759e-05
milder O 1 0.9779155850410461
clinical O 1 0.6617540717124939
phenotype O 0 0.49590617418289185
with O 0 1.1347685102691685e-07
respect O 0 7.143393787600871e-08
to O 0 2.0215955487401516e-07
both O 0 1.111479036808305e-06
cerebellar B-Disease 1 0.6539785861968994
degeneration I-Disease 1 0.9865803718566895
and O 0 4.1928492464649025e-06
cellular O 0 3.868459680234082e-05
features O 0 2.2865338905830868e-05
. O 0 4.369937869341811e-06

We O 0 5.994729235681007e-06
report O 0 1.6822449424580554e-06
, O 0 3.96569639349309e-08
in O 0 1.9645179705207738e-08
two O 0 1.9808443596502912e-07
A B-Disease 1 0.9998675584793091
- I-Disease 1 0.999988317489624
T I-Disease 1 0.999998927116394
families O 0 3.5088120853288274e-07
, O 0 1.2116601944001104e-08
an O 0 1.5879079384717443e-08
ATM O 0 1.8744525505098864e-06
mutation O 0 7.918741857793066e-07
( O 0 1.0261909544340142e-08
7271T O 0 1.4672680208605016e-06
- O 0 6.9822883233428e-05
- O 0 0.01109449751675129
> O 0 2.628414767968934e-05
G O 0 0.00026222385349683464
) O 0 2.9077142471578554e-08
that O 0 2.757719563817318e-08
may O 0 2.988288088090485e-07
be O 0 1.7650984673878156e-08
associated O 0 1.2432527896066858e-08
with O 0 6.909957939171818e-09
an O 0 1.0608178513393796e-07
increased O 0 1.1848568419736694e-06
risk O 0 1.8771041254694865e-07
of O 0 1.855090090430167e-07
breast B-Disease 1 0.9997549653053284
cancer I-Disease 1 0.9451161623001099
in O 0 3.0709654197380587e-07
both O 0 5.151479740561626e-07
homozygotes O 0 0.00031942522036843
and O 0 1.1601050573517568e-06
heterozygotes O 0 2.087591383315157e-05
( O 0 4.200802905529599e-08
relative O 0 4.921186018691515e-07
risk O 0 2.69216059223254e-07
12 O 0 7.317594707956232e-08
. O 0 1.4801322834046005e-08
7 O 0 3.2053813470156456e-07
; O 0 2.0958830759809643e-07
P O 0 5.328762563294731e-05
= O 0 1.2762868664140115e-06
. O 0 3.3119594178288025e-08
0025 O 0 2.6493128189031268e-06
) O 0 1.8628368181339283e-08
, O 0 5.268864011753749e-09
although O 0 1.4105538070907642e-08
there O 0 4.921520968537152e-09
is O 0 5.709237971274206e-09
a O 0 3.154994203669048e-07
less O 0 3.4336264889134327e-06
severe O 1 0.8675101399421692
A B-Disease 1 0.9999982118606567
- I-Disease 1 0.9999990463256836
T I-Disease 1 0.9999998807907104
phenotype O 1 0.8568547368049622
in O 0 7.816492342271886e-08
terms O 0 1.808011518278363e-08
of O 0 2.2463491067270525e-09
the O 0 1.4783041457633317e-08
degree O 0 1.9286427743736567e-07
of O 0 1.678426571061209e-07
cerebellar B-Disease 1 0.9219200611114502
degeneration I-Disease 1 0.9991638660430908
. O 0 2.6723218979896046e-05

This O 0 1.0259755072183907e-05
mutation O 0 2.5043776986422017e-05
( O 0 1.9572888732000138e-07
7271T O 0 4.341119620221434e-06
- O 0 7.400951290037483e-05
- O 0 0.0019647597800940275
> O 0 1.5248343515850138e-05
G O 0 8.40870852698572e-05
) O 0 1.6077905229394673e-08
also O 0 3.037127171978682e-08
allows O 0 1.0932187599621557e-08
expression O 0 1.0898542512904896e-08
of O 0 1.0618695922559596e-09
full O 0 5.549493664602778e-08
- O 0 1.8282654536960763e-06
length O 0 1.6147643577824056e-07
ATM O 0 8.291066677657e-08
protein O 0 1.4735634934481823e-08
at O 0 2.2947475031287468e-09
a O 0 4.017144306089904e-08
level O 0 1.7578681621444048e-08
comparable O 0 5.281604842366505e-08
with O 0 1.1630063134759894e-08
that O 0 6.43126583099729e-08
in O 0 1.8669777546165278e-07
unaffected O 0 0.00019552753656171262
individuals O 0 4.6543729581571824e-07
. O 0 1.5366924799309345e-06

In O 0 3.1406916605192237e-06
addition O 0 3.186879382610641e-07
, O 0 3.6191575958355315e-08
we O 0 2.1927656135289908e-08
have O 0 4.5685993654842605e-08
studied O 0 2.9531389600379043e-07
18 O 0 1.3785377177555347e-06
A B-Disease 1 0.9982452392578125
- I-Disease 1 0.9999963045120239
T I-Disease 1 1.0
patients O 1 0.6893995404243469
, O 0 3.7923452822496984e-08
in O 0 2.470976134816283e-08
15 O 0 1.0443893216915967e-07
families O 0 1.6338571384721945e-08
, O 0 2.053138459245929e-08
who O 0 7.973919309733901e-06
developed O 0 0.0019005356589332223
leukemia B-Disease 1 0.9996874332427979
, O 0 0.01610986515879631
lymphoma B-Disease 1 0.9999995231628418
, O 0 3.134437974949833e-06
preleukemic O 0 0.0005373224848881364
T O 0 0.00025164466933347285
- O 0 1.6513084119651467e-05
cell O 0 8.894081474863924e-06
proliferation O 0 3.8161965676408727e-07
, O 0 3.828670855909877e-07
or O 0 5.6929457059595734e-05
Hodgkin B-Disease 1 0.9999994039535522
lymphoma I-Disease 1 1.0
, O 0 1.5236115586958476e-06
mostly O 0 1.8643729049472313e-07
in O 0 2.7853778306052845e-07
childhood O 0 1.7322719941148534e-05
. O 0 2.558657797635533e-06

A O 0 3.421719156904146e-05
wide O 0 4.130664819967933e-06
variety O 0 2.4469096615575836e-07
of O 0 2.9835010906253956e-08
ATM O 0 7.780533451295923e-06
mutation O 0 5.210823928791797e-06
types O 0 1.008412340297582e-07
, O 0 4.6715737056501894e-08
including O 0 2.5457742935941496e-07
missense O 0 0.001954676117748022
mutations O 0 1.3790589946438558e-05
and O 0 9.5767838104166e-08
in O 0 8.383489102925523e-08
- O 0 0.00011953507782891393
frame O 0 0.01668221689760685
deletions O 0 6.845544248790247e-06
, O 0 6.411852382370853e-08
were O 0 3.2863486154610655e-08
seen O 0 1.5161440103383939e-07
in O 0 4.523278107626538e-08
these O 0 1.6844302308527404e-07
patients O 0 0.00010441784252179787
. O 0 3.618630444179871e-06

We O 0 3.0482983675028663e-06
also O 0 1.634493713709162e-07
show O 0 8.057065770117333e-08
that O 0 9.744825391067025e-09
25 O 0 2.7860783902156072e-08
% O 0 2.992059044970574e-09
of O 0 6.482911985017381e-10
all O 0 2.515044528195176e-08
A B-Disease 1 0.999980092048645
- I-Disease 1 0.9999986886978149
T I-Disease 1 1.0
patients O 0 0.4580919146537781
carried O 0 1.0253886557620717e-06
in O 0 2.4334420700711235e-08
- O 0 7.23414586900617e-06
frame O 0 0.00013187136210035533
deletions O 0 2.6554696432867786e-06
or O 0 2.8132646434642083e-07
missense O 0 0.000444963836343959
mutations O 0 1.0627884876157623e-05
, O 0 5.4167848873021285e-08
many O 0 4.465201097758609e-09
of O 0 3.2863218812906325e-09
which O 0 4.373746946839674e-07
were O 0 2.474122311468818e-07
also O 0 7.390828500319913e-07
associated O 0 3.746176346908214e-08
with O 0 8.126064265923105e-09
expression O 0 5.5481599758877564e-08
of O 0 8.225867098587969e-09
mutant O 0 2.3447812509402866e-06
ATM O 0 3.5850573567586252e-06
protein O 0 9.537096730127814e-07
. O 0 4.1888577584359155e-07

The O 0 3.7321590298233787e-06
DMPK O 0 7.627211743965745e-05
gene O 0 3.039213197553181e-06
of O 0 2.70632114052205e-07
severely O 0 0.17013293504714966
affected O 0 0.028007609769701958
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9999351501464844
is O 0 2.9113268738001352e-06
hypermethylated O 0 0.00014696073776576668
proximal O 0 5.023097401135601e-05
to O 0 2.1746980394254933e-07
the O 0 6.923060880126286e-08
largely O 0 5.437362347038288e-07
expanded O 0 6.039783784217434e-07
CTG O 0 4.425308361533098e-05
repeat O 0 1.4843348253634758e-05
. O 0 1.997171693801647e-06

Using O 0 6.941425453987904e-06
methylation O 0 9.375759873364586e-06
- O 0 1.502288523624884e-05
sensitive O 0 1.2637054851438734e-06
restriction O 0 7.675737947465677e-07
enzymes O 0 2.659037932062347e-07
, O 0 2.3713113250778406e-08
we O 0 9.307502324418238e-09
characterized O 0 7.731545537126294e-08
the O 0 6.688935183518652e-09
methylation O 0 2.072113431950129e-07
pattern O 0 1.9368708592537587e-07
on O 0 6.554521547741388e-08
the O 0 1.772392366206077e-08
5 O 0 6.962641663221802e-08
side O 0 5.925155477370936e-08
of O 0 1.9138441942345708e-09
the O 0 1.5009311127300862e-08
CTG O 0 2.495916123734787e-05
repeat O 0 1.0852451168830157e-06
in O 0 1.816002104249037e-08
the O 0 1.4167067519110788e-08
DMPK O 0 2.7325035262038e-05
gene O 0 1.2522134795744932e-07
of O 0 3.925208602595376e-09
normal O 0 9.500081432634033e-08
individuals O 0 5.4686877248855126e-09
and O 0 1.1656112519631279e-08
of O 0 6.080063741364938e-08
patients O 0 0.0026248516514897346
affected O 0 2.007479679377866e-06
with O 0 0.001897393143735826
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 3.870511591230752e-06
showing O 0 8.702745049049554e-07
expansions O 0 2.595720332010387e-07
of O 0 1.7370968663499298e-08
the O 0 7.625323661386574e-08
repetitive O 0 7.000008918112144e-05
sequence O 0 5.673684427165426e-06
. O 0 2.3193081233330304e-06

The O 0 6.324277364910813e-06
gene O 0 5.287186922942055e-06
segment O 0 2.718924633882125e-06
analyzed O 0 5.690492344001541e-07
corresponds O 0 3.1029421165840176e-07
to O 0 2.583724167948276e-08
the O 0 1.3910313789722295e-08
genomic O 0 8.467858378935489e-07
SacI O 0 2.1825233488925733e-05
- O 0 5.509381935553392e-06
HindIII O 0 3.4030090318992734e-06
fragment O 0 9.187863270199159e-07
carrying O 0 5.963585181234521e-07
exons O 0 2.4961400413303636e-06
11 O 0 2.444621713948436e-07
- O 0 5.63242656426155e-06
15 O 0 1.7742173668011674e-06
. O 0 9.461236913921311e-07

There O 0 6.236040007934207e-06
is O 0 2.420490545773646e-07
constitutive O 0 9.969469374482287e-07
methylation O 0 5.516487249224156e-07
in O 0 4.9175916672083986e-08
intron O 0 4.593476205627667e-06
12 O 0 5.689663140628909e-08
at O 0 2.984199332090043e-09
restriction O 0 1.792757942098433e-08
sites O 0 3.342648380311175e-09
of O 0 2.4197963632843766e-09
SacII O 0 3.659163212432759e-06
and O 0 6.192087909084876e-08
HhaI O 0 1.5257083987307851e-06
, O 0 1.83384774032902e-08
localized O 0 2.0153605362338567e-07
1 O 0 3.9754507241696047e-08
, O 0 1.5048641444082023e-08
159 O 0 2.8038044774802984e-07
- O 0 8.14794020698173e-06
1 O 0 9.415855117822503e-08
, O 0 3.152407046513872e-08
232 O 0 2.1252451176678733e-07
bp O 0 2.8142703740741126e-06
upstream O 0 5.50907017782265e-08
of O 0 3.6157332683472987e-09
the O 0 1.512322356234108e-08
CTG O 0 1.243901078851195e-05
repeat O 0 1.1030462019334664e-06
, O 0 2.504713769724276e-08
whereas O 0 3.966422568169037e-08
most O 0 8.15279754817766e-09
, O 0 4.949602061543601e-09
if O 0 7.3161539049237945e-09
not O 0 3.850785912362653e-09
all O 0 1.0125552618589495e-09
, O 0 1.0632416058697913e-09
of O 0 2.167489798754474e-10
the O 0 8.02872435201607e-10
other O 0 4.335411751821283e-10
sites O 0 8.851563371159443e-10
of O 0 1.6655667955944864e-09
SacII O 0 1.7431378864785074e-06
, O 0 2.8890951853099978e-08
HhaI O 0 6.93242157012719e-07
, O 0 1.0482545498291529e-08
and O 0 8.975402643329744e-09
HpaII O 0 2.1443959212774644e-06
in O 0 1.399592797213245e-08
this O 0 8.959734287827814e-09
region O 0 3.498787037869988e-08
are O 0 1.6837997662833004e-08
unmethylated O 0 3.769593149627326e-06
, O 0 3.6244145462660526e-08
in O 0 1.7975240851342278e-08
normal O 0 6.214319370201338e-08
individuals O 0 3.816579940973952e-09
and O 0 1.263004634211029e-08
most O 0 1.3043948143831585e-08
of O 0 9.842127113302013e-09
the O 0 7.614364108121663e-07
patients O 0 0.00028710553306154907
. O 0 3.332723963467288e-06

In O 0 3.2114658097270876e-06
a O 0 4.783273652719799e-07
number O 0 4.152416721581176e-08
of O 0 1.017255790713989e-08
young O 0 7.280152090061165e-07
and O 0 1.1831676829388016e-06
severely O 0 0.3416627049446106
affected O 0 2.632111863931641e-05
patients O 0 0.0002295885788043961
, O 0 5.392230661982467e-08
however O 0 8.003198104233888e-08
, O 0 4.4888373018636685e-09
complete O 0 1.0664267691140594e-08
methylation O 0 1.4330812092566703e-08
of O 0 6.701293409072662e-10
these O 0 1.6480282694075754e-09
restriction O 0 3.1485136275932746e-08
sites O 0 1.502586854940091e-08
was O 0 2.0792278121462004e-07
found O 0 1.9126188632867525e-08
in O 0 1.0694026997271067e-08
the O 0 4.828533306522331e-08
mutated O 0 5.431038516690023e-05
allele O 0 2.1227597244433127e-05
. O 0 1.85785529538407e-06

In O 0 2.7653547931549838e-06
most O 0 7.439226834549117e-08
of O 0 1.3554146249816768e-08
these O 0 1.6098563548894163e-07
patients O 0 1.3506911272997968e-05
, O 0 2.701245982450473e-08
the O 0 2.3990486042180237e-08
onset O 0 1.420285570929991e-06
of O 0 4.1287083973884364e-08
the O 0 6.154354650789173e-06
disease O 0 0.028168901801109314
was O 1 0.5595245957374573
congenital O 1 0.9999144077301025
. O 0 6.646042311331257e-05

Preliminary O 0 0.00015779696695972234
in O 0 4.603448815032607e-06
vivo O 0 0.0003827526525128633
footprinting O 0 0.0024908953346312046
data O 0 7.941232524899533e-07
gave O 0 3.1474030492972815e-07
evidence O 0 8.756160951861602e-08
for O 0 1.9041923593476895e-08
protein O 0 1.3979378366002493e-07
- O 0 7.870596164138988e-06
DNA O 0 1.561229851176904e-06
contact O 0 4.281786303295121e-08
in O 0 1.4052529806463099e-08
normal O 0 2.6909560801868793e-08
genes O 0 1.8255176925663363e-08
at O 0 4.432692435329955e-09
an O 0 1.972650842674284e-08
Sp1 O 0 9.71327040133474e-07
consensus O 0 4.708914147499854e-08
binding O 0 5.4414094563526305e-08
site O 0 1.8382287692020327e-08
upstream O 0 8.868027201458517e-09
of O 0 1.5082110005337768e-09
the O 0 1.1305919755955074e-08
CTG O 0 9.181117093248758e-06
repeat O 0 9.442208011023467e-07
and O 0 2.3361019785284043e-08
for O 0 6.9007124459119495e-09
a O 0 1.1176913972121838e-07
significant O 0 8.457851663479232e-08
reduction O 0 6.37564454564199e-08
of O 0 1.4548958704452275e-09
this O 0 6.683412934194166e-09
interaction O 0 1.3146228106108993e-08
in O 0 4.525357866214108e-08
cells O 0 9.916428922451814e-08
with O 0 2.4736923620594098e-08
a O 0 1.2883201634394936e-06
hypermethylated O 0 0.00024171327822841704
DMPK O 0 0.0003523984632920474
gene O 0 1.9205133412469877e-06
. O 0 2.286914906335369e-07
. O 0 7.119624001461489e-07

The O 0 4.097972123418003e-05
hemochromatosis B-Disease 1 0.9998739957809448
gene O 0 5.985515599604696e-06
product O 0 2.459895256379241e-07
complexes O 0 1.1322930504320539e-07
with O 0 2.8913882843539795e-08
the O 0 7.449435912576519e-08
transferrin O 0 1.4633449609391391e-05
receptor O 0 8.344896400558355e-07
and O 0 5.0806846729756217e-08
lowers O 0 3.3474752854090184e-06
its O 0 2.897621342867751e-08
affinity O 0 7.322216077909616e-08
for O 0 2.201511684063462e-08
ligand O 0 8.020166205824353e-06
binding O 0 1.0677755199139938e-05
. O 0 2.7472567580844043e-06

We O 0 1.0163656043005176e-05
recently O 0 8.279448593384586e-06
reported O 0 5.987388931316673e-07
the O 0 8.974888388024738e-09
positional O 0 9.354648682347033e-07
cloning O 0 3.002585913236544e-07
of O 0 7.724716866164272e-09
a O 0 2.6696486088439997e-07
candidate O 0 6.260446298256284e-06
gene O 0 3.0280457394837867e-06
for O 0 2.7210799089516513e-05
hereditary B-Disease 1 0.9999998807907104
hemochromatosis I-Disease 1 1.0
called O 0 0.07023914158344269
HFE O 0 0.39968249201774597
. O 0 6.670407856290694e-06

The O 0 1.6247399798885453e-06
gene O 0 1.0898251048274687e-06
product O 0 1.7013658748510352e-07
, O 0 2.981572322369175e-08
a O 0 5.966104765775526e-08
member O 0 1.7267836938117398e-08
of O 0 1.6174600547813611e-09
the O 0 1.4883876353621872e-08
major O 0 1.4054278096864437e-07
histocompatibility O 0 2.307200338691473e-05
complex O 0 7.82553115641349e-07
class O 0 5.999838208481378e-07
I O 0 1.0155168865821906e-06
- O 0 2.65622452388925e-06
like O 0 1.419471544750195e-07
family O 0 1.718758682045518e-07
, O 0 1.1586225312498755e-08
was O 0 2.5814244963839883e-07
found O 0 1.7856528700122e-08
to O 0 1.1315757220131673e-08
have O 0 2.676097210496664e-08
a O 0 5.549255206460657e-07
mutation O 0 1.3846064348399523e-06
, O 0 8.677503160470224e-08
Cys O 0 3.268050932092592e-05
- O 0 1.0923808986262884e-05
282 O 0 2.499162292224355e-06
- O 0 7.33390697860159e-05
- O 0 0.0003422069421503693
> O 0 4.04895945393946e-06
Tyr O 0 1.5367893865914084e-05
( O 0 3.3307994584674816e-08
C282Y O 0 6.886329515509715e-07
) O 0 1.4468438003234496e-08
, O 0 8.123661743297816e-09
in O 0 8.817125696225503e-09
85 O 0 1.8921693367701664e-07
% O 0 1.687831918673055e-08
of O 0 1.9102964543549206e-08
patient O 0 0.0001236676034750417
chromosomes O 0 2.136036528099794e-05
. O 0 2.805082431223127e-06

This O 0 8.553912266506813e-06
mutation O 0 1.9793762476183474e-05
eliminates O 0 2.082264927594224e-06
the O 0 6.74641569275991e-08
ability O 0 9.70587450410676e-08
of O 0 1.480533295961095e-08
HFE O 0 0.00013386858336161822
to O 0 3.2757728263277386e-07
associate O 0 1.544393768426744e-07
with O 0 8.179965504950815e-08
beta2 O 0 0.0001107046555262059
- O 0 0.0002692326088435948
microglobulin O 0 0.0009029270149767399
( O 0 7.760162645809032e-08
beta2m O 0 5.7670999922265764e-06
) O 0 2.8002764551615655e-08
and O 0 1.5822241294927153e-08
prevents O 0 2.791824442738289e-07
cell O 0 1.3591728020401206e-05
- O 0 0.0002759494527708739
surface O 0 0.00015180400805547833
expression O 0 7.744215508864727e-06
. O 0 2.1645626020472264e-06

A O 0 3.0818326195003465e-05
second O 0 1.0854359061340801e-05
mutation O 0 1.1267437002970837e-05
that O 0 1.1159340118638283e-07
has O 0 1.3293637834976835e-07
no O 0 7.409700941707342e-08
effect O 0 1.6127452795444697e-07
on O 0 6.34664729659562e-07
beta2m O 0 0.0005962668219581246
association O 0 7.675460977907278e-08
, O 0 2.668156717788861e-08
H63D O 0 3.46069828083273e-05
, O 0 3.406088566748622e-08
was O 0 1.6553654802464735e-07
found O 0 7.97470001145939e-09
in O 0 2.237070750865655e-09
eight O 0 7.817756220163119e-09
out O 0 1.0343478962226982e-08
of O 0 5.623309373703478e-09
nine O 0 3.571039314920199e-06
patients O 0 1.9946417523897253e-05
heterozygous O 0 8.839641054692038e-07
for O 0 2.8130010321092414e-08
the O 0 6.959999865330246e-08
C282Y O 0 3.7475208955584094e-05
mutant O 0 4.102727325516753e-05
. O 0 3.092866791121196e-06

In O 0 3.3686983442748897e-06
this O 0 2.861717973701161e-07
report O 0 2.524200226616813e-07
, O 0 2.123559106337325e-08
we O 0 1.6047206230496158e-08
demonstrate O 0 1.3751444782883482e-07
in O 0 5.8302354943862156e-08
cultured O 0 7.635315341758542e-06
293 O 0 9.382682947034482e-06
cells O 0 2.0404447695909766e-06
overexpressing O 0 1.5136638467083685e-05
wild O 0 2.040606972286696e-07
- O 0 5.140136636327952e-06
type O 0 1.1771709296226618e-06
or O 0 3.694969308298823e-08
mutant O 0 1.1597908269322943e-06
HFE O 0 9.377414244227111e-06
proteins O 0 1.9886838842353427e-08
that O 0 7.717838812482114e-09
both O 0 4.279979481935925e-09
the O 0 4.889176619116142e-09
wild O 0 6.719819367617674e-08
- O 0 3.805205051321536e-05
type O 0 3.746294623852009e-06
and O 0 2.6722520374278247e-07
H63D O 0 0.006797582842409611
HFE O 0 0.00017685437342152
proteins O 0 1.209058950735198e-07
form O 0 6.807893981886082e-08
stable O 0 1.6996014551295957e-07
complexes O 0 6.898293491985896e-08
with O 0 1.636814239702744e-08
the O 0 6.613127823129616e-08
transferrin O 0 0.0004094445030204952
receptor O 0 2.232013503089547e-05
( O 0 4.6471257064695237e-07
TfR O 0 7.656529487576336e-05
) O 0 4.989291255697026e-07
. O 0 8.914155955608294e-07

The O 0 5.303518264554441e-06
C282Y O 0 0.00010905444651143625
mutation O 0 1.3024084182688966e-05
nearly O 0 4.2716018811006506e-07
completely O 0 6.41389533484471e-07
prevents O 0 2.1711336728458264e-07
the O 0 1.9671690054678947e-08
association O 0 1.578185226946971e-08
of O 0 2.2693975587628756e-09
the O 0 3.235694734371464e-08
mutant O 0 7.75604166847188e-06
HFE O 0 2.7358120860299096e-05
protein O 0 2.0801262223812955e-07
with O 0 4.04696827160933e-08
the O 0 4.6602801262451976e-07
TfR O 0 0.001752877957187593
. O 0 5.783920641988516e-06

Studies O 0 2.189227416238282e-05
on O 0 1.7988329545914894e-06
cell O 0 1.1548853763088118e-05
- O 0 4.8647827497916296e-05
associated O 0 5.99403847445501e-07
transferrin O 0 2.3109776066121412e-06
at O 0 4.437270817447825e-08
37 O 0 2.3780810920470685e-07
degrees O 0 3.607744361033838e-07
C O 0 1.4331392321764724e-06
suggest O 0 1.708497308072765e-07
that O 0 3.0512829596318625e-08
the O 0 4.623951710414076e-08
overexpressed O 0 6.161666533444077e-06
wild O 0 2.0868043293376104e-07
- O 0 1.61811458383454e-05
type O 0 1.9153387711412506e-06
HFE O 0 2.3300215616472997e-05
protein O 0 1.1180347314621031e-07
decreases O 0 7.887119579663704e-08
the O 0 1.8197666706853965e-09
affinity O 0 1.1824166534779579e-08
of O 0 2.8676603314181648e-09
the O 0 7.373932930931915e-08
TfR O 0 7.495364843634889e-05
for O 0 5.930695010647469e-07
transferrin O 0 0.0006532460101880133
. O 0 6.628776191064389e-06

The O 0 8.241956493293401e-06
overexpressed O 0 0.00027606048388406634
H63D O 0 0.00028744954033754766
protein O 0 7.583404908473312e-07
does O 0 7.779917154948635e-08
not O 0 1.5110478202018385e-08
have O 0 1.1054789084141703e-08
this O 0 1.552704631535562e-08
effect O 0 1.9074934698437573e-07
, O 0 1.5240557260653986e-08
providing O 0 1.01788657502766e-08
the O 0 3.534448067554763e-09
first O 0 1.5958445231945007e-08
direct O 0 2.9011660629407743e-08
evidence O 0 3.29763807371819e-08
for O 0 7.315261285611996e-09
a O 0 3.864492441607581e-07
functional O 0 4.5093750600244675e-07
consequence O 0 8.405616824802564e-08
of O 0 4.1722620913731134e-09
the O 0 8.787313277025532e-08
H63D O 0 0.012388545088469982
mutation O 0 2.1007523173466325e-05
. O 0 7.828151069588785e-07

Addition O 0 5.687693828804186e-06
of O 0 1.534178295514721e-07
soluble O 0 2.2408401036955183e-06
wild O 0 5.75250965084706e-07
- O 0 8.806166442809626e-05
type O 0 3.9164846384665e-05
HFE O 0 0.0044554127380251884
/ O 0 2.488657264620997e-05
beta2m O 0 4.9292542826151475e-05
heterodimers O 0 2.2016722141415812e-05
to O 0 3.739858414064656e-07
cultured O 0 7.244356766022975e-06
cells O 0 1.7301154002780095e-06
also O 0 4.904328534394153e-07
decreased O 0 1.8635569176694844e-07
the O 0 4.761293581623249e-09
apparent O 0 4.692215327395388e-07
affinity O 0 3.218006128236084e-08
of O 0 2.926150433069097e-09
the O 0 2.3017447503548283e-08
TfR O 0 1.2743355910060927e-05
for O 0 1.2309688379730233e-08
its O 0 1.8594858985920837e-08
ligand O 0 7.291804422493442e-07
under O 0 2.0384499066494755e-07
steady O 0 2.3854115624999395e-06
- O 0 1.9827655705739744e-05
state O 0 2.918931443218753e-07
conditions O 0 1.6755523120082216e-06
, O 0 1.348817679769354e-08
both O 0 6.092075732766489e-09
in O 0 1.4162555572738711e-08
293 O 0 1.0167416348849656e-06
cells O 0 4.0073800278150884e-07
and O 0 7.233597187905616e-08
in O 0 4.7530301117149065e-07
HeLa O 0 0.0003617542970459908
cells O 0 1.4387579540198203e-05
. O 0 1.6687193920006393e-06

Furthermore O 0 3.0829058232484385e-05
, O 0 4.191855111912446e-07
at O 0 3.748384713730957e-08
4 O 0 8.902892290052478e-08
degrees O 0 5.738477284467081e-07
C O 0 1.1449764087956282e-06
, O 0 1.964840201651441e-08
the O 0 1.0536085781609472e-08
added O 0 2.1504486369394726e-07
soluble O 0 2.5651124246905965e-07
complex O 0 4.485228188855217e-08
of O 0 1.6867087282435023e-08
HFE O 0 0.0005277137970551848
/ O 0 7.0532114477828145e-06
beta2m O 0 1.2927538591611665e-05
inhibited O 0 6.515912218674202e-07
binding O 0 1.1302453373218668e-07
of O 0 1.1371926511571928e-08
transferrin O 0 3.5416887840256095e-06
to O 0 2.941813477264077e-07
HeLa O 0 6.0988255427218974e-05
cell O 0 3.6943663872079924e-05
TfR O 0 2.928066714957822e-05
in O 0 3.349031629795718e-08
a O 0 4.2912540720863035e-07
concentration O 0 8.653710210637655e-06
- O 0 1.8037659174297005e-05
dependent O 0 1.8585233192425221e-06
manner O 0 2.8667213882727083e-06
. O 0 3.0147048164508305e-06

Scatchard O 0 0.0009001104044727981
plots O 0 1.8612141502671875e-05
of O 0 8.176223076361566e-08
these O 0 2.6686045373480738e-08
data O 0 4.908829964733741e-08
indicate O 0 6.015719833385447e-08
that O 0 5.0966968423438175e-09
the O 0 8.249640082169662e-09
added O 0 7.329622064844443e-08
heterodimer O 0 1.1329598237352911e-05
substantially O 0 4.262679794919677e-06
reduced O 0 9.272652334857412e-08
the O 0 1.4431340567000461e-08
affinity O 0 1.705957402009517e-07
of O 0 7.30317779584766e-08
TfR O 0 5.1443341362755746e-05
for O 0 5.578039576903393e-07
transferrin O 0 0.0004906484973616898
. O 0 3.881762950186385e-06

These O 0 3.334698476464837e-06
results O 0 1.6687224615452578e-06
establish O 0 2.6229187710669066e-07
a O 0 4.974780836164427e-07
molecular O 0 2.7166800009581493e-06
link O 0 2.566867124187411e-06
between O 0 1.9589322164392797e-07
HFE O 0 0.0011535908561199903
and O 0 1.730912941866336e-07
a O 0 1.8436824689160858e-07
key O 0 5.8388046397794824e-08
protein O 0 3.7386886475587744e-08
involved O 0 1.161707174901494e-08
in O 0 2.190416559244568e-08
iron O 0 0.00027009984478354454
transport O 0 3.3952835565287387e-07
, O 0 1.7348254388593887e-08
the O 0 1.9822119057266718e-08
TfR O 0 8.329753472935408e-05
, O 0 3.438760032281607e-08
and O 0 1.8791741496215764e-08
raise O 0 5.190526053411304e-08
the O 0 4.462084923773091e-09
possibility O 0 2.906605267583018e-08
that O 0 3.023520989131612e-08
alterations O 0 1.3830781426804606e-06
in O 0 3.790797720171213e-08
this O 0 1.0566575170400938e-08
regulatory O 0 1.646512401975997e-07
mechanism O 0 2.0785695653557923e-07
may O 0 3.831081585303764e-07
play O 0 2.0717372706258175e-08
a O 0 5.1454396299277505e-08
role O 0 2.5503128497916805e-08
in O 0 1.345154032605933e-08
the O 0 7.719830108499082e-08
pathogenesis O 0 4.340720261097886e-05
of O 0 1.0700488019210752e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 6.219415081432089e-05
. O 0 2.637965508256457e-06

Genomic O 0 0.00011921043187612668
organization O 0 2.4812918582028942e-06
of O 0 9.446057447348721e-08
the O 0 2.7241961220170197e-07
UBE3A O 0 0.001744856359437108
/ O 0 7.261268910951912e-05
E6 O 0 0.001356323598884046
- O 0 0.09897725284099579
AP O 0 0.0002672811388038099
gene O 0 7.683193530283461e-07
and O 0 1.238885829479841e-07
related O 0 5.42930024494126e-07
pseudogenes O 0 4.374630225356668e-05
. O 0 8.745160812395625e-06

The O 0 1.1099897164967842e-05
UBE3A O 0 0.00040207296842709184
gene O 0 6.0724773902620655e-06
encodes O 0 2.7738569770008326e-06
the O 0 2.0534955069706484e-07
E6 O 0 8.824711403576657e-05
- O 0 0.0005741373752243817
AP O 0 1.7501539332442917e-05
ubiquitin O 0 1.0069916243082844e-06
- O 0 1.1082296396125457e-06
protein O 0 8.578223287258879e-08
ligase O 0 1.208630067139893e-07
and O 0 1.707486596558283e-08
has O 0 1.0704070518841036e-07
recently O 0 5.997183620820579e-07
been O 0 6.240748007257935e-08
shown O 0 9.022056701724068e-08
to O 0 2.8416087261007306e-08
be O 0 2.2902216301190492e-07
mutated O 0 0.0023277224972844124
in O 1 0.8069974780082703
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9996788501739502
who O 0 2.3254953703144565e-05
lack O 0 5.24419306202617e-07
15q11 O 0 2.709505133680068e-05
- O 0 3.0463244911516085e-05
q13 O 0 1.2043805327266455e-05
deletions O 0 4.845785952056758e-06
or O 0 3.5296471878609736e-07
chromosome O 0 3.4312502975808457e-05
15 O 0 2.2597248516831314e-06
paternal O 0 0.00018129100499209017
uniparental B-Disease 0 0.08680912852287292
disomy I-Disease 0 0.007682847790420055
. O 0 8.406516826653387e-06

Previous O 0 6.589743861695752e-05
UBE3A O 0 0.0003804317966569215
cDNA O 0 2.6210680516669527e-05
analysis O 0 2.3756811060593463e-06
has O 0 2.9523110356421967e-07
shown O 0 1.709207850808525e-07
a O 0 1.0162186470097367e-07
coding O 0 6.68076438614662e-07
region O 0 5.579050821324927e-08
of O 0 1.1327223603530001e-08
approximately O 0 1.7554333453517756e-07
2 O 0 6.631746032326191e-07
. O 0 9.900211352942279e-07

6 O 0 5.101723218103871e-05
kb O 0 9.409545600647107e-05
and O 0 4.3043863229286217e-07
a O 0 6.067650701879757e-07
3 O 0 9.264251730201067e-07
- O 0 0.0022216143552213907
untranslated O 0 0.008832890540361404
region O 0 1.7984538089876878e-06
( O 0 7.550686831336861e-08
UTR O 0 1.0980587830999866e-05
) O 0 2.4595122383175294e-08
of O 0 5.979979178505346e-09
< O 0 2.930336222561891e-07
50 O 0 1.1326666538025165e-07
bp O 0 8.871819773048628e-06
, O 0 2.6147040088631002e-08
whereas O 0 3.516952062909695e-08
Northern O 0 2.2829180323924447e-08
analysis O 0 2.0994033178567406e-08
has O 0 7.624726805488535e-08
indicated O 0 1.0115118698195147e-07
mRNA O 0 1.4423966021581691e-08
sizes O 0 1.930519033521705e-08
of O 0 3.2247016168440723e-09
5 O 0 8.298265186112985e-08
- O 0 1.198471636598697e-05
8 O 0 1.118251589105057e-06
kb O 0 9.992307604989037e-05
. O 0 1.106632794289908e-06

We O 0 3.1471199690713547e-06
have O 0 1.7346724234812427e-07
analyzed O 0 1.4023979133526154e-07
additional O 0 2.2558477752454564e-08
cDNA O 0 3.588785091324098e-07
clones O 0 3.923938152183837e-07
and O 0 3.9688138997462374e-08
provide O 0 2.8705020582719953e-08
evidence O 0 2.9597467587905157e-08
for O 0 7.97473020952566e-09
an O 0 9.16116178473203e-08
additional O 0 6.378820103236649e-07
0 O 0 3.8056673474784475e-06
. O 0 2.462677457515383e-06

5 O 0 1.6134472389239818e-05
kb O 0 1.638794128666632e-05
of O 0 6.03951804123426e-08
5 O 0 3.238108945424756e-07
- O 0 2.448185841785744e-05
UTR O 0 0.0003033615357708186
and O 0 2.1154922080768301e-07
> O 0 3.2880419098546554e-07
2 O 0 8.580612131936505e-08
kb O 0 1.4825531025053351e-06
of O 0 2.0999399552579234e-08
3 O 0 1.039260041579837e-06
- O 0 0.0010397388832643628
UTR O 0 0.02776600606739521
. O 0 6.890954409755068e-06

We O 0 4.943594831274822e-06
have O 0 4.1188971522387874e-07
established O 0 5.880941245095528e-08
the O 0 7.121937262155598e-09
genomic O 0 9.94004238918933e-08
organization O 0 1.3770009132940686e-08
of O 0 8.872629742029403e-09
UBE3A O 0 2.241672518721316e-05
and O 0 3.398904624418719e-08
the O 0 5.537057035098769e-09
sequence O 0 2.5223851451983137e-08
of O 0 1.371653368664738e-08
intron O 0 2.4286893676617183e-05
- O 0 9.364805737277493e-05
exon O 0 2.2408516088034958e-05
borders O 0 2.242268010377302e-06
. O 0 1.5899556728982134e-06

We O 0 3.862701305479277e-06
have O 0 3.71359391238002e-07
also O 0 1.4039355278328003e-07
mapped O 0 9.132181730819866e-07
two O 0 2.9206093543621137e-08
highly O 0 5.117779622310081e-08
homologous O 0 7.571800608729973e-08
processed O 0 2.0228007713285479e-07
pseudogenes O 0 2.0461698113649618e-06
, O 0 7.751286545953917e-08
UBE3AP1 O 0 1.3681420568900649e-05
and O 0 1.1811480504775318e-07
UBE3AP2 O 0 4.835477375308983e-05
, O 0 2.854793557105495e-08
to O 0 2.391332465379037e-08
chromosomes O 0 8.358453840173752e-08
2 O 0 7.893455489238477e-08
and O 0 4.9740595642333574e-08
21 O 0 3.0507771953125484e-07
, O 0 2.3105377167098595e-08
respectively O 0 9.295708025547356e-08
, O 0 5.4608597643834855e-09
and O 0 6.233061178306798e-09
determined O 0 8.960865471863144e-08
their O 0 1.1199679406104224e-08
genomic O 0 5.068658879281429e-07
organization O 0 2.092068740466857e-07
. O 0 5.737421133744647e-07

These O 0 3.4165495890192688e-06
results O 0 1.934337660713936e-06
will O 0 5.966401062096338e-08
form O 0 1.6245596867747736e-08
the O 0 6.468600766140753e-09
basis O 0 7.040038330075049e-09
for O 0 6.509915717600734e-09
studies O 0 1.889071121752295e-08
of O 0 8.728176403849375e-09
mutation O 0 5.969383778392512e-07
and O 0 5.3384233922315616e-08
imprinting O 0 5.6095263971656095e-06
of O 0 2.60511200167457e-07
UBE3A O 0 0.0014343959046527743
. O 0 3.7954532672301866e-06

Mutation O 0 0.03464100882411003
spectrum O 0 0.0006406597094610333
and O 0 6.54676478006877e-06
genotype O 0 0.0070149097591638565
- O 0 0.14481307566165924
phenotype O 0 0.29034924507141113
analyses O 0 1.4300156180979684e-05
in O 0 7.207037015177775e-06
Cowden B-Disease 1 0.9990924596786499
disease I-Disease 0 0.04343234375119209
and O 0 7.594459020765498e-06
Bannayan B-Disease 1 0.9476940631866455
- I-Disease 1 0.999942421913147
Zonana I-Disease 1 0.999992847442627
syndrome I-Disease 1 0.99998939037323
, O 0 4.849290462516365e-07
two O 0 4.582061592373066e-06
hamartoma B-Disease 1 0.9994872808456421
syndromes I-Disease 1 0.9782628417015076
with O 0 2.335405042686034e-05
germline O 0 0.14418576657772064
PTEN O 1 0.9302341938018799
mutation O 0 0.000323264132020995
. O 0 5.692908871424152e-06

The O 0 7.241553976200521e-05
tumour B-Disease 1 0.9993923902511597
suppressor O 0 0.005308014340698719
gene O 0 9.372954082209617e-05
PTEN O 0 0.0017859581857919693
, O 0 1.9234261117162532e-07
which O 0 8.732427403401744e-08
maps O 0 4.914385272059008e-07
to O 0 3.041202489839634e-07
10q23 O 0 4.778110087499954e-05
. O 0 1.9830379187624203e-06

3 O 0 2.3078362573869526e-05
and O 0 2.907507337113202e-07
encodes O 0 7.516931646023295e-07
a O 0 2.9751257102361706e-07
403 O 0 5.585203552982421e-07
amino O 0 2.2879576988543704e-07
acid O 0 7.416091420964221e-07
dual O 0 2.00403451344755e-06
specificity O 0 3.798451871261932e-06
phosphatase O 0 0.0006960995960980654
( O 0 4.268861175660277e-08
protein O 0 7.284187830691735e-08
tyrosine O 0 1.164404466180713e-06
phosphatase O 0 6.756755465175956e-05
; O 0 1.281266008845705e-07
PTPase O 0 1.4104469983067247e-06
) O 0 1.4503693357426073e-08
, O 0 1.3301622914241307e-08
was O 0 7.172528739829431e-07
shown O 0 3.0353322699738783e-07
recently O 0 2.849533586868347e-07
to O 0 2.3506551372065587e-08
play O 0 4.054423996535661e-08
a O 0 3.3375604857610597e-07
broad O 0 5.033710408497427e-07
role O 0 3.9343629509858147e-07
in O 0 4.72509952942346e-07
human O 0 2.5585384264559252e-06
malignancy B-Disease 0 0.0024763683322817087
. O 0 5.200388841331005e-06

Somatic O 0 0.009377960115671158
PTEN O 1 0.7133622169494629
deletions O 0 0.0052114613354206085
and O 0 1.743906432238873e-05
mutations O 0 9.994423453463241e-05
were O 0 5.992906721985491e-07
observed O 0 4.848767503062845e-07
in O 0 2.164505588098109e-07
sporadic B-Disease 0 0.01747029274702072
breast I-Disease 1 0.9961967468261719
, I-Disease 0 3.1817722629057243e-05
brain I-Disease 0 0.009222505614161491
, I-Disease 0 5.664217496814672e-06
prostate I-Disease 1 0.8536181449890137
and I-Disease 0 0.006699127610772848
kidney I-Disease 1 0.9997456669807434
cancer I-Disease 1 0.5978707075119019
cell O 0 3.124112481600605e-05
lines O 0 7.185166737144755e-07
and O 0 3.918156465942957e-08
in O 0 3.431971506984155e-08
several O 0 1.0637071312658009e-07
primary O 0 1.530151530459989e-05
tumours B-Disease 1 0.9998419284820557
such O 0 2.0082080709471484e-07
as O 0 5.86586284043733e-05
endometrial B-Disease 1 0.9996819496154785
carcinomas I-Disease 1 0.9999998807907104
, O 1 0.977170467376709
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9870202541351318
thyroid B-Disease 1 0.9999644756317139
tumours I-Disease 1 0.9999963045120239
. O 0 6.7896195105277e-05

In O 0 3.303044422864332e-06
addition O 0 4.823419885724434e-07
, O 0 2.499133699984668e-07
PTEN O 0 0.00040838500717654824
was O 0 5.670362952514552e-06
identified O 0 1.4096910661010043e-07
as O 0 1.5207744397116585e-08
the O 0 2.124393638780475e-08
susceptibility O 0 2.204710472142324e-05
gene O 0 3.9662376138949185e-07
for O 0 2.1169151409594633e-07
two O 0 9.949482773663476e-05
hamartoma B-Disease 1 0.999984622001648
syndromes I-Disease 1 0.9999927282333374
Cowden B-Disease 1 0.9999905824661255
disease I-Disease 1 0.9910125136375427
( O 0 2.8487133363341854e-07
CD B-Disease 0 6.552691047545522e-05
; O 0 7.541000286437338e-07
MIM O 0 5.158959174877964e-05
158350 O 0 3.2402454053226393e-06
) O 0 2.9484102270771473e-08
and O 0 6.895885462654405e-08
Bannayan B-Disease 0 6.336029036901891e-05
- I-Disease 0 0.006324002519249916
Zonana I-Disease 0 0.008095563389360905
( I-Disease 0 1.328973411318657e-07
BZS I-Disease 0 5.569843779085204e-06
) I-Disease 0 4.952919496759023e-08
or I-Disease 0 6.476207659034117e-08
Ruvalcaba I-Disease 0 5.09337660332676e-05
- I-Disease 0 7.437011663569137e-05
Riley I-Disease 0 8.904525020625442e-05
- I-Disease 1 0.9262831211090088
Smith I-Disease 1 0.9566200375556946
syndrome I-Disease 1 0.9994567036628723
( O 0 5.963568128208863e-07
MIM O 0 0.00028709208709187806
153480 O 0 3.928686783183366e-05
) O 0 6.243236612135661e-07
. O 0 1.2768834949383745e-06

Constitutive O 0 0.00048602232709527016
DNA O 0 5.4416246712207794e-05
from O 0 7.028676236586762e-07
37 O 0 1.413359427715477e-06
CD B-Disease 0 9.725767085910775e-06
families O 0 2.001168724063973e-07
and O 0 4.430860300885797e-08
seven O 0 1.6368070987482497e-07
BZS B-Disease 0 3.1884545023785904e-05
families O 0 3.0429259822994936e-07
was O 0 5.048430580245622e-07
screened O 0 4.089727553946432e-06
for O 0 8.216272249228496e-07
germline O 0 0.003789289388805628
PTEN O 1 0.7967774868011475
mutations O 0 0.00013420855975709856
. O 0 4.22475068262429e-06

PTEN O 1 0.9935088157653809
mutations O 1 0.8053662776947021
were O 0 1.939112553372979e-05
identified O 0 2.099048515447066e-06
in O 0 3.673970994100273e-08
30 O 0 3.9292853415417994e-08
of O 0 1.0892350132962747e-08
37 O 0 7.936787937978806e-07
( O 0 3.107763291154697e-08
81 O 0 2.449665316817118e-06
% O 0 2.4050823554944145e-08
) O 0 5.352470022756961e-09
CD B-Disease 0 6.6249144765606616e-06
families O 0 5.2963539332040455e-08
, O 0 9.764491437636025e-09
including O 0 1.654851722321382e-08
missense O 0 7.165539500419982e-06
and O 0 8.475988266809509e-08
nonsense O 0 4.22186258219881e-06
point O 0 8.086939260465442e-07
mutations O 0 1.2904425830129185e-06
, O 0 2.6440218903189816e-08
deletions O 0 5.598621442004514e-07
, O 0 5.3946685341088596e-08
insertions O 0 1.7753902739059413e-06
, O 0 6.309737443643826e-08
a O 0 3.290874701633584e-07
deletion O 0 2.6269210138707422e-05
/ O 0 2.5062749955395702e-06
insertion O 0 1.419527279722388e-06
and O 0 2.2434734603393736e-07
splice O 0 2.7130317903356627e-05
site O 0 1.024283301376272e-05
mutations O 0 1.5608424291713163e-05
. O 0 3.198246758984169e-06

These O 0 6.6820343818108086e-06
mutations O 0 3.091862527071498e-05
were O 0 2.8015085717925103e-07
scattered O 0 1.4948037119211222e-07
over O 0 5.5445845248414116e-08
the O 0 3.022840999733489e-08
entire O 0 8.789324823510469e-08
length O 0 3.032704967154132e-07
of O 0 2.2868663407393797e-08
PTEN O 0 0.0021850201301276684
, O 0 2.1249205062190413e-08
with O 0 5.017469550949727e-09
the O 0 4.820019494644612e-09
exception O 0 1.3658419284467982e-08
of O 0 6.101573135630645e-10
the O 0 1.866392373983672e-09
first O 0 2.1813066908293877e-08
, O 0 8.017434716123262e-09
fourth O 0 2.3476046351333935e-07
and O 0 1.3528401154871972e-07
last O 0 5.315437192621175e-06
exons O 0 2.227683762612287e-05
. O 0 1.5550215266557643e-06

A O 0 2.3482150936615653e-05
hot O 0 9.618531294108834e-06
spot O 0 2.7044761736760847e-06
for O 0 1.646933185384114e-07
PTEN O 0 0.01891782507300377
mutation O 0 3.923009444406489e-06
in O 0 5.852652407156711e-08
CD B-Disease 0 1.9737626644200645e-05
was O 0 1.0129005204362329e-05
identified O 0 1.5779453121922415e-07
in O 0 1.8011345304103088e-08
exon O 0 8.170702017196163e-07
5 O 0 5.7438217737626474e-08
that O 0 6.9185692730400206e-09
contains O 0 4.553807553264733e-09
the O 0 4.473111214764458e-09
PTPase O 0 5.246839691608329e-07
core O 0 7.531585310971423e-08
motif O 0 1.0101448566501858e-07
, O 0 1.1381040110336471e-08
with O 0 9.292442371133802e-09
13 O 0 1.3392863706940261e-08
of O 0 2.0046702076115253e-09
30 O 0 6.846947542271664e-08
( O 0 1.5263218244854215e-08
43 O 0 4.892210654361406e-07
% O 0 2.6116337537018808e-08
) O 0 1.3380531349582725e-08
CD B-Disease 0 8.171833178494126e-05
mutations O 0 4.188469119981164e-06
identified O 0 1.7716325828587287e-07
in O 0 1.3295990974881988e-08
this O 0 1.3623353822822537e-07
exon O 0 3.096405998803675e-05
. O 0 4.136436018598033e-06

Seven O 0 5.9058720580651425e-06
of O 0 2.4435516365883814e-07
30 O 0 3.1590769822287257e-07
( O 0 5.620888643420585e-08
23 O 0 4.917282581118343e-07
% O 0 3.5194151593032075e-08
) O 0 6.740754177059216e-09
were O 0 3.2209719336151466e-08
within O 0 2.5824959948295145e-09
the O 0 4.213817295095623e-09
core O 0 1.276828385243789e-07
motif O 0 3.2547535511184833e-07
, O 0 1.2208537292224264e-08
the O 0 8.03574451424538e-09
majority O 0 3.4116976621589856e-07
( O 0 3.2844043040825e-09
five O 0 4.117853613649913e-09
of O 0 1.4498928724293592e-09
seven O 0 1.0133439865001037e-08
) O 0 1.7859789203100718e-09
of O 0 9.107510856587453e-10
which O 0 6.898912374708743e-08
were O 0 2.8051925937688793e-07
missense O 0 0.0001922821393236518
mutations O 0 2.1574358015641337e-06
, O 0 3.6050270324494704e-08
possibly O 0 8.47293293304574e-08
pointing O 0 1.6686986725744646e-07
to O 0 1.9562769182357442e-08
the O 0 1.3636658913185329e-08
functional O 0 9.060097738711193e-08
significance O 0 1.766688306759079e-08
of O 0 6.0806408797020595e-09
this O 0 6.502162364085962e-08
region O 0 1.1078408306275378e-06
. O 0 2.0787331322935643e-06

Germline O 1 0.5586239099502563
PTEN O 1 0.9926310777664185
mutations O 1 0.7696500420570374
were O 0 2.7939979190705344e-05
identified O 0 1.4641634606959997e-06
in O 0 1.9816447149878513e-08
four O 0 1.8634906950865116e-08
of O 0 5.483519416316085e-09
seven O 0 2.173640467617588e-07
( O 0 4.685530541337357e-08
57 O 0 6.6693778535409365e-06
% O 0 1.4986976282216347e-07
) O 0 1.0097249258933516e-07
BZS B-Disease 0 8.394703036174178e-05
families O 0 8.132275866046257e-07
studied O 0 2.007380089708022e-06
. O 0 2.8545703116833465e-06

Interestingly O 0 0.0013250274350866675
, O 0 1.4285379847933655e-06
none O 0 1.534390463575619e-07
of O 0 4.639958195440386e-09
these O 0 2.0890100316250937e-08
mutations O 0 9.877162483462598e-07
was O 0 1.68630242569634e-06
observed O 0 1.500949053934164e-07
in O 0 1.2665267945521919e-08
the O 0 3.576126417215164e-08
PTPase O 0 2.344424501643516e-05
core O 0 2.6811662792169955e-06
motif O 0 4.84197016703547e-06
. O 0 8.713898296264233e-07

It O 0 4.3671129787981045e-06
is O 0 1.7792994810861273e-07
also O 0 9.23065428537484e-08
worthy O 0 9.876392681462676e-08
of O 0 7.334765239619401e-09
note O 0 1.8063471429741185e-07
that O 0 1.3503568929706944e-08
a O 0 4.412710552514909e-08
single O 0 1.678125585158341e-07
nonsense O 0 7.523070735260262e-07
point O 0 6.401661067911846e-08
mutation O 0 1.6296189642162062e-07
, O 0 7.802457346883784e-09
R233X O 0 9.483024996370659e-07
, O 0 1.763160284440346e-08
was O 0 2.098773137504395e-07
observed O 0 2.564130952009691e-08
in O 0 4.875366776957435e-09
the O 0 1.2880724931108034e-08
germline O 0 3.6294311485107755e-06
DNA O 0 6.722627290400851e-07
from O 0 9.688410962382932e-09
two O 0 2.572350688012648e-08
unrelated O 0 5.799026325803425e-07
CD B-Disease 0 3.195808676537126e-05
families O 0 2.3056429654388921e-07
and O 0 1.1715617631580244e-07
one O 0 5.427586415862606e-07
BZS B-Disease 0 0.0004466215905267745
family O 0 5.511978088179603e-06
. O 0 1.2118264294258552e-06

Genotype O 1 0.9833952188491821
- O 1 0.9200023412704468
phenotype O 1 0.978812038898468
studies O 0 2.2632275431533344e-06
were O 0 2.665130978130037e-07
not O 0 5.177375683729224e-08
performed O 0 4.5699462702941673e-07
on O 0 1.4929857172774064e-07
this O 0 1.0493628188612547e-08
small O 0 2.7491484644315278e-08
group O 0 5.184213591746811e-08
of O 0 2.8726985235039137e-08
BZS B-Disease 0 0.00020404724637046456
families O 0 2.946841505035991e-06
. O 0 1.7495714246251737e-06

However O 0 2.527671131247189e-05
, O 0 1.532970259177091e-06
genotype O 0 0.00014459782687481493
- O 0 0.0007844917709007859
phenotype O 0 0.0019960401114076376
analysis O 0 2.410148169929016e-07
inthe O 0 2.774735548882745e-06
group O 0 1.0254067461801242e-07
of O 0 4.816683496500218e-09
CD B-Disease 0 1.93004852917511e-05
families O 0 1.7690427966954303e-07
revealed O 0 2.0532900180114666e-07
two O 0 6.447746336846194e-09
possible O 0 1.2176305297373347e-08
associations O 0 2.375823759948048e-09
worthy O 0 2.1724504861708738e-08
of O 0 2.486202133056281e-09
follow O 0 4.787796825667101e-08
- O 0 2.818941766236094e-06
up O 0 1.3962365130737453e-07
in O 0 6.42084714286284e-08
independent O 0 3.6260570368540357e-07
analyses O 0 1.2734006986647728e-06
. O 0 7.010012836872193e-07

The O 0 1.7823542748374166e-06
first O 0 1.1946988252020674e-06
was O 0 5.603632189377095e-07
an O 0 7.141936464449827e-08
association O 0 6.468862068231829e-08
noted O 0 1.6173689232346078e-07
in O 0 9.663975397700142e-09
the O 0 5.786329193568918e-09
group O 0 1.7034107457902792e-08
of O 0 5.13756237552343e-09
CD B-Disease 0 0.00013956725888419896
families O 0 9.857476470642723e-07
with O 0 3.0408245947910473e-05
breast B-Disease 1 0.9998997449874878
disease I-Disease 0 0.36453577876091003
. O 0 1.2062172572768759e-05

A O 0 4.77313733426854e-05
correlation O 0 7.060136340442114e-06
was O 0 2.4332668999704765e-06
observed O 0 1.3912348606481828e-07
between O 0 1.0027156882586041e-08
the O 0 2.473093019261796e-08
presence O 0 2.7684924930326815e-07
/ O 0 1.6323938325513154e-06
absence O 0 1.812365866271648e-07
of O 0 9.103746201333252e-09
a O 0 9.335602953797206e-06
PTEN O 0 0.24923604726791382
mutation O 0 1.4322511106001912e-06
and O 0 1.4433791051260414e-08
the O 0 8.12510414505141e-09
type O 0 2.7772983912655036e-07
of O 0 7.977822491511688e-08
breast O 0 0.4310585856437683
involvement O 0 1.7923764971783385e-05
( O 0 2.989217477988859e-07
unaffected O 0 7.592538895551115e-05
versus O 0 0.0001262469741050154
benign O 0 0.004709751345217228
versus O 0 0.002509209094569087
malignant O 1 0.8113452196121216
) O 0 3.0814467208983842e-06
. O 0 2.9677287329832325e-06

Specifically O 0 1.2574767424666788e-05
and O 0 2.9448594318637333e-07
more O 0 6.32853982551751e-08
directly O 0 6.032517774201551e-08
, O 0 2.7593715756779602e-08
an O 0 8.305217136239662e-08
association O 0 6.627270465742185e-08
was O 0 1.2892382983409334e-06
also O 0 1.8388185196727136e-07
observed O 0 3.2417734274758914e-08
between O 0 2.2052801806893285e-09
the O 0 3.3788651876420772e-09
presence O 0 9.402015166415367e-09
of O 0 3.6558780447393247e-09
a O 0 1.6307210444210796e-06
PTEN O 0 0.3581541180610657
mutation O 0 2.5389870643266477e-05
and O 0 1.60064719239017e-05
malignant B-Disease 1 0.9999504089355469
breast I-Disease 1 0.999970555305481
disease I-Disease 1 0.6880201101303101
. O 0 1.7443520846427418e-05

Secondly O 0 0.0006014677346684039
, O 0 1.2115849585825345e-06
there O 0 1.8421569336624088e-07
appeared O 0 2.0329919152572984e-06
to O 0 1.7428847698397476e-08
be O 0 7.972814408674367e-09
an O 0 3.6283569926354176e-08
interdependent O 0 5.846873136761133e-06
association O 0 4.409286091799913e-08
between O 0 1.6032888794370592e-08
mutations O 0 2.448994678161398e-07
upstream O 0 4.7894953780769356e-08
and O 0 1.2258891679550743e-08
within O 0 2.4577291313221394e-09
the O 0 5.5671955934144535e-09
PTPase O 0 2.077046701742802e-06
core O 0 1.593972882574235e-07
motif O 0 1.3867297354863695e-07
, O 0 7.149838943121267e-09
the O 0 2.7896343013367186e-09
core O 0 6.866132906679923e-08
motif O 0 1.0956781437698737e-07
containing O 0 2.11183319720476e-08
the O 0 4.476150117227462e-09
majority O 0 1.5429394295551901e-07
of O 0 1.585879871868201e-08
missense O 0 0.0005328417173586786
mutations O 0 2.862710744011565e-06
, O 0 1.6254213974775666e-08
and O 0 6.375241223821604e-09
the O 0 4.006857956539989e-09
involvement O 0 2.4440103274514513e-08
of O 0 4.3118943970910095e-09
all O 0 6.844359301538816e-09
major O 0 8.547861085617114e-08
organ O 0 2.2221036488190293e-05
systems O 0 1.720080035738647e-06
( O 0 7.556950620823955e-09
central O 0 1.3350729410888107e-08
nervous O 0 1.701260202935373e-06
system O 0 8.736189442970499e-07
, O 0 3.523751729517244e-06
thyroid O 0 0.2165166437625885
, O 0 7.493822067772271e-06
breast O 0 0.1809396892786026
, O 0 1.7634885807638057e-05
skin O 1 0.9996377229690552
and O 1 0.7882179617881775
gastrointestinal O 1 0.9999973773956299
tract O 1 0.9994387030601501
) O 0 2.6007032829511445e-06
. O 0 2.851474164344836e-06

However O 0 3.926275530830026e-05
, O 0 5.571871497522807e-07
these O 0 2.3326069964468843e-08
observations O 0 2.4713395418984874e-07
would O 0 7.176004857001317e-08
need O 0 2.5672580505897713e-08
to O 0 6.925054663042829e-08
be O 0 2.1836217456439044e-07
confirmed O 0 6.981911155889975e-07
by O 0 6.881364367217202e-09
studying O 0 1.5417382925875245e-08
a O 0 4.379657170261453e-08
larger O 0 1.68366494079919e-08
number O 0 8.028559150830006e-09
of O 0 8.20258616585079e-09
CD B-Disease 0 9.010038047563285e-05
families O 0 1.7269176169065759e-06
. O 0 7.206371606116591e-07

Molecular O 0 0.3104219436645508
defects O 1 0.9969121217727661
leading O 0 8.256511137005873e-06
to O 0 2.4236805984401144e-07
human O 0 1.6714972161935293e-07
complement B-Disease 0 7.334169822570402e-06
component I-Disease 0 0.14240674674510956
C6 I-Disease 1 1.0
deficiency I-Disease 1 0.9999982118606567
in O 0 2.3586073893966386e-07
an O 0 1.64239565947355e-07
African O 0 2.1047803500096052e-07
- O 0 5.426799179986119e-05
American O 0 2.8661474971158896e-06
family O 0 4.267389613232808e-06
. O 0 1.2103110975658637e-06

Complement B-Disease 0 0.0010756548726931214
component I-Disease 1 0.6497532725334167
C6 I-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9999990463256836
( O 0 3.5660164030559827e-06
C6D B-Disease 0 0.0017779582412913442
) O 0 6.755171853001229e-07
was O 0 0.0005085633601993322
diagnosed O 0 0.3326461613178253
in O 0 4.4852708214193626e-08
a O 0 1.0971269830406527e-06
16 O 0 4.242671138854348e-07
- O 0 6.847144049970666e-06
year O 0 2.664109501893108e-07
- O 0 2.289848907821579e-06
old O 0 2.240230969619006e-06
African O 0 3.6445733542223024e-08
- O 0 2.1998132524458924e-06
American O 0 5.471725899042212e-07
male O 0 1.0071779797726776e-05
with O 0 6.509915692731738e-05
meningococcal B-Disease 1 0.9999926090240479
meningitis I-Disease 1 0.9999963045120239
. O 0 0.00011893144983332604

The O 0 3.323168493807316e-05
patients O 0 0.009246819652616978
father O 0 1.0393817319709342e-05
and O 0 1.3241647423001268e-07
two O 0 1.1522121212692582e-07
brothers O 0 2.87664101961127e-06
also O 0 1.2431323170858377e-07
had O 0 4.5011901761427e-07
C6D B-Disease 0 3.806101449299604e-05
, O 0 4.209192283610719e-08
but O 0 3.40566650436358e-08
gave O 0 9.320901028786466e-08
no O 0 3.097879641700274e-08
history O 0 1.4878596132916755e-08
of O 0 6.908919658599189e-08
meningitis B-Disease 1 0.9998010993003845
or O 0 5.289791715767933e-07
other O 0 6.456522783082619e-07
neisserial B-Disease 1 0.7374666333198547
infection I-Disease 0 0.05459491163492203
. O 0 9.859283636615146e-06

By O 0 1.8707505660131574e-06
using O 0 8.818675496513606e-07
exon O 0 4.298259682400385e-06
- O 0 1.1182462458236841e-06
specific O 0 5.556738358336588e-08
polymerase O 0 1.141841380558617e-06
chain O 0 1.575704573042458e-06
reaction O 0 4.212646160794975e-07
( O 0 1.3016262734311113e-08
PCR O 0 1.4747353134225705e-06
) O 0 3.708426277171384e-08
/ O 0 1.6392502288908872e-07
single O 0 1.2958895467818365e-07
- O 0 4.0980353332997765e-06
strand O 0 2.337984369660262e-06
conformation O 0 2.8657163397838303e-07
polymorphism O 0 8.01210035206168e-07
as O 0 4.977274148387778e-09
a O 0 2.153941558447059e-08
screening O 0 1.1283670886541586e-07
step O 0 6.151076092919538e-08
and O 0 7.539587620897237e-09
nucleotide O 0 1.4208335841203734e-08
sequencing O 0 1.2790581926935829e-08
of O 0 1.7582295619433808e-09
target O 0 4.034621170490027e-08
exons O 0 2.4963298983493587e-07
, O 0 1.112911007794537e-08
we O 0 4.02026989476667e-09
determined O 0 2.264720144751209e-08
that O 0 6.599302881937774e-09
the O 0 7.667336987537965e-09
proband O 0 6.137334821687546e-06
was O 0 5.880385742784711e-07
a O 0 1.1713215997133375e-07
compound O 0 5.927376491854375e-07
heterozygote O 0 5.657443125528516e-06
for O 0 3.998187381171192e-08
two O 0 4.1559593455531285e-07
C6 O 0 0.050893500447273254
gene O 0 4.103071478311904e-05
mutations O 0 2.6459387299837545e-05
. O 0 2.860230324586155e-06

The O 0 1.59447461101081e-06
first O 0 3.097372029969847e-07
, O 0 5.451267526268566e-08
1195delC O 0 8.970362728177861e-07
located O 0 3.40667369869152e-08
in O 0 2.812561206155806e-08
exon O 0 2.2390734102373244e-06
7 O 0 2.604712108222884e-07
, O 0 8.590236966199427e-09
is O 0 8.211602064989165e-09
a O 0 1.9270578377472702e-07
novel O 0 5.630444775306387e-06
mutation O 0 1.1257525329710916e-06
, O 0 1.1766930541057263e-08
while O 0 4.26192725555552e-09
the O 0 2.555838651829845e-09
second O 0 1.497860324661815e-07
, O 0 2.8523988504502995e-08
1936delG O 0 6.311410629677994e-07
in O 0 2.4097616346807627e-08
exon O 0 9.033194032781466e-07
12 O 0 1.0064869115922193e-07
, O 0 1.8081840025274687e-08
has O 0 1.4463283548593608e-07
been O 0 1.445545052547459e-07
described O 0 3.5908701079279126e-07
before O 0 3.1332131555927845e-08
to O 0 8.086918512617558e-08
cause O 0 1.213816972267523e-06
C6D B-Disease 0 0.00026087326114065945
in O 0 1.3960634248633141e-07
an O 0 1.3323311520707648e-07
unrelated O 0 1.2404126437104424e-06
African O 0 9.995385852334948e-08
- O 0 4.897242433798965e-06
American O 0 6.593297143808741e-07
individual O 0 2.1163963026538113e-07
. O 0 9.078889320335293e-07

Both O 0 3.496845602057874e-05
mutations O 0 0.00021165153884794563
result O 0 1.5548213241345366e-06
in O 0 8.602388561484986e-07
premature O 0 0.0022947436664253473
termination O 0 0.0001034243032336235
codons O 0 1.421005254087504e-05
and O 0 3.1000131457403768e-06
C6 O 0 0.19090741872787476
null O 0 0.004340220242738724
alleles O 0 4.227566023473628e-05
. O 0 7.0187215897021815e-06

Allele O 0 0.0011457408545538783
- O 0 3.2289248338202015e-05
specific O 0 3.172972071752156e-07
PCR O 0 1.8665179595700465e-05
indicated O 0 5.106501248519635e-06
that O 0 1.0940990335939205e-08
the O 0 1.1775552088977292e-08
probands O 0 2.0533208953565918e-05
two O 0 2.6476561743038474e-07
brothers O 0 2.9481232104444643e-06
also O 0 1.6946941627793422e-07
inherited O 0 3.1486399620916927e-07
the O 0 9.891375718495965e-09
1195delC O 0 7.018145879555959e-06
mutation O 0 3.8481891806441126e-07
from O 0 6.057767176770312e-09
their O 0 1.5887076543208423e-08
heterozygous O 0 4.770723080582684e-06
mother O 0 3.055662091355771e-06
and O 0 1.2181229358532164e-08
the O 0 1.204413724309461e-08
1936delG O 0 7.667195859539788e-06
mutation O 0 2.9895224429310474e-07
from O 0 4.299058886658713e-09
their O 0 1.7133588769979724e-08
homozygous O 0 3.1470208341488615e-06
father O 0 6.551224487338914e-06
. O 0 1.6009457226573431e-07
. O 0 7.098470860000816e-07

PAX6 O 1 0.9838082194328308
mutations O 1 0.9436350464820862
reviewed O 0 0.001781519502401352
. O 0 7.561701204394922e-05

Mutations O 0 0.12843380868434906
in O 0 8.10714755061781e-06
PAX6 O 0 0.007163928356021643
are O 0 3.2124933113664156e-07
responsible O 0 3.7727113522123545e-07
for O 0 5.204583430895582e-08
human O 0 3.8326601270455285e-07
aniridia B-Disease 1 0.9999620914459229
and O 0 1.675798444011889e-06
have O 0 3.307963822862803e-07
also O 0 3.42226883276453e-07
been O 0 1.7482577163718815e-07
found O 0 8.149365982035306e-08
in O 0 4.1240656400987064e-07
patients O 0 0.00018477259436622262
with O 0 1.3090752872813027e-05
Peters B-Disease 1 0.9999936819076538
anomaly I-Disease 1 0.9999973773956299
, O 0 7.152875332394615e-05
with O 0 0.14462235569953918
congenital B-Disease 1 0.9999998807907104
cataracts I-Disease 1 0.9999980926513672
, O 0 4.0695740608498454e-05
with O 0 4.1108338336925954e-05
autosomal B-Disease 1 0.9647443890571594
dominant I-Disease 0 0.17294438183307648
keratitis I-Disease 1 0.9980250597000122
, O 0 1.2368404895823915e-06
and O 0 2.659108986335923e-07
with O 0 2.9817199447279563e-06
isolated B-Disease 0 0.0023934117052704096
foveal I-Disease 1 0.9999817609786987
hypoplasia I-Disease 1 0.9999749660491943
. O 0 6.017754276399501e-05

No O 0 1.4321460184874013e-05
locus O 0 1.2988050912099425e-05
other O 0 1.2652282066483167e-07
than O 0 1.3497266593276436e-07
chromosome O 0 7.333442681556335e-06
11p13 O 0 2.213339030276984e-05
has O 0 7.384684863609436e-07
been O 0 2.725373349221627e-07
implicated O 0 1.1303914106974844e-06
in O 0 5.340964435163187e-07
aniridia B-Disease 1 0.9999310970306396
, O 0 3.454940156188968e-07
and O 0 7.728198170298128e-08
PAX6 O 0 0.0001395232102368027
is O 0 7.001434454423361e-08
clearly O 0 1.0927563209861546e-07
the O 0 8.868703993414329e-09
major O 0 2.891211892119827e-08
, O 0 1.7143657160545445e-08
if O 0 1.4341885901103524e-08
not O 0 1.2975659657854521e-08
only O 0 1.2425132034366015e-08
, O 0 3.991215535847914e-08
gene O 0 3.6700353689411713e-07
responsible O 0 1.0938089189949096e-06
. O 0 1.8586615624371916e-06

Twenty O 0 4.7674777306383476e-05
- O 0 3.2639050914440304e-05
eight O 0 7.097888783391681e-07
percent O 0 1.1381066400417694e-07
of O 0 5.503836941755935e-09
identified O 0 1.178488673758693e-06
PAX6 O 0 0.0049311392940580845
mutations O 0 1.2030924153805245e-05
are O 0 4.393503871824578e-08
C O 0 3.909015958925011e-06
- O 0 0.0015465564792975783
T O 0 0.0044235959649086
changes O 0 1.7378432914938458e-07
at O 0 1.548608352663905e-08
CpG O 0 8.719775337340252e-07
dinucleotides O 0 1.005885951599339e-05
, O 0 1.9810137530384964e-08
20 O 0 2.0918207610520767e-08
% O 0 4.114697027546299e-09
are O 0 1.4443284346299379e-09
splicing O 0 3.7734562852165254e-07
errors O 0 4.2317202542108134e-07
, O 0 1.6460845131405222e-08
and O 0 8.020095698668683e-09
more O 0 9.73408820215127e-09
than O 0 4.831573363617281e-08
30 O 0 7.527865619749718e-08
% O 0 1.1567941271550808e-08
are O 0 2.313468971948396e-09
deletion O 0 6.104687599872705e-07
or O 0 2.4902705675344805e-08
insertion O 0 1.706980810922687e-06
events O 0 8.905293498173705e-07
. O 0 2.2804431409895187e-06

There O 0 3.872342858812772e-06
is O 0 2.3306708385462116e-07
a O 0 6.250110686778498e-07
noticeably O 0 0.0001331509556621313
elevated O 0 7.764103065710515e-05
level O 0 4.965850308735753e-08
of O 0 9.829632219293671e-09
mutation O 0 6.896477202644746e-07
in O 0 1.2088648304597882e-08
the O 0 1.0176012921192523e-08
paired O 0 5.728209089284064e-07
domain O 0 1.3828392297909886e-07
compared O 0 8.864361689120415e-08
with O 0 3.793356295744843e-09
the O 0 3.981716734102747e-09
rest O 0 1.300901519840636e-08
of O 0 2.1019825879875498e-09
the O 0 4.3089531942541726e-08
gene O 0 1.185840346806799e-06
. O 0 8.975317200565769e-07

Increased O 0 7.632494816789404e-05
mutation O 0 3.81591817131266e-05
in O 0 1.4537683057369577e-07
the O 0 5.9276533903585005e-08
homeodomain O 0 1.6424955902039073e-05
is O 0 1.489430445644757e-07
accounted O 0 9.078364371362113e-08
for O 0 5.7275078013674374e-09
by O 0 2.113174879525559e-08
the O 0 1.1505014185786422e-07
hypermutable O 0 5.915656947763637e-05
CpG O 0 8.250890459748916e-06
dinucleotide O 0 1.1684062883432489e-05
in O 0 1.9177446120011155e-07
codon O 0 3.4791471534845186e-06
240 O 0 4.132355115871178e-06
. O 0 2.4214100449171383e-06

Very O 0 1.9031602278118953e-05
nearly O 0 1.4660763554275036e-06
all O 0 4.8173102840110005e-08
mutations O 0 1.3927058262197534e-06
appear O 0 4.3281991679577914e-07
to O 0 6.205424369909451e-07
cause O 0 5.241626058705151e-05
loss O 0 1.118994077842217e-05
of O 0 7.136378155081502e-09
function O 0 1.5543491826974787e-08
of O 0 1.3024350487000902e-09
the O 0 9.65933200092195e-09
mutant O 0 1.6008311831683386e-06
allele O 0 3.627170883646613e-07
, O 0 2.7583493267258063e-09
and O 0 2.940574006515817e-09
more O 0 3.977526752407812e-09
than O 0 1.2876966160035863e-08
80 O 0 3.168272755260659e-08
% O 0 4.403040154699056e-09
of O 0 1.714090092086451e-09
exonic O 0 2.370152515140944e-06
substitutions O 0 3.8936653368182306e-07
result O 0 2.0265621003545675e-07
in O 0 1.066714077069264e-07
nonsense O 0 1.3335124094737694e-05
codons O 0 1.7099273463827558e-05
. O 0 2.543122491260874e-06

In O 0 2.331398491151049e-06
a O 0 1.523662490399147e-06
gene O 0 3.5150014809914865e-07
with O 0 2.1416925122252906e-08
such O 0 1.7810540597906765e-08
extraordinarily O 0 2.4747389034018852e-05
high O 0 5.72674480281421e-07
sequence O 0 1.2831957008074824e-07
conservation O 0 2.0040863191184144e-08
throughout O 0 6.6182987978891106e-09
evolution O 0 2.000633791965356e-08
, O 0 1.3183566238694766e-08
there O 0 1.960288287250478e-08
are O 0 1.9964177866427235e-08
presumed O 0 9.732196485856548e-05
undiscovered O 0 0.0001115074337576516
missense O 0 0.0004546724376268685
mutations O 0 3.7437946502905106e-06
, O 0 1.720895070889128e-08
these O 0 2.4275117471717067e-09
are O 0 4.8765289584196125e-09
hypothesized O 0 9.612768963052076e-07
to O 0 5.7531305941438404e-08
exist O 0 1.1213658446251884e-08
in O 0 9.75319291995902e-09
as O 0 1.1830283597191737e-07
- O 0 5.9424277424113825e-05
yet O 0 1.725663423712831e-05
unidentified O 0 6.958703306736425e-05
phenotypes O 0 2.3613836674485356e-05
. O 0 2.0481307672071125e-07
. O 0 7.690612164878985e-07

Genetic O 0 0.00497144041582942
heterogeneity O 0 0.003921525087207556
and O 0 2.7257703550276347e-05
penetrance O 0 0.00022727165196556598
analysis O 0 1.7019338827140018e-07
of O 0 6.914255834544747e-09
the O 0 7.795588174985824e-08
BRCA1 O 0 5.29622811882291e-05
and O 0 2.0875695554423146e-06
BRCA2 O 0 0.0005930780898779631
genes O 0 1.355936547042802e-06
in O 0 1.2258223250682931e-05
breast B-Disease 1 0.9998966455459595
cancer I-Disease 1 0.9901450872421265
families O 0 6.094436685089022e-06
. O 0 3.942967396142194e-06

The O 0 0.000820488203316927
Breast B-Disease 1 0.9999910593032837
Cancer I-Disease 1 0.9999376535415649
Linkage O 0 0.0005613693501800299
Consortium O 0 0.00010145419219043106
. O 0 5.356213023333112e-06

The O 0 2.165539171983255e-06
contribution O 0 1.2876839718956035e-06
of O 0 1.6994360407807108e-07
BRCA1 O 0 0.00021259626373648643
and O 0 7.876355084590614e-06
BRCA2 O 1 0.559513509273529
to O 0 0.1757795214653015
inherited B-Disease 1 0.9999998807907104
breast I-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999997615814209
was O 0 0.015658892691135406
assessed O 0 2.433215740893502e-06
by O 0 6.352509274165641e-08
linkage O 0 2.982752448588144e-06
and O 0 5.569024210672069e-07
mutation O 0 1.2661034816119354e-06
analysis O 0 8.773479720503019e-08
in O 0 4.9330171947303825e-08
237 O 0 2.8148772344138706e-06
families O 0 1.8467285656242893e-07
, O 0 1.568965224407748e-08
each O 0 2.0277359791265326e-09
with O 0 3.795781022830624e-09
at O 0 1.885658562628123e-08
least O 0 5.3401240762696034e-08
four O 0 4.5168295770281475e-08
cases O 0 1.424413085260312e-07
of O 0 5.513080054697639e-07
breast B-Disease 1 0.9999586343765259
cancer I-Disease 1 0.9556170105934143
, O 0 1.018166599919823e-07
collected O 0 6.921608530774392e-08
by O 0 5.241383149723333e-08
the O 0 6.46378339297371e-06
Breast B-Disease 1 0.9999990463256836
Cancer I-Disease 1 0.9999809265136719
Linkage O 0 0.0002240670146420598
Consortium O 0 2.5047263989108615e-05
. O 0 2.843360107362969e-06

Families O 0 3.994542930740863e-05
were O 0 4.1452520349594124e-07
included O 0 1.0705132780230997e-07
without O 0 4.92959379982949e-08
regard O 0 2.7481419806463236e-08
to O 0 3.096969791727133e-08
the O 0 4.720874358099536e-08
occurrence O 0 5.06247545217775e-07
of O 0 2.2492362461434823e-07
ovarian B-Disease 1 0.6886999607086182
or I-Disease 0 1.1197445246580173e-06
other I-Disease 0 1.029417603604088e-06
cancers I-Disease 0 0.022600935772061348
. O 0 1.2152509953011759e-05

Overall O 0 0.0007851053378544748
, O 0 3.888996070600115e-05
disease O 0 9.433497325517237e-05
was O 0 2.310332092747558e-06
linked O 0 2.0029606275784317e-06
to O 0 5.83526400532719e-07
BRCA1 O 0 8.114595402730629e-05
in O 0 8.372814619406199e-08
an O 0 8.9840028749677e-08
estimated O 0 2.3376136937258707e-07
52 O 0 8.62071090068639e-07
% O 0 1.0302328767863855e-08
of O 0 2.1996260368695175e-09
families O 0 5.985355500115475e-08
, O 0 2.743177240915884e-08
to O 0 2.603338771223207e-07
BRCA2 O 0 8.0575053289067e-05
in O 0 3.337235199296629e-08
32 O 0 2.0239275499989162e-07
% O 0 9.155481706102364e-09
of O 0 2.1913011405416682e-09
families O 0 4.172654044509727e-08
, O 0 1.5124722807513535e-08
and O 0 1.319516407249921e-08
to O 0 3.923922875515018e-08
neither O 0 2.605705731184571e-07
gene O 0 5.43042943945693e-08
in O 0 2.1935226968139432e-08
16 O 0 1.296014318086236e-07
% O 0 1.5248785345534088e-08
( O 0 2.947042387901888e-09
95 O 0 6.320529877257286e-08
% O 0 2.4185196068060577e-08
confidence O 0 1.1202781280417184e-07
interval O 0 2.6645210482456605e-07
[ O 0 3.462081110683357e-07
CI O 0 2.4896044124034233e-06
] O 0 2.2736627158792544e-07
6 O 0 8.805164242176033e-08
% O 0 2.4355687244792534e-08
- O 0 8.965223059931304e-06
28 O 0 2.3490796593250707e-05
% O 0 2.990599767827007e-08
) O 0 7.85708653694428e-09
, O 0 2.4777058627023507e-08
suggesting O 0 3.6891213994749705e-07
other O 0 8.845074006558207e-08
predisposition O 0 0.0001243412698386237
genes O 0 7.309549800993409e-06
. O 0 3.8107300497358665e-06

The O 0 7.071477284625871e-06
majority O 0 2.3256261556525715e-05
( O 0 1.6430175264758873e-07
81 O 0 2.972135689560673e-06
% O 0 1.7843863275857075e-08
) O 0 2.6478661485640487e-09
of O 0 2.9770477194546174e-09
the O 0 7.81207916134008e-07
breast B-Disease 1 0.9999009370803833
- I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
families O 0 6.152989726615488e-07
were O 0 1.8712594851422182e-07
due O 0 2.339326528044694e-07
to O 0 4.049238953029999e-07
BRCA1 O 0 0.000171564519405365
, O 0 5.7713638312861804e-08
with O 0 3.739094722732261e-08
most O 0 1.1705900959668725e-07
others O 0 3.836126722944755e-07
( O 0 1.5626813620883695e-08
14 O 0 2.1962067364711402e-07
% O 0 2.2139548860877767e-08
) O 0 1.1014777534512632e-08
due O 0 3.9430472043022746e-07
to O 0 9.012988812173717e-06
BRCA2 O 0 0.03871917352080345
. O 0 6.7233977461000904e-06

Conversely O 0 0.00038253050297498703
, O 0 5.252797450339131e-07
the O 0 3.741527621059504e-08
majority O 0 1.5830941890726535e-07
of O 0 5.460391250267094e-09
families O 0 2.1855253606872793e-08
with O 0 4.3244732239600125e-08
male B-Disease 0 1.9124376194668002e-05
and I-Disease 0 6.5320591602358036e-06
female I-Disease 1 0.7754483819007874
breast I-Disease 1 0.9993019104003906
cancer I-Disease 0 0.2440752536058426
were O 0 4.59498295413141e-07
due O 0 1.1121554734927486e-06
to O 0 7.410827493004035e-06
BRCA2 O 0 0.23726977407932281
( O 0 1.8100789134223305e-07
76 O 0 6.845340976724401e-05
% O 0 4.562317030831764e-07
) O 0 2.4695160050214326e-07
. O 0 1.3657453337145853e-06

The O 0 3.247509312132024e-06
largest O 0 1.6496618400196894e-06
proportion O 0 9.05930846784031e-07
( O 0 7.785602917920187e-08
67 O 0 1.6215062714763917e-06
% O 0 2.3387011438558147e-08
) O 0 2.6173871958690142e-09
of O 0 3.8569747395911236e-09
families O 0 7.224318210319325e-08
due O 0 1.689826518713744e-07
to O 0 9.354918972803716e-08
other O 0 9.415546564639499e-09
genes O 0 3.313924779035915e-08
was O 0 2.009626996368752e-06
found O 0 7.862621487220167e-08
in O 0 1.4066904086007526e-08
families O 0 1.2377021185727699e-08
with O 0 5.733376884364816e-09
four O 0 2.303602641973157e-08
or O 0 6.0752620711923555e-09
five O 0 2.6160208221881476e-08
cases O 0 4.415379706301792e-08
of O 0 1.0287959639754263e-07
female O 1 0.9551121592521667
breast B-Disease 1 0.9999018907546997
cancer I-Disease 1 0.8467324376106262
only O 0 2.0162824512226507e-06
. O 0 2.2137830910651246e-06

These O 0 6.1903738242108375e-06
estimates O 0 4.74927810500958e-06
were O 0 3.1561199875795865e-07
not O 0 2.0500301900483464e-07
substantially O 0 3.226904937037034e-06
affected O 0 4.7457557883490153e-08
either O 0 2.3159602235978127e-08
by O 0 2.917792052414825e-08
changing O 0 7.485542141694168e-08
the O 0 2.9622825081787596e-08
assumed O 0 4.919505499856314e-06
penetrance O 0 5.001953013561433e-06
model O 0 6.456929213527474e-07
for O 0 7.372751298362346e-08
BRCA1 O 0 2.0789810150745325e-05
or O 0 3.681097382468579e-08
by O 0 1.74479062309274e-08
including O 0 4.537406184113024e-08
or O 0 1.3269635701362859e-07
excluding O 0 5.660713668476092e-06
BRCA1 O 0 0.006430920213460922
mutation O 0 1.0496376489754766e-05
data O 0 1.5473925714104553e-06
. O 0 2.1087998902658e-06

Among O 0 2.3038235667627305e-05
those O 0 8.219297455980268e-07
families O 0 8.193674148060381e-07
with O 0 4.299468855606392e-06
disease O 0 0.0015670888824388385
due O 0 8.132980838126969e-06
to O 0 5.0148209993494675e-06
BRCA1 O 0 0.00033093991805799305
that O 0 2.5681720217107795e-07
were O 0 5.87307170007989e-07
tested O 0 2.8984513278373925e-07
by O 0 5.581123119213771e-09
one O 0 3.0994384836446898e-09
of O 0 5.736294772518136e-10
the O 0 3.227587530574283e-09
standard O 0 1.4372643875049107e-07
screening O 0 9.04806043422468e-08
methods O 0 9.488166341498072e-08
, O 0 9.425611580127224e-08
mutations O 0 4.4607980953514925e-07
were O 0 3.9733510703854336e-08
detected O 0 1.8029808757091814e-07
in O 0 1.2373811308918903e-08
the O 0 1.3508722140898044e-08
coding O 0 1.8415703095797653e-07
sequence O 0 1.3503363760491993e-08
or O 0 2.2426673851327905e-09
splice O 0 1.3716329760882218e-07
sites O 0 9.110277865431726e-09
in O 0 4.450372514952505e-09
an O 0 2.6717927426034294e-08
estimated O 0 1.782830736374308e-07
63 O 0 1.0162201533603366e-06
% O 0 1.702744789611188e-08
( O 0 3.2831140028832806e-09
95 O 0 9.039643344976867e-08
% O 0 6.155841703048281e-08
CI O 0 4.197594080324052e-06
51 O 0 7.990239282662515e-06
% O 0 4.602604875003635e-08
- O 0 1.5058285498525947e-05
77 O 0 2.695760122151114e-05
% O 0 1.7437035637613008e-07
) O 0 8.959208486203352e-08
. O 0 6.438814352804911e-07

The O 0 7.887457286415156e-06
estimated O 0 3.4785300613293657e-06
sensitivity O 0 5.708936441806145e-06
was O 0 2.5543547508277697e-06
identical O 0 4.3713114905585826e-07
for O 0 7.669794577225275e-09
direct O 0 3.953416083390948e-08
sequencing O 0 1.1090674689739899e-07
and O 0 2.8344581792794088e-08
other O 0 1.8601385320948793e-08
techniques O 0 6.577151339115517e-07
. O 0 1.5732106248833588e-06

The O 0 3.0043295282666804e-06
penetrance O 0 6.446790212066844e-05
of O 0 6.715680456181872e-07
BRCA2 O 0 0.002223340328782797
was O 0 8.73732460604515e-06
estimated O 0 1.4275381943207321e-07
by O 0 1.6555905091308887e-08
maximizing O 0 1.5605048986344627e-07
the O 0 6.747728775735595e-08
LOD O 0 0.0046233986504375935
score O 0 1.5380749118776293e-06
in O 0 5.463633101498999e-07
BRCA2 O 0 0.002510127378627658
- O 0 0.0048837182112038136
mutation O 0 2.5717632524902e-05
families O 0 8.283969776812228e-08
, O 0 1.3523004049886822e-08
over O 0 1.8907364562892326e-08
all O 0 1.638763436062618e-08
possible O 0 4.661747254885995e-07
penetrance O 0 2.249248427688144e-05
functions O 0 8.626689123047981e-07
. O 0 1.6483456874993863e-06

The O 0 2.166609192499891e-06
estimated O 0 9.012370583150187e-07
cumulative O 0 6.128966560936533e-07
risk O 0 3.873794867104152e-07
of O 0 1.9574196130633936e-07
breast B-Disease 1 0.9985073208808899
cancer I-Disease 1 0.8069906234741211
reached O 0 2.5567112516000634e-06
28 O 0 2.5642980290285777e-06
% O 0 2.45411424515396e-08
( O 0 4.214926629941829e-09
95 O 0 1.118459067583899e-07
% O 0 5.617373233235412e-08
CI O 0 2.211040282418253e-06
9 O 0 6.611097091990814e-07
% O 0 3.011147953202453e-08
- O 0 2.6485374746698653e-06
44 O 0 3.353268311911961e-06
% O 0 1.934798810054872e-08
) O 0 2.155789768920613e-09
by O 0 6.699558241507475e-09
age O 0 7.525755307824511e-08
50 O 0 2.538321552947309e-08
years O 0 2.4978200841019316e-08
and O 0 2.8573866828196515e-08
84 O 0 1.2874604635726428e-06
% O 0 1.808259852964511e-08
( O 0 5.070961872633006e-09
95 O 0 1.1183695391991932e-07
% O 0 5.978954931151748e-08
CI O 0 6.105483407736756e-06
43 O 0 2.2204012566362508e-06
% O 0 2.5052154128957227e-08
- O 0 9.99883468466578e-07
95 O 0 6.515899713122053e-07
% O 0 3.225404654472186e-08
) O 0 6.3349259171729955e-09
by O 0 2.901454010384441e-08
age O 0 2.8749494163093914e-07
70 O 0 2.088321195969911e-07
years O 0 4.772024340127246e-07
. O 0 8.053767714955029e-07

The O 0 2.760078314167913e-05
corresponding O 0 0.04403309151530266
ovarian B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999983310699463
risks O 0 0.0002759197377599776
were O 0 3.871799890475813e-06
0 O 0 1.4582949006580748e-05
. O 0 2.023566139541799e-06

4 O 0 2.2181910026120022e-05
% O 0 6.694399985462951e-07
( O 0 4.034082579096321e-08
95 O 0 3.7296504729056323e-07
% O 0 1.4769435097150563e-07
CI O 0 9.30272744881222e-06
0 O 0 1.5580645822410588e-06
% O 0 4.3153274731366764e-08
- O 0 2.0752552245539846e-06
1 O 0 2.893634700740222e-07
% O 0 1.229654778001077e-08
) O 0 2.9541280532896508e-09
by O 0 9.734199224453732e-09
age O 0 4.702074818396795e-08
50 O 0 1.3681730415271431e-08
years O 0 2.7610878916561887e-08
and O 0 3.5457667024729744e-08
27 O 0 1.0615339078867692e-06
% O 0 1.2534196791591512e-08
( O 0 2.9139308743708625e-09
95 O 0 6.588263090634427e-08
% O 0 5.3448214742957134e-08
CI O 0 7.4331237556179985e-06
0 O 0 8.584644888287585e-07
% O 0 3.4961651351750334e-08
- O 0 3.181375632266281e-06
47 O 0 1.1988408914476167e-05
% O 0 1.9968595665886824e-08
) O 0 3.6134510938978792e-09
by O 0 1.0888736134972987e-08
age O 0 1.7893133019697416e-07
70 O 0 1.359770607223254e-07
years O 0 4.985153054803959e-07
. O 0 7.095026148817851e-07

The O 0 4.041687134304084e-06
lifetime O 0 1.3239314284874126e-05
risk O 0 1.6724872011764091e-06
of O 0 3.8673130120514543e-07
breast B-Disease 1 0.999933123588562
cancer I-Disease 1 0.9919877052307129
appears O 0 5.0220722187077627e-05
similar O 0 1.0893206336959338e-07
to O 0 3.7381465034513894e-08
the O 0 7.782499977793123e-08
risk O 0 3.73630399508329e-07
in O 0 7.249924038887912e-08
BRCA1 O 0 6.916865095263347e-05
carriers O 0 5.239614324636932e-07
, O 0 2.5099790690319423e-08
but O 0 3.178841012640987e-08
there O 0 1.1545149725122883e-08
was O 0 2.2179877134931303e-07
some O 0 3.5758520589013187e-09
suggestion O 0 3.609981291674558e-08
of O 0 2.019661105023829e-09
a O 0 1.388185637551942e-06
lower O 0 1.0082081644213758e-05
risk O 0 4.6149693844199646e-07
in O 0 1.7565032806032832e-07
BRCA2 O 0 0.00018394955259282142
carriers O 0 7.482628916477552e-07
< O 0 3.6056979979548487e-07
50 O 0 2.5586299301494364e-08
years O 0 1.603860866339346e-08
of O 0 1.0699270802660976e-08
age O 0 1.1542394986463478e-06
. O 0 1.2982561656826874e-06

Eye B-Disease 1 0.9883993864059448
movement I-Disease 0 0.0024941330775618553
abnormalities I-Disease 1 0.9852622151374817
correlate O 0 5.431716999737546e-05
with O 0 6.410246442101197e-06
genotype O 0 0.13718995451927185
in O 0 2.5083123546210118e-05
autosomal O 1 0.9964179992675781
dominant O 1 0.7184064388275146
cerebellar B-Disease 1 0.9990293979644775
ataxia I-Disease 1 0.9998689889907837
type I-Disease 0 0.02563672512769699
I I-Disease 0 0.0010367102222517133
. O 0 1.101532416214468e-05

We O 0 9.092033906199504e-06
compared O 0 6.138792286947137e-06
horizontal O 0 7.057429320411757e-05
eye O 0 0.005995780695229769
movements O 0 5.175132628210122e-06
( O 0 1.4455781638389453e-07
visually O 0 2.2821748189016944e-06
guided O 0 2.29680813390587e-06
saccades O 0 0.00020535786461550742
, O 0 1.9866200773321907e-07
antisaccades O 0 4.732491106551606e-06
, O 0 2.3574619589794565e-08
and O 0 1.1129831278822166e-08
smooth O 0 5.119380830365117e-07
pursuit O 0 4.6060392833169317e-07
) O 0 1.4219207145060864e-08
in O 0 2.049957181782247e-08
control O 0 1.8647406250238419e-06
subjects O 0 1.5162784166022902e-06
( O 0 4.518802754205353e-08
n O 0 1.1366176977389841e-06
= O 0 4.745326123156701e-07
14 O 0 7.009852964756647e-08
) O 0 2.367664286850868e-08
and O 0 4.834421361010754e-07
patients O 0 1.5705447367508896e-05
with O 0 1.7427053577989682e-08
three O 0 7.334222118515754e-08
forms O 0 6.017785381118301e-08
of O 0 4.8197183133424915e-08
autosomal O 0 0.097114697098732
dominant O 0 0.0002554666134528816
cerebellar B-Disease 0 0.0029368724208325148
ataxias I-Disease 0 0.002037621336057782
type I-Disease 0 1.1715717846527696e-05
I I-Disease 0 1.2313807019381784e-05
spinocerebellar B-Disease 0 0.0012276270426809788
ataxias I-Disease 0 0.000100387042039074
1 I-Disease 0 1.6945810443758091e-07
and I-Disease 0 5.17070475325454e-08
2 I-Disease 0 2.2724637460669328e-07
( O 0 2.2589995651856043e-08
SCA1 B-Disease 0 3.643480158643797e-05
, O 0 1.6297060767556104e-07
n O 0 9.299837415710499e-07
= O 0 6.929282108103507e-07
11 O 0 9.596512740017715e-08
; O 0 3.6698526884038074e-08
SCA2 B-Disease 0 1.5976993381627835e-05
, O 0 4.7093632105088545e-08
n O 0 3.72225969158535e-07
= O 0 1.804869640409379e-07
10 O 0 1.1415389522539954e-08
) O 0 5.059475061131025e-09
and O 0 1.20780740076043e-07
SCA3 B-Disease 1 0.9999555349349976
/ O 0 2.3260010493686423e-05
Machado B-Disease 0 1.5462992450920865e-05
- I-Disease 0 0.011814306490123272
Joseph I-Disease 0 0.033479850739240646
disease I-Disease 0 0.0007081475923769176
( O 0 2.368816609532587e-07
MJD B-Disease 1 0.999923586845398
) O 0 3.5294655731377134e-07
( O 0 7.7215531746333e-08
n O 0 3.1788099477125797e-06
= O 0 2.151311264242395e-06
16 O 0 5.126127575749706e-07
) O 0 2.2214889838778618e-07
. O 0 6.089221074034867e-07

In O 0 1.0567477147560567e-05
SCA1 B-Disease 0 0.00011260264727752656
, O 0 1.89982500842234e-07
saccade O 0 6.439455319195986e-06
amplitude O 0 2.1530454432650004e-06
was O 0 1.6282469914585818e-06
significantly O 0 6.528451308440708e-07
increased O 0 9.292428160279087e-08
, O 0 6.199485369506874e-08
resulting O 0 5.510314622370061e-07
in O 0 5.609941808870644e-07
hypermetria B-Disease 0 0.0006269498262554407
. O 0 5.4802148952148855e-06

The O 0 3.4614413380040787e-06
smooth O 0 9.661841431807261e-06
pursuit O 0 7.293457201740239e-06
gain O 0 1.965214869414922e-05
was O 0 4.5696138840867206e-05
decreased O 0 2.7643618523143232e-05
. O 0 2.3801123916200595e-06

In O 0 7.728013770247344e-06
SCA2 B-Disease 0 8.82629319676198e-05
, O 0 2.8607192348317767e-07
saccade O 0 1.118202544603264e-05
velocity O 0 5.755715847044485e-06
was O 0 1.0186916370003019e-05
markedly O 0 0.0001298198476433754
decreased O 0 1.9267399693490006e-05
. O 0 1.5457671906915493e-06

The O 0 2.0968536773580126e-06
percentage O 0 1.851892079685058e-06
of O 0 2.6226354421510223e-08
errors O 0 7.017471261860919e-07
in O 0 1.1827756907223375e-07
antisaccades O 0 0.00033713385346345603
was O 0 2.1559470042120665e-05
greatly O 0 3.814595572748658e-07
increased O 0 7.933090273581911e-08
and O 0 3.002991988410031e-08
was O 0 4.96953543915879e-06
significantly O 0 6.141751214272517e-07
correlated O 0 1.9760783231959067e-07
with O 0 1.2486276546042063e-07
age O 0 3.456324975559255e-06
at O 0 3.3855360470624873e-06
disease O 0 0.0008812735322862864
onset O 0 0.0005379525246098638
. O 0 2.2613012333749793e-05

In O 0 2.9338277727219975e-06
addition O 0 2.79345954368182e-07
, O 0 3.662084324673742e-08
a O 0 1.1685902023828021e-07
correlation O 0 1.0553970497539922e-07
between O 0 1.6614553288718525e-08
smooth O 0 4.2196529648208525e-06
pursuit O 0 2.856444098142674e-06
gain O 0 2.052948502750951e-06
and O 0 9.037587567206629e-09
the O 0 2.7478785913359616e-09
number O 0 5.262978497455606e-09
of O 0 7.722595007919608e-09
trinucleotide O 0 6.510411913041025e-05
repeats O 0 9.61638488661265e-06
was O 0 2.766380930552259e-06
found O 0 5.186795419831469e-07
. O 0 6.657822382294398e-07

In O 0 0.00011725082731572911
SCA3 B-Disease 1 0.9983155727386475
, O 0 5.282564870867645e-06
gaze B-Disease 0 0.0001705355243757367
- I-Disease 0 0.0012973301345482469
evoked I-Disease 0 0.007291693706065416
nystagmus I-Disease 0 0.0189363993704319
was O 0 1.0061718967335764e-05
often O 0 1.4496687583687162e-07
present O 0 3.520656832733948e-08
as O 0 2.4506713103278344e-08
was O 0 2.1876780920138117e-07
saccade O 0 2.2430465378420195e-06
hypometria O 0 3.49353717865597e-06
and O 0 2.7923984902145094e-08
smooth O 0 6.45518696273939e-07
pursuit O 0 2.1806927179568447e-06
gain O 0 1.0736643162090331e-05
was O 0 5.022359619033523e-05
markedly O 0 0.00045639771269634366
decreased O 0 3.438208295847289e-05
. O 0 1.6855724425113294e-06

Three O 0 3.6031310628459323e-06
major O 0 5.497333859239006e-07
criteria O 0 1.0262304783736909e-07
, O 0 2.7121028978172035e-08
saccade O 0 1.876765395536495e-06
amplitude O 0 6.156147378533205e-07
, O 0 3.3697922674491565e-08
saccade O 0 1.962606347660767e-06
velocity O 0 7.907376584626036e-07
, O 0 1.814506234154578e-08
and O 0 4.3949350825300826e-09
presence O 0 1.2182297837171063e-08
of O 0 7.880078811695057e-09
gaze B-Disease 0 0.00011199547589058056
- I-Disease 0 0.0022429556120187044
evoked I-Disease 0 0.012854975648224354
nystagmus I-Disease 0 0.0015712588792666793
, O 0 6.110546735271782e-08
permitted O 0 1.5617130699752124e-08
the O 0 4.34065139387485e-09
correct O 0 8.280778018843193e-08
assignment O 0 6.513396044738329e-08
of O 0 3.862098640894374e-09
90 O 0 7.459716044877496e-08
% O 0 5.854882800804262e-09
of O 0 9.79662906352985e-10
the O 0 1.4939223191845485e-08
SCA1 B-Disease 0 0.0001405487273586914
, O 0 3.3444358393808216e-08
90 O 0 2.755080252825337e-08
% O 0 1.8530976753083905e-09
of O 0 5.603883468374704e-10
the O 0 8.74427374952802e-09
SCA2 B-Disease 0 0.00013188995944801718
, O 0 3.57806442252695e-08
and O 0 1.521711645580126e-08
93 O 0 2.4437034085167397e-07
% O 0 4.87132290061254e-09
of O 0 9.642336928905593e-10
the O 0 2.777470626824652e-07
patients O 0 0.001085220486856997
with O 0 1.4660566876045777e-06
SCA3 B-Disease 1 0.9999858140945435
to O 0 7.034711302367214e-07
their O 0 7.56254863176764e-08
genetically O 0 1.0658339988367516e-06
confirmed O 0 4.468175393412821e-05
patient O 0 1.6125271940836683e-05
group O 0 2.508802481315797e-07
and O 0 5.282642945303451e-08
, O 0 4.7026308180875276e-08
therefore O 0 3.78257816180394e-08
, O 0 4.282594900928416e-08
may O 0 1.8648067623416864e-07
help O 0 8.058986367132093e-08
orient O 0 1.2436044926289469e-05
diagnoses O 0 0.0002648313238751143
of O 0 2.3314459696166523e-08
SCA1 B-Disease 0 0.00045838081859983504
, O 0 1.9682616425598098e-07
SCA2 B-Disease 0 4.511092629400082e-05
, O 0 4.9120796319357396e-08
and O 0 4.752621762804665e-08
SCA3 B-Disease 1 0.997183084487915
at O 0 7.101755272742594e-08
early O 0 3.670567139124614e-07
clinical O 0 1.3052194844931364e-06
stages O 0 2.0310199033701792e-07
of O 0 1.1528205945410264e-08
the O 0 8.263539825748012e-07
diseases O 0 0.0001048804770107381
. O 0 4.305375682633894e-07
. O 0 1.3027273553234409e-06

Genetic O 0 0.00048464920837432146
basis O 0 1.8131177057512105e-06
and O 0 2.492321868885483e-07
molecular O 0 2.7827384201373206e-06
mechanism O 0 2.3257755401573377e-06
for O 0 9.324670827481896e-05
idiopathic B-Disease 1 0.9999997615814209
ventricular I-Disease 1 0.999998927116394
fibrillation I-Disease 1 0.9999998807907104
. O 0 0.0015410262858495116

Ventricular B-Disease 1 0.9993852376937866
fibrillation I-Disease 1 0.9999500513076782
causes O 0 0.0013977508060634136
more O 0 5.479726610246871e-07
than O 0 1.532948203930573e-07
300 O 0 7.578171334898798e-08
, O 0 4.9260780343729493e-08
000 O 0 1.0975396946832916e-07
sudden O 0 1.781293576641474e-05
deaths O 0 1.0977551937685348e-05
each O 0 1.5890652349526135e-08
year O 0 5.235578015572173e-08
in O 0 2.0221326835212494e-08
the O 0 6.245582540032046e-08
USA O 0 6.064797162252944e-06
alone O 0 2.596190824988298e-06
. O 0 5.104336651129415e-07

In O 0 2.872424602173851e-06
approximately O 0 4.991880473426136e-07
5 O 0 2.173240432057355e-07
- O 0 4.049117706017569e-06
12 O 0 3.2277867489938217e-07
% O 0 7.468482721151304e-09
of O 0 9.88360282505596e-10
these O 0 1.2979917585198564e-08
cases O 0 2.7243183353675704e-07
, O 0 7.417690284228229e-08
there O 0 3.4566269846436626e-08
are O 0 8.929571748694798e-09
no O 0 1.2930624393447943e-07
demonstrable O 0 0.006045516114681959
cardiac O 1 0.9699752926826477
or O 0 4.597946201556624e-07
non O 0 1.983072024813737e-06
- O 1 0.9119613170623779
cardiac O 1 0.9999250173568726
causes O 0 2.531796599214431e-05
to O 0 2.39013388636522e-07
account O 0 4.641589157472481e-08
for O 0 3.306756646281883e-09
the O 0 6.993664758425666e-09
episode O 0 3.737231054401491e-06
, O 0 2.5590592755975194e-08
which O 0 2.8004153662664066e-08
is O 0 8.010361085553086e-08
therefore O 0 1.3105750440445263e-07
classified O 0 7.091562679306662e-07
as O 0 7.283113518496975e-05
idiopathic B-Disease 1 0.9999997615814209
ventricular I-Disease 1 0.9999995231628418
fibrillation I-Disease 1 1.0
( O 0 0.0005241020699031651
IVF B-Disease 1 0.9999700784683228
) O 0 4.188684670225484e-06
. O 0 1.4835827641945798e-06

A O 0 3.067571378778666e-05
distinct O 0 4.061842446390074e-06
group O 0 9.472774991081678e-07
of O 0 1.1843852831816548e-07
IVF B-Disease 1 0.9999985694885254
patients O 1 0.9867236018180847
has O 0 1.0169949746341445e-05
been O 0 2.3118035130664794e-07
found O 0 5.1918927823635386e-08
to O 0 2.3561764095347826e-08
present O 0 3.7526412199895276e-08
with O 0 2.9321409300564483e-08
a O 0 3.373967956576962e-06
characteristic O 0 1.341793904430233e-05
electrocardiographic O 0 0.0010568207362666726
pattern O 0 3.0075978429522365e-05
. O 0 2.6288064418622525e-06

Because O 0 4.467224243853707e-06
of O 0 2.7532310653555214e-08
the O 0 1.116376324716839e-08
small O 0 1.9835923126265698e-08
size O 0 2.5350749055519373e-08
of O 0 2.7570341565308354e-09
most O 0 2.2073349370543838e-08
pedigrees O 0 4.5434552475853707e-07
and O 0 3.994909292259763e-08
the O 0 1.9350720137367716e-08
high O 0 9.130161515713553e-07
incidence O 0 4.600512511387933e-06
of O 0 4.051154078865693e-08
sudden B-Disease 0 0.05862926319241524
death I-Disease 0 0.08939069509506226
, O 0 1.1232500440883086e-07
however O 0 1.631214416875082e-07
, O 0 3.080903354657494e-08
molecular O 0 3.144685081224452e-07
genetic O 0 7.046381256259338e-08
studies O 0 9.130717515404285e-09
of O 0 9.475882301046568e-09
IVF B-Disease 1 0.9999327659606934
have O 0 4.335282028478105e-06
not O 0 6.141358710465283e-08
yet O 0 2.321936420912607e-07
been O 0 4.5093318590261333e-07
done O 0 9.11422375793336e-07
. O 0 1.2975184517927119e-06

Because O 0 0.00043317885138094425
IVF B-Disease 1 0.9998032450675964
causes O 0 0.06758754700422287
cardiac O 1 0.9848607778549194
rhythm O 0 0.020573830232024193
disturbance O 0 0.0001568295992910862
, O 0 1.2376459324059397e-07
we O 0 2.8089102599437865e-08
investigated O 0 3.3563190982022206e-07
whether O 0 8.884622815230614e-08
malfunction O 0 1.9997880372102372e-05
of O 0 1.446258934834077e-08
ion O 0 1.689432428975124e-05
channels O 0 1.6030327287808177e-06
could O 0 1.3791097899229499e-06
cause O 0 1.4268060795075144e-06
the O 0 4.4236406893105595e-07
disorder O 0 0.02063499018549919
by O 0 2.9520847988351306e-08
studying O 0 2.5287758376180136e-07
mutations O 0 5.345096951714368e-07
in O 0 2.073880089881186e-08
the O 0 1.5315221446599026e-07
cardiac O 0 0.37842029333114624
sodium O 0 0.006391729693859816
channel O 0 5.690786201739684e-05
gene O 0 3.5808134271064773e-06
SCN5A O 0 7.037020259303972e-05
. O 0 1.635769308450108e-06

We O 0 3.566567556845257e-06
have O 0 3.2670340033291723e-07
now O 0 5.5483290850588673e-08
identified O 0 1.0981448639313385e-07
a O 0 3.3572956681382493e-07
missense O 0 0.00029924209229648113
mutation O 0 2.5834785901679425e-06
, O 0 2.585385416864483e-08
a O 0 7.483372144179157e-08
splice O 0 9.369074177811854e-06
- O 0 0.00010804935300257057
donor O 0 1.8827923895514687e-06
mutation O 0 3.19106288770854e-06
, O 0 1.7819306918909206e-08
and O 0 2.807528431958417e-08
a O 0 7.658769391127862e-06
frameshift O 1 0.5212572813034058
mutation O 0 2.064485215669265e-06
in O 0 1.909145552758673e-08
the O 0 2.6549374254614122e-08
coding O 0 1.1609173498072778e-06
region O 0 4.869300340715199e-08
of O 0 7.325174244954269e-09
SCN5A O 0 9.948590741259977e-05
in O 0 1.0287389784480183e-07
three O 0 5.2039388265257e-07
IVF B-Disease 1 0.9994482398033142
families O 0 2.1724811176682124e-06
. O 0 7.654495561837393e-07

We O 0 1.878839157143375e-06
show O 0 5.679643777511956e-07
that O 0 6.098925808828426e-08
sodium O 0 1.3050314464635449e-06
channels O 0 1.2794686199413263e-07
with O 0 2.0430482194910837e-08
the O 0 4.449967505593122e-08
missense O 0 5.913817585678771e-05
mutation O 0 3.5389571166888345e-06
recover O 0 2.052631543847383e-06
from O 0 4.806407005730762e-08
inactivation O 0 6.728227890562266e-05
more O 0 8.505640636258249e-08
rapidly O 0 1.0126141347654993e-07
than O 0 1.944187744129522e-08
normal O 0 2.2976960778464672e-08
and O 0 8.548133756391962e-09
that O 0 2.2655886056099916e-08
the O 0 1.301770709005723e-07
frameshift O 0 0.2143901139497757
mutation O 0 7.181959063018439e-06
causes O 0 4.0949859680949885e-07
the O 0 3.01119378320891e-08
sodium O 0 1.3082852092338726e-05
channel O 0 1.2508354529927601e-06
to O 0 1.2969052498590372e-08
be O 0 1.1227912821709651e-08
non O 0 5.570023375867095e-08
- O 0 3.301631295471452e-05
functional O 0 1.7159354683826678e-05
. O 0 2.603107986942632e-06

Our O 0 1.324741151620401e-05
results O 0 3.587177843655809e-06
indicate O 0 9.638848723625415e-07
that O 0 1.1393533583259341e-07
mutations O 0 9.74553245214338e-07
in O 0 5.65963844678663e-08
cardiac O 0 0.001838831463828683
ion O 0 0.00018993714184034616
- O 0 0.00021749215375166386
channel O 0 5.8404530136613175e-06
genes O 0 4.066653147560828e-08
contribute O 0 9.453299476547272e-09
to O 0 1.1084833495544899e-08
the O 0 1.9323794120396087e-08
risk O 0 1.5817600740319904e-07
of O 0 3.179587082513535e-08
developing O 0 2.92723211714474e-06
IVF B-Disease 1 0.9998229146003723
. O 0 2.996583589265356e-06
. O 0 1.196180960505444e-06

Molecular O 0 0.00022565977997146547
heterogeneity O 0 0.0002748749975580722
in O 0 4.8535280257056e-06
mucopolysaccharidosis B-Disease 0 0.0006630679126828909
IVA I-Disease 0 0.000517176347784698
in O 0 8.990634796646191e-07
Australia O 0 3.7167970390328264e-07
and O 0 7.782410449408417e-08
Northern O 0 4.150738845964952e-07
Ireland O 0 4.856852910961607e-07
: O 0 2.5470704656527232e-08
nine O 0 7.96284851389828e-08
novel O 0 9.993715366363176e-07
mutations O 0 4.183731618923048e-07
including O 0 2.504417651039148e-08
T312S O 0 8.965916094894055e-06
, O 0 4.8540371722083364e-08
a O 0 2.3564467710457393e-07
common O 0 1.25253947658166e-07
allele O 0 2.3009210963209625e-06
that O 0 8.474226120824824e-08
confers O 0 3.780616680160165e-05
a O 0 0.0004282529407646507
mild O 1 0.9983395338058472
phenotype O 1 0.9915664792060852
. O 0 8.137286386045162e-06

Mucopolysaccharidosis B-Disease 1 0.9398622512817383
IVA I-Disease 1 0.9971086382865906
( O 0 0.007808275055140257
MPS B-Disease 1 0.999987006187439
IVA I-Disease 1 0.9999545812606812
) O 0 1.4360877003127825e-06
is O 0 3.803697552484664e-07
an O 0 4.832877039007144e-06
autosomal B-Disease 1 0.9986515641212463
recessive I-Disease 1 0.9995269775390625
lysosomal I-Disease 1 0.998054027557373
storage I-Disease 1 0.9964305758476257
disorder I-Disease 1 0.9994388222694397
caused O 0 0.0001094657854991965
by O 0 4.1131033867713995e-07
a O 0 0.0057505653239786625
genetic B-Disease 1 0.9999206066131592
defect I-Disease 1 0.999873161315918
in O 0 5.034185051044915e-07
N O 0 1.7345779269817285e-05
- O 0 3.574889342417009e-05
acetylgalactosamine O 0 0.0002174602122977376
- O 0 0.00014050852041691542
6 O 0 3.6363355775392847e-06
- O 0 0.0042244913056492805
sulfate O 0 0.13963735103607178
sulfatase O 0 0.0004471951979212463
( O 0 3.5789895491689094e-07
GALNS O 0 5.244846033747308e-05
) O 0 3.814966760273819e-07
. O 0 6.670005632258835e-07

Previous O 0 2.8462351110647433e-05
studies O 0 2.1060022845631465e-06
of O 0 1.106749252244299e-07
patients O 0 2.1333657059585676e-05
from O 0 3.0565018960260204e-08
a O 0 1.09300503936538e-06
British O 0 6.598893378395587e-05
- O 0 0.0003619194030761719
Irish O 0 5.612255336018279e-06
population O 0 2.7821382531101335e-08
showed O 0 1.271557010795732e-07
that O 0 7.0409242880487e-09
the O 0 1.884701994470106e-08
I113F O 0 3.979986649937928e-05
mutation O 0 5.172559554011968e-07
is O 0 1.0011104834006801e-08
the O 0 5.069453301587146e-09
most O 0 1.1582203640614352e-08
common O 0 4.083776516949911e-08
single O 0 2.0123040940234205e-06
mutation O 0 8.353276825801004e-06
among O 0 1.5879977581789717e-06
MPS B-Disease 1 0.9999982118606567
IVA I-Disease 1 0.9999997615814209
patients O 1 0.9358307123184204
and O 0 4.3676070049514237e-07
produces O 0 3.152869794575963e-06
a O 0 5.920486728427932e-05
severe O 1 0.9977738261222839
clinical O 1 0.9535303711891174
phenotype O 1 0.9946953654289246
. O 0 1.0298486813553609e-05

We O 0 3.94760263588978e-06
studied O 0 3.2833054319780786e-06
mutations O 0 4.619853370968485e-06
in O 0 4.963899513654724e-08
the O 0 5.8359432841825765e-08
GALNS O 0 0.00017574455705471337
gene O 0 5.430687792795652e-07
from O 0 2.6515165174600952e-08
23 O 0 2.995635668412433e-07
additional O 0 6.690570444334298e-07
MPS B-Disease 1 0.9999929666519165
IVA I-Disease 1 0.9999985694885254
patients O 1 0.9426818490028381
( O 0 4.383885965353329e-08
15 O 0 6.289911169687912e-08
from O 0 8.199582346435363e-09
Australia O 0 2.4481627391992333e-08
, O 0 1.2745722699492035e-08
8 O 0 2.4437632362150907e-08
from O 0 8.441007004478251e-09
Northern O 0 1.0414811413284042e-07
Ireland O 0 1.0466327893254856e-07
) O 0 8.792540029389784e-09
, O 0 8.337829981996947e-09
with O 0 1.5771652428497873e-08
various O 0 3.4763498746315236e-08
clinical O 0 0.00044875021558254957
phenotypes O 0 0.1044204905629158
( O 0 3.0263893791016017e-07
severe O 0 0.03514644876122475
, O 0 8.1771719351309e-07
16 O 0 2.233739223811426e-06
cases O 0 9.919225476551219e-07
; O 0 1.249429288918691e-07
intermediate O 0 3.869024567393353e-07
, O 0 4.413181997620086e-08
4 O 0 5.963420335319825e-07
cases O 0 1.0117296369571704e-06
; O 0 2.915455752372509e-06
mild O 0 0.4647238552570343
, O 0 2.5095901037275326e-06
3 O 0 1.8592661490401952e-06
cases O 0 1.282771336263977e-06
) O 0 7.196674118858937e-07
. O 0 1.828317863328266e-06

We O 0 6.849874353065388e-06
found O 0 5.831642511111568e-07
two O 0 7.001675328410784e-08
common O 0 1.7055961620826565e-07
mutations O 0 7.650306201867352e-07
that O 0 1.9829530018000696e-08
together O 0 2.5229624611711188e-08
accounted O 0 6.52931646527577e-08
for O 0 1.0754737544971249e-08
32 O 0 9.896060504388515e-08
% O 0 3.316749763726534e-09
of O 0 8.08348721292873e-10
the O 0 1.3490930150794611e-08
44 O 0 4.218841809233709e-07
unrelated O 0 4.564283813124348e-07
alleles O 0 1.1315810297674034e-06
in O 0 2.2462630511199677e-07
these O 0 8.662972845741024e-07
patients O 0 0.0004431217093952
. O 0 5.635612524201861e-06

One O 0 5.551146387006156e-06
is O 0 2.3185221209587326e-07
the O 0 5.197857433358877e-08
T312S O 0 1.9476232409942895e-05
mutation O 0 2.8973895496164914e-06
, O 0 3.70145869510452e-08
a O 0 2.20194053213163e-07
novel O 0 4.010425982414745e-06
mutation O 0 6.954605282771809e-07
found O 0 2.9418997016250614e-08
exclusively O 0 9.864137240356285e-08
in O 0 4.282035490632552e-07
milder O 1 0.988470196723938
patients O 0 0.4878332316875458
. O 0 3.89126626032521e-06

The O 0 9.509415122010978e-07
other O 0 3.7899809512964566e-08
is O 0 2.2465473037414085e-08
the O 0 2.0083032126194666e-08
previously O 0 4.3613053435365146e-07
described O 0 8.161683808793896e-07
I113F O 0 1.021418256641482e-06
that O 0 3.760623101811689e-08
produces O 0 4.039681016365648e-07
a O 0 1.1290917427686509e-05
severe O 1 0.9616896510124207
phenotype O 1 0.9284287095069885
. O 0 9.205762580677401e-06

The O 0 3.3841511140053626e-06
I113F O 0 2.3718876036582515e-05
and O 0 3.282972329543554e-07
T312S O 0 1.1818452549050562e-05
mutations O 0 2.2168928808241617e-06
accounted O 0 1.6232719701747556e-07
for O 0 2.1455194954000945e-08
8 O 0 1.2570329488426069e-07
( O 0 1.9519124094813378e-08
18 O 0 1.6291031101900444e-07
% O 0 9.5675414257812e-09
) O 0 2.3485475786344523e-09
and O 0 2.279102417901413e-08
6 O 0 1.7448547851017793e-07
( O 0 9.278397605783084e-09
14 O 0 7.483043873435236e-08
% O 0 5.160218474742351e-09
) O 0 2.022968903503397e-09
of O 0 3.5856868585426582e-09
44 O 0 3.727929254182527e-07
unrelated O 0 1.2722814517474035e-06
alleles O 0 1.6185771301024943e-06
, O 0 3.4814897276191914e-07
respectively O 0 3.6360302146931645e-06
. O 0 1.835697730712127e-06

The O 0 4.524431460595224e-06
relatively O 0 5.100636826682603e-06
high O 0 5.423906941359746e-07
residual O 0 6.544842563016573e-06
GALNS O 0 3.0758521461393684e-05
activity O 0 1.0865317534580754e-07
seen O 0 1.0349837964440667e-07
when O 0 1.8667423162810337e-08
the O 0 9.332087103075537e-09
T312S O 0 6.310290814326436e-07
mutant O 0 4.920726155432931e-07
cDNA O 0 1.672364504656798e-07
is O 0 3.363460976402166e-08
overexpressed O 0 1.0871075346585712e-06
in O 0 3.242552537585652e-08
mutant O 0 4.519157300819643e-06
cells O 0 4.120865355616843e-07
provides O 0 4.083799609588823e-08
an O 0 2.1797553984015394e-08
explanation O 0 1.8318208105938538e-07
for O 0 2.0842181314151276e-08
the O 0 3.995424435743189e-07
mild O 1 0.9985648989677429
phenotype O 1 0.9989945292472839
in O 0 1.6464431610074826e-05
patients O 0 0.000119954020192381
with O 0 1.7442059174754831e-07
this O 0 5.316560987012053e-07
mutation O 0 2.0582945580827072e-05
. O 0 1.4439126516663237e-06

The O 0 5.751703611167613e-07
distribution O 0 9.746130302801248e-08
and O 0 1.8424023195962036e-08
relative O 0 5.954464654678304e-08
frequencies O 0 2.768465279245902e-08
of O 0 7.930556766844177e-10
the O 0 5.637979416661665e-09
I113F O 0 1.4528093288390664e-06
and O 0 9.496023523070107e-08
T312S O 0 1.4708568414789625e-05
mutations O 0 1.1353426998539362e-06
in O 0 2.1730636845518347e-08
Australia O 0 3.960812833270211e-08
corresponded O 0 1.0290215612940301e-07
to O 0 1.8944618318528228e-08
those O 0 7.738874430174292e-09
observed O 0 3.374088208829562e-08
in O 0 1.2757689127340655e-08
Northern O 0 8.643409188380247e-08
Ireland O 0 1.4974661155520153e-07
and O 0 1.4894440347745785e-08
are O 0 3.0275015827641027e-09
unique O 0 7.51721618286183e-09
to O 0 1.6624602139359013e-08
these O 0 3.864132125386277e-09
two O 0 1.2988833120175514e-08
populations O 0 1.2759198142475725e-08
, O 0 7.083435615840017e-09
suggesting O 0 7.289858672265837e-08
that O 0 1.9178902022076727e-08
both O 0 2.8173932520303424e-08
mutations O 0 3.4159199913119664e-07
were O 0 6.854526191091281e-08
probably O 0 1.5284608423371537e-07
introduced O 0 8.594076206236423e-08
to O 0 2.754008399108443e-08
Australia O 0 1.6024237936562713e-08
by O 0 1.1464659444015979e-08
Irish O 0 8.31927948752309e-08
migrants O 0 4.4838081691978005e-08
during O 0 2.1117164905604113e-08
the O 0 1.0496590263642247e-08
19th O 0 2.3915336555546673e-07
century O 0 8.942840850068023e-07
. O 0 1.8373616512690205e-06

Haplotype O 1 0.9127863645553589
analysis O 0 1.3653070709551685e-05
using O 0 1.05092703961418e-06
6 O 0 8.249515985880862e-07
RFLPs O 0 5.162242814549245e-06
provides O 0 8.042618304671123e-08
additional O 0 2.7756824394487012e-08
data O 0 1.568372809401808e-08
that O 0 8.533277195965638e-09
the O 0 1.093594104162321e-08
I113F O 0 1.0343150279368274e-05
mutation O 0 7.646607969036268e-07
originated O 0 5.528659841047556e-08
from O 0 1.1539645683456001e-08
a O 0 3.3994888326560613e-07
common O 0 6.043073312866909e-07
ancestor O 0 6.382303581631277e-06
. O 0 2.6768227598950034e-06

The O 0 3.410572844586568e-06
other O 0 1.448083963850877e-07
9 O 0 5.488481065185624e-07
novel O 0 1.4457190218308824e-06
mutations O 0 4.738804818771314e-06
identified O 0 2.867214448087907e-07
in O 0 1.9452929933549967e-08
these O 0 3.4057965336842244e-08
23 O 0 1.904605596791953e-05
patients O 0 1.2937576684635133e-05
were O 0 5.142261016999328e-08
each O 0 5.355962784392432e-09
limited O 0 2.5836799366629748e-08
to O 0 2.5709576689791902e-08
a O 0 5.955758979325765e-07
single O 0 7.738323802186642e-06
family O 0 4.48292848886922e-06
. O 0 9.925413451128406e-07

These O 0 2.1063719941594172e-06
data O 0 3.02702716226122e-07
provide O 0 5.385138734936845e-08
further O 0 2.1413494977196024e-08
evidence O 0 4.2528025545607306e-08
for O 0 2.1422073004373487e-08
extensive O 0 6.600626534236653e-07
allelic O 0 2.6825222448678687e-05
heterogeneity O 0 8.493162749800831e-05
in O 0 2.1757859940407798e-05
MPS B-Disease 1 0.9999804496765137
IVA I-Disease 1 0.9999104738235474
in O 0 1.3950552784081083e-05
British O 0 0.00042597000719979405
- O 0 0.024606745690107346
Irish O 0 0.004060658626258373
patients O 0 9.02334795682691e-05
and O 0 5.109528089519699e-08
provide O 0 6.790580897586551e-08
evidence O 0 4.8797133445077634e-08
for O 0 5.519384949081996e-09
their O 0 2.053902292686871e-08
transmission O 0 5.149077537680569e-07
to O 0 4.6328150204999474e-08
Australia O 0 3.11723802326469e-08
by O 0 2.6076067527469604e-08
British O 0 1.5517534848186187e-06
- O 0 8.142052138282452e-06
Irish O 0 1.3150287259122706e-06
migrants O 0 2.414215316548507e-07
. O 0 7.392140588535767e-08
. O 0 6.764841486983642e-07

Identification O 0 5.381193204812007e-06
of O 0 3.6410511938811396e-07
constitutional O 0 3.855995964840986e-05
WT1 O 1 0.953044056892395
mutations O 0 0.0003803247818723321
, O 0 1.9163661590937409e-07
in O 0 3.832773529666156e-07
patients O 0 1.6306777979480103e-05
with O 0 1.901963742056978e-06
isolated O 0 0.011196566745638847
diffuse B-Disease 1 0.999934196472168
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 0.9999998807907104
, O 0 1.924348680404364e-06
and O 0 8.799221262734136e-08
analysis O 0 9.48013436641304e-08
of O 0 7.224731746191537e-08
genotype O 0 0.059391558170318604
/ O 0 0.0034173489548265934
phenotype O 0 0.07491409778594971
correlations O 0 2.41631687458721e-06
by O 0 2.407124632952673e-08
use O 0 2.353616146422155e-08
of O 0 5.422653437392455e-09
a O 0 9.215198133460945e-07
computerized O 0 0.0003863596066366881
mutation O 0 2.5483774152235128e-05
database O 0 2.3600816803082125e-06
. O 0 1.6358441143893288e-06

Constitutional O 0 0.0002354440512135625
mutations O 0 0.00015244165842887014
of O 0 7.316646133403992e-08
the O 0 1.6926072987644147e-07
WT1 O 0 0.0002712407149374485
gene O 0 5.538511231861776e-07
, O 0 3.467158649073099e-08
encoding O 0 1.0269197048273782e-07
a O 0 8.534678954674746e-07
zinc O 0 0.00010626539005897939
- O 0 2.621000930957962e-06
finger O 0 2.0268146272428567e-06
transcription O 0 1.7152758857719164e-07
factor O 0 4.6639168971296385e-08
involved O 0 7.37262482175538e-08
in O 0 7.677348889956193e-07
renal O 1 0.997409999370575
and O 0 2.5559153073118068e-05
gonadal O 0 0.00019953840819653124
development O 0 1.0567788422122248e-07
, O 0 6.575871935865507e-08
are O 0 7.572735327698865e-09
found O 0 3.325765618455989e-08
in O 0 4.276521892165874e-08
most O 0 1.296831896979711e-06
patients O 0 5.121792491991073e-05
with O 0 6.435440354835009e-06
Denys B-Disease 1 0.9998451471328735
- I-Disease 1 0.999994158744812
Drash I-Disease 1 0.9999978542327881
syndrome I-Disease 1 0.9999996423721313
( O 0 2.2020108190190513e-06
DDS B-Disease 1 0.9999922513961792
) O 0 4.054428188737802e-07
, O 0 3.258641925185657e-07
or O 0 2.1915464003541274e-06
diffuse B-Disease 1 0.9998502731323242
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 1.9134846297674812e-05
DMS B-Disease 1 0.9366770386695862
) O 0 1.2661310222483735e-07
associated O 0 1.0528897576023155e-07
with O 0 1.426358409162276e-07
pseudohermaphroditism B-Disease 1 0.9999608993530273
and O 0 2.152629167539999e-05
/ O 0 0.00010969326103804633
or O 0 7.229808034026064e-06
Wilms B-Disease 1 0.9948563575744629
tumor I-Disease 1 0.8269569277763367
( O 0 3.3423398235754576e-06
WT B-Disease 1 0.999543309211731
) O 0 1.6869264527485939e-06
. O 0 1.791690124264278e-06

Most O 0 0.00013412936823442578
mutations O 0 0.010105270892381668
in O 0 0.000156743626575917
DDS B-Disease 1 0.9999998807907104
patients O 1 0.9998544454574585
lie O 0 8.672859257785603e-05
in O 0 1.3952168842479296e-07
exon O 0 3.5029183891310822e-06
8 O 0 1.5613562709404505e-07
or O 0 1.1297211166549914e-08
exon O 0 5.753327627644467e-07
9 O 0 7.493999021335185e-08
, O 0 1.2238450253221345e-08
encoding O 0 9.265015421533462e-08
zinc O 0 9.969184247893281e-06
finger O 0 3.7269521726557286e-06
2 O 0 3.8777127997491334e-07
or O 0 6.411790565152842e-08
zinc O 0 5.556480755330995e-05
finger O 0 2.5375782570336014e-05
3 O 0 4.514680256306747e-07
, O 0 4.9371493560101953e-08
respectively O 0 1.5483401227811555e-07
, O 0 5.65650593031819e-09
with O 0 3.4500515777580176e-09
a O 0 1.5282276422112773e-07
hot O 0 1.9746814359677956e-05
spot O 0 3.405736379136215e-06
( O 0 1.7160145304728758e-08
R394W O 0 6.750947250111494e-07
) O 0 9.011734469765997e-09
in O 0 2.3906164159370746e-08
exon O 0 3.1743447834742256e-06
9 O 0 1.8635548713064054e-06
. O 0 7.771217838126177e-07

We O 0 5.323513505572919e-06
analyzed O 0 2.862448582163779e-06
a O 0 1.6688706239165185e-07
series O 0 9.692536195871071e-08
of O 0 1.1672064204049093e-08
24 O 0 4.545877891359851e-05
patients O 0 3.038070644834079e-05
, O 0 2.6700096356080394e-08
10 O 0 2.992962322423409e-08
with O 0 1.0281956264179826e-07
isolated B-Disease 0 0.00011192553938599303
DMS I-Disease 1 0.9946958422660828
( O 0 5.50401750842866e-07
IDMS B-Disease 0 0.0005080865230411291
) O 0 6.118313677916376e-08
, O 0 2.375018581801669e-08
10 O 0 2.1482465584199417e-08
with O 0 2.2161735557801876e-07
DDS B-Disease 1 0.9999988079071045
, O 0 1.3847859463567147e-06
and O 0 8.640820681193873e-08
4 O 0 1.570384995375207e-07
with O 0 6.87635463236802e-07
urogenital B-Disease 1 0.9533940553665161
abnormalities I-Disease 1 0.9996815919876099
and O 0 2.2200574676389806e-05
/ O 0 0.009778467938303947
or O 0 3.756000296561979e-05
WT B-Disease 1 0.9999792575836182
. O 0 4.307853669160977e-05

We O 0 8.088096365099773e-06
report O 0 5.27943302586209e-06
WT1 O 0 0.00022865527716930956
heterozygous O 0 9.002326260088012e-05
mutations O 0 8.312843419844285e-06
in O 0 3.6835245964539354e-07
16 O 0 3.3662250643828884e-05
patients O 0 0.0001588253944646567
, O 0 5.4833964924227985e-08
4 O 0 8.3619617896602e-08
of O 0 2.020794909185497e-08
whom O 0 7.184096375567606e-06
presented O 0 2.834033921317314e-06
with O 0 2.6110815269930754e-06
IDMS B-Disease 0 0.41648709774017334
. O 0 1.5324629202950746e-05

One O 0 9.003547347674612e-06
male O 0 9.027347005030606e-06
and O 0 9.612358553567901e-08
two O 0 1.9326971312239039e-07
female O 0 0.0013995170593261719
IDMS B-Disease 1 0.9993588328361511
patients O 0 0.2866571843624115
with O 0 8.54163499752758e-06
WT1 O 1 0.9932557344436646
mutations O 0 0.0015655644237995148
underwent O 0 0.020760131999850273
normal O 0 1.1785677088482771e-05
puberty O 0 3.42458879458718e-05
. O 0 3.5554421629058197e-06

Two O 0 5.715035877074115e-05
mutations O 0 0.001015110989101231
associated O 0 3.0168100693117594e-06
with O 0 8.763676646594831e-07
IDMS B-Disease 0 0.14303255081176758
are O 0 7.780496957821015e-08
different O 0 5.339927611203166e-09
from O 0 1.6369828159668032e-08
those O 0 4.7020211724202454e-08
described O 0 2.442090590193402e-05
in O 0 1.4326351447380148e-05
DDS B-Disease 1 0.9999998807907104
patients O 1 0.9985347986221313
. O 0 1.6753967429394834e-05

No O 0 0.00012944666377734393
WT1 O 0 0.09420419484376907
mutations O 0 0.0012953608529642224
were O 0 1.9418696410866687e-06
detected O 0 1.3367186966206646e-06
in O 0 2.873471061093369e-08
the O 0 5.4367205848393496e-08
six O 0 7.121137741705752e-07
other O 0 5.674219210050069e-07
IDMS B-Disease 1 0.9985768795013428
patients O 0 0.49880450963974
, O 0 1.8455965289376763e-07
suggesting O 0 2.8618264877877664e-06
genetic O 0 5.158273097549682e-07
heterogeneity O 0 8.14797260773048e-07
of O 0 4.478841830746205e-08
this O 0 5.459645763039589e-06
disease O 0 0.0010549296857789159
. O 0 4.384171916171908e-06

We O 0 2.2067129975766875e-05
analyzed O 0 8.529506885679439e-05
genotype O 0 0.0026866088155657053
/ O 0 0.00045286311069503427
phenotype O 0 0.048695158213377
correlations O 0 2.1047428163001314e-05
, O 0 1.1979054193034244e-07
on O 0 8.630098591311253e-08
the O 0 1.0342039225008648e-08
basis O 0 5.895459675997472e-09
of O 0 1.1328536997368133e-09
the O 0 1.0899873892356027e-08
constitution O 0 1.0441204523203851e-07
of O 0 6.922423523292309e-09
a O 0 1.4933103784642299e-06
WT1 O 0 0.0032506228890269995
mutation O 0 5.533918283617822e-07
database O 0 1.7631435866860556e-08
of O 0 5.226705290795053e-09
84 O 0 3.37676084427585e-07
germ O 0 2.78417701338185e-06
- O 0 6.704824772896245e-05
line O 0 3.807975008385256e-05
mutations O 0 1.6326334844052326e-06
, O 0 1.4345908461166346e-08
to O 0 1.7445609401534057e-08
compare O 0 4.510329887352782e-08
the O 0 4.694428401563755e-09
distribution O 0 1.2556736983526662e-08
and O 0 2.1378722792064764e-08
type O 0 1.0258683857955475e-07
of O 0 1.571391017307633e-08
mutations O 0 3.722444262166391e-06
, O 0 4.1392112848370743e-08
according O 0 1.0803628214262062e-08
to O 0 1.5586330448513763e-08
the O 0 3.702489692614108e-08
different O 0 5.284537678562629e-07
symptoms O 0 0.0024835190270096064
. O 0 2.417769110252266e-06

This O 0 3.7722004435636336e-06
demonstrated O 0 7.1000536081555765e-06
( O 0 5.1940517664661456e-08
1 O 0 5.2247546733497074e-08
) O 0 1.5504939554489283e-08
the O 0 2.4120929253967915e-08
association O 0 3.0267234052416825e-08
between O 0 1.8237704679791022e-08
mutations O 0 5.060882131147082e-07
in O 0 4.3540531180497055e-08
exons O 0 1.5127282040339196e-06
8 O 0 1.286341984041428e-07
and O 0 4.6339550863194745e-08
9 O 0 2.654408888247417e-07
and O 0 6.191078227857361e-07
DMS B-Disease 1 0.9634631872177124
; O 0 1.3153874078852823e-06
( O 0 2.4592685221591637e-08
2 O 0 1.4440900031331694e-07
) O 0 4.154539823275627e-08
among O 0 2.679218482626311e-07
patients O 0 1.941986738529522e-05
with O 0 4.5819251681677997e-07
DMS B-Disease 1 0.9748519659042358
, O 0 7.967330617475454e-08
a O 0 7.341319019360526e-08
higher O 0 2.8703597720891594e-08
frequency O 0 8.429395137454776e-08
of O 0 5.596452190559376e-09
exon O 0 2.7909934487979626e-06
8 O 0 8.217440381486085e-07
mutations O 0 1.025025881062902e-06
among O 0 7.123692569166451e-08
46 O 0 1.5471033520952915e-06
, O 0 9.332995318800386e-07
XY O 1 0.9823092818260193
patients O 0 0.0229595098644495
with O 0 6.563303145412647e-07
female O 0 0.007506963796913624
phenotype O 0 0.0035646322648972273
than O 0 1.0634291669475715e-07
among O 0 3.991618768850458e-08
46 O 0 1.8766115772450576e-06
, O 0 1.4594361346098594e-06
XY O 1 0.9837844371795654
patients O 0 0.010279904119670391
with O 0 2.494958835086436e-07
sexual O 0 2.603899815767363e-07
ambiguity O 0 2.814665094774682e-06
or O 0 2.141645154551952e-06
male O 0 0.028989017009735107
phenotype O 0 0.420219361782074
; O 0 6.748578584847564e-07
and O 0 2.661801090653171e-07
( O 0 2.4744757354255853e-08
3 O 0 8.975577259207057e-08
) O 0 1.264130222722315e-08
statistically O 0 9.078831908482243e-08
significant O 0 3.25143325596855e-08
evidence O 0 5.701765104504375e-08
that O 0 1.074785132004763e-07
mutations O 0 8.469909289487987e-07
in O 0 4.166760803059333e-08
exons O 0 1.8027881196758244e-06
8 O 0 1.6727791773973877e-07
and O 0 4.476408221876227e-08
9 O 0 2.1342103195820528e-07
preferentially O 0 1.8163487993660965e-06
affect O 0 1.4137420123461197e-07
amino O 0 4.9300638238491956e-08
acids O 0 1.951126904486955e-08
with O 0 5.194306318401232e-09
different O 0 3.1873574890539658e-09
functions O 0 9.403090750481624e-09
. O 0 7.339848195897503e-08
. O 0 2.724609373672138e-07

The O 0 8.465955943393055e-06
185delAG O 0 0.0003152216668240726
BRCA1 O 0 0.0012039262801408768
mutation O 0 2.2059977709432133e-05
originated O 0 1.517040715270923e-07
before O 0 3.7444760181415404e-08
the O 0 1.607735278241762e-08
dispersion O 0 4.457493787413114e-07
of O 0 1.127151350033273e-08
Jews O 0 2.007043775620332e-07
in O 0 3.747977217471998e-08
the O 0 3.0207313983510176e-08
diaspora O 0 2.1313647380338807e-07
and O 0 6.233300808844433e-08
is O 0 3.956207095257014e-08
not O 0 2.2538522159720742e-08
limited O 0 7.656291955981942e-08
to O 0 4.015965089365636e-07
Ashkenazim O 0 1.3107317499816418e-05
. O 0 2.7184269129065797e-06

The O 0 3.199625780325732e-06
185delAG O 0 8.842324314173311e-05
mutation O 0 1.4196236406860407e-05
in O 0 2.2181991710112925e-07
BRCA1 O 0 3.217278572265059e-05
is O 0 2.1920594406310556e-07
detected O 0 1.4908500816090964e-06
in O 0 5.8050247275787115e-08
Ashkenazi O 0 5.054031589679653e-06
Jews O 0 1.2996407861010084e-07
both O 0 1.580945152568347e-08
in O 0 1.1031896463009616e-07
familial B-Disease 0 0.13942714035511017
breast I-Disease 1 0.9999626874923706
and I-Disease 1 0.9998785257339478
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
and O 0 5.496684138961427e-07
in O 0 4.844492451638871e-08
the O 0 4.3589224674178695e-08
general O 0 1.057481995303533e-06
population O 0 3.9394163309225405e-07
. O 0 1.069546442522551e-06

All O 0 7.3200976657972205e-06
tested O 0 4.038452243548818e-05
Ashkenazi O 0 7.21517571946606e-05
mutation O 0 1.0446903615957126e-05
carriers O 0 1.077439605978725e-06
share O 0 9.244873666602871e-08
the O 0 1.04606554529596e-08
same O 0 6.676649633163834e-08
allelic O 0 3.286773562649614e-06
pattern O 0 1.5027551398816286e-06
at O 0 6.79492160315931e-08
the O 0 2.361580442311606e-07
BRCA1 O 0 0.0003790756454691291
locus O 0 4.777690628543496e-05
. O 0 4.8118513404915575e-06

Our O 0 4.781527422892395e-06
previous O 0 2.3087461613613414e-06
study O 0 4.3360654444768443e-07
showed O 0 7.924861051833432e-07
that O 0 1.3915327556901502e-08
this O 0 3.4895563771897287e-08
Ashkenazi O 0 2.4295883122249506e-05
mutation O 0 1.10982466594578e-06
also O 0 1.6652457190957648e-07
occurs O 0 1.8290098324769133e-08
in O 0 1.0762946089926118e-08
Iraqi O 0 6.996862111918745e-07
Jews O 0 5.039569828113599e-08
with O 0 1.524904824634632e-08
a O 0 4.3197746890655253e-07
similar O 0 1.6748398365962203e-06
allelic O 0 4.56805391877424e-05
pattern O 0 3.675972766359337e-05
. O 0 3.3340179470542353e-06

We O 0 2.457346909068292e-06
extended O 0 6.27173790235247e-07
our O 0 2.4524668518211e-08
analysis O 0 1.6688874282522193e-08
to O 0 6.393800155990448e-09
other O 0 3.353127109306797e-09
non O 0 2.7488233911299176e-08
- O 0 1.87048647148913e-06
Ashkenazi O 0 1.3688878652828862e-06
subsets O 0 1.3587671787718136e-07
354 O 0 2.2582806025184254e-07
of O 0 1.2160846551978466e-08
Moroccan O 0 3.4641093407117296e-06
origin O 0 4.195774394588625e-08
, O 0 1.1442158331931296e-08
200 O 0 3.066692144670924e-08
Yemenites O 0 1.7199586181959603e-06
and O 0 4.638544481849749e-08
150 O 0 1.1830881874175248e-07
Iranian O 0 1.2904204140795628e-06
Jews O 0 1.180354615826218e-06
. O 0 9.579009656590642e-07

Heteroduplex O 0 0.0012176166055724025
analysis O 0 8.9491641119821e-06
complemented O 0 3.7663662624254357e-06
by O 0 6.744164693373023e-08
direct O 0 3.96624102450005e-08
DNA O 0 1.3591636616183678e-07
sequencing O 0 1.2391033976655308e-07
of O 0 2.5282712812213504e-08
abnormally O 0 2.225987827841891e-06
migrating O 0 2.3072882981978182e-07
bands O 0 2.9747397434221057e-07
were O 0 2.435495218833239e-07
employed O 0 2.340319952054415e-06
. O 0 1.5022966408650973e-06

Four O 0 3.264852466600132e-06
of O 0 1.7740130431320722e-07
Moroccan O 0 1.2534213965409435e-05
origin O 0 1.9784013716162008e-07
( O 0 1.0541473471903373e-08
1 O 0 2.485814576402845e-08
. O 0 4.888822235926682e-09
1 O 0 1.6651512169119087e-08
% O 0 8.061212142251861e-09
) O 0 4.914251228171906e-09
and O 0 1.7262239637716448e-08
none O 0 2.4774790219339593e-08
of O 0 7.222947795426649e-10
the O 0 7.610180041695003e-09
Yemenites O 0 1.77563583747542e-06
or O 0 1.594226084478123e-08
Iranians O 0 8.264825623882643e-08
was O 0 8.496706271898802e-08
a O 0 5.824833948508967e-08
carrier O 0 3.236639543047204e-07
of O 0 7.063279738872552e-09
the O 0 2.1372856906509696e-07
185delAG O 0 0.0002586502523627132
mutation O 0 1.8766131688607857e-05
. O 0 1.9770766357396496e-06

BRCA1 O 1 0.5537258386611938
allelic O 0 0.005844375118613243
patterns O 0 0.00015713241009507328
were O 0 2.872714958357392e-06
determined O 0 6.900884841343213e-07
for O 0 1.0829809049539563e-08
four O 0 1.0183701881771867e-08
of O 0 1.852366149357465e-09
these O 0 3.6463099206685e-09
individuals O 0 4.642719986236443e-09
and O 0 1.1566132052109879e-08
for O 0 1.9482635948975258e-08
12 O 0 8.760387260053903e-08
additional O 0 6.962682164157741e-08
non O 0 1.565352079069271e-07
- O 0 3.0270146453403868e-05
Ashkenazi O 0 2.281837623741012e-05
185delAG O 0 1.2228728337504435e-05
mutation O 0 2.096119715133682e-06
carriers O 0 5.388754402702034e-07
who O 0 3.3648261705820914e-06
had O 0 0.008124805055558681
breast B-Disease 1 0.9998950958251953
/ I-Disease 1 0.99998939037323
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
. O 0 5.474170757224783e-05

Six O 0 3.577272946131416e-05
non O 0 5.286904524837155e-06
- O 0 0.00021119957091286778
Ashkenazi O 0 0.00024529604706913233
individuals O 0 7.546266544977698e-08
shared O 0 5.756522369892991e-08
the O 0 2.939083998398928e-08
common O 0 4.6303151179927227e-07
Ashkenazi O 0 0.005530513357371092
haplotype O 0 0.029806043952703476
, O 0 9.861974348268632e-08
four O 0 6.642735428386004e-08
had O 0 1.883911835420804e-07
a O 0 1.129628941498595e-07
closely O 0 1.864159600017956e-07
related O 0 6.46270805759741e-08
pattern O 0 3.8869208651703957e-07
, O 0 2.0864256100594503e-08
and O 0 1.817471328990905e-08
the O 0 1.9317456079193107e-08
rest O 0 1.2896266810003e-07
( O 0 2.31508590076146e-08
n O 0 2.063443844235735e-06
= O 0 7.358715379268688e-07
6 O 0 5.2857775045822564e-08
) O 0 6.0499383280898655e-09
displayed O 0 6.898938664789966e-08
a O 0 1.1193041871138121e-07
distinct O 0 4.3782540615211474e-07
BRCA1 O 0 4.7370922402478755e-05
allelic O 0 4.144207923673093e-05
pattern O 0 3.7476209399756044e-05
. O 0 4.039090072183171e-06

We O 0 3.5283858323964523e-06
conclude O 0 2.041063680735533e-06
that O 0 4.495342764698762e-08
the O 0 3.7853641998708554e-08
185delAG O 0 4.8444959247717634e-05
BRCA1 O 0 0.00031844188924878836
mutation O 0 4.145036655245349e-06
occurs O 0 2.5139032189258614e-08
in O 0 7.56869233953239e-09
some O 0 1.503277680114934e-08
non O 0 1.1552180012586177e-07
- O 0 0.00020411612058524042
Ashkenazi O 0 7.759949221508577e-05
populations O 0 6.349747394551741e-08
at O 0 1.4251137159249083e-08
rates O 0 6.59636043565115e-08
comparable O 0 3.193158093495185e-08
with O 0 9.998852412707038e-09
that O 0 2.982971736287254e-08
of O 0 1.3659780506714014e-07
Ashkenazim O 0 4.9234949983656406e-05
. O 0 4.097823875781614e-06

The O 0 2.1768630631413544e-06
majority O 0 2.324095248695812e-06
of O 0 2.3575069008074934e-08
Jewish O 0 4.229642627251451e-07
185delAG O 0 2.9191976864240132e-05
mutation O 0 5.64881156606134e-06
carriers O 0 3.6312169982011255e-07
have O 0 4.62825795466415e-08
a O 0 2.1686959428279806e-07
common O 0 1.5912527828731982e-07
allelic O 0 1.695983337413054e-05
pattern O 0 7.752994861220941e-06
, O 0 4.058888336544442e-08
supporting O 0 5.961907589835391e-08
the O 0 1.7574391719676896e-08
founder O 0 1.2270492106836173e-06
effect O 0 5.419141047013909e-08
notion O 0 4.859447244598414e-08
, O 0 2.3691910655543325e-08
but O 0 1.4205435938663413e-08
dating O 0 3.195229680841294e-08
the O 0 1.826674100868786e-08
mutations O 0 1.987878590625769e-07
origin O 0 5.085627030609885e-09
to O 0 6.016371401074139e-09
an O 0 2.0544781875742046e-08
earlier O 0 7.398995194307645e-07
date O 0 1.2971605656275642e-07
than O 0 7.074554275732226e-08
currently O 0 5.047805302638153e-07
estimated O 0 6.498883067251882e-07
. O 0 5.081978997623082e-07

However O 0 1.0955775906040799e-05
, O 0 1.6110635669974727e-07
the O 0 2.0024549129971092e-08
different O 0 1.7563133170028777e-08
allelic O 0 1.8908699530584272e-06
pattern O 0 1.7417222579751979e-06
at O 0 5.7598828817617687e-08
the O 0 8.11389426758069e-08
BRCA1 O 0 2.8730970370816067e-05
locus O 0 2.9922712201368995e-06
even O 0 1.5485115056890209e-07
in O 0 6.99309055107733e-09
some O 0 1.0306377085100848e-08
Jewish O 0 1.0480371059884419e-07
mutation O 0 4.2781780962286575e-07
carriers O 0 1.0719680432202949e-07
, O 0 1.8421740577423407e-08
might O 0 7.358281095548591e-08
suggest O 0 4.6605020287415755e-08
that O 0 1.1971854618764155e-08
the O 0 1.9585618460382648e-08
mutation O 0 1.3680995607501245e-06
arose O 0 4.5668355141970096e-07
independently O 0 3.568713680124347e-07
. O 0 9.52750056626428e-08
. O 0 3.94457032371065e-07

Crystal O 0 0.0008797210175544024
structure O 0 2.9593825274787378e-06
of O 0 6.336668434414605e-08
the O 0 5.768556547991466e-07
hemochromatosis B-Disease 1 0.9999916553497314
protein O 0 7.853500392229762e-06
HFE O 0 6.917135760886595e-05
and O 0 1.2822084727304173e-07
characterization O 0 6.717846190440468e-07
of O 0 6.297194765636505e-09
its O 0 2.1477058353980283e-08
interaction O 0 6.288327369929902e-08
with O 0 5.224385972724122e-07
transferrin O 0 0.0006532257539220154
receptor O 0 3.729210948222317e-05
. O 0 4.876401362707838e-06

HFE O 0 0.46817004680633545
is O 0 7.651541636732873e-06
an O 0 2.0034956378367497e-06
MHC O 0 0.0008607446798123419
- O 0 0.0005509777693077922
related O 0 7.901203389337752e-07
protein O 0 1.7403279173322517e-07
that O 0 1.6089684251596736e-08
is O 0 1.6116343815042455e-08
mutated O 0 6.047541774023557e-07
in O 0 2.01839878144483e-08
the O 0 1.1372516439678293e-07
iron B-Disease 1 0.8399825096130371
- I-Disease 1 0.9996799230575562
overload I-Disease 1 0.9999785423278809
disease I-Disease 1 0.9998667240142822
hereditary B-Disease 1 0.9999998807907104
hemochromatosis I-Disease 1 1.0
. O 0 0.014475948177278042

HFE O 0 0.003667703829705715
binds O 0 4.58444919786416e-05
to O 0 2.5911201646522386e-06
transferrin O 0 4.181560143479146e-05
receptor O 0 4.608856215781998e-06
( O 0 1.7153935516489582e-07
TfR O 0 9.800291081774049e-06
) O 0 1.6993316975799644e-08
and O 0 1.7714661737500137e-08
reduces O 0 2.444059816752997e-07
its O 0 2.5770603429009498e-08
affinity O 0 8.741409374124487e-08
for O 0 4.043758394800534e-08
iron O 0 0.00042987646884284914
- O 0 1.1979907867498696e-05
loaded O 0 4.593239737005206e-06
transferrin O 0 2.1668220142601058e-05
, O 0 1.3343783678010368e-07
implicating O 0 8.266161785286386e-06
HFE O 0 0.0004915543249808252
in O 0 1.3731724948229385e-06
iron O 0 0.013936726376414299
metabolism O 0 4.216872184770182e-05
. O 0 4.602456556312973e-06

The O 0 1.108591186493868e-05
2 O 0 1.4476946489594411e-05
. O 0 4.5782571760355495e-06

6 O 0 8.132118091452867e-05
A O 0 1.889697705337312e-05
crystal O 0 9.136278094956651e-05
structure O 0 2.1724282817103813e-07
of O 0 1.0814967588146374e-08
HFE O 0 0.00011856129276566207
reveals O 0 1.2247367067175219e-06
the O 0 1.1475336236799194e-08
locations O 0 3.388431579764983e-08
of O 0 9.774594644795798e-08
hemochromatosis B-Disease 1 0.9999996423721313
mutations O 0 0.0019549245480448008
and O 0 1.232061634937054e-07
a O 0 1.170072778222675e-06
patch O 0 0.0005451529286801815
of O 0 3.050491415024226e-08
histidines O 0 6.0538317484315485e-05
that O 0 9.455737171037981e-08
could O 0 7.248569033890817e-08
be O 0 1.3150541100515056e-08
involved O 0 3.4465216458556824e-08
in O 0 1.8053518147098657e-07
pH O 0 7.189837924670428e-05
- O 0 8.430819434579462e-05
dependent O 0 2.4706966996745905e-06
interactions O 0 1.1546732139322557e-06
. O 0 1.0822261629073182e-06

We O 0 9.041813427757006e-06
also O 0 1.0644574786056182e-06
demonstrate O 0 8.422353516834846e-07
that O 0 4.819906962438836e-07
soluble O 0 2.5613317120587453e-05
TfR O 0 0.00011602783342823386
and O 0 2.0146646306784532e-07
HFE O 0 5.2719547966262326e-05
bind O 0 8.554023338547267e-07
tightly O 0 6.238980745365552e-07
at O 0 7.665597046013772e-09
the O 0 3.8180067996052e-09
basic O 0 3.1723420335083574e-08
pH O 0 2.9718304972448095e-07
of O 0 2.0508712506028814e-09
the O 0 1.4287552474456788e-08
cell O 0 5.177986167836934e-06
surface O 0 5.272433554637246e-06
, O 0 2.436298274233195e-08
but O 0 1.8651265420999152e-08
not O 0 7.279129299320175e-09
at O 0 5.5529847386992515e-09
the O 0 2.963842504755121e-08
acidic O 0 3.8258072891039774e-05
pH O 0 3.5872531043423805e-06
of O 0 2.7040758965313216e-08
intracellular O 0 4.359656031738268e-06
vesicles O 0 3.1160696380538866e-05
. O 0 1.9817032352875685e-06

TfR O 1 0.8643969893455505
HFE O 0 0.22989965975284576
stoichiometry O 0 0.0008935847436077893
( O 0 2.566950342952623e-06
2 O 0 4.812246174878965e-07
1 O 0 1.0613987200258634e-07
) O 0 2.7658421331011596e-08
differs O 0 4.828311830351595e-07
from O 0 8.750367186394215e-08
TfR O 0 5.086736200610176e-05
transferrin O 0 2.4247045075753704e-05
stoichiometry O 0 2.836797420968651e-06
( O 0 3.992456854007287e-08
2 O 0 4.416449073119111e-08
2 O 0 2.489510819714269e-08
) O 0 3.502771628305368e-09
, O 0 3.073172605283503e-09
implying O 0 2.382032171510673e-08
a O 0 1.615081046679734e-08
different O 0 7.666646206772043e-10
mode O 0 1.361841128755259e-08
of O 0 1.684794859180272e-09
binding O 0 1.2245996572346485e-07
for O 0 4.310144774422042e-08
HFE O 0 3.7294026697054505e-05
and O 0 1.5159213262450066e-07
transferrin O 0 1.1730240657925606e-05
to O 0 1.1947648772547836e-06
TfR O 0 0.0002952167997136712
, O 0 8.344149904360165e-08
consistent O 0 9.494411301602668e-08
with O 0 1.0435247332907238e-08
our O 0 1.4404116122079813e-08
demonstration O 0 2.364433555612777e-07
that O 0 9.278968349235583e-08
HFE O 0 5.9611749748000875e-05
, O 0 1.0876410527771441e-07
transferrin O 0 5.6049325394269545e-06
, O 0 6.352060921699376e-08
and O 0 8.506793136575652e-08
TfR O 0 7.551237649749964e-05
form O 0 2.3014557370970579e-07
a O 0 1.0283079063810874e-06
ternary O 0 9.127878911385778e-06
complex O 0 5.257962129689986e-06
. O 0 3.040981482627103e-06

Identification O 0 1.161339878308354e-05
of O 0 2.729558445935254e-07
three O 0 4.5441700535775453e-07
novel O 0 6.990424935793271e-06
mutations O 0 4.214625732856803e-06
and O 0 2.5163402028738346e-08
a O 0 1.5058695623793028e-07
high O 0 8.982667054624471e-08
frequency O 0 1.2639209501230653e-07
of O 0 1.4792285174536346e-09
the O 0 1.0308736086983572e-08
Arg778Leu O 0 3.246465712436475e-05
mutation O 0 1.4949903288652422e-06
in O 0 8.745461599346527e-08
Korean O 0 5.301728378981352e-06
patients O 0 0.0001805886422516778
with O 0 2.8250990453670966e-06
Wilson B-Disease 0 0.04543218016624451
disease I-Disease 0 0.0014783067163079977
. O 0 2.7415380827733316e-06

Four O 0 3.522137558320537e-05
mutations O 0 5.776164834969677e-05
- O 0 2.6004827304859646e-05
- O 0 9.0258356067352e-05
R778L O 0 2.12992999877315e-05
, O 0 6.450540723790255e-08
A874V O 0 9.13815881631308e-07
, O 0 2.032274792895805e-08
L1083F O 0 2.8262695650482783e-07
, O 0 5.814940085002718e-09
and O 0 6.0146154723383916e-09
2304delC O 0 4.85213490719616e-07
- O 0 3.1446359116671374e-06
- O 0 4.669240752264159e-06
in O 0 2.781618313463241e-08
the O 0 1.2585126718533957e-08
copper O 0 9.3228004516277e-07
- O 0 4.7542630454699975e-07
transporting O 0 2.3547754324226844e-07
enzyme O 0 9.456530847273825e-08
, O 0 2.0311896165026155e-08
P O 0 8.438931899945601e-07
- O 0 4.247470315021928e-06
type O 0 1.8997883444171748e-06
ATPase O 0 6.123834737081779e-06
( O 0 1.3021576705796178e-08
ATP7B O 0 3.589942934922874e-06
) O 0 7.476321783883577e-09
, O 0 7.836791660054132e-09
were O 0 2.4779943430530693e-08
identified O 0 1.24877416851632e-07
in O 0 3.153766314767381e-08
Korean O 0 8.291165613627527e-06
Patients O 0 3.1906933145364746e-05
with O 0 2.768650801954209e-06
Wilson B-Disease 0 0.0057714893482625484
disease I-Disease 0 0.0002678883320186287
. O 0 3.6005340007250197e-06

Arg778Leu O 0 0.000741674448363483
, O 0 1.548025693409727e-06
the O 0 6.606295244182547e-08
most O 0 9.393289701620233e-08
frequently O 0 1.2310684951444273e-06
reported O 0 2.6680681912694126e-06
mutation O 0 7.534472956649552e-08
of O 0 1.2767857882067801e-09
this O 0 8.398130191267228e-09
enzyme O 0 6.640872385332841e-08
, O 0 9.334187645038128e-09
was O 0 5.722492346649233e-07
found O 0 4.280814636103969e-08
in O 0 6.013400000171032e-09
six O 0 1.68166227609845e-08
of O 0 4.94933782846374e-09
eight O 0 7.414847118525358e-07
unrelated O 0 7.010262925177813e-05
patients O 0 0.00043409306090325117
studied O 0 2.855243508292915e-07
, O 0 1.4917183932539047e-08
an O 0 2.731404080691391e-08
allele O 0 3.809774682395073e-07
frequency O 0 1.471757968829479e-07
of O 0 1.951488037832405e-08
37 O 0 3.255220917708357e-06
. O 0 1.736650119710248e-06

5 O 0 4.6003860916243866e-05
% O 0 1.3796253597320174e-06
, O 0 2.971755996838965e-08
which O 0 2.7157572191072177e-08
is O 0 3.6154112592612364e-08
considerably O 0 1.4029063777343254e-06
higher O 0 3.7221525417407975e-08
than O 0 1.0855246479479774e-08
those O 0 4.185469304474054e-09
in O 0 1.0796211924457566e-08
other O 0 1.7718109646125413e-08
Asian O 0 1.7563745302595635e-07
populations O 0 6.732764177286299e-07
. O 0 9.520539947516227e-07

The O 0 2.1176149402890587e-06
novel O 0 1.1385880043235375e-06
single O 0 2.439716695334937e-07
nucleotide O 0 3.8218453823901655e-07
deletion O 0 1.756795995788707e-06
, O 0 5.3737494454253465e-08
2304delC O 0 2.104135319314082e-06
, O 0 1.4732823849783472e-08
was O 0 1.7162854248908843e-07
found O 0 3.41917889556953e-08
in O 0 3.0929676597679645e-08
one O 0 3.8102905364212347e-07
patient O 0 4.81136521557346e-05
. O 0 1.936931312229717e-06

Since O 0 7.823963642294984e-06
a O 0 1.052490802067041e-06
mutation O 0 1.2015567563139484e-06
at O 0 5.518145940186514e-08
cDNA O 0 1.1297490800643573e-06
nucleotide O 0 1.021018078972702e-06
2302 O 0 7.150194505811669e-06
( O 0 4.1685655816081635e-08
2302insC O 0 1.3075355127512012e-06
) O 0 4.191055325009074e-08
had O 0 3.840116562514595e-07
been O 0 1.259466415604038e-07
previously O 0 8.522300163349428e-07
described O 0 1.4309814559965162e-06
, O 0 1.0407121386890594e-08
this O 0 3.653842561845977e-09
region O 0 5.801612967815117e-09
of O 0 1.8878849594727853e-09
the O 0 2.5988034835222606e-08
ATP7B O 0 0.025986848399043083
gene O 0 2.84553311757918e-06
may O 0 7.379559860964946e-07
be O 0 5.152550031084502e-08
susceptible O 0 2.7091484753327677e-06
to O 0 4.1364771163898695e-07
gene O 0 6.078572823753348e-06
rearrangements O 0 0.0015112911351025105
causing O 0 0.001945925410836935
Wilson B-Disease 0 0.005160558968782425
disease I-Disease 0 0.0011785821989178658
. O 0 4.829942099604523e-06

Disruption O 0 0.00025613143225200474
of O 0 6.091254363127518e-07
splicing O 0 1.1041574907721952e-05
regulated O 0 9.081149983103387e-07
by O 0 5.99279204038794e-08
a O 0 4.54635085134214e-07
CUG O 0 0.00013583851978182793
- O 0 3.1715659133624285e-05
binding O 0 3.3979822546825744e-06
protein O 0 3.221223096261383e-06
in O 0 5.238592621026328e-06
myotonic B-Disease 1 0.9999948740005493
dystrophy I-Disease 1 0.999998927116394
. O 0 0.00022547974367626011

Myotonic B-Disease 1 0.9999990463256836
dystrophy I-Disease 1 1.0
( O 1 0.994940996170044
DM B-Disease 1 0.9999998807907104
) O 0 2.2640395400230773e-05
is O 0 1.1878959185196436e-06
caused O 0 2.102113512592041e-06
by O 0 4.6080511850732364e-08
a O 0 1.0238222785119433e-06
CTG O 0 4.5309032429941e-05
expansion O 0 2.582133618034277e-07
in O 0 5.2980713149963776e-08
the O 0 1.3402114085181438e-08
3 O 0 1.3917457408751943e-07
untranslated O 0 7.403445579257095e-06
region O 0 4.142701826026496e-08
of O 0 1.0648515846867213e-08
the O 0 9.18369323699153e-07
DM B-Disease 1 0.9999990463256836
gene O 0 8.28335978440009e-05
. O 0 2.556845402068575e-06

One O 0 8.497705493937247e-06
model O 0 8.680184691911563e-06
of O 0 8.123059274112165e-07
DM B-Disease 1 0.9999996423721313
pathogenesis O 0 0.12922687828540802
suggests O 0 4.315518708608579e-06
that O 0 6.127201146455263e-08
RNAs O 0 2.387903350609122e-07
from O 0 5.075993847469817e-09
the O 0 2.5292246075281355e-09
expanded O 0 5.656184853819468e-08
allele O 0 2.0428969094155036e-07
create O 0 2.0753086360514317e-08
a O 0 5.307619588279522e-08
gain O 0 2.7261168611403264e-07
- O 0 8.706007292857976e-07
of O 0 1.430997098594844e-08
- O 0 2.1817264496348798e-05
function O 0 8.543410956463049e-08
mutation O 0 6.117403472671867e-08
by O 0 3.27449645176614e-09
the O 0 6.068290758776129e-09
inappropriate O 0 1.648900820327981e-07
binding O 0 7.051114181422236e-08
of O 0 3.619204047566882e-09
proteins O 0 1.4505048717694535e-08
to O 0 3.6463951857967913e-08
the O 0 9.531971301157682e-08
CUG O 0 0.0009531729156151414
repeats O 0 2.0421428416739218e-05
. O 0 9.767975370778004e-07

Data O 0 2.009118179557845e-05
presented O 0 5.96523386775516e-06
here O 0 2.482664172021032e-07
indicate O 0 1.594086853629051e-07
that O 0 1.3143645283264505e-08
the O 0 9.794317357147975e-09
conserved O 0 1.4654945346137538e-07
heterogeneous O 0 4.1328061683998385e-07
nuclear O 0 6.39277800473792e-07
ribonucleoprotein O 0 5.794012849946739e-06
, O 0 7.973031301844458e-08
CUG O 0 1.4092520359554328e-05
- O 0 3.936707798857242e-06
binding O 0 4.817659942091268e-07
protein O 0 1.079353992849974e-07
( O 0 1.4140880466584349e-08
CUG O 0 1.8612619896885008e-05
- O 0 7.767612260067835e-05
BP O 0 0.007409519515931606
) O 0 4.800076425226507e-08
, O 0 3.6344729892334726e-08
may O 0 1.7931722595676547e-07
mediate O 0 2.164271563742659e-06
the O 0 4.8791740425713215e-08
trans O 0 4.6873807946212764e-07
- O 0 3.0237575629143976e-05
dominant O 0 1.8120873619409394e-06
effect O 0 7.265109758236576e-08
of O 0 1.2326040632615332e-08
the O 0 9.705892978217889e-08
RNA O 0 4.700048975792015e-06
. O 0 2.04344746634888e-06

CUG O 0 0.06935346126556396
- O 0 0.03925769776105881
BP O 0 0.03121035546064377
was O 0 1.8802281829266576e-06
found O 0 1.4862542307980675e-08
to O 0 6.270084451642788e-09
bind O 0 9.590785055024753e-08
to O 0 4.9933941426161255e-08
the O 0 5.299061811570027e-08
human O 0 1.5445455119333928e-06
cardiac O 1 0.9840942025184631
troponin O 1 0.8375442624092102
T O 0 0.004520997870713472
( O 0 1.1108436126505694e-07
cTNT O 0 1.2009335250695585e-06
) O 0 1.131001781118357e-08
pre O 0 2.0316009852194838e-07
- O 0 1.077288516171393e-06
messenger O 0 2.1666596694558393e-07
RNA O 0 5.75534784275078e-08
and O 0 5.995236751488164e-09
regulate O 0 3.127761516452665e-08
its O 0 3.411869187175398e-08
alternative O 0 6.928310085640987e-07
splicing O 0 1.2162793609604705e-05
. O 0 1.9718906969501404e-06

Splicing O 0 0.00024796254001557827
of O 0 2.3128804969019257e-06
cTNT O 0 9.033532842295244e-05
was O 0 9.242849955626298e-06
disrupted O 0 2.3044893168844283e-05
in O 0 2.9425054890452884e-06
DM B-Disease 1 0.9999979734420776
striated O 1 0.9675766229629517
muscle O 0 0.12026391923427582
and O 0 1.410633899467939e-06
in O 0 1.8560386649824068e-07
normal O 0 5.009984533899114e-07
cells O 0 4.3207964495195483e-07
expressing O 0 5.175539854462841e-07
transcripts O 0 8.512358249390672e-07
that O 0 1.2141592264924839e-07
contain O 0 9.688503723737085e-07
CUG O 0 0.0004936958430334926
repeats O 0 3.124067734461278e-05
. O 0 1.4878290812703199e-06

Altered O 0 0.0003292342880740762
expression O 0 6.855042101960862e-06
of O 0 1.116023398139987e-07
genes O 0 5.056554641669209e-07
regulated O 0 2.9983164040459087e-07
posttranscriptionally O 0 8.458490810880903e-06
by O 0 1.4114991131464194e-07
CUG O 0 0.00010325964103685692
- O 0 0.0003733461780939251
BP O 0 0.011691642925143242
therefore O 0 4.964894060321967e-07
may O 0 2.471094262546103e-07
contribute O 0 1.0052666965520984e-07
to O 0 2.3758668703521835e-06
DM B-Disease 1 0.9999997615814209
pathogenesis O 1 0.7836049199104309
. O 0 4.6409704737016e-06
. O 0 2.6702703053160803e-06

Identification O 0 9.970201972464565e-06
of O 0 1.5984285539616394e-07
a O 0 1.0651064030753332e-06
novel O 0 3.259224968132912e-06
nonsense O 0 1.2102799701096956e-05
mutation O 0 1.4353976212078123e-06
and O 0 2.2002312860536222e-08
a O 0 1.6323753015967668e-07
missense O 0 1.7453186273996835e-06
substitution O 0 5.332845987027213e-08
in O 0 2.6490393878475516e-08
the O 0 2.4386785923979915e-08
vasopressin O 0 9.053651410795283e-06
- O 0 2.7081307052867487e-05
neurophysin O 0 0.00015761051326990128
II O 0 1.937469278345816e-05
gene O 0 9.300904224573969e-08
in O 0 1.275586392068817e-08
two O 0 3.7276940645369905e-08
Spanish O 0 6.068652282920084e-07
kindreds O 0 6.994473096710863e-06
with O 0 1.306147055402107e-06
familial B-Disease 0 0.18295547366142273
neurohypophyseal I-Disease 1 0.9996675252914429
diabetes I-Disease 1 0.9999245405197144
insipidus I-Disease 1 0.9904153347015381
. O 0 5.3457417379831895e-05

Familial B-Disease 1 0.9988901019096375
neurohypophyseal I-Disease 1 0.9999388456344604
diabetes I-Disease 1 0.9999984502792358
insipidus I-Disease 1 0.999963641166687
( O 0 0.0010712494840845466
FNDI B-Disease 1 0.9999873638153076
) O 0 3.668726549221901e-07
is O 0 8.311143773198637e-08
an O 0 9.340688507109007e-07
autosomal B-Disease 1 0.8693304061889648
dominant I-Disease 1 0.9950841069221497
disease I-Disease 1 0.9052988886833191
caused O 0 0.022441284731030464
by O 0 0.00025229278253391385
deficiency O 1 0.5614412426948547
in O 0 1.497548964835005e-07
the O 0 2.2282299028120178e-07
antidiuretic O 0 0.00025810161605477333
hormone O 0 2.3239545043907128e-05
arginine O 0 2.6928407805826282e-06
vasopressin O 0 3.944426680391189e-06
( O 0 5.8606509867331624e-08
AVP O 0 2.388423126831185e-06
) O 0 1.732028387380069e-08
encoded O 0 2.475901439424888e-08
by O 0 7.742978702651726e-09
the O 0 1.5774661576983817e-08
AVP O 0 2.518297333153896e-05
- O 0 0.0002625034539960325
neurophysin O 0 0.001775061129592359
II O 0 0.00012865493772551417
( O 0 7.40242640517863e-08
AVP O 0 1.5054810319270473e-05
- O 0 0.00011813427408924326
NPII O 0 0.00036000573891215026
) O 0 6.404653163372132e-08
gene O 0 7.193229834001613e-08
on O 0 3.3659708265076915e-07
chromosome O 0 5.462572880787775e-05
20p13 O 0 0.00012412435899022967
. O 0 5.437068921310129e-06

In O 0 5.311251698003616e-06
this O 0 1.4942250459171191e-07
study O 0 1.0933714378325021e-07
, O 0 2.3062185050548578e-08
we O 0 1.4057435215875103e-08
analyzed O 0 1.4546031934514758e-07
two O 0 2.5955193549975775e-08
families O 0 2.061413972853643e-08
with O 0 4.040828471829627e-08
FNDI B-Disease 1 0.9989421963691711
using O 0 7.303386695411973e-08
direct O 0 2.274434152127469e-08
automated O 0 3.243777939587744e-07
fluorescent O 0 5.00512169310241e-06
, O 0 3.306253759660649e-08
solid O 0 2.2570964119950077e-07
phase O 0 1.6050657336563745e-07
, O 0 2.8700805287940057e-08
single O 0 9.982488080595431e-08
- O 0 2.15329396269226e-06
stranded O 0 5.274337127048057e-07
DNA O 0 1.0087970991889961e-07
sequencing O 0 4.9764320664280604e-08
of O 0 8.804824425112656e-09
PCR O 0 4.5260758270160295e-06
- O 0 1.5198981600406114e-05
amplified O 0 3.60434569302015e-05
AVP O 0 0.00011276038276264444
- O 0 7.481838838430122e-05
NPII O 0 0.00041334624984301627
DNA O 0 2.561141263868194e-05
. O 0 2.559104586907779e-06

In O 0 2.2554147562914295e-06
one O 0 1.4184242047576845e-07
of O 0 1.5706898892631216e-08
the O 0 6.111991979196318e-08
families O 0 1.7496320481313887e-07
, O 0 8.730761180686386e-08
affected O 0 2.5010766080413305e-07
individuals O 0 7.348348152191875e-09
presented O 0 7.158738668522346e-08
a O 0 4.5927572500659153e-07
novel O 0 2.5355957404826768e-06
nonsense O 0 5.896085895074066e-06
mutation O 0 5.072009798823274e-07
in O 0 1.2325289233672265e-08
exon O 0 3.814162710114033e-07
3 O 0 1.5576256728877524e-08
of O 0 7.348372466076114e-10
the O 0 8.089722669524235e-09
gene O 0 4.668367026283704e-08
, O 0 9.514403487287382e-09
consisting O 0 1.4774865775279977e-08
in O 0 1.0990309107228313e-08
a O 0 9.682435120339505e-07
G O 0 0.004619665443897247
to O 0 4.2992905946448445e-07
T O 0 3.693492544698529e-05
transition O 0 1.4772646750316198e-07
at O 0 2.7189189566456662e-08
nucleotide O 0 1.6281991577216104e-07
2101 O 0 2.6568504836177453e-06
, O 0 2.778606322806354e-08
which O 0 1.3149412225743617e-08
produces O 0 2.8282745034857726e-08
a O 0 2.1943387551459637e-08
stop O 0 9.125376720930944e-08
signal O 0 2.877813187751599e-07
in O 0 2.040088808996643e-08
codon O 0 1.189282215818821e-06
82 O 0 4.246887328918092e-06
( O 0 1.303402967778311e-07
Glu O 0 0.00010529424616834149
) O 0 5.936195890399176e-08
of O 0 4.741539783026383e-08
NPII O 0 0.000669945206027478
. O 0 4.4093890210206155e-06

The O 0 7.5016591836174484e-06
premature O 0 0.00026114474167115986
termination O 0 1.3049385415797587e-05
eliminates O 0 2.2694671315548476e-06
part O 0 5.636541544618012e-08
of O 0 7.128161616520856e-09
the O 0 3.420548466692708e-08
C O 0 1.4405649153559352e-06
- O 0 8.472562512906734e-06
terminal O 0 1.8231778540211963e-06
domain O 0 2.102464691233763e-08
of O 0 3.997575159786493e-09
NPII O 0 1.6299485650961287e-05
, O 0 8.978175536356048e-09
including O 0 1.914563396709923e-09
a O 0 1.7988616818342962e-08
cysteine O 0 2.207663385433989e-08
residue O 0 6.018646558914043e-08
in O 0 4.733350156271854e-09
position O 0 1.7983236944019154e-07
85 O 0 9.57840953219602e-08
, O 0 1.115393111206231e-08
which O 0 1.197598820112944e-08
could O 0 6.409259611928064e-08
be O 0 6.1626064251640855e-09
involved O 0 1.012490091767404e-08
in O 0 6.642681960045138e-09
the O 0 1.0102176872806012e-08
correct O 0 5.498844188878138e-07
folding O 0 2.911329829657916e-06
of O 0 2.33518431258517e-08
the O 0 3.2505161584595044e-07
prohormone O 0 0.0011658070143312216
. O 0 6.117139946582029e-06

In O 0 2.3035249796521384e-06
the O 0 1.2148981909376744e-07
second O 0 4.478765447402111e-07
family O 0 1.7813979980019212e-07
, O 0 8.290810704636442e-09
a O 0 5.408628922509706e-08
G279A O 0 6.004279953231162e-07
substitution O 0 4.674871334486852e-08
at O 0 1.2119468983939896e-08
position O 0 6.719217537920485e-08
- O 0 6.319022531897645e-07
1 O 0 1.3530434550546033e-08
of O 0 6.75874911593155e-10
the O 0 6.602135727007408e-09
signal O 0 4.470853411930875e-07
peptide O 0 1.242952265556596e-07
was O 0 1.6689676840542234e-07
observed O 0 3.5496643846499865e-08
in O 0 6.979365529957704e-09
all O 0 1.6049288120711935e-08
affected O 0 2.408264379027969e-07
individuals O 0 8.323390687792198e-08
. O 0 9.004982644000847e-07

This O 0 2.4487930204486474e-05
missense O 0 0.01575702615082264
mutation O 0 0.00043835947872139513
, O 0 4.397763007091271e-07
which O 0 2.2388141474039003e-07
replaces O 0 1.4834675312158652e-05
Ala O 0 2.278089232277125e-05
with O 0 3.3689573797346384e-07
Thr O 0 5.689315730705857e-05
, O 0 1.1781430941937288e-07
is O 0 5.964933080804258e-08
frequent O 0 4.299571628507692e-06
among O 0 5.564508228417253e-06
FNDI B-Disease 1 0.9999997615814209
patients O 1 0.9417905211448669
and O 0 2.016669640170221e-07
is O 0 8.858987143867125e-08
thought O 0 7.150210024065018e-08
to O 0 1.2746403932339945e-08
reduce O 0 8.82633415244527e-08
the O 0 8.935244544261423e-09
efficiency O 0 8.787581151636914e-08
of O 0 1.109638336771468e-08
cleavage O 0 1.3532030607166234e-06
by O 0 1.2990844311389083e-07
signal O 0 3.0113315006019548e-06
peptidases O 0 1.0266577191941906e-05
. O 0 2.5648384394116874e-07
. O 0 1.0069763902720297e-06

Genetic O 0 0.0005800574435852468
heterogeneity O 0 0.00011130886559840292
of O 0 2.004405359912198e-06
Saethre B-Disease 0 0.17024663090705872
- I-Disease 1 0.9996315240859985
Chotzen I-Disease 1 0.9999445676803589
syndrome I-Disease 1 0.999990701675415
, O 0 2.966758927414048e-07
due O 0 1.3987673241899756e-07
to O 0 1.239292402033243e-07
TWIST O 0 0.0005820944206789136
and O 0 6.764081263099797e-06
FGFR O 1 0.5343954563140869
mutations O 0 6.186685641296208e-05
. O 0 2.674511051736772e-06

Thirty O 0 0.00012235554459039122
- O 0 0.00025314794038422406
two O 0 2.259227130707586e-06
unrelated O 0 5.732261706725694e-05
patients O 0 3.625360841397196e-05
with O 0 8.278314567178313e-08
features O 0 8.320118922711117e-07
of O 0 6.953497688755306e-08
Saethre B-Disease 0 0.19468025863170624
- I-Disease 1 0.9993658661842346
Chotzen I-Disease 1 0.9999315738677979
syndrome I-Disease 1 0.9999849796295166
, O 0 8.343306490132818e-08
a O 0 3.1339329780166736e-06
common O 0 2.1038760678493418e-05
autosomal B-Disease 1 0.8948584198951721
dominant I-Disease 0 0.29513460397720337
condition I-Disease 0 0.004928133450448513
of O 0 1.4901493727847992e-07
craniosynostosis B-Disease 1 0.9379863739013672
and O 0 7.97971006250009e-05
limb B-Disease 1 0.9243848919868469
anomalies I-Disease 0 0.03423323109745979
, O 0 2.3541825555639662e-07
were O 0 1.1570880786848647e-07
screened O 0 2.533258566472796e-06
for O 0 1.0890069290780957e-07
mutations O 0 9.925272479449632e-07
in O 0 3.9974249688157215e-08
TWIST O 0 0.00011301486665615812
, O 0 5.469065627039527e-07
FGFR2 O 0 0.0002083180152112618
, O 0 1.9262660089225392e-07
and O 0 1.9564528486171184e-07
FGFR3 O 0 0.00047266561887227
. O 0 1.408908929079189e-06

Nine O 0 2.5210702006006613e-05
novel O 0 3.7484783206309658e-06
and O 0 9.561452429807105e-08
three O 0 1.0045863518826081e-07
recurrent O 0 7.425035437336192e-05
TWIST O 0 0.34348103404045105
mutations O 0 9.403445437783375e-05
were O 0 3.7618863757415966e-07
found O 0 2.0050484295097704e-07
in O 0 7.846517036114165e-08
12 O 0 5.452093887470255e-07
families O 0 3.9798894135856244e-07
. O 0 8.472890726807236e-07

Seven O 0 1.6390144082834013e-05
families O 0 1.5539244486717507e-06
were O 0 1.0764490099290924e-07
found O 0 7.916357702697496e-08
to O 0 2.167219292914524e-08
have O 0 4.1141657192156345e-08
the O 0 2.2992086456952165e-08
FGFR3 O 0 0.0018305026460438967
P250R O 0 0.00014121716958470643
mutation O 0 1.317752889917756e-06
, O 0 8.017725150466504e-09
and O 0 1.349363110136892e-08
one O 0 2.4368931761387103e-08
individual O 0 7.908823818070232e-09
was O 0 5.009258075006073e-07
found O 0 4.17699403953975e-08
to O 0 4.179241130941591e-08
have O 0 4.407444720300191e-08
an O 0 1.3661265541031753e-07
FGFR2 O 0 0.00031183709506876767
VV269 O 0 2.1842372007085942e-05
- O 0 1.4866000128677115e-05
270 O 0 1.0904003829637077e-05
deletion O 0 0.00010956289042951539
. O 0 3.219708787582931e-06

To O 0 4.1362623051099945e-06
date O 0 5.505424383045465e-07
, O 0 2.5720758856095927e-08
our O 0 8.691396047311173e-09
detection O 0 6.524947337993581e-08
rate O 0 3.7391590268498476e-08
for O 0 7.920659683691156e-09
TWIST O 0 7.812482363078743e-05
or O 0 3.8817233871668577e-07
FGFR O 0 0.005077586509287357
mutations O 0 4.440901193447644e-06
is O 0 1.2835566565172485e-07
68 O 0 2.715444452405791e-06
% O 0 3.3915998898237376e-08
in O 0 2.4587384572782867e-08
our O 0 8.969501408273572e-08
Saethre B-Disease 0 0.0025716309901326895
- I-Disease 1 0.9971227049827576
Chotzen I-Disease 1 0.9999788999557495
syndrome I-Disease 1 0.9999996423721313
patients O 0 0.08831020444631577
, O 0 3.3538132271360155e-08
including O 0 1.1628555007803243e-08
our O 0 1.8082047859024897e-08
five O 0 4.2164606384176295e-07
patients O 0 1.0194223250437062e-05
elsewhere O 0 2.263530944901504e-07
reported O 0 6.494112199106894e-07
with O 0 8.344913737801107e-08
TWIST O 0 0.10404731333255768
mutations O 0 0.0002071537746815011
. O 0 2.6097222871612757e-06

More O 0 3.236601060052635e-06
than O 0 5.674630187968432e-07
35 O 0 2.519087729524472e-07
different O 0 1.380148262342118e-08
TWIST O 0 0.00011027185246348381
mutations O 0 1.0306887816113885e-05
are O 0 2.000950516389821e-08
now O 0 6.049063472346461e-08
known O 0 4.145879728412183e-08
in O 0 2.587896652528343e-08
the O 0 1.0240112402470913e-07
literature O 0 8.923937571125862e-07
. O 0 2.1583412035397487e-06

The O 0 2.7856910946866265e-06
most O 0 4.2677297074078524e-07
common O 0 2.968799321934057e-07
phenotypic O 0 1.25371198009816e-05
features O 0 7.979806468938477e-06
, O 0 8.529604400564494e-08
present O 0 1.986583519908436e-08
in O 0 6.510561423311856e-09
more O 0 6.937955099317605e-09
than O 0 8.020218267290602e-09
a O 0 5.0615337698900476e-08
third O 0 8.886351565706718e-08
of O 0 3.79075970613485e-09
our O 0 1.1060887317171364e-07
patients O 0 3.859365278913174e-06
with O 0 9.22108185363868e-08
TWIST O 0 0.06765343248844147
mutations O 0 3.059927257709205e-05
, O 0 2.8291754716747164e-08
are O 0 1.1991691195589738e-08
coronal B-Disease 0 2.256704101455398e-05
synostosis I-Disease 0 6.788874452468008e-05
, O 0 1.1502030616838965e-07
brachycephaly B-Disease 0 5.442895144369686e-06
, O 0 1.145799686241844e-07
low B-Disease 0 5.137881998962257e-06
frontal I-Disease 1 0.9462169408798218
hairline I-Disease 1 0.9999234676361084
, O 0 1.1708211786753964e-05
facial B-Disease 1 0.8921780586242676
asymmetry I-Disease 0 0.004178410861641169
, O 0 8.489944775647018e-06
ptosis B-Disease 0 0.31809741258621216
, O 0 2.246219082735479e-06
hypertelorism B-Disease 0 0.011025299318134785
, O 0 2.765436875051819e-07
broad B-Disease 0 2.611713796341064e-07
great I-Disease 0 5.280960522213718e-07
toes I-Disease 0 4.2089053749805316e-05
, O 0 2.586239418178593e-07
and O 0 3.530249728100898e-07
clinodactyly B-Disease 0 0.000301829946693033
. O 0 4.090187758265529e-06

Significant O 0 1.525779862276977e-05
intra O 0 1.8082919268636033e-05
- O 0 6.219777424121276e-05
and O 0 1.0433266197651392e-06
interfamilial O 0 8.505157165927812e-05
phenotypic O 0 0.00010901202767854556
variability O 0 2.1620686311507598e-05
is O 0 1.756280596509896e-07
present O 0 3.4167406681717694e-08
for O 0 3.427235739650314e-08
either O 0 3.8264951740529796e-07
TWIST O 0 0.02162991091609001
mutations O 0 0.0001399864413542673
or O 0 7.850173915358027e-07
FGFR O 0 0.09700968116521835
mutations O 0 9.629156556911767e-05
. O 0 3.3516889743623324e-06

The O 0 5.433295882539824e-06
overlap O 0 4.219166385155404e-06
in O 0 7.361846314779541e-07
clinical O 0 5.219040303927613e-06
features O 0 6.25723203029338e-07
and O 0 4.5444043195175254e-08
the O 0 1.3679120058895933e-08
presence O 0 4.231861439052409e-08
, O 0 1.1258943111158715e-08
in O 0 3.3727807213779215e-09
the O 0 4.186994306820679e-09
same O 0 2.387617925592167e-08
genes O 0 1.6704987615412392e-08
, O 0 3.0555387109387766e-09
of O 0 1.2356117240486242e-09
mutations O 0 1.4498112932415097e-07
for O 0 7.68278152207813e-09
more O 0 1.2517258340949411e-08
than O 0 2.8735753332398417e-08
one O 0 1.2985418607058818e-07
craniosynostotic B-Disease 0 0.003291197121143341
condition I-Disease 0 3.7232857721392065e-06
- O 0 4.011127145986393e-07
such O 0 7.17352488521783e-09
as O 0 3.926827574218805e-08
Saethre B-Disease 0 1.647988824515778e-06
- I-Disease 0 3.4192548810096923e-06
Chotzen I-Disease 0 3.853333964798367e-06
, I-Disease 0 2.440581781115725e-08
Crouzon I-Disease 0 1.521731178399932e-06
, I-Disease 0 9.526482358523936e-08
and I-Disease 0 4.894268954558356e-07
Pfeiffer I-Disease 0 0.05356651172041893
syndromes I-Disease 0 0.1389331966638565
- O 0 5.2746956498594955e-05
support O 0 2.0177527915166138e-07
the O 0 2.560387457606339e-08
hypothesis O 0 8.628006185062986e-07
that O 0 4.2986346926454644e-08
TWIST O 0 9.954070264939219e-06
and O 0 1.2815102934382594e-07
FGFRs O 0 3.0328144475788577e-06
are O 0 4.185621182983823e-09
components O 0 1.1956382550692979e-08
of O 0 1.2964470608167744e-09
the O 0 7.352918718339652e-09
same O 0 3.667081927005711e-08
molecular O 0 1.7561734466653434e-07
pathway O 0 6.703280774900122e-08
involved O 0 2.6609551895262484e-08
in O 0 9.99801397227884e-09
the O 0 1.2146590400163859e-08
modulation O 0 5.081468316348037e-06
of O 0 7.805542168171087e-08
craniofacial O 1 0.98740154504776
and O 0 1.0808783372340258e-05
limb O 0 0.012447454035282135
development O 0 1.1650538311869241e-07
in O 0 3.227589786547469e-07
humans O 0 4.800310193786572e-07
. O 0 3.0233024972403655e-07
. O 0 1.2829793831770075e-06

Mutation O 0 0.0007060158532112837
analysis O 0 7.360157724178862e-06
of O 0 8.437756946477748e-07
UBE3A O 1 0.9621216654777527
in O 1 0.9499738216400146
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9993941783905029
. O 0 3.3417210943298414e-05

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.04457997530698776
AS B-Disease 1 0.9967489242553711
) O 0 3.75664143348331e-07
is O 0 2.801008918140724e-07
caused O 0 2.051836872851709e-06
by O 0 1.6603472374754347e-07
chromosome O 0 1.2138934835093096e-05
15q11 O 0 8.89101193024544e-06
- O 0 5.465480626298813e-06
q13 O 0 3.7494435218832223e-06
deletions O 0 6.004210604260152e-07
of O 0 1.318915021641942e-08
maternal O 0 1.0110706170962658e-05
origin O 0 1.0505687697559551e-07
, O 0 3.1274815626147756e-08
by O 0 1.1813936140470105e-07
paternal O 0 0.00045396029599942267
uniparental B-Disease 0 0.3349785804748535
disomy I-Disease 0 0.08822882175445557
( O 0 1.1131104429296101e-06
UPD B-Disease 1 0.9999104738235474
) O 0 9.436170955723355e-08
15 O 0 6.793793261294923e-08
, O 0 1.876702526715235e-08
by O 0 1.0298050057144792e-07
imprinting O 0 0.0707944929599762
defects O 1 0.9404997825622559
, O 0 5.0637257942298675e-08
and O 0 3.11360146554307e-08
by O 0 1.1938635680053267e-07
mutations O 0 8.262972528427781e-07
in O 0 2.9193619965894868e-08
the O 0 9.957442870245359e-08
UBE3A O 0 0.0009131786646321416
gene O 0 9.918999239744153e-06
. O 0 1.3039790474067559e-06

UBE3A O 0 0.005980959162116051
encodes O 0 9.146163938567042e-05
a O 0 3.849118002108298e-06
ubiquitin O 0 1.0319297871319577e-05
- O 0 8.802384400041774e-06
protein O 0 2.913894547873497e-07
ligase O 0 3.578487905997463e-07
and O 0 4.7729891150538606e-08
shows O 0 3.545611946265126e-07
brain O 0 5.514102213055594e-06
- O 0 3.1078991469257744e-06
specific O 0 1.749039739706859e-07
imprinting O 0 4.158753654337488e-05
. O 0 4.337995051173493e-06

Here O 0 1.0184323400608264e-05
we O 0 8.49163370730821e-07
describe O 0 3.232572453271132e-06
UBE3A O 0 0.0003091846883762628
coding O 0 2.7219988623983227e-05
- O 0 7.821650069672614e-05
region O 0 1.0970506991725415e-06
mutations O 0 2.8078393370378762e-06
detected O 0 8.865145559866505e-07
by O 0 6.491257664720251e-08
SSCP O 0 9.775371290743351e-05
analysis O 0 2.5704116524138954e-07
in O 0 5.443797235216152e-08
13 O 0 4.1957903818001796e-07
AS B-Disease 0 0.09826873987913132
individuals O 0 8.699411324641915e-08
or O 0 1.007737466807157e-07
families O 0 5.898544372939796e-07
. O 0 1.125265157497779e-06

Two O 0 6.3248685364669655e-06
identical O 0 5.935929038969334e-06
de O 0 8.753119686844002e-07
novo O 0 1.663734451540222e-06
5 O 0 1.0969244357283969e-07
- O 0 1.3679691619472578e-06
bp O 0 5.928054179094033e-06
duplications O 0 4.5485020905289275e-07
in O 0 4.983185419860092e-08
exon O 0 2.2474746401712764e-06
16 O 0 1.712392645458749e-07
were O 0 8.558676967140855e-08
found O 0 7.000967343628872e-07
. O 0 6.190298904584779e-07

Among O 0 4.027066552225733e-06
the O 0 8.390096439825356e-08
other O 0 1.5493586857928676e-08
11 O 0 9.712078252732681e-08
unique O 0 1.385521528618483e-07
mutations O 0 2.796577973640524e-06
, O 0 8.053132205532165e-08
8 O 0 4.159788957736055e-08
were O 0 2.4386134001019855e-08
small O 0 1.7706048183185885e-08
deletions O 0 7.903750542936905e-07
or O 0 3.0511433379842856e-08
insertions O 0 6.260697318793973e-06
predicted O 0 7.881916826590896e-05
to O 0 5.678122079189052e-07
cause O 0 3.8204311749723274e-06
frameshifts O 0 0.000749168626498431
, O 0 8.771405646257335e-08
1 O 0 3.0552314456144813e-08
was O 0 2.0572826997522498e-07
a O 0 2.0624568719540548e-07
mutation O 0 1.6592549911820242e-07
to O 0 1.1225171014928037e-08
a O 0 9.924905697289432e-08
stop O 0 1.5201602820980042e-07
codon O 0 1.6608619546332193e-07
, O 0 1.468333810095146e-08
1 O 0 1.0295885033428931e-08
was O 0 6.615260161879633e-08
a O 0 3.590459130009549e-07
missense O 0 5.8582547353580594e-05
mutation O 0 1.6260528354905546e-06
, O 0 1.54006905006554e-08
and O 0 1.5299885802733115e-08
1 O 0 6.371973171326317e-08
was O 0 3.2039617963164346e-06
predicted O 0 1.8227433429274242e-06
to O 0 9.109794518735725e-08
cause O 0 2.966863519304752e-07
insertion O 0 2.534374630158709e-07
of O 0 8.438688858802834e-09
an O 0 1.2774860636000085e-07
isoleucine O 0 2.8824717446696013e-05
in O 0 2.274165211701984e-08
the O 0 1.6225159882310436e-08
hect O 0 1.5620578324160306e-06
domain O 0 2.921985675641281e-08
of O 0 3.6723157847973198e-09
the O 0 1.8718408156814803e-08
UBE3A O 0 1.9700470147654414e-05
protein O 0 1.7205510971507465e-07
, O 0 8.588730615599616e-09
which O 0 5.2879127743210574e-09
functions O 0 3.0890161539787186e-09
in O 0 9.196646111320206e-09
E2 O 0 3.6009837458550464e-06
binding O 0 3.332137907818833e-07
and O 0 3.838849238491093e-08
ubiquitin O 0 1.2073805919499137e-06
transfer O 0 8.23283016870846e-07
. O 0 1.0015057796408655e-06

Eight O 0 6.058918188500684e-06
of O 0 9.813842893890978e-08
the O 0 1.0284113471925593e-07
cases O 0 6.028222969689523e-07
were O 0 5.957383564236807e-07
familial O 0 0.0001122198736993596
, O 0 9.252835297957063e-07
and O 0 1.4967837103085913e-07
five O 0 1.3846047863808053e-07
were O 0 2.377892798222092e-07
sporadic O 0 2.7954580218647607e-05
. O 0 5.119642992212903e-06

In O 0 6.931846655788831e-06
two O 0 1.2181599231553264e-06
familial O 0 0.000503686023876071
cases O 0 3.3681683362374315e-06
and O 0 1.1978346492469427e-07
one O 0 3.047345842333016e-07
sporadic O 0 7.754985563224182e-05
case O 0 1.9406166757107712e-05
, O 0 8.365024939394061e-08
mosaicism O 0 1.2279492693778593e-05
for O 0 6.380912509484915e-08
UBE3A O 0 0.0013575215125456452
mutations O 0 3.4736835914372932e-06
was O 0 3.596802855554415e-07
detected O 0 1.2609375232841558e-07
in O 0 8.721103839093303e-09
the O 0 1.8488092834445524e-08
mother O 0 1.1987938250968e-06
of O 0 3.129663639356295e-09
three O 0 8.501034898245052e-08
AS B-Disease 1 0.6766621470451355
sons O 0 3.5498920624377206e-05
, O 0 1.1991393655819138e-08
in O 0 6.348630510188968e-09
the O 0 9.718875482178646e-09
maternal O 0 1.0941699883915135e-06
grandfather O 0 5.908030402679287e-07
of O 0 2.7059423590714005e-09
two O 0 4.215555549080818e-08
AS B-Disease 0 0.027122098952531815
first O 0 6.079600325392676e-07
cousins O 0 1.2657233128265943e-06
, O 0 2.061508475037499e-08
and O 0 1.3373105289815612e-08
in O 0 1.0524296101266373e-08
the O 0 1.9460129507820056e-08
mother O 0 9.778376579561154e-07
of O 0 3.524955660694218e-09
an O 0 4.163373716892238e-07
AS B-Disease 1 0.9818726181983948
daughter O 0 0.24537235498428345
. O 0 4.416830051923171e-06

The O 0 6.553371463269286e-07
frequencies O 0 1.021428033709526e-06
with O 0 4.632028804962829e-08
which O 0 4.787175811316047e-08
we O 0 2.788332587044806e-08
detected O 0 1.0749364491857705e-06
mutations O 0 2.4491603767273773e-07
were O 0 6.480346570469919e-08
5 O 0 3.938994908025961e-08
( O 0 6.2950449297716204e-09
14 O 0 4.3070222943697445e-08
% O 0 3.2682692108210176e-09
) O 0 6.080916326034469e-10
of O 0 1.2456423670315075e-09
35 O 0 2.5176314366603947e-08
in O 0 1.753351064337494e-08
sporadic O 0 6.42946470179595e-05
cases O 0 2.5245519736927235e-06
and O 0 1.7806269170250744e-07
8 O 0 1.3570706869359128e-07
( O 0 9.910676723734468e-09
80 O 0 3.738752241133625e-08
% O 0 5.953609605313659e-09
) O 0 8.139277030139169e-10
of O 0 6.590004097972724e-10
10 O 0 2.141721111570405e-08
in O 0 6.546163433540642e-08
familial O 0 0.00030287980916909873
cases O 0 3.939443558920175e-05
. O 0 1.911439312607399e-06
. O 0 2.231146027042996e-06

The O 0 6.735700299032032e-05
hemochromatosis B-Disease 1 0.9998717308044434
845 O 0 0.013816159218549728
G O 0 0.09748411923646927
- O 0 0.0008114930824376643
- O 0 0.000543816655408591
> O 0 9.906227660394507e-07
A O 0 3.7851086176488025e-07
and O 0 7.284494074610848e-08
187 O 0 6.422378646675497e-07
C O 0 2.000789891098975e-06
- O 0 4.103497849428095e-05
- O 0 0.04195266216993332
> O 0 5.1407590945018455e-05
G O 0 0.08705656975507736
mutations O 0 3.3381188586645294e-06
: O 0 1.1282056533445939e-07
prevalence O 0 1.643335394874157e-06
in O 0 9.729673422498308e-08
non O 0 6.756795301043894e-07
- O 0 0.0008015591301955283
Caucasian O 0 0.0006118188612163067
populations O 0 2.3825650714570656e-06
. O 0 1.0422237437524018e-06

Hemochromatosis B-Disease 1 0.9971820116043091
, O 0 7.153645856305957e-05
the O 0 2.842551657522563e-05
inherited B-Disease 1 0.9999963045120239
disorder I-Disease 1 0.9999741315841675
of I-Disease 0 2.0127866662278393e-07
iron I-Disease 1 0.8414157032966614
metabolism I-Disease 0 8.54851350595709e-06
, O 0 9.999219230394374e-08
leads O 0 1.3889682577428175e-06
, O 0 1.5508582862366893e-07
if O 0 4.413746239606553e-07
untreated O 0 0.0007539205835200846
, O 0 6.674001440387656e-08
to O 0 2.0314344340022217e-07
progressive O 0 0.0003211470611859113
iron B-Disease 1 0.7857257723808289
overload I-Disease 0 0.01172569952905178
and O 0 4.547483968053712e-06
premature B-Disease 0 0.003032239619642496
death I-Disease 0 0.015546675771474838
. O 0 5.320245236362098e-06

The O 0 9.510370728094131e-05
hemochromatosis B-Disease 1 0.9999103546142578
gene O 0 8.151224756147712e-05
, O 0 9.611842415324645e-07
HFE O 0 0.0003774951910600066
, O 0 2.9268227308421046e-07
recently O 0 1.5446885299752466e-06
has O 0 2.8869476409454364e-07
been O 0 1.6942868796832045e-07
identified O 0 1.8431761361625831e-07
, O 0 1.1208868500034441e-08
and O 0 1.026339635501472e-08
characterization O 0 3.1021849622447917e-07
of O 0 3.2493734369865024e-09
this O 0 2.0895120300679082e-08
gene O 0 1.398559277276945e-07
has O 0 3.974488436142565e-07
shown O 0 1.8615587293879798e-07
that O 0 1.4034958084607752e-08
it O 0 1.2699446827468819e-08
contains O 0 1.6370764299722396e-08
two O 0 3.1639064701494135e-08
mutations O 0 1.4596614050788048e-07
that O 0 1.498997193039031e-08
result O 0 3.065598619400589e-08
in O 0 1.1689419210370033e-08
amino O 0 3.2808248562332665e-08
acid O 0 8.033848075683636e-08
substitutions O 0 4.786518204014101e-08
- O 0 2.2795595100433275e-07
cDNA O 0 6.046151383998222e-07
nucleotides O 0 4.408134657296614e-07
845 O 0 3.6482429095485713e-06
G O 0 3.538451710483059e-05
- O 0 1.8148813978768885e-05
- O 0 0.00017353652219753712
> O 0 1.4319056163003552e-06
A O 0 7.755825208732858e-07
( O 0 3.288618444230451e-08
C282Y O 0 1.0121215154867969e-06
) O 0 1.1366505070498079e-08
and O 0 1.7542175712037533e-08
187 O 0 1.190270495499135e-06
C O 0 3.457521643213113e-06
- O 0 0.00017998955445364118
- O 0 0.09397128224372864
> O 0 7.845988147892058e-05
G O 0 0.002898318227380514
( O 0 1.3428065415155288e-07
H63D O 0 7.814627315383404e-05
) O 0 4.480901338865806e-07
. O 0 8.39753852233116e-07

Although O 0 0.015242493711411953
hemochromatosis B-Disease 1 0.9999672174453735
is O 0 5.291428806231124e-06
common O 0 3.4299830531381303e-07
in O 0 1.7303386812272947e-07
Caucasians O 0 1.075827003660379e-05
, O 0 4.1501530745335913e-07
affecting O 0 6.351357910716615e-07
> O 0 1.94551762433548e-06
= O 0 9.311462463301723e-07
1 O 0 1.2289847006741184e-07
/ O 0 3.604828009429184e-07
300 O 0 3.972206741309492e-08
individuals O 0 2.157768630439705e-09
of O 0 2.2466577487278983e-09
northern O 0 8.060646905505564e-08
European O 0 5.6777164303412064e-08
origin O 0 3.11055643464897e-08
, O 0 9.06420805080188e-09
it O 0 1.2638722068913921e-08
has O 0 6.816989639446547e-08
not O 0 1.473108213190244e-08
been O 0 4.6573742196187595e-08
recognized O 0 1.905721980222097e-08
in O 0 1.4629497613327658e-08
other O 0 3.18586401704124e-08
populations O 0 3.226272724532464e-07
. O 0 8.8748060989019e-07

The O 0 2.861040456991759e-06
present O 0 5.059439445176395e-07
study O 0 8.806894413737609e-08
used O 0 6.444182787390673e-08
PCR O 0 3.353364263602998e-06
and O 0 7.20528632314199e-08
restriction O 0 2.1958256013476785e-07
- O 0 1.6115873222588561e-06
enzyme O 0 1.3742045723574847e-07
digestion O 0 9.291825620039162e-08
to O 0 7.757583908585275e-09
analyze O 0 3.140021576086838e-08
the O 0 5.195366803434354e-09
frequency O 0 4.036622414105295e-08
of O 0 8.540405049828337e-10
the O 0 2.0965661207128505e-08
845 O 0 1.0621338333294261e-05
G O 0 0.003986011259257793
- O 0 0.00012005470489384606
- O 0 0.00012473184324335307
> O 0 4.0729955230744963e-07
A O 0 1.5599781022501702e-07
and O 0 5.529281921212714e-08
187 O 0 6.143432074168231e-07
C O 0 9.44464886742935e-07
- O 0 1.7379907149006613e-05
- O 0 0.0031428374350070953
> O 0 2.082550599880051e-05
G O 0 0.00238575367256999
mutations O 0 1.1553385093066026e-06
in O 0 5.3662112975416676e-08
HLA O 0 0.000119714968604967
- O 0 6.669622962363064e-05
typed O 0 1.7925754036696162e-06
samples O 0 7.58938227818362e-08
from O 0 9.873657447201367e-09
non O 0 5.75527074886395e-08
- O 0 5.942726147623034e-06
Caucasian O 0 2.6909490770776756e-05
populations O 0 1.0261893379492903e-07
, O 0 1.987788778023969e-08
comprising O 0 1.9854622834714064e-08
Australian O 0 1.8525796008361795e-07
Aboriginal O 0 1.1681066069968438e-07
, O 0 7.927022593889888e-09
Chinese O 0 4.506165662832018e-09
, O 0 1.0229644686887696e-08
and O 0 3.243690471776972e-08
Pacific O 0 2.5712623141771473e-07
Islanders O 0 6.3095121731748804e-06
. O 0 1.2976979633094743e-06

Results O 0 0.00019757778500206769
showed O 0 1.3888732610212173e-05
that O 0 1.020052096123436e-07
the O 0 7.12547247871953e-08
845 O 0 2.5229313905583695e-05
G O 0 0.02907600998878479
- O 0 0.001221361686475575
- O 0 0.0015232842415571213
> O 0 1.0056538712888141e-06
A O 0 1.6213176650126115e-06
mutation O 0 1.3130861589161213e-06
was O 0 9.453390248381766e-07
present O 0 2.4918671570617335e-08
in O 0 7.263484924635577e-09
these O 0 4.013925636314752e-09
populations O 0 1.4563097394670876e-08
( O 0 7.298230464414246e-09
allele O 0 3.096255625223421e-07
frequency O 0 2.6829667376659927e-07
0 O 0 7.842402283131378e-08
. O 0 1.060694021504105e-08
32 O 0 7.264583246069378e-08
% O 0 9.830813496591873e-09
) O 0 4.133228870273342e-09
, O 0 9.74220526472891e-09
and O 0 3.798382763875452e-08
, O 0 8.253483940734441e-08
furthermore O 0 7.920163369590227e-08
, O 0 5.175269546242589e-09
it O 0 7.647662947363187e-09
was O 0 1.188950591313187e-07
always O 0 4.386495788821776e-08
seen O 0 6.062600732548162e-08
in O 0 1.0657517535150873e-08
conjunction O 0 2.1246574988253997e-07
with O 0 8.465887617603585e-07
HLA O 0 0.20038799941539764
haplotypes O 0 0.0010982874082401395
common O 0 4.631268950561207e-07
in O 0 1.1468283389604039e-07
Caucasians O 0 5.013065674575046e-06
, O 0 7.896361609027736e-08
suggesting O 0 2.2537990673754393e-07
that O 0 9.443949267051721e-08
845 O 0 1.1424882359278854e-05
G O 0 0.01019679382443428
- O 0 0.000958841061219573
- O 0 0.028253935277462006
> O 0 4.299571628507692e-06
A O 0 1.2980065548617858e-05
may O 0 2.5347424070787383e-06
have O 0 3.342369581105231e-08
been O 0 2.6147537468546034e-08
introduced O 0 3.116655378221367e-08
into O 0 6.635767491047773e-09
these O 0 5.804822844623914e-09
populations O 0 2.5078019660895734e-08
by O 0 7.137496993436798e-08
Caucasian O 0 1.410985532857012e-05
admixture O 0 6.553383718710393e-05
. O 0 1.0902662324951962e-05

187 O 0 0.00034825963666662574
C O 0 8.78581777215004e-05
- O 0 0.00015207636170089245
- O 0 0.002372347516939044
> O 0 1.4303430361906067e-05
G O 0 0.0001112793615902774
was O 0 4.900933845419786e-07
present O 0 1.3415310640141342e-08
at O 0 5.081418841257346e-09
an O 0 1.496803037071004e-08
allele O 0 3.100292076396727e-07
frequency O 0 1.596521173041765e-07
of O 0 1.1318435078067068e-08
2 O 0 1.0495989499759162e-06
. O 0 9.157107001556142e-07

68 O 0 0.0020452546887099743
% O 0 1.1564188753254712e-06
in O 0 2.0529975941485645e-08
the O 0 1.3700322654131014e-08
two O 0 1.2834672702410899e-07
populations O 0 1.2844689933899645e-07
analyzed O 0 9.828742122408585e-07
( O 0 3.673396165027043e-08
Australian O 0 3.5520355368134915e-07
Aboriginal O 0 2.4143670884768653e-07
and O 0 9.45564693211054e-08
Chinese O 0 1.1902370999905543e-07
) O 0 2.9054808692308143e-07
. O 0 1.2251210819158587e-06

In O 0 3.053579348488711e-06
the O 0 2.455254843880539e-07
Australian O 0 6.422182536880428e-07
Aboriginal O 0 2.96257439913461e-07
samples O 0 1.0356394142263525e-07
, O 0 2.4736166892580513e-08
187 O 0 3.9465572854169295e-07
C O 0 1.6412868717452511e-06
- O 0 3.576038216124289e-05
- O 0 0.00815550796687603
> O 0 9.867495464277454e-06
G O 0 8.325109229190275e-05
was O 0 4.1303792386315763e-07
found O 0 1.6420738546685243e-08
to O 0 1.5256379271022524e-08
be O 0 4.46275123522355e-08
associated O 0 3.643100043859704e-08
with O 0 2.086615182861351e-07
HLA O 1 0.620402991771698
haplotypes O 0 0.005875487346202135
common O 0 4.519621654708317e-07
in O 0 3.112521369530441e-07
Caucasians O 0 1.0959768587781582e-05
, O 0 1.328149892287911e-07
suggesting O 0 1.8464803019924148e-07
that O 0 2.3127643800080477e-08
it O 0 2.5683648985364016e-08
was O 0 2.9215186714282027e-07
introduced O 0 1.318487932167045e-07
by O 0 4.341481485425902e-08
recent O 0 1.0040860161097953e-06
admixture O 0 2.963894439744763e-05
. O 0 5.747307113779243e-06

In O 0 1.8745795387076214e-06
the O 0 1.0130062833013653e-07
Chinese O 0 7.165460402802637e-08
samples O 0 1.1295622215357071e-07
analyzed O 0 2.6061903213303594e-07
, O 0 2.4602208270607662e-08
187 O 0 2.922764394952537e-07
C O 0 1.3742912869929569e-06
- O 0 6.589260010514408e-05
- O 0 0.023814698681235313
> O 0 1.278741274290951e-05
G O 0 0.0005343082593753934
was O 0 9.034719141709502e-07
present O 0 2.4427473377386377e-08
in O 0 2.5433614325720555e-08
association O 0 1.101259261560017e-08
with O 0 6.454107470688086e-09
a O 0 2.0794081478925364e-07
wide O 0 3.2541422001486353e-07
variety O 0 4.579260703962973e-08
of O 0 2.607412952215782e-08
HLA O 0 0.09560389816761017
haplotypes O 0 0.000314962409902364
, O 0 8.44732426230621e-08
showing O 0 2.99191242447705e-07
this O 0 9.653843058288203e-09
mutation O 0 1.3793857078781002e-07
to O 0 1.7474750535484418e-08
be O 0 4.2463341287657386e-08
widespread O 0 5.962090199318482e-07
and O 0 7.317148060792533e-07
likely O 0 2.5191600343532627e-06
to O 0 1.1701135349539982e-07
predate O 0 8.409335237047344e-07
the O 0 1.725503118166216e-08
more O 0 2.2227640172900465e-08
genetically O 0 2.492899398021109e-07
restricted O 0 1.350277614164952e-07
845 O 0 1.2444729691196699e-05
G O 0 0.010343624278903008
- O 0 0.0006137274904176593
- O 0 0.006374593824148178
> O 0 5.324539415596519e-06
A O 0 8.632601748104207e-06
mutation O 0 1.2261518349987455e-05
. O 0 1.9208575849916087e-06

Genotype O 1 0.9851303100585938
- O 1 0.9321904182434082
phenotype O 1 0.9782580733299255
correlations O 0 0.0008766843238845468
in O 0 6.736985233146697e-05
attenuated B-Disease 1 0.9988766312599182
adenomatous I-Disease 1 0.9999949932098389
polyposis I-Disease 1 0.9999583959579468
coli I-Disease 1 0.9997726082801819
. O 0 0.00014098038082011044

Germ O 0 0.0008163720485754311
- O 0 0.0019009083043783903
line O 0 3.476582423900254e-05
mutations O 0 2.5459009975747904e-06
of O 0 2.3722204645082456e-08
the O 0 1.1675074773620508e-07
tumor B-Disease 0 7.020184420980513e-05
suppressor O 0 0.00022442726185545325
APC O 0 2.9946586437290534e-05
are O 0 2.505584006939898e-07
implicated O 0 1.3483410839398857e-05
in O 0 2.164779471058864e-05
attenuated B-Disease 1 0.9996770620346069
adenomatous I-Disease 1 0.9999995231628418
polyposis I-Disease 1 0.9999984502792358
coli I-Disease 1 0.9999960660934448
( O 0 0.0002490159240551293
AAPC B-Disease 1 0.9999632835388184
) O 0 6.29393753115437e-07
, O 0 6.504159699716183e-08
a O 0 4.707162872819026e-07
variant O 0 5.6324493925785646e-05
of O 0 1.8994894617208047e-06
familial B-Disease 1 0.9999974966049194
adenomatous I-Disease 1 0.9999949932098389
polyposis I-Disease 1 0.9999995231628418
( O 0 7.495379395550117e-05
FAP B-Disease 0 0.06065426766872406
) O 0 6.1393420764943585e-06
. O 0 4.87754596179002e-06

AAPC B-Disease 1 0.9999603033065796
is O 0 3.3077139960369095e-05
recognized O 0 6.252692514863156e-07
by O 0 3.144756632877943e-08
the O 0 1.904904323168921e-08
occurrence O 0 1.239467337654787e-07
of O 0 2.3210724009459227e-08
< O 0 2.299153038620716e-06
100 O 0 2.785494928048138e-07
colonic B-Disease 0 0.00040739463292993605
adenomas I-Disease 0 0.00023914083431009203
and O 0 1.2653103453885706e-07
a O 0 4.070199963734922e-07
later O 0 1.9674989744089544e-06
onset O 0 3.2895222830120474e-05
of O 0 0.00040940663893707097
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.9082738162978785e-06
age O 0 1.854166384873679e-06
> O 0 7.499781986552989e-07
40 O 0 2.124503453160287e-07
years O 0 1.9364460968063213e-07
) O 0 2.4333127157660783e-07
. O 0 7.436473765665141e-07

The O 0 1.5566536148980958e-06
aim O 0 1.0069801419376745e-06
of O 0 2.2495747487027984e-08
this O 0 1.4334448295016955e-08
study O 0 3.037022722196525e-08
was O 0 1.4631204692250321e-07
to O 0 8.668140338841113e-08
assess O 0 8.830154911265709e-06
genotype O 0 0.0038102781400084496
- O 0 0.041981618851423264
phenotype O 0 0.1524827778339386
correlations O 0 2.998791023856029e-05
in O 0 1.2628028343897313e-05
AAPC B-Disease 1 0.9999606609344482
families O 0 6.495423440355808e-05
. O 0 6.042696895747213e-06

By O 0 2.3237716959556565e-06
protein O 0 1.130435634877358e-06
- O 0 4.07707102567656e-06
truncation O 0 1.3900115845899563e-05
test O 0 2.3954560219863197e-06
( O 0 2.515044528195176e-08
PTT O 0 1.1024972081941087e-06
) O 0 1.25271224504786e-08
assay O 0 1.4946526505354996e-07
, O 0 2.8835993592934983e-09
the O 0 1.5465236868905663e-09
entire O 0 1.813440775322306e-08
coding O 0 1.6454261242415669e-07
region O 0 9.050560301204769e-09
of O 0 1.2368142066065957e-09
the O 0 9.161997382989284e-09
APC B-Disease 0 1.652163746257429e-06
gene O 0 1.8278525715231808e-07
was O 0 4.2630071561688965e-07
screened O 0 2.4375776774832048e-06
in O 0 9.155903768487406e-08
affected O 0 1.8766137088732648e-07
individuals O 0 1.3006533627901717e-08
from O 0 3.6597729291543146e-08
11 O 0 3.3135947887785733e-06
AAPC B-Disease 1 0.9999574422836304
kindreds O 0 0.0002424964914098382
, O 0 4.643306894536181e-08
and O 0 1.735997301466341e-08
their O 0 3.841222095957164e-08
phenotypic O 0 1.381211041007191e-05
differences O 0 3.0019123187230434e-06
were O 0 2.0602328731911257e-06
examined O 0 6.483089964604005e-05
. O 0 2.4703504095668904e-06

Five O 0 2.598744868009817e-05
novel O 0 1.8551992980064824e-05
germ O 0 2.877522820199374e-05
- O 0 9.121201583184302e-05
line O 0 1.278465788345784e-05
APC B-Disease 0 2.562367808423005e-05
mutations O 0 4.0702066144149285e-06
were O 0 1.74187533730219e-07
identified O 0 3.012164881965873e-07
in O 0 8.09685758440537e-08
seven O 0 1.0273306543240324e-06
kindreds O 0 7.458296022377908e-05
. O 0 3.228314653824782e-06

Mutations O 0 0.06957991421222687
were O 0 2.625231218189583e-06
located O 0 1.3190236813898082e-07
in O 0 2.491657902226052e-08
three O 0 2.5744906650970734e-08
different O 0 5.607435848986597e-09
regions O 0 6.326340340478964e-09
of O 0 2.2644728314702434e-09
the O 0 4.161137923119895e-08
APC B-Disease 0 5.021583092457149e-06
gene O 0 2.777388488084398e-07
( O 0 4.4339691918082735e-09
1 O 0 5.568002947597961e-09
) O 0 1.8800121459605634e-09
at O 0 2.0024386593320287e-09
the O 0 3.1720863713502467e-09
5 O 0 1.8330190698634397e-08
end O 0 5.804670877296303e-08
spanning O 0 2.824641853749199e-07
exons O 0 8.446468200418167e-07
4 O 0 6.641987937427984e-08
and O 0 1.7816113029311964e-08
5 O 0 4.883997206661661e-08
, O 0 2.148861355522058e-08
( O 0 5.693307603138464e-09
2 O 0 1.6997789842321254e-08
) O 0 4.164772082759782e-09
within O 0 2.6336020031436647e-09
exon O 0 2.587907204087969e-07
9 O 0 1.0904910396902778e-07
, O 0 1.6980809647293427e-08
and O 0 1.545560124327494e-08
( O 0 5.314079398743843e-09
3 O 0 1.2454552944518582e-08
) O 0 3.4142697558081636e-09
at O 0 3.98431510006958e-09
the O 0 1.0292822594237805e-08
3 O 0 1.0657623050747134e-07
distal O 0 4.153765985392965e-06
end O 0 1.4332238151837373e-07
of O 0 1.5963925292794556e-08
the O 0 1.9478738977340981e-07
gene O 0 3.163615929224761e-06
. O 0 1.301881525250792e-06

Variability O 0 0.010007984936237335
in O 0 1.8381223299002158e-06
the O 0 7.085235864678907e-08
number O 0 1.1861170179372493e-07
of O 0 1.6660493429299095e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999991655349731
was O 0 0.16234610974788666
most O 0 4.774764761350525e-07
apparent O 0 3.5301542084198445e-05
in O 0 9.216404350809171e-08
individuals O 0 1.6169797945053688e-08
with O 0 1.5408600972932618e-07
mutations O 0 2.484130618540803e-06
in O 0 7.847205552025116e-08
region O 0 1.105920048871667e-07
1 O 0 7.696644388488494e-08
, O 0 2.7109960498705732e-08
and O 0 1.9518012095431914e-07
upper O 0 0.0002671402762643993
- O 1 0.960042417049408
gastrointestinal O 1 0.9995798468589783
manifestations O 0 8.589631033828482e-05
were O 0 1.1233158829782042e-06
more O 0 1.7860317313989071e-07
severe O 0 0.008063310757279396
in O 0 2.1383213777426135e-07
them O 0 2.145151540844381e-07
. O 0 1.3944388683739817e-06

In O 0 2.7527392376214266e-05
individuals O 0 6.521886461996473e-07
with O 0 3.128761534298974e-07
mutations O 0 3.3074190923798596e-06
in O 0 8.409594443037349e-08
either O 0 1.49869336496522e-07
region O 0 1.5058581936955306e-07
2 O 0 3.0401326966966735e-07
or O 0 5.559547489042416e-08
region O 0 6.262664697942455e-08
3 O 0 3.4098327716947097e-08
, O 0 3.832014705551501e-09
the O 0 1.9610129076141902e-09
average O 0 2.2665092913598528e-08
number O 0 2.0646397924650728e-09
of O 0 4.301101252934814e-09
adenomas B-Disease 0 5.296152085065842e-05
tended O 0 2.3547809178126045e-05
to O 0 1.2204630195356003e-07
be O 0 9.599936134918607e-08
lower O 0 3.443157936544594e-07
than O 0 3.7284195286702015e-08
those O 0 1.1955470391455947e-08
in O 0 2.529332299161524e-08
individuals O 0 6.218597636831191e-09
with O 0 8.236813897610773e-08
mutations O 0 2.2074902972235577e-06
in O 0 3.88414456153896e-08
region O 0 6.280488662468997e-08
1 O 0 8.685269392572081e-08
, O 0 4.1399214723014666e-08
although O 0 1.0642834524787759e-07
age O 0 9.487406060770809e-08
at O 0 6.314721900935183e-08
diagnosis O 0 0.0009334289934486151
was O 0 1.3048303117102478e-05
similar O 0 1.55980546878709e-06
. O 0 2.183895503549138e-06

In O 0 8.93836568138795e-06
all O 0 2.082650098600425e-06
AAPC B-Disease 1 0.9992740750312805
kindreds O 0 0.0007591205649077892
, O 0 2.9319295435925596e-07
a O 0 2.6531967023402103e-07
predominance O 0 5.077365585748339e-06
of O 0 1.7513114869416313e-07
right O 0 0.00016983124078251421
- O 1 0.9985936284065247
sided O 1 0.9999990463256836
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999905824661255
and O 0 0.00035706712515093386
rectal B-Disease 1 0.9995342493057251
polyp I-Disease 1 0.942608118057251
sparing O 0 0.00016363842587452382
was O 0 6.707765714963898e-05
observed O 0 7.3577716648287605e-06
. O 0 2.055185632343637e-06

No O 0 0.00023638451239094138
desmoid B-Disease 1 0.7614673972129822
tumors I-Disease 1 0.9999679327011108
were O 0 1.8657688087841962e-06
found O 0 2.146543351955188e-07
in O 0 5.205179220979517e-08
these O 0 8.232071024849574e-08
kindreds O 0 5.0044545787386596e-05
. O 0 3.819932317128405e-06

Our O 0 4.967090262653073e-06
data O 0 6.003592716297135e-07
suggest O 0 2.518366954973317e-07
that O 0 4.905469808136331e-08
, O 0 1.5617256110544986e-07
in O 0 8.414084504693164e-07
AAPC B-Disease 1 0.9999926090240479
families O 0 1.4952314586480497e-06
, O 0 1.0947023731944228e-08
the O 0 4.219302240926481e-09
location O 0 1.9168151510484677e-08
of O 0 4.01414013140311e-09
the O 0 5.995948271220186e-08
APC B-Disease 0 0.0009732349426485598
mutation O 0 6.854996172478423e-05
may O 0 1.1420527243899414e-06
partially O 0 1.452925857847731e-06
predict O 0 9.060017305273504e-07
specific O 0 8.135652507235136e-08
phenotypic O 0 2.6800906198332086e-05
expression O 0 8.539468581147958e-06
. O 0 1.7314672504653572e-06

This O 0 8.74507520620682e-07
should O 0 1.1402512001268406e-07
help O 0 4.284555643607746e-08
in O 0 6.9201924191020225e-09
the O 0 4.769510564273105e-09
design O 0 1.9671207951432734e-07
of O 0 1.9608494383760444e-08
tailored O 0 0.00019081625214312226
clinical O 0 0.0013014946598559618
- O 0 0.03747553750872612
management O 0 7.473357754861354e-07
protocols O 0 3.711774070325191e-07
in O 0 2.2142335964758786e-08
this O 0 5.0985540234194104e-09
subset O 0 8.024888842328437e-08
of O 0 9.531135702900428e-08
FAP B-Disease 1 0.9677519202232361
patients O 1 0.993831992149353
. O 0 8.936959829952684e-07
. O 0 1.1271102948740008e-06

Wilms B-Disease 1 0.6836312413215637
' I-Disease 0 0.0004967348068021238
tumor I-Disease 0 0.00011836328485514969
1 O 0 2.6254238605361024e-07
and O 0 1.2651896952320385e-07
Dax O 0 8.529351907782257e-05
- O 0 2.538166518206708e-05
1 O 0 1.1355415097114019e-07
modulate O 0 8.724383633307298e-07
the O 0 1.9192881950402807e-08
orphan O 0 1.8862017441279022e-06
nuclear O 0 5.606614763564721e-07
receptor O 0 9.82862957243924e-07
SF O 0 0.0022651462350040674
- O 0 1.0529683095228393e-05
1 O 0 5.5761464778925074e-08
in O 0 1.0134696637464913e-08
sex O 0 1.002555407580985e-07
- O 0 2.361101678616251e-06
specific O 0 3.999278064270584e-08
gene O 0 5.945725547462644e-07
expression O 0 1.4259125009630225e-06
. O 0 1.3795004178973613e-06

Products O 0 6.576620307896519e-06
of O 0 2.5507247869427374e-07
steroidogenic O 0 6.384277367033064e-05
factor O 0 1.1354736670909915e-06
1 O 0 4.002514231160603e-07
( O 0 1.2173175889529375e-07
SF O 1 0.6526955366134644
- O 0 0.000889250950422138
1 O 0 2.8354054393275874e-07
) O 0 3.416649008158856e-08
and O 0 2.089383031034231e-07
Wilms B-Disease 0 0.13861356675624847
tumor I-Disease 0 0.0002566824550740421
1 O 0 3.524521048348106e-07
( O 0 4.5411638893710915e-08
WT1 O 0 2.7434280127636157e-05
) O 0 5.234969080447627e-08
genes O 0 3.6047037355046996e-08
are O 0 2.5315030072192712e-09
essential O 0 5.485234932933736e-09
for O 0 8.929282202529976e-09
mammalian O 0 3.6007014614369837e-07
gonadogenesis O 0 1.3405290701484773e-05
prior O 0 1.3810047505558032e-07
to O 0 7.430477211300968e-08
sexual O 0 3.92295049778113e-07
differentiation O 0 2.2714311853633262e-06
. O 0 2.7574992600420956e-06

In O 0 1.866158527263906e-05
males O 0 1.6716559912310913e-05
, O 0 1.0799403753480874e-06
SF O 1 0.649474024772644
- O 0 0.0003953780105803162
1 O 0 2.370717169242198e-07
participates O 0 5.1531792166770174e-08
in O 0 9.565023439961351e-09
sexual O 0 2.6613864889668548e-08
development O 0 3.5661258390717876e-09
by O 0 7.617934727477405e-09
regulating O 0 1.0185453191979832e-07
expression O 0 1.0116681892213819e-07
of O 0 8.692905062446243e-09
the O 0 4.9384400568897036e-08
polypeptide O 0 3.202496736776084e-05
hormone O 0 9.761394721863326e-06
Mullerian O 0 1.8529241060605273e-05
inhibiting O 0 6.279293756961124e-06
substance O 0 7.604684924444882e-06
( O 0 2.1354480850277469e-07
MIS O 0 4.784343036590144e-05
) O 0 1.3472744058162789e-06
. O 0 1.4937447758711642e-06

Here O 0 2.326946969333221e-06
, O 0 1.279126990993973e-07
we O 0 1.122187409663411e-08
show O 0 8.077407187556673e-08
that O 0 6.282441233906866e-08
WT1 O 0 8.260027243522927e-05
- O 0 9.213971497956663e-05
KTS O 0 0.001236847834661603
isoforms O 0 2.285616346853203e-06
associate O 0 2.702194876746944e-07
and O 0 6.661818474640313e-08
synergize O 0 8.886561772669666e-06
with O 0 2.5922990971594118e-06
SF O 1 0.9922299981117249
- O 0 0.0005246098153293133
1 O 0 2.029844523576685e-07
to O 0 8.262162509709015e-08
promote O 0 3.698699799770111e-07
MIS O 0 0.0002338810299988836
expression O 0 1.7041154933394864e-05
. O 0 4.50085235570441e-06

In O 0 1.878138391475659e-05
contrast O 0 2.275587758049369e-05
, O 0 1.210048026223376e-06
WT1 O 0 0.023283669725060463
missense O 0 0.037305790930986404
mutations O 0 0.00013757302076555789
, O 0 2.8820397801609943e-07
associated O 0 1.476459061677815e-07
with O 0 3.5514122487256827e-07
male B-Disease 0 0.0043087308295071125
pseudohermaphroditism I-Disease 1 0.9999765157699585
in O 0 2.1360405298764817e-05
Denys B-Disease 1 0.9513557553291321
- I-Disease 1 0.9997583031654358
Drash I-Disease 1 0.9999306201934814
syndrome I-Disease 1 0.9999855756759644
, O 0 2.7862546403412125e-07
fail O 0 1.2528815886980738e-06
to O 0 9.138719292423048e-08
synergize O 0 5.296091330819763e-05
with O 0 8.204314326576423e-06
SF O 1 0.9991260170936584
- O 0 0.009662985801696777
1 O 0 3.2709515380702214e-06
. O 0 1.7598042632016586e-06

Additionally O 0 5.386561679188162e-05
, O 0 5.298455789670697e-07
the O 0 4.470640391218694e-08
X O 0 0.0001056452383636497
- O 0 0.0027170879766345024
linked O 0 2.5563856979715638e-05
, O 0 6.241391048433798e-08
candidate O 0 3.614632362314296e-07
dosage O 0 1.973491634998936e-06
- O 0 2.7149681045557372e-06
sensitive O 0 3.824539760444168e-07
sex O 0 5.217892748987651e-07
- O 0 4.661561433749739e-06
reversal O 0 1.3879320249543525e-05
gene O 0 5.516429268936918e-07
, O 0 7.72812427385361e-08
Dax O 0 3.3520434953970835e-05
- O 0 1.5592593626934104e-05
1 O 0 1.371898576962849e-07
, O 0 3.3913540420371646e-08
antagonizes O 0 2.8978979571547825e-06
synergy O 0 1.214033432006545e-06
between O 0 2.6174538447776285e-07
SF O 1 0.8379542231559753
- O 0 0.0007501398795284331
1 O 0 3.191423445514374e-07
and O 0 6.438899902150297e-08
WT1 O 0 2.3844471797929145e-05
, O 0 3.191027175830641e-08
most O 0 1.4460630914925332e-08
likely O 0 3.658495728586786e-08
through O 0 2.126683051884015e-09
a O 0 3.2415506723282306e-08
direct O 0 3.122438840819086e-08
interaction O 0 2.951651190130633e-08
with O 0 6.234704414964654e-07
SF O 1 0.998218834400177
- O 0 0.02981412597000599
1 O 0 3.5812506666843547e-06
. O 0 9.165677852251974e-07

We O 0 2.9492873636627337e-06
propose O 0 4.083133262611227e-06
that O 0 3.24105371873884e-07
WT1 O 0 5.420261368271895e-05
and O 0 6.596114872081671e-07
Dax O 0 0.0006376881501637399
- O 0 0.0006394588272087276
1 O 0 6.722203806930338e-07
functionally O 0 1.3159394711692585e-06
oppose O 0 1.0943436024035691e-07
each O 0 8.263451256596e-09
other O 0 4.23263424309539e-09
in O 0 4.113592666499244e-08
testis O 0 1.4577832189388573e-05
development O 0 7.397937906716834e-08
by O 0 2.0185227356250834e-07
modulating O 0 0.00017946121806744486
SF O 1 0.9890215992927551
- O 0 0.0007671117782592773
1 O 0 2.348236421312322e-06
- O 0 3.71847563656047e-05
mediated O 0 0.00012341811088845134
transactivation O 0 0.00035662364098243415
. O 0 1.100562144529249e-06
. O 0 1.0459737040946493e-06

A O 0 3.287173603894189e-05
mouse O 0 5.0697191909421235e-05
model O 0 2.9261185773066245e-05
for O 0 1.6734073142288253e-05
Prader B-Disease 1 0.9999997615814209
- I-Disease 1 0.999998927116394
Willi I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.999997615814209
imprinting O 0 0.0014712868724018335
- O 0 0.04675741121172905
centre O 0 0.00017578010738361627
mutations O 0 6.582929927390069e-05
. O 0 2.642001390995574e-06

Imprinting O 0 0.0007973219035193324
in O 0 4.22298626290285e-06
the O 0 2.925112312368583e-07
15q11 O 0 1.0347926945541985e-05
- O 0 8.856848580762744e-06
q13 O 0 6.123082130216062e-06
region O 0 4.4380328745319275e-08
involves O 0 3.586126240406884e-08
an O 0 5.077894371652292e-08
imprinting O 0 7.284372259164229e-06
centre O 0 1.1738313787645893e-06
( O 0 2.1569425356915417e-08
IC O 0 1.2508915006037569e-06
) O 0 2.5262322012054028e-08
, O 0 1.00337373964976e-08
mapping O 0 5.2417231444223944e-08
in O 0 6.721240008999985e-09
part O 0 8.272124318864371e-09
to O 0 1.2777268132424524e-08
the O 0 9.425356495285087e-09
promoter O 0 1.0850153557839803e-06
and O 0 4.2814761513909616e-08
first O 0 1.0796505023336067e-07
exon O 0 1.464378556192969e-06
of O 0 1.4326745656489948e-07
SNRPN O 0 0.0006693074246868491
. O 0 3.0854430406179745e-06

Deletion O 0 0.0005219632876105607
of O 0 1.0299498853783007e-06
this O 0 2.735740167736367e-07
IC O 0 5.1821189117617905e-05
abolishes O 0 0.00020485954883042723
local O 0 3.1343972750619287e-07
paternally O 0 5.596088158199564e-06
derived O 0 1.1103882968654943e-07
gene O 0 1.2954545525190042e-07
expression O 0 1.1745319028477752e-07
and O 0 8.010101026911798e-08
results O 0 5.17361331731081e-06
in O 0 0.0004848058451898396
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 7.092735904734582e-05
PWS B-Disease 1 0.9999321699142456
) O 0 2.8266354092920665e-06
. O 0 2.7865200991072925e-06

We O 0 3.1268962175090564e-06
have O 0 1.765978225876097e-07
created O 0 1.3071223747829208e-07
two O 0 6.375255168222793e-08
deletion O 0 0.0001503470411989838
mutations O 0 6.565496732946485e-06
in O 0 1.1981956049567088e-07
mice O 0 0.0003527218068484217
to O 0 1.4887418728903867e-06
understand O 0 2.6140785848838277e-05
PWS B-Disease 1 0.9999535083770752
and O 0 2.1381991643920628e-07
the O 0 2.4675472332091886e-08
mechanism O 0 2.8905777327281612e-08
of O 0 7.814342950496211e-09
this O 0 2.2374096886323969e-07
IC O 0 0.0001911976287374273
. O 0 4.97968767376733e-06

Mice O 0 0.12182502448558807
harbouring O 0 0.000756902270950377
an O 0 4.048616119689541e-06
intragenic O 0 0.0002061893610516563
deletion O 0 2.909808790718671e-05
in O 0 2.452965759403014e-07
Snrpn O 0 3.528511297190562e-05
are O 0 1.0745412026835766e-07
phenotypically O 0 6.475472036981955e-05
normal O 0 2.0621816076982213e-07
, O 0 2.951251509841768e-08
suggesting O 0 1.6058267249263736e-07
that O 0 2.637167284547104e-08
mutations O 0 9.323994731857965e-08
of O 0 6.02051519749125e-09
SNRPN O 0 0.0011678342707455158
are O 0 3.005433057978735e-08
not O 0 3.497072142977231e-08
sufficient O 0 3.2511763947695727e-07
to O 0 1.4649554032075685e-06
induce O 0 0.0008185335318557918
PWS B-Disease 1 0.9999392032623291
. O 0 2.146328188246116e-05

Mice O 0 0.03142327070236206
with O 0 7.548352982666984e-07
a O 0 1.0662721479093307e-06
larger O 0 4.340550390224962e-07
deletion O 0 4.112309397896752e-06
involving O 0 1.1536282329416281e-07
both O 0 4.752522286821659e-08
Snrpn O 0 5.671828603226459e-06
and O 0 4.738031833539935e-08
the O 0 7.777024535471355e-08
putative O 0 0.0003877699200529605
PWS O 1 0.9999333620071411
- O 0 0.05544883385300636
IC O 0 0.00041101445094682276
lack O 0 2.173361735913204e-06
expression O 0 2.1541801231705904e-07
of O 0 7.927353884440436e-09
the O 0 3.9414754127165e-08
imprinted O 0 2.1288597054081038e-05
genes O 0 4.6890841076674405e-07
Zfp127 O 0 3.715673756232718e-06
( O 0 1.610767874637986e-08
mouse O 0 3.379273607606592e-07
homologue O 0 2.5956810532079544e-06
of O 0 7.434715598719777e-08
ZNF127 O 0 0.00012774784408975393
) O 0 6.985108313983801e-08
, O 0 4.280553156377209e-08
Ndn O 0 2.0495251646934776e-06
and O 0 5.3580397008090586e-08
Ipw O 0 1.628727295610588e-05
, O 0 9.977862447385633e-08
and O 0 4.922040020005625e-08
manifest O 0 3.2063276194094215e-06
several O 0 1.3689580669051793e-07
phenotypes O 0 1.779171361704357e-05
common O 0 3.5534958442440256e-07
to O 0 6.856290565337986e-05
PWS B-Disease 1 0.9999992847442627
infants O 1 0.9994365572929382
. O 0 8.255093234765809e-06

These O 0 1.3882331586501095e-06
data O 0 3.009506031048659e-07
demonstrate O 0 3.7517006035159284e-07
that O 0 1.5247943352392213e-08
both O 0 4.90144547171667e-09
the O 0 4.585306356830188e-09
position O 0 3.6360610522478964e-08
of O 0 2.218210060078718e-09
the O 0 1.9609915469231964e-08
IC O 0 5.303306352288928e-06
and O 0 6.268352592542215e-08
its O 0 1.6666383828578546e-08
role O 0 3.622728073082726e-08
in O 0 7.77995889933436e-09
the O 0 5.623588261727264e-09
coordinate O 0 1.0258175109356671e-07
expression O 0 1.409610348446222e-07
of O 0 4.245862328389194e-09
genes O 0 3.023751915520734e-08
is O 0 1.038729013913553e-08
conserved O 0 2.39283348690833e-08
between O 0 7.100966925577268e-09
mouse O 0 6.771605853828078e-07
and O 0 4.089302763077285e-08
human O 0 2.2778204211704178e-08
, O 0 1.7576235578076194e-08
and O 0 3.789365976558656e-08
indicate O 0 1.3632711670652498e-07
that O 0 6.5573324548040546e-09
the O 0 5.955835824522637e-09
mouse O 0 7.879614258854417e-07
is O 0 3.104007362253469e-08
a O 0 7.109304789310045e-08
suitable O 0 1.1741511229956814e-07
model O 0 4.3066569332950166e-07
system O 0 2.277203492440094e-08
in O 0 1.2688938788585347e-08
which O 0 2.2651780895444062e-08
to O 0 2.487991679345214e-08
investigate O 0 1.070423394367026e-07
the O 0 1.3507072793572661e-08
molecular O 0 9.095939645931139e-08
mechanisms O 0 1.0125016380868601e-08
of O 0 4.408199583139094e-09
imprinting O 0 2.0600423340511043e-06
in O 0 2.885075289782435e-08
this O 0 1.2154307782452634e-08
region O 0 1.6045921924501272e-08
of O 0 3.12482040243367e-09
the O 0 3.0595760591722865e-08
genome O 0 2.1406884798125247e-07
. O 0 1.189785336919158e-07
. O 0 4.725378914827161e-07

Mutations O 0 0.0006488488870672882
of O 0 3.461404389781819e-07
the O 0 1.2869898569078941e-07
ATM O 0 3.3973476547544124e-06
gene O 0 1.9961053112638183e-06
detected O 0 1.1000290669471724e-06
in O 0 1.6673608627115755e-07
Japanese O 0 0.0009444192983210087
ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999994039535522
telangiectasia I-Disease 1 0.9999998807907104
patients O 1 0.998806357383728
: O 0 1.1087079343496953e-07
possible O 0 8.042081134362888e-08
preponderance O 0 1.532268697701511e-06
of O 0 3.4749558786018042e-09
the O 0 1.814734851279809e-08
two O 0 9.568841363716274e-08
founder O 0 1.3927741747465916e-05
mutations O 0 1.5665004866605159e-06
4612del165 O 0 3.2288535294355825e-06
and O 0 4.1500067027300247e-07
7883del5 O 0 3.7208239518804476e-05
. O 0 2.003266445171903e-06

The O 0 4.3548402572923806e-06
ATM O 0 2.330768074898515e-05
( O 0 1.2922726000397233e-06
A O 1 0.9621893167495728
- O 1 0.9998027682304382
T O 1 0.9999918937683105
, O 0 3.7297570543159964e-07
mutated O 0 1.04437992831663e-06
) O 0 1.6722488282994163e-08
gene O 0 5.812936265670032e-08
on O 0 2.1526564353280264e-07
human O 0 5.873978921044909e-07
chromosome O 0 7.348426152020693e-05
11q22 O 0 7.735037797829136e-05
. O 0 2.1004841528338147e-06

3 O 0 4.9904007028089836e-05
has O 0 1.9996091396023985e-06
recently O 0 1.3267183476273203e-06
been O 0 2.2795659049279493e-07
identified O 0 1.1310260106256464e-07
as O 0 5.6768691969466545e-09
the O 0 2.666720400057443e-09
gene O 0 3.408889881484356e-08
responsible O 0 1.8254340261592006e-08
for O 0 4.447317625277947e-09
the O 0 1.1367485086566376e-07
human O 0 2.8802458473364823e-05
recessive B-Disease 1 0.9999372959136963
disease I-Disease 1 0.9999270439147949
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
telangiectasia I-Disease 1 0.9999995231628418
( O 0 6.768648017896339e-05
A B-Disease 1 0.9999456405639648
- I-Disease 1 0.999961256980896
T I-Disease 1 0.9999954700469971
) O 0 5.3923458835924976e-06
. O 0 2.778469024633523e-06

In O 0 3.910037321475102e-06
order O 0 2.9138999479982886e-07
to O 0 8.925659500391703e-08
define O 0 1.549059476246839e-07
the O 0 3.783300073223472e-08
types O 0 1.0590287757850092e-07
of O 0 1.0916439663333222e-07
disease O 0 8.562268340028822e-05
- O 0 0.0013687554746866226
causing O 0 1.1971957974310499e-05
ATM O 0 9.006545042211656e-06
mutations O 0 1.068643086910015e-06
in O 0 4.778144813144536e-08
Japanese O 0 3.3189078294526553e-06
A B-Disease 1 0.9999499320983887
- I-Disease 1 0.9999969005584717
T I-Disease 1 0.9999998807907104
patients O 0 0.08370828628540039
as O 0 5.428120530837077e-08
well O 0 9.927609845306051e-09
as O 0 7.870465168480223e-09
to O 0 1.3187865910424534e-08
look O 0 5.3727042370610434e-08
for O 0 1.1738551464191005e-08
possible O 0 7.94193226738571e-08
mutational O 0 3.3642896596575156e-05
hotspots O 0 3.4765334930852987e-06
, O 0 1.3799119358282042e-07
reverse O 0 3.3303665532002924e-06
- O 0 3.2221450965153053e-05
transcribed O 0 1.2473046808736399e-06
RNA O 0 1.0471120504007558e-07
derived O 0 1.832019513869909e-08
from O 0 3.3521936337876923e-09
ten O 0 3.3416810651942797e-08
patients O 0 2.9150953650969313e-07
belonging O 0 2.5513200441196204e-08
to O 0 2.1875273148452834e-08
eight O 0 1.1300653568468988e-07
unrelated O 0 5.178521860216279e-07
Japanese O 0 5.701738245988963e-06
A B-Disease 1 0.9994935989379883
- I-Disease 1 0.9999072551727295
T I-Disease 1 0.9999966621398926
families O 0 8.388325909436389e-07
was O 0 6.662783107458381e-07
analyzed O 0 1.6596887064679322e-07
for O 0 2.029218748589301e-08
mutations O 0 2.598880826099048e-07
by O 0 7.520557510076742e-09
the O 0 2.4959959432635515e-08
restriction O 0 6.683217748104653e-07
endonuclease O 0 2.8637965442612767e-05
fingerprinting O 0 1.4112439203017857e-05
method O 0 6.706773547193734e-06
. O 0 2.9102832286298508e-06

As O 0 1.0797820323205087e-05
has O 0 1.991173348869779e-06
been O 0 4.524132464212016e-07
reported O 0 1.0253730806653039e-06
by O 0 8.2709128434999e-08
others O 0 5.04255069699866e-07
, O 0 1.920577687997138e-07
mutations O 0 6.121564979366667e-07
that O 0 3.812747451092946e-08
lead O 0 1.855076021683999e-07
to O 0 1.4888652799527335e-07
exon O 0 1.9571298253140412e-06
skipping O 0 1.032088448482682e-06
or O 0 8.343593549398065e-08
premature O 0 2.8227668735780753e-06
protein O 0 6.762984128272365e-08
truncation O 0 9.47858552535763e-07
were O 0 3.259089567109186e-07
also O 0 1.831633937854349e-07
predominant O 0 5.000075589123298e-07
in O 0 3.264102943489888e-08
our O 0 9.831942548998995e-08
mutants O 0 6.106677119532833e-06
. O 0 6.799211860197829e-07

Six O 0 7.006156010902487e-06
different O 0 2.9089744657539995e-07
mutations O 0 1.8833203512258478e-06
were O 0 1.8172742954902787e-07
identified O 0 2.2201378158115403e-07
on O 0 9.196122618959635e-08
12 O 0 4.547230858520379e-08
of O 0 3.1034788072759056e-09
the O 0 3.556563044071481e-08
16 O 0 8.048185691222898e-07
alleles O 0 2.3793859327270184e-06
examined O 0 2.8271257178857923e-05
. O 0 2.004290536206099e-06

Four O 0 5.45503962712246e-06
were O 0 2.903026938838593e-07
deletions O 0 1.6682754448993364e-06
involving O 0 3.168131001984875e-07
a O 0 4.97435257784673e-06
loss O 0 5.153152869752375e-06
of O 0 8.306242804678732e-09
a O 0 3.797825343099248e-07
single O 0 6.056146162336518e-07
exon O 0 2.281534989378997e-06
exon O 0 9.441146175959148e-07
7 O 0 1.369599118561382e-07
, O 0 1.808494509702996e-08
exon O 0 7.368645356109482e-07
16 O 0 1.0516714610275812e-07
, O 0 3.0774089054830256e-08
exon O 0 1.3892807828597142e-06
33 O 0 6.897101911818027e-07
or O 0 8.952716257226712e-08
exon O 0 5.783573215012439e-06
35 O 0 4.614428689819761e-06
. O 0 2.5136380372714484e-06

The O 0 1.6047627013904275e-06
others O 0 6.453863079514122e-07
were O 0 4.189968549894729e-08
minute O 0 2.636313070070173e-07
deletions O 0 2.473726226526196e-06
, O 0 9.96395996821775e-08
4649delA O 0 3.2551554340898292e-06
in O 0 7.050979888845177e-08
exon O 0 1.7045568938556244e-06
33 O 0 4.725604298982944e-07
and O 0 4.694368271884741e-08
7883del5 O 0 5.277358468447346e-06
in O 0 2.5084625576710096e-07
exon O 0 2.076068449241575e-05
55 O 0 1.1032712791347876e-05
. O 0 2.4062585453066276e-06

The O 0 1.2836333553423174e-05
mutations O 0 9.575270814821124e-05
4612del165 O 0 2.2808977519162e-05
and O 0 3.296544548447855e-07
7883del5 O 0 5.540172423934564e-06
were O 0 1.3063996107121056e-07
found O 0 3.47611752715693e-08
in O 0 7.2273196316530175e-09
more O 0 1.1720294956774069e-08
than O 0 1.640937341562676e-08
two O 0 2.805799326210945e-08
unrelated O 0 7.778758117638063e-07
families O 0 1.2239655688972562e-07
; O 0 5.317955498185256e-08
44 O 0 4.4175530433676613e-07
% O 0 2.7105617306233398e-08
( O 0 2.7565241200733226e-09
7 O 0 2.8625906978163584e-08
of O 0 2.3456825370971046e-09
16 O 0 6.355393367130091e-08
) O 0 2.5889763666242516e-09
of O 0 6.704770627585788e-10
the O 0 9.066040362881722e-09
mutant O 0 8.01791793492157e-06
alleles O 0 3.8419005932155414e-07
had O 0 1.1928165122299106e-07
one O 0 3.218298960661059e-09
of O 0 1.1624247120423092e-09
the O 0 2.1900572022559572e-08
two O 0 3.8770360788475955e-07
mutations O 0 6.566936917806743e-06
. O 0 1.4068601785766077e-06

The O 0 3.752931661438197e-06
4612del165 O 0 4.6883931645425037e-05
mutations O 0 1.0433622264827136e-05
in O 0 3.3092820928004585e-08
three O 0 3.5922052887826794e-08
different O 0 7.07770952956821e-09
families O 0 1.2405548588390047e-08
were O 0 9.662574740332275e-09
all O 0 1.7779848704435608e-09
ascribed O 0 1.4557855365637806e-07
to O 0 2.2517296471846748e-08
the O 0 1.4880469301203902e-08
same O 0 1.7335908353288687e-07
T O 0 9.301190584665164e-05
- O 0 2.9631881261593662e-05
- O 0 4.43687749793753e-05
> O 0 1.8435243021031056e-07
A O 0 3.476230503451916e-08
substitution O 0 2.2454850423514472e-08
at O 0 5.892435428478393e-09
the O 0 1.1595200355429824e-08
splice O 0 1.1533900305948919e-06
donor O 0 2.5284091975663614e-07
site O 0 1.942931362464151e-07
in O 0 6.727334778133809e-08
intron O 0 0.0001234488154295832
33 O 0 8.87553505890537e-06
. O 0 1.6109910347950063e-06

Microsatellite O 0 0.003915084060281515
genotyping O 0 0.0008247607038356364
around O 0 1.5079893955771695e-06
the O 0 9.821258117881371e-08
ATM O 0 2.0657771528931335e-06
locus O 0 3.169846195305581e-06
also O 0 7.839856834834791e-07
indicated O 0 1.721494641060417e-06
that O 0 1.7996820034227312e-08
a O 0 7.35719936528767e-07
common O 0 1.6352717011614004e-06
haplotype O 0 0.025100285187363625
was O 0 3.943997853639303e-06
shared O 0 1.690512618779394e-08
by O 0 3.248394442323388e-09
the O 0 4.761365968164455e-09
mutant O 0 1.2821402606277843e-06
alleles O 0 2.628961794925999e-07
in O 0 4.228408201356615e-08
both O 0 2.5377946144544694e-07
mutations O 0 1.2794269423466176e-05
. O 0 1.580642674525734e-06

This O 0 1.8846499187930021e-06
suggests O 0 1.052733750839252e-06
that O 0 3.78591309413423e-08
these O 0 6.14849371416426e-09
two O 0 2.4131468379096077e-08
founder O 0 4.781688403454609e-05
mutations O 0 8.844162039167713e-06
may O 0 4.2882021489276667e-07
be O 0 2.1622273749244414e-08
predominant O 0 2.6325369617552496e-07
among O 0 1.304307684080186e-08
Japanese O 0 8.453933020291515e-08
ATM O 0 1.6389218444601283e-06
mutant O 0 1.4410485164262354e-05
alleles O 0 4.413697297422914e-06
. O 0 8.54730444643792e-07

W474C O 0 0.0005707656964659691
amino O 0 1.7630949514568783e-05
acid O 0 7.003563951002434e-06
substitution O 0 4.3487170842126943e-07
affects O 0 2.9803220513713313e-07
early O 0 3.9493013304081614e-08
processing O 0 1.7225927351205428e-08
of O 0 2.7243733935478076e-09
the O 0 6.841318622718973e-09
alpha O 0 3.9500093862443464e-08
- O 0 6.050932910284246e-08
subunit O 0 2.694597256436282e-08
of O 0 1.5970008648835687e-09
beta O 0 2.4975246759595393e-08
- O 0 5.399871270128642e-07
hexosaminidase O 0 4.496767814998748e-06
A O 0 3.2497226243322075e-07
and O 0 7.996575845936604e-08
is O 0 1.079860609820571e-07
associated O 0 2.2629632212556317e-07
with O 0 1.7881344547276967e-06
subacute O 1 0.9986357092857361
G B-Disease 1 0.9846888780593872
( I-Disease 0 4.483551663270191e-07
M2 I-Disease 0 8.546360731997993e-06
) I-Disease 0 5.897418873246352e-07
gangliosidosis I-Disease 0 4.596772851073183e-05
. O 0 3.1604436117049772e-06

Mutations O 0 0.01715286448597908
in O 0 3.1768097414897056e-06
the O 0 6.202548661349283e-07
HEXA O 0 0.0026631380897015333
gene O 0 1.4238415815270855e-06
, O 0 2.010361122017912e-08
encoding O 0 2.2900396245972843e-08
the O 0 3.2945683958729433e-09
alpha O 0 3.348788979451456e-08
- O 0 6.514377304256413e-08
subunit O 0 3.332439391101616e-08
of O 0 3.3302520741074204e-09
beta O 0 4.007119613902432e-08
- O 0 1.1515896858327324e-06
hexosaminidase O 0 8.48959734867094e-06
A O 0 5.766664799011778e-07
( O 0 1.287075335199006e-08
Hex O 0 5.284476856104448e-07
A O 0 4.194310179173044e-07
) O 0 1.971507401776762e-08
, O 0 8.97944296696096e-09
that O 0 1.1657157905631266e-08
abolish O 0 2.57216981935926e-07
Hex O 0 7.442745300068054e-07
A O 0 1.3539629151182453e-07
enzyme O 0 2.24452648467377e-07
activity O 0 1.932680504523887e-07
cause O 0 0.0004155203059781343
Tay B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999983310699463
Sachs I-Disease 1 0.9999996423721313
disease I-Disease 0 0.3359876573085785
( O 0 2.0721292059988627e-07
TSD B-Disease 0 0.00028278419631533325
) O 0 6.064844626507693e-08
, O 0 1.8219800779206707e-08
the O 0 3.9036624599475545e-08
fatal O 0 0.08978170156478882
infantile B-Disease 0 0.0644434466958046
form I-Disease 0 7.7073821103113e-07
of I-Disease 0 5.7761322835858664e-08
G I-Disease 0 0.05346207693219185
( I-Disease 0 8.800966355693163e-08
M2 I-Disease 0 1.4292943433247274e-06
) I-Disease 0 3.2639160707503834e-08
gangliosidosis I-Disease 0 8.948618415161036e-06
, I-Disease 0 8.905711723627974e-08
Type I-Disease 0 4.802842568096821e-07
1 I-Disease 0 6.140140840216191e-07
. O 0 1.7714023670123424e-06

Less O 0 0.0021908695343881845
severe O 1 0.9660916924476624
, O 0 5.158147541806102e-05
subacute O 1 0.9265820980072021
( O 0 5.451825472846394e-06
juvenile O 0 0.004424517974257469
- O 0 0.21043339371681213
onset O 0 0.0024290238507092
) O 0 7.355158118116378e-07
and O 0 1.5234853890433442e-05
chronic O 1 0.985582172870636
( O 0 2.7787501721832086e-07
adult O 0 2.4609971660538577e-05
- O 0 0.025513768196105957
onset O 0 0.00037231313763186336
) O 0 1.2701546836524358e-07
variants O 0 3.0489741220662836e-07
are O 0 1.1732508298223365e-08
characterized O 0 5.932250815021689e-07
by O 0 4.081572768654951e-08
a O 0 5.085677798888355e-07
broad O 0 1.0756265282907407e-06
spectrum O 0 2.344546601307229e-06
of O 0 1.6153613557889912e-08
clinical O 0 7.215522600745317e-06
manifestations O 0 1.1931404515053146e-05
and O 0 7.454381147908862e-07
are O 0 2.959701639326795e-08
associated O 0 4.18797085899314e-08
with O 0 2.0417626700464098e-08
residual O 0 1.426142353011528e-05
levels O 0 1.651840086935863e-08
of O 0 3.078035382131361e-09
Hex O 0 9.370086218041251e-07
A O 0 2.483114087681315e-07
enzyme O 0 2.5562599148543086e-07
activity O 0 2.9462523798429174e-07
. O 0 4.911138375973678e-07

We O 0 8.165349754563067e-06
identified O 0 5.327861344994744e-06
a O 0 2.4303449208673555e-06
1422 O 0 0.00019843548943754286
G O 0 0.002799092559143901
- O 0 0.0006754732457920909
- O 0 0.007477426901459694
> O 0 5.366868663259083e-06
C O 0 6.429266363738861e-07
( O 0 1.1775642683176102e-08
amino O 0 3.259729197679917e-08
acid O 0 9.145868773430266e-08
W474C O 0 1.3881681582006422e-07
) O 0 1.907113800214688e-09
substitution O 0 2.6212039205830706e-09
in O 0 2.4967563572175777e-09
the O 0 3.3780920283277283e-09
first O 0 3.899049261235632e-08
position O 0 9.170724979412626e-08
of O 0 9.017854907256151e-09
exon O 0 1.1193484397153952e-06
13 O 0 8.691284847373026e-08
of O 0 6.580963773927806e-09
HEXA O 0 1.3347542335395701e-05
of O 0 1.2067706833818193e-08
a O 0 3.3901972074090736e-07
non O 0 1.4057521013910446e-07
- O 0 4.807287496078061e-06
Jewish O 0 3.8713795902367565e-07
proband O 0 2.1298690626281314e-05
who O 0 1.4106258277024608e-06
manifested O 0 1.179148625851667e-06
a O 0 9.039623023454624e-07
subacute O 0 0.0064916606061160564
variant O 0 7.870545232435688e-05
of O 0 1.1329842664054013e-07
G B-Disease 0 0.039066117256879807
( I-Disease 0 1.716306741172957e-07
M2 I-Disease 0 4.693151367973769e-06
) I-Disease 0 2.464295505433256e-07
gangliosidosis I-Disease 0 5.4160300351213664e-05
. O 0 1.2133980362705188e-06

On O 0 4.612008979165694e-06
the O 0 4.1588458543628803e-07
second O 0 3.1569077236781595e-06
maternally O 0 0.00022941087081562728
inherited O 0 0.0001831834379117936
allele O 0 1.5087018255144358e-05
, O 0 6.740756930412317e-08
we O 0 1.586170306211443e-08
identified O 0 5.9181868294899687e-08
the O 0 2.32078463113794e-08
common O 0 5.19618470207206e-06
infantile O 1 0.9997151494026184
disease O 1 0.5291724801063538
- O 0 0.04304011911153793
causing O 0 1.2209268788865302e-05
4 O 0 2.2140186217711744e-07
- O 0 1.6200494428630918e-05
bp O 0 5.091803541290574e-05
insertion O 0 1.6633886161798728e-06
, O 0 4.1565061792425695e-07
+ O 0 9.145559829448757e-07
TATC O 0 1.4010015547682997e-05
1278 O 0 2.7637344828690402e-05
, O 0 1.1488524620517637e-07
in O 0 6.595315937829582e-08
exon O 0 1.1022154467354994e-05
11 O 0 1.8671003090275917e-06
. O 0 1.466094545321539e-06

Pulse O 0 0.0005036088405176997
- O 0 0.00025611461023800075
chase O 0 8.269907084468286e-06
analysis O 0 1.2683548789027554e-07
using O 0 5.421746607225941e-08
proband O 0 3.7889146824454656e-06
fibroblasts O 0 5.824099957862927e-07
revealed O 0 5.973290058136627e-07
that O 0 5.628685073588713e-09
the O 0 4.6515662432966565e-09
W474C O 0 4.795254540113092e-07
- O 0 3.3401906307517493e-07
containing O 0 2.5486837529342665e-08
alpha O 0 3.8530213686271964e-08
- O 0 5.2093408697828636e-08
subunit O 0 7.024856785164957e-08
precursor O 0 5.435082428562055e-08
was O 0 1.0907322689490684e-07
normally O 0 4.964694966247407e-08
synthesized O 0 2.4646175234011025e-07
, O 0 9.479082407892747e-09
but O 0 8.195642386965574e-09
not O 0 5.741945585668873e-09
phosphorylated O 0 9.05586503563427e-08
or O 0 8.637950799084138e-09
secreted O 0 7.764055709458262e-08
, O 0 7.238010635290948e-09
and O 0 5.372845279794092e-09
the O 0 1.3379534813395821e-08
mature O 0 2.528310574234638e-07
lysosomal O 0 1.0066768254546332e-06
alpha O 0 1.0652420456835898e-07
- O 0 1.724207550068968e-07
subunit O 0 1.6110851674966398e-07
was O 0 4.0055078898149077e-07
not O 0 1.1696382529180482e-07
detected O 0 2.9439142963383347e-06
. O 0 1.3379710708250059e-06

When O 0 9.519572813587729e-06
the O 0 2.666620844138379e-07
W474C O 0 4.004505626653554e-06
- O 0 1.3799187854601769e-06
containing O 0 7.859517836550367e-08
alpha O 0 8.068122525628496e-08
- O 0 2.2995602932951442e-07
subunit O 0 1.2729837806091382e-07
was O 0 3.518335347507673e-07
transiently O 0 4.369946054794127e-06
co O 0 1.9679248453030596e-06
- O 0 2.5124541025434155e-06
expressed O 0 1.3518804564682796e-07
with O 0 5.876341191424217e-09
the O 0 2.9804394507948473e-09
beta O 0 9.285408886228197e-09
- O 0 3.051317776225915e-08
subunit O 0 1.814859373894251e-08
to O 0 8.926642536266627e-09
produce O 0 2.819038158463627e-08
Hex O 0 5.387377655097225e-07
A O 0 3.1844277259551745e-07
( O 0 1.671799410019048e-08
alphabeta O 0 1.7337392819172237e-06
) O 0 1.841148211667587e-08
in O 0 4.3663533233484486e-08
COS O 0 2.1894862584304065e-05
- O 0 6.011514051351696e-05
7 O 0 1.3222721690908656e-06
cells O 0 7.678536206867648e-08
, O 0 3.6778111667246094e-09
the O 0 1.9412038643196183e-09
mature O 0 1.5238523332072873e-08
alpha O 0 2.2407744992847256e-08
- O 0 7.770115217908824e-08
subunit O 0 3.868942499707373e-08
was O 0 1.176452286699714e-07
present O 0 9.74489999805428e-09
, O 0 4.117869156772258e-09
but O 0 4.400353414979463e-09
its O 0 6.4280989420240076e-09
level O 0 6.587820511327891e-09
was O 0 1.5914559980956255e-07
much O 0 3.7793334684010915e-08
lower O 0 1.9335047340973688e-07
than O 0 8.78958861250112e-09
that O 0 2.594978232295375e-09
from O 0 2.316506764188375e-09
normal O 0 5.794955182381045e-09
alpha O 0 1.6017606796481232e-08
- O 0 9.273306744717047e-08
subunit O 0 1.0635772440537039e-07
transfections O 0 9.516728027847421e-07
, O 0 8.893909608786998e-09
although O 0 7.98139598856551e-09
higher O 0 7.772305465891804e-09
than O 0 7.361464327004796e-09
in O 0 1.5203278636022333e-08
those O 0 3.000575787837079e-08
cells O 0 1.267946032612599e-07
transfected O 0 2.957681090265396e-06
with O 0 1.189424114755866e-08
an O 0 1.634720625531827e-08
alpha O 0 1.1820112177929332e-07
- O 0 6.075798069105076e-07
subunit O 0 6.009641992932302e-07
associated O 0 2.896489661452506e-07
with O 0 7.157031518545409e-07
infantile O 1 0.530293881893158
TSD B-Disease 1 0.5841487050056458
. O 0 2.27938453463139e-05

Furthermore O 0 4.5959794078953564e-05
, O 0 2.133937613280068e-07
the O 0 1.6426753290943452e-08
precursor O 0 4.742670256518977e-08
level O 0 6.843798416866775e-09
of O 0 1.6973678018672445e-09
the O 0 7.607712682045076e-09
W474C O 0 4.3098575019939744e-07
alpha O 0 5.592837837298248e-08
- O 0 1.1770706009883725e-07
subunit O 0 7.857734374283609e-08
was O 0 9.185079363760451e-08
found O 0 6.202427904611341e-09
to O 0 1.1880954886578365e-08
accumulate O 0 2.2222009476990934e-07
in O 0 6.925342521668654e-09
comparison O 0 2.9479661378672972e-08
to O 0 7.927264178420046e-09
the O 0 5.429173555171474e-09
normal O 0 4.769767514289924e-08
alpha O 0 1.350035461200605e-07
- O 0 6.173880251481023e-07
subunit O 0 8.699276463630667e-07
precursor O 0 8.679172651682165e-07
levels O 0 2.596109140995395e-07
. O 0 5.276892807160039e-07

We O 0 3.116030939054326e-06
conclude O 0 3.279847078374587e-06
that O 0 8.724369138235488e-08
the O 0 7.90362406632994e-08
1422 O 0 0.00012666247494053096
G O 0 0.016239145770668983
- O 0 0.006451818626374006
- O 0 0.06611859053373337
> O 0 2.4940340153989382e-05
C O 0 2.6245429580740165e-06
mutation O 0 2.052806280516961e-07
is O 0 7.63708118967088e-09
the O 0 4.943733422635432e-09
cause O 0 5.157466631544594e-08
of O 0 1.1446851466700991e-08
Hex B-Disease 0 0.0009403657168149948
A I-Disease 0 0.10946410149335861
enzyme I-Disease 1 0.9998506307601929
deficiency I-Disease 1 0.999721348285675
in O 0 5.827634197430598e-08
the O 0 1.574896373313095e-07
proband O 0 0.0007469160482287407
. O 0 3.810628186329268e-06

The O 0 5.3028711590741295e-06
resulting O 0 6.153310096124187e-06
W474C O 0 7.411420938296942e-06
substitution O 0 4.0455759631186083e-07
clearly O 0 4.2598250615810684e-07
interferes O 0 4.167056033566041e-07
with O 0 1.4907627132743073e-08
alpha O 0 8.524431649448161e-08
- O 0 7.20671593512634e-08
subunit O 0 3.4760713418791056e-08
processing O 0 1.6526437107700076e-08
, O 0 9.618554841495097e-09
but O 0 1.6483937770317425e-08
because O 0 7.882754893273614e-09
the O 0 3.4575549090476443e-09
base O 0 3.1934444422176966e-08
substitution O 0 4.809176346043387e-08
falls O 0 1.3524521591534722e-06
at O 0 2.688374189929732e-09
the O 0 1.985332565013209e-09
first O 0 3.0266601669382e-08
position O 0 5.7636746930711524e-08
of O 0 5.2583830623120775e-09
exon O 0 7.572290314783459e-07
13 O 0 9.04543782098699e-08
, O 0 7.605029495039162e-09
aberrant O 0 2.8652408445850597e-07
splicing O 0 6.267758635658538e-06
may O 0 2.4367643618461443e-06
also O 0 1.2362491474959825e-07
contribute O 0 3.5721591018500476e-08
to O 0 6.7339591680593e-08
Hex B-Disease 0 0.00029739088495261967
A I-Disease 0 0.0947004109621048
deficiency I-Disease 0 0.007100349757820368
in O 0 2.106293983672458e-08
this O 0 3.388948854876617e-08
proband O 0 5.7970632042270154e-05
. O 0 2.5817988102971867e-07
. O 0 7.51072604998626e-07

Two O 0 1.8934626496047713e-05
frequent O 0 0.0002660698664840311
missense O 0 0.2673340141773224
mutations O 0 0.11009696871042252
in O 0 0.0019001377513632178
Pendred B-Disease 1 0.9999990463256836
syndrome I-Disease 1 1.0
. O 0 0.00017749734979588538

Pendred B-Disease 1 0.9999984502792358
syndrome I-Disease 1 1.0
is O 0 0.0006722974358126521
an O 0 0.29517367482185364
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.8789510130882263
by O 0 1.312694530497538e-05
early O 0 0.008773060515522957
childhood O 1 0.9737709164619446
deafness B-Disease 1 0.9999998807907104
and O 1 0.9812017679214478
goiter B-Disease 1 0.9999998807907104
. O 0 0.0009733285987749696

A O 0 2.418090844003018e-05
century O 0 1.520547357358737e-06
after O 0 3.933530194899504e-07
its O 0 4.948453380393403e-08
recognition O 0 1.4619683952332707e-07
as O 0 6.918762665009126e-07
a O 0 0.02488599345088005
syndrome O 1 0.9999667406082153
by O 0 3.569928992419591e-07
Vaughan O 0 4.463307777768932e-05
Pendred O 0 3.4003183827735484e-05
, O 0 1.1030339663875566e-07
the O 0 2.0616407425677608e-07
disease O 0 2.8166788979433477e-05
gene O 0 7.47603849049483e-07
( O 0 8.131727469162797e-08
PDS O 0 0.0033138885628432035
) O 0 6.116785300491756e-08
was O 0 8.764612857703469e-07
mapped O 0 2.7602616228250554e-06
to O 0 4.5948121396577335e-07
chromosome O 0 2.1156522052478977e-05
7q22 O 0 4.3669355363817886e-05
- O 0 7.202896813396364e-05
q31 O 0 0.00014887793804518878
. O 0 3.7924830849078717e-06

1 O 0 9.699796464701649e-06
and O 0 5.408086849456595e-07
, O 0 1.5639254513644119e-07
recently O 0 6.673537313872657e-07
, O 0 1.4946690995998324e-08
found O 0 1.3703145285148821e-08
to O 0 1.2546514938094333e-08
encode O 0 1.4405247839022195e-07
a O 0 6.975182031965232e-07
putative O 0 9.257565398002043e-05
sulfate O 0 0.001436826540157199
transporter O 0 0.0005580423166975379
. O 0 3.6012447708344553e-06

We O 0 9.475464139541145e-06
performed O 0 8.462371624773368e-06
mutation O 0 3.2237276172963902e-06
analysis O 0 3.9121747619219605e-08
of O 0 2.5400346270743057e-09
the O 0 3.4810472726576336e-08
PDS B-Disease 0 0.007187769282609224
gene O 0 1.864979026322544e-06
in O 0 4.6012624466129637e-07
patients O 0 1.7130052583524957e-05
from O 0 2.5394111702325972e-08
14 O 0 1.306023307279247e-07
Pendred B-Disease 0 7.940028808661737e-06
families O 0 5.508754696847973e-08
originating O 0 1.5644349815602254e-08
from O 0 4.920122531615334e-09
seven O 0 3.385666502708773e-08
countries O 0 4.523387886479213e-09
and O 0 6.858959977762424e-08
identified O 0 5.333660055839573e-07
all O 0 5.434709038354413e-08
mutations O 0 2.6200364118267316e-06
. O 0 8.223813665608759e-07

The O 0 8.174573849828448e-06
mutations O 0 4.454225563677028e-05
include O 0 1.081175469153095e-07
three O 0 4.694421917861291e-08
single O 0 1.782791656523841e-07
base O 0 1.7893422921133606e-07
deletions O 0 8.675092999510525e-07
, O 0 2.49230431847991e-08
one O 0 2.01116669984458e-08
splice O 0 3.6681003621197306e-06
site O 0 1.4814536370977294e-06
mutation O 0 1.5629564131813822e-06
and O 0 1.53914768930008e-07
10 O 0 9.002827141557646e-07
missense O 0 0.0006565511575900018
mutations O 0 7.730959623586386e-05
. O 0 3.3100066048064036e-06

One O 0 3.894377368851565e-05
missense O 0 0.005319284275174141
mutation O 0 0.00014519387332256883
( O 0 2.533664087422949e-07
L236P O 0 1.2066705494362395e-05
) O 0 8.128888850933436e-08
was O 0 1.3574439208241529e-06
found O 0 9.214787155542581e-08
in O 0 1.0056614208053816e-08
a O 0 3.4222784961457364e-07
homozygous O 0 8.614333069090208e-07
state O 0 8.920106431276054e-09
in O 0 6.69444899514815e-09
two O 0 2.61606061258135e-08
consanguineous O 0 2.1337462385417894e-05
families O 0 7.853808625668535e-08
and O 0 2.8303306365273784e-08
in O 0 1.4466119857559079e-08
a O 0 4.931380317430012e-07
heterozygous O 0 1.2506326356742647e-06
state O 0 1.0457024579579866e-08
in O 0 6.9629582100105836e-09
five O 0 2.4682250909791037e-08
additional O 0 5.5235794604868715e-08
non O 0 4.721225650428096e-07
- O 0 0.00012720086670015007
consanguineous O 0 0.002731813583523035
families O 0 3.7073275507282233e-06
. O 0 2.0818399661948206e-06

Another O 0 7.553419709438458e-05
missense O 0 0.013623910024762154
mutation O 0 0.00021512039529625326
( O 0 3.9649063410251983e-07
T416P O 0 8.194477231882047e-06
) O 0 4.925946583966834e-08
was O 0 1.3059117236480233e-06
found O 0 6.319167766832834e-08
in O 0 1.3202791748767595e-08
a O 0 2.7755137921303685e-07
homozygous O 0 1.3361375295062317e-06
state O 0 1.977872443603701e-08
in O 0 9.443819948273813e-09
one O 0 4.153073973611754e-08
family O 0 8.961019659636804e-08
and O 0 2.023170431186827e-08
in O 0 1.9362829561941908e-08
a O 0 1.0545172699494287e-06
heterozygous O 0 4.158332103543216e-06
state O 0 5.213744458387737e-08
in O 0 3.818387384058042e-08
four O 0 3.696329997637804e-07
families O 0 4.5814576310476696e-07
. O 0 1.5393693502119277e-06

Pendred B-Disease 1 0.9427171945571899
patients O 1 0.6542032361030579
in O 0 7.641162937943591e-07
three O 0 2.3658320458253002e-07
non O 0 2.829149536864861e-07
- O 0 4.8236772272503003e-05
consanguineous O 0 0.00023310762480832636
families O 0 2.3236486867972417e-07
were O 0 9.818523949434166e-08
shown O 0 1.0303747188800116e-07
to O 0 4.0154592539920486e-08
be O 0 5.520124446434238e-08
compound O 0 6.060676014385535e-07
heterozygotes O 0 1.9532030819391366e-06
for O 0 5.5582329849812595e-08
L236P O 0 8.084964974841569e-06
and O 0 4.494442862323922e-07
T416P O 0 4.13800407841336e-05
. O 0 1.6744436379667604e-06

In O 0 3.101355787293869e-06
total O 0 3.800426782163413e-07
, O 0 5.74312082335382e-08
one O 0 3.1266225164472417e-08
or O 0 6.461435830829032e-09
both O 0 3.5361609196371546e-09
of O 0 1.1932363985778238e-09
these O 0 1.2164141693915553e-08
mutations O 0 2.8840031518484466e-07
were O 0 3.37304619790757e-08
found O 0 2.6556566723456854e-08
in O 0 3.999611752902865e-09
nine O 0 1.644568747849462e-08
of O 0 1.8452077643615894e-09
the O 0 2.7094555932194453e-08
14 O 0 6.019587885930378e-07
families O 0 1.4773296186376683e-07
analyzed O 0 2.8879383080493426e-06
. O 0 1.3313955378180253e-06

The O 0 1.5630308780600899e-06
identification O 0 6.092265039114864e-07
of O 0 3.107425428083843e-08
two O 0 8.016169061875189e-08
frequent O 0 6.33859817753546e-05
PDS B-Disease 1 0.9793124198913574
mutations O 0 2.0214045434840955e-05
will O 0 2.5135674874832148e-08
facilitate O 0 3.257255443145368e-08
the O 0 6.884859971023616e-08
molecular O 0 7.885110971983522e-05
diagnosis O 0 0.30379608273506165
of O 0 4.0519775211578235e-05
Pendred B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
. O 0 2.8353148081805557e-05

Insertional O 0 0.01557900384068489
mutation O 0 0.0006182845681905746
by O 0 1.4668049743704614e-06
transposable O 0 7.91302663856186e-05
element O 0 3.7002946555730887e-06
, O 0 2.917375923061627e-07
L1 O 0 4.603348861564882e-05
, O 0 2.1913133707585075e-07
in O 0 8.478833279923492e-08
the O 0 5.703167289539124e-07
DMD B-Disease 1 0.9999984502792358
gene O 0 6.893008685437962e-05
results O 0 1.4903795317877666e-06
in O 0 3.9752237057655293e-07
X B-Disease 1 0.9492002129554749
- I-Disease 1 0.9958725571632385
linked I-Disease 1 0.9627258777618408
dilated I-Disease 1 0.9984374642372131
cardiomyopathy I-Disease 1 0.9999966621398926
. O 0 0.00014346039097290486

X B-Disease 1 0.9955109357833862
- I-Disease 1 0.9989001750946045
linked I-Disease 1 0.9959730505943298
dilated I-Disease 1 0.9998729228973389
cardiomyopathy I-Disease 1 0.9999996423721313
( O 0 1.4821863260294776e-05
XLDCM B-Disease 0 0.03739553689956665
) O 0 1.974910190938317e-07
is O 0 9.206530648953049e-08
a O 0 2.7193809728487395e-06
clinical O 0 0.00023946529836393893
phenotype O 0 0.0051386235281825066
of O 0 3.172009499508022e-08
dystrophinopathy B-Disease 0 0.0008828931022435427
which O 0 5.404786520557536e-07
is O 0 1.0576943765272517e-07
characterized O 0 1.6718429378670407e-06
by O 0 3.2167486097023357e-07
preferential O 0 0.00010497742186998948
myocardial B-Disease 1 0.9996298551559448
involvement I-Disease 0 4.164317033428233e-06
without O 0 6.371899985424534e-08
any O 0 1.9701165143715116e-08
overt O 0 2.2854287635709625e-06
clinical O 0 0.0001468317350372672
signs O 0 0.00011543279106263071
of O 0 8.05192394182086e-06
skeletal B-Disease 1 0.9999996423721313
myopathy I-Disease 1 1.0
. O 0 0.0016705075977370143

To O 0 3.613464514273801e-06
date O 0 1.0725730135163758e-06
, O 0 6.136522046062964e-08
several O 0 5.129213320742565e-08
mutations O 0 3.675257573831914e-07
in O 0 3.227041389664009e-08
the O 0 1.5207344858936267e-06
Duchenne B-Disease 1 0.9999014139175415
muscular I-Disease 1 0.9999915361404419
dystrophy I-Disease 1 0.999993085861206
gene O 0 0.0019897001329809427
, O 0 4.726992119685747e-05
DMD O 1 0.9999992847442627
, O 0 3.4644992865651147e-06
have O 0 2.4346195459656883e-07
been O 0 2.963967631330888e-07
identified O 0 6.780407488804485e-07
in O 0 1.4109446055954322e-07
patients O 0 1.7125839804066345e-05
with O 0 3.349671260366449e-07
XLDCM B-Disease 0 0.39228948950767517
, O 0 8.821015740068106e-08
but O 0 3.685734384362149e-08
a O 0 1.1238523001111389e-07
pathogenic O 0 1.7233199400834565e-07
correlation O 0 3.715456742270362e-08
of O 0 2.5544300008562004e-09
these O 0 1.448157949113238e-08
cardiospecific O 0 0.0036390090826898813
mutations O 0 2.5881890906021e-05
in O 0 9.559917089063674e-07
DMD O 1 0.9999933242797852
with O 0 1.5860634903219761e-06
the O 0 8.739097552279418e-07
XLDCM B-Disease 1 0.9749476909637451
phenotype O 1 0.7535256147384644
has O 0 5.5573013924004044e-06
remained O 0 1.376506702399638e-06
to O 0 1.0410480655309584e-07
be O 0 3.920564495274448e-07
elucidated O 0 0.0002083132421830669
. O 0 1.7719210063660285e-06

We O 0 7.174647635110887e-06
report O 0 5.873844770576397e-07
here O 0 2.290795464432449e-08
the O 0 4.411168319506942e-09
identification O 0 6.575881617010282e-09
of O 0 2.3520352332440098e-09
a O 0 2.5446382778682164e-07
unique O 0 9.076685358877512e-08
de O 0 1.286149426960037e-07
novo O 0 8.826087878333055e-07
L1 O 0 1.5704583802289562e-06
insertion O 0 4.055418401094357e-07
in O 0 3.975063833649983e-08
the O 0 3.327281916654101e-08
muscle O 0 5.398937446443597e-06
exon O 0 7.402972642012173e-06
1 O 0 6.527137657030835e-07
in O 0 6.957065465940104e-07
DMD O 1 0.9999978542327881
in O 0 9.301378668169491e-06
three O 0 3.975075287598884e-06
XLDCM B-Disease 1 0.9364382028579712
patients O 0 0.00043280015233904123
from O 0 1.924926706919905e-08
two O 0 4.293046629300079e-08
unrelated O 0 8.627693546259252e-07
Japanese O 0 2.308275043105823e-06
families O 0 1.1141958111693384e-06
. O 0 1.3043545550317504e-06

The O 0 3.136256054858677e-06
insertion O 0 1.3447454875858966e-05
was O 0 1.169926576949365e-06
a O 0 3.556862395726057e-07
5 O 0 2.5306118800472177e-07
- O 0 7.002729489613557e-06
truncated O 0 2.4215671601268696e-06
form O 0 5.735031649578559e-08
of O 0 3.4849785279789103e-09
human O 0 3.2718382669827406e-08
L1 O 0 1.886660470518109e-06
inversely O 0 7.439665523634176e-07
integrated O 0 4.256649219769315e-07
in O 0 2.8062915546911427e-08
the O 0 1.946302496946828e-08
5 O 0 1.3353051997455623e-07
- O 0 4.421857374836691e-05
untranslated O 0 9.840313578024507e-05
region O 0 2.2210950589851564e-07
in O 0 1.2920536640592672e-08
the O 0 1.7874281610374965e-08
muscle O 0 3.851967449008953e-06
exon O 0 3.6770422866538865e-06
1 O 0 1.3508855545296683e-07
, O 0 2.151026556873603e-08
which O 0 3.076387855571738e-08
affected O 0 2.410349786430288e-08
the O 0 5.624563925721304e-09
transcription O 0 4.6578271906128066e-08
or O 0 5.963645133277851e-09
the O 0 4.478609039182402e-09
stability O 0 2.5298341199686547e-08
of O 0 3.2648923564693177e-09
the O 0 3.6736764741363004e-08
muscle O 0 6.946855592104839e-06
form O 0 8.790431138550048e-08
of O 0 2.194133585931013e-08
dystrophin O 0 5.7710894907359034e-05
transcripts O 0 3.273878974141553e-06
but O 0 8.639519677444696e-08
not O 0 7.896945319885162e-09
that O 0 3.1767544150795857e-09
of O 0 1.1987248971223607e-09
the O 0 4.522967600451011e-08
brain O 0 4.1243572923121974e-05
or O 0 6.605677782545172e-08
Purkinje O 0 5.804536340292543e-05
cell O 0 3.955932334065437e-05
form O 0 1.8394131018339976e-07
, O 0 4.24585628877594e-08
probably O 0 2.5059878794309043e-07
due O 0 3.302503870372675e-08
to O 0 2.3140263039067577e-08
its O 0 1.1166234159531996e-08
unique O 0 2.8299096399564405e-08
site O 0 4.420721921860604e-08
of O 0 1.1646267950027323e-08
integration O 0 4.921195113638532e-07
. O 0 2.259776465507457e-06

We O 0 6.220750947250053e-06
speculate O 0 1.075958334695315e-05
that O 0 6.231304183756947e-08
this O 0 9.671203393679662e-09
insertion O 0 1.2118097458824195e-07
of O 0 7.287992431770363e-09
an O 0 6.765539239950158e-08
L1 O 0 2.1357553123380058e-05
sequence O 0 2.1192138888181944e-07
in O 0 4.7100863298510376e-07
DMD O 1 0.9999961853027344
is O 0 1.438088588656683e-06
responsible O 0 8.523554129169497e-08
for O 0 5.187652973859258e-09
some O 0 2.5397535186044706e-09
of O 0 1.2302641128059122e-09
the O 0 1.571124386146039e-08
population O 0 1.4945378268294007e-08
of O 0 7.064222540265064e-09
Japanese O 0 4.68343569082208e-06
patients O 0 7.58196838432923e-05
with O 0 3.017222240941919e-07
XLDCM B-Disease 0 0.0074105411767959595
. O 0 3.3545944688739837e-07
. O 0 9.608653499526554e-07

Severe O 1 0.9232162833213806
early O 0 0.00023182474251370877
- O 1 0.7365173697471619
onset O 1 0.9542324542999268
obesity B-Disease 1 0.9999867677688599
, O 0 0.0019500904018059373
adrenal B-Disease 1 0.9999762773513794
insufficiency I-Disease 1 0.9999932050704956
and O 0 0.00016358633001800627
red O 0 0.014410764910280704
hair O 1 0.9882397651672363
pigmentation O 1 0.984309196472168
caused O 0 0.009427954442799091
by O 0 8.381413863389753e-06
POMC O 1 0.962561845779419
mutations O 0 0.00024813899653963745
in O 0 1.1013579523933004e-06
humans O 0 3.8619978113274556e-06
. O 0 2.4218627459049458e-06

Sequential O 0 0.00012268991849850863
cleavage O 0 4.066781184519641e-05
of O 0 1.7374456717789144e-07
the O 0 5.6404559245493147e-08
precursor O 0 1.0988363641217802e-07
protein O 0 7.653708422594718e-08
pre O 0 6.656965751972166e-07
- O 0 2.1167274098843336e-05
pro O 0 1.5971356333466247e-05
- O 0 0.00025265722069889307
opiomelanocortin O 0 0.0003794279764406383
( O 0 1.4253370750338945e-07
POMC O 0 1.0901165296672843e-05
) O 0 2.6053548651816527e-08
generates O 0 8.278314567178313e-08
the O 0 3.304198514797463e-08
melanocortin O 0 1.3978947208670434e-05
peptides O 0 4.8957667786453385e-06
adrenocorticotrophin O 0 3.2437390473205596e-05
( O 0 1.1437264646474432e-07
ACTH O 0 1.0373190889367834e-05
) O 0 2.7266152002880517e-08
, O 0 2.2925350506852737e-08
melanocyte O 0 5.382445579016348e-06
- O 0 1.821878322516568e-05
stimulating O 0 2.0124768980167573e-06
hormones O 0 2.2778194761485793e-06
( O 0 3.619730648551922e-08
MSH O 0 1.3483551811077632e-05
) O 0 1.9505243642470305e-08
alpha O 0 3.3365605389690245e-08
, O 0 2.503891094463029e-09
beta O 0 3.6369467437680214e-09
and O 0 2.4109740870414953e-09
gamma O 0 3.2230307311920114e-08
as O 0 5.01159691523867e-09
well O 0 3.754629496199868e-09
as O 0 1.083977085869492e-08
the O 0 1.6904930788541606e-08
opioid O 0 9.513455552223604e-06
- O 0 1.5083955076988786e-05
receptor O 0 1.5821025272089173e-06
ligand O 0 2.070475375148817e-06
beta O 0 2.0971494905097643e-06
- O 0 2.3019194486550987e-05
endorphin O 0 0.00022288617037702352
. O 0 2.9192951842560433e-06

While O 0 4.495914254221134e-06
a O 0 5.83713415380771e-07
few O 0 1.8376930199792696e-07
cases O 0 1.2546304617444548e-07
of O 0 1.8584793792797427e-07
isolated O 0 0.14601153135299683
ACTH B-Disease 1 0.9999634027481079
deficiency I-Disease 1 0.9874609112739563
have O 0 1.1827638672912144e-06
been O 0 3.8169860090420116e-06
reported O 0 2.1636937162838876e-05
( O 0 1.5887977156125999e-07
OMIM O 0 0.0008953135693445802
201400 O 0 2.3094060452422127e-05
) O 0 7.606148955119352e-08
, O 0 5.990255402821276e-08
an O 0 7.489804261240351e-07
inherited O 0 0.01822243072092533
POMC O 1 0.9425945281982422
defect O 0 0.01842322386801243
has O 0 1.962477199413115e-06
not O 0 4.286223287408575e-08
been O 0 1.5042648726648622e-07
described O 0 1.4321036587716662e-06
so O 0 1.4002742432239756e-07
far O 0 4.967428139934782e-07
. O 0 1.0965475212287856e-06

Recent O 0 2.865227907022927e-05
studies O 0 1.954777644641581e-06
in O 0 1.5019497823232086e-07
animal O 0 5.356880024010024e-07
models O 0 1.970415041796514e-06
elucidated O 0 7.060722055030055e-06
a O 0 1.1283013634511008e-07
central O 0 6.241210215307547e-09
role O 0 6.693300136362268e-09
of O 0 5.939126523912819e-09
alpha O 0 2.783752677260054e-07
- O 0 2.9480637749657035e-05
MSH O 0 0.00025568154524080455
in O 0 2.617408334515403e-08
the O 0 4.721592450351864e-09
regulation O 0 3.347767218997433e-08
of O 0 4.908574435802393e-09
food O 0 3.9577923161004946e-08
intake O 0 1.3138228496245574e-06
by O 0 1.4449876850619603e-08
activation O 0 2.936741871906179e-08
of O 0 3.859624175817089e-09
the O 0 3.929180181216907e-08
brain O 0 1.2888172932434827e-05
melanocortin O 0 4.844103841605829e-06
- O 0 8.493573659507092e-06
4 O 0 2.7081929943051364e-07
- O 0 3.703235279317596e-06
receptor O 0 1.3141460613042e-06
( O 0 6.230793303529936e-08
MC4 O 0 3.456710692262277e-05
- O 0 4.319511936046183e-05
R O 0 0.00012133448763052002
; O 0 6.99931135272891e-08
refs O 0 7.801261290296679e-07
3 O 0 8.551823782454449e-08
- O 0 2.336132411073777e-06
5 O 0 9.913024712204788e-08
) O 0 3.9250287464653866e-09
and O 0 8.169749321496056e-09
the O 0 1.154426865213054e-08
linkage O 0 2.50734331075364e-07
of O 0 2.497472273432777e-08
human O 0 1.0872796565308818e-06
obesity B-Disease 1 0.9988228678703308
to O 0 4.915786121273413e-06
chromosome O 0 3.090597965638153e-05
2 O 0 2.2221374251785164e-07
in O 0 2.5514319546005026e-08
close O 0 6.031804389294848e-08
proximity O 0 1.130693760842405e-07
to O 0 1.290246558482977e-07
the O 0 1.7838715393736493e-07
POMC O 0 0.0031294478103518486
locus O 0 4.717900083051063e-06
, O 0 4.411448273344831e-08
led O 0 2.8764926440771887e-08
to O 0 6.044102107694016e-09
the O 0 4.203181358519714e-09
proposal O 0 2.3335196885909681e-07
of O 0 3.513892954387643e-09
an O 0 5.152795878871075e-08
association O 0 3.702581352627021e-08
of O 0 2.037529966969487e-08
POMC O 0 0.0012407308677211404
with O 0 4.0896961763792206e-06
human O 0 1.8844752048607916e-05
obesity B-Disease 1 0.9992982149124146
. O 0 9.480199878453277e-06

The O 0 1.7563119172336883e-06
dual O 0 3.631463414421887e-06
role O 0 1.447139794663599e-07
of O 0 2.1088343515884844e-08
alpha O 0 5.696796847587393e-07
- O 0 3.402832226129249e-05
MSH O 0 0.0003495747223496437
in O 0 1.0736274447253891e-07
regulating O 0 1.3234362938874256e-07
food O 0 5.1520000710070235e-08
intake O 0 6.341347216221038e-07
and O 0 3.224371170063023e-08
influencing O 0 4.894810103905911e-07
hair O 0 0.018017757683992386
pigmentation O 0 0.020342590287327766
predicts O 0 0.00038024780224077404
that O 0 1.8781391020183946e-07
the O 0 2.65483436123759e-07
phenotype O 0 0.11200657486915588
associated O 0 1.8466846540832194e-07
with O 0 5.5349268279769603e-08
a O 0 2.9428980269585736e-05
defect O 0 0.014603773131966591
in O 0 1.449284809496021e-06
POMC O 0 0.018714340403676033
function O 0 3.273817696936021e-07
would O 0 2.0777133613592014e-07
include O 0 2.885967660404276e-07
obesity B-Disease 1 0.9970303773880005
, O 0 1.4353674941958161e-06
alteration O 0 1.4543671568389982e-05
in O 0 6.2081330725050066e-06
pigmentation O 1 0.9788237810134888
and O 1 0.8069379329681396
ACTH B-Disease 1 0.9999805688858032
deficiency I-Disease 1 0.9985777139663696
. O 0 8.452563633909449e-06

The O 0 2.6101106413989328e-06
observation O 0 5.960275302641094e-06
of O 0 1.2759069534240552e-07
these O 0 3.4064663623212255e-07
symptoms O 0 0.0002800520451273769
in O 0 1.410834187254295e-07
two O 0 2.2143629507809237e-07
probands O 0 0.0002081770362565294
prompted O 0 5.4323631957231555e-06
us O 0 1.332600589876165e-07
to O 0 1.7747636249509924e-08
search O 0 7.898711373854894e-08
for O 0 6.553609210868672e-08
mutations O 0 8.351042311005585e-07
within O 0 2.5478479770413287e-08
their O 0 1.2081332556590496e-07
POMC O 0 0.0020337444730103016
genes O 0 5.361548119253712e-06
. O 0 1.954686240424053e-06

Patient O 0 0.23529554903507233
1 O 0 4.232719220453873e-06
was O 0 4.20511878473917e-06
found O 0 8.766303949414578e-08
to O 0 2.5270658454701334e-08
be O 0 1.3337290383219624e-08
a O 0 1.1874276140133588e-07
compound O 0 1.25915096305107e-06
heterozygote O 0 6.4404257500427775e-06
for O 0 2.475004201585307e-08
two O 0 6.76417144518382e-08
mutations O 0 3.573110234356136e-07
in O 0 2.25288090405229e-08
exon O 0 7.673513096051465e-07
3 O 0 1.2863714005106885e-07
( O 0 1.1645112429903293e-08
G7013T O 0 9.950377943823696e-07
, O 0 4.13483967065531e-08
C7133delta O 0 1.7777199445845326e-06
) O 0 7.1198051898591075e-09
which O 0 6.420526332817644e-09
interfere O 0 3.756673194743598e-08
with O 0 9.257874467039073e-09
appropriate O 0 2.121429609758252e-08
synthesis O 0 5.241703249225793e-08
of O 0 1.3417869482168499e-08
ACTH O 0 4.639407416107133e-05
and O 0 1.0986330778450792e-07
alpha O 0 1.2512911098383483e-06
- O 0 0.00010316810221411288
MSH O 0 0.0027495771646499634
. O 0 2.8345825739961583e-06

Patient O 0 0.06711418181657791
2 O 0 2.72994634542556e-06
was O 0 6.67211111249344e-07
homozygous O 0 5.463987235998502e-07
for O 0 1.2348772671089137e-08
a O 0 3.6204556863594917e-07
mutation O 0 9.372061526846664e-07
in O 0 6.50583444894437e-08
exon O 0 5.395879725256236e-06
2 O 0 3.296723889434361e-07
( O 0 3.147972904571361e-08
C3804A O 0 3.0316489301185356e-06
) O 0 4.498293293409006e-08
which O 0 2.007128045988793e-07
abolishes O 0 0.0007335623959079385
POMC O 0 0.02165650948882103
translation O 0 1.3420729374047369e-05
. O 0 2.281891966049443e-06

These O 0 3.957607077609282e-06
findings O 0 2.7436017262516543e-06
represent O 0 4.070199111083639e-08
the O 0 3.36801697642386e-09
first O 0 1.5911366446630382e-08
examples O 0 2.3310724017733264e-08
of O 0 1.121378723212274e-08
a O 0 0.0007207940798252821
genetic B-Disease 1 0.9997138381004333
defect I-Disease 1 0.9998564720153809
within O 0 3.459733477484406e-08
the O 0 9.657972555032757e-08
POMC O 0 0.0005809834110550582
gene O 0 2.7745292641156993e-07
and O 0 1.1037448288675478e-08
define O 0 9.870781525478378e-08
a O 0 5.590000000665896e-07
new O 0 1.1384619028831366e-05
monogenic B-Disease 1 0.9314277768135071
endocrine I-Disease 1 0.9682448506355286
disorder I-Disease 1 0.8492094278335571
resulting O 0 3.057810545215034e-06
in O 0 1.6049816053964605e-07
early O 0 1.7814159946283326e-05
- O 1 0.9854403138160706
onset O 1 0.9944572448730469
obesity B-Disease 1 0.9999979734420776
, O 0 0.003655551001429558
adrenal B-Disease 1 0.999971866607666
insufficiency I-Disease 1 0.9999881982803345
and O 0 1.9579625586629845e-05
red O 0 0.0010691166389733553
hair O 1 0.5667008757591248
pigmentation O 0 0.05920621380209923
. O 0 1.1674100051095593e-06
. O 0 1.1992946156169637e-06

A O 0 3.756530350074172e-05
European O 0 7.416143944283249e-06
multicenter O 0 0.011482206173241138
study O 0 4.9179243433172815e-06
of O 0 1.5176875649558497e-06
phenylalanine B-Disease 1 0.9999984502792358
hydroxylase I-Disease 1 0.9999953508377075
deficiency I-Disease 1 0.9999967813491821
: O 0 3.3713999414430873e-07
classification O 0 1.801282820679262e-07
of O 0 9.145969315227376e-09
105 O 0 1.960907411557855e-06
mutations O 0 3.4544696063676383e-06
and O 0 2.1654589232866783e-08
a O 0 2.9546629320975626e-07
general O 0 8.688085983976634e-08
system O 0 6.698832777374264e-08
for O 0 5.517135548416263e-08
genotype O 0 2.706813938857522e-05
- O 0 1.0016396117862314e-05
based O 0 4.5001428361501894e-07
prediction O 0 1.7545406763019855e-06
of O 0 8.517849181544079e-08
metabolic O 0 0.09730993956327438
phenotype O 0 0.06090385094285011
. O 0 3.2819311854836997e-06

Phenylketonuria B-Disease 1 0.9977450966835022
( O 0 0.000619483704213053
PKU B-Disease 1 0.6943681240081787
) O 0 4.818642992177047e-06
and O 0 1.8937515051220544e-05
mild B-Disease 1 0.9988223910331726
hyperphenylalaninemia I-Disease 1 0.9999991655349731
( O 0 6.893988756928593e-05
MHP B-Disease 1 0.9999985694885254
) O 0 2.448364512019907e-06
are O 0 7.774167443130864e-07
allelic B-Disease 1 0.8493063449859619
disorders I-Disease 1 0.9989287257194519
caused O 0 0.0005358198541216552
by O 0 1.5443716847585165e-06
mutations O 0 9.257555575459264e-06
in O 0 3.524910496821576e-08
the O 0 3.925779523683559e-08
gene O 0 1.0350426009608782e-06
encoding O 0 3.1905394735076698e-06
phenylalanine O 0 0.0008696400327607989
hydroxylase O 0 0.007551395334303379
( O 0 2.1485434444912244e-06
PAH O 0 0.0005569224595092237
) O 0 1.167611458186002e-06
. O 0 1.1000038284691982e-06

Previous O 0 2.8081713026040234e-05
studies O 0 1.4885530390529311e-06
have O 0 1.344828746141502e-07
suggested O 0 1.1328568660928795e-07
that O 0 1.5322635604775314e-08
the O 0 2.6628896421243553e-08
highly O 0 1.0611532843540772e-06
variable O 0 7.13348199496977e-05
metabolic O 0 0.016880454495549202
phenotypes O 0 0.0035610434133559465
of O 0 7.689191079407465e-06
PAH B-Disease 1 0.9999921321868896
deficiency I-Disease 1 0.9995988011360168
correlate O 0 0.00037766312016174197
with O 0 0.0001886227255454287
PAH O 1 0.998219907283783
genotypes O 0 0.010520093142986298
. O 0 1.2325497664278373e-05

We O 0 4.894627636531368e-06
identified O 0 1.4961884744479903e-06
both O 0 6.80756926385584e-08
causative O 0 4.635065579350339e-06
mutations O 0 8.897339284885675e-06
in O 0 6.803894621043582e-07
686 O 0 0.18994978070259094
patients O 0 0.025808723643422127
from O 0 5.195677132974197e-08
seven O 0 1.8293052050921688e-07
European O 0 3.330686126901128e-07
centers O 0 9.594003813617746e-07
. O 0 1.1883207662322093e-06

On O 0 1.6329308891727123e-06
the O 0 5.598696972697326e-08
basis O 0 1.198409993463656e-08
of O 0 2.0658608157475555e-09
the O 0 3.4943518301133736e-08
phenotypic O 0 6.164128990349127e-06
characteristics O 0 1.6854585282999324e-07
of O 0 2.5825810823221218e-08
297 O 0 1.154080564447213e-05
functionally O 0 0.0003767888993024826
hemizygous O 0 0.15875482559204102
patients O 0 0.0009254139731638134
, O 0 2.7108564282229963e-08
105 O 0 4.452106949770496e-08
of O 0 2.8621633951786407e-09
the O 0 2.2956156087161617e-08
mutations O 0 8.815530350148038e-07
were O 0 3.5627078176503346e-08
assigned O 0 2.696818590663952e-08
to O 0 7.783046207521238e-09
one O 0 1.061819521197549e-08
of O 0 4.985454715722426e-09
four O 0 1.2746480138048355e-07
arbitrary O 0 5.618306659016525e-06
phenotype O 0 0.0321982279419899
categories O 0 1.7549356243762304e-06
. O 0 1.6433009477623273e-06

We O 0 4.332888693170389e-06
proposed O 0 1.404684212502616e-06
and O 0 1.9006478169103502e-07
tested O 0 5.709665629183291e-07
a O 0 1.5647371753857442e-07
simple O 0 1.913911376050237e-07
model O 0 3.484296371425444e-07
for O 0 2.4739280846119982e-08
correlation O 0 2.8386165240590344e-07
between O 0 1.0974099495797418e-07
genotype O 0 1.8692933736019768e-05
and O 0 2.2901188856394583e-07
phenotypic O 0 4.129993976675905e-05
outcome O 0 1.0793198271130677e-05
. O 0 4.438588803168386e-06

The O 0 6.98629992257338e-06
observed O 0 1.997336767090019e-05
phenotype O 0 0.0003669038414955139
matched O 0 2.293599436598015e-06
the O 0 7.704444016098932e-08
predicted O 0 2.3039070583763532e-05
phenotype O 0 0.000249732518568635
in O 0 5.21593257474251e-08
79 O 0 6.332842076517409e-06
% O 0 1.6252354129164814e-08
of O 0 1.9120234284741855e-09
the O 0 6.378709827004059e-08
cases O 0 1.8157321619582945e-06
, O 0 1.5595884406138794e-07
and O 0 6.650899564419888e-08
in O 0 1.6776320777012188e-08
only O 0 1.4350204580182435e-08
5 O 0 7.955649472535242e-09
of O 0 4.511514717364662e-09
184 O 0 2.972987749672029e-05
patients O 0 0.008153988979756832
was O 0 3.7755291941721225e-06
the O 0 3.847895158060055e-08
observed O 0 9.668603979662294e-07
phenotype O 0 2.0727569790324196e-05
more O 0 1.7943827756994324e-08
than O 0 1.0661501903541648e-08
one O 0 1.5919441764822295e-08
category O 0 2.3919847436104646e-08
away O 0 2.730586246002531e-08
from O 0 8.749712065991844e-09
that O 0 4.673944431488053e-08
expected O 0 1.412424239788379e-06
. O 0 1.1411567584218574e-06

Among O 0 3.938074314646656e-06
the O 0 8.977699650358772e-08
seven O 0 1.2345738298336073e-07
contributing O 0 7.36167820036826e-08
centers O 0 1.982809294531762e-08
, O 0 1.3496257444955972e-08
the O 0 4.934294306480069e-09
proportion O 0 6.166487764858175e-08
of O 0 2.2811333266758993e-08
patients O 0 2.5163046302623115e-05
for O 0 7.822905701004856e-08
whom O 0 1.4947423778721713e-06
the O 0 3.928146341536376e-08
observed O 0 1.5757963183204993e-06
phenotype O 0 4.441034252522513e-05
did O 0 1.58554485096829e-07
not O 0 8.546992447122648e-09
match O 0 4.1626304181363594e-08
the O 0 3.651113544833606e-08
predicted O 0 6.187305552884936e-05
phenotype O 0 0.00011570299102459103
was O 0 9.38347341161716e-07
4 O 0 1.1681756717507596e-07
% O 0 2.491753114952644e-08
- O 0 7.916696631582454e-06
23 O 0 2.07670200325083e-05
% O 0 1.2760882839302212e-07
( O 0 5.4541068550406635e-08
P O 0 1.3340351870283484e-05
< O 0 6.428763867916132e-07
. O 0 3.2393320026358197e-08
0001 O 0 3.38821593004468e-07
) O 0 1.1851418513231238e-08
, O 0 1.0667990935075977e-08
suggesting O 0 1.0411195461301759e-07
that O 0 1.644521674393218e-08
differences O 0 4.3135827354490175e-08
in O 0 6.587406176095101e-09
methods O 0 2.2396763554866084e-08
used O 0 5.2426027963292654e-08
for O 0 3.1754840534858886e-08
mutation O 0 6.85206828165974e-07
detection O 0 5.268907443678472e-07
or O 0 1.0744280416474794e-06
phenotype O 1 0.9829617142677307
classification O 0 0.00018922347226180136
may O 0 9.05145952856401e-06
account O 0 6.701580446133448e-08
for O 0 6.850406464309344e-09
a O 0 1.3978538504488824e-07
considerable O 0 5.949015076112119e-07
proportion O 0 2.3591898923314147e-07
of O 0 7.370740462420144e-08
genotype O 0 0.006985727231949568
- O 1 0.555837869644165
phenotype O 0 0.2506300210952759
inconsistencies O 0 9.645845420891419e-05
. O 0 9.433168997929897e-06

Our O 0 3.956173259211937e-06
data O 0 5.923663479734387e-07
indicate O 0 3.6465070252234e-07
that O 0 4.712975254506091e-08
the O 0 2.850033808954322e-07
PAH O 0 0.1179814413189888
- O 0 0.1088489294052124
mutation O 0 7.526069384766743e-05
genotype O 0 1.2423432963259984e-05
is O 0 1.1996403870284666e-08
the O 0 3.2661129356625906e-09
main O 0 3.3957945788642974e-08
determinant O 0 3.2064423294286826e-07
of O 0 2.4452367242133732e-08
metabolic O 0 0.01289654616266489
phenotype O 0 0.004769668914377689
in O 0 2.0312793935772788e-07
most O 0 1.0646876035025343e-05
patients O 0 0.3969811201095581
with O 0 0.2594105005264282
PAH B-Disease 1 0.9999973773956299
deficiency I-Disease 1 0.9997449517250061
. O 0 1.183310268970672e-05

In O 0 3.6753874610440107e-06
the O 0 1.5283355025985657e-07
present O 0 1.8345218677495723e-07
study O 0 1.0357836544017118e-07
, O 0 1.8660731626596316e-08
the O 0 1.7930316786873846e-08
classification O 0 1.6310120543039375e-07
of O 0 1.664658988431711e-08
105 O 0 0.0001114324841182679
PAH O 1 0.9992978572845459
mutations O 0 0.0002944724401459098
may O 0 4.6476574766529666e-07
allow O 0 2.906688223447418e-08
the O 0 1.391808890360835e-08
prediction O 0 3.9441678723051155e-07
of O 0 1.587849407513886e-09
the O 0 2.3538136773026963e-08
biochemical O 0 1.6461635823361576e-05
phenotype O 0 0.00016152732132468373
in O 0 4.734129177563773e-08
> O 0 3.988986634340108e-07
10 O 0 5.596860574996754e-08
, O 0 2.1440305530973092e-08
000 O 0 1.445324642190826e-07
genotypes O 0 2.4194412162614753e-06
, O 0 8.523830530293708e-08
which O 0 1.5124355456919147e-07
may O 0 2.1109175918354595e-07
be O 0 5.786472634383699e-09
useful O 0 7.714792360502543e-09
for O 0 4.3501495738951235e-09
the O 0 1.2813753613727386e-08
management O 0 3.969676853898818e-08
of O 0 1.970879459634034e-08
hyperphenylalaninemia B-Disease 1 0.999885082244873
in O 0 2.2918893591850065e-05
newborns O 0 0.026964938268065453
. O 0 4.925279426970519e-06

Somatic O 0 0.001222059247083962
instability O 0 9.973904525395483e-05
of O 0 4.7031511485329247e-07
the O 0 5.26399560385471e-07
CTG O 0 0.00030066334875300527
repeat O 0 1.475203134759795e-05
in O 0 2.7573625516197353e-07
mice O 0 5.929942744842265e-06
transgenic O 0 6.944590040802723e-07
for O 0 1.2980169117327023e-07
the O 0 6.462378223659471e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 3.804638981819153e-05
is O 0 1.132115357904695e-06
age O 0 5.185672762308968e-07
dependent O 0 7.267479418260336e-08
but O 0 3.794805536472268e-08
not O 0 3.53803848440748e-08
correlated O 0 8.464856904311091e-08
to O 0 1.4198285214206408e-08
the O 0 9.400329403774776e-09
relative O 0 1.7591771950264956e-07
intertissue O 0 3.52558367922029e-06
transcription O 0 6.916573056514608e-07
levels O 0 1.6425397575403622e-07
and O 0 2.4570746859353676e-07
proliferative O 0 0.0246591679751873
capacities O 0 3.95117822336033e-05
. O 0 5.112734015710885e-06

A O 0 9.66427760431543e-05
( O 0 2.2145011371321743e-06
CTG O 0 3.5998393286718056e-05
) O 0 1.1889551387866959e-07
nexpansion O 0 5.720097760786302e-06
in O 0 3.238522694459789e-08
the O 0 2.7693261017702753e-08
3 O 0 6.638333047703782e-07
- O 0 0.003845777828246355
untranslated O 0 0.017713043838739395
region O 0 1.2437080840754788e-06
( O 0 7.471562923910824e-08
UTR O 0 6.268398465181235e-06
) O 0 7.469308727081625e-09
of O 0 4.010772602924817e-09
the O 0 2.0068219441782276e-07
DM O 1 0.9999995231628418
protein O 0 1.64684206538368e-05
kinase O 0 8.01557871454861e-06
gene O 0 3.036519160559692e-07
( O 0 2.2880488614873684e-08
DMPK O 0 8.842685929266736e-06
) O 0 2.0047133730827227e-08
is O 0 1.670135496567582e-08
responsible O 0 2.0438790215848712e-07
for O 0 9.980038839785266e-07
causing O 1 0.7447382211685181
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.02290525659918785
DM B-Disease 1 0.9999994039535522
) O 0 1.674657323746942e-05
. O 0 4.7113580876612104e-06

Major O 0 2.6387471734778956e-05
instability O 0 2.168585342587903e-05
, O 0 1.985548152561023e-07
with O 0 6.448412648296653e-08
very O 0 7.118028833019707e-08
large O 0 3.647076951551753e-08
expansions O 0 1.8841598148355843e-07
between O 0 1.8918294486525156e-08
generations O 0 4.143713638882218e-08
and O 0 1.8215040142877115e-08
high O 0 7.47250368249297e-08
levels O 0 8.988524591302394e-09
of O 0 4.149770305161837e-09
somatic O 0 2.4088803911581635e-06
mosaicism O 0 0.000525097653735429
, O 0 5.448513107353392e-08
is O 0 2.9313916627415892e-08
observed O 0 3.7376403838607075e-07
in O 0 9.355157430945837e-07
patients O 0 0.00016717879043426365
. O 0 3.604667199397227e-06

There O 0 6.473295798059553e-06
is O 0 2.586873222298891e-07
a O 0 3.7825827803317225e-07
good O 0 3.346360131217807e-07
correlation O 0 1.8518447575388564e-07
between O 0 2.524570419382144e-08
repeat O 0 8.317421702486172e-07
size O 0 1.50104057183853e-07
( O 0 6.121463336228317e-09
at O 0 5.952780934848079e-09
least O 0 3.8154318815486477e-08
in O 0 2.9371282295187484e-08
leucocytes O 0 7.072231528582051e-05
) O 0 7.793016720825108e-08
, O 0 6.003798347364864e-08
clinical O 0 5.972782673779875e-06
severity O 0 0.0005215246928855777
and O 0 5.68583288895752e-07
age O 0 4.291344168905198e-07
of O 0 1.4072034559831081e-07
onset O 0 0.00015030574286356568
. O 0 1.5344096027547494e-05

The O 0 6.783487606298877e-06
trinucleotide O 0 0.0002913772768806666
repeat O 0 4.950566653860733e-05
instability O 0 4.0828995224728715e-06
mechanisms O 0 9.939092251443071e-07
involved O 0 1.0972892141580814e-06
in O 0 3.8712423702236265e-06
DM B-Disease 1 0.9999998807907104
and O 0 2.0720019165310077e-05
other O 0 2.723939189763769e-07
human O 0 1.4115669728198554e-05
genetic B-Disease 1 0.9999594688415527
diseases I-Disease 1 0.9999440908432007
are O 0 1.2531373840829474e-06
unknown O 0 7.480776730517391e-06
. O 0 1.7836193819675827e-06

We O 0 6.321533874142915e-06
studied O 0 1.0530920917517506e-06
somatic O 0 5.977033197268611e-06
instability O 0 2.0087568373128306e-06
by O 0 6.724538081925857e-08
measuring O 0 8.750181450523087e-07
the O 0 1.0492431101738475e-07
CTG O 0 2.905516157625243e-05
repeat O 0 2.599161007310613e-06
length O 0 1.1997991578027722e-06
at O 0 3.053955666132424e-08
several O 0 8.887707991789284e-08
ages O 0 1.2421203621215682e-07
in O 0 4.721106172667078e-09
various O 0 3.775541657091708e-09
tissues O 0 8.75398953326112e-08
of O 0 5.6171347573297226e-09
transgenic O 0 6.2624171732750256e-06
mice O 0 4.534101753961295e-05
carrying O 0 2.720911709275242e-07
a O 0 3.240932926473761e-07
( O 0 4.679100129578728e-08
CTG O 0 9.193663572659716e-06
) O 0 5.28175654324059e-08
55expansion O 0 2.9342475045268657e-06
surrounded O 0 4.062990228703711e-07
by O 0 3.5813144450003165e-08
45 O 0 5.180892159728501e-08
kb O 0 4.859164732806676e-07
of O 0 3.8706975402647e-09
the O 0 3.37558176966013e-08
human O 0 1.6387656387450988e-06
DM B-Disease 1 0.9999997615814209
region O 0 4.047310994792497e-06
, O 0 2.5350653132250045e-08
using O 0 2.5004178283438705e-08
small O 0 3.0563036546027433e-08
- O 0 3.3377305044268724e-06
pool O 0 1.7204951063831686e-06
PCR O 0 3.838520933641121e-05
. O 0 1.998488414756139e-06

These O 0 8.699942554812878e-06
mice O 0 0.00011851608724100515
have O 0 1.6640376543364255e-07
been O 0 1.029286522680195e-07
shown O 0 1.2283143746572023e-07
to O 0 6.15673343418166e-08
reproduce O 0 2.3655054519622354e-06
the O 0 1.583951281247664e-08
intergenerational O 0 7.47755734664679e-07
and O 0 6.376799888130336e-08
somatic O 0 7.650284032933996e-07
instability O 0 2.514220227567421e-07
of O 0 3.27581428649637e-09
the O 0 2.471588800290192e-08
55 O 0 5.266632001621474e-07
CTG O 0 1.537479693070054e-05
repeat O 0 6.773079803679138e-06
suggesting O 0 5.954219659543014e-07
that O 0 3.416258209654188e-08
surrounding O 0 4.446522794410157e-08
sequences O 0 4.530073027808612e-08
and O 0 8.348842506222809e-09
the O 0 7.618283781596347e-09
chromatin O 0 5.318564149092708e-07
environment O 0 2.8770639914910134e-07
are O 0 1.1516886999629605e-08
involved O 0 3.634937328911292e-08
in O 0 1.0193693356086442e-07
instability O 0 5.564465936913621e-06
mechanisms O 0 7.840800208214205e-06
. O 0 4.991326932213269e-06

As O 0 4.418696335051209e-06
observed O 0 1.0162259513890604e-06
in O 0 2.008651733831357e-08
some O 0 3.500567391512277e-09
of O 0 2.354234585055792e-09
the O 0 3.196899811541698e-08
tissues O 0 4.371838713268517e-06
of O 0 3.0400997275137343e-06
DM B-Disease 1 1.0
patients O 1 0.9999616146087646
, O 0 3.5074137372248515e-07
there O 0 2.4663334485808264e-08
is O 0 1.8917681643415563e-08
a O 0 8.094140468983824e-08
tendency O 0 5.287320732350054e-07
for O 0 4.267241138222744e-08
repeat O 0 1.4069286180529161e-06
length O 0 1.8916617818831583e-06
and O 0 6.498417803868506e-08
somatic O 0 1.1056928315156256e-06
mosaicism O 0 3.392152939341031e-05
to O 0 1.311200037434901e-07
increase O 0 1.102726869817161e-07
with O 0 2.617533212401213e-08
the O 0 5.015778370420776e-08
age O 0 7.876025165387546e-08
of O 0 7.68835128894807e-09
the O 0 9.239901999080757e-08
mouse O 0 2.548404154367745e-05
. O 0 3.673610535770422e-06

Furthermore O 0 0.00011998236732324585
, O 0 5.593039418272383e-07
we O 0 4.5636529222292666e-08
observed O 0 5.0823320663084814e-08
no O 0 1.7015045372659188e-08
correlation O 0 4.284498444917517e-08
between O 0 6.736718294320099e-09
the O 0 3.0075430146325743e-08
somatic O 0 6.981883871048922e-06
mutation O 0 1.3138655958755407e-05
rate O 0 2.9559396352851763e-07
and O 0 9.258354793928447e-08
tissue O 0 4.840501787839457e-06
proliferation O 0 1.641469907553983e-06
capacity O 0 2.031745680142194e-06
. O 0 1.831434587984404e-06

The O 0 1.4312953453554655e-06
somatic O 0 4.946522312820889e-05
mutation O 0 7.503546657972038e-05
rates O 0 6.066910600566189e-07
in O 0 2.253559827636309e-08
different O 0 1.6181829209926946e-08
tissues O 0 6.202607778504898e-07
were O 0 1.3906922902151564e-07
also O 0 1.0012654172442126e-07
not O 0 2.0009618850735933e-08
correlated O 0 6.605173297202782e-08
to O 0 2.2505016517015974e-08
the O 0 6.856707202018697e-09
relative O 0 8.971554166237183e-08
inter O 0 1.941153584539279e-07
- O 0 0.00023543351562693715
tissue O 0 1.6905945813050494e-05
difference O 0 7.394481826850097e-08
in O 0 6.814230957274958e-09
transcriptional O 0 2.4491626504641317e-07
levels O 0 1.794653314846073e-08
of O 0 7.659279321892143e-10
the O 0 5.784905443562138e-09
three O 0 2.8763663451059074e-08
genes O 0 6.125051044136853e-08
( O 0 1.76288139641656e-08
DMAHP O 0 1.7239230146515183e-05
, O 0 7.653240885474588e-08
DMPK O 0 1.909130332933273e-05
and O 0 2.1759946378097084e-07
59 O 0 7.151170393626671e-07
) O 0 1.256136172855804e-08
surrounding O 0 4.392925490037669e-08
the O 0 1.0511400461155063e-07
repeat O 0 1.009248080663383e-05
. O 0 9.528860687169072e-07
. O 0 1.8617963633005274e-06

A O 0 8.622655877843499e-05
novel O 0 0.00013144451077096164
missense O 0 0.01576324738562107
mutation O 0 0.0002704717044252902
in O 0 2.8299853056523716e-06
patients O 0 9.784267604118213e-05
from O 0 6.059364210386775e-08
a O 0 7.954171451274306e-06
retinoblastoma B-Disease 0 0.0405002236366272
pedigree O 0 6.534756539622322e-05
showing O 0 7.3759397309913766e-06
only O 0 4.2150455215050897e-07
mild O 0 0.000512448837980628
expression O 0 8.848547849993338e-07
of O 0 7.987506478457362e-08
the O 0 2.3732536647003144e-06
tumor B-Disease 0 0.42080023884773254
phenotype O 0 0.07164623588323593
. O 0 3.1848667276790366e-06

We O 0 2.7237881567998556e-06
have O 0 9.297232850258297e-08
used O 0 4.0147696722669934e-08
single O 0 1.2749909217291133e-07
strand O 0 1.5275179521268e-06
conformation O 0 1.2426918374330853e-06
polymorphism O 0 7.61289174988633e-06
analysis O 0 7.900609944044845e-08
to O 0 2.2257040654949378e-08
study O 0 2.1795765192678118e-08
the O 0 1.5184470569806763e-08
27 O 0 4.651417668810609e-07
exons O 0 1.8918336763817933e-07
of O 0 4.494397298770991e-09
the O 0 8.952802232897739e-08
RB1 O 0 0.00016831602260936052
gene O 0 2.5272882453464263e-07
in O 0 1.7580829236862883e-08
individuals O 0 3.653521929436465e-09
from O 0 4.521568008897248e-09
a O 0 6.430971666304686e-07
family O 0 2.0563659290928626e-06
showing O 0 2.3515676730312407e-05
mild O 0 0.010443361476063728
expression O 0 1.2570873195727472e-06
of O 0 5.801483027312315e-08
the O 0 2.032540351137868e-06
retinoblastoma B-Disease 1 0.7196343541145325
phenotype O 1 0.5139111876487732
. O 0 8.777597031439655e-06

In O 0 5.024079200666165e-06
this O 0 2.992380530031369e-07
family O 0 1.2534708275779849e-06
affected O 0 2.1001608274673345e-07
individuals O 0 2.0593233784893528e-08
developed O 0 1.3466014934238046e-06
unilateral B-Disease 0 0.17086860537528992
tumors I-Disease 1 0.9999996423721313
and O 0 8.596172165198368e-07
, O 0 2.400815546366175e-08
as O 0 1.679444139313091e-08
a O 0 1.9194443723336008e-07
result O 0 5.1350376395475905e-08
of O 0 6.987584288964399e-09
linkage O 0 3.6885235203953926e-06
analysis O 0 2.725139438553015e-07
, O 0 6.692307152889043e-08
unaffected O 0 5.777873411716428e-06
mutation O 0 6.843350206509058e-07
carriers O 0 1.3660901743151044e-07
were O 0 6.266272833954645e-08
also O 0 2.2933272703085095e-07
identified O 0 1.9392145134133898e-07
within O 0 8.438367338214903e-09
the O 0 3.785176616588615e-08
pedigree O 0 2.3580754714203067e-05
. O 0 1.855254254223837e-06

A O 0 1.8895372704719193e-05
single O 0 1.497873199696187e-06
band O 0 4.984497650184494e-07
shift O 0 2.508103875697998e-07
using O 0 1.0343286049874223e-07
SSCP O 0 9.41091711865738e-05
was O 0 2.8166896299808286e-06
identified O 0 1.4730976261034812e-07
in O 0 1.7287741016502878e-08
exon O 0 1.5689075780755957e-06
21 O 0 2.813999913087173e-07
which O 0 2.101374363405739e-08
resulted O 0 7.037664317977033e-08
in O 0 1.2343686073279514e-08
a O 0 8.251152507909865e-07
missense O 0 4.6353827201528475e-05
mutation O 0 4.1141663587040966e-07
converting O 0 8.111310734193466e-08
a O 0 4.6806130171717086e-07
cys O 0 0.0008156911935657263
- O 0 0.00011374452878953889
- O 0 5.867664731340483e-05
> O 0 9.332212016488484e-07
arg O 0 1.5146655414355337e-06
at O 0 3.2605687039222175e-08
nucleotide O 0 7.39349417244739e-08
position O 0 1.3166533108233125e-07
28 O 0 7.388884171177779e-08
in O 0 9.64099911016092e-09
the O 0 2.9608987262008668e-08
exon O 0 1.1623469617916271e-05
. O 0 1.459546183468774e-06

The O 0 5.384729774959851e-06
mutation O 0 3.097761873505078e-05
destroyed O 0 1.706424200165202e-06
an O 0 1.7774965499484097e-07
NdeI O 0 1.342760424449807e-05
restriction O 0 1.7641025351622375e-06
enzyme O 0 9.806356047192821e-07
site O 0 1.3837932328897296e-06
. O 0 1.0688418115023524e-06

Analysis O 0 2.8678192393272184e-05
of O 0 3.41400522074764e-07
all O 0 7.955986802699044e-08
family O 0 3.5978902701572224e-07
members O 0 5.258405977315306e-08
demonstrated O 0 3.6569267081176804e-07
that O 0 3.0031294784294005e-08
the O 0 4.53690418567021e-08
missense O 0 8.908008021535352e-05
mutation O 0 4.636511221178807e-06
co O 0 3.1995832614484243e-06
- O 0 5.351684012566693e-05
segregated O 0 3.0349294775078306e-06
with O 0 1.5561783584416844e-05
patients O 0 0.038659192621707916
with O 0 0.0003564459038898349
tumors B-Disease 1 0.9999983310699463
or O 0 3.917761262073327e-07
who O 0 2.2620795334660215e-06
, O 0 9.203366957422077e-09
as O 0 6.857897361101095e-09
a O 0 1.1843129499311544e-07
result O 0 5.91059503562974e-08
of O 0 5.635839794848607e-09
linkage O 0 3.965162704844261e-06
analysis O 0 2.2375633079718682e-07
had O 0 5.582573407991731e-07
been O 0 5.337282615869299e-08
predicted O 0 1.731195311549527e-07
to O 0 1.0328654376223767e-08
carry O 0 1.0135125450005944e-07
the O 0 8.720443389620414e-08
predisposing O 0 5.034304194850847e-05
mutation O 0 2.704182406887412e-05
. O 0 1.8721533479038044e-06

These O 0 8.76439571584342e-07
observations O 0 1.2019498853987898e-06
point O 0 5.566539940105031e-08
to O 0 2.3901877810317274e-08
another O 0 8.064414203090564e-08
region O 0 2.3186652597928514e-08
of O 0 7.480928765346562e-09
the O 0 1.5786947926699213e-07
RB1 O 0 0.0006755401846021414
gene O 0 2.8408049956851755e-07
where O 0 7.20602884030086e-08
mutations O 0 1.7669670171471807e-07
only O 0 8.59476045889096e-09
modify O 0 1.2070979948930471e-07
the O 0 4.85669282568324e-09
function O 0 5.917484280359986e-09
of O 0 6.937104779503045e-10
the O 0 9.808469592087476e-09
gene O 0 6.465889157425408e-08
and O 0 1.956209594311531e-08
raise O 0 5.717534534710467e-08
important O 0 3.3644729224846515e-09
questions O 0 2.463493764537361e-08
for O 0 1.8390494460618356e-08
genetic O 0 8.006364282664435e-07
counseling O 0 6.702462087559979e-07
in O 0 9.86259465207695e-08
families O 0 3.192086595049659e-08
with O 0 2.09437587272987e-08
these O 0 3.0972653775052095e-08
distinctive O 0 3.3723004889907315e-05
phenotypes O 0 0.001715863007120788
. O 0 8.109568057079741e-07
. O 0 1.6228026424869313e-06

Maternal B-Disease 0 0.12217025458812714
disomy I-Disease 0 0.07973574846982956
and O 0 0.007534037344157696
Prader B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999995231628418
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999995231628418
consistent O 0 1.5316451026592404e-05
with O 0 1.9411386631418281e-07
gamete O 0 5.023810444981791e-06
complementation O 0 2.2932512365514413e-05
in O 0 1.3222845041127584e-07
a O 0 6.729715096298605e-07
case O 0 5.556621545110829e-07
of O 0 8.631794656821512e-08
familial O 0 0.0003231744922231883
translocation O 0 0.0005761728389188647
( O 0 2.1740177658102766e-07
3 O 0 2.2658312559542537e-07
; O 0 1.1459220417009419e-07
15 O 0 9.413250978695942e-08
) O 0 1.024991824749577e-08
( O 0 9.403019696208048e-09
p25 O 0 2.752058207988739e-06
; O 0 6.95835353781149e-08
q11 O 0 3.2656155326549197e-06
. O 0 3.944754212170665e-08
2 O 0 9.459056826699452e-08
) O 0 7.595884454758561e-08
. O 0 4.1956306517931807e-07

Maternal B-Disease 1 0.9653624892234802
uniparental I-Disease 1 0.985994815826416
disomy I-Disease 1 0.9593583345413208
( I-Disease 0 0.00023336915182881057
UPD I-Disease 1 0.9999184608459473
) I-Disease 0 1.1799742196672014e-06
for I-Disease 0 1.6857896412147966e-07
chromosome I-Disease 0 2.5341418222524226e-05
15 I-Disease 0 2.07292771392531e-07
is O 0 1.7632208582085696e-08
responsible O 0 2.3107977753511477e-08
for O 0 8.624056135886349e-09
an O 0 5.1157886815644815e-08
estimated O 0 1.8322681683002884e-07
30 O 0 3.582024632464709e-08
% O 0 4.462927805093386e-09
of O 0 5.6863616038071996e-09
cases O 0 6.419549549718795e-07
of O 0 2.5818138965405524e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 7.827200897736475e-05
PWS B-Disease 1 0.9999294281005859
) O 0 8.693506060808431e-06
. O 0 3.1824863526708214e-06

We O 0 3.278849817434093e-06
report O 0 6.227704147931945e-07
on O 0 5.440454842187137e-08
an O 0 4.646602747016004e-08
unusual O 0 3.1496401220465486e-07
case O 0 6.518317263726203e-07
of O 0 3.385201452488218e-08
maternal B-Disease 0 2.9692586394958198e-05
disomy I-Disease 0 0.0002909162431024015
15 I-Disease 0 6.732610131621186e-07
in O 0 2.1492492408015096e-07
PWS B-Disease 1 0.9999741315841675
that O 0 6.492929287560401e-07
is O 0 4.508988027396299e-08
most O 0 1.2126382564758842e-08
consistent O 0 1.034766725638292e-07
with O 0 4.6242341511515406e-08
adjacent O 0 1.1483747641705122e-07
- O 0 5.059341219748603e-06
1 O 0 1.2312159469729522e-07
segregation O 0 8.461546485705185e-08
of O 0 5.283053106097668e-09
a O 0 1.0710376727729454e-06
paternal O 0 0.00024993118131533265
t O 0 7.819144957466051e-05
( O 0 2.120709474695559e-08
3 O 0 4.496723349234344e-08
; O 0 2.1184455079037434e-08
15 O 0 3.120224079111722e-08
) O 0 6.900606752680005e-09
( O 0 9.596857530880243e-09
p25 O 0 1.818531018216163e-06
; O 0 7.747132713120664e-08
q11 O 0 1.7389686490787426e-06
. O 0 1.1748003458933454e-08
2 O 0 1.4540893822356793e-08
) O 0 4.414914211992027e-09
with O 0 8.437658571835982e-09
simultaneous O 0 9.377095011586789e-07
maternal O 0 8.51072218210902e-06
meiotic O 0 1.2601032722159289e-05
nondisjunction O 0 7.281050784513354e-05
for O 0 4.124152326312469e-07
chromosome O 0 2.6155672458116896e-05
15 O 0 7.363173040175752e-07
. O 0 1.1516863196447957e-06

The O 0 2.3267532014870085e-05
patient O 0 0.0005528313340619206
( O 0 1.1843304719150183e-06
J O 0 0.0012967302463948727
. O 0 2.268239569502839e-07
B O 0 6.584500056305842e-07
. O 0 1.3668897125285184e-08
) O 0 4.359169469836388e-09
, O 0 4.2229091334888835e-09
a O 0 6.712646438700176e-08
17 O 0 1.4740560061454744e-07
- O 0 1.6713852346583735e-06
year O 0 1.858086022821226e-07
- O 0 5.871112080058083e-06
old O 0 1.595063804415986e-05
white O 0 2.8374738576530945e-06
male O 0 1.3385223610384855e-05
with O 0 3.5435739391687093e-06
PWS B-Disease 1 0.9999966621398926
, O 0 5.436426363303326e-06
was O 0 1.0379771993029863e-05
found O 0 3.6158525063001434e-08
to O 0 1.1287497159173654e-08
have O 0 4.0470915507739846e-08
47 O 0 3.498934688650479e-07
chromosomes O 0 8.11434333058969e-08
with O 0 3.2945262518069285e-08
a O 0 2.40546455643198e-06
supernumerary O 0 0.0012355372309684753
, O 0 5.129624014443834e-07
paternal O 0 3.117122105322778e-05
der O 0 5.069535836810246e-05
( O 0 1.1442551794971223e-08
15 O 0 1.1161975344009534e-08
) O 0 2.9014415314776443e-09
consisting O 0 1.1323271209562336e-08
of O 0 1.5235666062096698e-09
the O 0 7.293193160506917e-09
short O 0 1.713928412527821e-07
arm O 0 3.446743221502402e-06
and O 0 3.141602888945272e-08
the O 0 2.4368743467562126e-08
proximal O 0 7.485051173716784e-05
long O 0 4.139695647609187e-06
arm O 0 8.889079254004173e-06
of O 0 2.753640693242687e-08
chromosome O 0 8.710867405170575e-06
15 O 0 1.7513900729682064e-07
, O 0 7.872765905858614e-08
and O 0 4.2218161411256006e-07
distal O 0 0.05141713097691536
chromosome O 0 0.07276538014411926
arm O 0 0.0026501112151890993
3p O 0 0.0004691553767770529
. O 0 4.213403826724971e-06

The O 0 8.55075541039696e-06
t O 0 0.00012746179709210992
( O 0 9.521704669168685e-08
3 O 0 1.692303754907698e-07
; O 0 5.8454237006344556e-08
15 O 0 4.952617516096325e-08
) O 0 6.837822752459033e-09
was O 0 7.041967364784796e-07
present O 0 1.7598946300267926e-08
in O 0 4.907301232037753e-09
the O 0 3.6452667551145623e-09
balanced O 0 8.732776279885002e-08
state O 0 1.8998679962578535e-08
in O 0 1.1082042838950201e-08
the O 0 1.4251250490815437e-07
patients O 0 3.040175033675041e-05
father O 0 7.787184586049989e-06
and O 0 2.0216899088154605e-07
a O 0 8.227789294323884e-06
sister O 0 0.00024700950598344207
. O 0 1.9755252651521005e-06

Fluorescent O 0 0.000628466485068202
in O 0 1.998051857299288e-06
situ O 0 9.9283597592148e-06
hybridization O 0 1.8258052705277805e-06
analysis O 0 7.993386930138513e-07
demonstrated O 0 1.7349036625091685e-06
that O 0 7.189581197053485e-08
the O 0 2.011581443639443e-07
PWS B-Disease 1 0.9999340772628784
critical O 0 7.189104508142918e-05
region O 0 1.0685718052627635e-06
resided O 0 1.540303173896973e-06
on O 0 6.384187400954033e-08
the O 0 1.9472009782361965e-08
derivative O 0 5.119674142406438e-07
chromosome O 0 3.963367362302961e-06
3 O 0 8.105170934413763e-08
and O 0 1.6884502684888503e-08
that O 0 1.540398031352197e-08
there O 0 2.0709114423311803e-08
was O 0 6.453697665165237e-07
no O 0 5.7358626293080306e-08
deletion O 0 1.8018171488165535e-07
of O 0 6.047953693411046e-09
the O 0 2.2139934685583285e-07
PWS B-Disease 1 0.9999610185623169
region O 0 6.233955218704068e-07
on O 0 9.491532892980103e-08
the O 0 1.8591880035501163e-08
normal O 0 5.316596229931747e-08
pair O 0 1.4222806044017489e-07
of O 0 8.667772277703989e-09
15s O 0 2.0989723452657927e-06
present O 0 4.6591424052166985e-07
in O 0 3.649154223239748e-07
J O 0 0.007251502946019173
. O 0 2.5303272650489816e-06

B O 0 0.0027448455803096294
. O 0 6.067876529414207e-05

Methylation O 0 0.00011555227683857083
analysis O 0 3.979376742790919e-06
at O 0 1.0646123627111592e-07
exon O 0 6.359649660225841e-07
alpha O 0 6.947863795403464e-08
of O 0 2.359377138105856e-09
the O 0 3.819886185141286e-09
small O 0 3.365116185705119e-08
nuclear O 0 8.929607133723039e-07
ribonucleoprotein O 0 2.5808243663050234e-05
- O 0 5.284503276925534e-05
associated O 0 3.76752666397806e-07
polypeptide O 0 2.795668478938751e-06
N O 0 1.513432493993605e-06
( O 0 1.3617736271953618e-08
SNRPN O 0 3.0094195153651526e-06
) O 0 1.0645835324396558e-08
gene O 0 5.442883477257965e-08
showed O 0 3.0034163955861004e-07
a O 0 1.3419423794402974e-07
pattern O 0 1.0650057902239496e-06
characteristic O 0 2.0872360551038582e-07
of O 0 4.2282284340444676e-09
only O 0 2.3587393371826693e-08
the O 0 4.416904175741365e-08
maternal O 0 4.727086707134731e-05
chromosome O 0 1.2296907698328141e-05
15 O 0 3.5505689766068826e-07
in O 0 2.512350647521089e-07
J O 0 0.008509010076522827
. O 0 3.3707228794810362e-06

B O 0 0.003910318948328495
. O 0 4.74315820611082e-05

Maternal B-Disease 0 0.04671832174062729
disomy I-Disease 0 0.003951606806367636
was O 0 1.895227615023032e-05
confirmed O 0 1.0332230431231437e-06
by O 0 1.9988943833482153e-08
polymerase O 0 9.230299724549695e-07
chain O 0 1.3292666380948504e-06
reaction O 0 1.6731685548165842e-07
analysis O 0 2.1499600322272272e-08
of O 0 7.352778386149339e-09
microsatellite O 0 7.416936114168493e-06
repeats O 0 9.078309517462912e-07
at O 0 1.7881749414527803e-08
the O 0 6.8251830853682804e-09
gamma O 0 2.606048781217396e-07
- O 0 2.5484855541435536e-06
aminobutyric O 0 1.4064150491321925e-05
acid O 0 1.4010799986863276e-06
receptor O 0 5.66165681448183e-07
beta3 O 0 2.2505525976157514e-06
subunit O 0 7.791551297486876e-07
( O 0 9.3783768306821e-08
GABRB3 O 0 2.943669824162498e-05
) O 0 4.21619915869087e-07
locus O 0 1.0038705113402102e-05
. O 0 2.3536263142887037e-06

A O 0 0.0005202360916882753
niece O 0 0.04464273154735565
( O 0 2.0742481865454465e-06
B O 0 3.4155398225266254e-06
. O 0 1.51519714108872e-07
B O 0 4.460828222363489e-07
. O 0 1.3826170430775164e-08
) O 0 2.089550754647007e-09
with O 0 9.77632552690011e-09
45 O 0 4.908464390496192e-08
chromosomes O 0 4.58585063256578e-08
and O 0 4.788250684839568e-09
the O 0 2.9295346148927592e-09
derivative O 0 1.511183995717147e-07
3 O 0 7.002436319680783e-08
but O 0 3.6912783940579175e-08
without O 0 1.710883523742268e-08
the O 0 2.7739517349800735e-08
der O 0 2.9905546398367733e-05
( O 0 7.072311625222483e-09
15 O 0 1.773562274820506e-08
) O 0 9.708092996163487e-09
demonstrated O 0 3.7400081964733545e-07
a O 0 2.578609610282001e-06
phenotype O 0 0.04412749037146568
consistent O 0 1.330210125161102e-06
with O 0 3.099416545637723e-08
that O 0 1.270858689395027e-07
reported O 0 3.106939630015404e-07
for O 0 7.757909870065305e-09
haploinsufficiency O 0 3.907278824044624e-06
of O 0 3.4522322778229864e-08
distal O 0 0.0024205059744417667
3 O 0 2.76334958471125e-05
p O 0 3.861832374241203e-05
. O 0 1.0329323458790896e-06

Uniparental B-Disease 1 0.9997921586036682
disomy I-Disease 1 0.999549925327301
associated O 0 0.00016525189857929945
with O 0 7.273628739312699e-07
unbalanced O 0 3.728677620529197e-05
segregation O 0 1.5352291029557819e-06
of O 0 2.6559048293961496e-08
non O 0 1.590999261225079e-07
- O 0 1.7219761502929032e-05
Robertsonian O 0 0.0001778487057890743
translocations O 0 6.479590956587344e-05
has O 0 3.740532747542602e-06
been O 0 1.4922512718840153e-06
reported O 0 1.3568303529609693e-06
previously O 0 1.4234055356610043e-07
but O 0 4.6351484428441836e-08
has O 0 1.0585642939986428e-07
not O 0 3.512018409423945e-08
, O 0 1.1248576292643975e-08
to O 0 1.3078277127931415e-08
our O 0 6.9674217506587866e-09
knowledge O 0 6.444905942259993e-09
, O 0 8.908680904085031e-09
been O 0 2.341682936446432e-08
observed O 0 1.662025894688668e-08
in O 0 4.776529394234785e-09
a O 0 3.4430132700435934e-07
case O 0 3.1719569051347207e-06
of O 0 6.279230433392513e-07
PWS B-Disease 1 0.99996018409729
. O 0 3.843583181151189e-05

Furthermore O 0 4.4072319724364206e-05
, O 0 4.092057679372374e-07
our O 0 9.3064763007078e-08
findings O 0 3.263089070060232e-07
are O 0 4.857192870133531e-09
best O 0 5.909084421773514e-08
interpreted O 0 2.3545663907498238e-07
as O 0 3.700823469898751e-08
true O 0 8.280967733753641e-08
gamete O 0 2.1452040073199896e-06
complementation O 0 1.358548161078943e-05
resulting O 0 2.3765921923768474e-06
in O 0 1.383648054797959e-06
maternal B-Disease 0 0.17867439985275269
UPD I-Disease 1 0.9999817609786987
15 I-Disease 0 3.7565270758932456e-05
and O 0 1.686046198301483e-05
PWS B-Disease 1 0.9998571872711182

Schwartz B-Disease 0 0.4031029939651489
- I-Disease 1 0.9972297549247742
Jampel I-Disease 1 0.9993570446968079
syndrome I-Disease 1 0.9999517202377319
type I-Disease 0 4.925213488604641e-06
2 I-Disease 0 4.2243212305947964e-07
and O 0 7.937219947962149e-07
Stuve B-Disease 1 0.6373788714408875
- I-Disease 1 0.999962568283081
Wiedemann I-Disease 1 0.9999986886978149
syndrome I-Disease 1 0.9999929666519165
: O 0 1.0165113906168699e-07
a O 0 3.146880942495045e-07
case O 0 6.068640345802123e-07
for O 0 2.5827240790476935e-08
" O 0 1.7329692525436258e-07
lumping O 0 2.0919401322316844e-06
" O 0 1.0432261206005933e-06
. O 0 6.562402177223703e-07

Recent O 0 7.436543091898784e-05
studies O 0 3.3087410429288866e-06
demonstrated O 0 2.0873724224657053e-06
the O 0 1.919192982313689e-08
existence O 0 2.859763803542137e-08
of O 0 3.937415726795734e-09
a O 0 8.224653242905333e-07
genetically O 0 1.4853524135105545e-06
distinct O 0 1.534949518600115e-07
, O 0 3.6817855431081625e-08
usually O 0 6.532518170843105e-08
lethal O 0 3.339935972235253e-07
form O 0 1.5684086918099638e-08
of O 0 4.660606567341574e-09
the O 0 2.7938378366343386e-07
Schwartz B-Disease 0 0.03605273738503456
- I-Disease 1 0.9988114833831787
Jampel I-Disease 1 0.9999483823776245
syndrome I-Disease 1 0.9999861717224121
( O 0 5.146947046341666e-07
SJS B-Disease 0 0.000296933576464653
) O 0 5.2052982368877565e-08
of O 0 2.6176380174547376e-08
myotonia B-Disease 1 0.9273260235786438
and O 0 7.545061816927046e-05
skeletal B-Disease 1 0.9993765950202942
dysplasia I-Disease 1 0.9999383687973022
, O 0 1.0605664328977582e-06
which O 0 9.885722107583206e-08
we O 0 3.582995233841757e-08
called O 0 2.0577351733663818e-06
SJS B-Disease 0 0.003665831172838807
type I-Disease 0 9.110148312174715e-06
2 I-Disease 0 1.9736949070647825e-06
. O 0 1.7278039194934536e-06

This O 0 0.0004852071579080075
disorder O 1 0.9165281057357788
is O 0 3.080668875554693e-07
reminiscent O 0 2.498445155652007e-06
of O 0 5.871660846423765e-08
another O 0 8.682603038323577e-06
rare O 0 0.00010034828301286325
condition O 0 7.021261262707412e-05
, O 0 4.2194493232727837e-08
the O 0 1.1352037176948215e-07
Stuve B-Disease 0 0.1776992231607437
- I-Disease 1 0.9998278617858887
Wiedemann I-Disease 1 0.9999964237213135
syndrome I-Disease 1 0.9999985694885254
( O 0 1.0612322967062937e-06
SWS B-Disease 0 0.06203565001487732
) O 0 1.1116194542637459e-07
, O 0 1.8544492164096482e-08
which O 0 1.7261514884125972e-08
comprises O 0 2.4148917532329506e-08
campomelia B-Disease 0 2.9438640467560617e-06
at O 0 3.510143642415642e-08
birth O 0 7.073555252645747e-07
with O 0 1.0517142072785646e-06
skeletal B-Disease 1 0.9990115165710449
dysplasia I-Disease 1 0.9999749660491943
, O 0 3.0418803362408653e-05
contractures B-Disease 0 0.1165786013007164
, O 0 3.328952118408779e-07
and O 0 1.4336914944124146e-07
early B-Disease 0 1.4391780496225692e-06
death I-Disease 0 0.0013308387715369463
. O 0 2.5996248496085173e-06

To O 0 5.0448484216758516e-06
test O 0 9.906879085974651e-07
for O 0 1.91652986814006e-08
possible O 0 6.143818609416485e-08
nosologic O 0 3.891726373694837e-05
identity O 0 2.1323384657989664e-07
between O 0 3.1957050339315174e-08
these O 0 2.3486367695113586e-07
disorders O 0 0.004338666796684265
, O 0 4.3284508421947976e-08
we O 0 2.9483034680310993e-08
reviewed O 0 1.0684041029662694e-07
the O 0 4.914616713591613e-09
literature O 0 1.6706454886161737e-08
and O 0 1.7772160632034684e-08
obtained O 0 6.060751189806979e-08
a O 0 6.581456091225846e-08
follow O 0 7.308820926255066e-08
- O 0 7.235556154228107e-07
up O 0 1.3970644197058846e-08
of O 0 1.0999152699753267e-09
the O 0 5.73366110145912e-09
only O 0 2.4438051582365006e-08
two O 0 1.2412630212566e-07
surviving O 0 0.0014327234821394086
patients O 0 5.566992695094086e-05
, O 0 1.9665799655399496e-08
one O 0 1.6580111505959394e-08
with O 0 5.407607872598419e-08
SJS B-Disease 0 0.0020954161882400513
type I-Disease 0 1.6511839930899441e-06
2 I-Disease 0 2.528994613726354e-08
at O 0 4.139935505520498e-09
age O 0 3.077479249213866e-08
10 O 0 5.5209850025050855e-09
years O 0 1.9987457022807575e-08
and O 0 1.1607260042012513e-08
another O 0 1.0345219436658226e-07
with O 0 2.261681828485962e-07
SWS B-Disease 0 0.024671779945492744
at O 0 9.655357047222424e-08
age O 0 3.892933762017492e-07
7 O 0 6.181055027809634e-07
years O 0 6.243629400159989e-07
. O 0 1.168294261333358e-06

Patients O 1 0.9974295496940613
reported O 0 4.384436033433303e-05
as O 0 2.4755124172770593e-07
having O 0 4.830808393307962e-07
either O 0 1.8105223489328637e-06
neonatal O 1 0.9998981952667236
SJS B-Disease 1 0.996947705745697
or O 0 1.6822463294374757e-05
SWS B-Disease 1 0.5967926979064941
presented O 0 7.299569801944017e-07
a O 0 1.00064880825812e-07
combination O 0 1.755254146473817e-07
of O 0 5.653302270758331e-09
a O 0 2.411123887213762e-06
severe O 0 0.10847319662570953
, O 0 7.147330506995786e-06
prenatal O 1 0.7644696235656738
- O 1 0.9997664093971252
onset O 1 0.9997983574867249
neuromuscular B-Disease 1 0.9999969005584717
disorder I-Disease 1 0.9999445676803589
( O 0 4.523744223661197e-07
with O 0 1.5505831470363773e-05
congenital B-Disease 1 0.999975323677063
joint I-Disease 1 0.9888684749603271
contractures I-Disease 1 0.9999904632568359
, O 0 0.4738679528236389
respiratory O 1 0.9995427131652832
and O 0 1.2013553714496084e-05
feeding O 0 1.460538351238938e-05
difficulties O 0 2.9184325285314117e-06
, O 0 8.3988538790436e-08
tendency O 0 1.1581383887460106e-06
to O 0 2.89648346551985e-06
hyperthermia B-Disease 1 0.9770764708518982
, O 0 4.01256585291776e-07
and O 0 1.7664061147115717e-07
frequent O 0 8.032877667574212e-05
death O 0 0.321760892868042
in O 0 1.851461206570093e-06
infancy O 0 0.00023717373551335186
) O 0 1.578341901620206e-08
with O 0 9.322729255245576e-09
a O 0 4.3201450239394035e-07
distinct O 0 4.3630569734887104e-07
campomelic B-Disease 0 0.0004029321135021746
- I-Disease 0 0.009443316608667374
metaphyseal I-Disease 0 0.372901052236557
skeletal I-Disease 1 0.9928836822509766
dysplasia I-Disease 1 0.9997186064720154
. O 0 5.6844721257220954e-05

The O 0 1.8418458012092742e-06
similarity O 0 1.5603932297381107e-06
of O 0 2.4661547470827827e-08
the O 0 1.0106922587738154e-07
clinical O 0 7.563387498521479e-06
and O 0 2.8945835310878465e-06
radiographic O 1 0.9616643786430359
findings O 0 0.00022821121092420071
is O 0 1.4303890338851488e-07
so O 0 6.060403734409192e-08
extensive O 0 2.955249271963112e-07
that O 0 5.586770157606225e-07
these O 0 5.1344159146538e-07
disorders O 0 0.003869278822094202
appear O 0 7.79412232532195e-07
to O 0 4.9783594135988096e-08
be O 0 2.77036686924248e-08
a O 0 1.7187767298310064e-07
single O 0 7.847472147659573e-07
entity O 0 1.5824585943846614e-06
. O 0 8.096646979538491e-07

The O 0 1.324089339505008e-06
follow O 0 6.471477718150709e-07
- O 0 3.412108299016836e-06
up O 0 7.22808124464791e-08
observation O 0 1.939798863759279e-07
of O 0 4.644367113115777e-09
an O 0 3.552997185352069e-08
identical O 0 2.507432100173901e-06
and O 0 2.2543165556498934e-08
unique O 0 3.3456863945957593e-08
pattern O 0 1.6743689457143773e-07
of O 0 2.948787169998468e-08
progressive O 0 0.08309679478406906
bone B-Disease 1 0.9191939234733582
dysplasia I-Disease 1 0.999901533126831
in O 0 7.302981543944043e-07
the O 0 1.7915996863848704e-07
two O 0 3.0006931410753168e-05
patients O 0 0.0003108356613665819
( O 0 5.923582069300437e-09
one O 0 1.2362322721060082e-08
with O 0 1.2688991546383477e-07
SJS B-Disease 0 0.052225615829229355
type I-Disease 0 4.694682502304204e-06
2 I-Disease 0 4.748010340449582e-08
, O 0 1.2437509688822956e-08
one O 0 1.9335999468239606e-08
with O 0 2.09003474083147e-07
SWS B-Disease 0 0.1219259724020958
) O 0 6.404701480278163e-08
surviving O 0 7.918575875009992e-07
beyond O 0 1.269511642476573e-07
infancy O 0 2.5137674128927756e-06
adds O 0 2.2822480616468965e-07
to O 0 1.863107002009201e-08
the O 0 9.658189803474215e-09
evidence O 0 5.173486172793673e-08
in O 0 1.2635396728910564e-08
favor O 0 1.0823081453281702e-07
of O 0 3.465664377699795e-08
identity O 0 9.148727144747681e-07
. O 0 1.2181552619949798e-06

The O 0 4.436434664967237e-06
hypothesis O 0 2.2523738152813166e-05
that O 0 6.829208700764866e-07
SWS B-Disease 0 0.016728922724723816
and O 0 2.1385674244811526e-06
SJS B-Disease 0 0.03187643736600876
type I-Disease 0 9.70734799921047e-06
2 I-Disease 0 2.1271512196108233e-07
are O 0 1.1156313206583945e-08
the O 0 5.387594015360264e-08
same O 0 1.560958662594203e-05
disorder O 0 0.02294217050075531
should O 0 2.1900618207837397e-07
be O 0 7.096501519754383e-08
testable O 0 4.583428392379574e-07
by O 0 2.7904127009037438e-08
molecular O 0 1.998708256678583e-07
methods O 0 2.0601018491106515e-07
. O 0 2.2417327727453085e-07
. O 0 6.130404699433711e-07

A O 0 3.1425424822373316e-05
mouse O 0 2.7017049433197826e-05
model O 0 6.04001752435579e-06
of O 0 1.294949697694392e-06
severe O 1 0.9997618794441223
von B-Disease 1 1.0
Willebrand I-Disease 1 0.9999997615814209
disease I-Disease 1 0.9999997615814209
: O 0 0.002448298502713442
defects O 1 0.992918074131012
in O 0 5.800668986921664e-06
hemostasis O 0 0.4047738015651703
and O 0 0.002347431145608425
thrombosis B-Disease 1 0.9989129304885864
. O 0 3.8371115806512535e-05

von B-Disease 1 0.9925088286399841
Willebrand I-Disease 1 0.9909834861755371
factor I-Disease 0 0.0006669927388429642
( I-Disease 0 2.2949905542191118e-05
vWf I-Disease 0 0.00647300761193037
) I-Disease 0 0.00023493482149206102
deficiency I-Disease 1 0.9861841797828674
causes O 0 0.16367241740226746
severe O 1 0.999991774559021
von B-Disease 1 1.0
Willebrand I-Disease 1 0.9999997615814209
disease I-Disease 1 0.9999992847442627
in O 0 2.2212412659428082e-05
humans O 0 8.287734090117738e-06
. O 0 3.2665373055351665e-06

We O 0 2.9118518796167336e-06
generated O 0 1.06074048744631e-06
a O 0 2.517396922030457e-07
mouse O 0 1.244056761606771e-06
model O 0 1.0443490054967697e-06
for O 0 4.7650573264945706e-08
this O 0 5.76954732878221e-07
disease O 0 4.635627192328684e-06
by O 0 2.2369695429347303e-08
using O 0 2.2213448858110496e-07
gene O 0 7.860475079723983e-07
targeting O 0 2.050545617748867e-06
. O 0 2.0594550278474344e-06

vWf B-Disease 0 0.1494922637939453
- I-Disease 1 0.9948005676269531
deficient I-Disease 1 0.9683082103729248
mice O 0 0.007195129059255123
appeared O 0 2.6837888071895577e-05
normal O 0 1.8837069148958108e-07
at O 0 3.158221062449229e-08
birth O 0 7.644704851372808e-07
; O 0 2.8187262302026284e-08
they O 0 1.7127511853232136e-08
were O 0 6.0350501485118e-08
viable O 0 3.511758279728383e-07
and O 0 3.8382856359930884e-07
fertile O 0 6.057462087483145e-06
. O 0 5.083218184154248e-06

Neither O 0 0.0005588029162026942
vWf O 0 0.0025713571812957525
nor O 0 0.0001902109943330288
vWf O 0 0.000300530664389953
propolypeptide O 0 0.0006032681558281183
( O 0 2.8588312943611527e-06
von B-Disease 0 0.01966770552098751
Willebrand I-Disease 0 0.10970006883144379
antigen O 0 0.0002875937498174608
II O 0 0.00010916889732470736
) O 0 5.726690943674839e-08
were O 0 8.307498688964188e-08
detectable O 0 4.070153352131456e-07
in O 0 3.028970141372156e-08
plasma O 0 8.558612535125576e-06
, O 0 1.345049298606682e-07
platelets O 0 2.0003149074909743e-06
, O 0 3.3904807850149155e-08
or O 0 2.1256418847315217e-08
endothelial O 0 3.2714538065192755e-06
cells O 0 1.1683216172286848e-07
of O 0 3.691579042452986e-09
the O 0 4.839025180558565e-08
homozygous O 0 1.226454787683906e-05
mutant O 0 3.648542406153865e-05
mice O 0 0.00011245329369558021
. O 0 2.173363782276283e-06

The O 0 8.035063729039393e-06
mutant O 0 0.0004029539704788476
mice O 0 0.22102098166942596
exhibited O 0 0.023379506543278694
defects O 1 0.6787292957305908
in O 0 1.089349211724766e-06
hemostasis O 0 0.002907764632254839
with O 0 3.392829910353612e-07
a O 0 3.87411182600772e-06
highly O 0 3.2590321552561363e-06
prolonged O 0 0.18128350377082825
bleeding O 1 0.9581142067909241
time O 0 2.71327792233933e-07
and O 0 9.307967019367425e-08
spontaneous O 0 2.315003484909539e-06
bleeding O 0 0.11796479672193527
events O 0 1.0472437850239658e-07
in O 0 5.2796309546465636e-08
approximately O 0 4.2847194237083386e-08
10 O 0 2.3984307873092803e-08
% O 0 1.871134003295083e-08
of O 0 3.3815748423648984e-08
neonates O 0 0.4414181113243103
. O 0 1.022834658215288e-05

As O 0 1.8995002619703882e-06
in O 0 8.765283610046026e-08
the O 0 1.0205852873923504e-07
human O 0 9.70214159679017e-07
disease O 0 1.629327016416937e-05
, O 0 2.363810658323473e-08
the O 0 2.0087208341124096e-08
factor O 0 1.7976927324525604e-07
VIII O 0 0.002000420121476054
level O 0 5.328555374717325e-08
in O 0 3.359293643256933e-08
these O 0 1.5328014413285018e-08
mice O 0 1.3171123100619297e-05
was O 0 3.6715721307700733e-06
reduced O 0 2.8426450171537e-07
strongly O 0 3.0469041689684673e-07
as O 0 1.5204960845949245e-08
a O 0 9.624503150007513e-08
result O 0 3.9379809635420315e-08
of O 0 2.0720247739802744e-09
the O 0 1.4477795851064457e-08
lack O 0 7.158656956107734e-08
of O 0 8.84453044136535e-09
protection O 0 4.3271961658319924e-07
provided O 0 2.309080144868858e-07
by O 0 2.1290306051469088e-07
vWf O 0 3.658298010122962e-05
. O 0 2.225750222351053e-06

Defective O 1 0.979454755783081
thrombosis B-Disease 1 0.9990313053131104
in O 0 8.120812708511949e-06
mutant O 0 0.0010068700648844242
mice O 0 0.008588124066591263
was O 0 6.46308080831659e-06
also O 0 3.6491718446995947e-07
evident O 0 2.558832932209043e-07
in O 0 1.9622822478027047e-08
an O 0 3.5591011027236163e-08
in O 0 5.03805139828728e-08
vivo O 0 1.024037101160502e-05
model O 0 5.042695079282566e-07
of O 0 1.40178144647507e-07
vascular B-Disease 1 0.9952173233032227
injury I-Disease 1 0.9184935688972473
. O 0 1.2660790162044577e-05

In O 0 4.849207016377477e-06
this O 0 1.587445126460807e-07
model O 0 7.774264076942927e-07
, O 0 3.132412373929583e-08
the O 0 2.477989369253919e-08
exteriorized O 0 1.5094531590875704e-05
mesentery O 0 1.6159972801688127e-05
was O 0 1.0126534562004963e-06
superfused O 0 3.3549572435731534e-06
with O 0 1.1331302118833264e-07
ferric O 0 0.000146531019709073
chloride O 0 0.00010080489300889894
and O 0 7.432829818299069e-08
the O 0 2.5087491195563416e-08
accumulation O 0 2.026884970973697e-07
of O 0 3.590985997448115e-08
fluorescently O 0 0.0006100565660744905
labeled O 0 5.1305429224157706e-05
platelets O 0 2.4443039364996366e-05
was O 0 2.260362862216425e-06
observed O 0 2.3178478159024962e-07
by O 0 1.036461512171627e-07
intravital O 0 5.111584687256254e-05
microscopy O 0 4.420660116011277e-05
. O 0 2.8919098440383095e-06

We O 0 6.7915598265244626e-06
conclude O 0 6.567444415850332e-06
that O 0 1.6302190886108292e-07
these O 0 4.296478905985168e-08
mice O 0 6.8195972744433675e-06
very O 0 1.1385864695512282e-07
closely O 0 7.593391728732968e-07
mimic O 0 0.000986000755801797
severe O 1 0.9415984153747559
human O 0 0.005083470139652491
von B-Disease 1 1.0
Willebrand I-Disease 1 0.999998927116394
disease I-Disease 1 0.9999973773956299
and O 0 2.823337581503438e-06
will O 0 5.415580517365015e-07
be O 0 5.1475602447226265e-08
very O 0 3.755333111143955e-08
useful O 0 1.6981521966386026e-08
for O 0 4.662082719875116e-09
investigating O 0 1.4120073998924454e-08
the O 0 3.032517792433964e-09
role O 0 1.1395332677466286e-08
of O 0 4.21954382545664e-09
vWf O 0 1.0297858352714684e-06
in O 0 2.211785421479817e-08
normal O 0 1.3741679083523195e-07
physiology O 0 1.2950508789799642e-06
and O 0 2.610931915114634e-07
in O 0 3.612341060943436e-06
disease O 0 9.182553185382858e-05
models O 0 8.866609277902171e-06
. O 0 2.9103952670084254e-07
. O 0 5.694612923434761e-07

Oral O 0 0.017348362132906914
contraceptives O 0 0.07356132566928864
and O 0 3.237831265323621e-07
the O 0 1.0733265298767947e-07
risk O 0 9.58612872636877e-07
of O 0 2.156687060050899e-06
hereditary B-Disease 1 0.9999985694885254
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
. O 0 0.00010129332804353908

Hereditary B-Disease 1 0.9999735355377197
Ovarian I-Disease 1 0.9999940395355225
Cancer I-Disease 1 0.9999071359634399
Clinical O 0 0.020890014246106148
Study O 0 2.817135646182578e-05
Group O 0 6.342016149574192e-06
. O 0 3.200492528776522e-06

BACKGROUND O 0 0.0035131953191012144
Women O 0 1.873090695880819e-05
with O 0 8.076549988800252e-07
mutations O 0 5.500262886926066e-06
in O 0 5.0416272046049926e-08
either O 0 8.22707946213086e-08
the O 0 9.155957059192588e-08
BRCA1 O 0 0.00010519256466068327
or O 0 6.437954169769e-08
the O 0 1.6113001777284808e-07
BRCA2 O 0 0.00014949319302104414
gene O 0 2.313514926299831e-07
have O 0 3.284468519382244e-08
a O 0 1.721575273450071e-07
high O 0 1.0302032933395822e-06
lifetime O 0 7.803815606166609e-06
risk O 0 3.264519364165608e-06
of O 0 1.4413081771635916e-05
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999984502792358
. O 0 2.8982160074519925e-05

Oral O 0 0.003917651250958443
contraceptives O 0 0.28717926144599915
protect O 0 0.0003201715589966625
against O 1 0.63814777135849
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999985694885254
in O 0 1.4213235317583894e-06
general O 0 4.012007082110358e-07
, O 0 7.551262370952827e-08
but O 0 3.939543447017968e-08
it O 0 2.1805870886737466e-08
is O 0 2.021754852421509e-08
not O 0 1.5008424725238e-08
known O 0 1.8945629065569847e-08
whether O 0 2.7525798529381973e-08
they O 0 1.9549638352600596e-08
also O 0 7.616210240257715e-08
protect O 0 1.4084199051467294e-07
against O 0 5.063542403149768e-07
hereditary B-Disease 0 0.008439620025455952
forms I-Disease 0 2.2177514438226353e-06
of I-Disease 0 0.00014076236402615905
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999985694885254
. O 0 2.8522808861453086e-05

METHODS O 0 3.512583862175234e-05
We O 0 1.1911914725715178e-06
enrolled O 0 8.348008577740984e-07
207 O 0 1.690864451120433e-06
women O 0 3.623672455432825e-06
with O 0 0.00043399250716902316
hereditary B-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
and O 0 5.171419843463809e-07
161 O 0 5.997972607474367e-07
of O 0 1.0633071312327047e-08
their O 0 2.019030276301237e-08
sisters O 0 2.766972215795249e-07
as O 0 2.4519525965160938e-08
controls O 0 3.4208034094262985e-07
in O 0 2.226455642073688e-08
a O 0 1.0172052498091944e-06
case O 0 1.1298673598503228e-05
- O 0 0.00019996159244328737
control O 0 2.604009205242619e-05
study O 0 2.1345003915484995e-06
. O 0 1.2462369340937585e-06

All O 0 3.646955747171887e-06
the O 0 1.4650071307187318e-06
patients O 0 3.072257823077962e-05
carried O 0 6.556846869898436e-07
a O 0 8.581624229009321e-07
pathogenic O 0 6.8467652454273775e-06
mutation O 0 2.7868945835507475e-06
in O 0 7.453088102238326e-08
either O 0 4.4050079850421753e-07
BRCA1 O 0 9.634658636059612e-05
( O 0 5.2144802253906164e-08
179 O 0 2.273589643664309e-06
women O 0 1.1647599649222684e-06
) O 0 1.0585480936242675e-07
or O 0 6.568525918737578e-07
BRCA2 O 0 0.001179961604066193
( O 0 1.1688933199138773e-07
28 O 0 4.434988113644067e-06
women O 0 5.8750771358973e-07
) O 0 1.9444736665263918e-07
. O 0 1.1701698667820892e-06

The O 0 3.897554506693268e-06
control O 0 7.044142876111437e-06
women O 0 1.1017782526323572e-06
were O 0 1.54158769305468e-07
enrolled O 0 1.2735387144857668e-07
regardless O 0 1.8642339227881166e-08
of O 0 1.95963689719747e-09
whether O 0 5.2867452637883616e-08
or O 0 1.821913997446245e-08
not O 0 4.4109267349767833e-08
they O 0 9.388148924927009e-08
had O 0 3.810512225754792e-06
either O 0 1.2505657878136844e-06
mutation O 0 7.639401701453608e-06
. O 0 1.451514549444255e-06

Lifetime O 0 0.0004631054471246898
histories O 0 2.734758709266316e-05
of O 0 3.755470174837683e-07
oral O 0 1.676689862506464e-05
- O 0 0.0004939259961247444
contraceptive O 0 0.024031097069382668
use O 0 3.4487052857912204e-07
were O 0 1.631523929290779e-07
obtained O 0 6.544802744201661e-08
by O 0 3.517918401030329e-08
interview O 0 3.553357601049356e-05
or O 0 1.444268615813371e-08
by O 0 1.564184337610186e-08
written O 0 4.789029617313645e-07
questionnaire O 0 2.5555755200912245e-06
and O 0 4.915041174058388e-08
were O 0 1.769606257084888e-07
compared O 0 1.1366264516254887e-06
between O 0 1.876320254723396e-07
patients O 0 2.560013126640115e-05
and O 0 1.6235165389844042e-07
control O 0 1.5902947779977694e-05
women O 0 4.618764819497301e-07
, O 0 9.902098696557005e-09
after O 0 2.8581061073396086e-08
adjustment O 0 1.4347199339681538e-07
for O 0 1.0516972182017525e-08
year O 0 4.4231761364699196e-08
of O 0 1.2247392433550885e-08
birth O 0 1.450556851523288e-06
and O 0 2.2935415699976147e-07
parity O 0 2.7840017082780832e-06
. O 0 1.427591541869333e-06

RESULTS O 0 7.813197589712217e-05
The O 0 5.419129820438684e-07
adjusted O 0 7.995559826667886e-06
odds O 0 3.6907811590936035e-05
ratio O 0 2.202554424002301e-05
for O 0 0.003395235864445567
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
associated O 0 1.369826804875629e-06
with O 0 1.9443657350848298e-08
any O 0 1.2724444609091279e-08
past O 0 2.7047672546132162e-08
use O 0 5.066875274906124e-08
of O 0 2.323304570950313e-08
oral O 0 4.688813351094723e-05
contraceptives O 1 0.5760052800178528
was O 0 7.872429705457762e-05
0 O 0 3.2317248042090796e-06
. O 0 1.0411777111585252e-06

5 O 0 9.456181942368858e-06
( O 0 2.374167564767049e-07
95 O 0 2.4306524437633925e-07
percent O 0 2.2922866094177152e-07
confidence O 0 1.317922198040833e-07
interval O 0 9.053533034375505e-08
, O 0 1.5342960679731732e-08
0 O 0 5.358059951277028e-08
. O 0 3.773309664723001e-09
3 O 0 1.3848709734531894e-08
to O 0 4.428106237241991e-08
0 O 0 3.0845376386423595e-07
. O 0 4.75712056413613e-08
8 O 0 2.7754848019867495e-07
) O 0 2.1235027247712424e-07
. O 0 8.599829470767872e-07

The O 0 7.358592483797111e-06
risk O 0 1.273647831112612e-05
decreased O 0 1.0160069905396085e-06
with O 0 1.6362211141540683e-08
increasing O 0 3.953778104914818e-08
duration O 0 3.127078969100694e-07
of O 0 6.323590096002363e-09
use O 0 1.3978326762753568e-07
( O 0 3.120224079111722e-08
P O 0 5.314670374900743e-07
for O 0 7.682018576815608e-09
trend O 0 8.052194999663698e-08
, O 0 2.1909889014182227e-08
< O 0 2.403035921361152e-07
0 O 0 1.2971172225206828e-07
. O 0 1.4393872760365412e-08
001 O 0 4.817144940716389e-07
) O 0 7.165211091120227e-09
; O 0 2.5947901605150037e-09
use O 0 7.048610584092785e-09
for O 0 1.2276721861326223e-08
six O 0 1.4170478834785172e-07
or O 0 1.574135843895874e-08
more O 0 3.089106215270476e-08
years O 0 7.409220188492327e-07
was O 0 3.069146032430581e-06
associated O 0 1.9641245074808467e-08
with O 0 5.639743339003189e-09
a O 0 2.861619918803626e-07
60 O 0 3.892288020779233e-07
percent O 0 5.084621079731733e-07
reduction O 0 4.4915120156474586e-07
in O 0 3.7396799257294333e-07
risk O 0 3.6748651837115176e-06
. O 0 2.359951167818508e-06

Oral O 0 0.0011576330289244652
- O 0 0.0019158095819875598
contraceptive O 0 0.006783708930015564
use O 0 3.8528819459315855e-06
protected O 0 2.6077317670569755e-05
against O 0 0.04753199219703674
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999977350234985
both O 0 1.5811778553143085e-07
for O 0 1.9887824720399294e-08
carriers O 0 5.7256535512806295e-08
of O 0 2.4193487213608478e-09
the O 0 1.3669136933458503e-07
BRCA1 O 0 0.0013974246103316545
mutation O 0 4.546356649370864e-06
( O 0 3.1017229673580005e-08
odds O 0 3.5121943255944643e-06
ratio O 0 5.976606303192966e-07
, O 0 4.31801154832101e-08
0 O 0 7.202057616950697e-08
. O 0 4.6005839138274496e-09
5 O 0 9.23549414721947e-09
; O 0 4.258140950952338e-09
95 O 0 3.7826865195711434e-08
percent O 0 6.756834380894361e-08
confidence O 0 4.38306635430763e-08
interval O 0 3.44317037104247e-08
, O 0 1.745652866702585e-08
0 O 0 3.391625824633593e-08
. O 0 3.6267637781861595e-09
3 O 0 6.72421451852756e-09
to O 0 1.6386884738039953e-08
0 O 0 1.6835451788210776e-07
. O 0 1.3915301799727331e-08
9 O 0 1.9425307584697293e-08
) O 0 1.2623633249830846e-09
and O 0 3.3690965572930054e-09
for O 0 6.419987652606096e-09
carriers O 0 3.863551967242529e-08
of O 0 2.8788182948602525e-09
the O 0 1.5947406950544973e-07
BRCA2 O 0 0.0042143152095377445
mutation O 0 3.3973026347666746e-06
( O 0 3.807943471656472e-08
odds O 0 3.1779977689438965e-06
ratio O 0 6.830589995843184e-07
, O 0 3.0584324406390806e-08
0 O 0 6.88777532786844e-08
. O 0 5.9147309272589155e-09
4 O 0 1.5223706739675436e-08
; O 0 4.639214790103097e-09
95 O 0 3.3106708485775016e-08
percent O 0 1.7040939326307125e-07
confidence O 0 5.0545292396009245e-08
interval O 0 5.171316175278662e-08
, O 0 2.2576038816168875e-08
0 O 0 4.766438976844256e-08
. O 0 3.3745823913022832e-09
2 O 0 9.133313660925069e-09
to O 0 2.0540669609658835e-08
1 O 0 6.804803831528261e-08
. O 0 2.2962284518257547e-08
1 O 0 4.578090440077176e-08
) O 0 7.303999183250198e-08
. O 0 4.7633764665988565e-07

CONCLUSIONS O 0 0.0008431965252384543
Oral O 0 0.00014766065578442067
- O 0 0.0019523600349202752
contraceptive O 0 0.014183382503688335
use O 0 7.884169122007734e-07
may O 0 5.387022952163534e-07
reduce O 0 1.0759502089285888e-07
the O 0 6.827542620158056e-08
risk O 0 7.375830932687677e-07
of O 0 8.564613381167874e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
in O 0 3.4633958421181887e-06
women O 0 1.6658556205584318e-06
with O 0 5.680840899913164e-07
pathogenic O 0 1.1103751603513956e-05
mutations O 0 2.7007208700524643e-06
in O 0 5.620910314974026e-08
the O 0 5.606283366432763e-07
BRCA1 O 0 0.003985829185694456
or O 0 8.738183169043623e-06
BRCA2 O 0 0.00215541897341609
gene O 0 9.192732977680862e-05

A O 0 4.929178976453841e-05
Japanese O 0 1.7116335584432818e-05
family O 0 5.153069650987163e-06
with O 0 2.20864831135259e-06
adrenoleukodystrophy B-Disease 1 0.9999403953552246
with O 0 6.306663635768928e-07
a O 0 6.470058906415943e-07
codon O 0 9.211893825522566e-07
291 O 0 8.005653739928675e-07
deletion O 0 4.846811862080358e-06
: O 0 4.031182854191684e-08
a O 0 8.114255933833192e-07
clinical O 0 4.39648965766537e-06
, O 0 1.5327698577038973e-07
biochemical O 0 4.632683612726396e-06
, O 0 8.345312352275869e-08
pathological O 0 5.6347957979596686e-06
, O 0 1.503834567984086e-07
and O 0 3.0549230700671615e-07
genetic O 0 4.53848542747437e-06
report O 0 2.0943055005773203e-06
. O 0 9.113858254750085e-07

We O 0 3.995049610239221e-06
report O 0 3.8801834989499184e-07
a O 0 1.44549559877305e-07
Japanese O 0 6.560380825249013e-07
family O 0 1.689148007244512e-06
with O 0 2.7537504138308577e-05
adrenoleukodystrophy B-Disease 1 0.9999997615814209
( O 0 0.0008840455557219684
ALD B-Disease 1 0.9999988079071045
) O 0 1.6261492419289425e-07
with O 0 3.021082761733851e-08
a O 0 3.1559423518956464e-07
three O 0 8.022470865398645e-08
base O 0 1.704688799009091e-07
pair O 0 2.96978964797745e-06
deletion O 0 8.19909018900944e-06
( O 0 5.502401378976174e-08
delGAG O 0 2.8562396892084507e-06
291 O 0 7.980057716849842e-07
) O 0 5.352227461230541e-08
in O 0 6.329155155526678e-08
the O 0 1.5381704088213155e-06
ALD B-Disease 1 0.9999881982803345
gene O 0 0.00032839886262081563
. O 0 8.601949048170354e-06

A O 0 4.400714533403516e-05
variety O 0 2.93479865831614e-06
of O 0 1.2879353050720965e-07
phenotypes O 0 9.928831423167139e-05
were O 0 1.0417189741929178e-06
observed O 0 3.5312567092660174e-07
within O 0 4.722477697782779e-08
this O 0 1.2407635097133607e-07
family O 0 2.3503671400249004e-06
. O 0 1.427661004527181e-06

While O 0 5.023144694860093e-06
the O 0 3.121135421224608e-07
proband O 0 6.759121606592089e-05
( O 0 2.5557091021255474e-07
patient O 0 1.9398172298679128e-05
1 O 0 1.8999519113549468e-07
) O 0 2.3129318904580032e-08
was O 0 3.0653291105409153e-06
classified O 0 9.731678574098623e-08
as O 0 1.781230807296197e-08
having O 0 2.8149116815257003e-08
a O 0 2.5717477569742186e-07
rare O 0 7.862394113544724e-07
intermediate O 0 3.0052328270357975e-07
type O 0 8.423705111226809e-08
of O 0 1.039718178219573e-08
adult O 0 2.8650092644966207e-05
cerebral O 0 0.07336759567260742
and O 0 1.3089927506371168e-06
cerebello O 0 0.018670344725251198
- O 0 0.06298185139894485
brain O 0 0.004102790262550116
stem O 0 1.0122275853063911e-06
forms O 0 1.7231127458217088e-07
, O 0 1.1082554607355632e-07
his O 0 2.0426293758646352e-06
younger O 0 1.8875221940106712e-05
brother O 0 5.4368272685678676e-05
( O 0 5.950558801259831e-08
patient O 0 3.840841600322165e-06
2 O 0 2.7776215461017273e-07
) O 0 4.124843755448637e-08
and O 0 4.4410009536477446e-07
nephew O 0 0.1460379660129547
( O 0 2.760161805781536e-07
patient O 0 0.00011955855006817728
3 O 0 2.928832998350117e-07
) O 0 2.7650509437648907e-08
had O 0 5.591103331425984e-07
a O 0 1.1424631338741165e-05
childhood O 0 0.02518106810748577
ALD B-Disease 1 0.999997615814209
type O 0 0.00923316553235054
. O 0 5.342866643331945e-06

Another O 0 7.064250530675054e-05
nephew O 0 0.013175618834793568
( O 0 2.006424892897485e-06
patient O 0 2.785792457871139e-05
4 O 0 2.8247254135749245e-07
) O 0 3.050014640848531e-08
of O 0 1.5225390725959187e-08
patient O 0 9.742948896018788e-05
1 O 0 5.020042408432346e-07
was O 0 5.37480809725821e-06
classified O 0 1.0018194984695583e-07
as O 0 2.0127552957660555e-08
having O 0 4.54215118850243e-08
an O 0 1.7095257476285042e-07
adolescent O 0 0.0002942375431302935
form O 0 4.285113845980959e-06
. O 0 3.358164804012631e-06

The O 0 3.0333580980368424e-06
tau O 0 3.4258616778970463e-06
level O 0 1.8744172791684832e-07
in O 0 3.059243169900583e-08
the O 0 1.627491172939699e-07
cerebrospinal O 0 0.011155637912452221
fluid O 0 0.012889846228063107
( O 0 4.605116714628821e-07
CSF O 0 0.23442699015140533
) O 0 5.265561853207146e-08
in O 0 7.29654985320849e-08
patient O 0 4.315518162911758e-05
1 O 0 1.7651969130838552e-07
was O 0 1.2428804438968655e-06
as O 0 2.5197405051358146e-08
high O 0 4.7211628384502546e-08
as O 0 1.3022072309354371e-08
that O 0 1.314881004077506e-08
of O 0 3.880427357216831e-08
patients O 0 0.0007088308921083808
with O 0 0.009937098249793053
Alzheimers B-Disease 1 0.9999951124191284
disease I-Disease 1 0.7045820951461792
( O 0 2.146977209349643e-07
AD B-Disease 0 4.936583718517795e-05
) O 0 7.751033876957081e-07
. O 0 1.1591018846957013e-06

His O 0 7.02397373970598e-05
brain O 0 0.0001586357393534854
magnetic O 0 2.9367050956352614e-05
resonance O 0 0.0001881008065538481
image O 0 0.00011003288818756118
( O 0 2.8399327334227564e-07
MRI O 0 0.11449993401765823
) O 0 2.415873723293771e-07
showed O 0 0.004087008070200682
abnormalities B-Disease 0 0.022946517914533615
in I-Disease 0 6.107050865011843e-08
the I-Disease 0 5.6680217852544956e-08
bilateral I-Disease 0 2.5539991383993765e-06
cerebellar I-Disease 0 0.47362130880355835
hemispheres I-Disease 0 0.0672629326581955
and O 0 5.462838544190163e-06
brain O 0 0.0010958826169371605
stem O 0 1.833661144701182e-06
, O 0 7.809860846919037e-08
but O 0 4.591626989736142e-08
not O 0 2.501906237739604e-08
in O 0 2.10442259174215e-08
the O 0 2.5194529484906525e-07
cerebral O 0 0.46278515458106995
white O 0 1.5519990483880974e-05
matter O 0 2.813750370478374e-07
, O 0 2.6876833203459682e-08
where O 0 2.478585159337854e-08
marked O 0 1.2097970625291055e-07
reductions O 0 1.6754040643718326e-07
of O 0 4.443002410425834e-09
the O 0 6.318673229088745e-08
cerebral O 0 0.0590926893055439
blood O 0 5.524460448214086e-06
flow O 0 2.983825595492817e-07
and O 0 2.451775458212069e-07
oxygen O 0 4.983346116205212e-06
metabolism O 0 2.014195956689946e-07
were O 0 7.84160931743827e-08
clearly O 0 4.36674895354372e-07
demonstrated O 0 3.66560698239482e-07
by O 0 5.0910159643535735e-08
positron O 0 3.9827740692999214e-05
emission O 0 5.621093350782758e-06
tomography O 0 4.8075493396027014e-05
( O 0 2.3231368118104e-07
PET O 0 1.1536998499650508e-05
) O 0 5.359082138056692e-07
. O 0 1.120355591410771e-06

In O 0 0.00012886020704172552
patients O 0 0.0016106916591525078
2 O 0 2.4713230573070177e-07
and O 0 5.035918704265896e-08
3 O 0 9.290815938811647e-08
, O 0 1.7086009052036388e-08
the O 0 3.253989433460447e-08
autopsy O 1 0.6468966007232666
findings O 0 1.6421370673924685e-05
showed O 0 8.984533451439347e-06
massive O 0 2.6529194656177424e-05
demyelination B-Disease 1 0.9996986389160156
of I-Disease 0 9.286262780960897e-08
the I-Disease 0 7.967601618474873e-07
cerebral I-Disease 1 0.6357667446136475
white I-Disease 0 6.80590164847672e-06
matter I-Disease 0 1.1092620866293146e-07
with O 0 1.9718608967878026e-08
sparing O 0 3.2076715683615475e-07
of O 0 9.370398679209302e-09
the O 0 3.1463642358176e-08
U O 0 0.0004196654772385955
- O 0 0.015148529782891273
fibers O 0 8.641604654258117e-05
, O 0 1.530470150612473e-08
compatible O 0 4.0086181485321504e-08
with O 0 9.956528046473068e-09
the O 0 1.7394841123063998e-08
findings O 0 1.1766524039558135e-06
of O 0 3.49250029785253e-07
childhood O 0 0.0057084341533482075
ALD B-Disease 1 0.9999908208847046
. O 0 0.00020709667296614498

Oleic O 0 0.06954051554203033
and O 0 2.7953834432992153e-05
erucic O 0 0.05991555005311966
acids O 0 3.648270876510651e-06
( O 0 9.660625721608085e-08
Lorenzos O 0 1.7887228977997438e-06
Oil O 0 1.3032774859311758e-07
) O 0 1.699176088720833e-08
were O 0 2.5227892663792773e-08
administered O 0 4.523519692156697e-08
to O 0 3.4357844924670644e-07
patients O 0 7.780934538459405e-06
1 O 0 3.9790311490151e-08
and O 0 4.207571180359082e-08
4 O 0 1.7603419166789536e-07
, O 0 1.6353787657408247e-08
but O 0 1.186761444671447e-08
sufficient O 0 6.551722009362493e-08
effectiveness O 0 3.735687812422839e-07
was O 0 4.071429430041462e-06
not O 0 1.3080838812129514e-07
obtained O 0 7.656765887986694e-07
. O 0 1.2200760011182865e-06

The O 0 6.957297955523245e-06
findings O 0 9.55553878156934e-06
in O 0 8.311698707075266e-08
this O 0 8.092658276837028e-08
family O 0 4.319510935602011e-07
suggest O 0 1.4044375973298884e-07
that O 0 5.60284227901775e-08
delGAG291 O 0 2.210367711086292e-06
is O 0 2.210275695802011e-08
part O 0 6.408682917680153e-09
of O 0 4.173798195949985e-09
the O 0 4.743312587152104e-08
cause O 0 3.3602040616642626e-07
of O 0 5.101513878003061e-08
Japanese O 0 0.00012744343257509172
ALD B-Disease 1 0.9999823570251465
with O 0 9.913448593579233e-06
phenotypic O 0 0.00029667041962966323
variations O 0 4.717342017102055e-05
. O 0 3.850659595627803e-06

Moreover O 0 5.1879931561416015e-05
, O 0 3.5320346114531276e-07
although O 0 2.036954960260573e-08
the O 0 3.3391691633966047e-09
scale O 0 2.3789537451079923e-08
of O 0 2.9294899839271693e-09
the O 0 1.8707201121515027e-08
study O 0 6.749813508122315e-08
is O 0 2.913298757789562e-08
limited O 0 5.5370495744000436e-08
, O 0 1.4397744330096884e-08
there O 0 1.133024962740592e-08
is O 0 1.0885663037640825e-08
a O 0 7.23230115795559e-08
possibility O 0 7.01346394293978e-08
that O 0 7.688677783335152e-08
PET O 0 1.85544172381924e-06
can O 0 3.9370423365880924e-08
detect O 0 1.1514797506606556e-06
an O 0 4.1159677266477956e-07
insidious B-Disease 0 0.06411650776863098
lesion I-Disease 1 0.9805418252944946
which O 0 1.3612512930194498e-06
is O 0 7.554907455187276e-08
undetectable O 0 4.779215601047326e-07
by O 0 1.7095819870860396e-08
computed O 0 3.0781845339333813e-07
tomogram O 0 8.537645044270903e-06
( O 0 2.7691781312455532e-08
CT O 0 0.00013110128929838538
) O 0 2.2491027706905697e-08
or O 0 1.7690554798832636e-08
MRI O 0 0.047061171382665634
analysis O 0 1.276119832027689e-07
, O 0 1.5225216642988926e-08
and O 0 5.490887300396707e-09
that O 0 7.2774635206940275e-09
the O 0 3.6780214429654734e-09
higher O 0 1.207440636363799e-08
level O 0 2.47616438464604e-09
of O 0 1.9457857547422464e-09
tau O 0 5.740612607496587e-08
reflects O 0 5.488178089763096e-08
the O 0 2.73799050098944e-09
process O 0 9.922176857912746e-09
of O 0 3.31909895123772e-08
neuronal B-Disease 0 0.0003844281891360879
degeneration I-Disease 1 0.9852924942970276
in O 0 0.0001980081869987771
ALD B-Disease 1 0.9999972581863403
. O 0 0.0001814073621062562

Lorenzos O 0 0.000822199450340122
Oil O 0 8.829978469293565e-06
should O 0 1.824066799827051e-07
be O 0 1.843221397734851e-08
given O 0 9.733605921269373e-09
in O 0 3.441763540834586e-09
the O 0 1.1347745854095592e-08
early O 0 5.915094902775309e-07
stage O 0 1.480547507526353e-05
. O 0 1.1731162885553204e-06
. O 0 2.0218376448610798e-06

Nonsense O 0 0.001948102843016386
mutation O 0 0.000714035821147263
in O 0 1.357414021185832e-06
exon O 0 8.799102943157777e-06
4 O 0 2.9341728691179014e-07
of O 0 1.6489156706711583e-08
human O 0 5.929802071591439e-08
complement O 0 5.342314466361131e-07
C9 O 0 0.00022049553808756173
gene O 0 6.446506972679344e-07
is O 0 1.3939129850371046e-08
the O 0 4.3938954696898236e-09
major O 0 4.0651947585956805e-08
cause O 0 2.2318410231036978e-07
of O 0 2.4684606358960082e-08
Japanese O 0 1.1193302270839922e-05
complement B-Disease 0 0.00015859052655287087
C9 I-Disease 1 0.9991058707237244
deficiency I-Disease 1 0.9929774403572083
. O 0 8.414482181251515e-06

Deficiency B-Disease 1 0.9967771172523499
of I-Disease 0 3.470947547157266e-07
the I-Disease 0 1.7292268239543773e-07
ninth I-Disease 0 2.210947513958672e-06
component I-Disease 0 2.6452988777236897e-07
of I-Disease 0 1.7977503929955674e-08
human I-Disease 0 9.224283559206015e-08
complement I-Disease 0 3.2622304502183397e-07
( O 0 4.7772331868145557e-08
C9 O 0 2.60062406596262e-05
) O 0 2.165859491753963e-08
is O 0 8.85131523631344e-09
the O 0 9.782293197702074e-09
most O 0 1.5845049006202316e-07
common O 0 6.481956461357186e-06
complement B-Disease 1 0.9999403953552246
deficiency I-Disease 1 0.9999927282333374
in O 0 1.1473240135728702e-07
Japan O 0 2.714352262955799e-07
but O 0 1.3700380918635346e-07
is O 0 3.5100967465950816e-08
rare O 0 2.4876436555132386e-07
in O 0 4.3987949283064154e-08
other O 0 4.2337344297038726e-08
countries O 0 9.53438998863021e-08
. O 0 1.9278459149063565e-06

We O 0 2.4488499548169784e-06
studied O 0 8.519122616235109e-07
the O 0 2.0170826786625184e-08
molecular O 0 1.7301124444202287e-07
basis O 0 3.151228966657982e-08
of O 0 1.456813265576784e-07
C9 B-Disease 1 0.999619722366333
deficiency I-Disease 1 0.9655866026878357
in O 0 1.1624900508877545e-07
four O 0 2.0250629972906609e-07
Japanese O 0 4.873281795880757e-06
C9 B-Disease 0 0.11646994203329086
- I-Disease 1 0.9919615387916565
deficient I-Disease 1 0.9610722661018372
patients O 0 0.012984592467546463
who O 0 2.1019146515754983e-05
had O 0 0.0003463923931121826
suffered O 1 0.9691849946975708
from O 0 0.00015625476953573525
meningococcal B-Disease 1 0.9999942779541016
meningitis I-Disease 1 0.9999977350234985
. O 0 0.00025005987845361233

Direct O 0 7.421931513817981e-06
sequencing O 0 3.223420208087191e-06
of O 0 2.3646657609788235e-07
amplified O 0 1.5838757462915964e-05
C9 O 0 5.677813896909356e-05
cDNA O 0 5.491306183103006e-06
and O 0 3.973647153543425e-07
DNA O 0 1.113957864617987e-06
revealed O 0 1.2259204140718793e-06
a O 0 2.1378363612711837e-07
nonsense O 0 1.7441972204323974e-06
substitution O 0 1.3197761461469781e-07
( O 0 2.3006561988836438e-08
CGA O 0 2.735127054620534e-06
- O 0 6.215294706635177e-05
- O 0 0.00024218180624302477
> O 0 1.876493342933827e-06
TGA O 0 9.54171446210239e-06
) O 0 1.8519042299658395e-08
at O 0 3.659680336554061e-09
codon O 0 3.297487083386841e-08
95 O 0 2.9397233092254282e-08
in O 0 1.1170770974899824e-08
exon O 0 2.389703013250255e-07
4 O 0 3.661567404833477e-08
in O 0 6.7407412984721304e-09
the O 0 1.9924881300426023e-08
four O 0 9.454057590119191e-07
C9 B-Disease 0 0.019205594435334206
- I-Disease 0 0.4473951458930969
deficient I-Disease 0 0.11419298499822617
individuals O 0 3.548013580711995e-07
. O 0 9.882306812869501e-07

An O 0 6.7475298237695824e-06
allele O 0 1.9780231014010496e-05
- O 0 1.8568543964647688e-06
specific O 0 2.3637566570755553e-08
polymerase O 0 6.435081445488322e-07
chain O 0 9.255438158106699e-07
reaction O 0 2.645672054768511e-07
system O 0 1.788229653243434e-08
designed O 0 1.905526261225532e-07
to O 0 4.5246846269719754e-08
detect O 0 1.1529083394634654e-06
exclusively O 0 1.269146139293298e-07
only O 0 1.1125841581360874e-08
one O 0 4.687565891003942e-09
of O 0 1.8191178563498056e-09
the O 0 7.773551580214644e-09
normal O 0 2.78214891125117e-08
and O 0 1.7264149221318803e-08
mutant O 0 2.3726765903120395e-06
alleles O 0 3.913496584573295e-07
indicated O 0 6.430689154512947e-07
that O 0 8.523858952003138e-09
all O 0 1.3205202487043266e-09
the O 0 4.16661594115908e-09
four O 0 5.20400817549671e-07
patients O 0 5.5108953347371425e-06
were O 0 6.880146941057319e-08
homozygous O 0 3.2308108188772167e-07
for O 0 6.560585408266206e-09
the O 0 1.060489740467574e-08
mutation O 0 2.813769128806598e-07
in O 0 2.0148640089701075e-08
exon O 0 4.998768758923688e-07
4 O 0 5.14035853882433e-08
and O 0 1.0350011514503876e-08
that O 0 8.380128591056746e-09
the O 0 1.2349102185282845e-08
parents O 0 4.719469970382306e-08
of O 0 6.0602634022188795e-09
patient O 0 1.2889548088423908e-05
2 O 0 5.934384716965724e-07
were O 0 1.7437581618651166e-06
heterozygous O 0 2.0096125808777288e-05
. O 0 1.0423251524116495e-06

The O 0 1.7253488522328553e-06
common O 0 5.037902610638412e-07
mutation O 0 7.22364234206907e-07
at O 0 2.8214158120931643e-08
codon O 0 1.2330325205311965e-07
95 O 0 1.7935930429757718e-07
in O 0 3.515235391660099e-08
exon O 0 1.5177497516560834e-06
4 O 0 2.0363650321542082e-07
might O 0 6.14746440419367e-08
be O 0 8.600369305611366e-09
responsible O 0 2.7961187143432653e-08
for O 0 1.2657635828361435e-08
most O 0 9.625622965359071e-08
Japanese O 0 0.00041212141513824463
C9 B-Disease 1 0.9996764659881592
deficiency I-Disease 1 0.954975426197052
. O 0 4.751824747017963e-07
. O 0 1.3725112921747495e-06

BRCA1 O 0 0.23334480822086334
required O 0 5.219413651502691e-06
for O 0 1.3954324629139592e-07
transcription O 0 1.031258989314665e-06
- O 0 6.64426333969459e-05
coupled O 0 1.6464620784972794e-05
repair O 0 6.292398211371619e-06
of O 0 5.298839411693734e-08
oxidative O 0 0.0006423361483030021
DNA O 0 0.0004669918562285602
damage O 0 8.450652239844203e-05
. O 0 2.55338522947568e-06

The O 0 3.744738205568865e-05
breast B-Disease 1 0.9795802235603333
and I-Disease 1 0.9519068002700806
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
susceptibility O 1 0.993833065032959
gene O 0 7.345792255364358e-05
BRCA1 O 0 0.00014225635095499456
encodes O 0 3.3245785289182095e-06
a O 0 3.1061715617397567e-06
zinc O 0 0.00070758763467893
finger O 0 7.348894087044755e-06
protein O 0 1.8658990086350968e-07
of O 0 7.586412387183827e-09
unknown O 0 2.7859780971084547e-07
function O 0 1.8105450294569891e-07
. O 0 6.587703182958649e-07

Association O 0 9.249542017641943e-06
of O 0 1.1054370929741708e-07
the O 0 1.6978842154458107e-07
BRCA1 O 0 2.0087254597456194e-05
protein O 0 1.1490190132690259e-07
with O 0 1.4605574527593035e-08
the O 0 2.794401865457985e-08
DNA O 0 2.5961710434785346e-06
repair O 0 1.784217602107674e-05
protein O 0 4.5673974113924487e-07
Rad51 O 0 3.5651119105750695e-06
and O 0 3.321575192671844e-08
changes O 0 1.2483044820044142e-08
in O 0 2.398324427943521e-09
the O 0 1.5891856719463249e-09
phosphorylation O 0 2.0873370587537465e-08
and O 0 1.4281940075022703e-08
cellular O 0 1.2594375675689662e-07
localization O 0 3.7691037846343534e-08
of O 0 9.835496861398951e-10
the O 0 4.490618543684377e-09
protein O 0 4.21481622936426e-08
after O 0 1.588226581361596e-07
exposure O 0 4.005389371286583e-07
to O 0 4.6111988893926537e-08
DNA O 0 1.0025876235886244e-06
- O 0 3.5121651308145374e-05
damaging O 0 5.184528617974138e-06
agents O 0 5.065957253691522e-08
are O 0 3.921451607880044e-09
consistent O 0 8.657251981958325e-08
with O 0 1.1877646421964982e-08
a O 0 3.985609851042682e-07
role O 0 3.2254112625196285e-07
for O 0 2.508505758669344e-07
BRCA1 O 0 6.629800918744877e-05
in O 0 2.9486193398042815e-07
DNA O 0 1.574967973283492e-05
repair O 0 0.0002746732789091766
. O 0 5.022756795369787e-06

Here O 0 2.3648970454814844e-05
, O 0 3.2637925073686347e-07
it O 0 5.713674866569818e-08
is O 0 2.957021294491824e-08
shown O 0 1.273462260087399e-07
that O 0 3.982493623766459e-08
mouse O 0 2.7110895644000266e-06
embryonic O 0 4.910065399599262e-06
stem O 0 9.406093340658117e-06
cells O 0 1.991000317502767e-05
deficient B-Disease 0 0.00033140243613161147
in I-Disease 0 3.195221154328465e-07
BRCA1 I-Disease 0 8.51855002110824e-05
are O 0 5.8587286133615635e-08
defective O 0 1.4457466022577137e-05
in O 0 3.3748865035931885e-08
the O 0 1.1574761593635685e-08
ability O 0 3.3174533342616996e-08
to O 0 2.2659126130974983e-08
carry O 0 6.934042318107458e-08
out O 0 3.0472875778286834e-08
transcription O 0 2.1951012740828446e-07
- O 0 1.0322733032808173e-05
coupled O 0 4.525316398940049e-06
repair O 0 5.32549438503338e-06
of O 0 7.394834256047034e-08
oxidative O 0 0.0024398118257522583
DNA O 0 0.00020574810332618654
damage O 0 4.388142406241968e-05
, O 0 4.1593128941030955e-08
and O 0 3.9232492810015174e-08
are O 0 2.595153070217293e-08
hypersensitive O 0 0.00014291168190538883
to O 0 2.9476282179530244e-06
ionizing O 0 0.0019007897935807705
radiation O 0 0.013085616752505302
and O 0 3.91658801390804e-07
hydrogen O 0 1.145884016295895e-05
peroxide O 0 0.0005137725383974612
. O 0 2.8101967473048717e-06

These O 0 6.95409426043625e-06
results O 0 4.780907147505786e-06
suggest O 0 6.306115665211109e-07
that O 0 9.197157879725637e-08
BRCA1 O 0 1.0532516171224415e-05
participates O 0 1.9806894613338955e-07
, O 0 3.429060058124378e-08
directly O 0 3.8763513288131435e-08
or O 0 1.5005246822852314e-08
indirectly O 0 5.64865388241742e-07
, O 0 1.788809456115814e-08
in O 0 7.648320199393766e-09
transcription O 0 1.3659989406278328e-07
- O 0 1.9536986656021327e-05
coupled O 0 8.160834113368765e-06
repair O 0 4.897471171716461e-06
of O 0 3.1098860375777804e-08
oxidative O 0 0.0002160661679226905
DNA O 0 0.00013143160322215408
damage O 0 4.6001187001820654e-05
. O 0 5.183586040402588e-07
. O 0 9.232245474777301e-07

Truncation O 0 0.0020980031695216894
mutations O 0 0.014631479978561401
in O 0 8.043581374295172e-07
the O 0 2.441997821733821e-07
transactivation O 0 5.7761379139265046e-05
region O 0 5.315795306159998e-07
of O 0 4.9988258865596435e-08
PAX6 O 0 0.0006656648474745452
result O 0 3.796800456257188e-07
in O 0 6.582510536645714e-08
dominant O 0 1.5927541880955687e-06
- O 0 5.611149754258804e-05
negative O 0 7.247113899211399e-06
mutants O 0 2.4932682208600454e-05
. O 0 1.4712852589582326e-06

PAX6 O 0 0.07689274102449417
is O 0 4.523987172433408e-06
a O 0 6.938301453374152e-07
transcription O 0 5.982342941024399e-07
factor O 0 8.255027239556512e-08
with O 0 7.249050248958611e-09
two O 0 3.303158635503678e-08
DNA O 0 5.225741119829763e-07
- O 0 2.056046469078865e-05
binding O 0 1.2794408803529222e-06
domains O 0 9.486031160577113e-08
( O 0 7.784649369568797e-09
paired O 0 1.551586308323749e-07
box O 0 2.6047641767945606e-06
and O 0 2.48019830451085e-07
homeobox O 0 1.4786230167374015e-05
) O 0 8.60509441480417e-09
and O 0 7.659020084815893e-09
a O 0 1.2364708368295396e-07
proline O 0 3.447798462730134e-06
- O 0 1.4057710586712346e-06
serine O 0 6.369506877490494e-07
- O 0 4.469605755730299e-06
threonine O 0 2.5389083475602092e-06
( O 0 3.67418095947869e-08
PST O 0 5.231313480180688e-06
) O 0 4.951474608105855e-08
- O 0 3.3664118745946325e-06
rich O 0 5.775426643594983e-07
transactivation O 0 2.1688398192054592e-05
domain O 0 2.269417564093601e-06
. O 0 1.3041405964031583e-06

PAX6 O 0 0.07296748459339142
regulates O 0 0.00029761690529994667
eye O 0 0.005234820302575827
development O 0 5.228372970123019e-07
in O 0 3.934749486234068e-07
animals O 0 1.6171237859907706e-07
ranging O 0 4.683064389610081e-07
from O 0 6.553146647547692e-08
jellyfish O 0 1.5711116247985046e-06
to O 0 9.691316904536507e-08
Drosophila O 0 6.336366027426266e-07
to O 0 7.520782219216926e-07
humans O 0 1.7013250044328743e-06
. O 0 1.550688352836005e-06

Heterozygous O 1 0.5173076391220093
mutations O 0 0.004412944428622723
in O 0 1.0907182286246098e-06
the O 0 1.813942844819394e-07
human O 0 3.067991372063261e-07
PAX6 O 0 0.0021092502865940332
gene O 0 4.2495489651628304e-06
result O 0 3.16849650516815e-07
in O 0 3.927082303789575e-08
various O 0 3.281838445445828e-08
phenotypes O 0 8.007837459445e-05
, O 0 1.4940839321297972e-07
including O 0 3.216521804461081e-07
aniridia B-Disease 1 0.9999908208847046
, O 0 0.00019267450261395425
Peters B-Disease 1 0.9999202489852905
anomaly I-Disease 1 0.9999889135360718
, O 0 4.11259061365854e-05
autosomal B-Disease 0 0.06845379620790482
dominant I-Disease 0 0.0029468797147274017
keratitis I-Disease 1 0.9632000923156738
, O 0 1.4055685824132524e-06
and O 0 3.82683447242016e-06
familial B-Disease 0 0.1994134485721588
foveal I-Disease 1 0.9993833303451538
dysplasia I-Disease 1 0.9998986721038818
. O 0 6.669317372143269e-05

It O 0 3.1319041227106936e-06
is O 0 1.48068068028806e-07
believed O 0 1.5760141991449927e-07
that O 0 1.1175353087367057e-08
the O 0 1.619523004592338e-08
mutated O 0 2.6002271624747664e-06
allele O 0 9.728577197165578e-07
of O 0 1.5083468696275304e-08
PAX6 O 0 7.761718734400347e-05
produces O 0 1.0757403288153e-06
an O 0 6.410274977497465e-08
inactive O 0 5.527551820705412e-07
protein O 0 1.1007809064267349e-07
and O 0 7.740737117956087e-08
aniridia B-Disease 1 0.9998185038566589
is O 0 1.2836867426813114e-06
caused O 0 7.4911567935487255e-06
due O 0 6.364479645526444e-07
to O 0 9.526480084787181e-07
genetic O 0 1.2490957487898413e-05
haploinsufficiency O 0 0.0010632353369146585
. O 0 3.3639823868725216e-06

However O 0 1.3699477676709648e-05
, O 0 1.607352828614239e-07
several O 0 5.344556441855275e-08
truncation O 0 4.4630724005401134e-06
mutations O 0 9.63561706157634e-06
have O 0 7.95211789750283e-08
been O 0 1.6838873762026196e-07
found O 0 3.5779141427383365e-08
to O 0 4.346767923379957e-08
occur O 0 2.247001695820927e-08
in O 0 1.529084237006373e-08
the O 0 4.1903998493353356e-08
C O 0 2.269556034661946e-06
- O 0 4.624393113772385e-05
terminal O 0 8.641422937216703e-06
half O 0 6.468467006470746e-08
of O 0 1.4193032527032301e-08
PAX6 O 0 0.0006955293356440961
in O 0 5.162351044418756e-06
patients O 0 0.00021912924421485513
with O 0 1.083410552382702e-06
Aniridia B-Disease 1 0.9999513626098633
resulting O 0 3.7255306324368576e-06
in O 0 1.8037541238413723e-08
mutant O 0 3.27601327398952e-07
proteins O 0 6.798366758431484e-09
that O 0 6.649958361748531e-09
retain O 0 2.1984217823955987e-07
the O 0 1.2772833457574961e-08
DNA O 0 5.156753672963532e-07
- O 0 6.991531790845329e-06
binding O 0 4.5194494191491685e-07
domains O 0 5.287854776270251e-08
but O 0 2.5382826507325262e-08
have O 0 1.2144505845412823e-08
lost O 0 1.2215063804887905e-07
most O 0 4.451034651964392e-09
of O 0 3.583068730605987e-09
the O 0 4.592678237713699e-08
transactivation O 0 3.050054147024639e-05
domain O 0 1.7814162447393755e-06
. O 0 1.1806586144302855e-06

It O 0 2.5720471512613585e-06
is O 0 1.3570655710282153e-07
not O 0 3.207600940413613e-08
clear O 0 1.0300309583044509e-07
whether O 0 3.1899499930432285e-08
such O 0 1.0604289890636664e-08
mutants O 0 3.555516286724014e-06
really O 0 9.241767315870675e-07
behave O 0 3.6268215808377136e-07
as O 0 3.0572600451250764e-08
loss O 0 2.3932929593684094e-07
- O 0 4.755229383590631e-07
of O 0 1.2537113569521807e-08
- O 0 1.5638328477507457e-05
function O 0 8.055729239231368e-08
mutants O 0 7.611423029629805e-07
as O 0 2.913532348713943e-08
predicted O 0 5.267822302812419e-07
by O 0 1.567977108152263e-07
haploinsufficiency O 0 0.000147265411214903
. O 0 2.7768903692049207e-06

Contrary O 0 3.2187363103730604e-05
to O 0 4.055066540331609e-07
this O 0 4.8760107063117175e-08
theory O 0 8.118073679952431e-08
, O 0 1.0539743300341797e-08
our O 0 2.3350139599642716e-09
data O 0 9.982236370831288e-09
showed O 0 8.659514350028985e-08
that O 0 2.1268087291304028e-09
these O 0 1.2627390244546177e-09
mutants O 0 2.2042097214125533e-07
are O 0 3.6900724698085696e-09
dominant O 0 1.4666690617559652e-07
- O 0 2.1804678453918314e-06
negative O 0 2.8284534892009106e-07
in O 0 2.2695113344184392e-08
transient O 0 2.4848059183568694e-06
transfection O 0 2.3566142772324383e-05
assays O 0 1.9667413653223775e-06
when O 0 5.367910560494238e-08
they O 0 8.73390515465644e-09
are O 0 4.479173032478911e-09
coexpressed O 0 2.3369077553070383e-06
with O 0 7.064225115982481e-08
wild O 0 4.220302400881337e-07
- O 0 0.00022745375463273376
type O 0 3.847239349852316e-05
PAX6 O 0 0.002136936876922846
. O 0 7.273300525412196e-06

We O 0 2.8356398615869693e-06
found O 0 2.3513419478149444e-07
that O 0 9.110625143193829e-09
the O 0 8.079345192868459e-09
dominant O 0 9.562096465742798e-07
- O 0 4.8261161282425746e-05
negative O 0 3.3507524221931817e-06
effects O 0 1.360093847324606e-06
result O 0 6.587949030745222e-08
from O 0 5.390541346628197e-09
the O 0 6.396080554083028e-09
enhanced O 0 4.6489830651808006e-07
DNA O 0 7.877525263211282e-07
binding O 0 1.1923479803499504e-07
ability O 0 4.8843510569440696e-08
of O 0 5.528867585979924e-09
these O 0 4.084859384079209e-08
mutants O 0 8.729179171496071e-06
. O 0 1.686477617113269e-06

Kinetic O 0 5.4880430980119854e-05
studies O 0 1.564663989483961e-06
of O 0 4.5143920601731224e-08
binding O 0 1.3435344499157509e-06
and O 0 3.879802648043551e-07
dissociation O 0 2.4790806492092088e-05
revealed O 0 9.588477496436099e-07
that O 0 7.603215834706134e-09
various O 0 2.7665583157698848e-09
truncation O 0 6.212150651663251e-07
mutants O 0 7.952411579026375e-06
have O 0 5.191427021600248e-08
3 O 0 3.597869380200791e-08
- O 0 1.2395091744110687e-06
5 O 0 1.5108093975868542e-07
- O 0 3.1606305128661916e-06
fold O 0 2.114601784342085e-06
higher O 0 3.053611763448316e-08
affinity O 0 1.902718338442355e-08
to O 0 7.239998822683447e-09
various O 0 1.6090474508345665e-09
DNA O 0 8.718048150058166e-08
- O 0 7.624348086210375e-07
binding O 0 2.0561213887049234e-07
sites O 0 1.4958954963617543e-08
when O 0 2.961582090676984e-08
compared O 0 3.13651362660039e-08
with O 0 2.389644038203187e-09
the O 0 6.611006408974163e-09
wild O 0 1.4317620866677316e-07
- O 0 0.0003257413045503199
type O 0 6.008912532706745e-05
PAX6 O 0 0.008469407446682453
. O 0 5.26358144270489e-06

These O 0 7.230055871332297e-06
results O 0 1.726749701447261e-06
provide O 0 1.0410222728296503e-07
a O 0 9.477331985863202e-08
new O 0 8.426436437503071e-08
insight O 0 1.2177842734217847e-07
into O 0 7.167233917471094e-09
the O 0 3.33437055743957e-09
role O 0 1.910810354388559e-08
of O 0 9.873695638873414e-09
mutant O 0 7.5989360084349755e-06
PAX6 O 0 0.0001667487813392654
in O 0 1.772695100044075e-06
causing O 0 3.4883352782344446e-05
aniridia B-Disease 1 0.999290943145752
. O 0 2.084347215713933e-06
. O 0 2.0362188024591887e-06

Reversal O 0 0.0008249288075603545
of O 0 2.129479071300011e-05
severe O 1 0.9992054104804993
hypertrophic B-Disease 1 0.9999732971191406
cardiomyopathy I-Disease 1 0.9999997615814209
and O 0 0.00021717138588428497
excellent O 0 5.026048529543914e-05
neuropsychologic O 0 0.001183199230581522
outcome O 0 2.0357001631055027e-06
in O 0 6.343718439438817e-08
very B-Disease 0 3.0948092444305075e-07
- I-Disease 0 5.3327737987274304e-05
long I-Disease 0 5.589847205555998e-06
- I-Disease 0 3.790421396843158e-05
chain I-Disease 0 6.922281045262935e-06
acyl I-Disease 0 4.794861069967737e-06
- I-Disease 0 2.0751222109538503e-05
coenzyme I-Disease 0 1.6467431123601273e-05
A I-Disease 0 0.0003040190786123276
dehydrogenase I-Disease 0 0.24043774604797363
deficiency I-Disease 0 0.09093153476715088
. O 0 3.8669286368531175e-06

Very B-Disease 0 4.5096945541445166e-05
- I-Disease 0 0.0001480198698118329
long I-Disease 0 5.0400785767124034e-06
- I-Disease 0 8.001685637282208e-05
chain I-Disease 0 1.1676243047986645e-05
acyl I-Disease 0 7.2585198722663336e-06
- I-Disease 0 9.276008313463535e-06
coenzyme I-Disease 0 2.917461188189918e-06
A I-Disease 0 1.1800601896538865e-05
dehydrogenase I-Disease 0 3.055108027183451e-05
( I-Disease 0 2.7194172957933915e-07
VLCAD I-Disease 0 0.03676009178161621
) I-Disease 0 1.8131686374545097e-05
deficiency I-Disease 0 0.004007331095635891
is O 0 1.857777647273906e-07
a O 0 0.00024852139176800847
disorder O 0 0.059568967670202255
of O 0 7.77100410687126e-08
fatty O 0 3.0380945190700004e-06
acid O 0 1.8820024934029789e-06
beta O 0 6.36608206150413e-08
oxidation O 0 7.186976347384189e-08
that O 0 2.963593637161921e-08
reportedly O 0 4.9179479901795276e-06
has O 0 1.2565033102873713e-07
high O 0 9.663666133974402e-08
rates O 0 7.510225685791738e-08
of O 0 2.8091138304375818e-08
morbidity O 0 0.399051696062088
and O 0 2.919840881077107e-05
mortality O 0 0.0012596510350704193
. O 0 5.214448265178362e-06

We O 0 2.1749624465883244e-06
describe O 0 1.0704026180974324e-06
the O 0 3.460961295331799e-08
outcome O 0 1.0062911570685174e-07
of O 0 5.328410601634914e-09
a O 0 4.598358316343365e-07
5 O 0 1.7167944577067829e-07
- O 0 1.7315882359980606e-05
year O 0 3.522488043472549e-07
- O 0 5.452948698803084e-06
old O 0 4.4556869397638366e-05
girl O 0 0.0002820362278725952
with O 0 3.682111855596304e-05
VLCAD B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999974966049194
who O 0 2.547173608036246e-06
was O 0 2.861955294974905e-07
first O 0 4.376617113166503e-08
seen O 0 1.8097303211561666e-07
at O 0 7.127535894824177e-09
5 O 0 2.2763957829852188e-08
months O 0 6.741219493733297e-08
of O 0 4.195516378757702e-09
age O 0 3.4064598253280565e-07
with O 0 1.3862778587281355e-06
severe O 1 0.999739944934845
hypertrophic B-Disease 1 0.9999898672103882
cardiomyopathy I-Disease 1 1.0
, O 1 0.6147878170013428
hepatomegaly B-Disease 1 0.9999982118606567
, O 0 0.0005834572366438806
encephalopathy B-Disease 0 0.0005483370623551309
, O 0 3.485732236185868e-07
and O 0 1.4031259070179658e-06
hypotonia B-Disease 0 0.4379946291446686
. O 0 1.3633152775582857e-05

Biochemical O 0 0.05314090847969055
studies O 0 0.0017647140193730593
indicated O 1 0.9989979863166809
VLCAD B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999998807907104
caused O 0 0.0036495672538876534
by O 0 4.2488298390708223e-07
a O 0 4.831526894122362e-06
stable O 0 1.2903396964247804e-05
yet O 0 1.8389954448139179e-06
inactive O 0 6.597633728233632e-06
enzyme O 0 1.9308949958940502e-06
. O 0 1.171602548311057e-06

Molecular O 0 0.0005015644710510969
genetic O 0 9.573453280609101e-05
analysis O 0 9.947474381988286e-07
of O 0 5.044955742050661e-08
her O 0 7.4397044045326766e-06
VLCAD O 0 0.027874330058693886
gene O 0 2.8196136554470286e-06
revealed O 0 1.682649440226669e-06
a O 0 4.538232758477534e-07
T1372C O 0 2.34136387007311e-05
( O 0 4.948660858872245e-08
F458L O 0 2.493442025297554e-06
) O 0 5.884756149043824e-08
missense O 0 1.5152323612710461e-05
mutation O 0 2.024932655331213e-06
and O 0 1.709661034965393e-07
a O 0 2.2676396838505752e-05
1668 O 1 0.6519795656204224
ACAG O 0 0.10606218874454498
1669 O 0 0.0004306808696128428
splice O 0 0.00013716223475057632
site O 0 1.7963035134016536e-05
mutation O 0 2.4306567866005935e-05
. O 0 2.9436730528686894e-06

After O 0 2.011858123296406e-05
initial O 0 1.2575211258081254e-05
treatment O 0 1.5018845260783564e-05
with O 0 4.754226949899021e-07
intravenous O 0 0.0001830364199122414
glucose O 0 9.024863538797945e-05
and O 0 6.68177733587072e-07
carnitine O 0 6.731501343892887e-05
, O 0 1.1190117987780468e-07
the O 0 8.05906381629029e-08
patient O 0 2.5587243726477027e-05
has O 0 6.309159630291106e-07
thrived O 0 7.158628818615398e-07
on O 0 5.464457331072481e-08
a O 0 2.4688660005267593e-07
low O 0 8.043842854021932e-07
- O 0 3.055387787753716e-05
fat O 0 5.818496720166877e-05
diet O 0 2.1738653686043108e-06
supplemented O 0 9.873059525489225e-08
with O 0 7.1679999713580855e-09
medium O 0 1.4954852645132632e-07
- O 0 1.4024782331034658e-06
chain O 0 9.030273986354587e-07
triglyceride O 0 6.208212539604574e-07
oil O 0 1.506613784840738e-07
and O 0 5.818193571371921e-08
carnitine O 0 9.96900416794233e-06
and O 0 1.3347424498988403e-07
avoidance O 0 3.2108259802043904e-06
of O 0 2.041249302919823e-07
fasting O 0 3.124243812635541e-05
. O 0 1.8865075617213733e-06

Her O 0 0.0007082255906425416
ventricular O 1 0.7536658048629761
hypertrophy O 1 0.645203709602356
resolved O 0 0.0004413433198351413
significantly O 0 1.606770820217207e-05
over O 0 4.129319677304011e-07
1 O 0 4.0727468331169803e-07
year O 0 5.260021112007962e-07
, O 0 7.025955994777178e-08
and O 0 9.333638928410437e-08
cognitively O 0 3.61853490176145e-05
, O 0 3.404400317208456e-08
she O 0 1.8732986006853025e-07
is O 0 3.6072744791226796e-09
in O 0 1.7853420963831468e-09
the O 0 4.651743434891387e-09
superior O 0 2.1157727303489082e-07
range O 0 4.375498718900417e-08
for O 0 5.4827687279157544e-08
age O 0 9.453859206587367e-07
. O 0 9.980885806726292e-07

Clinical O 0 0.005658969283103943
recognition O 0 3.0448871257249266e-05
of O 0 2.3211325242300518e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
is O 0 3.0892095992385293e-07
important O 0 1.6016322490486345e-08
because O 0 4.3980396213783024e-08
it O 0 1.289237516743924e-08
is O 0 6.654792716886959e-09
one O 0 2.4607405002541327e-09
of O 0 4.3755946088630537e-10
the O 0 7.353311293201159e-09
few O 0 1.411699628306451e-07
directly O 0 3.951278813474346e-06
treatable O 0 0.39717310667037964
causes O 0 5.378771220421186e-06
of O 0 9.41754080940882e-07
cardiomyopathy B-Disease 1 0.9999995231628418
in O 0 0.0012280306546017528
children O 0 9.042522287927568e-05
. O 0 6.046422527106188e-07
. O 0 1.7189011032314738e-06

Cloning O 0 6.547350494656712e-05
of O 0 3.2389058901571843e-07
a O 0 9.647134220358566e-07
novel O 0 1.164706645795377e-06
member O 0 2.1508295589001136e-08
of O 0 2.128976106519076e-09
the O 0 1.8259076028925847e-08
low O 0 1.0026374184235465e-06
- O 0 9.131574188359082e-05
density O 0 5.462645731313387e-06
lipoprotein O 0 9.722918912302703e-05
receptor O 0 1.2706645065918565e-05
family O 0 2.217506107626832e-06
. O 0 1.0084697805723408e-06

A O 0 3.985460352851078e-05
gene O 0 7.883907528594136e-06
encoding O 0 2.8194847345730523e-06
a O 0 1.4389063380804146e-06
novel O 0 5.579695880442159e-06
transmembrane O 0 7.237140835059108e-06
protein O 0 3.7402045904855186e-07
was O 0 3.923908309388935e-07
identified O 0 1.486938145944805e-07
by O 0 1.3702622148059618e-08
DNA O 0 1.1167601599026966e-07
sequence O 0 1.4426195349415138e-08
analysis O 0 1.0240342795952984e-08
within O 0 3.1721407722784534e-09
the O 0 3.2495858448555737e-08
insulin B-Disease 0 0.037533149123191833
- I-Disease 1 0.9928693175315857
dependent I-Disease 1 0.9832624197006226
diabetes I-Disease 1 0.9999998807907104
mellitus I-Disease 1 0.9999994039535522
( O 0 2.645909262355417e-06
IDDM B-Disease 0 0.00318048894405365
) O 0 1.9435189813066245e-07
locus O 0 4.225854809192242e-06
IDDM4 O 0 6.176299211801961e-05
on O 0 2.5278309294662904e-06
chromosome O 0 5.692299237125553e-05
11q13 O 0 6.0672227846225724e-05
. O 0 3.6770211409020703e-06

Based O 0 1.5925406842143275e-05
on O 0 6.920023452039459e-07
its O 0 2.0107259501855879e-07
chromosomal O 0 7.551453745691106e-05
position O 0 8.496846021444071e-06
, O 0 4.621712434982328e-08
this O 0 1.2273513760874266e-08
gene O 0 4.2401023137017546e-08
is O 0 7.723876649379235e-09
a O 0 3.199773246365112e-08
candidate O 0 2.8833431997554726e-07
for O 0 3.8167563332081045e-08
conferring O 0 5.2888844948029146e-05
susceptibility O 1 0.7986569404602051
to O 0 0.00398019514977932
diabetes B-Disease 1 0.9990750551223755
. O 0 3.271281093475409e-05

The O 0 1.757186396389443e-06
gene O 0 1.6374846154576517e-06
, O 0 1.0355130086736608e-07
termed O 0 1.0371728649261058e-06
low O 0 1.436345201000222e-06
- O 0 2.1529906007344835e-05
density O 0 2.7416924694989575e-06
lipoprotein O 0 2.9226461265352555e-05
receptor O 0 3.7839822653040756e-06
related O 0 5.417362558546301e-07
protein O 0 5.022959044254094e-07
5 O 0 1.8785475219829095e-07
( O 0 3.260363357071583e-08
LRP5 O 0 3.9470207411795855e-05
) O 0 3.844946050435283e-08
, O 0 1.3456108227671848e-08
encodes O 0 4.551786858542073e-08
a O 0 3.6217606691479887e-08
protein O 0 1.826555617867598e-08
of O 0 2.706133317431636e-09
1615 O 0 4.252975031704409e-06
amino O 0 1.0134391459359904e-07
acids O 0 1.6400830915586084e-08
that O 0 4.397551212065309e-09
contains O 0 9.77285719017118e-09
conserved O 0 2.0828908375847277e-08
modules O 0 1.1191697524282063e-07
which O 0 1.031440088894442e-08
are O 0 2.3684034733406634e-09
characteristic O 0 2.2929024012796617e-08
of O 0 2.7605437935562804e-09
the O 0 5.515062539984683e-08
low O 0 5.387200872064568e-06
- O 0 0.007093620020896196
density O 0 6.549805402755737e-05
lipoprotein O 0 0.0018557512667030096
( O 0 1.1531590189406415e-06
LDL O 0 0.00010947642294922844
) O 0 4.349351456767181e-07
receptor O 0 4.307977178541478e-06
family O 0 1.3858640386388288e-06
. O 0 8.256458272626332e-07

These O 0 2.69054339696595e-06
modules O 0 3.609627810874372e-06
include O 0 1.5066481751091487e-07
a O 0 3.277972950854746e-07
putative O 0 2.3776033231115434e-06
signal O 0 1.0422664900033851e-06
peptide O 0 1.2463945608942595e-07
for O 0 4.265961361937798e-09
protein O 0 1.0735923261506741e-08
export O 0 7.124219880694227e-09
, O 0 5.432478022981968e-09
four O 0 2.5978323492381605e-08
epidermal O 0 6.656064215349033e-07
growth O 0 1.2092641554772854e-07
factor O 0 8.993912814503346e-08
( O 0 3.189092367961166e-08
EGF O 0 2.8259075861569727e-06
) O 0 4.3043449693414004e-08
repeats O 0 4.920528908769484e-07
with O 0 5.7140020714996353e-08
associated O 0 1.0463752886380462e-07
spacer O 0 2.933220685008564e-06
domains O 0 2.1244527204089536e-07
, O 0 2.5522059132754293e-08
three O 0 5.262288738094867e-08
LDL O 0 6.540318736369954e-06
- O 0 3.935410495614633e-05
receptor O 0 3.436588031036081e-06
( O 0 5.2475247258598756e-08
LDLR O 0 2.382519596721977e-05
) O 0 2.983905034170675e-08
repeats O 0 3.346382584368257e-07
, O 0 1.2404577809377315e-08
a O 0 6.357478810059547e-08
single O 0 2.1063445387881075e-07
transmembrane O 0 9.63699221756542e-07
spanning O 0 1.2329313392456243e-07
domain O 0 6.988040013311547e-08
, O 0 1.0955231388720676e-08
and O 0 1.2776269819880781e-08
a O 0 5.185613076719164e-07
cytoplasmic O 0 7.89350724517135e-06
domain O 0 2.2063261440052884e-06
. O 0 1.543129201309057e-06

The O 0 1.471815608056204e-06
encoded O 0 1.0474070677446434e-06
protein O 0 4.290730259981501e-07
has O 0 7.725324024931979e-08
a O 0 7.353665409937094e-08
unique O 0 4.805893638604175e-08
organization O 0 1.462433552035236e-08
of O 0 1.398947002684281e-08
EGF O 0 1.1222718967474066e-05
and O 0 1.5646520523660001e-06
LDLR O 0 0.005834722891449928
repeats O 0 1.0489551641512662e-05
; O 0 1.1139520239566991e-07
therefore O 0 4.7202625808040466e-08
, O 0 2.8404601337683744e-08
LRP5 O 0 5.322825018083677e-05
likely O 0 8.34920285797125e-07
represents O 0 2.3882737565372736e-08
a O 0 4.257948305053105e-08
new O 0 4.4451148539792484e-08
category O 0 1.141996364140141e-08
of O 0 2.5060935548992802e-09
the O 0 4.702218703300787e-08
LDLR O 0 0.014728579670190811
family O 0 4.436747985891998e-06
. O 0 9.227809414369403e-07

Both O 0 7.240129889396485e-06
human O 0 7.020288990133849e-07
and O 0 3.3721687486831797e-07
mouse O 0 1.0832394764292985e-05
LRP5 O 0 0.0002284909860463813
cDNAs O 0 1.6211311958613805e-05
have O 0 1.2116861114463973e-07
been O 0 1.9884568303041306e-07
isolated O 0 2.4155141886694764e-07
and O 0 7.623138564838428e-09
the O 0 3.9878198521137165e-09
encoded O 0 1.0199898525797835e-07
mature O 0 3.741092413633851e-08
proteins O 0 6.958364107134685e-09
are O 0 4.221169636053901e-09
95 O 0 9.34844450739547e-08
% O 0 4.953051657707874e-08
identical O 0 2.826894842655747e-07
, O 0 2.8656499395651736e-08
indicating O 0 2.0571825132265076e-07
a O 0 3.4388656899864145e-07
high O 0 3.196760189894121e-07
degree O 0 6.980673106227187e-08
of O 0 6.2860703309297605e-09
evolutionary O 0 3.892061499755073e-07
conservation O 0 1.8980448146521667e-07
. O 0 2.0150528712292726e-07
. O 0 1.0632116982378648e-06

The O 0 4.0453737710777204e-06
APC B-Disease 0 3.316596121294424e-05
variants O 0 8.320172128151171e-06
I1307K O 0 1.4332377759274095e-05
and O 0 2.4834218947944464e-07
E1317Q O 0 8.478188647131901e-06
are O 0 1.300827534578275e-07
associated O 0 1.7789291177905397e-06
with O 1 0.892574667930603
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 4.7094446927076206e-05
but O 0 4.0785073451843346e-07
not O 0 3.6041470252712315e-08
always O 0 5.4992330689174196e-08
with O 0 1.73836962602536e-08
a O 0 1.5294800732590375e-06
family O 0 1.0910741821135161e-06
history O 0 8.377110134460963e-07
. O 0 1.5123445109566092e-06

Classical O 0 0.15855419635772705
familial B-Disease 1 0.9999939203262329
adenomatous I-Disease 1 0.9999881982803345
polyposis I-Disease 1 0.9999996423721313
( O 0 0.008814758621156216
FAP B-Disease 1 0.6858307719230652
) O 0 1.1852162060677074e-06
is O 0 1.477578877029373e-07
a O 0 1.6968236877801246e-06
high O 0 3.7501875340240076e-05
- O 1 0.9837238788604736
penetrance O 1 0.9929792284965515
autosomal B-Disease 1 0.9978087544441223
dominant I-Disease 1 0.74148029088974
disease I-Disease 0 0.0011457639047876
that O 0 2.954854778636218e-07
predisposes O 0 7.360488962149248e-05
to O 0 1.6254655577085941e-07
hundreds O 0 1.6068071317931754e-07
or O 0 3.56410119195516e-08
thousands O 0 1.906806090801183e-07
of O 0 6.897227194713196e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
and I-Disease 1 0.9998138546943665
carcinoma I-Disease 1 1.0
and O 0 1.2989673450647388e-05
that O 0 4.511237534643442e-07
results O 0 3.2127232429957076e-07
from O 0 1.7972668686638826e-08
truncating O 0 5.630864052363904e-06
mutations O 0 1.4818435829511145e-06
in O 0 1.4563069861139866e-08
the O 0 4.2239101105678856e-08
APC B-Disease 0 2.626926107041072e-05
gene O 0 7.099234153429279e-06
. O 0 1.4836676882623578e-06

A O 0 0.0001061894217855297
variant O 0 9.865250467555597e-05
of O 0 7.514165076827339e-07
FAP B-Disease 0 0.029446620494127274
is O 0 0.0013788319192826748
attenuated B-Disease 1 0.9988616704940796
adenomatous I-Disease 1 0.9999964237213135
polyposis I-Disease 1 0.9999765157699585
coli I-Disease 1 0.9999030828475952
, O 0 4.454682311916258e-06
which O 0 3.4992081054951996e-07
results O 0 8.031534548536001e-08
from O 0 1.020318229905115e-08
germ O 0 1.1991573956038337e-06
- O 0 3.894488691003062e-05
line O 0 8.691185030329507e-06
mutations O 0 3.9392435269292037e-07
in O 0 7.848504068874718e-09
the O 0 1.397581428363992e-08
5 O 0 9.50415923739456e-08
and O 0 5.0393200723419795e-08
3 O 0 5.587293117059744e-08
regions O 0 1.9946021723171725e-08
of O 0 8.435470100209841e-09
the O 0 1.1747381023496928e-07
APC B-Disease 0 4.735529000754468e-05
gene O 0 6.0431179917941336e-06
. O 0 1.1752910040740971e-06

Attenuated B-Disease 1 0.998816728591919
adenomatous I-Disease 1 0.9999618530273438
polyposis I-Disease 1 0.9999889135360718
coli I-Disease 1 0.9999947547912598
patients O 1 0.9999089241027832
have O 0 1.3308736015460454e-05
" O 0 3.153158559143776e-06
multiple O 0 1.2955614693055395e-05
" O 0 0.11360500007867813
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999935626983643
( O 0 7.748912480565195e-07
typically O 0 1.984412278943637e-07
fewer O 0 6.715617217878389e-08
than O 0 1.369823188213104e-08
100 O 0 1.0212022338862425e-08
) O 0 8.658304295749986e-09
without O 0 1.1681708045330197e-08
the O 0 3.5503280315651864e-08
florid O 0 0.07956212759017944
phenotype O 0 0.0016741767758503556
of O 0 7.415907532504207e-08
classical O 0 5.7883239605871495e-06
FAP B-Disease 0 0.002997645875439048
. O 0 1.5098749827302527e-05

Another O 0 9.12517643882893e-05
group O 0 6.943054358998779e-06
of O 0 2.1880576639432547e-07
patients O 0 6.003402086207643e-05
with O 0 6.842841457910254e-07
multiple O 0 4.247116157785058e-05
adenomas B-Disease 0 0.006154178641736507
has O 0 1.2186712410766631e-05
no O 0 6.669585559393454e-07
mutations O 0 5.250573735793296e-07
in O 0 9.461794903131704e-09
the O 0 1.676902705582961e-08
APC B-Disease 0 2.3118241188058164e-06
gene O 0 1.4910449408489512e-07
, O 0 1.2444295371949465e-08
and O 0 3.0434073039486975e-08
their O 0 1.6336180408416112e-07
phenotype O 0 0.0070228069089353085
probably O 0 2.113908294631983e-06
results O 0 7.517764544218153e-08
from O 0 3.563909167780821e-09
variation O 0 7.838139737259553e-08
at O 0 2.0182911342203624e-08
a O 0 4.542809506347112e-07
locus O 0 3.0194407827366376e-06
, O 0 6.338155600360551e-08
or O 0 1.0566051145133315e-08
loci O 0 1.5360593863533722e-07
, O 0 5.4954686135033626e-08
elsewhere O 0 4.3417465178663406e-08
in O 0 1.492244905421103e-08
the O 0 5.253613721833972e-08
genome O 0 1.9344613519933773e-06
. O 0 1.8008686311077327e-06

Recently O 0 0.0001979230291908607
, O 0 1.2884872830909444e-06
however O 0 1.3952740118838847e-07
, O 0 1.5404655329120942e-08
a O 0 2.5279342708017793e-07
missense O 0 1.9446832084213383e-05
variant O 0 4.773535692947917e-06
of O 0 3.466100650939552e-08
APC B-Disease 0 2.2788954083807766e-05
( O 0 6.460872015168206e-08
I1307K O 0 2.4315529572049854e-06
) O 0 3.007439985935889e-08
was O 0 6.113787662798131e-07
described O 0 9.883607390293037e-07
that O 0 2.919005659407503e-08
confers O 0 1.4169588666845812e-06
an O 0 8.624652281241652e-08
increased O 0 9.368541213916615e-07
risk O 0 7.952191367621708e-07
of O 0 2.8221529646543786e-05
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.2288747711863834e-05
including O 0 6.944676442799391e-07
multiple O 0 1.4466291759163141e-05
adenomas B-Disease 0 0.00033363798866048455
, O 0 5.202415422900231e-07
in O 0 3.180919065925991e-07
Ashkenazim O 0 2.8580367143149488e-05
. O 0 4.274835646356223e-06

We O 0 2.252238118671812e-06
have O 0 1.494507131383216e-07
studied O 0 6.607403690850333e-08
a O 0 3.3013765943223916e-08
set O 0 2.8135270113693878e-08
of O 0 9.763019725994582e-09
164 O 0 1.323584365309216e-05
patients O 0 9.658833005232736e-05
with O 0 6.700719040964032e-06
multiple O 1 0.9874651432037354
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999980926513672
and I-Disease 0 0.012171890586614609
/ I-Disease 0 0.17082205414772034
or I-Disease 0 0.0024360825773328543
carcinoma I-Disease 1 1.0
and O 0 1.7406728147761896e-05
analyzed O 0 1.3841198779118713e-05
codons O 0 6.297357231233036e-06
1263 O 0 5.681968468707055e-05
- O 0 9.454913379158825e-05
1377 O 0 0.00023818714544177055
( O 0 1.8647463662091468e-07
exon O 0 1.7708077848510584e-06
15G O 0 4.6087816372164525e-06
) O 0 1.1400811850137416e-08
of O 0 1.8295462922424122e-09
the O 0 9.168395820324804e-09
APC B-Disease 0 9.989809086619061e-07
gene O 0 1.0291432772646658e-07
for O 0 2.157469225494424e-08
germ O 0 3.0596745546063175e-06
- O 0 4.962998355040327e-05
line O 0 1.4270021893025842e-05
variants O 0 6.789921371819219e-06
. O 0 2.4387450139329303e-06

Three O 0 6.524930358864367e-05
patients O 0 0.0001895096938824281
with O 0 9.530317868211569e-08
the O 0 9.997006600315217e-08
I1307K O 0 3.810397538472898e-05
allele O 0 7.209175237221643e-06
were O 0 1.3829316003466374e-07
detected O 0 4.140044893574668e-07
, O 0 9.730097616511557e-09
each O 0 5.406418868147966e-09
of O 0 3.832396444636288e-08
Ashkenazi O 0 3.3951306249946356e-05
descent O 0 5.036656875745393e-05
. O 0 2.25914959628426e-06

Four O 0 0.00036905601155012846
patients O 0 0.002898862585425377
had O 0 2.049347358479281e-06
a O 0 4.865828486799728e-07
germ O 0 8.72029340825975e-06
- O 0 5.158826388651505e-05
line O 0 3.997008207079489e-06
E1317Q O 0 6.487281098088715e-06
missense O 0 7.444644325005356e-06
variant O 0 1.3356864201341523e-06
of O 0 1.5447231049847687e-08
APC O 0 3.6472758893069113e-06
that O 0 2.106121712586173e-07
was O 0 3.2482275855727494e-06
not O 0 1.8474944241120284e-08
present O 0 1.4214543320179018e-08
in O 0 2.5973120543199002e-08
controls O 0 1.3171048522053752e-05
; O 0 3.7107611206010915e-08
one O 0 8.820826735700393e-09
of O 0 1.3041204782737736e-09
these O 0 4.6538199960366455e-09
individuals O 0 2.86188472919946e-09
had O 0 1.3939853715783102e-07
an O 0 3.421853733698299e-08
unusually O 0 2.0889852748950943e-05
large O 0 3.83470712961298e-08
number O 0 1.6573535432939934e-08
of O 0 9.804410616709447e-09
metaplastic B-Disease 0 0.00016246027371380478
polyps I-Disease 0 5.622085609502392e-06
of I-Disease 0 2.6921110674038573e-08
the I-Disease 0 1.3271079524201923e-07
colorectum I-Disease 0 0.00019457457528915256
. O 0 3.1866652534517925e-06

There O 0 9.684526048658881e-06
is O 0 2.9869292461626173e-07
increasing O 0 1.0213583578888574e-07
evidence O 0 1.2542022886918858e-07
that O 0 3.11330481395089e-08
there O 0 1.6600868235627786e-08
exist O 0 1.642738034490776e-08
germ O 0 5.318199214343622e-07
- O 0 3.6681003621197306e-06
line O 0 4.7219282350852154e-07
variants O 0 2.994595149630186e-08
of O 0 1.1081783268807044e-09
the O 0 1.0073469169924465e-08
APC B-Disease 0 3.2211767120315926e-06
gene O 0 1.8981191374223272e-07
that O 0 3.888028743403993e-08
predispose O 0 6.114639745646855e-07
to O 0 2.2475244776387626e-08
the O 0 7.731379980668862e-09
development O 0 1.4945094051199703e-08
of O 0 1.2867396037563594e-07
multiple O 1 0.9575514197349548
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
and I-Disease 1 0.9997057318687439
carcinoma I-Disease 1 1.0
, O 0 2.0645422409870662e-05
but O 0 3.303411517663335e-07
without O 0 6.832010512880515e-08
the O 0 5.126631208440813e-08
florid O 0 0.08635438978672028
phenotype O 0 0.0036853167694061995
of O 0 3.6537606717956805e-08
classical O 0 1.2140346825617598e-06
FAP B-Disease 0 0.001050337334163487
, O 0 5.038743324803363e-07
and O 0 5.077875186998426e-08
possibly O 0 7.230176635175667e-08
with O 0 2.9167793513806828e-08
importance O 0 5.756126029154984e-07
for O 1 0.5239610075950623
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 3.887968705384992e-05
in O 0 5.45620899572441e-08
the O 0 3.613963173165757e-08
general O 0 6.137927357485751e-07
population O 0 2.0732321104333096e-07
. O 0 1.1065002780696886e-07
. O 0 5.111185146233765e-07

Genomic O 0 0.00013687559112440795
structure O 0 3.7359125144575955e-06
of O 0 6.473428726394559e-08
the O 0 8.137830604937335e-07
human O 0 0.0005105597665533423
congenital B-Disease 1 0.9999995231628418
chloride I-Disease 1 0.9999996423721313
diarrhea I-Disease 1 1.0
( O 0 0.0009582419879734516
CLD B-Disease 1 0.9144234657287598
) O 0 1.5176643728409545e-06
gene O 0 4.244308001943864e-06
. O 0 1.364291165373288e-06

Congenital B-Disease 1 0.9999990463256836
chloride I-Disease 1 0.9999977350234985
diarrhea I-Disease 1 1.0
( O 0 0.010210929438471794
CLD B-Disease 1 0.9972537159919739
) O 0 2.831135134329088e-06
is O 0 1.0938820196315646e-06
caused O 0 4.7825765250308905e-06
by O 0 2.2524905318732635e-07
mutations O 0 4.432743025972741e-06
in O 0 3.2391401560971644e-08
a O 0 1.056461883308657e-06
gene O 0 5.693619300473074e-07
which O 0 1.1410475053708069e-07
encodes O 0 1.3382275483309058e-06
an O 0 1.7120217989941011e-06
intestinal O 1 0.9669057130813599
anion O 0 0.004064766224473715
transporter O 0 0.0004691052599810064
. O 0 3.1955062240740517e-06

We O 0 8.364549103134777e-06
report O 0 1.0520622026888304e-06
here O 0 2.7719789130742356e-08
the O 0 3.801207348885782e-09
complete O 0 5.132618596803695e-08
genomic O 0 1.4211092036475748e-07
organization O 0 8.077635449410536e-09
of O 0 1.6374815947628463e-09
the O 0 1.867689647383486e-08
human O 0 2.010833526355782e-07
CLD B-Disease 0 0.0013080218341201544
gene O 0 1.6136326621563057e-06
which O 0 1.4268263726080477e-07
spans O 0 7.47525405131455e-07
approximately O 0 1.2607739563463838e-07
39kb O 0 3.2223904327111086e-06
, O 0 6.266954954980974e-08
and O 0 6.18020550291476e-08
comprises O 0 2.168348487430194e-07
21 O 0 1.7122894178100978e-06
exons O 0 1.189012618851848e-05
. O 0 1.8973729538629414e-06

All O 0 6.605326689168578e-06
exon O 0 4.5460772525984794e-05
/ O 0 1.2984571185370442e-05
intron O 0 4.238513793097809e-05
boundaries O 0 5.523736490431475e-07
conform O 0 4.399688577905181e-07
to O 0 7.449649075397247e-08
the O 0 1.7248883921183733e-07
GT O 0 0.00046159682096913457
/ O 0 0.005746839568018913
AG O 1 0.9682776927947998
rule O 0 1.6494732335559092e-05
. O 0 2.6873713068198413e-06

An O 0 2.92719869321445e-06
analysis O 0 5.706975798602798e-07
of O 0 1.3963398437510932e-08
the O 0 3.089500566488823e-08
putative O 0 2.9780342174490215e-06
promoter O 0 5.488478564075194e-06
region O 0 8.341302049075239e-08
sequence O 0 4.5660733860586333e-08
shows O 0 4.784674345614803e-08
a O 0 1.7401751506440633e-07
putative O 0 9.290775778936222e-06
TATA O 0 9.694757318357006e-05
box O 0 1.0186458894168027e-06
and O 0 7.690569958640481e-08
predicts O 0 2.361754695812124e-06
multiple O 0 8.389199734892827e-08
transcription O 0 1.977363979221991e-07
factor O 0 1.8354388942043443e-07
binding O 0 4.886816213911516e-07
sites O 0 3.819582730102411e-07
. O 0 1.4481214520856156e-06

The O 0 1.4960614862502553e-06
genomic O 0 2.3210914150695316e-06
structure O 0 4.39518032635533e-07
was O 0 5.178669653105317e-07
determined O 0 1.60295627438245e-07
using O 0 5.632457700244231e-08
DNA O 0 1.7823225562096923e-07
from O 0 6.273924935129571e-09
several O 0 6.339144320577361e-09
sources O 0 1.1054956949863026e-08
including O 0 1.0511116421696443e-08
multiple O 0 5.217703602511392e-08
large O 0 4.3858097598103996e-08
- O 0 1.2079992302460596e-05
insert O 0 1.400942710461095e-05
libaries O 0 1.2271286323084496e-05
and O 0 2.645918861787777e-08
genomic O 0 1.2124583292916213e-07
DNA O 0 3.8411604919019737e-07
from O 0 4.248311213927991e-08
Finnish O 0 0.2722397446632385
CLD B-Disease 1 0.9991257786750793
patients O 0 0.15668706595897675
and O 0 7.751905855002406e-07
controls O 0 0.00020268833031877875
. O 0 4.3264267333142925e-06

Exon O 0 0.000556803832296282
- O 0 0.00011473418999230489
specific O 0 6.118267492638552e-07
primers O 0 1.3054287592240144e-05
developed O 0 1.0946188240268384e-06
in O 0 1.991443276949667e-08
this O 0 1.2579414843116865e-08
study O 0 3.453970975897391e-08
will O 0 1.014554662503997e-08
facilitate O 0 3.704799667048064e-08
mutation O 0 8.867656902111776e-07
screening O 0 3.838516420273663e-07
studies O 0 5.490638699257033e-08
of O 0 2.6613815151677045e-08
patients O 0 5.99589548073709e-05
with O 0 4.991718469682382e-07
the O 0 1.8542759789852425e-05
disease O 0 0.002079164143651724
. O 0 4.304716640035622e-06

Genomic O 0 8.178943971870467e-05
sequencing O 0 8.510210136591922e-06
of O 0 3.3696707646413415e-07
a O 0 3.342754098412115e-06
BAC O 0 0.0004945372347719967
clone O 0 0.00040977407479658723
H O 1 0.9995973706245422
_ O 0 5.002126499675796e-07
RG364P16 O 0 2.2560902834811714e-06
revealed O 0 5.127179178998631e-07
the O 0 3.5166218825821716e-09
presence O 0 1.3784987373810509e-08
of O 0 2.01586636272566e-09
another O 0 1.1401870381178014e-07
, O 0 3.430715267427331e-08
highly O 0 5.513179957006287e-08
homologous O 0 1.1442970304642586e-07
gene O 0 1.1048026493654106e-07
3 O 0 1.5136729203391042e-08
of O 0 2.6325472912702708e-09
the O 0 1.0533577921023607e-07
CLD B-Disease 0 0.15706263482570648
gene O 0 1.1400547919038218e-06
, O 0 1.5702166678011054e-08
with O 0 6.934727458940415e-09
a O 0 2.0307797399254923e-07
similar O 0 8.323311107005793e-08
genomic O 0 2.2631360252489685e-07
structure O 0 1.4859600128147576e-07
, O 0 3.817368110503594e-08
recently O 0 5.259549311631417e-07
identified O 0 1.0932420480003202e-07
as O 0 4.3774104341309794e-08
the O 0 4.818826710106805e-06
Pendred B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
gene O 0 4.089126014150679e-05
( O 0 2.683862589947239e-07
PDS B-Disease 0 0.0018538867589086294
) O 0 3.6485940313468745e-07
. O 0 2.948121675672155e-07
. O 0 9.747726608111407e-07

The O 0 5.625657195196254e-06
APCI1307K O 0 0.001100296969525516
allele O 0 0.000784765463322401
and O 0 4.35474248661194e-05
cancer B-Disease 0 0.14868037402629852
risk O 0 7.289565928658703e-07
in O 0 3.9469970403160914e-08
a O 0 1.2697020110863377e-06
community O 0 9.626486274783019e-08
- O 0 1.5993686247384176e-05
based O 0 3.584711123494344e-07
study O 0 5.2718124976536274e-08
of O 0 2.9693762115812206e-08
Ashkenazi O 0 1.9766333934967406e-05
Jews O 0 1.5974060261214618e-06
. O 0 1.2069592685293173e-06

Mutations O 1 0.648788571357727
in O 0 1.9008570234291255e-05
APC O 0 0.0008636859711259604
are O 0 2.240901949335239e-06
classically O 1 0.8746265769004822
associated O 0 5.9329722716938704e-05
with O 0 0.0004110009176656604
familial B-Disease 1 0.9999996423721313
adenomatous I-Disease 1 0.9999986886978149
polyposis I-Disease 1 0.9999998807907104
( O 0 0.00016648854943923652
FAP B-Disease 0 0.1248021051287651
) O 0 1.0631346185618895e-06
, O 0 1.6050489648478106e-07
a O 0 2.177849410145427e-06
highly O 0 0.00016436165606137365
penetrant O 1 0.9998028874397278
autosomal B-Disease 1 0.9999997615814209
dominant I-Disease 1 0.9999833106994629
disorder I-Disease 1 0.9999997615814209
characterized O 0 0.030605744570493698
by O 0 8.573815648560412e-06
multiple O 0 0.0010282568400725722
intestinal O 1 0.999929666519165
polyps B-Disease 0 0.21700990200042725
and O 0 8.379219025300699e-07
, O 0 9.341207629631754e-08
without O 0 5.2744574929874943e-08
surgical O 0 9.043253157869913e-06
intervention O 0 3.0845788501210336e-07
, O 0 1.7780536154532456e-08
the O 0 5.865904206814321e-09
development O 0 4.366944494904601e-08
of O 0 0.00036694968002848327
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 7.605518931086408e-06
CRC B-Disease 0 0.00052076909923926
) O 0 1.8249313598062145e-06
. O 0 2.2981885194894858e-06

APC B-Disease 0 0.0033538693096488714
is O 0 1.9373121176613495e-05
a O 0 5.500271436176263e-05
tumour O 1 0.9997581839561462
- O 0 0.00024422325077466667
suppressor O 0 0.0001342686009593308
gene O 0 1.0419613545309403e-06
, O 0 3.4937652770850036e-08
and O 0 2.8237845839385045e-08
somatic O 0 6.260387181100668e-06
loss O 0 0.0004282888548914343
occurs O 0 1.3996376537761535e-06
in O 0 3.822960479737958e-06
tumours B-Disease 1 0.9999924898147583
. O 0 1.4381462278834078e-05

The O 0 9.735242201713845e-06
germline O 0 0.0006009391508996487
T O 0 0.0012712640454992652
- O 0 4.012195859104395e-05
to O 0 4.6970643552413094e-07
- O 0 1.7542732166475616e-05
A O 0 4.902270575257717e-06
transversion O 0 2.3049396986607462e-05
responsible O 0 1.1469202831904113e-07
for O 0 1.1651778208943142e-08
the O 0 1.52691868038346e-08
APC O 0 2.038942966464674e-06
I1307K O 0 2.7143130409967853e-06
allele O 0 2.671477545845846e-07
converts O 0 1.0841490194479775e-07
the O 0 4.259709029952319e-09
wild O 0 4.198592051807282e-08
- O 0 3.224173269700259e-06
type O 0 2.4176529223041143e-07
sequence O 0 2.1854919651786986e-08
to O 0 2.8959970421738035e-08
a O 0 7.47860121919075e-06
homopolymer O 1 0.9898576736450195
tract O 1 0.8671292066574097
( O 0 1.5787429674674058e-07
A8 O 0 0.006941624917089939
) O 0 1.2672255422785383e-07
that O 0 8.758966885125119e-08
is O 0 1.5306721934393863e-07
genetically O 0 9.447909974369395e-07
unstable O 0 2.6182275178143755e-05
and O 0 2.3418577654865658e-07
prone O 0 1.5758663721499033e-05
to O 0 9.295598601966049e-07
somatic O 0 0.00019881976186297834
mutation O 0 8.648825314594433e-05
. O 0 3.3955923299799906e-06

The O 0 3.738560735655483e-06
I1307K O 0 4.17940755141899e-05
allele O 0 3.665547774289735e-05
was O 0 9.11617178189772e-07
found O 0 2.731295296598546e-07
in O 0 1.6482043463383889e-07
6 O 0 5.647362741001416e-06
. O 0 1.219014052367129e-06

1 O 0 1.1665736565191764e-05
% O 0 4.82470795759582e-07
of O 0 5.2794092653130065e-08
unselected O 0 0.00048296182649210095
Ashkenazi O 0 0.00016856208094395697
Jews O 0 1.0655544429027941e-06
and O 0 1.0136691486195559e-07
higher O 0 1.4992779995282035e-07
proportions O 0 4.651222411666822e-07
of O 0 1.5839937361761258e-08
Ashkenazim O 0 5.575014711212134e-06
with O 0 3.175793494847312e-07
family O 0 4.810461291526735e-07
or O 0 3.192963404785587e-08
personal O 0 1.44959722092608e-06
histories O 0 2.991455971823598e-07
of O 0 7.721612149680368e-08
CRC B-Disease 0 0.00042129887151531875
( O 0 2.7836173899231653e-07
ref O 0 0.0010901750065386295
. O 0 1.2081852673873072e-07
2 O 0 1.9329237943566113e-07
) O 0 1.521755876865427e-07
. O 0 7.800971388860489e-07

To O 0 4.325176178099355e-06
evaluate O 0 2.4328539893758716e-06
the O 0 2.642015672904563e-08
role O 0 7.652072753216999e-08
of O 0 2.1188455434639764e-08
I1307K O 0 3.26316112477798e-05
in O 0 3.165891484968597e-06
cancer B-Disease 0 0.0001635567023186013
, O 0 3.1977659631365896e-08
we O 0 2.2225012941134992e-08
genotyped O 0 1.8238473558085389e-06
5 O 0 6.103953609226664e-08
, O 0 8.37247924323492e-08
081 O 0 8.039271961024497e-06
Ashkenazi O 0 2.87600732917781e-06
volunteers O 0 1.9682840957102599e-07
in O 0 3.4444447294390557e-08
a O 0 5.352227958610456e-07
community O 0 4.565019651181501e-07
survey O 0 2.7974688237009104e-06
. O 0 8.813159411147353e-07

Risk O 0 0.00012347602751106024
of O 0 9.949486639015959e-07
developing O 0 2.9574346626759507e-05
colorectal B-Disease 1 0.999998927116394
, I-Disease 0 0.0007527933339588344
breast I-Disease 0 0.4314996302127838
and I-Disease 0 2.760024926828919e-06
other I-Disease 0 4.2707836200861493e-07
cancers I-Disease 0 0.013161931186914444
were O 0 2.2269223336479627e-06
compared O 0 1.1062813882745104e-06
between O 0 3.987540253547195e-08
genotyped O 0 5.938037793384865e-05
I1307K O 0 7.625127636856632e-06
carriers O 0 1.6160662141828652e-07
and O 0 1.4455445729311123e-08
non O 0 2.704406121267766e-08
- O 0 2.9684417768294225e-06
carriers O 0 2.903481117755291e-07
and O 0 1.3046336455602159e-08
their O 0 4.932073860430819e-09
first O 0 1.7837371046880435e-07
- O 0 2.1615902369376272e-05
degree O 0 4.4038292799086776e-06
relatives O 0 7.739003194728866e-06
. O 0 2.01143689082528e-06

Sperm O 0 0.0002419715456198901
DNA O 0 4.569870725390501e-05
analysis O 0 1.6187499340958311e-06
in O 0 1.168165724152459e-07
a O 0 1.3333037713891827e-05
Friedreich B-Disease 1 0.9760525226593018
ataxia I-Disease 1 0.9926678538322449
premutation O 0 0.015972133725881577
carrier O 0 6.576127634616569e-05
suggests O 0 2.109740222522305e-07
both O 0 8.235553572433219e-09
meiotic O 0 7.394932026727474e-07
and O 0 3.7317136047931854e-08
mitotic O 0 6.522620310533966e-07
expansion O 0 3.0239831971812237e-07
in O 0 6.309472411203387e-08
the O 0 1.111577034862421e-07
FRDA B-Disease 0 0.0011820957297459245
gene O 0 8.583805538364686e-06
. O 0 2.3085083284968277e-06

Friedreich B-Disease 1 0.9997286200523376
ataxia I-Disease 1 0.9999328851699829
is O 0 0.008096019737422466
usually O 0 0.00011867882130900398
caused O 0 5.853819402545923e-06
by O 0 2.0151446733507328e-08
an O 0 1.2762994217041523e-08
expansion O 0 8.850694399598069e-08
of O 0 7.605652996289791e-09
a O 0 9.001753937809553e-07
GAA O 0 1.4968049981689546e-06
trinucleotide O 0 1.1514356629049871e-05
repeat O 0 8.779319387031137e-07
in O 0 3.252810643061821e-08
intron O 0 1.078863897419069e-05
1 O 0 6.121862128338762e-08
of O 0 1.464172338927483e-08
the O 0 1.7142161823358038e-07
FRDA B-Disease 0 0.0012858228292316198
gene O 0 8.031892321014311e-06
. O 0 2.8072931854694616e-06

Occasionally O 0 3.4251697798026726e-05
, O 0 3.742348724244948e-07
a O 0 2.0280720036680577e-07
fully O 0 3.3609796901146183e-07
expanded O 0 1.8035447624242806e-07
allele O 0 1.2069466492903302e-06
has O 0 9.378090481959589e-08
been O 0 5.446351991622578e-08
found O 0 1.72321072966497e-08
to O 0 3.9162589615671095e-08
arise O 0 4.504157047335866e-08
from O 0 2.0737722650210344e-09
a O 0 3.7986147560786776e-08
premutation O 0 1.5072948826855281e-06
of O 0 2.829271261717281e-09
100 O 0 1.6420580450926536e-08
or O 0 2.7942528291191593e-08
less O 0 5.06710250647302e-07
triplet O 0 0.0019618007354438305
repeats O 0 3.578566247597337e-05
. O 0 1.781769697117852e-06

We O 0 5.556702490139287e-06
have O 0 3.267046793098416e-07
examined O 0 3.264751171627722e-07
the O 0 1.3439384716207314e-08
sperm O 0 2.499507729680772e-07
DNA O 0 1.6325029150721093e-07
of O 0 1.2495813273005751e-08
a O 0 1.3495789517037338e-06
premutation O 0 0.0007619630196131766
carrier O 0 0.00014374002057593316
. O 0 2.7403905278333696e-06

This O 0 7.985608135641087e-06
mans O 0 0.00016204919666051865
leucocyte O 0 0.00019678589887917042
DNA O 0 9.855739335762337e-06
showed O 0 1.9718399926205166e-06
one O 0 2.8049109701555608e-08
normal O 0 5.7267019570872435e-08
allele O 0 3.153219836349308e-07
and O 0 1.2298047913361643e-08
one O 0 4.1793526861511054e-08
allele O 0 2.9910424359513854e-07
of O 0 9.524971034124974e-09
approximately O 0 9.970461434249955e-08
100 O 0 1.9207462287340604e-07
repeats O 0 4.7551839088555425e-06
. O 0 1.872453253781714e-06

His O 0 1.507437900727382e-05
sperm O 0 6.9991638156352565e-06
showed O 0 2.2580059066967806e-06
an O 0 2.4597468950560142e-08
expanded O 0 1.6541201830477803e-07
allele O 0 7.98576763827441e-07
in O 0 2.2055170134649416e-08
a O 0 1.7493567838755553e-07
tight O 0 6.1801279116480146e-06
range O 0 1.0144080420104729e-07
centering O 0 1.8268295320922334e-07
on O 0 1.4232955436455086e-07
a O 0 6.906996219413486e-08
size O 0 7.122524436908861e-08
of O 0 1.2029030216353931e-08
approximately O 0 1.8871774898343574e-07
320 O 0 3.265808572905371e-06
trinucleotide O 0 0.0001424876827513799
repeats O 0 5.132676233188249e-05
. O 0 2.3780023639119463e-06

His O 0 4.417979289428331e-05
affected O 0 8.189321306417696e-06
son O 0 6.350977491820231e-05
has O 0 8.061259677560884e-07
repeat O 0 1.138895299845899e-06
sizes O 0 2.6632608296495164e-07
of O 0 2.21885034790148e-08
1040 O 0 4.412834186950931e-06
and O 0 5.734970613957557e-07
540 O 0 1.56950864038663e-05
. O 0 4.420605819177581e-06

These O 0 5.016443651584268e-07
data O 0 2.3324318476625194e-07
suggest O 0 9.454493010707665e-08
that O 0 1.214916256486731e-08
expansion O 0 6.141861774722202e-08
occurs O 0 1.625805801097613e-08
in O 0 3.790918690071976e-09
two O 0 1.728332321704329e-08
stages O 0 2.0272966594347963e-07
, O 0 8.98293706086406e-09
the O 0 2.5250890267614068e-09
first O 0 1.52590562407795e-08
during O 0 4.215781146399422e-08
meiosis O 0 7.224249287673956e-08
followed O 0 4.601130498826933e-08
by O 0 6.405725727631761e-09
a O 0 4.469122671935111e-08
second O 0 1.7838817711890442e-07
mitotic O 0 3.844535513053415e-06
expansion O 0 3.30194825437502e-06
. O 0 1.7585695104571641e-06

We O 0 2.4574549115641275e-06
also O 0 3.8294379578474036e-07
show O 0 1.368532451806459e-07
that O 0 7.982841943032781e-09
in O 0 5.110031953137195e-09
all O 0 2.024482137485961e-09
informative O 0 1.1318979176166977e-07
carrier O 0 4.084013653482543e-06
father O 0 9.66471361607546e-07
to O 0 1.0789402438149409e-07
affected O 0 1.2580451880239707e-07
child O 0 2.3205382149171783e-06
transmissions O 0 1.0978200407407712e-05
, O 0 2.1100776237403807e-08
with O 0 5.955937965040903e-09
the O 0 1.1088999052333293e-08
notable O 0 5.642866440780381e-08
exception O 0 2.4719188473909526e-08
of O 0 1.676358163393843e-09
the O 0 9.288756430692047e-09
premutation O 0 2.7738682547351345e-05
carrier O 0 2.459389179421123e-06
, O 0 1.071356514614763e-08
the O 0 3.064328346624734e-09
expansion O 0 1.3534491927202907e-07
size O 0 3.8427103277172137e-07
decreases O 0 2.2244578303798335e-06
. O 0 1.5080570392456139e-07
. O 0 9.15484520191967e-07

The O 0 4.253307452017907e-06
R496H O 0 5.50138320249971e-05
mutation O 0 5.18164688401157e-06
of O 0 4.867164804522872e-08
arylsulfatase O 0 3.559444667189382e-05
A O 0 9.1823694674531e-06
does O 0 1.5297630397981266e-06
not O 0 9.214960527970106e-07
cause O 0 0.0001659317931625992
metachromatic B-Disease 1 0.9999741315841675
leukodystrophy I-Disease 1 0.9999821186065674
. O 0 5.900815813220106e-05

Deficiency B-Disease 1 0.9976134300231934
of I-Disease 0 2.8749022931151558e-06
arylsulfatase I-Disease 0 0.0009116667206399143
A I-Disease 0 0.00012186195817776024
( O 0 1.40562758588203e-06
ARSA O 0 0.0017992773791775107
) O 0 3.0654058491563774e-07
enzyme O 0 1.0655015785232536e-06
activity O 0 7.614980859216303e-07
causes O 0 6.440185097744688e-05
metachromatic B-Disease 1 0.9999922513961792
leukodystrophy I-Disease 1 0.9999979734420776
( O 0 0.00020530774781946093
MLD B-Disease 1 0.9997619986534119
) O 0 7.958055903145578e-06
. O 0 3.843861122732051e-06

A O 0 2.17394444916863e-05
number O 0 2.852511045148276e-07
of O 0 5.706856853748832e-08
ARSA O 0 0.12154676020145416
gene O 0 1.2840141607739497e-05
mutations O 0 3.6793328490603017e-06
responsible O 0 3.163997348565317e-07
for O 0 2.9967898740324017e-07
MLD B-Disease 1 0.9999784231185913
have O 0 2.1589099560515024e-05
been O 0 4.765566245623631e-06
identified O 0 5.4271281442197505e-06
. O 0 1.264754359908693e-06

Recently O 0 4.0389182686340064e-05
, O 0 2.119707005476812e-07
the O 0 3.910444235089017e-08
R496H O 0 4.286797775421292e-06
mutation O 0 5.259067847873666e-07
of O 0 1.5519438179012468e-08
ARSA O 0 0.00364245125092566
was O 0 4.732107299787458e-06
proposed O 0 8.886877367331181e-08
to O 0 2.1766934921174652e-08
be O 0 2.1284412454747326e-08
a O 0 4.951266987518466e-07
cause O 0 3.4766230783134233e-06
of O 0 2.61964629544309e-07
MLD B-Disease 1 0.9999891519546509
( O 0 1.2155244348832639e-06
Draghia O 0 0.00014523236313834786
et O 0 8.905063623387832e-06
al O 0 3.2750406262493925e-06
. O 0 5.617073384200921e-08
, O 0 7.760088038821777e-08
1997 O 0 2.4537496301491046e-07
) O 0 1.7944211094800266e-07
. O 0 7.708661087235669e-07

We O 0 3.4556624086690135e-06
have O 0 4.826235908694798e-07
investigated O 0 5.622313778985699e-07
the O 0 5.187161278286112e-08
R496H O 0 4.0013859688770026e-05
mutation O 0 2.4776502414169954e-06
and O 0 2.5534815151218027e-08
found O 0 3.137112258855268e-08
this O 0 8.13884604156101e-09
mutation O 0 1.0383809012637357e-07
at O 0 5.024556326560514e-09
a O 0 2.1535043970288825e-07
relatively O 0 5.581721325143008e-07
high O 0 1.863564023096842e-07
frequency O 0 7.384122113762714e-07
in O 0 1.9503382020502613e-08
an O 0 3.597087072648719e-08
African O 0 3.098270084933574e-08
American O 0 6.208490788139898e-08
population O 0 2.716114799738989e-08
( O 0 1.5375038131537622e-08
f O 0 7.507904911108199e-07
= O 0 5.338902155926917e-07
0 O 0 9.514062071502849e-08
. O 0 9.65909219274863e-09
09 O 0 1.679486558714416e-07
, O 0 5.05726838184728e-08
n O 0 1.4332719047160936e-06
= O 0 1.7506379208498402e-06
61 O 0 1.5416700307469e-06
subjects O 0 6.084223400648625e-07
) O 0 2.483848504652997e-07
. O 0 8.117042398225749e-07

The O 0 3.7255695133353584e-06
ARSA O 0 0.000419650663388893
enzyme O 0 1.5040023981782724e-06
activity O 0 9.827930114170158e-08
in O 0 3.204090859298958e-08
subjects O 0 1.7678317476566008e-07
with O 0 6.86483616618716e-08
and O 0 1.4090619515627623e-07
without O 0 4.2872368766211366e-08
the O 0 1.3745499849449061e-08
R496H O 0 1.1413893844292033e-05
mutation O 0 8.275993081952038e-07
was O 0 3.679487008412252e-07
determined O 0 1.2364968426936684e-07
and O 0 1.1742649519419501e-08
found O 0 2.0584124627021083e-08
to O 0 2.388355824223254e-08
be O 0 1.2476837696340226e-07
normal O 0 6.070515610190341e-07
. O 0 1.1614411050686613e-06

It O 0 4.6968589231255464e-06
is O 0 3.535566577284044e-07
therefore O 0 1.2582010811001965e-07
concluded O 0 9.432248049279224e-08
that O 0 6.8210184167583066e-09
the O 0 1.532170124107779e-08
R496H O 0 4.783611984748859e-06
mutation O 0 1.9908191006834386e-07
of O 0 4.234556261195621e-09
ARSA O 0 0.00044126721331849694
does O 0 2.0663236455220613e-07
not O 0 1.0550504470074884e-08
negatively O 0 6.267157459660666e-08
influence O 0 1.4843391404895101e-08
the O 0 5.336445507708731e-09
activity O 0 1.0418283125090966e-08
of O 0 1.069680166665421e-08
ARSA O 0 0.011137248016893864
and O 0 1.8003588309056795e-07
is O 0 2.009655730716986e-08
not O 0 3.339081899866869e-08
a O 0 8.970876024250174e-07
cause O 0 1.2388980394462124e-05
of O 0 3.6719713989441516e-06
MLD B-Disease 1 0.9999451637268066

Down O 0 8.650343806948513e-05
- O 0 1.6429828974651173e-05
regulation O 0 7.636077725692303e-07
of O 0 6.568375710003238e-08
transmembrane O 0 1.6199195670196787e-05
carbonic O 0 5.457225415739231e-05
anhydrases O 0 9.746841533342376e-05
in O 0 7.306260158657096e-06
renal B-Disease 1 0.9999668598175049
cell I-Disease 1 0.9999642372131348
carcinoma I-Disease 1 1.0
cell O 1 0.5475539565086365
lines O 0 3.4410154512443114e-06
by O 0 4.7712596540350205e-08
wild O 0 2.603391067168559e-07
- O 0 8.008769509615377e-05
type O 0 4.9485744966659695e-05
von B-Disease 0 0.19975771009922028
Hippel I-Disease 0 0.4131157398223877
- I-Disease 0 0.013694977387785912
Lindau I-Disease 0 0.031254447996616364
transgenes O 0 0.00039463615394197404
. O 0 6.263845079956809e-06

To O 0 1.1238602382945828e-05
discover O 0 5.850130492035532e-06
genes O 0 1.1589007726797718e-06
involved O 0 3.335224789680069e-07
in O 0 6.84443989484862e-07
von B-Disease 1 0.9914612770080566
Hippel I-Disease 1 0.998939573764801
- I-Disease 1 0.9913246631622314
Lindau I-Disease 1 0.9690295457839966
( O 0 6.05910997819592e-07
VHL B-Disease 0 4.236986569594592e-05
) O 0 1.6365370925086609e-07
- O 0 7.874859875300899e-06
mediated O 0 6.811091589042917e-05
carcinogenesis O 0 0.000265696260612458
, O 0 6.854408951539881e-08
we O 0 3.600697695560484e-08
used O 0 7.159917731769383e-05
renal B-Disease 1 0.9999610185623169
cell I-Disease 1 0.9999852180480957
carcinoma I-Disease 1 1.0
cell O 1 0.8589299321174622
lines O 0 5.135888568474911e-05
stably O 0 5.454519487102516e-05
transfected O 0 0.0001237443066202104
with O 0 3.0856585908622947e-07
wild O 0 1.2277796486159787e-06
- O 0 0.00023264644551090896
type O 0 8.094362419797108e-05
VHL O 0 0.001160528976470232
- O 0 0.00030763071845285594
expressing O 0 3.187129186699167e-05
transgenes O 0 0.00019069330301135778
. O 0 7.936213478387799e-06

Large O 0 1.0640947039064486e-05
- O 0 1.6710153431631625e-05
scale O 0 1.3814067187922774e-06
RNA O 0 8.46575062496413e-07
differential O 0 2.1608932456729235e-06
display O 0 4.4562781909007754e-07
technology O 0 1.970180960597645e-07
applied O 0 1.367602209256802e-07
to O 0 2.2478332084574504e-08
these O 0 6.192191648324297e-09
cell O 0 5.109516223456012e-06
lines O 0 2.1422620193334296e-06
identified O 0 3.6428224348128424e-07
several O 0 2.7565310034560753e-08
differentially O 0 3.771775936911581e-06
expressed O 0 2.935294958206214e-07
genes O 0 4.0733134198944754e-08
, O 0 9.895037678120389e-09
including O 0 7.0615016056763125e-09
an O 0 6.096414040257514e-08
alpha O 0 2.083446815959178e-06
carbonic O 0 2.338231024623383e-05
anhydrase O 0 2.4421928173978813e-05
gene O 0 9.588322882336797e-07
, O 0 1.4707056550378184e-07
termed O 0 4.361444098321954e-06
CA12 O 0 0.0010696941753849387
. O 0 4.449268999451306e-06

The O 0 2.3658440113649704e-06
deduced O 0 5.320864147506654e-06
protein O 0 3.1100435649022984e-07
sequence O 0 4.939739639553409e-08
was O 0 1.4352536936712568e-07
classified O 0 4.795894170683823e-08
as O 0 1.548652583949206e-08
a O 0 1.7349255188037205e-07
one O 0 1.7674305752279906e-07
- O 0 3.284519334556535e-05
pass O 0 3.879002633766504e-06
transmembrane O 0 7.816081051714718e-06
CA O 0 6.618844281547354e-07
possessing O 0 5.115671442013081e-08
an O 0 2.3667972470775567e-08
apparently O 0 7.301895266209613e-07
intact O 0 7.328629436642586e-08
catalytic O 0 5.107579070795509e-08
domain O 0 2.822642919397822e-08
in O 0 7.304832294607877e-09
the O 0 2.1725249155224446e-08
extracellular O 0 1.5721248018962797e-06
CA O 0 2.535923704272136e-05
module O 0 9.92265049717389e-05
. O 0 3.0205353596102213e-06

Reintroduced O 0 0.000211386926821433
wild O 0 1.4350636774906889e-05
- O 0 0.00041448697447776794
type O 0 2.1288740754243918e-05
VHL B-Disease 0 0.00012205255188746378
strongly O 0 2.588326651675743e-06
inhibited O 0 7.081816875142977e-07
the O 0 3.052586805551982e-08
overexpression O 0 1.2041826948916423e-06
of O 0 9.897943797909647e-09
the O 0 3.0636812198281405e-08
CA12 O 0 9.452299127588049e-05
gene O 0 2.0435614089819865e-07
in O 0 2.4263417941483567e-08
the O 0 1.7737896484959492e-07
parental O 1 0.7522577047348022
renal B-Disease 1 0.9999971389770508
cell I-Disease 1 0.9999954700469971
carcinoma I-Disease 1 1.0
cell O 1 0.9792182445526123
lines O 0 0.00016260718984995037
. O 0 4.757302122015972e-06

Similar O 0 0.00014094490325078368
results O 0 2.651435170264449e-05
were O 0 7.151000431804277e-07
obtained O 0 4.990228603674041e-07
with O 0 3.48978034026004e-07
CA9 O 0 0.09847057610750198
, O 0 1.3118528841005173e-07
encoding O 0 1.6747394226968026e-07
another O 0 3.50470884313836e-07
transmembrane O 0 4.369196176412515e-06
CA O 0 8.419542609772179e-07
with O 0 2.0113967380552822e-08
an O 0 8.682817309590973e-08
intact O 0 2.2834419723949395e-06
catalytic O 0 1.7031903780662105e-06
domain O 0 1.073937369255873e-06
. O 0 8.601625154369685e-07

Although O 0 5.596461505774641e-06
both O 0 1.1456335613502233e-07
domains O 0 5.450009865626271e-08
of O 0 9.98833105114727e-09
the O 0 5.071022712854756e-08
VHL B-Disease 0 8.063716086326167e-05
protein O 0 2.7581489803196746e-07
contribute O 0 3.2050934350991156e-08
to O 0 1.4662907332763098e-08
regulation O 0 4.174954781888118e-08
of O 0 1.3166327583746806e-08
CA12 O 0 0.0031894936691969633
expression O 0 5.430869123301818e-07
, O 0 1.4532990810778301e-08
the O 0 6.7764105438072875e-09
elongin O 0 3.2139660106622614e-06
binding O 0 2.2591724757603515e-07
domain O 0 8.498489023622824e-08
alone O 0 2.7185853923583636e-07
could O 0 7.858513129122002e-08
effectively O 0 9.192350489684031e-07
regulate O 0 1.109581262426218e-05
CA9 O 0 0.00883114617317915
expression O 0 2.01154725800734e-05
. O 0 3.3393353078281507e-06

We O 0 4.655408247344894e-06
mapped O 0 2.2328118575387634e-05
CA12 O 0 0.0002731072308961302
and O 0 8.154696615747525e-07
CA9 O 0 0.00047387147787958384
loci O 0 1.009530251394608e-06
to O 0 1.649479628440531e-07
chromosome O 0 5.84724648433621e-06
bands O 0 1.2374044899843284e-06
15q22 O 0 1.2926565432280768e-05
and O 0 4.793919288204052e-07
17q21 O 0 5.835945557919331e-05
. O 0 3.5071034290012904e-06

2 O 0 3.294784255558625e-05
respectively O 0 3.391391601326177e-06
, O 0 7.418680780801878e-08
regions O 0 5.5209461891081446e-08
prone O 0 3.419577979002497e-06
to O 0 2.2374908326128207e-07
amplification O 0 1.9639484889921732e-05
in O 0 2.4666280751262093e-07
some O 0 2.339246094607006e-07
human O 0 6.866879175504437e-06
cancers B-Disease 0 0.03060472197830677
. O 0 9.800328371056821e-06

Additional O 0 1.2843166587117594e-05
experiments O 0 6.031648354110075e-06
are O 0 7.144634395217508e-08
needed O 0 1.5366281047590746e-07
to O 0 2.9862793127222176e-08
define O 0 9.105382048346655e-08
the O 0 1.2927340087287575e-08
role O 0 5.9125003559756806e-08
of O 0 1.6986996698165058e-08
CA O 0 3.2686835766071454e-05
IX O 0 0.00936933048069477
and O 0 3.3793101010815008e-06
CA O 0 6.17091209278442e-05
XII O 0 0.0005748738767579198
enzymes O 0 1.2440693808457581e-07
in O 0 4.558604604909533e-09
the O 0 3.6191074581637395e-09
regulation O 0 2.443996116596736e-08
of O 0 7.898678155981997e-09
pH O 0 3.283991418356891e-06
in O 0 9.954933766209706e-09
the O 0 9.046521753930392e-09
extracellular O 0 1.3582101132669777e-07
microenvironment O 0 4.015006197732873e-06
and O 0 1.9055221400776645e-08
its O 0 1.872419375104073e-08
potential O 0 7.164653226254813e-08
impact O 0 3.0348894597409526e-07
on O 0 6.349524483084679e-05
cancer B-Disease 0 0.04758496955037117
cell O 0 5.1792882004519925e-05
growth O 0 2.567283218013472e-06
. O 0 1.553923084429698e-06

A O 0 2.8811196898459457e-05
gene O 0 7.11343909642892e-06
encoding O 0 1.3848916751157958e-06
a O 0 1.0319448620066396e-06
transmembrane O 0 5.236519882600987e-06
protein O 0 1.2076300492935843e-07
is O 0 2.986142533245584e-08
mutated O 0 2.2339224869938334e-06
in O 0 1.0599577535685967e-06
patients O 0 0.008187863044440746
with O 1 0.563284158706665
diabetes B-Disease 1 1.0
mellitus I-Disease 1 0.9999998807907104
and O 1 0.8894430994987488
optic B-Disease 1 0.9999985694885254
atrophy I-Disease 1 0.9999549388885498
( O 0 0.04231463372707367
Wolfram B-Disease 1 0.9999994039535522
syndrome I-Disease 1 1.0
) O 0 1.6736978068365715e-05
. O 0 8.744018487050198e-06

Wolfram B-Disease 1 0.9999979734420776
syndrome I-Disease 1 1.0
( O 0 0.02041400969028473
WFS B-Disease 1 0.9966576099395752
; O 0 0.0012214896269142628
OMIM O 1 0.765023410320282
222300 O 0 0.00011559712584130466
) O 0 1.8168896076531382e-07
is O 0 1.3387914066242956e-07
an O 0 7.1953277256398e-06
autosomal B-Disease 1 0.9999216794967651
recessive I-Disease 1 0.9999969005584717
neurodegenerative I-Disease 1 0.9999994039535522
disorder I-Disease 1 0.9999487400054932
defined O 0 1.8510834252083441e-06
by O 0 2.2208577377114125e-07
young O 0 3.85440762329381e-06
- O 0 0.00045451390906237066
onset O 0 9.378729009767994e-05
non O 0 2.1711077806685353e-06
- O 0 0.06258923560380936
immune O 0 0.005999932065606117
insulin B-Disease 1 0.8879381418228149
- I-Disease 1 0.9499699473381042
dependent I-Disease 1 0.5138117671012878
diabetes I-Disease 1 0.9999994039535522
mellitus I-Disease 1 0.9999971389770508
and O 0 0.00024551176466047764
progressive O 1 0.9889553189277649
optic B-Disease 1 0.9999914169311523
atrophy I-Disease 1 0.9968679547309875
. O 0 3.701595414895564e-05

Linkage O 0 0.00015322539547923952
to O 0 2.318480937901768e-06
markers O 0 8.573169907322153e-06
on O 0 2.495930402801605e-06
chromosome O 0 0.00030996324494481087
4p O 0 0.0224191602319479
was O 0 5.596642949967645e-06
confirmed O 0 1.2251549605934997e-06
in O 0 1.9519273308787888e-08
five O 0 1.79850559334227e-07
families O 0 3.107360555532068e-07
. O 0 1.0269466201862087e-06

On O 0 9.949447985491133e-07
the O 0 4.0448998817055326e-08
basis O 0 1.3819526856195807e-08
of O 0 5.136748804090985e-09
meiotic O 0 1.4466237189481035e-05
recombinants O 0 0.042576149106025696
and O 0 6.163984653539956e-05
disease O 0 0.000372227601474151
- O 0 0.045965682715177536
associated O 0 2.3047132344800048e-05
haplotypes O 0 0.00011420620285207406
, O 0 1.2825815076666913e-07
the O 0 6.465260327104261e-08
WFS B-Disease 0 0.00022426724899560213
gene O 0 5.56861550649046e-07
was O 0 3.340595355894038e-07
localized O 0 2.7660723844746826e-07
to O 0 1.4117144075953547e-07
a O 0 3.2550528885622043e-06
BAC O 0 0.001700270688161254
/ O 0 6.97386485626339e-06
P1 O 0 2.5803668904700316e-05
contig O 0 5.652696927427314e-06
of O 0 2.1389737980825885e-08
less O 0 1.184892539640714e-07
than O 0 9.482340601607575e-08
250 O 0 3.7665387253582594e-07
kb O 0 0.00016788803623057902
. O 0 1.8095212226398871e-06

Mutations O 0 0.15712693333625793
in O 0 3.098086381214671e-06
a O 0 2.9626892228407087e-06
novel O 0 7.863715836720075e-06
gene O 0 1.0195847153227078e-06
( O 0 5.6139565884905096e-08
WFS1 O 0 1.6440048057120293e-05
) O 0 1.663681459262989e-08
encoding O 0 4.6788681373755026e-08
a O 0 9.087598584756051e-08
putative O 0 1.6205354995690868e-06
transmembrane O 0 8.082367344286467e-07
protein O 0 4.43897256729997e-08
were O 0 1.5808426567787137e-08
found O 0 1.6180194961634697e-08
in O 0 5.161183036506145e-09
all O 0 6.694066190249259e-09
affected O 0 7.76839641503102e-08
individuals O 0 1.0330349020648555e-08
in O 0 4.4963805123643397e-08
six O 0 3.4070649235218298e-06
WFS B-Disease 0 0.08606088161468506
families O 0 3.4680820704124926e-07
, O 0 1.3539986909449908e-08
and O 0 8.901122505733383e-09
these O 0 1.0968508767916774e-08
mutations O 0 5.376629701459024e-07
were O 0 7.862892204002492e-08
associated O 0 5.23963414877926e-08
with O 0 2.5485337573627476e-07
the O 0 4.988165164832026e-05
disease O 1 0.7252443432807922
phenotype O 1 0.8231321573257446
. O 0 1.2030487596348394e-05

WFS1 O 0 0.11848056316375732
appears O 0 6.561483314726502e-05
to O 0 5.401066687227285e-07
function O 0 1.1719293979695067e-07
in O 0 6.680637198996919e-08
survival O 0 1.6298021137117757e-06
of O 0 1.8761442177606114e-08
islet O 0 2.0639477952499874e-05
beta O 0 6.602099915653525e-07
- O 0 9.397996109328233e-06
cells O 0 5.624480650112673e-07
and O 0 1.3067484871953639e-07
neurons O 0 2.5632073175074765e-06
. O 0 1.768216151276647e-07
. O 0 5.898808694837498e-07

Stable O 0 0.000207477729418315
interaction O 0 1.9019365709027625e-06
between O 0 1.0727944044219839e-07
the O 0 1.581463848765452e-08
products O 0 1.3489488637219438e-08
of O 0 2.9345006424819076e-09
the O 0 4.7261359270578396e-08
BRCA1 O 0 0.0002453793422318995
and O 0 6.189329269545851e-06
BRCA2 O 0 0.016075707972049713
tumor B-Disease 0 6.341052358038723e-05
suppressor O 0 2.1303058019839227e-05
genes O 0 3.2366642699344084e-07
in O 0 4.146306409325007e-08
mitotic O 0 4.59913098893594e-06
and O 0 1.4704800150866504e-06
meiotic O 0 0.00043342114076949656
cells O 0 0.00012903381139039993
. O 0 6.048179784556851e-06

BRCA1 O 1 0.9717498421669006
and O 0 8.778298069955781e-05
BRCA2 O 0 0.01966106705367565
account O 0 1.4913620134393568e-06
for O 0 6.003730135262231e-08
most O 0 6.848815559123977e-08
cases O 0 6.395046625584655e-08
of O 0 1.721193854109515e-08
familial O 0 0.00014284125063568354
, O 0 1.2310930515013752e-06
early O 0 1.4893686966388486e-05
onset O 0 0.0034130821004509926
breast B-Disease 1 0.5875981450080872
and I-Disease 0 4.737105336971581e-05
/ I-Disease 0 0.33778277039527893
or I-Disease 0 0.2769050598144531
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999984502792358
and O 0 1.7958745957002975e-07
encode O 0 2.2199260740762838e-07
products O 0 4.071744541533917e-08
that O 0 9.446090132314566e-09
each O 0 8.128963280285006e-09
interact O 0 5.289166082889096e-08
with O 0 1.1777443376104202e-07
hRAD51 O 0 8.414081821683794e-05
. O 0 3.6995572827436263e-06

Results O 0 0.00018944610201288015
presented O 0 4.748870651383186e-06
here O 0 2.070596281100734e-07
show O 0 4.063862206749036e-07
that O 0 1.136360481268639e-07
BRCA1 O 0 6.40728248981759e-05
and O 0 9.174237675324548e-06
BRCA2 O 0 0.02721090242266655
coexist O 0 1.634811815165449e-05
in O 0 7.571756555080356e-08
a O 0 5.971000973659102e-07
biochemical O 0 2.527013975850423e-06
complex O 0 3.260581991071376e-07
and O 0 8.07934839031077e-08
colocalize O 0 1.1848968824779149e-05
in O 0 6.191497448071459e-08
subnuclear O 0 1.5143713426368777e-05
foci O 0 2.1098296656418825e-06
in O 0 4.192094849031491e-08
somatic O 0 1.694894308457151e-06
cells O 0 3.754933004529448e-07
and O 0 1.1077794681568776e-08
on O 0 2.3215283917465968e-08
the O 0 1.1628067397850828e-08
axial O 0 1.406440219398064e-06
elements O 0 7.122184797481168e-08
of O 0 1.4642449919222145e-08
developing O 0 6.131129453024187e-07
synaptonemal O 0 0.00033813074696809053
complexes O 0 1.6715923266019672e-05
. O 0 2.1350460883695632e-06

Like O 0 5.790896830148995e-05
BRCA1 O 0 0.0011577046243473887
and O 0 5.815558324684389e-06
RAD51 O 0 0.022396627813577652
, O 0 3.7173606415308313e-06
BRCA2 O 0 8.084921137196943e-05
relocates O 0 2.144648169633001e-05
to O 0 1.8673835029403563e-06
PCNA O 0 0.00029048911528661847
+ O 0 8.611318662588019e-07
replication O 0 1.1368298657998821e-07
sites O 0 4.2493642382623875e-08
following O 0 3.6357349131321826e-08
exposure O 0 1.6863558016666502e-07
of O 0 8.967462328257625e-09
S O 0 0.00014036401989869773
phase O 0 2.407833108009072e-06
cells O 0 5.18489628120733e-07
to O 0 2.4866403691703454e-07
hydroxyurea O 0 0.00020479786326177418
or O 0 8.355822274097591e-07
UV O 0 0.0027121645398437977
irradiation O 0 0.0002118370757671073
. O 0 4.891081061941804e-06

Thus O 0 4.9121506890514866e-05
, O 0 2.571046479715733e-06
BRCA1 O 0 6.317766383290291e-05
and O 0 1.3601080581793212e-06
BRCA2 O 0 0.00014140934217721224
participate O 0 9.31203345544418e-08
, O 0 3.588192498682474e-08
together O 0 4.5488619093703164e-08
, O 0 1.9803563233722343e-08
in O 0 8.799989181795809e-09
a O 0 4.240430087065761e-07
pathway O 0 6.048775844647025e-07
( O 0 3.673872939202738e-08
s O 0 2.290029988216702e-05
) O 0 2.7024208648640524e-08
associated O 0 1.6202275077148443e-08
with O 0 2.2012291989170762e-09
the O 0 3.44592820944456e-09
activation O 0 1.721896403239498e-08
of O 0 2.550447852911475e-09
double O 0 1.4110886468188255e-06
- O 0 0.00012045421317452565
strand O 0 3.240628575440496e-05
break O 0 1.624038077352452e-06
repair O 0 1.4378059859154746e-05
and O 0 2.3248546199283737e-07
/ O 0 1.4801712495682295e-06
or O 0 6.444761169177582e-08
homologous O 0 1.0853341336769518e-06
recombination O 0 5.2620653150370345e-06
. O 0 4.265627921995474e-06

Dysfunction O 0 0.21027199923992157
of O 0 1.2468931345210876e-06
this O 0 4.852130928156839e-07
pathway O 0 1.9469357539492194e-06
may O 0 8.68535778408841e-07
be O 0 9.73290070760413e-09
a O 0 8.971605325314158e-08
general O 0 1.3104525464768813e-07
phenomenon O 0 2.091621951194611e-07
in O 0 8.321815236911334e-09
the O 0 1.1900821661470218e-08
majority O 0 1.4961470640173502e-07
of O 0 5.868925789798141e-09
cases O 0 1.0114347048784111e-07
of O 0 1.0250195714434085e-07
hereditary B-Disease 1 0.9995217323303223
breast I-Disease 1 0.9989314675331116
and I-Disease 0 0.005428034346550703
/ I-Disease 1 0.9173179864883423
or I-Disease 0 0.4217909276485443
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999988079071045
. O 0 3.650209009720129e-06
. O 0 3.1072588626557263e-06

A O 0 5.3305007895687595e-05
novel O 0 3.0689760023960844e-05
Arg362Ser O 0 6.308868614723906e-05
mutation O 0 4.948659807268996e-06
in O 0 1.9363161740670876e-08
the O 0 3.832425576888454e-08
sterol O 0 0.00022324516612570733
27 O 0 7.43251393942046e-06
- O 0 2.1319725419743918e-05
hydroxylase O 0 8.947739843279123e-05
gene O 0 2.7831791271637485e-07
( O 0 1.718359676772252e-08
CYP27 O 0 6.092605872254353e-06
) O 0 1.4837956641144956e-08
: O 0 7.731615347950083e-09
its O 0 9.540898737725456e-09
effects O 0 1.3051169389655115e-07
on O 0 7.688178982334648e-08
pre O 0 6.523677598124777e-07
- O 0 7.742345928818395e-07
mRNA O 0 9.110836884929085e-08
splicing O 0 5.669037363986718e-07
and O 0 3.5946452925372796e-08
enzyme O 0 3.0429811204157886e-07
activity O 0 1.4065727782508475e-07
. O 0 5.908599405302084e-07

A O 0 0.0001204856889671646
novel O 0 3.6537370760925114e-05
C O 0 4.483146312850295e-06
to O 0 7.175771798983988e-08
A O 0 1.4732129329786403e-06
mutation O 0 1.0423590310892905e-06
in O 0 2.5957618277061556e-08
the O 0 3.60759955242429e-08
sterol O 0 0.00012831554340664297
27 O 0 8.53798701427877e-06
- O 0 3.417492553126067e-05
hydroxylase O 0 0.0001357776636723429
gene O 0 8.21660933070234e-07
( O 0 2.918126007500632e-08
CYP27 O 0 2.1037434635218233e-05
) O 0 4.816915222249918e-08
was O 0 5.299203849062906e-07
identified O 0 7.163136217513966e-08
by O 0 7.973681270811994e-09
sequencing O 0 1.2326914600180316e-07
amplified O 0 8.00183079263661e-06
CYP27 O 0 5.497335223481059e-05
gene O 0 3.1044132242641354e-07
products O 0 3.5503010309412275e-08
from O 0 1.1663184196208931e-08
a O 0 7.842504601285327e-07
patient O 0 7.199586980277672e-05
with O 0 1.4650247067038435e-05
cerebrotendinous B-Disease 1 0.9999933242797852
xanthomatosis I-Disease 1 0.9999690055847168
( O 0 3.6239625842426904e-06
CTX B-Disease 0 0.02790914848446846
) O 0 1.951441618075478e-06
. O 0 2.7934859190281713e-06

The O 0 4.7655298658355605e-06
mutation O 0 2.0554603906930424e-05
changed O 0 4.079631423792307e-07
the O 0 1.731397603066398e-08
adrenodoxin O 0 3.910663963324623e-06
cofactor O 0 2.0170632524241228e-06
binding O 0 3.3365611784574867e-07
residue O 0 5.90974877923145e-07
362Arg O 0 1.8260108163303812e-06
to O 0 1.3117903563397704e-07
362Ser O 0 4.84470456285635e-06
( O 0 6.389522866356856e-08
CGT O 0 2.8562915304064518e-06
362Arg O 0 3.838944849121617e-06
to O 0 2.9350292152230395e-07
AGT O 0 5.237689401837997e-05
362Ser O 0 1.1411869309085887e-05
) O 0 2.5597136854571545e-08
, O 0 1.6176583628180197e-08
and O 0 3.261893510853042e-08
was O 0 3.3445621738792397e-06
responsible O 0 6.955712592571217e-07
for O 0 6.765746093151392e-06
deficiency O 0 0.0025718831457197666
in O 0 2.0073112949603455e-08
the O 0 4.46913119844794e-08
sterol O 0 0.00012321103713475168
27 O 0 2.4722146463318495e-06
- O 0 1.6599038872300298e-06
hydroxylase O 0 3.791676363107399e-06
activity O 0 1.1714171854748656e-08
, O 0 4.259448793675347e-09
as O 0 1.0481726597788565e-08
confirmed O 0 1.1152169321348993e-07
by O 0 5.2260871186149416e-09
expression O 0 9.36800415018979e-09
of O 0 1.778154401499421e-09
mutant O 0 1.1692166168586482e-07
cDNA O 0 1.3630605621983705e-07
into O 0 6.394058260639213e-08
COS O 0 5.8564546634443104e-06
- O 0 1.9067538232775405e-05
1 O 0 1.5824646197870607e-06
cells O 0 1.546972043797723e-06
. O 0 8.178482175935642e-07

Quantitative O 0 4.852023266721517e-05
analysis O 0 9.551929906592704e-06
showed O 0 6.6523534769658e-06
that O 0 3.0558140906578046e-08
the O 0 7.64611662873449e-09
expression O 0 2.8934405094105387e-08
of O 0 6.444696776242154e-09
CYP27 O 0 2.34663239098154e-05
gene O 0 1.0774328984552994e-07
mRNA O 0 3.2219674039879465e-08
in O 0 6.822189924093891e-09
the O 0 1.7252890671670684e-08
patient O 0 3.6454744076763745e-06
represented O 0 4.931615649184096e-07
52 O 0 1.3358825526665896e-05
. O 0 2.2449855805461993e-06

5 O 0 2.028867311310023e-05
% O 0 7.266882562362298e-07
of O 0 9.50975920233077e-09
the O 0 3.055581032640475e-08
normal O 0 4.2426106006132613e-07
level O 0 4.782202154274273e-07
. O 0 1.5906335875115474e-06

As O 0 3.094513431278756e-06
the O 0 2.730529615746491e-07
mutation O 0 1.645493284740951e-06
occurred O 0 1.8781480548568652e-07
at O 0 9.705945380744652e-09
the O 0 8.509660531785812e-09
penultimate O 0 9.583934570400743e-07
nucleotide O 0 1.908669133854346e-07
of O 0 1.2183413389266207e-08
exon O 0 8.563083042645303e-07
6 O 0 1.5464040359347564e-07
( O 0 8.391596750811914e-09
- O 0 3.7279363596098847e-07
2 O 0 6.315708844795154e-08
position O 0 6.726577339577489e-08
of O 0 4.342108894661578e-09
exon O 0 6.498486300188233e-07
6 O 0 1.0579647380382085e-07
- O 0 1.2917846561322222e-06
intron O 0 2.2831609385320917e-05
6 O 0 2.7908126298825664e-07
splice O 0 7.252744467223238e-07
site O 0 9.530172206950738e-08
) O 0 2.4190718317385063e-09
of O 0 6.308780720054585e-10
the O 0 2.5349915500072484e-09
gene O 0 5.447557427373795e-08
, O 0 1.3614957161678376e-08
we O 0 1.0833177022107066e-08
hypothesized O 0 2.385308448538126e-07
that O 0 1.347120814898517e-08
the O 0 6.178791522870597e-08
mutation O 0 5.734074420615798e-06
may O 0 1.6688736650394276e-06
partially O 0 1.5476006183234858e-06
affect O 0 2.9076309360220876e-08
the O 0 6.932717067087424e-09
normal O 0 4.144780518799962e-08
splicing O 0 2.593508270365419e-07
efficiency O 0 1.363385564445707e-07
in O 0 3.974222551050843e-08
exon O 0 1.5381262983282795e-06
6 O 0 1.6202713482016406e-07
and O 0 5.150457482727688e-08
cause O 0 3.434581969941064e-07
alternative O 0 3.2116022907757724e-07
splicing O 0 4.012713816337055e-06
elsewhere O 0 4.48191855184632e-07
, O 0 1.840502150685097e-08
which O 0 2.8167594479100444e-08
resulted O 0 2.521491069273907e-07
in O 0 1.9745938573123567e-07
decreased O 0 8.513319698977284e-06
transcript O 0 1.2783377314917743e-05
in O 0 7.122496725742167e-08
the O 0 3.361117535405356e-07
patient O 0 0.00014622422168031335
. O 0 3.6108187941863434e-06

Transfection O 0 0.001486737746745348
of O 0 2.5257322704419494e-06
constructed O 0 1.8802762497216463e-05
minigenes O 0 0.0003726583090610802
, O 0 1.700136351701076e-07
with O 0 2.911243512926376e-08
or O 0 2.0253480670362478e-08
without O 0 2.2310807423764345e-08
the O 0 2.0930778887873203e-08
mutation O 0 3.5750122151512187e-07
, O 0 8.452285094051604e-09
into O 0 1.8839974913476e-08
COS O 0 5.704131126549328e-06
- O 0 1.8888293197960593e-05
1 O 0 3.1519658705292386e-07
cells O 0 1.3296225631620473e-07
confirmed O 0 6.068871272191245e-08
that O 0 2.370202034640556e-09
the O 0 2.739024784759181e-09
mutant O 0 1.056961764334119e-06
minigene O 0 4.602500666806009e-06
was O 0 2.3078933963915915e-07
responsible O 0 1.9066128231770563e-08
for O 0 2.752126970761992e-09
a O 0 1.3176909874346165e-07
mRNA O 0 2.2170529234699643e-07
species O 0 1.7149609732314275e-08
alternatively O 0 1.7170827959489543e-07
spliced O 0 6.759296866221121e-06
at O 0 2.500532225724328e-08
an O 0 5.612436027035983e-08
activated O 0 5.461702585307648e-06
cryptic O 0 4.827400516660418e-06
5 O 0 1.187015499226618e-07
splice O 0 1.0680796549422666e-06
site O 0 2.8101808879910095e-07
88 O 0 5.257263069324836e-07
bp O 0 1.5219110309772077e-06
upstream O 0 1.0449273446511143e-07
from O 0 6.277348418848305e-09
the O 0 5.236763911398157e-09
3 O 0 2.562546796980314e-08
end O 0 1.732028387380069e-08
of O 0 2.3102863622170844e-08
exon O 0 7.346581696765497e-06
6 O 0 3.07564528156945e-06
. O 0 1.0170074347115587e-06

Our O 0 3.9152168938016985e-06
data O 0 9.579283641869552e-07
suggest O 0 2.1216425238890224e-07
that O 0 1.2283981831728852e-08
the O 0 7.3569026426412165e-09
C O 0 1.1805229860328836e-07
to O 0 2.0887789276002877e-08
A O 0 1.8237760741612874e-06
mutation O 0 4.425851898304245e-07
at O 0 5.389760193708071e-09
the O 0 2.855783165500725e-09
penultimate O 0 5.182968152439571e-07
nucleotide O 0 5.134391045658049e-08
of O 0 3.4275737803568518e-09
exon O 0 6.34016203093779e-07
6 O 0 2.7407820013536366e-08
of O 0 1.0057241706107334e-09
the O 0 1.078275424504227e-08
CYP27 O 0 6.324861897155643e-05
gene O 0 1.2030963603137934e-07
not O 0 2.9731847206448947e-08
only O 0 7.170189775251856e-08
causes O 0 7.14262341716676e-07
the O 0 2.155083393517998e-06
deficiency B-Disease 0 0.02060539461672306
in I-Disease 0 3.0997831856893754e-08
the I-Disease 0 4.522260255157562e-08
sterol I-Disease 0 0.00015265286492649466
27 I-Disease 0 1.447540171284345e-06
- I-Disease 0 1.220745161845116e-06
hydroxylase I-Disease 0 4.190115305391373e-06
activity I-Disease 0 1.5140480869035855e-08
, O 0 9.577876269872831e-09
but O 0 3.6064161434978814e-08
also O 0 2.5041913431778084e-07
partially O 0 1.8875134628615342e-06
leads O 0 7.71969794755023e-08
to O 0 1.2893260681323682e-08
alternative O 0 3.142783455700737e-08
pre O 0 1.1612844730279903e-07
- O 0 2.124758822219519e-07
mRNA O 0 4.207402781730707e-08
splicing O 0 1.4094948141973873e-07
of O 0 5.268040226269477e-09
the O 0 3.542501758602157e-08
gene O 0 1.8828642396329087e-06
. O 0 9.593380809747032e-07

To O 0 1.5511217270613997e-06
our O 0 1.6389049051213078e-07
knowledge O 0 4.958297949997359e-08
, O 0 1.2241414104607884e-08
this O 0 6.6534857623423704e-09
is O 0 7.4522610304939e-09
the O 0 4.7912016576390215e-09
first O 0 1.4917817736659345e-07
report O 0 6.264719587534273e-08
regarding O 0 1.7668668306214386e-08
effects O 0 1.3038653889907437e-07
on O 0 4.5483758981390565e-08
pre O 0 4.487975218125939e-07
- O 0 5.207959929975914e-07
mRNA O 0 3.546159277334482e-08
splicing O 0 5.5688126110453595e-08
of O 0 1.3955936406517822e-09
a O 0 3.9976001176000864e-08
mutation O 0 1.4312568907826062e-07
at O 0 5.023875981891024e-09
the O 0 7.648057298581534e-09
- O 0 4.063023880007677e-06
2 O 0 1.0085719992503073e-07
position O 0 4.647932527745979e-08
of O 0 1.2845191577071091e-09
a O 0 1.3827205691541167e-07
5 O 0 2.1124701277130953e-07
splice O 0 7.272176844708156e-06
site O 0 2.4902005861804355e-06
. O 0 8.366068300347251e-07

ATM O 0 0.002738673472777009
germline O 0 0.23127782344818115
mutations O 0 0.2551380395889282
in O 0 1.90516329894308e-05
classical O 0 0.02965562604367733
ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999992847442627
telangiectasia I-Disease 1 0.9999997615814209
patients O 1 0.9991173148155212
in O 0 3.649613518064143e-07
the O 0 1.537008955665442e-07
Dutch O 0 0.0011940115364268422
population O 0 9.735213097883388e-07
. O 0 1.2517732557171257e-06

Germline O 1 0.5718457698822021
mutations O 0 0.277915358543396
in O 0 1.294036110266461e-06
the O 0 1.3778934260244569e-07
ATM O 0 2.3745078578940593e-06
gene O 0 3.065098894694529e-07
are O 0 6.9544636716045716e-09
responsible O 0 7.077496633201008e-08
for O 0 1.5237307593451987e-07
the O 0 0.00881967507302761
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
telangiectasia I-Disease 1 0.9999995231628418
( O 0 6.437157571781427e-05
A B-Disease 1 0.9999483823776245
- I-Disease 1 0.9999749660491943
T I-Disease 1 0.9999926090240479
) O 0 1.3689505067304708e-06
. O 0 1.7386436184096965e-06

In O 0 3.087432787651778e-06
our O 0 1.4348293575494608e-07
study O 0 6.447145750598793e-08
, O 0 1.2388287728981595e-08
we O 0 6.1029732378869994e-09
have O 0 1.219904000038241e-08
determined O 0 4.676494924638064e-08
the O 0 9.865864569746918e-09
ATM O 0 1.2388946970531833e-06
mutation O 0 5.875351689610397e-07
spectrum O 0 2.100240834579381e-07
in O 0 1.2435350527084665e-08
19 O 0 1.2797224258065398e-07
classical O 0 9.199401915793715e-07
A B-Disease 1 0.9999586343765259
- I-Disease 1 0.9999983310699463
T I-Disease 1 1.0
patients O 1 0.6336042284965515
, O 0 2.8842828569963785e-08
including O 0 7.0685359787603375e-09
some O 0 1.1691247969736196e-08
immigrant O 0 3.009149850186077e-06
populations O 0 3.018773142571263e-08
, O 0 1.1134926758415986e-08
as O 0 7.668901957913477e-09
well O 0 6.44420516948685e-09
as O 0 1.0938215666556061e-08
12 O 0 1.7210229685815648e-08
of O 0 7.092682885456725e-09
Dutch O 0 2.6186195100308396e-05
ethnic O 0 8.208761528294417e-07
origin O 0 8.501049251208315e-07
. O 0 1.0951783906421042e-06

Both O 0 1.367288291476143e-06
the O 0 6.772989280534603e-08
protein O 0 1.4301707551567233e-07
truncation O 0 1.2651174756683758e-06
test O 0 1.2766216741511016e-06
( O 0 3.001726511797642e-08
PTT O 0 2.2249755602388177e-06
) O 0 1.0314677112432946e-08
and O 0 6.0189311312797145e-09
the O 0 7.899100040731355e-09
restriction O 0 2.749353598119342e-07
endonuclease O 0 1.4436977835430298e-05
fingerprinting O 0 7.928043487481773e-06
( O 0 5.264768176971302e-08
REF O 0 1.560172859171871e-05
) O 0 6.408475528019153e-09
method O 0 1.833148388641348e-08
were O 0 2.3355273270908583e-08
used O 0 4.713280787882468e-08
and O 0 6.542593666836183e-08
compared O 0 1.359948242907194e-07
for O 0 6.054163392832379e-09
their O 0 1.0644981784935226e-08
detection O 0 1.0946421014068619e-07
efficiency O 0 2.613699905396061e-07
, O 0 2.1423707252665736e-08
identifying O 0 4.478013337916309e-08
76 O 0 1.244804479938466e-06
% O 0 1.2762994217041523e-08
and O 0 9.154765834296086e-09
60 O 0 5.084445930947368e-08
% O 0 4.437133327428455e-09
of O 0 1.1904266461471025e-09
the O 0 1.065554897650145e-07
mutations O 0 8.674474884173833e-06
, O 0 1.4423422101117467e-07
respectively O 0 2.352333694943809e-06
. O 0 1.6007380736482446e-06

Most O 0 0.0004223657015245408
patients O 0 0.013665682636201382
were O 0 8.510004363415646e-07
found O 0 1.550036188291415e-07
to O 0 9.787056143295558e-08
be O 0 2.813608261931222e-07
compound O 0 2.2694221115671098e-05
heterozygote O 0 0.00025030894903466105
. O 0 4.086429271410452e-06

Seventeen O 0 0.00042319350177422166
mutations O 0 0.0006450882647186518
were O 0 1.3274018328957027e-06
distinct O 0 1.7297281829087297e-07
, O 0 1.6722074391850583e-08
of O 0 2.8865048129489423e-09
which O 0 6.288663456643917e-08
10 O 0 3.47816033752224e-08
were O 0 6.73019684427345e-08
not O 0 1.9259336170307506e-07
reported O 0 7.057463790260954e-06
previously O 0 2.6863719995162683e-06
. O 0 1.56021462771605e-06

Mutations O 0 0.15039017796516418
are O 0 2.1601720163744176e-06
small O 0 4.0906064668888575e-07
deletions O 0 8.606724804849364e-06
or O 0 2.681406670035358e-07
point O 0 7.40878192573291e-07
mutations O 0 4.80197741126176e-06
frequently O 0 1.3503012041837792e-06
affecting O 0 9.388378998664848e-07
splice O 0 2.7861060516443104e-05
sites O 0 1.971618075913284e-06
. O 0 2.129171662090812e-06

Moreover O 0 0.00013995547487866133
, O 0 2.227072855021106e-06
a O 0 3.698082764458377e-06
16 O 0 6.040329026291147e-06
. O 0 2.3580682864121627e-06

7 O 0 6.795430090278387e-05
- O 0 3.472271782811731e-05
kb O 0 2.2631393221672624e-05
genomic O 0 1.6384435639338335e-06
deletion O 0 2.619311771923094e-06
of O 0 1.72122653907536e-08
the O 0 1.931410409383716e-08
3 O 0 5.5161986978191635e-08
end O 0 2.0715910764579348e-08
of O 0 2.614802152578477e-09
the O 0 8.031453724299809e-09
gene O 0 4.732342162583336e-08
, O 0 1.0700719421663507e-08
most O 0 1.042695085828882e-08
likely O 0 8.425311648352363e-08
a O 0 7.357115805461945e-08
result O 0 2.1185867282724757e-08
of O 0 1.8251964384319308e-09
recombination O 0 6.36174846135873e-08
between O 0 1.4901969436209583e-08
two O 0 4.2209304496054756e-08
LINE O 0 1.476122747590125e-06
elements O 0 1.4707001128044794e-07
, O 0 1.4827578809217812e-07
was O 0 4.62187199445907e-06
identified O 0 2.443433686494245e-06
. O 0 1.0095552624989068e-06

The O 0 2.7197181680094218e-06
most O 0 5.347824867385498e-07
frequently O 0 8.740256021155801e-07
found O 0 2.3469999632652616e-07
mutation O 0 9.305568369200046e-07
, O 0 4.831140287819835e-08
identified O 0 1.2554994555102894e-07
in O 0 1.490384704538883e-08
three O 0 7.628887743749146e-08
unrelated O 0 1.8408765072308597e-06
Turkish O 0 0.002429795917123556
A B-Disease 1 0.9999419450759888
- I-Disease 1 0.9999475479125977
T I-Disease 1 0.9999984502792358
individuals O 0 7.539246382748388e-08
, O 0 5.0892001723923386e-08
was O 0 2.0562463305395795e-06
previously O 0 5.66781523048121e-07
described O 0 2.8699335530291137e-07
to O 0 1.2190200848749555e-08
be O 0 8.229601888842808e-09
a O 0 2.0918213294862653e-07
Turkish O 0 0.0003258744836784899
A B-Disease 1 0.9998272061347961
- I-Disease 1 0.9999107122421265
T I-Disease 1 0.9999933242797852
founder O 0 0.0005265867221169174
mutation O 0 1.2598772627825383e-05
. O 0 8.436276743850613e-07

The O 0 1.8695556036618655e-06
presence O 0 3.025771775355679e-07
of O 0 1.667786264647475e-08
a O 0 4.104830964024586e-07
founder O 0 2.5523637305013835e-05
mutation O 0 2.381967533438001e-06
among O 0 2.3824958006457564e-08
relatively O 0 4.788170926417479e-08
small O 0 1.9578035193035248e-08
ethnic O 0 1.364796986536021e-07
population O 0 4.155292643304165e-08
groups O 0 5.403923974967029e-09
in O 0 6.612645986336929e-09
Western O 0 2.6135221986578472e-08
Europe O 0 3.86232166249556e-08
could O 0 1.0936842187447837e-07
indicate O 0 5.390585045006446e-08
a O 0 1.1645472852706007e-07
high O 0 2.398747085408104e-07
carrier O 0 2.468774709996069e-06
frequency O 0 3.751389101580571e-07
in O 0 1.7289060849634552e-08
such O 0 2.7152861292734087e-08
communities O 0 3.096066905072803e-07
. O 0 8.706862786311831e-07

In O 0 6.902026507304981e-05
patients O 0 0.00017584615852683783
of O 0 6.697759857843266e-08
Dutch O 0 4.354966586106457e-05
ethnic O 0 4.921166691929102e-07
origin O 0 1.0183763521354194e-07
, O 0 3.981620011472842e-08
however O 0 4.499451833339663e-08
, O 0 1.632810331386736e-08
no O 0 5.1279023693950876e-08
significant O 0 3.1064889327581113e-08
founder O 0 7.159243295973283e-07
effect O 0 2.0810767864531954e-07
could O 0 2.9389309474936454e-07
be O 0 2.606140583338856e-07
identified O 0 1.998814241233049e-06
. O 0 1.167092818832316e-06

The O 0 4.02208888772293e-06
observed O 0 5.093743766337866e-06
genetic O 0 2.1445719085022574e-06
heterogeneity O 0 4.8988586058840156e-06
including O 0 7.895307163607868e-08
the O 0 3.9371848004066123e-08
relative O 0 5.109947665005166e-07
high O 0 2.3305929630623723e-07
percentage O 0 5.256821111743193e-08
of O 0 2.963806755573728e-09
splice O 0 4.267833446647273e-06
- O 0 0.0006859964341856539
site O 0 4.418001481099054e-06
mutations O 0 8.933184858506138e-07
had O 0 1.5115530516141007e-07
no O 0 3.660862191168235e-08
reflection O 0 2.4368728190893307e-07
on O 0 9.7917120456259e-07
the O 0 1.7235054201591993e-06
phenotype O 0 0.05833309143781662
. O 0 3.717740128195146e-06

All O 0 2.664641579031013e-05
patients O 0 0.0012904868926852942
manifested O 0 2.4829469111864455e-05
classical O 0 6.32591218163725e-06
A B-Disease 1 0.9979148507118225
- I-Disease 1 0.9997244477272034
T I-Disease 1 0.9999669790267944
and O 0 1.1339176353430958e-06
increased O 0 7.367521561718604e-07
cellular O 0 3.157094170092023e-06
radioresistant O 0 2.4312246750923805e-05
DNA O 0 5.8654986787587404e-06
synthesis O 0 3.992558958998416e-06
. O 0 1.5164143860602053e-06

Determination O 0 4.22709017584566e-05
of O 0 1.0252795590304231e-07
the O 0 3.653412505855158e-08
genomic O 0 2.976493647111056e-07
structure O 0 4.3603527899449546e-08
of O 0 2.9872575524336753e-09
the O 0 2.0138459788654473e-08
COL4A4 O 0 0.00020530166511889547
gene O 0 2.489207702183194e-07
and O 0 7.636294263591026e-09
of O 0 2.5778517098729026e-08
novel O 0 9.63554994086735e-05
mutations O 0 0.0012454023817554116
causing O 0 0.003980997018516064
autosomal B-Disease 1 0.9998682737350464
recessive I-Disease 1 0.9999969005584717
Alport I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999994039535522
. O 0 4.0307884773937985e-05

Autosomal B-Disease 1 0.999990701675415
recessive I-Disease 1 0.9999992847442627
Alport I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999998807907104
is O 0 2.9768854801659472e-05
a O 0 4.155003261985257e-05
progressive O 0 0.256062388420105
hematuric B-Disease 1 0.9984443783760071
glomerulonephritis I-Disease 1 0.9999986886978149
characterized O 0 0.02258904092013836
by O 0 2.415084281892632e-06
glomerular B-Disease 0 0.016942664980888367
basement I-Disease 0 0.12444242089986801
membrane I-Disease 0 0.04468828812241554
abnormalities I-Disease 1 0.9373460412025452
and O 0 9.284993325309188e-07
associated O 0 5.642693849949865e-07
with O 0 2.093927236046511e-07
mutations O 0 9.786823284230195e-06
in O 0 4.641465167765091e-08
either O 0 6.016580300638452e-08
the O 0 3.4546957294878666e-08
COL4A3 O 0 0.0002544480958022177
or O 0 1.4711483586893337e-08
the O 0 1.430653284728578e-08
COL4A4 O 0 0.00035205981112085283
gene O 0 4.6030794464968494e-07
, O 0 6.367305793730793e-09
which O 0 4.581197199371445e-09
encode O 0 3.067891185537519e-08
the O 0 1.501612700849364e-08
alpha3 O 0 5.587667146755848e-06
and O 0 1.5674089581807493e-07
alpha4 O 0 5.985018651699647e-05
type O 0 1.1437702596595045e-05
IV O 0 0.04739527404308319
collagen O 0 6.638999184360728e-05
chains O 0 1.1132145118608605e-05
, O 0 2.5560333938301483e-07
respectively O 0 1.0944037285298691e-06
. O 0 9.264145433007798e-07

To O 0 5.056553163740318e-06
date O 0 1.7543800368002849e-06
, O 0 1.232276645168895e-07
mutation O 0 4.1863657429530576e-07
screening O 0 1.0288822238635476e-07
in O 0 1.7333768198568578e-08
the O 0 9.132929967847758e-09
two O 0 2.875570892513224e-08
genes O 0 5.909659250846744e-08
has O 0 3.085879427544569e-07
been O 0 4.536190374437865e-07
hampered O 0 7.5137668318348005e-06
by O 0 6.111805106456814e-08
the O 0 2.2152050860313466e-08
lack O 0 6.757220916142614e-08
of O 0 9.19008780186914e-09
genomic O 0 1.0048524927697144e-06
structure O 0 6.030005010870809e-07
information O 0 1.6653712009429e-07
. O 0 4.2117144971598464e-07

We O 0 9.979324204323348e-06
report O 0 1.4246619457480847e-06
here O 0 4.0743081797245395e-08
the O 0 6.847140632260107e-09
complete O 0 1.2422897555097734e-07
characterization O 0 9.013951967062894e-07
of O 0 1.1646045017243978e-08
the O 0 4.123875996242532e-08
48 O 0 3.2269463190459646e-07
exons O 0 1.1198935823131251e-07
of O 0 5.430002225637054e-09
the O 0 2.1787412762819258e-08
COL4A4 O 0 0.000146899648825638
gene O 0 2.1688821050247498e-07
, O 0 1.048526510061265e-08
a O 0 4.6582272261730395e-08
comprehensive O 0 1.3668602605321212e-07
gene O 0 1.4185540919697814e-07
screen O 0 2.969500883409637e-06
, O 0 1.8968698611843138e-08
and O 0 6.972420418804859e-09
the O 0 5.009962222857212e-09
subsequent O 0 5.03812849217411e-08
detection O 0 3.57192746491819e-08
of O 0 3.6917970902550223e-09
10 O 0 4.71793093481665e-08
novel O 0 7.015925689302094e-07
mutations O 0 6.735101578669855e-07
in O 0 7.33602760760732e-08
eight O 0 0.00011162562441313639
patients O 1 0.6682663559913635
diagnosed O 1 0.9981683492660522
with O 0 0.02309778705239296
autosomal B-Disease 1 0.9999891519546509
recessive I-Disease 1 0.9999966621398926
Alport I-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.999998927116394
. O 0 7.275777170434594e-05

Furthermore O 0 0.0001373312115902081
, O 0 1.0701983228500467e-06
we O 0 6.192323809273148e-08
identified O 0 6.16023427824075e-08
a O 0 2.2833622992379787e-08
glycine O 0 1.3262942388791998e-07
to O 0 1.982510511311375e-08
alanine O 0 1.0215941159685826e-07
substitution O 0 3.405809678724836e-08
in O 0 1.2787947589742998e-08
the O 0 2.8749349567647187e-08
collagenous O 0 8.42885856400244e-05
domain O 0 1.4850307650249306e-07
that O 0 2.3582535035870933e-08
is O 0 2.723907144286386e-08
apparently O 0 1.2908290045743342e-06
silent O 0 2.84896509583632e-06
in O 0 1.9628249248171414e-08
the O 0 2.9914211552295455e-08
heterozygous O 0 4.34441608376801e-06
carriers O 0 1.7231013771379367e-07
, O 0 5.124744362206002e-08
in O 0 6.104139771423434e-08
11 O 0 1.1562755162231042e-06
. O 0 1.0341959750803653e-06

5 O 0 2.276760096719954e-05
% O 0 3.853190833069675e-07
of O 0 6.561085896805707e-09
all O 0 7.0716104083601294e-09
control O 0 4.540895304216974e-07
individuals O 0 2.121550934930383e-08
, O 0 2.538611987290551e-08
and O 0 3.04150979957285e-08
in O 0 2.2925350506852737e-08
one O 0 2.759718853440063e-08
control O 0 1.9332280487560638e-07
individual O 0 1.0593616650567128e-08
homozygous O 0 2.6079084136654274e-07
for O 0 1.2283490669062758e-08
this O 0 3.250739055715712e-08
glycine O 0 1.2273254696992808e-06
substitution O 0 2.0119164219067898e-06
. O 0 9.69438247011567e-07

There O 0 5.848194632562809e-06
has O 0 8.300353329104837e-07
been O 0 1.0324935573180483e-07
no O 0 2.9218798047736527e-08
previous O 0 3.420059258019137e-08
finding O 0 9.116500443440145e-09
of O 0 9.976958148527615e-10
a O 0 2.445497671033081e-08
glycine O 0 1.033748802115042e-07
substitution O 0 5.5068746007691516e-08
that O 0 3.48736080013623e-08
is O 0 2.508146401680733e-08
not O 0 2.799854392776524e-08
associated O 0 1.4415330262806947e-08
with O 0 7.785362576839816e-09
any O 0 5.3087937601503654e-08
obvious O 0 1.4829002793703694e-05
phenotype O 0 0.00994689017534256
in O 0 2.414583661902725e-07
homozygous O 0 3.2609492336632684e-05
individuals O 0 1.9748216573134414e-07
. O 0 7.315382504202717e-07

Founder O 0 0.0028719475958496332
BRCA1 O 0 0.13484999537467957
and O 0 2.894045610446483e-05
BRCA2 O 0 0.009531106799840927
mutations O 0 4.309078576625325e-05
in O 0 4.43470753452857e-07
French O 0 3.109204044449143e-05
Canadian O 0 0.00248630135320127
breast B-Disease 1 0.9985247254371643
and I-Disease 1 0.9981459379196167
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
families O 0 1.926152253872715e-05
. O 0 4.823884410143364e-06

We O 0 7.702246875851415e-06
have O 0 7.82890424488869e-07
identified O 0 3.601395519581274e-07
four O 0 6.58799947927946e-08
mutations O 0 1.5494391902848292e-07
in O 0 6.50418208181236e-09
each O 0 3.0303728415503883e-09
of O 0 7.025283021988571e-09
the O 0 5.69962321605999e-06
breast B-Disease 1 0.9998906850814819
cancer I-Disease 1 0.9954612851142883
- O 1 0.6835594773292542
susceptibility O 1 0.5391825437545776
genes O 0 1.2951053349752328e-06
, O 0 3.1792723120815936e-07
BRCA1 O 0 3.8606096495641395e-05
and O 0 2.647383553266991e-06
BRCA2 O 0 0.00021411260240711272
, O 0 6.932494756028973e-08
in O 0 5.0530065465181906e-08
French O 0 2.4365239369217306e-05
Canadian O 0 0.0007637827075086534
breast B-Disease 1 0.9980679154396057
cancer I-Disease 1 0.8923668265342712
and O 0 0.011148197576403618
breast B-Disease 1 0.9999924898147583
/ I-Disease 1 0.9999977350234985
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
families O 0 7.312875368370442e-06
from O 0 4.097040289252618e-07
Quebec O 0 0.0001951903832377866
. O 0 4.269115834176773e-06

To O 0 1.2574430911627132e-05
identify O 0 9.92018249235116e-06
founder O 0 3.8018537452444434e-05
effects O 0 1.2502422578108963e-05
, O 0 1.3482522831509414e-07
we O 0 5.4410982386343676e-08
examined O 0 1.131016801991791e-06
independently O 0 4.192606581909786e-07
ascertained O 0 1.6840153875818942e-06
French O 0 3.857400315609993e-06
Canadian O 0 7.774949335725978e-05
cancer B-Disease 0 0.001880024909041822
families O 0 3.832630213196353e-08
for O 0 5.067422925719711e-09
the O 0 5.5165010337532294e-09
distribution O 0 5.226465926710944e-09
of O 0 2.329026971281678e-09
these O 0 1.0368901293134059e-08
eight O 0 5.315815769790788e-07
mutations O 0 4.165186510363128e-06
. O 0 5.194071377445653e-07

Mutations O 0 0.027545025572180748
were O 0 4.801047452929197e-06
found O 0 4.214973046146042e-07
in O 0 7.096650733728893e-08
41 O 0 8.295866678054153e-07
of O 0 6.440508570904058e-08
97 O 0 6.327118626359152e-06
families O 0 1.6354540548491059e-06
. O 0 2.0399816094140988e-06

Six O 0 3.0492694804706844e-06
of O 0 8.419640806778261e-08
eight O 0 2.90805331815136e-07
mutations O 0 9.489521062278072e-07
were O 0 1.3592025993602874e-07
observed O 0 2.1503338132333738e-07
at O 0 4.180245838369956e-08
least O 0 3.333749418743537e-07
twice O 0 4.992893536837073e-06
. O 0 1.7226673207915155e-06

The O 0 1.2107499060221016e-05
BRCA1 O 0 0.0012544139754027128
C4446T O 0 0.00040852598613128066
mutation O 0 4.949896174366586e-05
was O 0 4.938552820021869e-07
the O 0 1.5367708883218256e-08
most O 0 3.1518780474470987e-08
common O 0 3.977385460984806e-07
mutation O 0 7.648944119864609e-06
found O 0 1.515302727739254e-07
, O 0 1.2798170523353747e-08
followed O 0 5.13471434260282e-08
by O 0 3.906947654286341e-08
the O 0 3.435168309806613e-07
BRCA2 O 0 0.0009604942169971764
8765delAG O 0 0.00015516675193794072
mutation O 0 2.919932740041986e-05
. O 0 1.7979823496716563e-06

Together O 0 1.0073076737171505e-05
, O 0 2.4213818505813833e-07
these O 0 2.998407566678907e-08
mutations O 0 3.169104161315772e-07
were O 0 5.846672479492554e-08
found O 0 5.359910204560947e-08
in O 0 2.632970463878337e-08
28 O 0 3.266168278059922e-07
of O 0 9.495875197274017e-09
41 O 0 7.881870260462165e-06
families O 0 6.899359306089536e-08
identified O 0 6.97252957593264e-08
to O 0 2.7743803698854208e-08
have O 0 1.1595890470061931e-07
a O 0 5.6742042033874895e-06
mutation O 0 3.1591505830874667e-05
. O 0 2.342392008358729e-06

The O 0 1.473405404794903e-06
odds O 0 8.901395631255582e-06
of O 0 3.0569101028277146e-08
detection O 0 1.0610202849647976e-07
of O 0 2.9206748131116456e-09
any O 0 3.888182664724127e-09
of O 0 1.1387244480687286e-09
the O 0 1.5668897290765926e-08
four O 0 3.4527036518738896e-07
BRCA1 O 0 0.0005984151503071189
mutations O 0 8.300865374621935e-06
was O 0 6.1084888329787645e-06
18 O 0 3.193066049789195e-06
. O 0 1.2362780807961826e-06

7x O 0 0.05522669479250908
greater O 0 3.0133653126540594e-05
if O 0 5.30248939867306e-07
one O 0 6.179085687563202e-08
or O 0 1.2273162930398485e-08
more O 0 2.7020186976756122e-08
cases O 0 4.138130407227436e-07
of O 0 0.00021914596436545253
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
were O 0 2.361320730415173e-05
also O 0 6.699292498524301e-07
present O 0 3.6606945030825955e-08
in O 0 3.753815036589003e-08
the O 0 1.7543104036121804e-07
family O 0 2.5340318643429782e-06
. O 0 1.632853013688873e-06

The O 0 1.2643877198570408e-06
odds O 0 7.924295459815767e-06
of O 0 2.7032767135892755e-08
detection O 0 1.0110894521631053e-07
of O 0 2.875734095297844e-09
any O 0 3.338608722813774e-09
of O 0 2.3916322255956857e-09
the O 0 3.2362255097950765e-08
four O 0 2.578722842372372e-06
BRCA2 O 0 0.004151274915784597
mutations O 0 5.7003462643479e-06
was O 0 1.342357450084819e-06
5 O 0 6.449242846429115e-07
. O 0 1.0160138117498718e-06

3x O 0 0.0023819925263524055
greater O 0 4.513635758485179e-06
if O 0 2.2884029249325977e-07
there O 0 3.552387184413419e-08
were O 0 3.864620623517112e-08
at O 0 1.0855474741333637e-08
least O 0 2.6719456869273017e-08
five O 0 3.6904754807665086e-08
cases O 0 1.1706112701403981e-07
of O 0 6.890284112159861e-07
breast B-Disease 1 0.9998606443405151
cancer I-Disease 0 0.42953503131866455
in O 0 1.2360418111256877e-07
the O 0 2.8905674298584927e-07
family O 0 4.330839146859944e-06
. O 0 1.7919942365551833e-06

Interestingly O 0 0.00039034124347381294
, O 0 4.7437194439226005e-07
the O 0 1.5749016313293396e-08
presence O 0 2.8008800612155937e-08
of O 0 1.6191524565556392e-08
a O 0 0.0015694750472903252
breast B-Disease 1 0.9998966455459595
cancer I-Disease 1 0.7542325854301453
case O 0 6.25604297965765e-06
< O 0 1.1083881190643297e-06
36 O 0 3.1259878596756607e-07
years O 0 3.3688152711874864e-08
of O 0 3.7115663875653127e-09
age O 0 2.533045631025743e-07
was O 0 6.522807325382018e-07
strongly O 0 1.0326412791528128e-07
predictive O 0 7.042861227546382e-08
of O 0 2.074104665794607e-09
the O 0 8.149129371304298e-09
presence O 0 2.2080971717741704e-08
of O 0 1.4007778270652693e-09
any O 0 2.534237264484318e-09
of O 0 1.6625324450458834e-09
the O 0 1.2745090316457208e-08
eight O 0 5.646828071803611e-07
mutations O 0 3.643566287792055e-06
screened O 0 1.8399779946776107e-05
. O 0 2.018610530285514e-06

Carriers O 0 3.675092739285901e-05
of O 0 2.0078593365724373e-07
the O 0 3.6963790250865713e-08
same O 0 1.4449565810537024e-07
mutation O 0 4.32361161983863e-07
, O 0 1.0493227620145262e-08
from O 0 6.5646661440155185e-09
different O 0 6.067410573962206e-09
families O 0 3.298135098361854e-08
, O 0 1.9095388381629164e-08
shared O 0 4.671145958923262e-08
similar O 0 1.9600329892455193e-07
haplotypes O 0 1.2739722478727344e-05
, O 0 3.821885030674821e-08
indicating O 0 1.1915920339333752e-07
that O 0 4.521119478795299e-09
the O 0 2.9246327581944342e-09
mutant O 0 4.429331283972715e-07
alleles O 0 8.09685758440537e-08
were O 0 4.843734657811183e-08
likely O 0 1.1428738844188047e-07
to O 0 3.780703394795637e-08
be O 0 6.923047379814307e-08
identical O 0 1.1429842743382324e-06
by O 0 2.827924028281359e-08
descent O 0 1.1080467174906516e-06
for O 0 2.298182621984779e-08
a O 0 2.215798303950578e-06
mutation O 0 1.4575930435967166e-06
in O 0 1.6772032651601876e-08
the O 0 3.654436753208756e-08
founder O 0 2.0089055396965705e-05
population O 0 3.0335496603584033e-07
. O 0 4.6900814254513534e-07

The O 0 1.1331802625136334e-06
identification O 0 7.587318577861879e-07
of O 0 5.6599841258275774e-08
common O 0 1.921431248774752e-06
BRCA1 O 0 0.0021241542417556047
and O 0 5.279793549561873e-05
BRCA2 O 0 0.3066771924495697
mutations O 0 5.274253908282844e-06
will O 0 3.817418914309201e-08
facilitate O 0 7.654233513676445e-08
carrier O 0 9.327512998424936e-06
detection O 0 4.0431035586152575e-07
in O 0 1.1007325895207032e-07
French O 0 1.3005540495214518e-05
Canadian O 0 0.0011177496053278446
breast B-Disease 1 0.9984157085418701
cancer I-Disease 1 0.8840270638465881
and O 0 0.013927791267633438
breast B-Disease 1 0.9999963045120239
/ I-Disease 1 0.9999984502792358
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
families O 0 2.722250428632833e-05
. O 0 4.191126208752394e-06

Are O 0 8.489969332003966e-06
Dp71 O 0 9.817857790039852e-05
and O 0 2.0522045360849006e-06
Dp140 O 0 0.00019286162569187582
brain O 0 0.0001595203939359635
dystrophin O 0 6.310432945610955e-05
isoforms O 0 3.9051592466421425e-06
related O 0 2.89619407567443e-07
to O 0 4.4676482957584085e-07
cognitive B-Disease 0 0.0021799453534185886
impairment I-Disease 0 0.10188495367765427
in O 0 8.228220394812524e-05
Duchenne B-Disease 1 0.9999581575393677
muscular I-Disease 1 0.9999901056289673
dystrophy I-Disease 1 0.9999775886535645
? O 0 0.002415094990283251

Molecular O 0 0.0002773190790321678
study O 0 5.7546349125914276e-06
and O 0 3.5413674481787893e-07
neuropsychological O 0 1.727547169139143e-05
analysis O 0 1.3040444457601552e-07
were O 0 8.534453144193321e-08
performed O 0 1.675803531497877e-07
concurrently O 0 1.1396021903919973e-07
on O 0 1.2210141449031653e-06
49 O 0 0.00017323647625744343
patients O 0 1.1228275070607197e-05
with O 0 1.1173209713888355e-05
Duchenne B-Disease 1 0.9999899864196777
muscular I-Disease 1 0.9999995231628418
dystrophy I-Disease 1 0.9999994039535522
( O 0 0.00036746967816725373
DMD B-Disease 1 0.9999992847442627
) O 0 3.450679173511162e-07
in O 0 3.368609569065484e-08
order O 0 2.02537115967516e-08
to O 0 1.556898077126334e-08
find O 0 3.52351889887359e-08
a O 0 5.302585464050935e-07
molecular O 0 9.137409051618306e-07
explanation O 0 2.1466681232595874e-07
for O 0 1.587265963109985e-08
the O 0 8.284854402518249e-08
cognitive B-Disease 0 0.00010335549450246617
impairment I-Disease 0 7.468480907846242e-05
observed O 0 5.066131620878878e-07
in O 0 1.7315799993866676e-07
most O 0 4.4175707444082946e-05
DMD B-Disease 1 0.9999998807907104
patients O 1 0.9997287392616272
. O 0 1.9520000932971016e-05

Complete O 0 2.3664264517719857e-05
analysis O 0 1.742386643854843e-06
of O 0 2.5934109970648933e-08
the O 0 4.103608830519079e-08
dystrophin O 0 2.9938906664028764e-05
gene O 0 7.67363758313877e-07
was O 0 4.5464503273251466e-07
performed O 0 1.4966980188546586e-07
to O 0 1.3429313661106335e-08
define O 0 3.549894600496373e-08
the O 0 9.734719697007677e-09
localization O 0 8.34123810022902e-08
of O 0 3.1165348080008926e-09
deletions O 0 5.347538944988628e-07
and O 0 4.8766619187290416e-08
duplications O 0 8.088852041510108e-07
in O 0 6.189076628970724e-08
relation O 0 8.620671820835923e-08
to O 0 4.216601112716489e-08
the O 0 9.525828659207036e-08
different O 0 3.387359583939542e-07
DMD B-Disease 1 0.999987006187439
promoters O 0 0.0006582170608453453
. O 0 4.617734703060705e-06

Qualitative O 0 7.5800962804351e-05
analysis O 0 2.338735839657602e-06
of O 0 6.24704838969592e-08
the O 0 7.547360780790768e-08
Dp71 O 0 2.0035351553815417e-05
transcript O 0 1.3979653886053711e-05
and O 0 3.4469422871552524e-08
testing O 0 2.620610395354106e-08
for O 0 2.8353543957138072e-09
the O 0 1.6482829545694244e-09
specific O 0 2.19921902910869e-09
first O 0 1.8129149736978434e-08
exon O 0 1.9318346744512382e-07
of O 0 5.175763373443942e-09
Dp140 O 0 2.0361992483231006e-06
were O 0 7.955227232514517e-08
also O 0 6.746981995320311e-08
carried O 0 4.483363511553762e-07
out O 0 2.268391057214103e-07
. O 0 9.016221724778006e-07

Neuropsychological O 0 0.00986394751816988
analysis O 0 3.8440964999608696e-05
assessed O 0 2.306733949808404e-05
verbal O 0 1.167582013295032e-05
and O 0 4.518531113717472e-07
visuospatial O 0 3.9662521885475144e-05
intelligence O 0 9.891830359265441e-07
, O 0 5.815864057012732e-08
verbal O 0 8.792138714852626e-07
memory O 0 2.3439517917722696e-06
, O 0 4.54563533480723e-08
and O 0 1.1420033274589514e-07
reading O 0 1.1969477782258764e-06
skills O 0 1.3816965065416298e-06
. O 0 1.500472535553854e-06

Comparison O 0 2.9387889298959635e-05
of O 0 2.574113295850111e-07
molecular O 0 2.2277272364590317e-06
and O 0 1.6061943597378558e-07
psychometric O 0 4.5696702727582306e-05
findings O 0 1.0158801160287112e-05
demonstrated O 0 5.360544150789792e-07
that O 0 2.7209992481402878e-08
deletions O 0 5.457477527670562e-07
and O 0 8.072000667880275e-08
duplications O 0 5.953839377070835e-07
that O 0 5.2326328159324476e-08
were O 0 6.917186823329757e-08
localized O 0 8.059261062953738e-07
in O 0 2.994903880448874e-08
the O 0 3.7640390360138554e-08
distal O 0 1.6525338651263155e-05
part O 0 4.383969454124781e-08
of O 0 1.9636028358860358e-09
the O 0 8.170700560583555e-09
gene O 0 7.331299656243573e-08
seemed O 0 2.8901595783281664e-07
to O 0 3.086956112952066e-08
be O 0 7.931199519362053e-08
preferentially O 0 2.528983486627112e-06
associated O 0 2.6434048550072475e-07
with O 0 5.399217570811743e-07
cognitive B-Disease 0 0.009413638152182102
impairment I-Disease 0 0.006674925331026316
. O 0 2.3377190245810198e-06

Two O 0 1.2937503015564289e-05
altered O 0 1.6651627447572537e-05
Dp71 O 0 2.313896948180627e-05
transcripts O 0 2.280138460264425e-06
and O 0 3.916639812473477e-08
two O 0 3.022356764859069e-08
deleted O 0 8.087201877060579e-07
Dp140 O 0 1.3163084986445028e-06
DNA O 0 2.6298192778995144e-07
sequences O 0 5.375133227403239e-08
were O 0 1.54675152685968e-08
found O 0 1.1850718628636514e-08
in O 0 1.1168108215997563e-08
four O 0 6.449581633205526e-07
patients O 0 2.408622640359681e-05
with O 0 2.4624689103802666e-05
severe O 1 0.9998546838760376
cerebral B-Disease 1 0.999983549118042
dysfunction I-Disease 1 0.9994538426399231
. O 0 7.95136220403947e-05

These O 0 2.681892510736361e-06
findings O 0 4.938769052387215e-06
suggest O 0 3.717038055128796e-07
that O 0 2.9203643947539604e-08
some O 0 1.3460318193381227e-08
sequences O 0 4.238970419123689e-08
located O 0 1.677862293547605e-08
in O 0 8.546177987511783e-09
the O 0 1.020528461737058e-08
distal O 0 6.965231932554161e-06
part O 0 5.202717900942844e-08
of O 0 2.6576314482440466e-09
the O 0 8.838527243426597e-09
gene O 0 5.99793850142305e-08
and O 0 2.2822693068746958e-08
, O 0 1.3314391367202916e-08
in O 0 1.3204000559596807e-08
particular O 0 2.998407566678907e-08
, O 0 4.342011550306779e-08
some O 0 8.371074500246323e-08
DMD B-Disease 1 0.9999934434890747
isoforms O 0 9.810184565139934e-06
expressed O 0 5.575901127485849e-07
in O 0 1.935035065514512e-08
the O 0 1.066903294599797e-07
brain O 0 0.009422874078154564
may O 0 9.341740110357932e-07
be O 0 1.1544400990715076e-08
related O 0 9.54852730217226e-09
to O 0 1.890696843531714e-08
the O 0 2.3751867672672233e-07
cognitive B-Disease 0 0.13401329517364502
impairment I-Disease 0 0.1755283772945404
associated O 0 2.411123887213762e-06
with O 0 1.2457387128961273e-05
DMD B-Disease 1 0.9999995231628418
. O 0 2.948659675894305e-05
. O 0 2.646270331752021e-06

I1307K O 0 0.0015655659371986985
APC O 0 0.0002531824284233153
and O 0 2.11097494684509e-06
hMLH1 O 0 0.0001060741487890482
mutations O 0 5.469438292493578e-06
in O 0 2.7018899118047557e-08
a O 0 3.7981334344294737e-07
non O 0 2.8165825938231137e-07
- O 0 6.81332458043471e-05
Jewish O 0 5.415523673946154e-07
family O 0 2.5184536411870795e-07
with O 0 1.8815883606748685e-07
hereditary B-Disease 0 0.12441032379865646
non I-Disease 0 0.0002549916098359972
- I-Disease 1 0.9999836683273315
polyposis I-Disease 1 0.9999994039535522
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 6.442396261263639e-05

We O 0 4.421309768076753e-06
describe O 0 3.891222149832174e-06
a O 0 9.256639259547228e-07
French O 0 1.0319327884644736e-05
Canadian O 0 1.172350766864838e-05
hereditary B-Disease 0 0.011086402460932732
non I-Disease 0 0.00014903418195899576
- I-Disease 1 0.9999837875366211
polyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.00015168506070040166
HNPCC B-Disease 1 0.962292492389679
) O 0 5.579656772169983e-07
kindred O 0 1.5044706742628478e-05
which O 0 9.285926694246882e-08
carries O 0 4.4832268031314015e-07
a O 0 2.984947116146941e-07
novel O 0 1.6323407407980994e-06
truncating O 0 1.520109799457714e-05
mutation O 0 5.55153292225441e-06
in O 0 2.3700074791577208e-07
hMLH1 O 0 6.879173452034593e-05
. O 0 3.009006150023197e-06

Interestingly O 0 0.000498174864333123
, O 0 7.341416221606778e-07
the O 0 1.0838699182613709e-07
I1307K O 0 1.656797576288227e-05
APC O 0 3.3283828088315204e-05
polymorphism O 0 0.0006223128875717521
, O 0 1.8748140462321317e-07
associated O 0 4.66942680077409e-08
with O 0 8.490902203561745e-09
an O 0 8.657829653202498e-08
increased O 0 1.9039417793464963e-06
risk O 0 1.1218941153856576e-06
of O 0 5.375990804168396e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 4.926815563521814e-06
is O 0 1.3430626211174967e-07
also O 0 4.399827275847201e-07
present O 0 4.126921382408e-08
in O 0 6.004749053545311e-08
this O 0 2.061184858348497e-07
family O 0 3.474624236332602e-06
. O 0 2.1560351797234034e-06

The O 0 3.368647185197915e-06
I1307K O 0 7.164479757193476e-05
polymorphism O 0 0.00042535993270576
has O 0 2.1607490907626925e-06
previously O 0 2.5989081109401013e-07
only O 0 2.3329583598297177e-08
been O 0 1.1510765318689664e-07
identified O 0 8.655699446080689e-08
in O 0 3.12058556772854e-09
individuals O 0 1.141484018418737e-09
of O 0 3.5943970022600524e-09
self O 0 7.994774932740256e-05
- O 0 0.14629967510700226
reported O 0 0.0001581708638696
Ashkenazi O 0 5.273509941616794e-06
Jewish O 0 4.003682363418193e-07
origins O 0 7.646133894922968e-07
. O 0 1.6187668734346516e-06

In O 0 2.894566932809539e-06
addition O 0 3.2260695093100367e-07
, O 0 4.1020047802931003e-08
in O 0 2.1221660873038672e-08
this O 0 4.1074539325336445e-08
family O 0 1.758016594521905e-07
, O 0 1.9241339188624806e-08
there O 0 2.1603515421020347e-08
appears O 0 6.439010462599981e-07
to O 0 2.565221635109083e-08
be O 0 2.2443888525458533e-08
no O 0 3.1874261452458086e-08
relationship O 0 1.8673976143190885e-08
between O 0 8.279512186959437e-09
the O 0 1.9713041865543346e-08
I1307K O 0 1.3919350749347359e-05
polymorphism O 0 5.605232217931189e-06
and O 0 1.3017354305588924e-08
the O 0 3.4262144232855007e-09
presence O 0 3.331613029899927e-08
or O 0 1.9919333738016576e-08
absence O 0 2.1143083017705067e-07
of O 0 2.0199284733735112e-07
cancer B-Disease 0 0.14398525655269623
. O 0 1.2634548056666972e-06
. O 0 2.5264787382184295e-06

Identification O 0 8.586081094108522e-06
of O 0 1.1977752478742332e-07
a O 0 1.1608121894823853e-06
novel O 0 5.2399318519746885e-06
mutation O 0 9.275691468246805e-07
of O 0 4.290081179192384e-09
the O 0 2.5168295891830894e-08
CPO O 0 2.9166683816583827e-05
gene O 0 1.913143137244333e-07
in O 0 1.57032147285463e-08
a O 0 4.318893047638994e-07
Japanese O 0 1.3560135812440421e-05
hereditary B-Disease 0 0.14157672226428986
coproporphyria I-Disease 0 0.04192103445529938
family O 0 9.229946954292245e-06
. O 0 1.14924409899686e-06

Hereditary B-Disease 1 0.9997321963310242
coproporphyria I-Disease 1 0.9957595467567444
( O 0 8.739850454730913e-05
HCP B-Disease 0 0.1890694499015808
) O 0 6.029470114299329e-07
is O 0 2.1878511802242429e-07
an O 0 3.2716225177864544e-06
autosomal B-Disease 1 0.9959138035774231
dominant I-Disease 1 0.9991996884346008
disease I-Disease 1 0.7271104454994202
characterized O 0 0.00040584371890872717
by O 0 2.969245997519465e-06
a O 0 0.025033270940184593
deficiency B-Disease 0 0.021923426538705826
of I-Disease 0 6.246785488883688e-08
coproporphyrinogen I-Disease 0 0.0024674967862665653
oxidase I-Disease 0 1.1110138075309806e-05
( O 0 8.109964966251937e-08
CPO O 0 1.4975737940403633e-05
) O 0 3.263586378920991e-08
caused O 0 3.302390894077689e-07
by O 0 1.3013581323662038e-08
a O 0 1.2612167665793095e-06
mutation O 0 1.6729881053834106e-06
in O 0 4.028131428412962e-08
the O 0 1.3657175657044718e-07
CPO O 0 0.0008072308846749365
gene O 0 7.542937055404764e-06
. O 0 1.4099547342993901e-06

Only O 0 1.2374077414278872e-05
11 O 0 2.559407221269794e-06
mutations O 0 1.3618628145195544e-06
of O 0 9.963328828632712e-09
the O 0 3.4336611776097925e-08
gene O 0 2.8215134761921945e-07
have O 0 6.299648447338768e-08
been O 0 7.379637168014597e-07
reported O 0 9.253750249627046e-06
in O 0 1.50246864905057e-06
HCP B-Disease 1 0.999455988407135
patients O 1 0.8663253784179688
. O 0 1.1020862075383775e-05

We O 0 6.914983259775909e-06
report O 0 1.1232741599087603e-06
another O 0 3.706521169988264e-07
mutation O 0 1.0260578164889012e-06
in O 0 3.354030653213158e-08
a O 0 9.281009170081234e-07
Japanese O 0 1.0812907021318097e-05
family O 0 5.458360192278633e-06
. O 0 1.625310233066557e-06

Polymerase O 0 0.00027981106541119516
chain O 0 7.03640325809829e-05
reaction O 0 7.977204404596705e-06
- O 0 5.659849648509407e-06
single O 0 7.565779469587142e-07
strand O 0 4.112101123610046e-06
conformational O 0 2.4051616946962895e-06
polymorphism O 0 8.645980415167287e-06
and O 0 3.870197318178725e-08
direct O 0 3.409020266076368e-08
sequence O 0 6.245416273031879e-08
analyses O 0 2.1490298252047069e-07
demonstrated O 0 2.259775868651559e-07
a O 0 1.8648174204827228e-07
C O 0 2.054735546153097e-07
to O 0 2.5786187407561556e-08
T O 0 2.4377868612646125e-06
substitution O 0 4.889944094088605e-08
in O 0 2.487659500616246e-08
exon O 0 3.5713389934244333e-07
1 O 0 1.1587418136116412e-08
of O 0 1.707563868080797e-09
the O 0 1.116065551087786e-08
CPO O 0 4.149399046582403e-06
gene O 0 8.57249844443686e-08
at O 0 9.223664498847484e-09
nucleotide O 0 4.0120447408753535e-08
position O 0 1.1666804766718997e-07
85 O 0 1.2266964688478765e-07
, O 0 1.899096169211134e-08
which O 0 3.935405246124901e-08
lies O 0 8.81716388789755e-08
in O 0 1.0539904948814183e-08
the O 0 9.37973343440035e-09
putative O 0 1.0149465197173413e-06
presequence O 0 2.3894349396869075e-06
for O 0 3.0279995399951076e-08
targeting O 0 2.336396818236608e-07
to O 0 3.3121494880106184e-07
mitochondria O 0 1.325082212133566e-05
. O 0 2.1574833226623014e-06

This O 0 3.7673110000469023e-06
mutation O 0 7.301266123249661e-06
changes O 0 1.116996557470884e-07
the O 0 1.163214857768935e-08
codon O 0 1.1352729245572846e-07
for O 0 1.0212060530534472e-08
glutamine O 0 6.0726233641617e-07
to O 0 7.677041935494344e-08
a O 0 2.9701786274927144e-07
termination O 0 1.2587175888256752e-06
codon O 0 3.2068552968667063e-07
at O 0 3.666144721137243e-08
amino O 0 1.6219348708546022e-07
acid O 0 5.273728334032057e-07
position O 0 7.134467523428611e-07
29 O 0 3.2742034363764105e-06
. O 0 5.593791456703912e-07

MaeI O 0 0.0010268614860251546
restriction O 0 3.410004865145311e-05
analysis O 0 4.8848160076886415e-06
showed O 0 1.726282107483712e-06
two O 0 5.730591823294162e-08
other O 0 1.1180384618114658e-08
carriers O 0 1.0273664230453505e-07
in O 0 2.3248695413258247e-08
the O 0 2.0653207855048095e-07
family O 0 3.674595518532442e-06
. O 0 1.5620638578184298e-06

The O 0 1.3474258594214916e-05
C O 0 0.00022931052080821246
- O 0 0.04175157845020294
T O 0 0.4208182692527771
mutation O 0 4.411235750012565e-06
is O 0 4.232329331443907e-08
located O 0 1.6695622662155074e-08
within O 0 3.791070568581745e-09
a O 0 9.7756199579635e-08
recently O 0 1.0709886737458874e-06
proposed O 0 1.906835080944802e-07
putative O 0 6.043275107003865e-07
alternative O 0 8.959481334613884e-08
translation O 0 5.027377270039324e-08
initiation O 0 4.5101916867906766e-08
codon O 0 2.7373400257602043e-07
( O 0 1.4601229558763862e-08
TIC O 0 1.508964828644821e-06
- O 0 2.4101741473714355e-06
1 O 0 8.84495605646407e-08
) O 0 9.26048837612825e-09
, O 0 6.588625200976139e-09
supporting O 0 2.0385446219961523e-08
that O 0 4.3439499108899327e-08
TIC O 0 1.6600921298959292e-05
- O 0 2.4385435608564876e-05
1 O 0 4.794577179723092e-08
is O 0 3.870033182806765e-09
the O 0 3.2259688254043795e-09
real O 0 3.9520138273019256e-08
TIC O 0 2.242575874333852e-06
rather O 0 4.276146370330025e-08
than O 0 4.424146737846968e-08
TIC O 0 1.157168753707083e-05
- O 0 3.9772323361830786e-05
2 O 0 5.833355771756032e-07
. O 0 1.0916625825529991e-07
. O 0 4.686388592745061e-07

Human B-Disease 0 3.440962973400019e-05
complement I-Disease 0 4.42226228187792e-05
factor I-Disease 0 0.0012622498907148838
H I-Disease 1 0.999998927116394
deficiency I-Disease 1 0.9994860887527466
associated O 0 9.92350178421475e-05
with O 0 0.07184305787086487
hemolytic B-Disease 1 0.9999991655349731
uremic I-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
. O 0 0.0001371455000480637

This O 0 4.539640940492973e-06
study O 0 1.5687953691667644e-06
reports O 0 2.532895848617045e-07
on O 0 1.2891027267869504e-07
six O 0 1.1232505130465142e-06
cases O 0 9.93021444628539e-07
of O 0 1.1726352795449202e-06
deficiency B-Disease 0 0.4135110676288605
in I-Disease 0 3.972161266574403e-08
the I-Disease 0 2.633533036089375e-08
human I-Disease 0 2.9194900719176076e-08
complement I-Disease 0 6.327742596567987e-08
regulatory I-Disease 0 1.5652236129426456e-07
protein I-Disease 0 1.1570108426894876e-07
Factor I-Disease 0 1.0480751200248051e-07
H I-Disease 1 0.9921410083770752
( O 0 1.3696853784495033e-07
FH O 0 0.00048004958080127835
) O 0 1.2690462902753552e-08
in O 0 2.1513044679011273e-09
the O 0 1.8610958330000926e-09
context O 0 6.818820175169549e-09
of O 0 1.8531480350247875e-08
an O 0 0.004838043823838234
acute B-Disease 1 0.9999992847442627
renal I-Disease 1 1.0
disease I-Disease 1 0.9999996423721313
. O 0 0.00013744400348514318

Five O 0 3.3893675208673812e-06
of O 0 6.338771640912455e-08
the O 0 6.347785586058308e-08
cases O 0 2.0247925647254306e-07
were O 0 2.802457004236203e-07
observed O 0 4.288095851734397e-07
in O 0 1.5290876831386413e-07
children O 0 1.1552152727745124e-06
presenting O 0 8.572809747420251e-06
with O 0 0.04121930152177811
idiopathic O 1 0.9999998807907104
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0013464841758832335
HUS B-Disease 1 0.9998999834060669
) O 0 1.0028917131421622e-05
. O 0 4.887504928774433e-06

Two O 0 1.2702324738711468e-06
of O 0 7.197868967523391e-08
the O 0 9.852103488583452e-08
children O 0 1.8754002439891337e-06
exhibited O 0 9.707448771223426e-05
a O 0 0.36895594000816345
homozygous O 1 0.9998754262924194
deficiency O 1 0.9836412668228149
characterized O 0 1.2708585018117446e-05
by O 0 6.016821174625875e-08
the O 0 2.416638089641765e-08
absence O 0 1.0102682779233874e-07
of O 0 4.138988263235888e-09
the O 0 2.1669215755082405e-08
150 O 0 7.572739235683912e-08
- O 0 1.8450507468514843e-06
kD O 0 3.7493077797989827e-06
form O 0 5.196905661364326e-08
of O 0 5.529848579044483e-09
Factor O 0 1.864874548118678e-07
H O 1 0.8435063362121582
and O 0 1.5422795485164897e-08
the O 0 6.646357242345857e-09
presence O 0 5.891022425430492e-08
, O 0 2.0952549917296892e-08
upon O 0 2.3796344450488505e-08
immunoblotting O 0 1.4841644997432013e-06
, O 0 5.7452873569729945e-09
of O 0 1.0792253757330172e-09
the O 0 7.39151717610298e-09
42 O 0 2.9945471169412485e-07
- O 0 3.0639641863672296e-06
kD O 0 8.67420676513575e-05
Factor O 0 1.5491954172830447e-06
H O 1 0.5938935875892639
- O 0 7.042806373647181e-06
like O 0 1.351480847233688e-07
protein O 0 9.117321297935632e-08
1 O 0 4.355647931220119e-08
( O 0 1.468955623806778e-08
FHL O 0 3.3667811294435523e-06
- O 0 1.2656324543058872e-05
1 O 0 8.40016767256202e-08
) O 0 9.909202347557766e-09
and O 0 1.733938859160844e-08
other O 0 2.9199966888882045e-08
FH O 0 0.005401978734880686
- O 0 0.0004899781197309494
related O 0 4.3883451894544123e-07
protein O 0 2.532673590849299e-07
( O 0 4.1259688998707134e-08
FHR O 0 2.033958116953727e-05
) O 0 1.4009287951921578e-07
bands O 0 1.2290742006371147e-06
. O 0 1.0418053761895862e-06

Southern O 0 7.650821498828009e-05
blot O 0 0.0005767392576672137
and O 0 7.367113425971183e-07
PCR O 0 2.303030669281725e-05
analysis O 0 2.6656903173716273e-07
of O 0 7.159364212583341e-09
DNA O 0 1.5664780050883564e-07
of O 0 6.848263733871818e-09
one O 0 2.3597209519721218e-07
patient O 0 2.1869322154088877e-05
with O 0 7.0146402322279755e-06
homozygous O 1 0.8642241358757019
deficiency O 0 0.00961203034967184
ruled O 0 1.00702527561225e-06
out O 0 2.2631397200711945e-08
the O 0 2.4481379146124027e-09
presence O 0 3.725382669017563e-09
of O 0 1.080265432662486e-09
a O 0 7.316408101587513e-08
large O 0 2.6320366330878642e-08
deletion O 0 5.095319579595525e-07
of O 0 5.599089192287465e-09
the O 0 5.045600204311995e-08
FH O 0 0.003631406696513295
gene O 0 1.6980072814476443e-07
as O 0 1.0637553948811274e-08
the O 0 1.2230958468251174e-08
underlying O 0 3.4758772926579695e-06
defect O 0 1.2839002920372877e-05
for O 0 1.7545796993090335e-07
the O 0 2.9739601814071648e-05
deficiency O 1 0.815305233001709
. O 0 3.5715402191272005e-06

The O 0 1.9439466996118426e-06
other O 0 1.5160341604314453e-07
four O 0 2.2151844802920095e-07
children O 0 1.9682016727529117e-07
presented O 0 1.3660188642461435e-06
with O 0 1.6521587895113043e-05
heterozygous O 1 0.9967285394668579
deficiency O 0 0.2652176022529602
and O 0 2.145213073845298e-07
exhibited O 0 7.584926152048865e-06
a O 0 9.88894385045569e-07
normal O 0 2.4708825208108465e-07
immunoblotting O 0 8.20511286292458e-06
pattern O 0 1.430048115480531e-07
of O 0 3.031419115728795e-09
proteins O 0 6.63364163600022e-09
of O 0 5.295260230298027e-09
the O 0 4.230118406667316e-07
FH O 1 0.9550844430923462
family O 0 1.1755110790545586e-05
. O 0 1.5290368082787609e-06

Factor B-Disease 1 0.936747670173645
H I-Disease 1 0.999998927116394
deficiency I-Disease 1 0.9982435703277588
is O 0 2.2856939096982387e-07
the O 0 1.0134063188615983e-07
only O 0 9.33265528146876e-06
complement B-Disease 1 0.9999574422836304
deficiency I-Disease 1 0.9999984502792358
associated O 0 9.864982530416455e-06
with O 0 2.1717707568313926e-05
HUS B-Disease 1 0.9998977184295654
. O 0 5.802117448183708e-05

These O 0 1.5985352774805506e-06
observations O 0 3.5758719150180696e-06
suggest O 0 5.732876502406725e-07
a O 0 9.117773913658311e-08
role O 0 9.548985957508194e-08
for O 0 1.016274921994409e-07
FH O 0 0.00991483498364687
and O 0 1.3824610505253077e-06
/ O 0 7.437520253006369e-06
or O 0 2.2936598043088452e-07
FH O 0 0.02050681971013546
receptors O 0 2.1166133592487313e-06
in O 0 7.746453434265277e-08
the O 0 9.246389964800983e-08
pathogenesis O 0 4.006995732197538e-05
of O 0 1.2756019032167387e-06
idiopathic O 1 0.9999213218688965
HUS B-Disease 1 0.9999905824661255
. O 0 1.8925184122053906e-05
. O 0 3.203509550075978e-06

Further O 0 1.0395384379080497e-05
evidence O 0 6.756357038284477e-07
for O 0 2.3992361875002644e-08
a O 0 1.0833822017275452e-07
major O 0 9.960501756722806e-08
ancient O 0 8.156073363352334e-07
mutation O 0 0.00027335056802257895
underlying O 0 0.02853984385728836
myotonic B-Disease 1 0.9999995231628418
dystrophy I-Disease 1 0.9999997615814209
from O 0 2.1272414869599743e-06
linkage O 0 7.808206282788888e-05
disequilibrium O 0 0.006154797039926052
studies O 0 6.585680694115581e-07
in O 0 4.715447943226536e-08
the O 0 2.868799775512798e-08
Japanese O 0 3.0152941690175794e-06
population O 0 5.225980430623167e-07
. O 0 1.5978646388248308e-06

The O 0 0.0037610570434480906
myotonic B-Disease 1 0.9999983310699463
dystrophy I-Disease 1 1.0
( O 1 0.5038763880729675
DM B-Disease 1 0.9999998807907104
) O 0 3.436388578847982e-05
mutation O 0 2.8202695830259472e-05
is O 0 2.0302221059864678e-07
an O 0 4.116941170195787e-07
unstable O 0 0.0005204292247071862
( O 0 1.0955235296705723e-07
CTG O 0 2.5353554519824684e-05
) O 0 5.8265893443376626e-08
n O 0 3.2625229096083785e-07
repeat O 0 2.477153770996665e-07
, O 0 1.223795909055525e-08
present O 0 7.812255731209916e-09
at O 0 3.237687007384693e-09
a O 0 4.2889791274092204e-08
copy O 0 1.5667230002236465e-07
number O 0 3.92270838034392e-09
of O 0 1.5593192292939762e-09
5 O 0 6.9192978457977e-08
- O 0 5.552533821173711e-06
37 O 0 5.983769710837805e-07
repeats O 0 1.731789751602264e-07
on O 0 4.763385419437327e-08
normal O 0 4.249299934144801e-08
chromosomes O 0 7.183851380432316e-08
but O 0 1.5421385057834414e-08
amplified O 0 2.1596395072265295e-07
to O 0 2.4407075471799544e-08
50 O 0 5.0072994639549506e-08
- O 0 1.7718163007884868e-06
3000 O 0 9.483875373916817e-07
copies O 0 5.690513944500708e-07
on O 0 3.0812673230684595e-06
DM B-Disease 1 0.9999932050704956
chromosomes O 0 0.00011050617467844859
. O 0 3.935934728360735e-06

Previous O 0 6.387602479662746e-05
findings O 0 2.6394745873403735e-05
in O 0 7.20411776455876e-07
Caucasian O 0 2.6058100047521293e-05
populations O 0 1.4819860894021986e-07
of O 0 1.660207438192174e-08
a O 0 0.0008589758654125035
DM B-Disease 1 1.0
founder O 0 0.058251671493053436
chromosome O 0 5.161114677321166e-05
raise O 0 3.404128108286386e-07
a O 0 1.513426610699753e-07
question O 0 5.868503194506047e-08
about O 0 6.920483297534474e-09
the O 0 3.6403196013168326e-09
molecular O 0 8.105696736038226e-08
events O 0 7.006468294434853e-09
involved O 0 1.2752604305887871e-08
in O 0 8.30381896577137e-09
the O 0 3.726080421984079e-08
expansion O 0 5.179581421543844e-06
mutation O 0 1.5284829714801162e-05
. O 0 1.8735124740487663e-06

To O 0 5.645585588354152e-06
investigate O 0 5.4849570005899295e-06
whether O 0 5.697269216398126e-07
a O 0 6.285785616455541e-07
founder O 0 9.888897693599574e-06
chromosome O 0 4.581323537422577e-06
for O 0 7.575743410370706e-08
the O 0 1.3036557220402756e-06
DM B-Disease 1 0.9999998807907104
mutation O 0 0.002261265879496932
exists O 0 8.211214463926808e-08
in O 0 9.727443739393493e-09
the O 0 9.870193551364537e-09
Japanese O 0 3.308689429104561e-07
population O 0 2.925275843779218e-08
, O 0 1.4603792841683116e-08
we O 0 1.8589467742913257e-08
genotyped O 0 2.428139396215556e-06
families O 0 1.6300036875804835e-08
using O 0 2.3598465404006674e-08
polymorphic O 0 2.9573991469078464e-06
markers O 0 1.192522290693887e-06
near O 0 3.8699249671481084e-07
the O 0 6.425821652555896e-08
( O 0 7.01133728853165e-08
CTG O 0 9.020642210089136e-06
) O 0 5.409278713841559e-08
n O 0 3.6529041835819953e-07
repeat O 0 6.298632797552273e-07
region O 0 1.529076172346322e-07
and O 0 2.3808655669199652e-07
constructed O 0 8.035614155232906e-05
haplotypes O 0 0.0003710270975716412
. O 0 5.640570634568576e-06

Six O 0 8.258290108642541e-06
different O 0 3.116923323887022e-07
haplotypes O 0 9.428950761503074e-06
were O 0 3.5715805779545917e-07
found O 0 6.882974048494361e-07
and O 0 7.167152489273576e-06
DM B-Disease 1 0.9999998807907104
alleles O 0 0.0007309869979508221
were O 0 2.183291599067161e-06
always O 0 2.1029557046858827e-06
haplotype O 0 0.00022824799816589803
A O 0 2.1954514522803947e-05
. O 0 4.5132828745408915e-06

To O 0 4.4990838432568125e-06
find O 0 1.3343534419618663e-06
an O 0 8.28858475188099e-08
origin O 0 3.2934895699554545e-08
of O 0 5.427392757439975e-09
the O 0 3.792764857735165e-08
( O 0 4.253751484384338e-08
CTG O 0 1.4211841516953427e-05
) O 0 3.388618807775856e-08
n O 0 3.5470662851366797e-07
repeat O 0 9.282381370212534e-07
mutation O 0 4.5359740852290997e-07
and O 0 2.1675621297845282e-08
to O 0 1.731110366165467e-08
investigate O 0 5.692919913258265e-08
the O 0 4.4014276667780905e-09
mechanism O 0 5.080953435765423e-09
of O 0 9.163076408746917e-10
the O 0 3.804776493865347e-09
expansion O 0 9.825418345599246e-08
mutation O 0 1.4487332578028145e-07
in O 0 2.7107929234659878e-09
the O 0 2.4373751905670815e-09
Japanese O 0 6.15356441358017e-08
population O 0 5.500405020342214e-09
we O 0 2.4687794031308385e-09
have O 0 4.340096726451748e-09
studied O 0 3.332121423227363e-08
90 O 0 4.6492267813391663e-08
Japanese O 0 1.934256488311803e-06
DM B-Disease 1 0.9999969005584717
families O 0 7.260828169819433e-07
comprising O 0 6.752865999715141e-08
190 O 0 1.7061461221601348e-07
affected O 0 9.826430158454968e-08
and O 0 6.389157647390675e-08
130 O 0 9.326757890448789e-07
unaffected O 0 1.9308070477563888e-05
members O 0 4.16134128045087e-07
. O 0 1.3325005738806794e-06

The O 0 4.059995262650773e-06
results O 0 2.835420673363842e-06
suggest O 0 4.0404515289083065e-07
that O 0 2.6643528272529693e-08
a O 0 2.6550850407147664e-07
few O 0 2.563192822435667e-07
common O 0 1.3914895191646792e-07
ancestral O 0 1.3744079296884593e-06
mutations O 0 1.0100020517711528e-06
in O 0 1.4953078775192807e-08
both O 0 2.1770295788314797e-08
Caucasian O 0 1.4656793609901797e-06
and O 0 7.727343387387009e-08
Japanese O 0 5.562702654060558e-07
populations O 0 5.4048335584866436e-08
have O 0 1.878787081466271e-08
originated O 0 1.5824776156136977e-08
by O 0 3.982727037055156e-09
expansion O 0 1.911189428938087e-08
of O 0 3.856416075365132e-09
an O 0 5.388827162278176e-08
ancestral O 0 6.334203135338612e-07
n O 0 1.017920453705301e-06
= O 0 2.1406310679594753e-07
5 O 0 1.9727862010654462e-08
repeat O 0 1.2198648846606375e-07
to O 0 1.2643644708987267e-07
n O 0 3.6664778235717677e-06
= O 0 1.4771168252991629e-06
19 O 0 2.961300538117939e-07
- O 0 3.6303206343291095e-06
37 O 0 1.9173710370523622e-06
copies O 0 1.238393792846182e-06
. O 0 6.901852884766413e-07

These O 0 1.3255346402729629e-06
data O 0 6.528059657284757e-07
support O 0 2.1364645874655253e-07
multistep O 0 4.720734978036489e-06
models O 0 5.881131528440164e-07
of O 0 2.5041595463903832e-08
triplet O 0 4.932372030452825e-05
repeat O 0 7.262531767082692e-07
expansion O 0 6.928859619392824e-08
that O 0 2.0627750174639914e-08
have O 0 1.8203161644692045e-08
been O 0 3.398204384552628e-08
proposed O 0 4.852871171578954e-08
for O 0 3.658119140936833e-08
both O 0 2.015123300225241e-06
DM B-Disease 1 0.9999995231628418
and O 0 0.00018280025688000023
Friedreichs B-Disease 0 0.037541989237070084
ataxia I-Disease 1 0.7412553429603577
. O 0 1.7566870837981696e-06
. O 0 2.2365145468938863e-06

The O 0 1.6782710190454964e-06
molecular O 0 2.0855143247899832e-06
basis O 0 1.760798511440953e-07
of O 0 1.5613370578648755e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 0.9999991655349731
in O 0 4.028662203836575e-07
the O 0 8.064645840022422e-08
western O 0 4.223036285111448e-07
Cape O 0 1.592886405887839e-06
, O 0 6.933248641871614e-08
South O 0 9.329972527893915e-08
Africa O 0 2.7172166028321953e-07
. O 0 1.034576712299895e-06

Deficiency B-Disease 1 0.9971733093261719
of I-Disease 0 2.927313857981062e-07
the I-Disease 0 9.497545505610105e-08
sixth I-Disease 0 3.811911710727145e-07
component I-Disease 0 5.381750156630005e-08
of I-Disease 0 4.2486978379940865e-09
human I-Disease 0 5.422511861752355e-08
complement I-Disease 0 3.1274964840122266e-07
( O 0 9.649392040955718e-08
C6 O 0 0.0007824267377145588
) O 0 5.179686723977284e-08
has O 0 8.887908506949316e-07
been O 0 1.2131607718401938e-06
reported O 0 6.772807523702795e-07
in O 0 6.2642149245561995e-09
a O 0 3.213412114178027e-08
number O 0 5.690854010254043e-09
of O 0 2.6466442371031462e-09
families O 0 1.860521692265138e-08
from O 0 3.801388537283401e-09
the O 0 7.675135194062932e-09
western O 0 1.8674158752673975e-07
Cape O 0 1.1632014320639428e-06
, O 0 1.4953226923353213e-07
South O 0 1.4229549094579852e-07
Africa O 0 2.688473728085228e-07
. O 0 7.612207468810084e-07

Meningococcal B-Disease 1 0.9999035596847534
disease I-Disease 1 0.9983319640159607
is O 0 9.070366104424465e-06
endemic O 0 2.83802046396886e-06
in O 0 1.5834262967473478e-07
the O 0 9.111845145071129e-08
Cape O 0 1.8804614683176624e-06
and O 0 6.048855283324883e-08
almost O 0 2.5410921367097217e-08
all O 0 5.663296054336797e-09
pedigrees O 0 1.8147491687159345e-07
of O 0 6.649592876328825e-08
total O 0 0.0034698345698416233
C6 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
( O 0 4.6644865392408974e-07
C6Q0 O 0 0.0032450163271278143
) O 0 9.985896554098872e-08
have O 0 3.2853709086566596e-08
been O 0 1.2266170301700186e-07
ascertained O 0 8.724375675228657e-07
because O 0 4.536038744618054e-08
of O 0 7.779235033922305e-08
recurrent O 1 0.9970705509185791
disease O 1 0.896037757396698
. O 0 8.976619938039221e-06

We O 0 5.659245289280079e-06
have O 0 4.4990699166191916e-07
sequenced O 0 6.74503951358929e-07
the O 0 7.841234861416524e-08
expressed O 0 2.5624621002862114e-07
exons O 0 4.731980709493655e-07
of O 0 1.0109578951755793e-08
the O 0 4.016547094920497e-08
C6 O 0 0.00058919278671965
gene O 0 2.600859545509593e-07
from O 0 1.0108151649035335e-08
selected O 0 3.117921920647859e-08
cases O 0 3.0588115151886086e-08
and O 0 5.637691913307208e-08
have O 0 2.1395474902874412e-07
found O 0 1.1904163699227865e-07
three O 0 5.274840120250701e-08
molecular O 0 7.950652616273146e-06
defects O 0 0.00863280426710844
leading O 0 7.620844257871795e-07
to O 0 2.70783903033589e-06
total O 0 0.0004137696814723313
deficiency O 1 0.5933814644813538
879delG O 0 7.290534995263442e-05
, O 0 6.973765920292863e-08
which O 0 2.9527042144650295e-08
is O 0 7.54393170154799e-09
the O 0 1.3398151921251156e-08
common O 0 1.905333704144141e-07
defect O 0 1.6149189832503907e-05
in O 0 6.845028366342376e-08
the O 0 7.846935545785527e-08
Cape O 0 8.865973768479307e-07
and O 0 1.4862732200526807e-07
hitherto O 0 3.3773835639294703e-06
unreported O 0 3.8957787751314754e-07
, O 0 2.5626642141673983e-08
and O 0 2.5373580569976184e-08
1195delC O 0 2.0260840756236576e-06
and O 0 4.3048128617328985e-08
1936delG O 0 2.945223059214186e-06
, O 0 2.8859005851700203e-08
which O 0 2.0443188475383067e-08
have O 0 2.789923314594489e-08
been O 0 6.80727083590682e-08
previously O 0 3.7133037267267355e-07
reported O 0 2.5550949089847563e-07
in O 0 1.7207341329594783e-08
African O 0 1.0995932342439119e-07
- O 0 4.747240018332377e-05
Americans O 0 1.3308419966051588e-06
. O 0 7.765801797177119e-07

We O 0 2.614759523567045e-06
also O 0 3.1668653832639393e-07
show O 0 1.0982957121541403e-07
that O 0 6.7394556602096145e-09
the O 0 1.0544066952888898e-08
879delG O 0 2.622291276566102e-06
and O 0 1.8375668275893986e-07
1195delC O 0 0.008778647519648075
defects O 1 0.5579304099082947
are O 0 4.762358329912786e-08
associated O 0 1.104697346931971e-07
with O 0 1.4091614275457687e-07
characteristic O 0 0.0006814691005274653
C6 O 1 0.9986532926559448
/ O 0 0.004359533078968525
C7 O 0 0.013243031688034534
region O 0 1.1876512644448667e-06
DNA O 0 3.5028883758059237e-06
marker O 0 4.8855639761313796e-05
haplotypes O 0 6.823320291005075e-05
, O 0 8.923786509740239e-08
although O 0 2.414090438662697e-08
small O 0 1.7518400952099e-08
variations O 0 5.221088485996006e-07
were O 0 3.3688931466713257e-07
observed O 0 2.0160227904852945e-06
. O 0 1.3806663901050342e-06

The O 0 6.424249477277044e-06
1936delG O 0 0.00011697912123054266
defect O 0 0.00011958683171542361
was O 0 2.5831016046140576e-06
observed O 0 2.2651829567621462e-07
only O 0 2.5376341028504612e-08
once O 0 3.8169606142446355e-08
in O 0 8.735637990753276e-09
the O 0 1.2319389064430197e-08
Cape O 0 7.59451381782128e-07
, O 0 1.672883875869502e-08
but O 0 4.299971223531429e-08
its O 0 1.7682549469100195e-07
associated O 0 3.010384034496383e-06
haplotype O 0 0.0001714588433969766
could O 0 7.933526831038762e-07
be O 0 2.3567702100990573e-07
deduced O 0 8.386530680581927e-06
. O 0 1.6194586578421877e-06

The O 0 2.13958946915227e-06
data O 0 3.4148908412134915e-07
from O 0 1.6620386844579116e-08
the O 0 3.197912334940156e-08
haplotypes O 0 2.3409573259414174e-05
indicate O 0 1.1773888672905741e-06
that O 0 4.276635934274964e-08
these O 0 8.203712376086969e-09
three O 0 4.331225511577941e-08
molecular O 0 2.7048914489569142e-05
defects O 0 0.0438314750790596
account O 0 1.2466560406210192e-07
for O 0 1.8986797911679787e-08
the O 0 2.672099128631089e-07
defects O 0 0.09335089474916458
in O 0 5.487372334300744e-08
all O 0 9.641992981812564e-09
the O 0 3.120670655221147e-08
38 O 0 9.898851658363128e-07
unrelated O 0 8.993035862658871e-07
C6Q0 O 0 0.0006520613678731024
individuals O 0 2.051118741519531e-08
we O 0 5.197696051340017e-09
have O 0 1.1817086864596149e-08
studied O 0 5.194250007889423e-08
from O 0 1.0995718113804287e-08
the O 0 4.811194642684313e-08
Cape O 0 8.169975444616284e-06
. O 0 2.2099884517956525e-06

We O 0 6.463068530138116e-06
have O 0 5.578283435170306e-07
also O 0 1.264236715314837e-07
observed O 0 8.018508879104047e-08
the O 0 1.9743071177913407e-08
879delG O 0 1.6188230802072212e-05
defect O 0 1.2691968549916055e-05
in O 0 1.3437622214951261e-07
two O 0 1.8035980247077532e-06
Dutch O 1 0.8833318948745728
C6 B-Disease 1 0.9999966621398926
- I-Disease 1 0.999934196472168
deficient I-Disease 1 0.9999901056289673
kindreds O 0 0.00025931396521627903
, O 0 1.6357850540771324e-07
but O 0 4.335258907417483e-08
the O 0 1.7020466813733037e-08
879delG O 0 1.040473762259353e-05
defect O 0 5.542613962461473e-06
in O 0 2.1235427638544024e-08
the O 0 3.3305838087471784e-08
Cape O 0 1.5845334928599186e-06
probably O 0 1.7748282061802456e-06
did O 0 1.0432525243686541e-07
not O 0 7.2525070393680835e-09
come O 0 7.632158904868902e-09
from O 0 3.807709259007197e-09
The O 0 8.979785803830964e-09
Netherlands O 0 1.926654931594385e-06
. O 0 1.4229495093331934e-07
. O 0 4.6636594674964726e-07

Complement B-Disease 1 0.9882083535194397
C7 I-Disease 1 0.9999994039535522
deficiency I-Disease 1 0.9999994039535522
: O 0 6.354427114274586e-06
seven O 0 1.0315561667084694e-06
further O 0 5.065793402536656e-07
molecular O 0 7.347066275542602e-05
defects O 0 0.2037658840417862
and O 0 2.1268996874823642e-07
their O 0 1.591006792978078e-07
associated O 0 2.3945606244524242e-06
marker O 0 0.00016205151041503996
haplotypes O 0 0.0013689257903024554
. O 0 6.59768420518958e-06

Seven O 0 3.300661774119362e-05
further O 0 1.776519980012381e-06
molecular O 0 2.615103767311666e-06
bases O 0 1.1564629858185071e-06
of O 0 5.877050170965958e-06
C7 B-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
are O 0 3.92500032830867e-06
described O 0 9.677944763097912e-05
. O 0 4.596250164468074e-06

All O 0 7.519828386648442e-07
these O 0 3.743019405533232e-08
new O 0 1.3714578983581305e-07
molecular O 0 1.4097454368311446e-05
defects O 0 0.005516423843801022
involve O 0 1.3165127654701791e-07
single O 0 5.177247430765419e-07
- O 0 2.3730681277811527e-06
nucleotide O 0 1.2230682955305383e-07
events O 0 1.2638432522749099e-08
, O 0 8.588434852185856e-09
deletions O 0 1.6210411502015631e-07
and O 0 1.2972293461643858e-08
substitutions O 0 1.0771821479238497e-07
, O 0 1.3218135919146334e-08
some O 0 1.6581240824820043e-09
of O 0 1.2805074778299286e-09
which O 0 5.252712043102292e-08
alter O 0 5.43558940080402e-07
splice O 0 1.8061197124552564e-06
sites O 0 4.6234401196443287e-08
, O 0 1.7195727508578784e-08
and O 0 4.220761340434365e-08
others O 0 5.894157766306307e-07
codons O 0 5.093394065625034e-06
. O 0 1.624564902158454e-06

They O 0 2.7763157959270757e-06
are O 0 4.9770488175227e-08
distributed O 0 4.8174022992952814e-08
along O 0 1.924926706919905e-08
the O 0 2.1146830064822097e-08
C7 O 0 8.733793220017105e-05
gene O 0 3.5142170418112073e-07
, O 0 2.4833644474142602e-08
but O 0 2.1241017833517617e-08
predominantly O 0 3.3157391499116784e-08
towards O 0 2.1569096730900128e-08
the O 0 4.537025333206657e-08
3 O 0 3.2308108188772167e-07
end O 0 5.896243919778499e-07
. O 0 1.4030214288140996e-06

All O 0 1.3963978062747628e-06
were O 0 3.7757530435555964e-07
found O 0 1.0781852921581958e-07
in O 0 6.358473569889611e-08
compound O 0 2.6803691071108915e-05
heterozygous O 0 0.00014209002256393433
individuals O 0 8.168505019057193e-07
. O 0 1.3386372756940546e-06

The O 0 4.8460668040206656e-05
C6 O 1 0.8485514521598816
/ O 0 0.004636838566511869
C7 O 0 0.35920464992523193
marker O 0 0.0073011708445847034
haplotypes O 0 0.01800435781478882
associated O 0 8.581055226386525e-06
with O 0 6.923686441950849e-07
most O 0 1.845976476033684e-05
C7 B-Disease 1 0.9997738003730774
defects I-Disease 1 0.999326229095459
are O 0 8.724167628315627e-07
tabulated O 0 1.0848625606740825e-05
. O 0 4.1664796412987926e-07
. O 0 5.766191861766856e-07

A O 0 0.00010806211503222585
genome O 0 1.0332483725505881e-05
- O 0 9.816978490562178e-06
wide O 0 5.951954449301411e-07
search O 0 2.1940064698355854e-07
for O 0 9.084808283432722e-08
chromosomal O 0 3.301637843833305e-05
loci O 0 3.7574077396129724e-06
linked O 0 2.1025081878178753e-05
to O 0 1.9980741853942163e-05
mental O 1 0.873032808303833
health O 0 6.389229383785278e-05
wellness O 0 6.598226173082367e-05
in O 0 7.009718956396682e-07
relatives O 0 2.6613568024913548e-06
at O 0 5.800166391622952e-08
high O 0 1.7070751709979959e-06
risk O 0 1.6520676808795542e-06
for O 0 5.876567684026668e-06
bipolar B-Disease 1 0.9999980926513672
affective I-Disease 1 0.9999804496765137
disorder I-Disease 1 0.9985613226890564
among O 0 1.267883220634758e-07
the O 0 4.2130317012833984e-08
Old O 0 3.486737114144489e-06
Order O 0 4.3713367858799757e-07
Amish O 0 2.141004370059818e-05
. O 0 2.444030087644933e-06

Bipolar B-Disease 1 0.999992847442627
affective I-Disease 1 0.9999871253967285
disorder I-Disease 1 0.9999951124191284
( O 0 0.0006828304030932486
BPAD B-Disease 1 0.9999916553497314
; O 0 0.00195709359832108
manic B-Disease 1 0.9999018907546997
- I-Disease 1 0.9999759197235107
depressive I-Disease 1 0.9999992847442627
illness I-Disease 1 0.9991256594657898
) O 0 2.4028409484344593e-07
is O 0 2.3740453514164983e-07
characterized O 0 9.371435680805007e-07
by O 0 4.4888224692840595e-08
episodes O 0 5.780143510492053e-07
of O 0 4.385868024314732e-08
mania B-Disease 0 0.0002702716155909002
and O 0 2.4220985324063804e-06
/ O 0 1.892094405775424e-05
or O 0 3.3115998121502344e-07
hypomania B-Disease 0 0.00706491619348526
interspersed O 0 1.6135025362018496e-05
with O 0 1.6302874428220093e-07
periods O 0 7.452134695995483e-07
of O 0 1.8077379593250953e-07
depression B-Disease 0 0.0004183358105365187
. O 0 4.435068603925174e-06

Compelling O 0 0.00035352518898434937
evidence O 0 1.3612145266961306e-05
supports O 0 1.9127667201246368e-06
a O 0 4.3549673023335345e-07
significant O 0 2.1895147028772044e-07
genetic O 0 2.8348102887321147e-07
component O 0 6.684766873377157e-08
in O 0 2.8748143421353234e-08
the O 0 8.219503655482185e-08
susceptibility O 0 0.00036455216468311846
to O 0 2.2690885543852346e-06
develop O 0 8.021962275961414e-05
BPAD B-Disease 1 0.9999682903289795
. O 0 3.574067886802368e-05

To O 0 6.401174687198363e-06
date O 0 2.566509692769614e-06
, O 0 1.8417880198740022e-07
however O 0 1.1397793286960223e-07
, O 0 5.1521571009516265e-08
linkage O 0 1.9291924218123313e-06
studies O 0 1.224410368649842e-07
have O 0 3.421951433324466e-08
attempted O 0 3.6752646792592714e-06
only O 0 3.22696749321949e-08
to O 0 3.836309048210751e-08
identify O 0 3.256535876516864e-07
chromosomal O 0 1.640091613808181e-05
loci O 0 6.163137982184708e-07
that O 0 2.7612887265604513e-07
cause O 0 6.58045792079065e-07
or O 0 2.2699010671090036e-08
increase O 0 1.7617794867419434e-07
the O 0 6.03957488465312e-08
risk O 0 3.2144487249752274e-07
of O 0 3.481611798861195e-08
developing O 0 4.459417141333688e-06
BPAD B-Disease 1 0.9999605417251587
. O 0 1.1748667020583525e-05

To O 0 2.692491761990823e-06
determine O 0 6.075983378650562e-07
whether O 0 1.300797691783373e-07
there O 0 4.243581486207404e-08
could O 0 1.549232422348723e-07
be O 0 3.927307190565443e-08
protective O 0 4.938594884151826e-06
alleles O 0 4.0930257227955735e-07
that O 0 3.684918681301497e-08
prevent O 0 6.588677337049376e-08
or O 0 3.12011714242999e-08
reduce O 0 5.403678642323939e-07
the O 0 1.3796962150536274e-07
risk O 0 1.5417303700360208e-07
of O 0 1.0801670669025043e-08
developing O 0 5.121597723700688e-07
BPAD B-Disease 1 0.9999935626983643
, O 0 4.099049135675159e-07
similar O 0 4.687192856067668e-08
to O 0 2.6206652847804435e-08
what O 0 1.409902861126966e-08
is O 0 2.7848246375583585e-08
observed O 0 1.0234957414922974e-07
in O 0 4.705807299387743e-08
other O 0 1.330899067397695e-06
genetic B-Disease 1 0.9999148845672607
disorders I-Disease 1 0.999993085861206
, O 0 4.316154900152469e-07
we O 0 1.1365014529474138e-07
used O 0 4.638106838683598e-05
mental O 1 0.7008545398712158
health O 0 3.002413723152131e-05
wellness O 0 2.806139673339203e-05
( O 0 4.3478539879515665e-08
absence O 0 1.8398394274754537e-07
of O 0 4.277002929597984e-08
any O 0 9.920939191943035e-06
psychiatric B-Disease 1 0.9999785423278809
disorder I-Disease 1 0.931274950504303
) O 0 4.544248355387026e-08
as O 0 7.82374129926211e-08
the O 0 1.3484168448485434e-07
phenotype O 0 0.0006847006734460592
in O 0 3.170243090266922e-08
our O 0 8.167054588170686e-09
genome O 0 4.086901128630416e-08
- O 0 9.5634186436655e-07
wide O 0 3.064286318021914e-07
linkage O 0 4.385033207654487e-06
scan O 0 1.7489361198386177e-05
of O 0 6.640097804933021e-09
several O 0 2.645626118180644e-08
large O 0 6.127504548203433e-08
multigeneration O 0 6.403690349543467e-06
Old O 0 6.53667541428149e-07
Order O 0 5.893314991567422e-08
Amish O 0 1.836960450418701e-06
pedigrees O 0 3.0688186143379426e-06
exhibiting O 0 8.54167296893138e-07
an O 0 1.4019283867128252e-07
extremely O 0 4.626061127055436e-06
high O 0 1.3481494534062222e-05
incidence O 0 0.0006858902634121478
of O 0 1.409213950864796e-06
BPAD B-Disease 1 0.9999756813049316
. O 0 7.683524745516479e-05

We O 0 2.867700459319167e-06
have O 0 2.0331437156073662e-07
found O 0 5.7796590624548116e-08
strong O 0 9.345770735080805e-08
evidence O 0 8.22668724254072e-08
for O 0 1.1266010346844268e-08
a O 0 4.099455566120014e-07
locus O 0 1.9510509901010664e-06
on O 0 9.838898904490634e-07
chromosome O 0 1.4344082956085913e-05
4p O 0 6.676062184851617e-05
at O 0 6.145705100379928e-08
D4S2949 O 0 1.6615177855783259e-06
( O 0 1.9353043612113652e-08
maximum O 0 3.328393347601377e-07
GENEHUNTER O 0 2.522262730053626e-05
- O 0 7.8693201430724e-06
PLUS O 0 1.1415006611059653e-06
nonparametric O 0 2.8028844099026173e-06
linkage O 0 2.158158167731017e-06
score O 0 8.035921723603678e-07
= O 0 8.309065719913633e-07
4 O 0 9.641039611096858e-08
. O 0 3.152834082698064e-08
05 O 0 1.755169819261937e-06
, O 0 6.543279340576191e-08
P O 0 2.1896119051234564e-06
= O 0 1.6801145363842807e-07
5 O 0 1.9316718891104756e-08
. O 0 4.841035128322346e-09
22 O 0 3.3647953756599236e-08
x O 0 1.0271151040797122e-06
10 O 0 3.569148532278632e-08
( O 0 9.83775372276341e-09
- O 0 2.2213798729353584e-06
4 O 0 1.8485805242107745e-07
) O 0 2.3504131974050324e-08
; O 0 4.808213205365064e-08
SIBPAL O 0 1.3848354683432262e-05
Pempirical O 0 3.4290351322852075e-06
value O 0 1.860681564380684e-08
< O 0 1.0737073807831621e-07
3 O 0 6.929692375479135e-08
x O 0 1.0172595921176253e-06
10 O 0 5.4715908248681444e-08
( O 0 1.4788624547179552e-08
- O 0 2.279862655996112e-06
5 O 0 9.714635496038682e-08
) O 0 5.280041293076465e-09
) O 0 5.174647821348799e-09
and O 0 3.3670168875232775e-08
suggestive O 0 3.0186204185156384e-06
evidence O 0 7.818878344778568e-08
for O 0 6.2289724489517084e-09
a O 0 2.0959869573289325e-07
locus O 0 1.7450789755457663e-06
on O 0 2.8054812446498545e-06
chromosome O 0 0.0005354078602977097
4q O 1 0.9882159233093262
at O 0 1.384760679457031e-07
D4S397 O 0 2.397997604930424e-06
( O 0 2.040135527181519e-08
maximum O 0 2.0204987549732323e-07
GENEHUNTER O 0 1.493359468440758e-05
- O 0 3.1546142054139636e-06
PLUS O 0 4.930045065520972e-07
nonparametric O 0 2.0969096112821717e-06
linkage O 0 1.3519337471734616e-06
score O 0 7.39996892207273e-07
= O 0 9.896170922729652e-07
3 O 0 8.177563870503946e-08
. O 0 1.6954013304371074e-08
29 O 0 1.54681401909329e-07
, O 0 3.8685147529804453e-08
P O 0 1.6777988776084385e-06
= O 0 1.339455479865137e-07
2 O 0 1.4188539232407038e-08
. O 0 3.308314955319247e-09
57 O 0 1.0996791388606653e-07
x O 0 8.968045221990906e-07
10 O 0 2.6110360096254226e-08
( O 0 5.759583476816488e-09
- O 0 2.761957375696511e-06
3 O 0 1.6416456105616817e-07
) O 0 2.1090919233301975e-08
; O 0 3.647577884180464e-08
SIBPAL O 0 5.819802481710212e-06
Pempirical O 0 1.392623516949243e-06
value O 0 1.5104310691071987e-08
< O 0 5.883005371742911e-08
1 O 0 1.9610512325130003e-08
x O 0 8.72207124302804e-07
10 O 0 5.57206369933283e-08
( O 0 8.71018190906625e-09
- O 0 3.069541207878501e-06
3 O 0 1.3457126613047876e-07
) O 0 5.1112603038916404e-09
) O 0 1.9625845393278496e-09
that O 0 5.2110173953678895e-09
are O 0 1.2291975437506153e-08
linked O 0 8.778649203122768e-07
to O 0 3.9229312278621364e-06
mental O 1 0.5423936247825623
health O 0 8.504258585162461e-05
wellness O 0 0.0004110679146833718
. O 0 6.80056155033526e-06

These O 0 6.82904783388949e-06
findings O 0 1.2259507457201835e-05
are O 0 5.0846303167872975e-08
consistent O 0 4.935586730425712e-07
with O 0 6.410886044250219e-08
the O 0 8.868505574355368e-08
hypothesis O 0 1.710256015030609e-06
that O 0 1.4056068309287184e-08
certain O 0 5.997089491671659e-09
alleles O 0 1.607723874030853e-07
could O 0 3.2335111654901993e-07
prevent O 0 1.6532324309537216e-07
or O 0 5.92837743340624e-08
modify O 0 1.1420636383263627e-06
the O 0 9.143077051021464e-08
clinical O 0 2.8697195375571027e-06
manifestations O 0 1.3757481838183594e-06
of O 0 9.638520737098588e-08
BPAD B-Disease 1 0.9999871253967285
and O 0 1.0668926506696153e-06
perhaps O 0 1.898209660566863e-07
other O 0 4.149305254941282e-08
related O 0 5.961969691270497e-06
affective B-Disease 1 0.9996181726455688
disorders I-Disease 1 0.998737633228302
. O 0 1.7025364286382683e-05

Segregation O 0 0.006445731967687607
distortion O 0 0.08287769556045532
in O 0 0.0034504311624914408
myotonic B-Disease 1 0.9999954700469971
dystrophy I-Disease 1 0.9999995231628418
. O 0 0.004049929324537516

Myotonic B-Disease 1 0.999998927116394
dystrophy I-Disease 1 1.0
( O 1 0.9961915016174316
DM B-Disease 1 0.9999998807907104
) O 0 2.9579310648841783e-05
is O 0 1.4537644119627657e-06
an O 0 5.318226158124162e-06
autosomal B-Disease 1 0.9933767914772034
dominant I-Disease 1 0.9972973465919495
disease I-Disease 0 0.20633746683597565
which O 0 6.250361366255675e-07
, O 0 3.171876272745067e-08
in O 0 5.907199618349068e-09
the O 0 8.132267304006291e-09
typical O 0 4.1129698047370766e-07
pedigree O 0 1.9169322058587568e-06
, O 0 9.9530534924952e-09
shows O 0 1.3340191173938365e-08
a O 0 2.7164359650555525e-08
three O 0 3.0611694512572285e-08
generation O 0 9.860493719315855e-07
anticipation O 0 1.8400726276013302e-06
cascade O 0 1.7463711628806777e-05
. O 0 2.195198703702772e-06

This O 0 4.295464805181837e-06
results O 0 5.340156349120662e-06
in O 0 1.8909258869825862e-06
infertility B-Disease 1 0.9849550724029541
and O 1 0.9887682795524597
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 2.2826909116702154e-05
CDM B-Disease 0 0.00014007469872012734
) O 0 4.369710637774915e-08
with O 0 1.6363896904181274e-08
the O 0 2.5718208007674548e-08
disappearance O 0 2.893316604968277e-06
of O 0 1.3092308392970153e-07
DM B-Disease 1 0.9999994039535522
in O 0 3.7814641018485418e-06
that O 0 1.0890666999330278e-06
pedigree O 0 2.9227019695099443e-05
. O 0 2.747662847468746e-06

The O 0 6.905690952407895e-07
concept O 0 3.5653732766149915e-07
of O 0 3.172663198824921e-08
segregation O 0 1.420635157955985e-06
distortion O 0 5.358179259928875e-05
, O 0 1.3034912171860924e-07
where O 0 4.683573706643074e-08
there O 0 1.4025431482878048e-08
is O 0 3.058332964656074e-08
preferential O 0 3.1913441489450634e-07
transmission O 0 1.0950519708785578e-06
of O 0 2.7495876686600695e-09
the O 0 6.245616468447679e-09
larger O 0 5.232772792851392e-08
allele O 0 3.361030849191593e-07
at O 0 1.2965763573902223e-08
the O 0 8.459868894306055e-08
DM B-Disease 1 0.9999992847442627
locus O 0 0.0006805448210798204
, O 0 2.495063711194234e-07
has O 0 9.439663273269616e-08
been O 0 2.8989978417826023e-08
put O 0 5.0186589106715473e-08
forward O 0 7.276842239889447e-08
to O 0 7.499976106828399e-08
explain O 0 4.99990335356415e-07
partially O 0 1.3468736597133102e-06
the O 0 1.626320766945355e-08
maintenance O 0 3.8577428540520486e-07
of O 0 7.797299161893534e-08
DM B-Disease 1 0.9999994039535522
in O 0 2.1038301838416373e-06
the O 0 2.1065577016088355e-07
population O 0 4.364080439245299e-07
. O 0 5.649575314237154e-07

In O 0 6.129859229986323e-06
a O 0 1.5379840760942898e-06
survey O 0 1.3320026255314588e-06
of O 0 1.047793247721529e-07
DM B-Disease 1 0.9999957084655762
in O 0 3.7627721667377045e-06
Northern O 0 8.209849511331413e-07
Ireland O 0 2.7761439014284406e-07
, O 0 4.8943203267981517e-08
59 O 0 6.581085472134873e-07
pedigrees O 0 2.0790544112969656e-06
were O 0 6.741888114447647e-07
ascertained O 0 2.0436800696188584e-05
. O 0 3.641815510491142e-06

Sibships O 0 0.0002655792632140219
where O 0 5.840464041284577e-07
the O 0 2.8406171637129773e-08
status O 0 1.3344696014883084e-08
of O 0 1.6908954236782847e-09
all O 0 1.7697665555260755e-09
the O 0 8.128296258291812e-09
members O 0 3.379879132126007e-08
had O 0 1.7225324882019777e-06
been O 0 2.991901055793278e-07
identified O 0 2.2824266920906666e-07
were O 0 2.7247281764175568e-08
examined O 0 2.6525137286625977e-07
to O 0 1.6497084587285826e-08
determine O 0 2.8327285406248848e-08
the O 0 6.5171583685241785e-09
transmission O 0 1.909189819571111e-07
of O 0 3.58539975486849e-09
the O 0 2.4974298185043153e-07
DM B-Disease 1 0.9999971389770508
expansion O 0 1.8022483345703222e-06
from O 0 3.34732028761664e-08
affected O 0 8.98895677892142e-08
parents O 0 5.995216412202353e-08
to O 0 3.17687138817746e-08
their O 0 7.489726527865059e-08
offspring O 0 6.155657956696814e-06
. O 0 1.3772263400824158e-06

Where O 0 5.090315426059533e-06
the O 0 3.4826021533262974e-07
transmitting O 0 7.3212631832575426e-06
parent O 0 2.3816360226192046e-06
was O 0 4.4760665218746e-07
male O 0 8.739356189835235e-07
, O 0 2.178731364210762e-07
58 O 0 5.369034170144005e-06
. O 0 1.6341413129339344e-06

3 O 0 2.8638458388741128e-05
% O 0 3.8931790413698764e-07
of O 0 7.534326051938933e-09
the O 0 3.311555119012155e-08
offspring O 0 3.928486876247916e-06
were O 0 3.5755337535192666e-07
affected O 0 6.183260126135792e-08
, O 0 1.4866568420757176e-08
and O 0 1.7041678290752316e-08
in O 0 1.144883921000428e-08
the O 0 1.591400788925057e-08
case O 0 1.1538131161614729e-07
of O 0 7.036494498180446e-09
a O 0 2.1181965621508425e-06
female O 0 6.361645500874147e-05
transmitting O 0 2.2721269488101825e-05
parent O 0 2.446249936838285e-06
, O 0 1.1375446007377832e-07
68 O 0 2.9964007808302995e-06
. O 0 7.428705544043623e-07

7 O 0 0.00011282877676421776
% O 0 4.398985311127035e-06
were O 0 8.334461654158076e-07
affected O 0 3.0126932415441843e-06
. O 0 4.566867119137896e-06

Studies O 0 7.025311333563877e-06
on O 0 5.314194027050689e-07
meiotic O 0 9.630031854612753e-06
drive O 0 7.786479727656115e-06
in O 0 4.26001361120143e-06
DM B-Disease 1 0.9999995231628418
have O 0 0.00014138707774691284
shown O 0 2.153564992113388e-06
increased O 0 1.1771245311820167e-07
transmission O 0 2.1425327645374637e-07
of O 0 2.621928896218151e-09
the O 0 1.2201622823226899e-08
larger O 0 6.765358762095275e-08
allele O 0 6.017854161655123e-07
at O 0 3.181643748462193e-08
the O 0 1.7769185944871424e-07
DM B-Disease 1 0.9999936819076538
locus O 0 0.00015637744218111038
in O 0 9.265223184229399e-07
non O 0 2.2529898160428274e-06
- O 0 0.2116817981004715
DM O 1 0.9999992847442627
heterozygotes O 0 0.002072908915579319
for O 0 2.1057653611933347e-06
CTGn O 0 0.0001953203318407759
. O 0 3.9518213270639535e-06

This O 0 2.7843364023283357e-06
study O 0 5.832265514982282e-07
provides O 0 1.5179524837094505e-07
further O 0 5.401124170134608e-08
evidence O 0 5.7860006563714705e-08
that O 0 1.4883592136527568e-08
the O 0 1.3248796904008486e-07
DM B-Disease 1 0.9999967813491821
expansion O 0 2.5507129066681955e-06
tends O 0 6.502720566459175e-07
to O 0 8.164799680798751e-08
be O 0 2.2850446157463011e-07
transmitted O 0 4.81406868857448e-06
preferentially O 0 8.75826481205877e-06
. O 0 2.8177482818136923e-06

Diagnosis O 1 0.9953922033309937
of O 0 0.00024958778521977365
hemochromatosis B-Disease 1 0.9999663829803467
. O 0 0.00029305386124178767

If O 0 0.00025908093084581196
untreated O 1 0.7733515501022339
, O 0 5.5890621297294274e-05
hemochromatosis B-Disease 1 0.9999940395355225
can O 0 7.70903643569909e-05
cause O 0 0.00031720256083644927
serious O 0 0.42836806178092957
illness O 1 0.9623717665672302
and O 0 4.947810793964891e-06
early B-Disease 0 4.2049778130603954e-05
death I-Disease 0 0.04396921396255493
, O 0 1.7532616425341985e-07
but O 0 4.820017238671426e-07
the O 0 7.900201239863236e-07
disease O 0 4.031503340229392e-05
is O 0 2.260797629105582e-07
still O 0 1.8935858179247589e-06
substantially O 0 6.392555405909661e-06
under O 0 4.900466137769399e-06
- O 1 0.9912992119789124
diagnosed O 1 0.9987745881080627
. O 0 3.723307145264698e-06

The O 0 1.6360297649953282e-06
cornerstone O 0 3.3414887639082735e-06
of O 0 6.47833218181404e-08
screening O 0 5.14165265030897e-07
and O 0 2.219400982994557e-07
case O 0 1.228777591677499e-06
detection O 0 3.357647813118092e-07
is O 0 2.553130862281705e-08
the O 0 6.659935269937023e-09
measurement O 0 1.2288474238175695e-07
of O 0 9.405100698245406e-09
serum O 0 9.619435559216072e-07
transferrin O 0 3.4769648209476145e-06
saturation O 0 1.2453673434720258e-06
and O 0 3.108047863520369e-08
the O 0 4.30360600489621e-08
serum O 0 2.874896836146945e-06
ferritin O 0 2.6623632948030718e-05
level O 0 4.4232356799511763e-07
. O 0 9.152549296231882e-07

Once O 0 2.0830411813221872e-05
the O 0 6.425361789297312e-07
diagnosis O 0 0.0006094377022236586
is O 0 1.4319860497380432e-07
suspected O 0 3.55631686943525e-06
, O 0 1.0209859055976267e-06
physicians O 0 2.172369022446219e-06
must O 0 9.687990143447678e-08
use O 0 1.642347058350424e-07
serum O 0 8.465955943393055e-06
ferritin O 0 0.0001444042136427015
levels O 0 1.86417736358635e-07
and O 0 1.7602008028916316e-07
hepatic O 0 6.974780990276486e-05
iron O 0 0.005588205065578222
stores O 0 8.91803324520879e-07
on O 0 3.330347453811555e-06
liver O 0 0.000601449457462877
biopsy O 0 0.160127654671669
specimens O 0 1.5244589803842246e-06
to O 0 3.826334591394698e-07
assess O 0 0.00011854670447064564
patients O 0 0.00019842528854496777
for O 0 1.667137539129726e-08
the O 0 1.856994025217773e-08
presence O 0 1.0412924211777863e-07
of O 0 6.134298757842771e-08
iron B-Disease 0 0.4913681149482727
overload I-Disease 0 0.04387645050883293
. O 0 6.438792297558393e-06

Liver O 1 0.9953615069389343
biopsy O 1 0.9792030453681946
is O 0 3.630923174569034e-06
also O 0 2.615617233914236e-07
used O 0 6.587295331428322e-08
to O 0 2.3832864570749734e-08
establish O 0 2.1690429008458523e-08
the O 0 1.0369632263973472e-08
presence O 0 4.763839456245478e-08
or O 0 1.4388409574905836e-08
absence O 0 1.7572054389347613e-07
of O 0 1.2005220639821346e-07
cirrhosis B-Disease 1 0.8877000212669373
, O 0 5.314158215696807e-07
which O 0 2.2143143496577977e-07
can O 0 3.8850490113873093e-07
affect O 0 2.6264835923939245e-06
prognosis O 1 0.7546687722206116
and O 0 3.734441406777478e-06
management O 0 6.846869837318081e-06
. O 0 1.922851652125246e-06

A O 0 4.741358134197071e-05
DNA O 0 1.2309226804063655e-05
- O 0 3.1563075026497245e-05
based O 0 4.733217622288066e-07
test O 0 7.30381799485258e-08
for O 0 3.90392917992699e-09
the O 0 1.5777580131270952e-08
HFE O 0 9.140948532149196e-05
gene O 0 2.444805886625545e-07
is O 0 2.1736772382041636e-08
commercially O 0 1.0498697378125144e-07
available O 0 1.4438087170276503e-08
, O 0 4.8857460299700506e-09
but O 0 4.145356058415928e-09
its O 0 7.716234762256136e-09
place O 0 2.8734165269383993e-08
in O 0 2.772528873151714e-08
the O 0 1.5898359606580925e-07
diagnosis O 0 0.010529558174312115
of O 0 1.1373236930012354e-06
hemochromatosis B-Disease 1 0.9999995231628418
is O 0 1.075907039194135e-05
still O 0 2.3383879579341738e-06
being O 0 1.073739667845075e-06
evaluated O 0 3.428721356613096e-06
. O 0 1.0522409183977288e-06

Currently O 0 8.083530701696873e-06
, O 0 7.188936734792151e-08
the O 0 5.686904280821636e-09
most O 0 8.210161439592412e-09
useful O 0 8.071073587245792e-09
role O 0 1.6086248777469336e-08
for O 0 1.0359866742248869e-08
this O 0 1.7155301179627713e-08
test O 0 1.5690795862610685e-07
is O 0 1.2734131971114948e-08
in O 0 4.520265939333967e-09
the O 0 7.23729298712783e-09
detection O 0 1.4499744338536402e-07
of O 0 9.723272853534581e-08
hemochromatosis B-Disease 1 0.9999980926513672
in O 0 2.0948998269432195e-07
the O 0 3.034023521308882e-08
family O 0 1.1315179193616132e-07
members O 0 5.940055558539825e-09
of O 0 1.7242429706243456e-08
patients O 0 1.808202432584949e-05
with O 0 7.766455212276924e-08
a O 0 8.489977517456282e-06
proven O 0 2.9003977033426054e-05
case O 0 4.710701659860206e-07
of O 0 2.1228220958846578e-08
the O 0 1.438003664588905e-06
disease O 0 0.00021493794338312
. O 0 4.15132672060281e-06

It O 0 1.368517132505076e-06
is O 0 9.968654524072917e-08
crucial O 0 3.429067589877377e-07
to O 0 5.091728326078737e-06
diagnose O 1 0.9998997449874878
hemochromatosis B-Disease 1 0.9999997615814209
before O 0 0.03019060753285885
hepatic B-Disease 1 0.9991631507873535
cirrhosis I-Disease 1 0.9987916350364685
develops O 0 0.0015291578602045774
because O 0 4.9135223889607005e-06
phlebotomy O 0 0.012924693524837494
therapy O 0 0.003955453634262085
can O 0 1.3306313348948606e-06
avert O 0 0.006695907562971115
serious O 1 0.9998362064361572
chronic O 1 0.9999997615814209
disease O 1 0.9939007759094238
and O 0 5.514470103662461e-06
can O 0 2.730253925165016e-07
even O 0 1.018028683574812e-07
lead O 0 1.0179932132814429e-06
to O 0 3.718683103670628e-07
normal O 0 6.726789365529839e-07
life O 0 3.987513991887681e-06
expectancy O 0 1.2134421012888197e-05
. O 0 2.1060473898160126e-07
. O 0 7.308995009225328e-07

Prevalence O 0 0.0029310581739991903
of O 0 5.599540031653305e-07
the O 0 3.8425670823016844e-07
I1307K O 0 3.427440606174059e-05
APC B-Disease 0 6.68897064315388e-06
gene O 0 9.112667953559139e-07
variant O 0 2.202357563874102e-06
in O 0 3.275397375546163e-08
Israeli O 0 2.4175940325221745e-06
Jews O 0 8.20140044766049e-08
of O 0 6.366917215672174e-09
differing O 0 2.0520781163213542e-07
ethnic O 0 9.150108581934546e-08
origin O 0 5.344556441855275e-08
and O 0 1.9079011792655365e-07
risk O 0 3.133496647933498e-06
for O 0 0.011208262294530869
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.0001551978348288685

BACKGROUND O 0 0.0014738742029294372
& O 0 3.0767616408411413e-05
AIMS O 0 6.758833023923216e-06
Israeli O 0 6.581369689229177e-06
Jews O 0 1.8221959408037947e-07
of O 0 4.959657573522236e-09
European O 0 8.77068586646601e-08
birth O 0 7.562663313365192e-07
, O 0 1.5889408899738555e-08
i O 0 6.876918945408761e-08
. O 0 9.334721440268368e-09
e O 0 2.3360751555401293e-08
. O 0 7.514234567906897e-09
, O 0 1.5630092775609228e-08
Ashkenazim O 0 3.0926582894608146e-07
, O 0 1.1945942013369404e-08
have O 0 1.6655102186291515e-08
the O 0 1.6689836002115044e-07
highest O 1 0.8739522695541382
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.048266638070344925
of O 0 2.1454090060046838e-08
any O 0 4.3397594851057875e-08
Israeli O 0 5.10357995153754e-06
ethnic O 0 1.1513327535794815e-06
group O 0 5.090917056804756e-06
. O 0 9.590910394763341e-07

The O 0 5.856812094862107e-06
I1307K O 0 7.911849388619885e-05
APC B-Disease 0 4.664053631131537e-05
gene O 0 2.679655381143675e-06
variant O 0 1.2884509487776086e-05
was O 0 2.2987542251939885e-06
found O 0 1.475019359986618e-07
in O 0 1.2535851112716045e-07
6 O 0 3.718804009622545e-06
. O 0 2.5350734631501837e-06

1 O 0 1.024037101160502e-05
% O 0 2.9423691216834413e-07
of O 0 1.1063500338082122e-08
American O 0 5.5256236919376533e-08
Jews O 0 1.955837234390856e-07
, O 0 6.281302944444178e-08
28 O 0 2.9292718295437226e-07
% O 0 4.3271772831587896e-09
of O 0 2.482870575803986e-09
their O 0 1.266718300030334e-06
familial O 1 0.9999836683273315
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 0.002940832171589136
, O 0 4.935012611895218e-07
but O 0 1.2016148787097336e-07
not O 0 2.3868759413403495e-08
in O 0 2.8958035969139928e-08
non O 0 2.826668321631587e-07
- O 0 9.481720189796761e-05
Jews O 0 4.025964699394535e-06
. O 0 1.521194235465373e-06

We O 0 4.836053904000437e-06
assessed O 0 1.684617814134981e-06
the O 0 5.366272404216943e-08
I1307K O 0 2.4395390937570482e-05
prevalence O 0 4.310550139052793e-06
in O 0 2.678670973921271e-08
Israeli O 0 3.83283168048365e-06
Jews O 0 1.0064984934388121e-07
of O 0 5.2055235677528344e-09
differing O 0 1.6203331654196518e-07
ethnic O 0 1.05219520207811e-07
origin O 0 6.872710400784854e-08
and O 0 2.2609614802604483e-07
risk O 0 6.082382697059074e-06
for O 0 0.015019656158983707
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.0001259931013919413

METHODS O 0 5.14505518367514e-05
DNA O 0 2.9944016205263324e-05
samples O 0 8.803490914033318e-07
from O 0 3.377359192313634e-08
500 O 0 6.829717591472217e-08
unrelated O 0 1.4610708376494586e-07
Jews O 0 6.268687968713493e-08
of O 0 4.996392632961033e-09
European O 0 8.475664259322002e-08
or O 0 3.2475039546397966e-08
non O 0 8.36022380212853e-08
- O 0 7.289424047485227e-06
European O 0 1.3515698071842053e-07
origin O 0 3.062290687694258e-08
, O 0 5.5595452685963664e-09
with O 0 6.755761727816889e-09
or O 0 1.1923360965226948e-08
without O 0 1.7453997358529705e-08
a O 0 2.2800530530275864e-07
personal O 0 7.620465680702182e-07
and O 0 3.6071597264708544e-07
/ O 0 5.269131179375108e-06
or O 0 4.055212698972355e-08
family O 0 4.892033445003108e-08
history O 0 6.84876022560843e-09
of O 0 1.5432153332994858e-08
neoplasia B-Disease 0 0.00016877823509275913
, O 0 1.5130412123198766e-07
were O 0 2.002207111218013e-07
examined O 0 6.448412932513747e-07
for O 0 1.8353944142290857e-08
the O 0 5.189288643236978e-08
I1307K O 0 1.3573127034760546e-05
variant O 0 1.9811777747236192e-06
by O 0 1.6114439560510618e-08
the O 0 2.9148218061436637e-08
allele O 0 1.4143491853246815e-06
- O 0 2.01019793166779e-06
specific O 0 1.1288923218444324e-07
oligonucleotide O 0 8.36374019854702e-05
( O 0 2.9486895414265746e-07
ASO O 0 0.00021290744189172983
) O 0 1.8798664314090274e-07
method O 0 1.5208968306978932e-06
. O 0 8.554235364499618e-07

RESULTS O 0 0.0002265116636408493
In O 0 3.6958294913347345e-07
persons O 0 1.1762559637418235e-07
at O 0 4.568712697050614e-08
average O 0 5.896237667002424e-07
risk O 0 7.547453151346417e-07
for O 0 0.00503821624442935
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 3.365596512594493e-06
I1307K O 0 6.121754267951474e-05
was O 0 4.8354545469919685e-06
found O 0 1.4976917839248927e-07
in O 0 5.115827761414948e-08
5 O 0 4.944773763781996e-07
. O 0 7.050770705063769e-07

0 O 0 0.0001770440285326913
% O 0 1.1217005067010177e-06
of O 0 5.000466174465146e-08
120 O 0 1.6604201391601237e-07
European O 0 3.124152101463551e-07
and O 0 6.513756147796812e-07
1 O 0 1.887212988549436e-06
. O 0 2.6419431833346607e-06

6 O 0 6.715895142406225e-05
% O 0 4.7024246896398836e-07
of O 0 1.5793265362162856e-08
188 O 0 4.908989126306551e-07
non O 0 2.976042310365301e-07
- O 0 2.7130963644594885e-05
European O 0 1.9365766092960257e-06
Jews O 0 1.6828852267281036e-06
( O 0 1.5034100897537428e-07
P O 0 1.8593689674162306e-05
= O 0 1.2269871376702213e-06
0 O 0 2.400234677679691e-07
. O 0 2.4543293619672113e-08
08 O 0 4.7209289277816424e-07
) O 0 1.4732999886746256e-07
. O 0 4.026941269330564e-07

It O 0 6.5026847551052924e-06
occurred O 0 6.328983545245137e-06
in O 0 4.894320113635331e-07
15 O 0 2.0333352495072177e-06
. O 0 1.1270178674749332e-06

4 O 0 2.2409756638808176e-05
% O 0 5.499599637914798e-07
of O 0 3.8113004308115705e-08
52 O 0 9.145463081949856e-06
Ashkenazi O 0 3.3612974220886827e-05
Israelis O 0 4.121322126593441e-05
with O 0 5.561998932535062e-06
familial O 1 0.9865896701812744
cancer B-Disease 1 0.9940966367721558
( O 0 4.5707960794061364e-07
P O 0 0.0002872876066248864
= O 0 1.5434279703185894e-06
0 O 0 1.8228321607693942e-07
. O 0 2.5768931877223622e-08
02 O 0 2.1311960551884113e-07
) O 0 2.755204731030858e-09
and O 0 5.258222746107322e-09
was O 0 3.7014098097643e-07
not O 0 1.5131359276665535e-08
detected O 0 1.2287713957448432e-07
in O 0 1.3938012521919063e-08
51 O 0 4.0676775370229734e-07
non O 0 5.004931935559398e-08
- O 0 7.405758424283704e-07
European O 0 1.1529431276358082e-07
Jews O 0 2.2895162032909866e-07
at O 0 1.1370911323638211e-07
increased O 0 2.780786599032581e-05
cancer B-Disease 0 0.05336637422442436
risk O 0 1.0031299098045565e-05
. O 0 2.2575882212549914e-06

Colorectal B-Disease 1 0.999409556388855
neoplasia I-Disease 1 0.9799490571022034
occurred O 0 0.000747096783015877
personally O 0 8.01475252956152e-05
or O 0 1.7367929672218452e-07
in O 0 2.8631038873072612e-08
the O 0 2.7020186976756122e-08
families O 0 2.026700585133767e-08
of O 0 2.8562407994314754e-09
13 O 0 3.073601817504823e-08
of O 0 5.109408451886566e-09
20 O 0 1.7919789740972192e-07
Ashkenazi O 0 1.9567528397601563e-06
I1307K O 0 4.4096414058003575e-06
carriers O 0 3.689395668970974e-07
, O 0 2.0888982987798954e-08
8 O 0 1.3406204146804157e-08
of O 0 4.732520153538644e-09
whom O 0 1.466147637074755e-06
also O 0 3.611000636283279e-07
had O 0 2.883887475491065e-07
a O 0 1.2271341631731048e-07
personal O 0 6.753845127605018e-07
or O 0 2.9772081688861363e-08
family O 0 5.4202264010427825e-08
history O 0 3.235016166058813e-08
of O 0 5.088316967771789e-08
noncolonic O 0 0.0025730023626238108
neoplasia B-Disease 0 0.0069533539935946465
. O 0 5.431467343441909e-06

CONCLUSIONS O 0 0.00018145305512007326
The O 0 2.280249418618041e-06
I1307K O 0 6.208127160789445e-05
APC O 0 0.00014860434748698026
variant O 0 0.0005590271321125329
may O 0 3.958698016504059e-06
represent O 0 6.430627763620578e-08
a O 0 1.009091306514165e-06
susceptibility O 0 0.007411175407469273
gene O 0 7.153822480177041e-06
for O 0 8.842458555591293e-06
colorectal B-Disease 1 0.9999994039535522
, I-Disease 0 1.8780543769025826e-06
or I-Disease 0 3.461258302195347e-08
other I-Disease 0 1.665361004654642e-08
, I-Disease 0 1.961479938472621e-06
cancers I-Disease 0 0.005840830504894257
in O 0 6.356945050356444e-07
Ashkenazi O 0 0.00016011775005608797
Jews O 0 3.1258238664122473e-07
, O 0 3.000037906986108e-08
and O 0 4.86813043210077e-08
partially O 0 3.1825470614421647e-06
explains O 0 1.2665030624248175e-07
the O 0 6.752889358807579e-09
higher O 0 1.1683962952702132e-07
incidence O 0 7.630587788298726e-05
of O 0 0.00015286960115190595
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
in O 0 4.408245786180487e-06
European O 0 1.949600118678063e-06
Israelis O 0 0.0001151787000708282
. O 0 4.2534938984317705e-06

Systematic O 0 4.269446435500868e-05
analysis O 0 3.399084562261123e-06
of O 0 2.387987478869036e-07
coproporphyrinogen O 0 0.00021151230612304062
oxidase O 0 8.911931945476681e-05
gene O 0 5.678832167177461e-05
defects O 0 0.06133906915783882
in O 0 8.652932592667639e-07
hereditary B-Disease 0 0.2075417935848236
coproporphyria I-Disease 0 0.09410206973552704
and O 0 1.0958284292428289e-05
mutation O 0 1.7892751202452928e-05
update O 0 4.232140781823546e-05
. O 0 3.5426885460765334e-06

Hereditary B-Disease 1 0.9992796778678894
coproporphyria I-Disease 1 0.9733390808105469
( O 0 9.558784950058907e-05
HC B-Disease 1 0.8091927170753479
) O 0 1.631284021641477e-06
is O 0 6.394424190148129e-07
an O 0 5.056113877799362e-05
acute O 1 0.9999712705612183
hepatic B-Disease 1 0.9999858140945435
porphyria I-Disease 1 0.9999898672103882
with O 0 0.019037501886487007
autosomal O 1 0.9990023970603943
dominant O 0 0.06632369756698608
inheritance O 0 0.0026032805908471346
caused O 0 0.00013341849262360483
by O 0 6.646453698522237e-07
deficient B-Disease 0 3.456275589996949e-05
activity I-Disease 0 4.0654200006429164e-08
of I-Disease 0 2.026932577336993e-08
coproporphyrinogen I-Disease 0 0.004592160694301128
III I-Disease 0 0.2621132731437683
oxidase I-Disease 0 8.98746384336846e-06
( O 0 1.4207797960352764e-07
CPO O 0 2.4773269615252502e-05
) O 0 3.7381860806817713e-07
. O 0 9.544813792672358e-07

Clinical O 0 0.004993370734155178
manifestations O 0 9.998750465456396e-05
of O 0 4.7528487812087405e-07
the O 0 1.12624420580687e-05
disease O 0 0.008741073310375214
are O 0 2.2278389621988026e-07
characterized O 0 0.00010445051157148555
by O 0 8.190407243091613e-06
acute O 1 0.9645780324935913
attacks O 0 0.03894398733973503
of O 0 6.097372079238994e-06
neurological B-Disease 1 0.9999409914016724
dysfunction I-Disease 1 0.9976145029067993
often O 0 8.665584755362943e-05
precipitated O 0 0.00023704511113464832
by O 0 1.2477146071887546e-07
drugs O 0 1.400044595811778e-07
, O 0 2.990936209812389e-08
fasting O 0 4.0485554109181976e-07
, O 0 3.180011631798152e-08
cyclical O 0 2.247813426947687e-06
hormonal O 0 4.606993752531707e-05
changes O 0 2.1258573212890042e-07
, O 0 1.9176951582267066e-07
or O 0 1.7999381043409812e-06
infectious B-Disease 0 0.06298167258501053
diseases I-Disease 0 0.02876748889684677
. O 0 1.3855289580533281e-05

Skin O 1 0.9999566078186035
photosensitivity O 1 0.9998880624771118
may O 0 0.004272982943803072
also O 0 1.7659929198998725e-06
be O 0 2.560549319241545e-07
present O 0 8.798664907772036e-07
. O 0 2.1798755369673017e-06

The O 0 1.8508733319322346e-06
seven O 0 8.161597975231416e-07
exons O 0 2.039343598880805e-06
, O 0 3.201366638450054e-08
the O 0 1.4544360382728883e-08
exon O 0 1.129548650169454e-06
/ O 0 5.3056260185258e-07
intron O 0 2.979224518639967e-06
boundaries O 0 6.191497448071459e-08
and O 0 8.895301384370669e-09
part O 0 5.5005306975886015e-09
of O 0 2.517414054992173e-09
3 O 0 4.121532626299995e-08
noncoding O 0 5.199706833991513e-07
sequence O 0 1.2704364671378698e-08
of O 0 1.3694124723073742e-09
the O 0 7.194380202690809e-09
CPO O 0 1.0942557310045231e-05
gene O 0 1.229403068236934e-07
were O 0 4.5823185246263165e-08
systematically O 0 4.9157728199134e-07
analyzed O 0 1.4931879377400037e-07
by O 0 8.074739099583894e-09
an O 0 2.0436834446968533e-08
exon O 0 1.3396718259173213e-06
- O 0 3.0299117952381494e-06
by O 0 6.972981481112583e-08
- O 0 3.8473344829981215e-06
exon O 0 5.109555786475539e-06
denaturing O 0 5.6024829973466694e-05
gradient O 0 0.0006154161528684199
gel O 0 0.0001372341939713806
electrophoresis O 0 9.526421308692079e-06
( O 0 2.472503624062483e-08
DGGE O 0 3.0017149583727587e-06
) O 0 1.5063113423252616e-08
strategy O 0 6.599720592248559e-08
followed O 0 2.7771600130677143e-08
by O 0 5.590861107407363e-09
direct O 0 1.3367342788228598e-08
sequencing O 0 5.661128454903519e-08
in O 0 1.960598794426005e-08
seven O 0 1.1683160749953458e-07
unrelated O 0 1.6831114635351696e-06
heterozygous O 0 0.0002123371377820149
HC B-Disease 1 0.972679615020752
patients O 0 0.12478113174438477
from O 0 3.3357085271745746e-07
France O 0 1.1814418030553497e-05
, O 0 3.93626180539286e-07
Holland O 0 1.2490457265812438e-05
, O 0 9.471278161754526e-08
and O 0 1.2348660050065519e-07
Czech O 0 1.1441291462688241e-05
Republic O 0 7.728388595751312e-07
. O 0 2.608916020108154e-06

Seven O 0 9.68741878750734e-05
novel O 0 6.428183405660093e-05
mutations O 0 4.3927855585934594e-05
and O 0 1.1803282973232854e-07
two O 0 5.3200658101104636e-08
new O 0 2.94088522423408e-07
polymorphisms O 0 6.063287855795352e-06
were O 0 7.230700020954828e-07
detected O 0 8.207351129385643e-06
. O 0 1.7832044250098988e-06

Among O 0 1.97529934666818e-05
these O 0 5.366308073462278e-07
mutations O 0 2.478962187524303e-06
two O 0 9.025085034863878e-08
are O 0 6.587308121197566e-08
missense O 0 1.918643101816997e-05
( O 0 5.627325094792468e-08
G197W O 0 5.099187546875328e-06
, O 0 5.509837208705903e-08
W427R O 0 1.3188580396672478e-06
) O 0 7.158408088514534e-09
, O 0 4.980502676943388e-09
two O 0 6.171239963492781e-09
are O 0 7.688791825444241e-09
nonsense O 0 1.0526674714128603e-06
( O 0 1.1025665713759736e-08
Q306X O 0 8.887773219612427e-07
, O 0 1.9794651251459072e-08
Q385X O 0 6.312349114523386e-07
) O 0 6.073455072197476e-09
, O 0 4.415537269153447e-09
two O 0 6.766543325653629e-09
are O 0 4.531280684005878e-09
small O 0 3.238238477365485e-08
deletions O 0 2.0250950001354795e-06
( O 0 7.803070900536113e-08
662de14bp O 0 4.354345492174616e-06
; O 0 4.6094928762840937e-08
1168del3bp O 0 7.650043585272215e-07
removing O 0 4.38477236741619e-08
a O 0 5.7728172464521776e-08
glycine O 0 1.8963078218803275e-07
at O 0 2.607880489335912e-08
position O 0 1.592237879322056e-07
390 O 0 5.66451944905566e-07
) O 0 2.499273499267929e-08
, O 0 1.345000022467957e-08
and O 0 7.400587698214167e-09
one O 0 1.2487188172372043e-08
is O 0 1.1990981541032397e-08
a O 0 1.470833268513161e-07
splicing O 0 6.418450084311189e-06
mutation O 0 1.8155053567170398e-06
( O 0 2.864152648385243e-08
IVS1 O 0 5.836332547914935e-06
- O 0 2.9617334803333506e-05
15c O 0 8.578073175158352e-05
- O 0 6.912103708600625e-05
- O 0 0.0005737448227591813
> O 0 8.230991625168826e-06
g O 0 1.0133256182598416e-05
) O 0 7.572619864504304e-09
which O 0 8.334078316352134e-09
creates O 0 5.1372417431139183e-08
a O 0 4.264954611699068e-08
new O 0 6.672652119732447e-08
acceptor O 0 2.113243908752338e-07
splice O 0 4.378456196718616e-06
site O 0 2.774412678263616e-06
. O 0 9.338568816019688e-07

The O 0 4.1337029870192055e-06
pathological O 0 1.8659948182175867e-05
significance O 0 2.587004246379365e-07
of O 0 1.2496957246810325e-08
the O 0 2.311238489483003e-08
point O 0 1.690558377731577e-07
mutations O 0 5.96749373471539e-07
G197W O 0 1.4389446505447268e-06
, O 0 7.585460082282225e-08
W427R O 0 1.586402504472062e-06
, O 0 1.6517990530928728e-08
and O 0 3.935733516868822e-09
the O 0 3.306870111075e-09
in O 0 1.426832607620554e-08
- O 0 1.4502577869279776e-05
frame O 0 0.0027063125744462013
deletion O 0 1.0764139915409032e-05
390delGly O 0 5.468165454658447e-06
were O 0 8.708309451321838e-08
assessed O 0 4.2279562961766715e-08
by O 0 4.324619773399263e-09
their O 0 6.646128980491994e-09
respective O 0 1.2285341632889413e-08
expression O 0 7.533294876793661e-08
in O 0 1.0911813674852056e-08
a O 0 1.295618972108059e-07
prokaryotic O 0 1.7121264761499333e-07
system O 0 2.408925148245089e-08
using O 0 3.5254213770485876e-08
site O 0 1.2836778751079692e-07
- O 0 1.407207605552685e-06
directed O 0 3.60854710379499e-06
mutagenesis O 0 7.499847561120987e-05
. O 0 1.6756226841607713e-06

These O 0 1.1099230505351443e-05
mutations O 0 8.770741987973452e-05
resulted O 0 2.2804931631981162e-06
in O 0 3.622168520678315e-08
the O 0 1.724499476551955e-08
absence O 0 3.496245994938363e-07
or O 0 1.8073702534593394e-08
a O 0 4.7219103294082743e-07
dramatic O 0 4.328971772338264e-05
decrease O 0 2.2925275970919756e-06
of O 0 2.3480964728150866e-08
CPO O 0 0.00014298103633336723
activity O 0 7.528224159614183e-07
. O 0 8.336194809999142e-07

The O 0 1.2319081861278391e-06
two O 0 5.202360853218124e-07
polymorphisms O 0 8.681840881763492e-06
were O 0 4.365308541309787e-07
localized O 0 3.3785431696742307e-06
in O 0 1.5688910082189977e-07
noncoding O 0 2.9632883524755016e-06
part O 0 2.4068951276490225e-08
of O 0 3.4234837187341327e-09
the O 0 1.0560611940491071e-08
gene O 0 5.53870762587394e-08
1 O 0 2.17377671418717e-08
) O 0 1.4100104195335916e-08
a O 0 1.3693421578864218e-06
C O 0 2.4293172828038223e-05
/ O 0 1.7193851817864925e-05
G O 0 0.0121455742046237
polymorphism O 0 3.104152710875496e-05
in O 0 2.4433438383653083e-08
the O 0 2.179543479030599e-08
promotor O 0 9.469457836530637e-06
region O 0 1.0423534746450969e-07
, O 0 3.461132891402485e-08
142 O 0 1.2989481490421895e-07
bp O 0 3.2357895634049783e-06
upstream O 0 4.073018189387767e-08
from O 0 1.4949449456125308e-09
the O 0 1.6914535327927638e-09
transcriptional O 0 1.065156709501025e-07
initiation O 0 7.939629398379111e-08
site O 0 1.1088009443938063e-07
( O 0 1.2767134904834165e-08
- O 0 1.311539335802081e-06
142C O 0 2.9301254471647553e-05
/ O 0 2.961960490210913e-06
G O 0 4.2115876567550004e-05
) O 0 1.7163943155651396e-08
, O 0 1.5125904084811737e-08
and O 0 1.081637002187108e-08
2 O 0 2.6452122270370637e-08
) O 0 5.5335518389654226e-09
a O 0 6.764274473880505e-08
6 O 0 1.1706080016438136e-07
bp O 0 1.5768600860610604e-05
deletion O 0 2.4324549485754687e-06
polymorphism O 0 3.5428677165327827e-06
in O 0 1.651033798566459e-08
the O 0 1.3046685509721101e-08
3 O 0 9.526646493895896e-08
noncoding O 0 8.780156690590957e-07
part O 0 1.8461346229514675e-08
of O 0 2.1023596197267125e-09
the O 0 9.719320459566916e-09
CPO O 0 8.279645953734871e-06
gene O 0 1.3017321975894447e-07
, O 0 1.3543808741189878e-08
574 O 0 3.572125706341467e-07
bp O 0 3.901723175658844e-06
downstream O 0 6.430149568359411e-08
of O 0 1.5889916049616204e-09
the O 0 1.0400096783769186e-08
last O 0 1.3126539499808132e-07
base O 0 3.4023877049094153e-08
of O 0 1.8341161922563742e-09
the O 0 2.1287577922635137e-08
normal O 0 2.2989681269791618e-07
termination O 0 1.2975704066775506e-06
codon O 0 9.917486067934078e-07
( O 0 1.3672683962795418e-07
+ O 0 1.2248757457200554e-06
574 O 0 3.5205778203817317e-06
delATTCTT O 0 2.8299687983235344e-05
) O 0 5.521508796846319e-07
. O 0 1.1196954119441216e-06

Five O 0 2.638218575157225e-05
intragenic O 0 0.00026750346296466887
dimorphisms O 0 0.00014961996930651367
are O 0 3.09258467723339e-07
now O 0 2.236744194306084e-07
well O 0 4.934522834787458e-08
characterized O 0 5.440651307253574e-07
and O 0 2.1262501093133324e-08
the O 0 8.362707859532748e-09
high O 0 1.0232498226514508e-07
degree O 0 4.634264527680898e-08
of O 0 1.3203169224595968e-08
allelic O 0 1.2370715012366418e-05
heterogeneity O 0 6.85251216054894e-05
in O 0 2.1252949409245048e-06
HC B-Disease 1 0.7356141209602356
is O 0 7.06924538462772e-06
demonstrated O 0 2.0575250800902722e-06
with O 0 1.4260844061197986e-08
seven O 0 2.272109966838798e-08
new O 0 1.2366497159632672e-08
different O 0 2.380255326173142e-09
mutations O 0 3.3716052172394484e-08
making O 0 4.0860963501643255e-09
a O 0 2.8730930523579445e-08
total O 0 8.850268073956613e-09
of O 0 5.665532931686812e-09
nineteen O 0 1.202422254209523e-06
CPO O 0 0.00038950247108004987
gene B-Disease 0 1.1939030628127512e-05
defects I-Disease 0 0.03275613859295845
reported O 0 1.3890344234823715e-06
so O 0 5.973129901803986e-08
far O 0 3.1239227382684476e-07
. O 0 1.9112046345526323e-07
. O 0 1.2013574632874224e-06

Coincidence O 0 8.406222332268953e-05
of O 0 3.205216216883855e-07
two O 0 2.6983784096046293e-07
novel O 0 1.7087724017983419e-06
arylsulfatase O 0 1.0903879228862934e-05
A O 0 1.3142864645487862e-06
alleles O 0 1.5830368056413135e-06
and O 0 6.101346912146255e-07
mutation O 0 7.766700036881957e-06
459 O 0 2.0736504666274413e-05
+ O 0 8.404536856687628e-06
1G O 0 0.000373927119653672
> O 0 1.3527900364351808e-06
A O 0 3.5681216559169115e-07
within O 0 1.0297181773921693e-08
a O 0 2.0907803843783768e-07
family O 0 7.97009420239192e-07
with O 0 4.51128153144964e-06
metachromatic B-Disease 1 0.9999964237213135
leukodystrophy I-Disease 1 0.9999853372573853
: O 0 1.6912841260818823e-07
molecular O 0 1.6222504939378268e-07
basis O 0 1.680302830209257e-08
of O 0 1.975911700924371e-08
phenotypic O 0 6.486132770078257e-05
heterogeneity O 0 0.0004034167795907706
. O 0 7.031075710983714e-06

In O 0 3.3091514524130616e-06
a O 0 2.343194182685693e-06
family O 0 8.034366487663647e-07
with O 0 5.511361322874109e-08
three O 0 2.8790017836399784e-07
siblings O 0 4.119260211155051e-06
, O 0 2.0938767164579986e-08
one O 0 1.18721423802981e-08
developed O 0 8.423206310226306e-08
classical O 0 8.228913088714762e-07
late O 0 0.0003452858072705567
infantile O 1 0.9975336790084839
metachromatic B-Disease 1 0.9999978542327881
leukodystrophy I-Disease 1 0.9999974966049194
( O 0 9.62646026891889e-06
MLD B-Disease 1 0.999839186668396
) O 0 4.107642723738536e-07
, O 0 2.09477605039865e-07
fatal O 0 0.00043207837734371424
at O 0 2.219544938952822e-07
age O 0 8.683196028869133e-07
5 O 0 6.49052722678789e-08
years O 0 1.832177218830111e-07
, O 0 3.636948520124861e-08
with O 0 2.604602684641577e-07
deficient O 0 0.002242846880108118
arylsulfatase O 0 0.0001331503299297765
A O 0 7.20230991646531e-06
( O 0 1.4640249901276547e-07
ARSA O 0 4.032256765640341e-05
) O 0 9.935508415992444e-09
activity O 0 1.0186809618062398e-08
and O 0 2.8596437218197934e-08
increased O 0 5.485618999045982e-07
galactosylsulfatide O 0 0.0008306645904667675
( O 0 5.45259808859555e-07
GS O 1 0.9995439648628235
) O 0 6.820734483881097e-07
excretion O 0 3.3882104162330506e-06
. O 0 1.0798385119414888e-06

The O 0 2.10366988540045e-06
two O 0 3.038993554582703e-07
other O 0 3.73662807362507e-08
siblings O 0 1.942014023370575e-06
, O 0 7.031532334167423e-08
apparently O 0 2.700715640457929e-06
healthy O 0 6.502162364085962e-08
at O 0 1.0437934072626831e-08
12 O 0 4.8675548924848044e-08
( O 0 3.9253431616259604e-09
1 O 0 2.397977993950917e-08
/ O 0 2.0801142852633348e-07
2 O 0 3.522698932556523e-08
) O 0 4.923708996074083e-09
and O 0 1.3945884447252865e-08
15 O 0 3.6683829307548876e-08
years O 0 3.260910830249486e-08
, O 0 1.7149838882346558e-08
respectively O 0 1.1300793545387933e-07
, O 0 7.131044199581993e-09
and O 0 5.385670132085352e-09
their O 0 7.113601707686712e-09
father O 0 1.3442046338241198e-06
, O 0 1.9680733487348334e-08
apparently O 0 8.806169944364228e-07
healthy O 0 5.524632840092636e-08
as O 0 1.386306003325899e-08
well O 0 2.0114734766707443e-08
, O 0 6.708895483598099e-08
presented O 0 1.0242198413834558e-06
ARSA O 0 0.0014526443555951118
and O 0 1.294749608860002e-06
GS O 1 0.9983307719230652
values O 0 7.363757248413094e-08
within O 0 1.903886381882103e-09
the O 0 8.006905360957717e-09
range O 0 1.6167274452527636e-07
of O 0 5.741280233451107e-07
MLD B-Disease 1 0.999997615814209
patients O 1 0.9977697134017944
. O 0 1.1048790838685818e-05

Mutation O 0 0.0015643811784684658
screening O 0 2.3078937374521047e-05
and O 0 3.0360300229403947e-07
sequence O 0 2.2906824881374632e-07
analysis O 0 1.4992293984050775e-07
disclosed O 0 4.573543037622585e-07
the O 0 5.494533272809576e-09
involvement O 0 3.387384595043841e-08
of O 0 5.944497782905955e-09
three O 0 4.888283910986502e-08
different O 0 5.773841493805776e-08
ARSA O 0 0.06475020945072174
mutations O 0 4.342328793427441e-06
being O 0 4.6576140277920786e-08
the O 0 1.065302512870403e-08
molecular O 0 1.2619793210433272e-07
basis O 0 1.7994553402900237e-08
of O 0 2.556152089994157e-08
intrafamilial O 0 0.00018727850692812353
phenotypic O 0 0.0003543290658853948
heterogeneity O 0 0.0002382160018896684
. O 0 1.2510104170360137e-05

The O 0 8.707645065442193e-06
late O 0 9.747650619829074e-05
infantile O 1 0.9529147744178772
patient O 1 0.9276688694953918
inherited O 0 0.0018216581083834171
from O 0 1.3910954521634267e-07
his O 0 1.5738229421913275e-06
mother O 0 1.4982079846959095e-05
the O 0 3.979623031113988e-08
frequent O 0 3.0730855087313103e-06
0 O 0 1.3199112345319008e-06
- O 0 0.0001304451288888231
type O 0 2.901318839576561e-05
mutation O 0 2.411988361927797e-06
459 O 0 3.3333599276375026e-06
+ O 0 1.4462224271483137e-06
1G O 0 6.571376434294507e-05
> O 0 1.3931575040260213e-06
A O 0 7.092658620422299e-07
, O 0 4.027624456170997e-08
and O 0 1.7158638954128946e-08
from O 0 5.0511053117929805e-09
his O 0 2.990135499203461e-07
father O 0 2.9668428851437056e-06
a O 0 1.317580284876385e-07
novel O 0 1.7451043277105782e-07
, O 0 1.1036585867429949e-08
single O 0 8.177064358960706e-08
basepair O 0 1.647377530389349e-06
microdeletion O 0 5.43061503321951e-07
of O 0 3.3432607793315583e-09
guanine O 0 1.6523860324468842e-07
at O 0 1.2898695445073827e-08
nucleotide O 0 5.6613547627648586e-08
7 O 0 7.917142852420511e-08
in O 0 2.124328624120153e-08
exon O 0 2.599094386823708e-06
1 O 0 4.611427755207842e-07
( O 0 1.5390889984701062e-07
7delG O 0 9.005694664665498e-06
) O 0 5.233371780377638e-07
. O 0 8.83200755197322e-07

The O 0 2.5938497856259346e-06
two O 0 1.8884858263845672e-06
clinically O 0 0.0005247338558547199
unaffected O 0 7.965385884745046e-05
siblings O 0 7.380379884125432e-06
carried O 0 5.5907781870701e-07
the O 0 1.0688647478218627e-07
maternal O 0 2.3620683350600302e-05
mutation O 0 7.378599093499361e-06
459 O 0 1.084583254851168e-05
+ O 0 3.284379772594548e-06
1G O 0 0.00024619107716716826
> O 0 1.7659390323387925e-06
A O 0 1.209778019983787e-06
and O 0 7.750413999474404e-08
, O 0 3.1052330484726554e-08
on O 0 1.0431092789531249e-07
their O 0 4.55026736290165e-08
paternal O 0 1.695698665571399e-05
allele O 0 1.2604040193764376e-06
, O 0 1.0725832666480528e-08
a O 0 4.1841623499294656e-08
novel O 0 2.1441107378450397e-07
cytosine O 0 1.0455612908799594e-07
to O 0 2.4836486645085643e-08
thymidine O 0 6.309189757303102e-07
transition O 0 8.56785646874414e-08
at O 0 1.3148533817286534e-08
nucleotide O 0 9.967019565237933e-08
2435 O 0 2.212896788478247e-06
in O 0 4.327493030586993e-08
exon O 0 1.1372640074114315e-06
8 O 0 1.8024891801360354e-07
, O 0 1.5541091968884757e-08
resulting O 0 4.343510795479233e-08
in O 0 7.2818648888528514e-09
substitution O 0 3.7900022675785294e-08
of O 0 1.6070178077143282e-08
alanine O 0 4.245380750944605e-06
464 O 0 1.4892649232933763e-05
by O 0 7.880996690801112e-07
valine O 0 0.00039827232831157744
( O 0 3.0085533353485516e-07
A464V O 0 1.619426802790258e-05
) O 0 5.991701073071454e-07
. O 0 1.1592213695621467e-06

The O 0 4.274093953426927e-06
fathers O 0 1.5517547581112012e-05
genotype O 0 7.694978557992727e-05
thus O 0 1.8887884607465821e-06
was O 0 6.235350156202912e-06
7delG O 0 7.754593389108777e-05
/ O 0 3.800156991928816e-05
A464V O 0 9.851046343101189e-05
. O 0 4.725631242763484e-06

Mutation O 0 0.0054407245479524136
A464V O 0 0.0002754508168436587
was O 0 5.453193352877861e-06
not O 0 8.075265611751092e-08
found O 0 1.1026974533479006e-07
in O 0 9.914688803291938e-08
18 O 0 2.2034478206478525e-06
unrelated O 0 0.0009474696707911789
MLD B-Disease 1 0.9999997615814209
patients O 1 0.9821779727935791
and O 0 6.47556532840099e-07
50 O 0 4.959749730915064e-07
controls O 0 1.8080108930007555e-05
. O 0 2.102367943734862e-06

A464V O 0 0.0012895615072920918
, O 0 2.75843012786936e-06
although O 0 4.4580468738786294e-07
clearly O 0 3.99486452806741e-07
modifying O 0 1.6689070889697177e-06
ARSA O 0 0.0021714898757636547
and O 0 1.0064070011139847e-05
GS O 1 0.9999463558197021
levels O 0 5.659524617840361e-07
, O 0 2.3053697617569924e-08
apparently O 0 5.64738797947939e-07
bears O 0 2.0080547358247713e-07
little O 0 3.6999622921030095e-08
significance O 0 2.1668057570423116e-08
for O 0 3.6177009832272233e-08
clinical O 0 3.4494958072173176e-06
manifestation O 0 9.242665328201838e-06
of O 0 3.230428831102472e-07
MLD B-Disease 1 0.9999567270278931
, O 0 5.581285336120345e-07
mimicking O 0 2.7815124212793307e-06
the O 0 1.751172788999611e-07
frequent O 0 2.7703394152922556e-05
ARSA O 0 0.1866443008184433
pseudodeficiency O 0 0.0029366041999310255
allele O 0 9.675841283751652e-05
. O 0 2.5178103442158317e-06

Our O 0 3.930682851205347e-06
results O 0 3.5042683066421887e-06
demonstrate O 0 1.009131665341556e-06
that O 0 5.251910906167723e-08
in O 0 3.012365468180178e-08
certain O 0 5.829435067994382e-08
genetic O 0 4.553759481495945e-06
conditions O 0 0.0007214437937363982
MLD B-Disease 1 0.999964714050293
- O 0 0.04993223026394844
like O 0 4.889747287961654e-06
ARSA O 0 0.010386941023170948
and O 0 2.1649775590049103e-06
GS O 1 0.9996123909950256
values O 0 1.415292132378454e-07
need O 0 3.1987053006332644e-08
not O 0 1.2800782656086085e-08
be O 0 1.7809453467521053e-08
paralleled O 0 1.192522290693887e-06
by O 0 1.2180205430922797e-06
clinical O 0 0.13452136516571045
disease O 0 0.000532109581399709
, O 0 3.5762766970037774e-08
a O 0 1.3874625892640324e-07
finding O 0 5.996656682327739e-08
with O 0 1.4438106177294685e-07
serious O 0 3.934483902412467e-05
diagnostic O 0 0.00017116907110903412
and O 0 2.2937786070542643e-06
prognostic O 0 0.03262310475111008
implications O 0 1.765662818797864e-05
. O 0 4.565770268527558e-06

Moreover O 0 0.00012616538151632994
, O 0 2.5211550109816017e-06
further O 0 1.0564750709818327e-06
ARSA O 0 0.009001854807138443
alleles O 0 2.01742604986066e-05
functionally O 0 5.4950146477494854e-06
similar O 0 2.417205848814774e-07
to O 0 8.157654463047948e-08
A464V O 0 1.946186057466548e-05
might O 0 1.25015435514797e-06
exist O 0 2.5427990379967014e-08
which O 0 1.7932094920070085e-08
, O 0 1.3119900721392241e-08
together O 0 1.249676717662851e-08
with O 0 4.8976353639318404e-08
0 O 0 1.0128571830136934e-06
- O 0 0.0012670259457081556
type O 0 0.0001652244827710092
mutations O 0 7.306629413506016e-06
, O 0 1.3234387097327271e-07
may O 0 2.8312272206676425e-06
cause O 0 1.9392621197766857e-06
pathological O 0 8.346571121364832e-05
ARSA O 1 0.8921257853507996
and O 0 0.00010628890595398843
GS O 1 0.999992847442627
levels O 0 9.210462508235651e-07
, O 0 2.692532063974795e-08
but O 0 3.7492501547831125e-08
not O 0 7.496858245303883e-08
clinical O 0 1.0191356523137074e-06
outbreak O 0 4.4448270841712656e-07
of O 0 2.2600683990958714e-08
the O 0 3.083824822169845e-06
disease O 0 0.00014711789845023304
. O 0 5.47602724054741e-07
. O 0 1.6499373032274889e-06

Human O 0 0.00939378421753645
MLH1 O 1 0.9996323585510254
deficiency O 1 0.9994240999221802
predisposes O 0 0.05970318242907524
to O 0 6.525620847241953e-05
hematological B-Disease 1 0.989101231098175
malignancy I-Disease 1 0.8991838097572327
and O 0 9.595004667062312e-05
neurofibromatosis B-Disease 1 0.995014488697052
type I-Disease 0 0.0002648164227139205
1 I-Disease 0 5.160082309885183e-06
. O 0 4.317676030041184e-06

Heterozygous O 0 0.001853513647802174
germ O 0 0.00034221934038214386
- O 0 0.001997184008359909
line O 0 3.9995509723667055e-05
mutations O 0 1.8169049553762306e-06
in O 0 1.1837435032191479e-08
the O 0 2.8180274114220083e-08
DNA O 0 2.964885425171815e-06
mismatch O 0 0.0002698102907743305
repair O 0 0.0002526582102291286
genes O 0 7.936735642033454e-07
lead O 0 2.1476585061463993e-06
to O 0 1.448277362214867e-05
hereditary B-Disease 1 0.9998621940612793
nonpolyposis I-Disease 1 0.9999961853027344
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.0001261511933989823

The O 0 0.00011785309470724314
disease O 0 0.08895966410636902
susceptibility O 0 0.0006914791883900762
of O 0 1.8798020562371676e-07
individuals O 0 2.7915342570850044e-07
who O 0 2.7568326913751662e-05
constitutionally O 0 0.00013953997404314578
lack O 0 8.627923762105638e-07
both O 0 8.116154504023143e-08
wild O 0 5.093502295494545e-07
- O 0 0.0001798411540221423
type O 0 3.0047482141526416e-05
alleles O 0 2.3984985091374256e-06
is O 0 3.3536667842781753e-07
unknown O 0 1.4622266917285742e-06
. O 0 9.185602607431065e-07

We O 0 3.2471314170834376e-06
have O 0 2.1550802387082513e-07
identified O 0 1.4265664560753066e-07
three O 0 2.3658945025317735e-08
offspring O 0 3.2863866294974287e-07
in O 0 5.845758010991631e-08
a O 0 6.053895049262792e-05
hereditary B-Disease 1 0.9999654293060303
nonpolyposis I-Disease 1 0.9999991655349731
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.0005349395796656609
who O 0 3.285020648036152e-05
developed O 0 1.3738045709033031e-05
hematological B-Disease 0 0.40471982955932617
malignancy I-Disease 0 0.0018167311791330576
at O 0 3.629353528822321e-08
a O 0 1.2651220515635941e-07
very O 0 1.151035888824481e-07
early O 0 9.177293236461992e-07
age O 0 2.2965664925322926e-07
, O 0 1.1373770369971226e-08
and O 0 5.181185702696212e-09
at O 0 4.452902935270231e-09
least O 0 4.528748931420523e-09
two O 0 9.67821045527728e-10
of O 0 7.04218350300323e-10
them O 0 9.069603734701559e-09
displayed O 0 5.109109224576969e-07
signs O 0 5.913537961532711e-07
of O 0 4.2989544368765564e-08
neurofibromatosis B-Disease 1 0.6262382864952087
type I-Disease 0 2.678615965123754e-05
1 I-Disease 0 1.669895709710545e-06
( O 0 3.174037033204513e-07
NF1 B-Disease 0 0.00019222382979933172
) O 0 4.41453778421419e-07
. O 0 9.425052098777087e-07

DNA O 0 0.00010250980267301202
sequence O 0 3.2986561109282775e-06
analysis O 0 9.145559829448757e-07
and O 0 1.0215162404847433e-07
allele O 0 1.8858402199839475e-06
- O 0 1.5209766388579737e-06
specific O 0 3.751925348183249e-08
amplification O 0 2.3577465526614105e-06
in O 0 6.244963657309199e-08
two O 0 2.0272115364150523e-07
siblings O 0 9.809482435230166e-06
revealed O 0 1.2095173360648914e-06
a O 0 8.914104796531319e-07
homozygous O 0 9.982250048778951e-05
MLH1 O 0 0.018024509772658348
mutation O 0 6.793295142415445e-06
( O 0 9.47944727158756e-08
C676T O 0 5.947103090875316e-06
- O 0 6.443016172852367e-05
- O 0 0.006234017666429281
> O 0 1.9007065930054523e-05
Arg226Stop O 0 3.9124381146393716e-05
) O 0 5.003404908165976e-07
. O 0 7.500555057049496e-07

Thus O 0 1.8589487808640115e-05
, O 0 4.2974789948857506e-07
a O 0 7.611002388330235e-07
homozygous O 0 8.591217010689434e-06
germ O 0 1.529188739368692e-05
- O 0 0.00019635891658253968
line O 0 0.00014495523646473885
MLH1 O 0 0.09566356986761093
mutation O 0 8.735792107472662e-06
and O 0 4.0028041325967934e-07
consequent O 0 0.0013722648145630956
mismatch O 1 0.9991821646690369
repair O 1 0.9999741315841675
deficiency O 1 0.999855637550354
results O 0 7.774784535286017e-06
in O 0 3.7439551192619547e-07
a O 0 0.00011384587560314685
mutator O 1 0.9992927312850952
phenotype O 1 0.9927166104316711
characterized O 0 0.0001434883160982281
by O 0 1.197515484818723e-05
leukemia B-Disease 1 0.9949867725372314
and O 0 8.660280582262203e-05
/ O 1 0.8186770677566528
or O 0 0.22265098989009857
lymphoma B-Disease 1 1.0
associated O 0 0.0009540683822706342
with O 0 2.360865801165346e-05
neurofibromatosis B-Disease 1 0.997177243232727
type I-Disease 0 3.42321400239598e-05
1 I-Disease 0 5.637680260406341e-07
. O 0 3.088163964548585e-07
. O 0 1.8031578292720951e-06

Missense O 1 0.8610440492630005
mutations O 0 0.07298220694065094
in O 0 1.3956508837509318e-06
the O 0 1.536578082550477e-07
most O 0 4.570116374225108e-08
ancient O 0 2.0455280136388865e-08
residues O 0 3.383355462460713e-08
of O 0 5.021298932206264e-09
the O 0 8.945666962745236e-08
PAX6 O 0 0.0005231451941654086
paired O 0 4.297075065551326e-06
domain O 0 3.199242826212867e-07
underlie O 0 1.1082358923886204e-06
a O 0 5.507425271389366e-07
spectrum O 0 2.654330501172808e-06
of O 0 1.8156700321014796e-07
human O 0 0.00010898604523390532
congenital B-Disease 1 0.9999957084655762
eye I-Disease 1 0.99997878074646
malformations I-Disease 1 0.9999383687973022
. O 0 6.258880603127182e-05

Mutations O 0 0.0020241490565240383
of O 0 5.322278298081073e-07
the O 0 2.1043648246177327e-07
human O 0 4.035607048535894e-07
PAX6 O 0 0.03118062950670719
gene O 0 9.071411477634683e-05
underlie O 0 0.03665921837091446
aniridia B-Disease 1 0.9999973773956299
( O 0 0.00035966068389825523
congenital B-Disease 1 0.9999023675918579
absence I-Disease 0 1.2802299352188129e-05
of I-Disease 0 3.7216128845329877e-08
the I-Disease 0 5.886647045372229e-07
iris I-Disease 0 0.017440399155020714
) O 0 4.3892573131643076e-08
, O 0 2.4085023753173118e-08
a O 0 6.205240765666531e-07
rare O 0 3.166974784107879e-05
dominant O 0 0.002259318483993411
malformation B-Disease 0 0.20292410254478455
of I-Disease 0 9.069641748737922e-08
the I-Disease 0 8.809731184555858e-07
eye I-Disease 0 0.07991308718919754
. O 0 1.0604497219901532e-05

The O 0 3.4161130315624177e-06
spectrum O 0 5.330992280505598e-06
of O 0 1.1971687285949884e-07
PAX6 O 0 0.04756792262196541
mutations O 0 0.00025249060126952827
in O 0 5.864682407263899e-06
aniridia B-Disease 1 0.9999991655349731
patients O 0 0.4198388159275055
is O 0 1.5855600565828354e-07
highly O 0 2.2958043643939163e-07
biased O 0 2.6970942599291448e-06
, O 0 1.0818458662242847e-07
with O 0 5.780408329769671e-08
92 O 0 1.5207214119072887e-06
% O 0 8.109899418684563e-09
of O 0 1.5395396069095568e-09
all O 0 1.4897281630510406e-08
reported O 0 5.3280646170605905e-06
mutations O 0 4.4730114723279257e-07
leading O 0 1.388402495194896e-07
to O 0 2.922666908489191e-07
premature O 0 2.4195765945478342e-05
truncation O 0 5.953731374575e-07
of O 0 5.36917754700994e-09
the O 0 1.0908151715227632e-08
protein O 0 6.602629554208761e-08
( O 0 6.898396076593372e-09
nonsense O 0 3.5432560707704397e-07
, O 0 1.4930876091057144e-08
splicing O 0 1.5570321920677088e-07
, O 0 1.2785996261754917e-08
insertions O 0 2.5958391347558063e-07
and O 0 3.582926666467756e-08
deletions O 0 4.452573989510711e-07
) O 0 1.2910387425790759e-08
and O 0 1.5208033943281407e-08
just O 0 3.388050373587248e-08
2 O 0 7.978659510854413e-08
% O 0 9.220937791099004e-09
leading O 0 8.450543376170572e-09
to O 0 4.941452136364433e-09
substitution O 0 1.7141369212936297e-08
of O 0 4.649241880372301e-09
one O 0 4.4066378990237354e-08
amino O 0 6.140174946267507e-08
acid O 0 2.320150116474906e-07
by O 0 2.33728751908302e-08
another O 0 2.4179180968531e-07
( O 0 1.1650516285044432e-07
missense O 0 1.2820589290640783e-05
) O 0 2.5955841920222156e-07
. O 0 1.7833064021033351e-06

The O 0 2.9833925054845167e-06
extraordinary O 0 3.209313490515342e-06
conservation O 0 1.9757352731630817e-07
of O 0 1.2645497093899394e-08
the O 0 2.8381043293279618e-08
PAX6 O 0 0.00011494828504510224
protein O 0 2.120042665865185e-07
at O 0 4.33629887552911e-09
the O 0 3.4443510266157773e-09
amino O 0 5.3192842131011275e-08
acid O 0 3.5347471794011653e-07
level O 0 1.2156766260318363e-08
amongst O 0 1.960826878644184e-08
vertebrates O 0 1.5226819982672168e-07
predicts O 0 3.5793043480225606e-06
that O 0 1.7230225068942673e-07
pathological O 0 3.932360777980648e-05
missense O 0 0.002955434378236532
mutations O 0 1.3495078746927902e-05
should O 0 9.281959734153133e-08
in O 0 3.222477573672222e-08
fact O 0 5.664800895033295e-08
be O 0 6.266213858907577e-08
common O 0 4.545756837615045e-08
even O 0 1.6789900314506667e-07
though O 0 9.559848024309758e-08
they O 0 2.9413387281351788e-08
are O 0 4.700494216081097e-09
hardly O 0 1.4284601945746545e-07
ever O 0 2.4451276203762973e-07
seen O 0 1.007817900244845e-06
in O 0 1.0083350616696407e-06
aniridia B-Disease 1 0.9999948740005493
patients O 1 0.7942971587181091
. O 0 3.820132405962795e-06

This O 0 6.043936082278378e-06
indicates O 0 1.641239919081272e-06
that O 0 5.174591422019148e-08
there O 0 1.2257511450286529e-08
is O 0 5.623491450279516e-09
a O 0 5.0181611754851474e-08
heavy O 0 3.2061085221357644e-05
ascertainment O 0 9.813233918976039e-05
bias O 0 2.263018541270867e-05
in O 0 2.3810509119925882e-08
the O 0 7.944867874698502e-09
selection O 0 2.6063984748248004e-08
of O 0 3.8554766490506154e-08
patients O 0 2.653245974215679e-05
for O 0 2.1252188275866501e-07
PAX6 O 1 0.822477400302887
mutation O 0 2.378183853579685e-05
analysis O 0 8.754523861398411e-08
and O 0 1.512420411131643e-08
that O 0 1.2158992035438132e-08
the O 0 3.890083277724443e-08
missing O 0 6.194088655320229e-06
PAX6 O 0 0.052422456443309784
missense O 0 0.09880419820547104
mutations O 0 0.00011372911831131205
frequently O 0 2.1389761968748644e-05
may O 0 9.45563442655839e-05
underlie O 0 0.001767746522091329
phenotypes O 0 0.0013193304184824228
distinct O 0 7.747560744064685e-07
from O 0 4.10976667808427e-07
textbook O 0 0.0005271582631394267
aniridia B-Disease 1 0.9998886585235596
. O 0 9.847199180512689e-06

Here O 0 8.117777724692132e-06
we O 0 2.524715512208786e-07
present O 0 1.348627733932517e-07
four O 0 1.2082013256531354e-07
novel O 0 2.8263980311749037e-06
PAX6 O 0 0.01338142342865467
missense O 0 0.010026558302342892
mutations O 0 4.2360050429124385e-05
, O 0 7.20529982345397e-08
two O 0 7.377730781854552e-08
in O 0 8.775253945714212e-08
association O 0 7.804991497550873e-08
with O 0 1.5606983083671366e-07
atypical O 0 0.09257253259420395
phenotypes O 0 0.29786166548728943
ectopia B-Disease 0 0.011447996832430363
pupillae I-Disease 0 0.0016524241073057055
( O 0 1.1554329404361852e-07
displaced B-Disease 0 1.1701954463205766e-06
pupils I-Disease 0 5.258757482806686e-07
) O 0 4.219353115786362e-07
and O 0 0.0005572104710154235
congenital B-Disease 1 0.9999918937683105
nystagmus I-Disease 1 0.889805257320404
( O 0 1.245410743422326e-07
searching B-Disease 0 5.144213446328649e-07
gaze I-Disease 0 3.599217961891554e-05
) O 0 2.9270784906998415e-08
, O 0 9.202278050679524e-09
and O 0 8.254377625860343e-09
two O 0 1.4076350751679456e-08
in O 0 2.651789721141995e-08
association O 0 1.8297285464541346e-08
with O 0 2.8598510226629514e-08
more O 0 1.9388056671232334e-07
recognizable O 0 0.0036245964001864195
aniridia B-Disease 1 0.9999679327011108
phenotypes O 0 0.013830648735165596
. O 0 3.1308709367294796e-06

Strikingly O 0 0.03249374032020569
, O 0 5.305337253957987e-07
all O 0 1.8053649242233405e-08
four O 0 8.232024129029014e-08
mutations O 0 3.1013004786473175e-07
are O 0 7.700973192470428e-09
located O 0 1.4363676470452447e-08
within O 0 2.9208084839638104e-09
the O 0 1.6089684251596736e-08
PAX6 O 0 0.00021845128503628075
paired O 0 4.47339198217378e-06
domain O 0 2.1347699430407374e-07
and O 0 4.143349841001509e-08
affect O 0 3.0088514790804766e-08
amino O 0 4.8468216107266926e-08
acids O 0 1.957814710351613e-08
which O 0 8.109388716093235e-09
are O 0 1.7618819736497926e-09
highly O 0 1.3817102129110026e-08
conserved O 0 3.998164643803648e-08
in O 0 8.355470093590611e-09
all O 0 4.148915433432876e-09
known O 0 1.2433743279416376e-07
paired O 0 1.1485537925182143e-06
domain O 0 5.959963687018899e-07
proteins O 0 5.203586397328763e-07
. O 0 9.899644055622048e-07

Our O 0 2.8885635856568115e-06
results O 0 1.8506985952626565e-06
support O 0 8.711415944162582e-08
the O 0 1.8200280393898538e-08
hypothesis O 0 5.226364123700478e-07
that O 0 7.431097959198496e-09
the O 0 4.028152478241509e-09
under O 0 4.2139316036582386e-08
- O 0 1.0715137932493235e-06
representation O 0 1.1888099749057801e-07
of O 0 2.395472975535995e-08
missense O 0 0.00043504542554728687
mutations O 0 6.44233023194829e-06
is O 0 7.738361063047705e-08
caused O 0 3.1664092148275813e-07
by O 0 3.205619236723578e-08
ascertainment O 0 6.374677468556911e-05
bias O 0 0.00042179517913609743
and O 0 5.116471584187821e-07
suggest O 0 2.644985954702861e-07
that O 0 2.6102391359472676e-08
a O 0 3.2279652373290446e-07
substantial O 0 8.57342854487797e-07
burden O 0 2.272007577630575e-06
of O 0 6.972010879735535e-08
PAX6 B-Disease 0 0.2817820906639099
- I-Disease 1 0.9521005749702454
related I-Disease 0 0.00030945034814067185
disease I-Disease 0 0.00036923549487255514
remains O 0 2.9194595754233887e-06
to O 0 1.0701764097120758e-07
be O 0 1.3570758028436103e-07
uncovered O 0 2.5386709694430465e-06
. O 0 5.557384383791941e-07
. O 0 1.030769340104598e-06

The O 0 4.3109939724672586e-06
chromosomal O 0 0.00010108220885740593
order O 0 3.5386463537179225e-07
of O 0 2.2079666095464745e-08
genes O 0 1.744841426898347e-07
controlling O 0 9.75436591943435e-07
the O 0 5.754183973749605e-08
major O 0 2.550520434851933e-07
histocompatibility O 0 2.72356719506206e-05
complex O 0 4.495433074680477e-07
, O 0 4.461406533096124e-08
properdin O 0 2.412048388578114e-06
factor O 0 2.2661791376776819e-07
B O 0 1.3100817568556522e-06
, O 0 1.2230590584749734e-07
and O 0 4.296337465348188e-06
deficiency B-Disease 0 0.00011071194603573531
of I-Disease 0 3.60352658823615e-09
the I-Disease 0 1.365839352729381e-08
second I-Disease 0 2.0283680157717754e-07
component I-Disease 0 6.643596606181745e-08
of I-Disease 0 9.012214974291055e-09
complement I-Disease 0 9.59605245043349e-07
. O 0 1.1447133374531404e-06

The O 0 2.141767708963016e-06
relationship O 0 1.0508930472497013e-06
of O 0 2.1801461969062075e-08
the O 0 4.905151484990711e-08
genes O 0 2.180924525418959e-07
coding O 0 5.252717301118537e-07
for O 0 3.6221614152509574e-08
HLA O 0 6.219730130396783e-05
to O 0 8.630707526435799e-08
those O 0 1.2649020497690344e-08
coding O 0 2.0776143117018364e-07
for O 0 1.537169680432271e-08
properdin O 0 4.4345906644593924e-06
Factor O 0 1.0377452497323247e-07
B O 0 4.3870227273146156e-07
allotypes O 0 6.891835710121086e-06
and O 0 2.4032672740759153e-07
for O 0 1.3847200079908362e-06
deficiency B-Disease 0 0.0002057143283309415
of I-Disease 0 3.18544923771924e-09
the I-Disease 0 6.588323664402651e-09
second I-Disease 0 8.603588241840043e-08
component I-Disease 0 1.4840673578930819e-08
of I-Disease 0 2.3102764146187837e-09
complement I-Disease 0 1.3857091119007237e-07
( O 0 6.631898230580191e-08
C2 O 0 1.3200181456340943e-05
) O 0 1.0218061063937967e-08
was O 0 1.8855689631891437e-07
studied O 0 4.6677261167360484e-08
in O 0 2.8668907248174946e-08
families O 0 3.628066380656492e-08
of O 0 3.33733716217921e-08
patients O 0 0.00019606745627243072
with O 0 7.740948785794899e-05
connective O 1 0.9998146891593933
tissue O 1 0.9999198913574219
disorders O 1 0.9991693496704102
. O 0 2.0344510630820878e-05

Patients O 1 0.9650865793228149
were O 0 2.4312373625434702e-06
selected O 0 6.896017623603257e-08
because O 0 3.5614643678627544e-08
they O 0 1.9165957709788017e-08
were O 0 7.090751807936613e-08
heterozygous O 0 1.7935295772986137e-06
or O 0 9.474440787471394e-08
homozygous O 0 5.34411083208397e-05
for O 0 0.0007813054253347218
C2 B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999974966049194
. O 0 6.0246446082601324e-05

12 O 0 2.5665693101473153e-05
families O 0 1.3086544186080573e-06
with O 0 1.0523717719479464e-07
15 O 0 2.966965269024513e-07
matings O 0 1.835545845096931e-05
informative O 0 1.9141525626764633e-05
for O 0 0.019374191761016846
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999988079071045
were O 0 6.760147698514629e-06
found O 0 2.7105181743536377e-06
. O 0 1.213769564856193e-06

Of O 0 3.4204749681521207e-06
57 O 0 9.552585652272683e-06
informative O 0 2.728062099777162e-06
meioses O 0 2.1950831069261767e-05
, O 0 3.479162202779662e-08
two O 0 1.440590224888183e-08
crossovers O 0 5.338830533219152e-07
were O 0 7.83338762744279e-08
noted O 0 1.2109676106319966e-07
between O 0 6.44983941811006e-08
the O 0 0.0001954447798198089
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999970197677612
gene O 0 4.920988772028068e-07
and O 0 3.8980825678436304e-08
the O 0 6.913243311146289e-08
HLA O 0 0.006036208011209965
- O 0 0.025400549173355103
B O 0 1.1526133675943129e-05
gene O 0 9.113739452004666e-08
, O 0 6.311985600859771e-09
with O 0 5.801148006412404e-09
a O 0 5.41122915365122e-08
recombinant O 0 2.1000606409415923e-07
fraction O 0 1.0164454522509914e-07
of O 0 1.8685733849110875e-08
0 O 0 2.3324059839069378e-06
. O 0 1.0996504897775594e-06

035 O 0 0.24380670487880707
. O 0 0.0005736291059292853

A O 0 6.409214256564155e-05
lod O 0 0.0012799667892977595
score O 0 1.4074935279495548e-06
of O 0 2.199719340012507e-08
13 O 0 2.0534366740321275e-07
was O 0 2.1384906290222716e-07
calculated O 0 1.4502731460197538e-07
for O 0 3.516858271268575e-08
linkage O 0 2.2076390450820327e-05
between O 0 0.002623466309159994
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999988079071045
and O 0 7.65486947784666e-06
HLA O 0 0.012788224965333939
- O 0 0.001207153545692563
B O 0 2.1183946046221536e-06
at O 0 7.021639714110961e-09
a O 0 3.5879189397292066e-08
maximum O 0 1.9537884554665652e-07
likelihood O 0 6.205898017697109e-08
value O 0 1.4014833737974186e-09
of O 0 8.64457117000228e-10
the O 0 4.6404267095567775e-09
recombinant O 0 1.2387654635404033e-07
fraction O 0 1.7438998156649177e-07
of O 0 2.6290763344150037e-08
0 O 0 1.926089225889882e-06
. O 0 1.3436522294796305e-06

04 O 0 0.021038327366113663
. O 0 9.327800216851756e-05

18 O 0 9.680585208116099e-05
families O 0 1.2977696997040766e-06
with O 0 1.0135163819313675e-07
21 O 0 4.386566843095352e-07
informative O 0 5.000361511520168e-07
matings O 0 6.032603323546937e-06
for O 0 4.3435356644749845e-08
both O 0 2.4900332462607366e-08
properdin O 0 4.033831828564871e-06
Factor O 0 1.7657609419075015e-07
B O 0 5.492586296895752e-07
allotype O 0 3.11597136715136e-06
and O 0 1.829551194987289e-07
HLA O 0 0.0005579034332185984
- O 0 0.004607498645782471
B O 0 1.3418707567325328e-05
were O 0 2.1294732732712873e-07
found O 0 5.849884701092378e-07
. O 0 1.3013117268201313e-06

Of O 0 1.769526420503098e-06
72 O 0 6.555892923643114e-06
informative O 0 3.4658510230656248e-06
meioses O 0 3.165069574606605e-05
, O 0 8.569359977173008e-08
three O 0 3.17079980050039e-08
recombinants O 0 1.3577502613770775e-05
were O 0 1.2922266989789932e-07
found O 0 3.56859750638705e-08
, O 0 7.57100249160203e-09
giving O 0 1.1154100754140472e-08
a O 0 7.396413792548628e-08
recombinant O 0 1.570621606106215e-07
fraction O 0 1.883726667983865e-07
of O 0 2.6546134179739056e-08
0 O 0 1.8853941128327278e-06
. O 0 1.3046756066614762e-06

042 O 0 0.012767539359629154
. O 0 0.0002780871873255819

A O 0 0.00014141541032586247
lod O 0 0.002279989654198289
score O 0 2.8863632905995473e-06
of O 0 5.23552827758067e-08
16 O 0 1.8901583587194182e-07
between O 0 7.33835037181052e-08
HLA O 0 8.995005919132382e-05
- O 0 0.00011157475091749802
B O 0 1.4240887367122923e-06
and O 0 1.5758873317395228e-08
Factor O 0 2.4337344584068887e-08
B O 0 1.1881277117709033e-07
allotypes O 0 1.1325072364343214e-06
was O 0 1.0272468387029221e-07
calculated O 0 1.919485725920822e-08
at O 0 1.0279437301363714e-09
a O 0 1.5138576614504018e-08
maximum O 0 1.0526728999593615e-07
likelihood O 0 2.933444598340884e-08
value O 0 1.5762471328173433e-09
of O 0 4.698529343372115e-10
the O 0 2.65611133087873e-09
recombinant O 0 7.759732767453897e-08
fraction O 0 1.1346873662887447e-07
of O 0 2.611543870045807e-08
0 O 0 1.7820415223468444e-06
. O 0 1.0941063237623894e-06

04 O 0 0.019762136042118073
. O 0 0.00011006899876520038

A O 0 9.98038194666151e-06
crossover O 0 1.0475266208231915e-05
was O 0 3.7319564398785587e-06
shown O 0 2.4278051569126546e-07
to O 0 2.5200481701403987e-08
have O 0 6.04033587592312e-08
occurred O 0 5.7046150914175087e-08
between O 0 2.870117477016265e-09
genes O 0 9.480329410394006e-09
for O 0 6.580561873192892e-09
Factor O 0 3.6073519282808775e-08
B O 0 3.0852967825012456e-07
and O 0 1.1103247032906438e-07
HLA O 0 0.0024281274527311325
- O 0 0.042642734944820404
D O 0 0.008710527792572975
, O 0 4.178627577289262e-08
in O 0 2.610637572786345e-08
which O 0 9.445243449590635e-07
HLA O 0 0.001999618485569954
- O 0 0.03888554871082306
D O 0 0.002696023555472493
segregared O 0 1.539495679026004e-05
with O 0 1.464656236294104e-07
HLA O 0 0.00015374773647636175
- O 0 4.178714152658358e-05
A O 0 1.1169298886670731e-05
and O 0 1.9830399651254993e-06
B O 0 1.0482991456228774e-05
. O 0 9.68996346273343e-07

These O 0 4.879001608060207e-06
studies O 0 1.1457946129667107e-06
suggest O 0 4.3698196350305807e-07
that O 0 1.43722269640989e-08
the O 0 8.583293187314212e-09
genes O 0 2.6856183055201654e-08
for O 0 1.0727571719826301e-08
Factor O 0 1.0798234484354907e-07
B O 0 2.6334751964895986e-05
and O 0 0.04748189076781273
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999984502792358
are O 0 2.0608558415347034e-08
located O 0 1.4643901202759935e-08
outside O 0 1.709376462599721e-08
those O 0 7.17858927856696e-09
for O 0 3.366849554709006e-08
HLA O 0 0.003160623600706458
, O 0 1.015586974517646e-07
that O 0 6.0375344723695434e-09
the O 0 2.1810933059640547e-09
order O 0 8.514352778377088e-09
of O 0 3.787081315209662e-09
genese O 0 1.164188506663777e-05
is O 0 4.2332095517849666e-07
HLA O 0 5.69900767004583e-05
- O 0 2.973407208628487e-05
A O 0 5.327332928573014e-06
, O 0 1.8919779165571526e-07
- O 0 9.826758287090342e-06
B O 0 1.995865659409901e-06
, O 0 5.6020084571173356e-08
- O 0 9.5279201559606e-06
D O 0 3.214622847735882e-05
, O 0 5.348288567574855e-08
Factor O 0 8.667776540960404e-08
B O 0 9.718561386762303e-07
allotype O 0 0.0017386878607794642
, O 0 0.04302532970905304
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999986886978149
, O 0 6.269476671150187e-08
that O 0 8.213451252458981e-09
the O 0 5.237882572117769e-09
genes O 0 6.833939636408104e-08
coding O 0 2.3968614186742343e-06
for O 0 7.165005808928981e-05
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999899864196777
and O 0 2.7899238830286777e-07
Factor O 0 1.2983203134808718e-07
B O 0 1.24422297176352e-06
allotypes O 0 1.1521210581122432e-05
are O 0 1.597952348220133e-08
approximately O 0 1.26019408241973e-08
3 O 0 3.0004727591403935e-08
- O 0 1.8070242049361696e-06
- O 0 1.7204465621034615e-05
5 O 0 1.1364255669832346e-07
centimorgans O 0 7.673249342587951e-07
from O 0 1.0376992598537527e-08
the O 0 1.5932684505060024e-08
HLA O 0 3.892940003424883e-05
- O 0 2.144813879567664e-05
A O 0 5.070005499874242e-06
and O 0 5.443578174890717e-07
HLA O 0 0.00031531392596662045
- O 0 0.00047812561388127506
B O 0 3.987407581007574e-06
loci O 0 1.445968536017972e-07
, O 0 1.7603042579139583e-08
and O 0 6.710198174886273e-09
that O 0 9.272860701514674e-09
the O 0 1.3763287398660395e-08
apparent O 0 1.9169514416716993e-05
lack O 0 8.133355322570424e-08
of O 0 7.887672737183493e-09
recombinants O 0 8.858478395268321e-06
between O 0 1.3274047638844877e-08
the O 0 1.3737374793265644e-08
Factor O 0 1.078279936450599e-07
B O 0 3.493423946565599e-06
gene O 0 4.585283022606745e-06
and O 0 0.02099093236029148
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999994039535522
gene O 0 1.0111208212038036e-05
suggests O 0 3.2858068266250484e-07
that O 0 9.383669841156461e-09
these O 0 2.749047434136287e-09
two O 0 1.255434245450715e-08
genes O 0 4.7510539502582105e-08
lie O 0 1.5596121727412537e-07
in O 0 5.391590285341863e-09
close O 0 2.1451349141443643e-08
proximity O 0 5.468669428410067e-08
to O 0 1.1567834690140444e-07
one O 0 3.4666535952965205e-07
another O 0 3.094330395470024e-06
. O 0 3.58644228981575e-06

Distribution O 0 4.273637387086637e-06
of O 0 1.6312019113229326e-07
emerin O 0 2.0448611394385807e-05
and O 0 4.1275833950749075e-07
lamins O 0 2.955991294584237e-05
in O 0 6.186421330767189e-08
the O 0 3.560527161994287e-08
heart O 0 1.8462018488207832e-05
and O 0 1.6309017780713475e-07
implications O 0 4.649683376101166e-07
for O 0 2.7724186679733975e-07
Emery B-Disease 0 0.024289939552545547
- I-Disease 1 0.9847761392593384
Dreifuss I-Disease 1 0.9999034404754639
muscular I-Disease 1 0.9999111890792847
dystrophy I-Disease 1 0.9998359680175781
. O 0 4.294457539799623e-05

Emerin O 0 0.0020610059145838022
is O 0 2.50116045208415e-06
a O 0 7.342158028222912e-07
nuclear O 0 6.458851089519158e-07
membrane O 0 5.945566954324022e-07
protein O 0 9.915823540040947e-08
which O 0 1.0786703086296257e-08
is O 0 1.4326684727450356e-08
missing O 0 1.4918300905719661e-07
or O 0 3.319054542316735e-08
defective O 0 1.158084978669649e-05
in O 0 7.962178187881364e-07
Emery B-Disease 1 0.5709484815597534
- I-Disease 1 0.9997550845146179
Dreifuss I-Disease 1 0.999992847442627
muscular I-Disease 1 0.9999946355819702
dystrophy I-Disease 1 0.9999949932098389
( O 0 4.973278919351287e-05
EDMD B-Disease 1 0.9999439716339111
) O 0 4.358047590358183e-06
. O 0 2.299975449204794e-06

It O 0 3.7069455629534787e-06
is O 0 9.208269347027453e-08
one O 0 2.795281517364856e-08
member O 0 8.370176551864006e-09
of O 0 2.2935486843067565e-09
a O 0 8.367312602786114e-07
family O 0 5.242957854534325e-07
of O 0 2.0115654919550252e-08
lamina O 0 0.0005197714199312031
- O 0 0.02249172143638134
associated O 0 3.1568754366162466e-07
proteins O 0 1.348658162925176e-08
which O 0 1.7269945473685766e-08
includes O 0 4.8991488199590094e-08
LAP1 O 0 3.986695810453966e-05
, O 0 1.5685020571254427e-07
LAP2 O 0 4.2295905586797744e-05
and O 0 6.200082793839101e-07
lamin O 0 0.0409550666809082
B O 0 0.00036531628575176
receptor O 0 2.1617715901811607e-05
( O 0 9.528351938570268e-07
LBR O 0 0.0010552069870755076
) O 0 6.643887218160671e-07
. O 0 9.355799761578965e-07

A O 0 1.9636132492450997e-05
panel O 0 3.5817661228065845e-06
of O 0 1.0011127216102977e-07
16 O 0 6.662751275143819e-07
monoclonal O 0 1.6632024198770523e-05
antibodies O 0 7.390374321403215e-06
( O 0 7.837765991780543e-08
mAbs O 0 3.2661760087648872e-06
) O 0 3.529397574197901e-08
has O 0 9.082538809934704e-08
been O 0 5.2770133152080234e-08
mapped O 0 4.128173713979777e-07
to O 0 1.4779488743954516e-08
six O 0 1.3043450763916553e-08
specific O 0 2.217330319354005e-09
sites O 0 4.913295104103099e-09
throughout O 0 4.599127745308351e-09
the O 0 4.2691521429105705e-09
emerin O 0 7.413333946715284e-07
molecule O 0 5.541074443726757e-08
using O 0 4.380467544251587e-08
phage O 0 8.212731472667656e-07
- O 0 1.9443787095951848e-06
displayed O 0 6.588803103113605e-07
peptide O 0 1.0142881023966765e-07
libraries O 0 8.199050327561963e-09
and O 0 4.877487302934469e-09
has O 0 3.9459656875351357e-08
been O 0 2.5700261474526087e-08
used O 0 2.0774590936412096e-08
to O 0 3.6704687289557114e-08
localize O 0 2.35584047914017e-06
emerin O 0 2.7592786864261143e-05
in O 0 9.723329696953442e-08
human O 0 5.482413811819242e-08
and O 0 2.930297000602877e-07
rabbit O 0 0.004069652874022722
heart O 0 0.03616243228316307
. O 0 5.425358722277451e-06

Several O 0 1.0797800314321648e-05
mAbs O 0 5.311092172632925e-05
against O 0 4.1525680671838927e-07
different O 0 5.1134279033249186e-08
emerin O 0 1.526874621049501e-05
epitopes O 0 4.231793718645349e-05
did O 0 8.87211456301884e-07
not O 0 2.8922212180759743e-08
recognize O 0 6.018703402332903e-08
intercalated O 0 1.047049522640009e-06
discs O 0 2.0409161152201705e-05
in O 0 3.5636592343735174e-08
the O 0 4.211296555922672e-08
heart O 0 4.6413893869612366e-05
, O 0 4.14947152194145e-08
though O 0 4.299569411614357e-08
they O 0 1.1450803860668657e-08
recognized O 0 2.1064465727249626e-08
cardiomyocyte O 0 2.0547818166960496e-06
nuclei O 0 2.756681567461783e-07
strongly O 0 2.8557582254506997e-07
, O 0 1.1555327361634227e-08
both O 0 3.840626927598123e-09
at O 0 4.3820693740315164e-09
the O 0 1.031030993914328e-08
rim O 0 3.323584678582847e-07
and O 0 5.340011810517353e-08
in O 0 3.716923657748339e-08
intranuclear O 0 1.4910613572283182e-05
spots O 0 9.010230996864266e-07
or O 0 1.0195735455909016e-07
channels O 0 1.795888238120824e-06
. O 0 9.155430120699748e-07

A O 0 0.00011818126949947327
polyclonal O 0 0.000752946943975985
rabbit O 0 0.0002297085738973692
antiserum O 0 0.00019408378284424543
against O 0 2.0858344669250073e-06
emerin O 0 0.00010815449786605313
did O 0 1.335601155005861e-06
recognize O 0 1.449844404532996e-07
both O 0 2.031119983314511e-08
nuclear O 0 8.119839378650795e-08
membrane O 0 2.2967526547290618e-07
and O 0 6.19736937323978e-08
intercalated O 0 1.3518460946215782e-06
discs O 0 4.30741420132108e-05
but O 0 8.48443093559581e-08
, O 0 7.990047734551808e-09
after O 0 1.374938118914315e-08
affinity O 0 1.4192842456850485e-08
purification O 0 5.776749389951874e-08
against O 0 1.0513902637399042e-08
a O 0 5.05537798289879e-08
pure O 0 9.918452548163259e-08
- O 0 5.3499179557547905e-06
emerin O 0 5.0438434300303925e-06
band O 0 1.8390780098798132e-07
on O 0 1.0561900687378056e-08
a O 0 4.770431516476492e-08
western O 0 8.523537786686575e-08
blot O 0 0.0001309418585151434
, O 0 4.441386280973347e-08
it O 0 2.0829542535238943e-08
stained O 0 3.849495897156885e-06
only O 0 1.4818554383566607e-08
the O 0 1.8944618318528228e-08
nuclear O 0 7.836553095330601e-07
membrane O 0 5.156038696441101e-06
. O 0 1.306418653257424e-06

These O 0 4.642245585273486e-06
results O 0 2.4193120680138236e-06
would O 0 9.430539193999721e-08
not O 0 1.6084806375715743e-08
be O 0 1.1335631988629302e-08
expected O 0 9.865021866062307e-08
if O 0 2.445026758834956e-08
immunostaining O 0 1.1725660442607477e-06
at O 0 9.877726192542013e-09
intercalated O 0 2.5351820909236267e-07
discs O 0 8.961607818491757e-06
were O 0 1.0225357982562855e-07
due O 0 2.2130766552663772e-08
to O 0 1.893536882846547e-08
a O 0 1.1205452210560907e-07
product O 0 2.1092930069244176e-08
of O 0 1.5316550250332739e-09
the O 0 7.828514725360947e-09
emerin O 0 7.525003638875205e-06
gene O 0 1.5989499502211402e-07
and O 0 3.7583426149012666e-08
, O 0 2.8675252394805284e-08
therefore O 0 2.5647961976460465e-08
, O 0 9.884417728756034e-09
cast O 0 2.626558455176564e-07
some O 0 6.831590848577207e-09
doubt O 0 7.939781454524564e-08
upon O 0 2.0480149132140468e-08
the O 0 2.6271514741438295e-08
hypothesis O 0 1.5358469909187988e-06
that O 0 6.006833928040578e-07
cardiac B-Disease 1 0.9952433705329895
defects I-Disease 1 0.9967526793479919
in O 0 2.2337084374157712e-05
EDMD B-Disease 1 0.9999991655349731
are O 0 3.932167601305991e-06
caused O 0 5.367319317883812e-06
by O 0 6.131818963694968e-08
absence O 0 2.289055629489667e-07
of O 0 2.1973209030079488e-08
emerin O 0 4.44264842371922e-05
from O 0 1.545084700182997e-07
intercalated O 0 1.1929071661143098e-05
discs O 0 0.00010259036935167387
. O 0 1.7922129700309597e-06

Although O 0 2.2075886590755545e-05
emerin O 0 0.00013461100752465427
was O 0 1.7743019498084323e-06
abundant O 0 1.6701109473160614e-07
in O 0 2.0298806191476615e-08
the O 0 9.356825536599445e-09
membranes O 0 1.4701335260269843e-07
of O 0 1.037117591806691e-08
cardiomyocyte O 0 2.6620815333444625e-05
nuclei O 0 1.0003145689552184e-06
, O 0 1.8858383299402703e-08
it O 0 1.875600474932071e-08
was O 0 1.051548679242842e-06
absent O 0 1.1078158479449485e-07
from O 0 5.492395871442568e-09
many O 0 4.76312855823835e-09
non O 0 2.4046466151617096e-08
- O 0 2.594782563392073e-05
myocyte O 0 0.006202135235071182
cells O 0 9.8909242751688e-07
in O 0 4.081479332285198e-08
the O 0 1.7297563204010658e-07
heart O 0 0.0001153155171778053
. O 0 2.25919052354584e-06

This O 0 1.3020255664741853e-06
distribution O 0 1.6943675973379868e-07
of O 0 3.031096795780286e-08
emerin O 0 7.7164797403384e-05
was O 0 3.2215148166869767e-06
similar O 0 3.9478553759408896e-08
to O 0 1.8524552558574214e-08
that O 0 1.0054926669056385e-08
of O 0 4.203606351893541e-09
lamin O 0 0.00015308418369386345
A O 0 4.886987881036475e-06
, O 0 1.983914010850185e-08
a O 0 9.753550500590791e-08
candidate O 0 7.618388053742819e-07
gene O 0 7.259998113795518e-08
for O 0 1.2176397667928995e-08
an O 0 7.19204990673461e-07
autosomal O 0 0.012736665084958076
form O 0 2.067290779450559e-06
of O 0 5.727509915232076e-07
EDMD B-Disease 1 0.9999803304672241
. O 0 3.142986315651797e-05

In O 0 2.988262531289365e-05
contrast O 0 4.226743840263225e-05
, O 0 2.3765446712786797e-06
lamin O 0 0.009007572196424007
B1 O 0 0.016457419842481613
was O 0 9.422818948223721e-06
absent O 0 5.13677662183909e-07
from O 0 2.7926436274583466e-08
cardiomyocyte O 0 4.278433152649086e-06
nuclei O 0 7.488825417567568e-07
, O 0 2.6192562785354312e-08
showing O 0 3.0976201514931745e-07
that O 0 3.148150540255301e-07
lamin O 0 0.02562367357313633
B1 O 0 0.013422342948615551
is O 0 5.7389048180311875e-08
not O 0 1.2081202704905536e-08
essential O 0 2.525647913032003e-09
for O 0 2.9020503777843487e-09
localization O 0 7.840442606266151e-08
of O 0 7.170132931832995e-09
emerin O 0 5.5070545386115555e-06
to O 0 1.3107549534652208e-07
the O 0 8.452771993461283e-08
nuclear O 0 4.079365680809133e-06
lamina O 0 0.00016646823496557772
. O 0 5.426254119811347e-06

Lamin O 1 0.9812743067741394
B1 O 1 0.9907123446464539
is O 0 7.99650570115773e-06
also O 0 5.367193125493941e-07
almost O 0 1.1186575221699968e-07
completely O 0 5.325593974703224e-07
absent O 0 1.14525175831659e-06
from O 0 9.93354163369986e-08
skeletal O 0 0.0002695046132430434
muscle O 0 0.0003241238882765174
nuclei O 0 7.355674460995942e-05
. O 0 2.693364876904525e-06

In O 0 3.79256161977537e-05
EDMD B-Disease 1 0.9982707500457764
, O 0 3.3573275004528114e-07
the O 0 1.7828963194688185e-08
additional O 0 7.085303366238804e-08
absence O 0 2.209256280139016e-07
of O 0 1.1373145980542176e-07
lamin O 0 0.4455835223197937
B1 O 0 0.13057485222816467
from O 0 2.902260121118161e-07
heart O 0 3.900327646988444e-05
and O 0 4.7154213689282187e-07
skeletal O 0 0.007838854566216469
muscle O 0 0.00016241906268987805
nuclei O 0 6.5694493969203904e-06
which O 0 4.210071722354769e-07
already O 0 9.500840292275825e-07
lack O 0 5.385887789088883e-07
emerin O 0 0.021212950348854065
may O 0 9.16546650842065e-06
offer O 0 1.1549514766784341e-07
an O 0 1.6626726662138935e-08
alternative O 0 9.004555323599561e-08
explanation O 0 1.1739037120150897e-07
of O 0 3.7240042161101883e-09
why O 0 5.6285056615479334e-08
these O 0 8.254566807863739e-09
tissues O 0 1.9997951028472016e-07
are O 0 1.144359895732805e-08
particularly O 0 3.8404169799832744e-07
affected O 0 4.812021074940276e-07
. O 0 2.894512363127433e-07
. O 0 9.063949164556107e-07

Genetic O 0 0.00030455575324594975
mapping O 0 7.3487676672812086e-06
of O 0 1.2121854808810895e-07
the O 0 2.050765459671311e-07
copper B-Disease 0 8.530483319191262e-05
toxicosis I-Disease 0 0.002428374718874693
locus O 0 5.811644314235309e-06
in O 0 2.2381097153356677e-07
Bedlington O 0 1.1147208169859368e-05
terriers O 0 7.739600732747931e-06
to O 0 3.5232977779742214e-07
dog O 0 5.7408939028391615e-05
chromosome O 0 3.5321470932103693e-05
10 O 0 1.3538338805574313e-07
, O 0 2.9634298570613282e-08
in O 0 1.4338220388765421e-08
a O 0 3.660715890418942e-07
region O 0 3.822005965048447e-07
syntenic O 0 5.4796229960629717e-05
to O 0 4.2355276264061104e-07
human O 0 1.9208671631076868e-07
chromosome O 0 1.6561356460442767e-05
region O 0 1.4374716101883678e-06
2p13 O 0 5.385093027143739e-05
- O 0 0.0001072563391062431
p16 O 0 0.00011417768109822646
. O 0 4.2205383579130284e-06

Abnormal O 1 0.9818693995475769
hepatic B-Disease 1 0.9967825412750244
copper I-Disease 0 0.005332031287252903
accumulation I-Disease 0 1.3979533832753077e-05
is O 0 3.023273791313841e-07
recognized O 0 1.9040422216676234e-07
as O 0 1.5560792121505074e-07
an O 0 8.127125329338014e-05
inherited B-Disease 1 0.9999996423721313
disorder I-Disease 1 0.9999988079071045
in O 0 1.586780626894324e-06
man O 0 0.0007413584971800447
, O 0 2.9006938007114513e-07
mouse O 0 4.978581728209974e-06
, O 0 1.4515683233184973e-07
rat O 0 2.6883302780333906e-05
and O 0 7.479005148525175e-07
dog O 0 3.849235872621648e-05
. O 0 2.354780235691578e-06

The O 0 2.4427904463664163e-06
major O 0 1.961558382390649e-06
cause O 0 3.7552654248429462e-06
of O 0 2.4319601266142854e-07
hepatic B-Disease 0 0.07740291208028793
copper I-Disease 0 0.00104337849188596
accumulation I-Disease 0 1.5651489775336813e-06
in O 0 1.6394629653859738e-07
man O 0 1.3553801181842573e-05
is O 0 8.897544745423147e-08
a O 0 5.775966656074161e-07
dysfunctional O 0 2.4003084035939537e-05
ATP7B O 0 0.001578596537001431
gene O 0 1.9744254586839816e-06
, O 0 3.7923749118817796e-07
causing O 0 7.249237387441099e-05
Wilson B-Disease 0 0.14368189871311188
disease I-Disease 0 0.12389885634183884
( O 0 2.8049862521584146e-06
WD B-Disease 1 0.6645004749298096
) O 0 2.5675378765299683e-06
. O 0 1.8237760741612874e-06

Mutations O 0 0.010912029072642326
in O 0 1.4868944617774105e-06
the O 0 1.965065621334361e-07
ATP7B O 0 0.0003467236238066107
genes O 0 4.3027773699577665e-07
have O 0 7.284994296696823e-08
also O 0 5.6816379156998664e-08
been O 0 1.0261326366389767e-07
demonstrated O 0 4.6779666718066437e-07
in O 0 5.462914742793146e-08
mouse O 0 4.302947218093323e-06
and O 0 1.6976523511402775e-06
rat O 0 0.003329417435452342
. O 0 3.140092758258106e-06

The O 0 5.683670224243542e-06
ATP7B O 0 0.00021413729700725526
gene O 0 4.561078640108462e-06
has O 0 6.297630079643568e-07
been O 0 1.7164474286346376e-07
excluded O 0 1.352143499389058e-07
in O 0 1.4905523926245223e-08
the O 0 1.3966381828822705e-08
much O 0 2.0192349836634094e-07
rarer O 0 0.00019283624715171754
human O 0 2.551471879996825e-06
copper B-Disease 0 0.20278188586235046
overload I-Disease 1 0.9497925639152527
disease O 0 0.0004537152126431465
non B-Disease 0 3.937846315693605e-07
- I-Disease 0 8.879019878804684e-05
Indian I-Disease 0 6.224228400242282e-06
childhood I-Disease 0 0.00020744983339682221
cirrhosis I-Disease 0 0.045935019850730896
, O 0 4.361920957762777e-07
indicating O 0 1.0265167475154158e-05
genetic O 0 8.526408237230498e-06
heterogeneity O 0 0.00011183167225681245
. O 0 6.77788739267271e-06

By O 0 4.356430963525781e-06
investigating O 0 2.810025080179912e-06
the O 0 3.588846766433562e-07
common O 0 6.0679271882690955e-06
autosomal O 1 0.9683966040611267
recessive O 1 0.9922631978988647
copper B-Disease 1 0.7011069059371948
toxicosis I-Disease 1 0.7200169563293457
( O 0 4.3982663555652834e-07
CT B-Disease 0 0.002340201521292329
) O 0 5.832259830640396e-08
in O 0 5.554502635618519e-08
Bedlington O 0 8.076179256022442e-06
terriers O 0 1.0283451047143899e-05
, O 0 5.9525568474327883e-08
we O 0 1.4016819704920636e-08
have O 0 1.26019408241973e-08
identified O 0 2.239496765810145e-08
a O 0 2.0382024956688838e-08
new O 0 4.055460323115767e-08
locus O 0 6.449470788538747e-07
involved O 0 1.8011076008406235e-07
in O 0 9.561339311403572e-07
progressive O 1 0.9997296929359436
liver B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999942779541016
. O 0 6.01104402448982e-05

We O 0 5.827939730806975e-06
examined O 0 7.476761311409064e-06
whether O 0 2.216824555034691e-07
the O 0 1.499538342386586e-07
WD B-Disease 0 0.003684427123516798
gene O 0 2.0699815195257543e-06
ATP7B O 0 0.00011801582877524197
was O 0 1.2307139058975736e-06
also O 0 1.0203576294998129e-07
causative O 0 4.173458592049428e-07
for O 0 6.407341146541512e-08
CT B-Disease 0 0.07023538649082184
by O 0 7.192640083530932e-08
investigating O 0 2.0722399085570942e-07
the O 0 6.573263533482532e-08
chromosomal O 0 2.3522181436419487e-05
co O 0 5.665130629495252e-06
- O 0 2.360682628932409e-06
localization O 0 2.928483979758312e-07
of O 0 9.150157076476262e-09
ATP7B O 0 2.8257618396310136e-05
and O 0 4.687550259063755e-08
C04107 O 0 1.0742251106421463e-06
, O 0 1.3741960458446556e-08
using O 0 2.4186023850347738e-08
fluorescence O 0 7.838541478122352e-07
in O 0 6.042709088660558e-08
situ O 0 5.6627213780302554e-06
hybridization O 0 1.8877008187700994e-06
( O 0 8.801184492313041e-08
FISH O 0 2.8024464882037137e-07
) O 0 2.0403112444000726e-07
. O 0 9.696295819594525e-07

C04107 O 0 0.0008296784944832325
is O 0 2.590403710200917e-06
an O 0 2.4397238007622946e-07
anonymous O 0 6.828180403317674e-07
microsatellite O 0 3.324505814816803e-05
marker O 0 9.28300778468838e-06
closely O 0 1.59472858740628e-06
linked O 0 3.947930508729769e-06
to O 0 1.3929674196333508e-06
CT B-Disease 1 0.9415401816368103
. O 0 1.0606600881146733e-05

However O 0 2.2873344278195873e-05
, O 0 1.4704154409628245e-06
BAC O 0 3.646371987997554e-05
clones O 0 1.655737946748559e-06
containing O 0 5.190328238313668e-07
ATP7B O 0 2.0334675355115905e-05
and O 0 1.0405300088223157e-07
C04107 O 0 1.7448327298552613e-06
mapped O 0 9.034745289682178e-07
to O 0 3.065399667434576e-08
the O 0 2.3433850415699453e-08
canine O 0 6.592576937691774e-06
chromosome O 0 1.6521777070011012e-05
regions O 0 8.130269435469017e-08
CFA22q11 O 0 4.2178303374384996e-06
and O 0 6.068848534823701e-08
CFA10q26 O 0 9.981323273677845e-06
, O 0 3.932554193397664e-08
respectively O 0 5.3726427751144e-08
, O 0 9.502922893034338e-09
demonstrating O 0 7.040443961159326e-08
that O 0 1.1708614522376593e-07
WD B-Disease 0 0.0026104554999619722
cannot O 0 3.123550129657815e-07
be O 0 1.0827021057480124e-08
homologous O 0 1.04369831888107e-07
to O 0 3.569149384929915e-07
CT B-Disease 1 0.7237094640731812
. O 0 5.677343324350659e-06

The O 0 6.490691248473013e-06
copper O 0 1.3625055544252973e-05
transport O 0 1.0753640253824415e-06
genes O 0 3.2117304726853035e-07
CTR1 O 0 1.4964487490942702e-05
and O 0 2.2891450157658255e-07
CTR2 O 0 0.00012512852845247835
were O 0 4.5574509499601845e-07
also O 0 1.6789900314506667e-07
excluded O 0 5.081421505792605e-08
as O 0 1.3116848052163732e-08
candidate O 0 2.3576426144700235e-07
genes O 0 4.404655129519597e-08
for O 0 3.403069470664377e-08
CT B-Disease 1 0.757341206073761
since O 0 1.0865581998587004e-06
they O 0 1.1923725118379025e-08
both O 0 3.9899425985368e-09
mapped O 0 4.3618547351798043e-07
to O 0 1.7123370810168126e-07
canine O 0 2.198510628659278e-05
chromosome O 0 0.00011358584015397355
region O 0 2.1274909158819355e-06
CFA11q22 O 0 0.00025979551719501615
. O 0 3.1476122330786893e-06

2 O 0 8.584857278037816e-05
- O 0 0.0002819437358994037
22 O 0 2.2146165065350942e-05
. O 0 2.972668653455912e-06

5 O 0 0.00028942039352841675
. O 0 4.781825191457756e-05

A O 0 4.958409408573061e-05
transcribed O 0 1.3443582247418817e-05
sequence O 0 1.287779696212965e-06
identified O 0 4.5797366965416586e-07
from O 0 8.099356740842723e-09
the O 0 1.5142560982894793e-08
C04107 O 0 2.5499614366708556e-06
- O 0 4.415886451170081e-06
containing O 0 5.602825012829271e-07
BAC O 0 2.138555828423705e-05
was O 0 8.151407655532239e-07
found O 0 1.6700273164360624e-08
to O 0 8.069334533900019e-09
be O 0 6.911671679432629e-09
homologous O 0 2.3712162899869327e-08
to O 0 2.6846963763205167e-08
a O 0 6.832414101154427e-07
gene O 0 6.67487995542615e-07
expressed O 0 1.673174949701206e-07
from O 0 1.6019255255628195e-08
human O 0 9.735428818657965e-08
chromosome O 0 7.5101702350366395e-06
2p13 O 0 1.034206616168376e-05
- O 0 1.647674616833683e-05
p16 O 0 4.5824945118511096e-06
, O 0 4.340918380307812e-08
a O 0 1.0823081453281702e-07
region O 0 9.102707565489254e-08
devoid O 0 2.105035292743196e-07
of O 0 4.054267588315952e-09
any O 0 1.4048402441346752e-08
positional O 0 9.997842425946146e-06
candidate O 0 1.3002761988900602e-05
genes O 0 2.407924966973951e-06
. O 0 2.879050498449942e-06

Molecular O 0 0.00015004799934104085
analysis O 0 2.8301581096457085e-06
of O 0 7.734657003766188e-08
the O 0 5.5417086031184226e-08
APC B-Disease 0 2.266951696583419e-06
gene O 0 3.9272180174521054e-07
in O 0 5.127022362216849e-08
205 O 0 1.171872895611159e-06
families O 0 1.1002162381146263e-07
: O 0 3.757339683829741e-08
extended O 0 3.778782229346689e-06
genotype O 0 0.0013382131000980735
- O 0 0.0019056956516578794
phenotype O 0 0.0016746282344684005
correlations O 0 1.0535140972933732e-06
in O 0 1.2658607317916903e-07
FAP B-Disease 0 0.00047588400775566697
and O 0 3.807624125329312e-06
evidence O 0 4.0288850300385093e-07
for O 0 1.0375647008231681e-08
the O 0 6.00123151173193e-09
role O 0 3.6983959006420264e-08
of O 0 8.299861242733186e-09
APC B-Disease 0 2.1733969788328977e-06
amino O 0 1.5996972990706126e-07
acid O 0 9.984389635064872e-07
changes O 0 5.832704346175888e-07
in O 0 0.00016980567306745797
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
predisposition O 1 0.9839310050010681
. O 0 3.45597873092629e-05

BACKGROUND O 0 0.002470993436872959
/ O 0 0.00013382313773036003
AIMS O 0 8.03622151579475e-06
The O 0 1.1201306904240482e-07
development O 0 1.3654648967076355e-07
of O 0 2.1544712581089698e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 0 3.07867958326824e-06
a O 0 3.6206085951562272e-06
variable O 0 9.183727911477035e-07
range O 0 2.3210104060922276e-08
of O 0 8.79868000680517e-09
extracolonic O 0 0.0002089428307954222
manifestations O 0 1.5849833289394155e-05
in O 0 5.9076228353660554e-05
familial B-Disease 1 0.9999982118606567
adenomatous I-Disease 1 0.9999967813491821
polyposis I-Disease 1 0.9999997615814209
( O 0 2.3717653675703332e-05
FAP B-Disease 0 0.014812368899583817
) O 0 2.9659412348337355e-07
is O 0 3.2661517934684525e-08
the O 0 1.1405465016878225e-08
result O 0 1.766657931057125e-08
of O 0 2.1031376640223698e-09
the O 0 2.633221463099744e-08
dominant O 0 1.3007797861064319e-05
inheritance O 0 4.2484163714107126e-05
of O 0 8.310703378811013e-06
adenomatous B-Disease 1 0.999997615814209
polyposis I-Disease 1 0.9999916553497314
coli I-Disease 1 0.9998958110809326
( O 0 2.5363358417962445e-06
APC B-Disease 0 4.391968832351267e-05
) O 0 8.395392683269165e-07
gene O 0 7.80979280534666e-06
mutations O 0 1.3380577001953498e-05
. O 0 1.9792798866546946e-06

In O 0 2.1173684672248783e-06
this O 0 1.6326197282978683e-07
study O 0 1.3190324921197316e-07
, O 0 1.6273384417786474e-08
direct O 0 9.422107183354456e-08
mutation O 0 7.900396781224117e-07
analysis O 0 2.7822443016134457e-08
of O 0 3.081954025319078e-09
the O 0 1.8000697821207723e-08
APC B-Disease 0 3.7255588267726125e-06
gene O 0 2.581897149411816e-07
was O 0 3.501571654851432e-07
performed O 0 1.4164412220907252e-07
to O 0 2.8255300321688992e-08
determine O 0 2.848626081686234e-07
genotype O 0 0.00025207590078935027
- O 0 0.005074684973806143
phenotype O 0 0.001701862784102559
correlations O 0 3.703549396050221e-07
for O 0 3.4803303350372516e-08
nine O 0 2.5845432105597865e-07
extracolonic O 0 2.710559783736244e-05
manifestations O 0 8.340472845702607e-07
and O 0 1.767783786021937e-08
to O 0 4.3033434593553466e-08
investigate O 0 2.905491953697492e-07
the O 0 1.7396641283085046e-07
incidence O 0 2.6560763217275962e-05
of O 0 4.9568416926604186e-08
APC B-Disease 0 0.00014772433496546
mutations O 0 9.971951840270776e-06
in O 0 1.6942124148044968e-07
non O 0 5.947227691649459e-06
- O 1 0.9992772936820984
FAP O 1 0.9999974966049194
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.00017264940834138542

METHODS O 0 1.5673847883590497e-05
The O 0 5.828445637234836e-07
APC B-Disease 0 5.50514869246399e-06
gene O 0 5.74740454339917e-07
was O 0 4.4839495672022167e-07
analysed O 0 7.159174515436462e-07
in O 0 6.463003643375487e-08
190 O 0 8.188143851839413e-07
unrelated O 0 4.3311451918270905e-06
FAP B-Disease 0 0.00016034295549616218
and O 0 1.3228801662990008e-06
15 O 0 7.153714705054881e-07
non O 0 2.3323236746364273e-06
- O 1 0.991489052772522
FAP O 1 0.9999970197677612
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.7008883953094482
using O 0 2.2753229131922126e-06
denaturing O 0 0.00021584030764643103
gradient O 0 0.00330581096932292
gel O 0 0.0003390272322576493
electrophoresis O 0 6.730095265083946e-06
, O 0 3.115680868859272e-08
the O 0 9.113232835034069e-09
protein O 0 5.6758324262773385e-08
truncation O 0 7.917004722912679e-07
test O 0 7.342339927163266e-07
, O 0 2.43495090757051e-08
and O 0 1.88714803783796e-08
direct O 0 9.496820041476894e-08
sequencing O 0 2.9924055979790865e-06
. O 0 1.7508816654299153e-06

RESULTS O 0 0.00039650662802159786
Chain O 0 1.767617322911974e-05
terminating O 0 3.8895746001799125e-06
signals O 0 2.3725251594441943e-06
were O 0 1.728684253521351e-07
only O 0 5.663968494218352e-08
identified O 0 7.319757742152433e-07
in O 0 3.054451269690617e-07
patients O 0 1.378024353471119e-05
belonging O 0 1.0196357891345542e-07
to O 0 5.919451240288254e-08
the O 0 4.650610563317059e-08
FAP B-Disease 0 0.0015805937582626939
group O 0 1.4610732250730507e-05
( O 0 9.456999805479427e-08
105 O 0 1.3421419680526014e-05
patients O 0 0.0013025797670707107
) O 0 5.805356977361953e-07
. O 0 1.4255140285968082e-06

Amino O 0 0.00016364592011086643
acid O 0 7.197362720035017e-05
changes O 0 7.63899890898756e-07
were O 0 1.8942492374662834e-07
identified O 0 2.4974110601760913e-07
in O 0 4.429981359521662e-08
four O 0 2.164729721698677e-06
patients O 0 5.0059345085173845e-05
, O 0 3.337916254508855e-08
three O 0 1.2557960005210589e-08
of O 0 5.674487102425019e-09
whom O 0 7.169088576119975e-07
belonged O 0 5.411848746916803e-08
to O 0 7.668228718671344e-09
the O 0 1.1123762355680356e-08
non O 0 1.0126565541668242e-07
- O 0 1.178954425995471e-05
FAP O 0 0.0024245544336736202
group O 0 0.00016730731294956058
of O 0 0.00013559315993916243
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9983572363853455
. O 0 2.159809992008377e-05

Genotype O 1 0.9945390820503235
- O 1 0.9908571839332581
phenotype O 1 0.9839175939559937
correlations O 0 0.0001810223766369745
identified O 0 1.5751904356875457e-05
significant O 0 2.5189891061927483e-07
differences O 0 7.127605954337923e-07
in O 0 4.5126444803145205e-08
the O 0 2.3158630568786975e-08
nature O 0 2.8390028106173304e-08
of O 0 4.323852387244642e-09
certain O 0 4.106803785930424e-08
extracolonic O 0 0.0001911989093059674
manifestations O 0 6.4171590565820225e-06
in O 0 1.7512306840217207e-06
FAP B-Disease 1 0.9732367396354675
patients O 1 0.6650484800338745
belonging O 0 3.773916716909298e-07
to O 0 1.6277085990168416e-07
three O 0 7.628158300576615e-07
mutation O 0 1.0337422281736508e-05
subgroups O 0 4.549691766442265e-06
. O 0 2.8502995519374963e-06

CONCLUSIONS O 0 0.00046726479195058346
Extended O 0 7.035610906314105e-05
genotype O 0 0.005959054920822382
- O 0 0.05467464029788971
phenotype O 0 0.10754445195198059
correlations O 0 7.457277661160333e-06
made O 0 3.9961943798516586e-07
in O 0 3.3491211581804237e-08
this O 0 3.512608159894626e-08
study O 0 2.6761594540403166e-07
may O 0 9.329480121778033e-07
have O 0 9.724289817825138e-09
the O 0 3.578362717249206e-09
potential O 0 8.048230526469524e-09
to O 0 1.163250384905723e-08
determine O 0 1.4061538600174117e-08
the O 0 1.8504592302903689e-09
most O 0 3.517447000334073e-09
appropriate O 0 1.2159409479295391e-08
surveillance O 0 2.3755877975872863e-07
and O 0 2.464222745857114e-07
prophylactic O 0 0.0057203141041100025
treatment O 0 0.3142603933811188
regimens O 0 0.0010680502746254206
for O 0 6.511544938803127e-07
those O 0 1.0396882998975343e-06
patients O 0 3.6614361306419596e-05
with O 0 9.969451184588252e-07
mutations O 0 2.3404685634886846e-05
associated O 0 1.1826110579704618e-07
with O 0 1.2700928664344246e-07
life O 0 1.1477060979814269e-05
threatening O 0 0.000656227464787662
conditions O 0 0.00018900026043411344
. O 0 8.828217687550932e-06

This O 0 1.032669115375029e-05
study O 0 2.624900844239164e-06
also O 0 2.741316222909518e-07
provided O 0 7.103367494210033e-08
evidence O 0 4.360602545716574e-08
for O 0 1.0287720009216628e-08
the O 0 4.353604765583441e-08
pathological O 0 1.982737194339279e-05
nature O 0 6.495059778899304e-08
of O 0 3.462860886926933e-09
amino O 0 9.97430333882221e-08
acid O 0 4.1156889096782834e-07
changes O 0 4.618821947133256e-08
in O 0 2.525707110123676e-08
APC O 0 1.0472040230524726e-05
associated O 0 1.6041215644690965e-07
with O 0 2.306843072119591e-08
both O 0 8.777379889579606e-08
FAP B-Disease 0 9.469856013311073e-05
and O 0 5.045074885856593e-06
non O 0 1.022557626129128e-05
- O 1 0.9996240139007568
FAP O 1 0.9999983310699463
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9996341466903687
. O 0 2.0064057935087476e-06
. O 0 1.63427375809988e-06

Inherited B-Disease 1 0.9998472929000854
colorectal I-Disease 1 0.9999996423721313
polyposis I-Disease 1 0.9999691247940063
and O 1 0.9676728844642639
cancer B-Disease 1 0.9992361068725586
risk O 0 2.419263637420954e-06
of O 0 4.2844739311931335e-08
the O 0 3.274813877851557e-07
APC O 0 0.00019589945441111922
I1307K O 0 0.0004135815252084285
polymorphism O 0 0.00042279597255401313
. O 0 7.962034032971133e-06

Germ O 0 0.0007160761160776019
- O 0 0.0007692581275478005
line O 0 1.1486225048429333e-05
and O 0 2.4987713231894304e-07
somatic O 0 3.868179192068055e-06
truncating O 0 2.1606832888210192e-05
mutations O 0 4.206009180052206e-06
of O 0 1.0515346815509474e-08
the O 0 8.771923631911704e-08
APC B-Disease 0 7.4751715146703646e-06
gene O 0 2.490140786903794e-07
are O 0 5.001522307424011e-09
thought O 0 4.9890342523895015e-08
to O 0 6.956190645723836e-08
initiate O 0 0.0005087691242806613
colorectal B-Disease 1 0.9999996423721313
tumor I-Disease 1 0.9689555764198303
formation O 0 8.510430234309752e-06
in O 0 1.1849940165120643e-05
familial B-Disease 1 0.9999959468841553
adenomatous I-Disease 1 0.9999986886978149
polyposis I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
and O 0 0.00021012015349697322
sporadic O 1 0.9750077724456787
colorectal O 1 0.9999997615814209
carcinogenesis O 1 0.9963185787200928
, O 0 8.335182428709231e-06
respectively O 0 8.488997991662472e-06
. O 0 1.6060564576036995e-06

Recently O 0 0.00010258352267555892
, O 0 5.390779733716045e-07
an O 0 1.787729075886091e-07
isoleucine O 0 8.091460767900571e-05
- O 0 0.00010058029874926433
- O 0 0.00023598682309966534
> O 0 2.5499393814243376e-06
lysine O 0 1.9524895833455957e-06
polymorphism O 0 2.184226786994259e-06
at O 0 4.443063872372477e-08
codon O 0 5.031176328884612e-07
1307 O 0 8.61359694681596e-06
( O 0 4.1945259710018945e-08
I1307K O 0 5.865906587132486e-07
) O 0 4.136036846347224e-09
of O 0 1.2950506222964009e-09
the O 0 1.0423092611233642e-08
APC B-Disease 0 2.1604193989333e-06
gene O 0 1.8088466902099753e-07
has O 0 1.7172791899611184e-07
been O 0 5.9019654941039335e-08
identified O 0 4.5466581610753565e-08
in O 0 4.846319345830352e-09
6 O 0 3.7925195783827803e-07
% O 0 2.1770295788314797e-08
- O 0 1.892719183160807e-06
7 O 0 4.266411224307376e-07
% O 0 8.554430053209217e-09
of O 0 2.251006936404565e-09
the O 0 6.204312086310892e-08
Ashkenazi O 0 1.670616984483786e-05
Jewish O 0 4.0103890341924853e-07
population O 0 3.7808516140103166e-07
. O 0 8.504227366756822e-07

To O 0 7.125470801838674e-06
assess O 0 9.497990504314657e-06
the O 0 4.4290439404903736e-07
risk O 0 1.7255267437121802e-07
of O 0 3.841527984604909e-09
this O 0 3.258448799670077e-08
common O 0 1.8184634598128468e-07
APC B-Disease 0 2.465843499521725e-05
allelic O 0 8.464459824608639e-05
variant O 0 0.00557648716494441
in O 0 2.0994324586354196e-05
colorectal O 1 0.9999990463256836
carcinogenesis O 1 0.9748989939689636
, O 0 1.4416478961720713e-06
we O 0 4.146623311385156e-08
have O 0 1.5562330091256626e-08
analyzed O 0 4.314570034580356e-08
a O 0 1.8592587025523244e-08
large O 0 1.8985421235129252e-08
cohort O 0 3.686318450490944e-07
of O 0 5.709074990534191e-09
unselected O 0 6.78947035339661e-05
Ashkenazi O 0 6.385919732565526e-06
Jewish O 0 1.2362539791865856e-07
subjects O 0 2.0619221174911218e-07
with O 0 4.678435345795151e-07
adenomatous B-Disease 0 0.15675507485866547
polyps I-Disease 0 0.054115861654281616
and O 0 2.482809122739127e-06
. O 0 4.599806288752006e-06
or O 0 0.048151955008506775
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 8.20615468910546e-07
for O 0 3.6362479249874013e-08
the O 0 9.180718052448356e-08
APC O 0 3.777776510105468e-05
I1307K O 0 0.00013263989239931107
polymorphism O 0 0.0001384816860081628
. O 0 2.2876029106555507e-06

The O 0 8.908358722692356e-06
APC O 0 5.223158950684592e-05
I1307K O 0 4.252644066582434e-05
allele O 0 3.0082892408245243e-05
was O 0 1.8250497078042827e-06
identified O 0 1.583559310347482e-07
in O 0 2.2002270227972076e-08
48 O 0 2.6109717055078363e-07
( O 0 8.412847307681659e-09
10 O 0 1.2322703746292518e-08
. O 0 1.0154684204621844e-08
1 O 0 2.8597474610592144e-08
% O 0 9.501382791654578e-09
) O 0 6.952116216041304e-09
of O 0 2.214258820742998e-08
476 O 0 0.0036932812072336674
patients O 0 0.1176600456237793
. O 0 2.8205390663060825e-06

Compared O 0 9.658990165917203e-05
with O 0 1.0577024056601658e-07
the O 0 3.274972826261546e-08
frequency O 0 7.250670250869007e-07
in O 0 1.5494917349201387e-08
two O 0 1.2340908739361112e-08
separate O 0 4.2118585952266585e-08
population O 0 1.3675363952359021e-08
control O 0 1.4703830686357833e-07
groups O 0 4.68298155809066e-09
, O 0 6.428368948263596e-09
the O 0 6.489955239885603e-09
APC O 0 5.188390332477866e-06
I1307K O 0 4.64992226625327e-05
allele O 0 2.979994633278693e-06
is O 0 4.9978631011526886e-08
associated O 0 1.1756700502019157e-08
with O 0 5.005024394932889e-09
an O 0 7.321433770357544e-08
estimated O 0 2.0261272482002823e-07
relative O 0 4.5369256440608297e-07
risk O 0 7.468912599506439e-08
of O 0 1.8936598067398336e-08
1 O 0 1.9341771348990733e-06
. O 0 2.369452204220579e-06

5 O 0 0.0003033699467778206
- O 0 0.000561087450478226
1 O 0 1.9067028915742412e-05
. O 0 5.764972229371779e-06

7 O 0 0.0005218483856879175
for O 0 0.00011603413440752774
colorectal B-Disease 1 0.9999979734420776
neoplasia I-Disease 1 0.9303127527236938
( O 0 1.4721638308401452e-06
both O 0 1.5130456176848384e-06
P O 0 0.0004561927926260978
= O 0 1.0780947377497796e-05
. O 0 3.9093933423828275e-07
01 O 0 6.987439064687351e-06
) O 0 3.2962805107672466e-07
. O 0 7.71002873989346e-07

Furthermore O 0 4.83740477648098e-05
, O 0 7.275522762029141e-07
compared O 0 6.820662861173332e-07
with O 0 5.978749584301113e-08
noncarriers O 0 1.8003252989728935e-05
, O 0 4.01771131919304e-08
APC O 0 9.415187491867982e-07
I1307K O 0 2.3619033981958637e-06
carriers O 0 2.916657990681415e-07
had O 0 2.544378787661117e-07
increased O 0 3.205888177149063e-08
numbers O 0 1.3676198840073539e-08
of O 0 1.4358582767215466e-08
adenomas B-Disease 0 0.0005147433839738369
and O 0 0.02867759019136429
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9998451471328735
per O 0 0.00010219046089332551
patient O 0 0.01903943344950676
( O 0 3.9811271790313185e-07
P O 0 0.0001276649272767827
= O 0 2.138347099389648e-06
. O 0 3.6852423335176354e-08
03 O 0 2.7252616519035655e-07
) O 0 5.749518638964446e-09
, O 0 5.249083834257817e-09
as O 0 6.95582969001407e-09
well O 0 7.555912340251325e-09
as O 0 1.2061747156622005e-08
a O 0 3.7511961181735387e-07
younger O 0 1.8360884496360086e-05
age O 0 4.442835290774383e-07
at O 0 3.499321508115827e-07
diagnosis O 0 0.0014292586129158735
. O 0 3.4321269595238846e-06

We O 0 2.502551524230512e-06
conclude O 0 3.615250307120732e-06
that O 0 7.863057049917188e-08
the O 0 3.907357637444875e-08
APC O 0 3.3998235267063137e-06
I1307K O 0 8.977073775895406e-06
variant O 0 9.171875717584044e-06
leads O 0 2.9635492637680727e-07
to O 0 2.732327288867964e-07
increased O 0 2.744519224506803e-05
adenoma B-Disease 1 0.9999592304229736
formation O 0 1.8530049601395149e-06
and O 0 9.014762269998755e-08
directly O 0 4.7818279114153484e-08
contributes O 0 7.699728143961693e-08
to O 0 3.497339307045877e-08
3 O 0 1.2333688914623053e-07
% O 0 2.4319943392470122e-08
- O 0 1.6632950519124279e-06
4 O 0 2.0529550681658293e-07
% O 0 4.926751895339976e-09
of O 0 1.2830843054700836e-09
all O 0 2.6035863243123458e-08
Ashkenazi O 0 0.0006074115517549217
Jewish O 0 0.06501246243715286
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
. O 0 5.3938201745040715e-05

The O 0 3.2844861834746553e-06
estimated O 0 2.108395619870862e-06
relative O 0 9.826427458392573e-07
risk O 0 3.470202614153095e-07
for O 0 4.091479510748286e-08
carriers O 0 1.2547517371785943e-06
may O 0 1.107118350773817e-06
justify O 0 5.4263392712528e-07
specific O 0 4.2264808541858656e-08
clinical O 0 6.603623887713184e-07
screening O 0 4.100675710105861e-07
for O 0 2.8268939189501907e-08
the O 0 3.773138956830735e-08
360 O 0 9.92396621768421e-07
, O 0 3.2948403116961344e-08
000 O 0 3.916579771612305e-08
Americans O 0 1.9412231822002468e-08
expected O 0 4.5459476183395964e-08
to O 0 2.980463520430021e-08
harbor O 0 2.930460823336034e-06
this O 0 8.103949511450992e-08
allele O 0 1.4126102314548916e-06
, O 0 2.3406157012573203e-08
and O 0 6.447920242180771e-08
genetic O 0 1.3523047925900755e-07
testing O 0 4.4851081071328736e-08
in O 0 7.498456966459344e-09
the O 0 4.615595905477221e-09
setting O 0 2.2523137133134696e-08
of O 0 5.8456994800337725e-09
long O 0 5.612435529656068e-07
- O 0 0.00015576490841340274
term O 0 3.3744668144208845e-06
- O 0 8.710020665603224e-06
outcome O 0 7.480517183466873e-07
studies O 0 8.501601911348189e-08
may O 0 1.4338691300963546e-07
impact O 0 2.032054453593446e-07
significantly O 0 1.594928471604362e-05
on O 1 0.9502566456794739
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 0.0005750253912992775
in O 0 3.2177027264879143e-07
this O 0 2.899944604450866e-07
population O 0 4.7676800818408083e-07
. O 0 1.7982241615754901e-06

Localization O 0 8.415462798438966e-05
of O 0 7.862964253035898e-07
human O 0 5.841973234055331e-07
BRCA1 O 0 5.0676891987677664e-05
and O 0 1.5842056200199295e-07
its O 0 1.29237704982188e-07
loss O 0 1.2521491044026334e-05
in O 0 8.653669425484622e-08
high O 0 1.6202666301978752e-06
- O 0 7.891083805589005e-05
grade O 0 7.194389013420732e-07
, O 0 7.354324793595879e-08
non B-Disease 0 4.959632065038022e-07
- I-Disease 1 0.5252649784088135
inherited I-Disease 1 0.9922997951507568
breast I-Disease 1 0.9988934397697449
carcinomas I-Disease 1 0.9999934434890747
. O 0 0.00018438995175529271

Although O 0 7.045856364129577e-06
the O 0 1.3278129529226135e-07
link O 0 5.418778528110124e-07
between O 0 3.075419741094265e-08
the O 0 1.861169920402972e-07
BRCA1 O 0 0.1875697821378708
tumour B-Disease 1 0.9999737739562988
- O 0 0.0006503744516521692
suppressor O 0 0.000221485024667345
gene O 0 1.0923474746959982e-06
and O 0 4.163647417954053e-07
hereditary B-Disease 1 0.9743106365203857
breast I-Disease 1 0.9999426603317261
and I-Disease 1 0.9999431371688843
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
is O 0 1.2191594578325748e-06
established O 0 7.162030613017123e-08
, O 0 6.253054074534248e-09
the O 0 1.8116075306551238e-09
role O 0 1.3671921372804263e-08
, O 0 1.2393297055268704e-08
if O 0 4.735517755705132e-09
any O 0 2.224451067789346e-09
, O 0 4.703651246273921e-09
of O 0 3.974917728299943e-09
BRCA1 O 0 9.775946637091693e-06
in O 0 2.1866475208298652e-07
non B-Disease 0 1.3994800838190713e-06
- I-Disease 1 0.6305122375488281
familial I-Disease 1 0.9950903654098511
cancers I-Disease 1 0.9966496825218201
is O 0 4.526162229012698e-06
unclear O 0 2.3624264940735884e-05
. O 0 4.035717211081646e-06

BRCA1 O 1 0.9977892637252808
mutations O 1 0.705845057964325
are O 0 4.899797659163596e-06
rare O 0 7.573997208965011e-06
in O 0 9.070641908692778e-07
sporadic B-Disease 0 0.35759711265563965
cancers I-Disease 1 0.9825044274330139
, O 0 4.899616214970592e-07
but O 0 6.992852945586492e-07
loss O 0 4.1254679672420025e-06
of O 0 6.121021556282358e-08
BRCA1 O 0 0.0005191096570342779
resulting O 0 2.8543770440592198e-06
from O 0 6.14083148775535e-08
reduced O 0 7.002769848440948e-07
expression O 0 3.0724478961019486e-07
or O 0 3.524338865190657e-08
incorrect O 0 5.004817467124667e-07
subcellular O 0 1.750295723468298e-06
localization O 0 7.540797923866194e-07
is O 0 5.596241337002539e-08
postulated O 0 3.9633528103877325e-07
to O 0 2.8663494688885294e-08
be O 0 5.769940969457821e-09
important O 0 2.863921544360437e-09
in O 0 1.3361276529622046e-08
non B-Disease 0 1.481426465943514e-07
- I-Disease 0 0.019206276163458824
familial I-Disease 1 0.7085104584693909
breast I-Disease 1 0.9999233484268188
and I-Disease 1 0.9908384680747986
ovarian I-Disease 1 1.0
cancers I-Disease 1 0.999997615814209
. O 0 3.4226293792016804e-05

Epigenetic O 0 0.05850548669695854
loss O 0 0.12289214879274368
, O 0 1.7367195823680959e-06
however O 0 2.7227730470258393e-07
, O 0 3.4714929597612354e-08
has O 0 2.207158757983052e-07
not O 0 4.798035391218036e-08
received O 0 8.65898570623358e-08
general O 0 6.078370518025622e-08
acceptance O 0 4.974382363798213e-07
due O 0 2.768188949175965e-07
to O 0 7.974460913828807e-08
controversy O 0 7.694295049986977e-07
regarding O 0 7.331048124115114e-08
the O 0 2.0203170691956984e-08
subcellular O 0 1.0911335266428068e-06
localization O 0 2.6241798423143337e-07
of O 0 1.7644353533796675e-08
BRCA1 O 0 1.1654126865323633e-05
proteins O 0 4.4826794720620455e-08
, O 0 2.3117323166843562e-08
reports O 0 2.5287533844675636e-08
of O 0 2.2714241598720264e-09
which O 0 9.094430453160385e-08
have O 0 1.001483198592723e-07
ranged O 0 4.2900836660919595e-07
from O 0 1.1981379444137019e-08
exclusively O 0 5.489507870493071e-08
nuclear O 0 1.909257179022461e-07
, O 0 1.190813314622119e-08
to O 0 1.8730514028675316e-08
conditionally O 0 7.871278285165317e-06
nuclear O 0 1.468068262511224e-07
, O 0 6.089531545683258e-09
to O 0 1.2466769838681557e-08
the O 0 4.750791049445979e-08
ER O 0 0.0011253441916778684
/ O 0 4.528981662588194e-06
golgi O 0 5.8684705436462536e-05
, O 0 9.642143083965493e-08
to O 0 4.3871313692989133e-08
cytoplasmic O 0 9.082795600079407e-07
invaginations O 0 2.7429948659118963e-06
into O 0 6.11565340591369e-08
the O 0 4.23354045153701e-08
nucleus O 0 7.542366802226752e-07
. O 0 8.990797937258321e-07

In O 0 2.102027337969048e-06
an O 0 1.0551776341571895e-07
attempt O 0 1.3078833944746293e-06
to O 0 1.560105999942607e-07
resolve O 0 1.0778639989439398e-06
this O 0 6.944233632566466e-08
issue O 0 2.9324050387913303e-07
, O 0 3.6206419196105344e-08
we O 0 1.1105974806469021e-08
have O 0 2.37132482538982e-08
comprehensively O 0 7.248801011883188e-06
characterized O 0 3.440523187236977e-06
19 O 0 9.740626865095692e-07
anti O 0 4.339031511335634e-05
- O 0 0.05124642327427864
BRCA1 O 0 0.01334773562848568
antibodies O 0 2.9823695513186976e-05
. O 0 1.6866820260474924e-06

These O 0 1.4817418332313537e-06
reagents O 0 2.5416313746973174e-06
detect O 0 2.269960759804235e-06
a O 0 2.5477538656559773e-07
220 O 0 3.4499748835514765e-07
- O 0 9.691530067357235e-06
kD O 0 3.122989437542856e-05
protein O 0 2.30204193485406e-07
localized O 0 2.2250128495215904e-07
in O 0 1.329231480440285e-08
discrete O 0 1.5437518641192582e-07
nuclear O 0 1.8367818199749308e-07
foci O 0 1.677941213529266e-06
in O 0 4.573638889837639e-08
all O 0 2.6324533664023875e-08
epithelial O 0 0.00025851980899460614
cell O 0 0.001494800322689116
lines O 0 2.3058416900312295e-06
, O 0 2.5987539231664414e-08
including O 0 1.336994337464148e-08
those O 0 1.4717572938138801e-08
derived O 0 1.3012245858590177e-07
from O 0 2.422513603050902e-07
breast B-Disease 0 0.15080423653125763
malignancies I-Disease 0 0.2737455666065216
. O 0 2.4747909264988266e-05

Immunohistochemical O 0 0.0186455175280571
staining O 0 0.001963549293577671
of O 0 2.3332090677286033e-06
human O 0 1.2520272321125958e-05
breast O 1 0.828148365020752
specimens O 0 3.5999455576529726e-05
also O 0 7.312847628782038e-06
revealed O 0 1.9344859538250603e-05
BRCA1 O 0 7.748559255560394e-06
nuclear O 0 4.783178155776113e-07
foci O 0 9.269348993257154e-06
in O 0 8.95221035079885e-07
benign O 0 0.0710359588265419
breast O 1 0.9263665676116943
, O 0 1.0794979061756749e-05
invasive B-Disease 0 0.018768584355711937
lobular I-Disease 1 0.9999126195907593
cancers I-Disease 1 0.9940518736839294
and O 0 2.352827323193196e-06
low B-Disease 0 7.435337465722114e-05
- I-Disease 0 0.16369563341140747
grade I-Disease 0 0.0004364487831480801
ductal I-Disease 1 0.9980353713035583
carcinomas I-Disease 1 0.9999967813491821
. O 0 0.00014174100942909718

Conversely O 0 0.00035130628384649754
, O 0 3.641040848378907e-06
BRCA1 O 0 6.47409469820559e-05
expression O 0 1.845138626777043e-06
was O 0 4.70829536425299e-06
reduced O 0 5.11300868311082e-07
or O 0 5.485687637474257e-08
undetectable O 0 6.587728762497136e-07
in O 0 1.2452654019057263e-08
the O 0 1.5841687073248067e-08
majority O 0 3.308935276891134e-07
of O 0 1.4125542513454548e-08
high O 0 8.457575972897757e-07
- O 0 0.00032209392520599067
grade O 0 3.000443939527031e-06
, O 0 9.792413493414642e-07
ductal B-Disease 1 0.9555118083953857
carcinomas I-Disease 1 0.9999985694885254
, O 0 6.321614591797697e-07
suggesting O 0 6.147224667074624e-07
that O 0 2.0097170150279453e-08
absence O 0 9.879652651534343e-08
of O 0 6.136873764717166e-08
BRCA1 O 0 0.0006219891365617514
may O 0 4.360616912890691e-06
contribute O 0 2.506219054509984e-08
to O 0 2.4659005504190645e-08
the O 0 1.912214031563053e-08
pathogenesis O 0 9.557054454489844e-07
of O 0 4.239760542645854e-09
a O 0 1.2797298154509917e-07
significant O 0 5.0715836863446384e-08
percentage O 0 5.585684448305983e-08
of O 0 2.917803421098597e-08
sporadic B-Disease 0 0.18225327134132385
breast I-Disease 1 0.9999502897262573
cancers I-Disease 1 0.9925379157066345
. O 0 2.254120317957131e-06
. O 0 2.746667632891331e-06

